<SEC-DOCUMENT>0000950123-18-010005.txt : 20190301
<SEC-HEADER>0000950123-18-010005.hdr.sgml : 20190301
<ACCEPTANCE-DATETIME>20181018195558
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-18-010005
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		29
FILED AS OF DATE:		20181019
<PUBLIC-REL-DATE>20190301
DATE AS OF CHANGE:		20181116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECISION BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001357874
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02324
		FILM NUMBER:		181129152

	BUSINESS ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
		BUSINESS PHONE:		919-314-5512

	MAIL ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>As confidentially submitted to the Securities and Exchange Commission on October 19, 2018
</B></FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="4"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="4"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>REGISTRATION STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>UNDER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>THE SECURITIES ACT OF
1933 </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>2836</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B><FONT STYLE="white-space:nowrap">20-4206017</FONT></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>302 East Pettigrew St., Suite <FONT STYLE="white-space:nowrap">A-100</FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Durham, North Carolina 27701 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(919) <FONT STYLE="white-space:nowrap">314-5512</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1">(Address, including zip code, and telephone number, including </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">area code, of registrant&#146;s
principal executive offices) </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Matthew Kane </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>President and
Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>302 East Pettigrew St., Suite <FONT STYLE="white-space:nowrap">A-100</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Durham, North
Carolina 27701 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(919) <FONT STYLE="white-space:nowrap">314-5512</FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">(Name, address, including zip code, and telephone number, including </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1">area code, of agent for service) </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Michael P. Saber</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Amy M. Batten</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Heyward D. Armstrong</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Smith, Anderson, Blount, Dorsett,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Mitchell&nbsp;&amp; Jernigan, LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>150 Fayetteville Street, Suite 2300</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Raleigh, North Carolina 27601</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(919)
<FONT STYLE="white-space:nowrap">821-1220</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Peter N. Handrinos</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Nathan Ajiashvili</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Latham&nbsp;&amp; Watkins LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>200 Clarendon Street</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Boston,
Massachusetts 02116</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B><FONT STYLE="white-space:nowrap">(617)&nbsp;948-6000</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Divakar Gupta</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Darren DeStefano</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Yvan-Claude Pierre</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Kristin VanderPas</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Cooley
LLP</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>1114 Avenue of the Americas</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>New York, New York 10036</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(212)
<FONT STYLE="white-space:nowrap">479-6000</FONT></B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Approximate date of commencement of proposed sale to the public: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1">As soon as practicable after this Registration Statement is declared effective. </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp; <FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. &nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated
filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#9746;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Emerging&nbsp;growth&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#9746;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1">&#9744;</FONT> </FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>CALCULATION OF REGISTRATION FEE </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Title&nbsp;of&nbsp;each&nbsp;class&nbsp;of&nbsp;securities</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>to&nbsp;be&nbsp;registered</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Proposed</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>maximum</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>aggregate<BR>offering&nbsp;price(1)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Amount&nbsp;of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>registration&nbsp;fee(2)</B></FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Common Stock, $0.000005 par value per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933. Includes the aggregate offering price of
additional shares that the underwriters have the option to purchase. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. </FONT></TD></TR></TABLE>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that
this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant
to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#8b3f4e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any
state where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#8b3f4e"><B>Subject to Completion, dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019
</B></FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Preliminary prospectus </B></FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </I></B></FONT></P>
<P STYLE="font-size:14px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%">


<IMG SRC="g367280g28u01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Common stock </I></B></FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This is an initial public offering of shares of common stock by Precision BioSciences, Inc. We are
offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. The initial public offering price is expected to be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to this offering, there has been
no public market for our common stock.&nbsp;We intend to apply to list our common stock on The Nasdaq Global Market under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148;
</FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an &#147;emerging growth company&#148; under the federal securities laws and are subject to reduced public company reporting requirements for
this prospectus and future filings. </FONT></P> <P STYLE="font-size:14px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Per&nbsp;share</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Underwriting discounts and commissions(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds to Precision BioSciences, Inc., before expenses</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See &#147;Underwriting&#148; for a description of compensation payable to the underwriters. </FONT></TD></TR></TABLE> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have granted the underwriters an option for a period of 30 days to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock. </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#toc367280_2">Risk factors</A>&#148; beginning on page 11 of this prospectus.
</B></FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters expect to deliver the
shares of commons stock to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </FONT></P> <P STYLE="font-size:14px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P.&nbsp;Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="5"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="5"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Barclays</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:14px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </B></FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc"></A>Table of contents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_1">Prospectus&nbsp;summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_2">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_3">Special note regarding forward-looking statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_4">Industry and other data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_5">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_6">Dividend policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_7">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_8">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_9">Selected consolidated financial data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_10">Management&#146;s discussion and analysis of financial condition and results of operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_11">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_12">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">155</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_13">Executive compensation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">161</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_14">Certain relationships and related party transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">173</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_15">Principal stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_16">Description of capital stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">178</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_17">Shares eligible for future sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">184</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_18">Material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_19">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">192</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_20">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">203</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_21">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">203</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_22">Where you can find more information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">203</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc367280_23">Index to consolidated financial statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those
contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others
may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing
prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (the 25th day after the date of
this prospectus) all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when
acting as underwriters and with respect to their unsold allotments or subscriptions. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">We have proprietary rights to trademarks,
trade names and service marks appearing in this prospectus that are important to our business. Solely for convenience, the trademarks, trade names and service marks may appear in this prospectus without the&nbsp;<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&nbsp;and
<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> symbols, but any such references are not intended to indicate, in any way, that we forgo or will not assert, to the
fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this prospectus are the property of their
respective owners. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">i </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_1"></A>Prospectus summary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>This summary highlights selected information contained in greater detail elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common
stock. You should read this entire prospectus carefully, especially the risks of investing in our common stock discussed under &#147;Risk factors&#148; and our financial statements and the related notes thereto included at the end of this
prospectus, before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the Company&#148; and &#147;Precision&#148; refer to Precision
BioSciences, Inc. and its subsidiaries on a consolidated basis. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are a leading genome editing company dedicated to improving life. We have developed a groundbreaking proprietary genome editing platform to treat human diseases and create healthy and sustainable food and
agricultural solutions: we call this platform &#147;ARCUS.&#148; The versatility and breadth of ARCUS support our ability to develop product platforms in a variety of applications. We are initially focusing on three innovative and high value areas
where we believe our technology addresses the limitations of other genome editing technologies: cancer immunotherapy (allogeneic CAR T cells), <I>in vivo</I> gene corrections and food and agriculture. We expect to commence a Phase 1/2a clinical
trial with our lead gene-edited allogeneic CAR T cell candidate targeting CD19 in the first quarter of 2019. We believe our team, whom we call Precisioneers, has the deepest scientific experience and capabilities of all genome editing companies.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our genome editing platform&#151;ARCUS </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Genome
editing is a biotechnology process that removes, inserts or repairs a portion of DNA at a specific location in a cell&#146;s genome. Our proprietary genome editing platform, ARCUS, is a collection of protein engineering methods that were developed
specifically to re-program the DNA recognition properties of I-CreI. In nature, I-CreI is an endonuclease found in the genome of algae, <I>Chlamydomonas reinhardtii</I>, which evolved for the purpose of carrying out a complex gene insertion edit.
I-CreI is responsible for modifying a specific location in the algae&#146;s genome by inserting a gene using a very precise cellular repair mechanism called homology directed repair, or HDR. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We believe I-CreI has a number of attributes that are beneficial for genome editing applications, such as: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Specificity</B>. Complex applications of genome editing technology, especially those involving the human body, require a very high level of endonuclease
specificity to limit the likelihood that the endonuclease will recognize and cut any genetic sequence other than its intended target. I-CreI recognizes and cuts a DNA sequence that is 22 base pairs in length through a large number of complex
molecular interactions with the bases. I-CreI physically couples the functions of DNA binding with DNA cutting, and acts through a slow catalytic mechanism and low turnover rate, remaining inactive in the absence of its DNA target site.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Efficiency</B>. Most applications of genome editing technology require that a sufficient portion of the targeted cells are edited to achieve the desired
result. The activity level of the endonuclease is one factor that can affect how many cells are edited. Given its slow catalytic activity, I-CreI is able to achieve a high level of on-target editing while rarely cutting off-target.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Delivery</B>. Size and structural simplicity affect the ease with which endonucleases can be delivered to cells for editing. I-CreI is very small relative to
other genome editing endonucleases. As such, it is compatible with many different delivery mechanisms, and its small size and simple structure facilitate the simultaneous delivery of multiple engineered endonucleases to introduce more than one edit
to a cell. Both of these </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
properties significantly broaden the spectrum of potential applications for I-CreI-based genome editing endonucleases. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Type of cut</B>. I-CreI creates four base 3&#146; overhangs when it cuts its DNA site, which increases the likelihood that the cell will repair the DNA cut
through HDR. HDR is a mechanism of DNA repair whereby the cell uses a second DNA molecule with a sequence similar to that of the cut DNA molecule to guide the repair process. Since HDR uses a template of similar genetic information to guide the
repair process, it is the more precise mechanism of cellular repair compared to the other mechanism, non-homologous end joining, or NHEJ, which prioritizes speed over accuracy, making it prone to leaving insertions and/or deletions of DNA bases at
the cut site. As such, the DNA cuts created by I-CreI can be exploited to efficiently insert or repair DNA as well as delete DNA. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Programmability</B>. I-CreI recognizes its DNA target site through a complex network of contacts between the endonuclease and the DNA bases which makes the
enzyme very challenging to re-program for new editing applications involving different DNA sequences. This engineering challenge represents a very high barrier to entry and has enabled us to secure a strong intellectual property position and control
over what we believe to be a superior genome editing technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To apply <FONT STYLE="white-space:nowrap">I-CreI</FONT> to genome
editing in other cells or organisms, we must modify it to recognize and cut a different DNA sequence for each new application we pursue. Since the <FONT STYLE="white-space:nowrap">I-CreI</FONT> endonuclease evolved to recognize its target sequence
in the algae genome with a very high degree of selectivity, it is difficult to <FONT STYLE="white-space:nowrap">re-design</FONT> it to bind and cut a different DNA sequence. Using the ARCUS process, we create customized endonucleases for particular
applications. We call these custom endonucleases &#147;ARCUS nucleases.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are able to redirect the ARCUS nucleases to a new location in a genome
without compromising its editing abilities. In addition to changing the parts of the enzyme involved in recognizing a target DNA site, we can modify the active site of the enzyme and parts of the enzyme involved in anchoring it to the DNA. These
modifications allow us to control how tightly the enzyme binds to DNA or how quickly it cuts, both of which play an important role in determining the efficiency with which the endonuclease cuts its intended target site or any potential off-target
sites. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe ARCUS nucleases are the smallest and easiest to deliver genome editing endonucleases. Like I-CreI, ARCUS nucleases produce DNA cuts
with 3&#146; overhangs that promote HDR, facilitating gene insertions and gene repairs in addition to gene knockouts. We believe that these attributes will enable us to translate ARCUS into a wide array of products that have the potential to address
the limitations of other genome editing technologies and improve life. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our product platforms </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We leverage ARCUS to build platforms designed to rapidly generate new products in a given field. We are currently developing products from three such platforms: cancer immunotherapy (allogeneic CAR T cells), <I>in
vivo</I> gene corrections, and food and agriculture. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g72b13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Cancer immunotherapy (allogeneic CAR T cells).</B> We believe that we have developed the world&#146;s leading allogeneic
gene-edited CAR T cell platform with the potential to overcome certain limitations of autologous CAR T cell therapies and significantly increase patient access to these cutting-edge treatments. The allogeneic approach involves the use of
donor-derived cells which can be selected using specific criteria to define &#147;healthy&#148; T cells. We expect the allogeneic approach will lessen the product-to-product variability seen in autologous therapies, which are derived from the
patient&#146;s own cells. Additionally, donor-derived cells could be used in any patient, eliminating the &#147;one patient: one product&#148; burden of autologous CAR T cell therapies. We are also initially developing product candidates for
well-validated CAR T cell targets. Our most advanced program, PBCAR0191, is an allogeneic CAR T cell therapy targeting the well-validated tumor target CD19 and being developed for Acute Lymphoblastic Leukemia, or ALL, and Non-Hodgkin Lymphoma, or
NHL. In February 2016, we entered into an agreement with Les Laboratories Servier, or Servier and we have agreed to develop allogeneic CAR T cell therapies for up to six unique antigen targets selected by Servier, one of these antigen targets is
CD19. We submitted an IND for PBCAR0191 to the U.S. Food and Drug Administration in October 2018. We have used the qualities of ARCUS to create a one-step cell engineering process for allogeneic CAR T cells that we believe will rapidly yield a
consistent cell product at a significantly lower cost than autologous CAR T cell therapies. Due to our one-step editing method and the decision early in the development of the platform to invest in process development, our manufacturing process
today is scaled as opposed to scalable. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>In vivo </I></B><B>gene corrections.</B> Our goal is to cure genetic diseases by correcting the DNA errors
responsible for causing them. We are advancing a deep portfolio of diverse programs toward <I>in vivo</I> efficacy and toxicity studies. We are generating a significant large animal dataset that we believe will be the most comprehensive of any in
the field. The potential of ARCUS for <I>in vivo</I> genome editing is highlighted in our July 2018 publication in <I>Nature Biotechnology</I>, which we believe is the first peer-reviewed publication of <I>in vivo</I> genome editing data in
non-human primates. The publication reported high-efficiency editing of the PCSK9 gene in non-human primates using ARCUS and, even at the highest dose, the treatment was observed to be well tolerated. Because this therapeutic effect is due to
modifications to the DNA itself, the benefit of the treatment appears to be permanent. In September 2018, we announced a collaboration with Gilead Sciences Inc. to co-develop an ARCUS-based cure for chronic Hepatitis B infection. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Food and agriculture.</B> This platform, which we operate through our wholly owned subsidiary, Elo Life Systems, or Elo, is an integrated suite of gene discovery
and plant engineering technologies that allows us to generate pre-breeding material for food producers. We believe we have the most in-depth experience in crop genome editing in the industry. Over the last decade, we have developed highly efficient
methods to improve delivery and functionality of ARCUS nucleases to edit DNA in plants. By combining the power of our ARCUS technology platform with target discovery, transformation and high throughput evaluation, we are enabling our partners to
address emerging opportunities in food and agriculture. Our differentiated collaboration-based business model enables us to remain capital efficient throughout the product-development cycle while generating revenue through various revenue-sharing
models. Since 2014, Elo and Cargill have been engaged in a collaboration to produce ARCUS-optimized canola varieties and have achieved significantly lower levels (less than 4.5%) of saturated fatty acids compared to the current levels (7%). These
edited varieties are currently being evaluated in greenhouse and field trials. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our strategy </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our goal is to broadly translate the potential of genome editing into permanent genetic solutions for significant unmet needs. Our strategy to achieve this goal
includes the following key elements: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Create a fully integrated genome editing company capable of delivering solutions that address unmet needs in human health. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Accelerate advancement of our first four cancer immunotherapy product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Advance <I>in vivo </I>genetic correction programs for the liver and eye. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Build a human health-focused food business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Continue investing in the optimization of ARCUS and enabling technologies. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Create an environment that is a destination of choice for premier talent within the life sciences industry. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Expand the breadth of our operations through additional product platforms and strategic relationships. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Private financings </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since 2015, we have raised approximately
$136 million in gross proceeds from preferred stock financings. Across these financings, we received investments from venBio, F-Prime, ArrowMark Partners, Franklin Templeton, Cowen Healthcare, Gilead, Brace Pharma, Portfax AgTech, OCV Partners,
Adage Capital, RA Capital, Amgen Ventures, Vivo and Ridgeback Capital, among others. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks associated with our business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our business is subject to a number of risks that you should be aware of before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular,
should evaluate the specific factors set forth under &#147;Risk factors&#148; in deciding whether to invest in our common stock. Among these important risks are the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have incurred significant operating losses since our inception and expect to continue to incur losses for the foreseeable future. We have never been
profitable, and may never achieve or maintain profitability. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We will need substantial additional funding, and if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be
forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate development. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The regulatory landscape that will apply to development of therapeutic product candidates by us or our collaborators is rigorous, complex, uncertain and subject
to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of potential products.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our research and development programs may not lead to the successful identification, development or commercialization of any potential products.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Positive results, if any, obtained from early preclinical studies or clinical trials of our product candidates may not be predictive of results of later studies
or trials, and failure to replicate positive results from early studies or clinical trials may inhibit our ability to further develop and commercialize product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to obtain regulatory
approval for product candidates would substantially harm our business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">If any of our product candidates do not work as intended or cause undesirable side effects, it could hinder or prevent receipt of regulatory approval or
realization of commercial potential for them or our other product candidates and could substantially harm our business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Delays in completing our planned manufacturing facility or failure to achieve operating efficiencies from it may require us to devote additional resources and
management time to manufacturing operations and may delay our product development timelines. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our ability to compete may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential
threats to our competitive advantage. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend
or enforce our patents, either of which could prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Implications of being an emerging growth company </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of
the fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion or more, (2)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering, (3)&nbsp;the date on which we have
issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years or (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC, which means
the market value of our common shares that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June&nbsp;30th. For so long as we remain an emerging growth company, we are permitted and intend
to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">being permitted to present only two years of audited financial statements and only two years of related &#147;Management&#146;s discussion and analysis of
financial condition and results of operations&#148; in this prospectus; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or
a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports, proxy statements and registration statements; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have taken advantage of reduced reporting burdens in this prospectus and may elect to take advantage of other
reduced reporting requirements in future filings. In particular, in this prospectus, we have provided only two years of audited financial statements and corresponding &#147;Management&#146;s discussion and analysis of financial condition and results
of operations&#148; disclosure and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision of the JOBS Act allows
an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to take advantage of this extended transition period. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Corporate information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We were incorporated in Delaware in
January 2006. Our principal executive offices are located at 302 East Pettigrew St., Suite <FONT STYLE="white-space:nowrap">A-100,</FONT> Durham, North Carolina 27701, and our telephone number is (919)
<FONT STYLE="white-space:nowrap">314-5512.</FONT> Our website address is www.precisionbiosciences.com. The information contained in, or accessible through, our website does not constitute a part of this prospectus. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>The offering </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="35%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Common&nbsp;stock offered by&nbsp;us </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="35%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Common stock to be outstanding immediately after this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2"><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters
exercise their option to purchase additional shares in full). </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="35%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Option to purchase additional shares </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2"><BR>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of our common stock at the public offering price less the underwriting discounts and commissions. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="35%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Use of proceeds </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in full their option to purchase additional shares of common stock), at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, after deducting estimated underwriting discounts and commissions and the estimated offering expenses payable by us. We anticipate that we will use the net proceeds of this offering to advance and expand our clinical and preclinical
development programs and for working capital and other general corporate purposes, which may include the costs of establishing a manufacturing facility. For a more complete description of our intended use of the proceeds from this offering, see
&#147;Use of proceeds.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="35%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Risk factors </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">You should carefully read the &#147;Risk factors&#148; beginning on page 11 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding
to invest in our common stock. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="35%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Proposed Nasdaq Global Market symbol </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2"><BR>&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
number of shares of our common stock to be outstanding after this offering is based on 81,390,126 shares of our common stock outstanding as of September&nbsp;30, 2018, assuming the conversion of all outstanding shares of our convertible preferred
stock into an aggregate of 47,606,095 shares of our common stock upon the closing of this offering, and excludes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon exercise of stock options outstanding under our 2006
Stock Incentive Plan, referred to as our 2006 Plan, and our 2015 Stock Incentive Plan, referred to as our 2015 Plan, in each case as of September&nbsp;30, 2018, at a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019 Incentive Award
Plan, referred to as our 2019 Plan, which will become effective in connection with this offering, which number does not include any automatic increases in the number of shares of our common stock reserved for future issuance under our 2019 Plan; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019 Employee Stock
Purchase Plan, referred to as our 2019 ESPP, which will become effective in connection with this offering, which </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
number does not include any automatic increases in the number of shares of our common stock reserved for future issuance under our 2019 ESPP. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless otherwise indicated, this prospectus reflects and assumes the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-for-&nbsp;&nbsp;&nbsp;&nbsp;reverse</FONT></FONT> stock split of our
common stock, which will become effective prior to the effectiveness of the registration statement of which this prospectus forms a part; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the automatic conversion of all outstanding shares of our convertible preferred stock outstanding as of September&nbsp;30, 2018 into an aggregate of 47,606,095
shares of our common stock upon the closing of this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no exercise of outstanding options after September&nbsp;30, 2018; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the filing of our amended and restated certificate of incorporation, which will occur upon the closing of this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no exercise by the underwriters of their option to purchase additional shares of our common stock. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Summary consolidated financial data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following tables present a summary of our historical financial data for the periods ended on and as of the dates indicated. We have derived the summary consolidated statements of operations data for the years
ended December&nbsp;31, 2016 and 2017 and our summary consolidated balance sheet data as of December&nbsp;31, 2017 from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily
indicative of the results that should be expected for any future period. You should read the following summary consolidated financial data together with the more detailed information contained in &#147;Selected consolidated financial data,&#148;
&#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Statements of Operations Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Impairment of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss and net loss attributable to common stockholders&#151;basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share attributable to common stockholders&#151;basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of common stock outstanding&#151;basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,825,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,956,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted<BR>(unaudited)(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma weighted-average shares of common stock outstanding&#151;basic and diluted<BR>(unaudited)(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See Note&nbsp;10 to our audited consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical and pro
forma basic and diluted net loss per share of common stock and the weighted-average number of shares used in the computation of the per share amounts. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro&nbsp;forma(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro&nbsp;forma<BR>as&nbsp;adjusted(2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Working capital(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">55,129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stockholders&#146; (deficit) equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(26,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The pro forma consolidated balance sheet data gives effect to the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, which will occur upon the closing of this offering. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Reflects the pro forma adjustments described in footnote (2)&nbsp;and the issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We define working capital as current assets less current liabilities. See our consolidated financial statements included elsewhere in this prospectus for further details
regarding our current assets and current liabilities. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each $1.00
increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the
pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets, and stockholders&#146; (deficit) equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us,
as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the
assumed initial public offering price would increase (decrease) each of cash and cash equivalents, working capital, total assets, and stockholders&#146; (deficit) equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the
assumed initial public offering price per share remains the same and after deducting estimated underwriting discounts and commissions. The pro forma information discussed above is illustrative only and will be adjusted based on the actual initial
public offering price and other terms of our initial public offering determined at pricing. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">10 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_2"></A>Risk factors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in this
prospectus, including our consolidated financial statements and the related notes appearing herein. The occurrence of any of the following risks could materially adversely affect our business, financial condition, results of operations and
prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks
related to our financial condition, limited operating history and need for additional capital </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have incurred significant operating losses
since our inception and expect to continue to incur losses for the foreseeable future. We have never been profitable, and may never achieve or maintain profitability. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have never been profitable and do not expect to be profitable in the foreseeable future. Since inception, we have incurred significant operating losses. If our product candidates are not successfully developed
and approved, we may never generate any revenue from product sales. Our net losses were $8.3&nbsp;million and $21.1&nbsp;million for the years ended December&nbsp;31, 2016 and 2017, respectively. As of December&nbsp;31, 2017, we had an accumulated
deficit of $39.1&nbsp;million. In addition, we have not commercialized any products and have never generated any revenue from product sales. Substantially all of our losses have resulted from expenses incurred in connection with our research and
development activities, including our preclinical development activities, and from general and administrative costs associated with our operations. We have financed our operations primarily through private placements of our convertible preferred
stock and our development and commercial license agreement dated February&nbsp;24, 2016, as amended, with Les Laboratoires Servier, which we refer to as the Servier Agreement. The amount of our future net losses will depend, in part, on the amount
and growth rate of our expenses and our ability to generate revenues. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All of our research and development activities in our cancer immunotherapy
(allogeneic CAR T cells) and <I>in vivo </I>gene correction platforms are preclinical, and our food and agriculture platform is early stage. We have not yet received authorization from the U.S. Food and Drug Administration, or the FDA, to proceed
with a clinical trial under an investigational new drug application, or IND, or advanced any potential therapeutic product candidates to human clinical trials. All of our current or future product candidates will require substantial additional
development time and resources before we may realize revenue from product sales, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase
substantially if and as we: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">continue our current research and development programs, including conducting laboratory, preclinical and greenhouse studies for product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">initiate clinical or field trials for product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seek to identify, assess, acquire or develop additional research programs or product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">maintain, expand and protect our intellectual property portfolio; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seek marketing approvals for any product candidates that may successfully complete development; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establish a sales, marketing and distribution infrastructure to commercialize any products that may obtain marketing approval; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">further develop and refine the manufacturing process for our product candidates; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">11 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">change or add additional manufacturers or suppliers of biological materials or product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">validate a commercial-scale manufacturing facility compliant with current Good Manufacturing Practices, or cGMP; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">further develop our genome editing technology; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seek to attract and retain new and existing personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expand our facilities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">operate as a public company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No clinical
studies have begun on any of our therapeutic product candidates, and it will be several years, if ever, before we obtain regulatory approval for, and are ready for commercialization of, a therapeutic product candidate. Similarly, only one product
candidate from our food and agriculture platform has advanced to field testing, and it will be several years, if ever, before we or our collaborators commercialize any such product candidate. Even if a product candidate receives regulatory approval,
future revenues for such product candidate will depend upon many factors, such as, as applicable, the size of any markets in which such product candidate is approved for sale, the market share captured by such product candidate, including as a
result of the market acceptance of such product candidate and the effectiveness of manufacturing, sales, marketing and distribution operations related to such product candidate, the terms of any collaboration or other strategic arrangement we may
have with respect to such product candidate and levels of reimbursement from third-party payors. If we are unable to develop and commercialize one or more product candidates either alone or with collaborators, or if revenues from any product
candidate that receives marketing approval or is commercialized are insufficient, we may not achieve profitability.&nbsp;Even if we do achieve profitability, we may not be able to sustain or increase profitability.&nbsp;If we are unable to achieve
and maintain profitability, the value of our common stock will be materially adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We will need substantial additional funding, and
if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The process of identifying product candidates and conducting preclinical or greenhouse studies and clinical or field trials is time consuming,
expensive, uncertain and takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate clinical or field trials of, and seek
marketing approval for, product candidates. In addition, if any therapeutic product candidate that we develop alone or with collaborators obtains marketing approval, we may incur significant commercialization expenses related to product
manufacturing, sales, marketing and distribution efforts. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional
funding in connection with our continuing operations. If we are unable to raise sufficient capital when needed, we may be forced to delay, reduce or eliminate current or future research programs, product development activities and/or
commercialization efforts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect that our existing cash and cash equivalents, together with the net proceeds from this offering, will be sufficient
to fund our expected operating expenses and capital expenditure requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be
wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors, including factors unknown to us, and we may need to seek additional
funds sooner </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">12 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. We do not currently expect future grant revenues to be a material source of
revenue. Attempting to secure additional financing may divert our management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">our&nbsp;day-to-day&nbsp;activities,</FONT></FONT> which may adversely affect our ability to develop
product candidates. Our future capital requirements will depend on many factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing, scope, progress, costs, results and analysis of results of research activities, preclinical or greenhouse studies and clinical or field trials for
any of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs of future activities, including product manufacturing, sales, marketing and distribution activities for any product candidates that receive regulatory
approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the success of our existing collaborative relationships; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which we exercise any development or commercialization rights under collaborative relationships; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to establish and maintain additional collaborative relationships on favorable terms, or at all; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which we expand our operations and the timing of such expansion, including with respect to facilities, employees and product development platforms;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending
intellectual property-related claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies or product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which we acquire or invest in other businesses; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs of operating as a public company; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the amount of revenues, if any, received from commercial sales of any products that we develop alone or with collaborators that receive regulatory approval.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market
conditions are favorable or in light of specific strategic considerations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis or on favorable
terms, we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization efforts. We may also be unable to expand our operations or otherwise capitalize on business
opportunities as desired. Any of these events could materially adversely affect our financial condition and business prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Raising additional
capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and/or debt
financings and collaborations, licensing agreements or other strategic arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of
such securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. To the extent that we raise additional capital through debt financing, it would result in increased fixed payment obligations and
a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. In addition, debt financing may involve agreements that include restrictive covenants that impose operating restrictions,
such as restrictions on the incurrence of additional debt, the making of certain </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">13 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
capital expenditures or the declaration of dividends. To the extent we raise additional capital through arrangements with collaborators or otherwise, we may be required to relinquish some of our
technologies, research programs, product development activities, product candidates and/or future revenue streams, license our technologies and/or product candidates on unfavorable terms or otherwise agree to terms unfavorable to us. Furthermore,
any capital raising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to advance research programs, product
development activities or product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have a limited operating history, which makes it difficult to evaluate our current business and
future prospects and may increase the risk of your investment. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a preclinical-stage genome editing company with a limited operating
history. We formed our company in 2006 and spent the first nine years of our company&#146;s history developing and refining our core technology, and only during the past several years have we focused our efforts on advancing the development of
product candidates. Investment in biopharmaceutical and agricultural biotechnology product development is a highly speculative endeavor. It entails substantial upfront capital expenditures, and there is significant risk that any product candidate
will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain any required regulatory approvals or become commercially viable. Our genome editing platform and the technologies we are using are new and unproven. All of our
therapeutic product candidates are in preclinical stages. We have not yet advanced any product candidates to human clinical trials, and only one of the product candidates from our food and agriculture platform has progressed to field trials. We have
not yet demonstrated an ability to initiate or successfully complete any clinical or field trials, obtain any required marketing approvals, manufacture products, conduct sales, marketing and distribution activities, or arrange for a third party to
do any of the foregoing on our behalf. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing products. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, we encounter risks and difficulties frequently experienced by new and growing companies in rapidly developing and changing industries, including
challenges in forecasting accuracy, determining appropriate investments of our limited resources, gaining market acceptance of our technology, managing a complex regulatory landscape and developing new product candidates, which may make it more
difficult to evaluate our likelihood of success. Our current operating model may require changes in order for us to adjust to these challenges or scale our operations efficiently. Our limited operating history, particularly in light of the rapidly
evolving nature of the biopharmaceutical and agricultural biotechnology industries and the genome editing field, may make it difficult to evaluate our technology and business prospects or to predict our future performance. Additionally, due to the
stage of our operations, we expect that our financial condition and operating results may fluctuate significantly from quarter to quarter as a result of many factors as we build our business, and you should not rely upon the results of any
particular quarterly or annual period as indications of future operating performance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may expend our limited resources pursuing particular
research programs or product candidates that may be less successful or profitable than other programs or product candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research programs
to identify new product candidates and product development platforms require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs, product candidates or product development platforms that
ultimately prove to be unsuccessful. Any time, effort and financial resources we expend on identifying and researching new product candidates and product development platforms may divert our attention from, and adversely affect our ability to
continue, development and commercialization of existing research programs, product candidates and product development platforms. Clinical trials or field trials, as applicable, of any of our product candidates may never
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">14 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
commence despite the expenditure of significant resources in pursuit of their development, and our spending on current and future research and development programs, product candidates and product
development platforms may not yield any commercially viable products. As a result of having limited financial and managerial resources, we may forego or delay pursuit of opportunities that later prove to have greater commercial potential. Our
resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Additionally, if we do not accurately evaluate the commercial potential or target market for a particular
product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We expect to take advantage of a Research&nbsp;and Development Tax Incentive program in
Australia, which could be amended or changed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may be eligible to receive a financial incentive from the Australian government as part of its
Research and Development Tax Incentive program, or R&amp;D Tax Incentive program. The R&amp;D Tax Incentive program is one of the key elements of the Australian government&#146;s support for Australia&#146;s innovation system and, if eligible,
provides the recipient with a 43.5% refundable tax offset for research and development activities in Australia. There have been recent proposals to change the structure of the innovation and research and development funding landscape in Australia,
which may impact the research and development tax incentive receivable for the 2018 financial year and beyond. There can be no assurance that we will qualify and be eligible for such incentives or that the Australian government will continue to
provide incentives, offset, grants and rebates on similar terms or at all. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to the identification, development and commercialization of
our product candidates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate
development. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our success depends on our ability to develop and commercialize product candidates using our novel genome editing technology. The
novel nature of our technology makes it difficult to accurately predict the developmental challenges we may face for product candidates as they proceed through research, preclinical or greenhouse studies and clinical or field trials. There have been
a limited number of clinical trials of products created with genome editing technologies, none of which has utilized our technology, and no therapeutic product candidates created with other genome editing technologies have received marketing
approval in the United States or Europe. Because our therapeutic research programs are all in research or preclinical stages, we have not yet been able to assess the safety or efficacy of any product candidates in humans. Current or future product
candidates may not meet safety and efficacy requirements for continued development or ultimate approval in humans and may cause significant adverse events or toxicities. All of our product candidates are designed to act at the level of DNA, and
because animal DNA differs from human DNA, it will be difficult for us to test our therapeutic product candidates in animal models for either safety or efficacy, and any testing that we conduct may not translate to their effects in humans. Moreover,
animal models may not exist for some of the targets, diseases or indications that we intend to pursue. Similarly, we and our collaborators have not yet completed field trials for any agricultural product candidates created with our technology. Our
product candidates may not be able to properly implement desired genetic edits with sufficient accuracy to be viable therapeutic or agricultural products, and there may be long-term effects associated with them that we cannot predict at this time.
Any problems we experience related to the development of our genome editing technology or any of our or our collaborators&#146; research programs or product candidates may cause significant delays or unanticipated costs, and we may not be able to
satisfactorily solve such problems. These factors may prevent us </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">15 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or our collaborators from completing our preclinical or greenhouse studies or any clinical or field trials that we or our collaborators may initiate, or profitably commercializing any product
candidates on a timely basis, or at all. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process as we develop and prepare to commercialize product candidates. These factors make it more difficult
for us to predict the time, cost and potential success of product candidate development. If our product development activities take longer or cost more than anticipated, or if they ultimately are not successful, it would materially adversely affect
our business and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The genome editing field is relatively new and evolving rapidly, and other existing or future technologies
may provide significant advantages over our ARCUS platform, which could materially harm our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To date, we have focused our efforts on
optimizing our proprietary genome editing technology and exploring its potential applications. ARCUS is a novel genome editing technology using sequence-specific <FONT STYLE="white-space:nowrap">DNA-cutting</FONT> enzymes, or nucleases, to perform
modifications in the DNA of living cells and organisms. Other companies have previously undertaken research and development of genome editing technologies using zinc finger nucleases, transcription activator-like effector nucleases, or TALENs, and
clustered regularly interspaced short palindromic repeats associated <FONT STYLE="white-space:nowrap">protein-9</FONT> nuclease, or CRISPR/Cas9, although none has obtained marketing approval for a product candidate developed using such technologies.
Other genome editing technologies, or other existing or future technologies, may lead to the development of treatments or products that may be considered better suited for use in human therapeutics or agriculture, which could reduce or eliminate our
commercial opportunity. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are heavily dependent on the successful development and translation of ARCUS, and due to the early stages of our
product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
are at an early stage of development of the product candidates currently in our programs and are continuing to develop our ARCUS technology. To date, we have invested substantially all of our efforts and financial resources to develop ARCUS and
advance our current product development programs, including conducting preclinical studies and other early research and development activities, and providing general and administrative support for these operations. Our future success is dependent on
our ability to successfully develop and, where applicable, obtain regulatory approval for, including marketing approval for, and then successfully commercialize, product candidates, either alone or with collaborators. We have not yet developed and
commercialized any product candidates, and we may not be able to do so, alone or with collaborators. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our research and development programs may not
lead to the successful identification, development or commercialization of any products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The success of our business depends primarily upon our
ability to identify, develop and commercialize products using our genome editing technology. With the exception of one product candidate for food and agriculture that is in field trials, all current product candidates and product development
programs are still in the discovery, preclinical or greenhouse stages. We may be unsuccessful in advancing those product candidates into clinical development or field trials or in identifying any developing additional product candidates. Our ability
to identify and develop product candidates is subject to the numerous risks associated with preclinical and early stage biotechnology development activities, including that: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the use of ARCUS may be ineffective in identifying additional product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not be able to enter into collaborative arrangements to facilitate development of product candidates; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">16 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">competitors may develop alternatives that render our product candidates obsolete or less attractive; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our product candidates may be covered by third parties&#146; patents or other exclusive rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the regulatory pathway for a product candidate may be too complex, expensive or otherwise difficult to navigate successfully; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our product candidates may be shown to not be effective, have harmful side effects or otherwise pose risks not outweighed by such product candidate&#146;s
benefits or have other characteristics that may make the products impractical to manufacture, unlikely to receive any required marketing approval, unlikely to generate sufficient market demand or otherwise not achieve profitable commercialization.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if we do commence clinical trials of product candidates and continue to identify new product candidates, such product candidates
may never be approved. Failure to successfully identify and develop new product candidates and obtain regulatory approvals for our products would have a material adverse effect on our business and financial condition and could cause us to cease
operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If our product candidates do not achieve projected development milestones or commercialization in the announced or expected
timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones may include our expectations regarding the
commencement or completion of scientific studies or clinical or field trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives. The achievement of many of these
milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the
receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from our estimates. If we or our collaborators fail to achieve announced milestones in the expected timeframes,
the commercialization of the product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the trading price of our common stock may decline. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of products that we develop alone or with
collaborators. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The developmental and commercial success of our current product candidates, or any that we develop alone or with collaborators in
the future, will depend in part on public acceptance of the use of genome editing technology for the prevention or treatment of human diseases or for application in food or agricultural products. Adverse public perception of applying genome editing
technology for these purposes may negatively impact our ability to raise capital or enter into strategic agreements for the development of product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The commercial success of any food or agricultural products that we develop alone or with collaborators may be adversely affected by claims that biotechnology plant products are unsafe for consumption or use, pose
risks of damage to the environment or create legal, social or ethical dilemmas. Additionally, the public may perceive any potential food or agricultural products created with ARCUS to constitute genetically modified organisms, or GMO, even if they
do not constitute genetically modified organisms under relevant regulatory requirements, and may be unwilling to consume them because of negative opinions regarding consumption of genetically modified organisms. This may result in expenses, delays
or other impediments to development programs in our food and agriculture platform or the market acceptance and commercialization of any potential food or agricultural products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">17 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any therapeutic product candidates may involve editing the human genome. The commercial success of any such
potential therapeutic products, if successfully developed and approved, may be adversely affected by claims that genome editing is unsafe, unethical or immoral. This may lead to unfavorable public perception and the inability of any therapeutic
product candidates to gain the acceptance of the public or the medical community. Unfavorable public perceptions may also adversely impact our or our collaborators&#146; ability to enroll clinical trials for therapeutic product candidates. Moreover,
success in commercializing any therapeutic product candidates that receive regulatory approval will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of such product candidates in lieu
of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. Publicity of any adverse events in, or unfavorable results of, preclinical studies or clinical trials for any
current or future product candidates, or with respect to the studies or trials of our competitors or of academic researchers utilizing genome editing technologies, even if not ultimately attributable to our technology or product candidates, could
negatively influence public opinion. Negative public perception about the use of genome editing technology in human therapeutics and food or agricultural products, whether related to our technology or a competitor&#146;s technology, could result in
increased governmental regulation, delays in the development and commercialization of product candidates or decreased demand for the resulting products, any of which may have a negative impact on our business and financial condition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Interim&nbsp;&#147;top-line&#148;&nbsp;and</FONT> preliminary data from studies or trials that we announce or publish from
time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">From time to time, we may publish <FONT STYLE="white-space:nowrap">interim&nbsp;&#147;top-line&#148;&nbsp;or</FONT> preliminary data from preclinical or greenhouse studies or clinical or field trials. Interim data
are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had
the opportunity to fully and carefully evaluate all data.&nbsp;As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional
data have been received and fully evaluated. Preliminary <FONT STYLE="white-space:nowrap">or&nbsp;&#147;top-line&#148;&nbsp;data</FONT> also remain subject to audit and verification procedures that may result in the final data being materially
different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject
to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our
business prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions
or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise
appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a
particular product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize, product candidates may be harmed, which could significantly harm our business prospects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">18 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We face significant competition in industries experiencing rapid technological change, and there is a
possibility that our competitors may achieve regulatory approval before us or develop product candidates or treatments that are safer or more effective than ours, which may harm our financial condition and our ability to successfully market or
commercialize any of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The development and commercialization of new drug products is highly competitive, and the genome
editing field is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We will face competition with respect to our current and future therapeutic product candidates from major
pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct
research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization of products. Competition for improving plant genetics comes from conventional and advanced plant breeding
techniques, as well as from the development of advanced biotechnology traits. Other potentially competitive sources of improvement in crop yields include improvements in crop protection chemicals, fertilizer formulations, farm mechanization, other
biotechnology and information management. Programs to improve genetics and crop protection chemicals are generally concentrated within a relatively small number of large companies, while <FONT STYLE="white-space:nowrap">non-genetic</FONT> approaches
are underway with a broader set of companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are a number of large pharmaceutical and biotechnology companies that currently market and sell
products or are pursuing the development of products for the treatment of the disease indications for which we have research programs. Some of these competitive products and therapies are based on scientific approaches that are similar to our
approach, and others are based on entirely different approaches. We principally compete with others developing and utilizing genome editing technology in the human health and plant sciences sectors, including companies such as Cellectis S.A., CRISPR
Therapeutics, AG, Editas Medicine, Inc., Intellia Therapeutics, Inc. and Sangamo Therapeutics, Inc. Several companies, including Novartis Pharmaceuticals Corp. and Gilead Sciences, Inc., or Gilead, have obtained FDA approval for autologous
immunotherapies, and a number of companies, including Cellectis S.A., Celgene Corp., Allogene Therapeutics and CRISPR Therapeutics AG, are pursuing allogeneic immunotherapies. We expect that our operations focused on developing products for <I>in
vivo</I> gene correction will face substantial competition from others focusing on gene therapy treatments, especially those that may focus on conditions that our product candidates target. Moreover, any human therapeutics products that we develop
alone or with collaborators will compete with existing standards of care for the diseases and conditions that our product candidates target and other types of treatments, such as small molecule, antibody or protein therapies. Our competitors in the
agricultural biotechnology space include Pairwise Plants, LLC, Caribou Biosciences, Inc., Corteva Agriscience, Tropic Biosciences UK LTD, Calyxt, Inc. and Cibus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Many of our current or potential competitors, either alone or with their collaborators, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical or
greenhouse testing, conducting clinical or field trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and agricultural biotechnology industries may result in
even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are
less expensive than any products we develop alone or with collaborators or that would render </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">19 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
any such products obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we or
our collaborators may obtain approval for any that we develop, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our
product candidates uneconomical or obsolete, and we or our collaborators may not be successful in marketing any product candidates we may develop against competitors. The availability of our competitors&#146; products could limit the demand, and the
price we are able to charge, for any products that we develop alone or with collaborators. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our future profitability, if any, depends in part on
our and our collaborators&#146; ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our
business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our future profitability, if any, will depend in part on our ability and the ability of our collaborators to commercialize any
products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the applicable marketing authorization
from the competent regulatory authority; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our
collaborators pursue; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">differing medical and agricultural practices and customs affecting acceptance in the marketplace; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">import or export licensing requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">governmental controls, trade restrictions or changes in tariffs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">economic weakness, including inflation, or political instability in particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">longer accounts receivable collection times; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">longer lead times for shipping; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">language barriers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">foreign currency exchange rate fluctuations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">foreign reimbursement, pricing and insurance regimes; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have no prior experience in these areas, and our collaborators may have limited experience in these areas. Failure to successfully navigate these risks and
uncertainties may limit or prevent market penetration for any products that we or our collaborators may develop, which would limit their commercial potential and our revenues. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">20 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and could limit
commercialization of any products that we develop alone or with collaborators. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We face an inherent risk of product liability and professional
indemnity exposure related to the testing in clinical or field trials of our product candidates. We will face an even greater liability risk if we commercially sell any products that we or our collaborators may develop for human use or consumption.
Manufacturing defects, errors in product distribution or storage processes, improper administration or application and known or unknown side effects of product usage may result in liability claims against us or third parties with which we have
relationships. These actions could include claims resulting from acts by our collaborators, licensees and subcontractors over which we have little or no control. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For example, our liability could be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects, improper product administration or the
deterioration of a patient&#146;s condition, patient injury or even death. Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any
product candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves
against claims that product candidates or products we develop alone or with collaborators caused harm, we could incur substantial liabilities. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Regardless of merit or eventual outcome, liability claims may result in: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">significant time and costs to defend the related litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injury to our reputation and significant negative media attention; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">diversion of management&#146;s attention from pursuing our strategy; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delay or termination of clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">decreased demand for any products that we develop alone or with collaborators; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">substantial monetary awards to trial participants or patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product recalls, withdrawals or labeling, marketing or promotional restrictions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">loss of revenue; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability to further develop or commercialize any products. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Although the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is
always possible that a drug or biologic, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial
liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. If any of our product candidates are approved for commercial sale, we will be
highly dependent upon consumer perceptions of us and the safety and quality of such products. We could be adversely affected if we are subject to negative publicity associated with illness or other adverse effects resulting from patients&#146; use
or misuse of such products or any similar products distributed by other companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we maintain product liability insurance coverage, it may not
be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage when we begin clinical trials </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">21 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
and if we or our collaborators successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in
an amount adequate to satisfy any liabilities to which we may become subject. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Additional risks related to the identification, development and
commercialization of our therapeutic product candidates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The regulatory landscape that will apply to development of therapeutic product
candidates by us or our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Regulatory requirements governing products created with genome editing technology or involving gene therapy treatment have changed frequently
and will likely continue to change in the future. Approvals by one regulatory agency may not be indicative of what any other regulatory agency may require for approval, and there is substantial, and sometimes uncoordinated, overlap in those
responsible for regulation of gene therapy products, cell therapy products and other products created with genome editing technology.&nbsp;For example, in addition to the submission of an investigational new drug application, or IND, to the FDA,
before initiation of a clinical trial in the United States, certain human clinical trials for cell therapy products and gene therapy had historically been subject to review by the Recombinant DNA Advisory Committee, or the RAC, of the National
Institutes of Health, or NIH, Office of Biotechnology Activities, or OBA, pursuant to the NIH Guidelines for Research Involving Recombinant DNA Molecules, or NIH Guidelines. Following an initial review, RAC members would make a recommendation as to
whether the protocol raises important scientific, safety, medical, ethical or social issues that warrant <FONT STYLE="white-space:nowrap">in-depth</FONT> discussion at the RAC&#146;s quarterly meetings. Even though the FDA decides whether individual
cell therapy or gene therapy protocols may proceed under an IND, the RAC&#146;s recommendations were shared with the FDA and the RAC public review process, if undertaken, could delay the initiation of a clinical trial, even if the FDA had reviewed
the trial design and details and has not objected to its initiation or has notified the sponsor that the study may begin. Conversely, the FDA can put an IND on clinical hold even if the RAC provided a favorable review or has recommended against an <FONT
STYLE="white-space:nowrap">in-depth,</FONT> public review. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;17, 2018, the NIH issued a notice in the Federal Register and issued a public
statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH Guidelines to modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products,
and requesting public comment on its proposed modifications. During the public comment period, which closed October&nbsp;16, 2018, the NIH has announced that it will no longer accept new human gene transfer protocols for review as part of the
protocol registration process under the existing NIH Guidelines or convene the RAC to review individual clinical protocols. These trials will remain subject to the FDA&#146;s oversight and other clinical trial regulations, and oversight at the local
level will continue as otherwise set forth in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local
institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the
environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of
recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Even though we may not be required to submit a protocol for our gene therapy product
candidates through the NIH for RAC review, we will still be subject to significant regulatory oversight by the FDA, and in addition to the government regulators, the applicable IBC and institutional review board, or IRB, of each institution at which
we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, would need to review and approve the proposed clinical trial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">22 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The same applies in the European Union, or the EU. The European Medicines Agency, or the EMA, has a Committee for
Advanced Therapies, or CAT, that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products. Advanced-therapy medical products include gene therapy medicine, somatic-cell therapy medicines and
tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the EU, the development and evaluation of a gene
therapy medicinal product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with
these new guidelines. Similarly complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. As a result, the
procedures and standards applied to gene therapy products and cell therapy products may be applied to any of our gene therapy or genome editing product candidates, but that remains uncertain at this point. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to evaluate the safety and efficacy of a
product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products.&nbsp;The regulatory approval process for product candidates created with novel genome editing technology such as
ours can be more lengthy, rigorous and expensive than the process for other better known or more extensively studied product candidates and technologies. Since we are developing novel treatments for diseases in which there is little clinical
experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or comparable regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data
and results may be more difficult to analyze. This may be a particularly significant risk for many of the genetically defined diseases for which we may develop product candidates alone or with collaborators due to small patient populations for those
diseases, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations.&nbsp;Regulatory agencies administering existing or future regulations or
legislation may not allow production and marketing of products utilizing genome editing technology in a timely manner or under technically or commercially feasible conditions. Even if our product candidates obtain required regulatory approvals, such
approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Changes
in applicable regulatory guidelines may lengthen the regulatory review process for our product candidates, require additional studies or trials, increase development costs, lead to changes in regulatory positions and interpretations, delay or
prevent approval and commercialization of such product candidates, or lead to significant post-approval limitations or restrictions.&nbsp;Additionally, adverse developments in clinical trials conducted by others of gene therapy products or products
created using genome editing technology, such as products developed through the application of a CRISPR/Cas9 technology, or adverse public perception of the field of genome editing, may cause the FDA, the EMA and other regulatory bodies to revise
the requirements for approval of any product candidates we may develop or limit the use of products utilizing genome editing technologies, either of which could materially harm our business.&nbsp;Furthermore, regulatory action or private litigation
could result in expenses, delays or other impediments to our research programs or the development or commercialization of current or future product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As we advance product candidates alone or with collaborators, we will be required to consult with these regulatory and advisory groups and comply with all applicable guidelines, rules and regulations. If we fail to
do so, we or our collaborators may be required to delay or terminate development of such product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could
decrease our ability to generate sufficient product revenue to maintain our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">23 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming
and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We and any collaborators are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities,
such as the EMA, impose similar requirements. The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon
numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product
candidate&#146;s clinical development and may vary among jurisdictions. To date, we have not submitted a biologics license application, or BLA, or other marketing authorization application to the FDA or similar drug approval submissions to
comparable foreign regulatory authorities for any product candidate. We and any collaborators must complete additional preclinical or nonclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans
to the satisfaction of the regulatory authorities before we will be able to obtain these approvals. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our product candidates could fail to receive
regulatory approval for many reasons, including the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our or our collaborators&#146; clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we or our collaborators may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe
and effective for its proposed indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we or our collaborators may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA or comparable foreign regulatory authorities may disagree with our or our collaborators&#146; interpretation of data from preclinical studies or clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the data collected from clinical trials of product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain
regulatory approval in the United States or elsewhere; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we or
our collaborators contract for clinical and commercial supplies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing with collaborators; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our or our
collaborators&#146; clinical data insufficient for approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This lengthy approval process as well as the unpredictability of future
clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we
request, may impose significant limitations in the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">24 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS. Regulatory authorities may not approve the price we or our collaborators intend to charge for products
we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful
commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully and
timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical testing
is expensive and usually takes many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and product candidates in later stages of clinical trials may fail to show the desired
safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. To date, neither we nor our collaborators have initiated any clinical trials for any product candidates. We do not know whether planned
clinical trials will begin on time, need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including in connection with:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability to generate sufficient preclinical, toxicology or other <I>in vivo</I> or <I>in vitro</I> data to support the initiation of clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">applicable regulatory authorities disagreeing as to the design or implementation of the clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining regulatory authorization to commence a trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject
to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining IRB approval at each site; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developing and validating the companion diagnostic to be used in a clinical trial, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing,
characterizing or controlling a manufacturing process suitable for clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recruiting and retaining enough suitable patients to participate in a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">having enough patients complete a trial or return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">adding a sufficient number of clinical trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical sites deviating from trial protocol or dropping out of a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability to demonstrate the efficacy and benefits of a product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">discovering that product candidates have unforeseen safety issues, undesirable side effects or other unexpected characteristics; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">addressing patient safety concerns that arise during the course of a trial; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">25 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">receiving untimely or unfavorable feedback from applicable regulatory authorities regarding the trial or requests from regulatory authorities to modify the
design of a trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">non-compliance</FONT> with applicable regulatory requirements by us or third parties or changes in such regulations or
administrative actions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">suspensions or terminations by IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or
by the FDA or other regulatory authorities due to a number of factors, including those described above; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">third parties being unable or unwilling to satisfy their contractual obligations to us; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in our financial priorities, greater than anticipated costs of completing a trial or our inability to continue funding the trial.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to
the denial of regulatory approval of our product candidates. Additionally, we or our collaborators may experience unforeseen events during or resulting from clinical trials that could delay or prevent receipt of marketing approval for or
commercialization of product candidates. For example, clinical trials of product candidates may produce negative, inconsistent or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon
development programs. Regulators may also revise the requirements for approving the product candidates, or such requirements may not be as we anticipate. If we or our collaborators are required to conduct additional clinical trials or other testing
of product candidates beyond those that we or our collaborators currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of such product candidates, if the results of these trials or
tests are not positive or are only modestly positive or if there are safety concerns, we may: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">incur unplanned costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be delayed in obtaining or fail to obtain marketing approval for product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain marketing approval in some countries and not in others; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be subject to additional post-marketing testing requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be subject to changes in the way the product is administered; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">have regulatory authorities withdraw or suspend their approval of the product or impose restrictions on its distribution; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be sued; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">experience damage to our reputation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we or
our collaborators experience delays in the commencement or completion of our clinical trials, or if we or our collaborators terminate a clinical trial prior to completion, we may experience increased costs, have difficulty raising capital and/or be
required to slow down the development and approval process timelines. Furthermore, the product candidates that are the subject of such trials may never receive regulatory approval, and their commercial prospects and our ability to generate product
revenues from them could be impaired or not realized at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">26 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Any product candidates that we or our collaborators may develop will be novel and may be complex and
difficult to manufacture, and if we experience manufacturing problems, it could result in delays in development and commercialization of such product candidates or otherwise harm our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our product candidates involve or will involve novel genome editing technology and will require processing steps that are more complex than those required for most
small molecule drugs, resulting in a relatively higher manufacturing cost. Moreover, unlike small molecules, the physical and chemical properties of biologics generally cannot be fully characterized. As a result, assays of the finished product may
not be sufficient to ensure that such product will perform in the intended manner. Although we intend to employ multiple steps to control the manufacturing process, we may experience manufacturing issues with any of our product candidates that could
cause production interruptions, including contamination, equipment or reagent failure, improper installation or operation of equipment, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility
services, human error, disruptions in the operations of our suppliers, inconsistency in cell growth and variability in product characteristics. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet
FDA, EMA or other comparable applicable standards or specifications with consistent and acceptable production yields and costs. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and
other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which such product candidates are made, such manufacturing facilities may need to be closed for an
extended period of time to investigate and remedy the contamination. Our manufacturing process for any allogeneic CAR T cell product candidate that we develop alone or with collaborators will be susceptible to product loss or failure due to
logistical issues associated with the collection of white blood cells, or starting material, from healthy third-party donors, shipping such material to the manufacturing site, ensuring standardized production <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">batch-to-batch</FONT></FONT> in the context of mass production, freezing the manufactured product, shipping the final product globally and infusing patients with such product. Problems with the manufacturing process, even
minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, we expect that various aspects of the
development program, such as manufacturing methods, may be altered along the way in an effort to help optimize processes and results. Such changes carry the risk that they will not achieve the intended objectives, and any of these changes could
cause our product candidates to perform differently and affect the results of future clinical trials or our reliance on results of trials that have previously been conducted using the product candidate in its previous form. If the manufacturing
process is changed during the course of product development, we or our collaborators may be required to repeat some or all of the previously conducted trials or conduct additional bridging trials, which could increase our costs and delay or impede
our ability to obtain marketing approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect our manufacturing strategy for one or more of our product candidates may involve the use of contract
manufacturing organizations, or CMOs, as well as establishing our own capabilities and infrastructure, including a manufacturing facility. We believe that development of our own manufacturing facility will provide us with enhanced control of
material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes and help us achieve better long-term margins. We have no experience in developing a manufacturing facility and may never be
successful in developing our own manufacturing facility or capability. The facilities used by us and our contract manufacturers to manufacture therapeutic product candidates must be approved by the FDA pursuant to inspections that will be conducted
after we submit our BLA to the FDA. We do not control the manufacturing process of, and are currently completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">27 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
current good manufacturing practices, or cGMP, for the manufacture of our product candidates. We may establish multiple manufacturing facilities as we expand our commercial footprint to multiple
geographies, which will be costly and time consuming and may lead to regulatory delays. Even if we are successful, our manufacturing capabilities could be affected by cost-overruns, potential problems with
<FONT STYLE="white-space:nowrap">scale-out,</FONT> process reproducibility, stability issues, lot inconsistency, timely availability of reagents or raw materials, unexpected delays, equipment failures, labor shortages, natural disasters, utility
failures, regulatory issues and other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA, the EMA and other foreign regulatory authorities may require us to submit samples of any lot of any product that may receive approval together with the protocols showing the results of applicable tests at
any time. Under some circumstances, the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a lot until the relevant agency authorizes its release. Slight deviations in the manufacturing process, including those
affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us or our collaborators to delay product launches or
clinical trials, which could be costly to us and otherwise harm our business. Problems in our manufacturing process also could restrict our or our collaborators&#146; ability to meet market demand for products. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger pharmaceutical
companies and academic research institutions, which could limit our access to additional attractive development opportunities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We will rely on
donors of T cells to manufacture product candidates from our cancer immunotherapy platform, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are developing a pipeline of allogeneic T cell product candidates that are engineered from healthy donor T cells, which vary in type and
quality. This variability in type and quality of a donor&#146;s T cells makes producing standardized product candidates more difficult and makes the development and commercialization pathway of those product candidates more uncertain. We have
developed a screening process designed to enhance the quality and consistency of T cells used in the manufacture of our CAR T cell product candidates. If we are unable to identify and obtain T cells from donors that satisfy our criteria in
sufficient quantity, to obtain such cells in a timely manner or to address variability in donor T cells, development of our CAR T cell product candidates may be delayed or there may be inconsistencies in the product candidates we produce, which
could negatively impact development of such product candidates, harm our reputation and adversely impact our business and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Delays in
completing the manufacturing facility we are building or failure to achieve operating efficiencies from it may require us to devote additional resources and management time to manufacturing operations and may delay our product development timelines.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have leased approximately 17,300 square feet of space for our manufacturing facility at a location approximately seven miles from our
headquarters in Durham, North Carolina, at which we intend to establish and equip a manufacturing facility compliant with cGMP. We may face delays in the completion of the manufacturing facility and cannot guarantee that this facility will be
available for manufacturing beginning with our BCMA product candidate. In addition, we may not experience the anticipated operating efficiencies as we commence manufacturing operations at the new facility. Any such delays may disrupt or delay the
supply of our product candidates if we have not maintained a sufficient <FONT STYLE="white-space:nowrap">back-up</FONT> supply of such product candidates through third-party manufacturers. Moreover, changing manufacturing facilities may also require
that we or our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">28 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
collaborators conduct additional studies, make notifications to regulatory authorities, make additional filings to regulatory authorities, and obtain regulatory authority approval for the new
facilities, which may be delayed or which we may never receive. We will further need to comply with the FDA&#146;s and applicable foreign regulatory authorities&#146; cGMP requirements for the production of product candidates for clinical trials
and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspection. These requirements include the qualification and validation of our manufacturing equipment and processes. We may not be able to
develop or acquire the internal expertise and resources necessary for compliance with these requirements. Should we fail to comply with cGMP requirements, the opening of our manufacturing facility will be delayed. If we fail to achieve the operating
efficiencies that we anticipate, our manufacturing and operating costs may be greater than expected, which could have a material adverse impact on our operating results. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In order to complete our planned manufacturing facility, we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations, quality, regulatory,
facilities and information technology. We also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes. If we experience unanticipated employee
shortage or turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from the new facility, which may negatively affect our
product development timeline or result in difficulties in maintaining compliance with applicable regulatory requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any such problems could result
in the delay, prevention or impairment of clinical development and commercialization of our product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We or our collaborators may
experience delays or difficulties in enrolling patients in clinical trials, which could delay or prevent receipt of regulatory approvals. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We or
our collaborators may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we or our collaborators identify or develop if we or our collaborators are unable to locate and enroll a sufficient
number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. Additionally, some of our competitors may have ongoing clinical trials for
product candidates that would treat the same indications as one or more of our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in our competitors&#146; clinical trials. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patient enrollment may also affected by many factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">severity and difficulty of diagnosing of the disease under investigation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">size of the patient population and process for identifying subjects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">eligibility and exclusion criteria for the trial in question; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our or our collaborators&#146; ability to recruit clinical trial investigators with the appropriate competencies and experience; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">design of the trial protocol; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">availability and efficacy of approved medications or therapies, or other clinical trials, for the disease or condition under investigation;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">perceived risks and benefits of the product candidate under trial or testing, or of the application of genome editing to human indications;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">29 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">availability of genetic testing for potential patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">efforts to facilitate timely enrollment in clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">patient referral practices of physicians; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">ability to obtain and maintain subject consent; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">risk that enrolled subjects will drop out before completion of the trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">ability to monitor patients adequately during and after treatment; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">proximity and availability of clinical trial sites for prospective patients. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We expect that some of our product candidates will focus on rare genetically defined diseases with limited patient pools from which to draw for enrollment in clinical trials. The eligibility criteria of our
clinical trials will further limit the pool of available trial participants. In addition to the factors identified above, patient enrollment in any clinical trials we or our collaborators may conduct may be adversely impacted by any negative
outcomes our competitors may experience, including adverse side effects, clinical data showing inadequate efficacy or failures to obtain regulatory approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Furthermore, our or our collaborators&#146; ability to successfully initiate, enroll and conduct a clinical trial outside the United States is subject to numerous additional risks, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">difficulty in establishing or managing relationships with CROs and physicians; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">differing standards for the conduct of clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">differing standards of care for patients with a particular disease; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an inability to locate qualified local consultants, physicians and partners; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and
biotechnology products and treatments. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Enrollment delays in clinical trials may result in increased development costs for any of our
product candidates, which may cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct clinical trials as planned,
we may need to delay, limit or terminate ongoing or planned clinical trials, any of which may have an adverse effect on our results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Results of preclinical studies and early clinical trials of product candidates may not be predictive of results of later studies or trials. Our product candidates may not have favorable results in later
clinical trials, if any, or receive regulatory approval. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Preclinical and clinical drug development is expensive and can take many years to
complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of
preclinical or clinical development. The historical failure rate for product candidates in our industry is high. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The results from preclinical studies or
early clinical trials of a product candidate may not be predictive of the results from later preclinical studies or clinical trials, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later
stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical and biotechnology industries have
suffered significant setbacks at later </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">30 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
stages of development after achieving positive results in early stages of development, and we may face similar setbacks. These setbacks have been caused by, among other things, preclinical
findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported adverse events. Moreover, <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical data are often
susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval. The use of our
genome editing technology in our product candidates has never undergone testing in humans and has only been tested in a limited manner in animals, and results from animal studies may not be predictive of clinical trial results. Even if any product
candidates progress to clinical trials, these product candidates may fail to show the safety and efficacy in clinical development required to obtain regulatory approval, despite the observation of positive results in animal studies. Our or our
collaborators&#146; failure to replicate positive results from early research programs and preclinical or greenhouse studies may prevent us from further developing and commercializing those or other product candidates, which would limit our
potential to generate revenues from them and harm our business and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the foregoing reasons, we cannot be certain that any ongoing or future
preclinical studies or clinical trials will be successful. Any safety or efficacy concerns observed in any one of our preclinical studies or clinical trials in a targeted area could limit the prospects for regulatory approval of product candidates
in that and other areas, which could have a material adverse effect on our business and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If any of our product candidates do not work as
intended or cause undesirable side effects, it could hinder or prevent receipt of regulatory approval or realization of commercial potential for them or our other product candidates and could substantially harm our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our product candidates may be associated with <FONT STYLE="white-space:nowrap">off-target</FONT> editing or other serious adverse events, undesirable side effects
or unexpected characteristics. Results of clinical trials could reveal severe or recurring side effects, toxicities or unexpected events, including <FONT STYLE="white-space:nowrap">death.&nbsp;Off-target</FONT> cuts could lead to disruption of a
gene or a genetic regulatory sequence at an unintended site in the DNA. In those instances where we also provide a segment of DNA, it is possible that following <FONT STYLE="white-space:nowrap">off-target</FONT> cut events, such DNA could be
integrated into the genome at an unintended site, potentially disrupting another important gene or genomic element. There may also be delayed adverse events following exposure to therapeutics made with genome editing technologies due to persistent
biologic activity of the genetic material or other components of products used to carry the genetic material. In addition to serious adverse events or side effects caused by product candidates we develop alone or with collaborators, the
administration process or related procedures may also cause undesirable side effects. Any side effects may not be appropriately recognized or managed by the treating medical staff. We or our collaborators expect to have to train medical personnel
using any product candidates we may develop to understand the side effect profiles for our clinical trials and upon any commercialization of such product candidates. Inadequate training in recognizing or managing the potential side effects of such
product candidates could result in patient injury or death. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any such events occur, clinical trials or commercial distribution of any product
candidates or products we develop alone or with collaborators could be suspended or terminated, and our business and reputation could suffer substantial harm. Treatment-related side effects could affect patient recruitment and the ability of
enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us or our collaborators to cease further development of, deny approval of or require us to cease selling any product candidates or
products for any or all targeted indications. If we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be
harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">31 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, if we successfully develop a product candidate alone or with collaborators and it receives
marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health
care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We or our collaborators may also be required to
adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with
collaborators. Such identification could also have several additional significant negative consequences, such as: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory authorities may require additional warnings on the label, including &#147;boxed&#148; warnings, or issue safety alerts, Dear Healthcare Provider
letters, press releases or other communications containing warnings or other safety information about the product; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be required to change the way a product is administered or conduct additional trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the product may become less competitive; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we or our collaborators may decide to remove the product from the marketplace; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we could be sued and be held liable for harm caused to patients; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any of these events
could prevent us or our collaborators from achieving or maintaining market acceptance of any potential product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are subject to federal, state
and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> healthcare and privacy laws and regulations relating to our business, and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an
adverse impact on our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our business operations, as well as our current and anticipated future arrangements with investigators,
healthcare professionals, consultants, third-party payors, customers and patients, expose or will expose us to broadly applicable foreign, federal, and state fraud and abuse and other healthcare and privacy laws and regulations. These laws constrain
the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any potential products for which we may obtain marketing approval. Such laws include:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or
providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made
under a U.S. healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the U.S. federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition,
the government may assert that a claim including items or services resulting from a violation of the </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">32 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which can be enforced through civil
whistleblower or qui tam actions, prohibits, among other things, individuals and entities from knowingly presenting, or causing to be presented, to the U.S. government, claims for payment or approval that are false or fraudulent, knowingly making,
using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and
willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false
statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, impose
obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such
as health plans, healthcare clearinghouses and certain healthcare providers, as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available
under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other &#147;transfers of value&#148; made to physicians (defined to include doctors,
dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the Centers for Medicare and Medicaid Services, or CMS, ownership and
investment interests held by the physicians described above and their immediate family members; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">analogous state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations, such as state anti-kickback and false claims laws, which may apply to
our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party
payors, including private insurers, or by the patients themselves; state laws that require pharmaceutical and device companies to comply with the industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the
U.S. government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require manufacturers to report information related to payments and other transfers of
value to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws which require the registration of pharmaceutical sales representatives; state and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA; state and <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> enacted and proposed, laws and regulations regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals (including the EU
General Data Protection Regulation 2016/679 and the California Consumer Protection Act); and federal and state consumer protection laws are </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">33 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
being applied to enforce regulations related to the online collection, use, and dissemination of data, thus complicating compliance efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations
are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages,
monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity
agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, it could adversely affect our ability to operate our business and our results of
operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may seek orphan drug designation for some or all of our product candidates, but we may be unable to obtain such designations or to
maintain the benefits associated with orphan drug designation, which may negatively impact our ability to develop or obtain regulatory approval for such product candidates and may reduce our revenue if we obtain such approval. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the
use of these products. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the
United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the
United States for that drug or biologic. Orphan drug designation must be requested before submitting a biologics license application, or BLA. In the United States, orphan drug designation entitles a party to financial incentives such as
opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use
are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Although we may seek orphan product designation for some or all of our product
candidates, we may never receive such designations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If a product that has orphan drug designation subsequently receives the first FDA approval for a
particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for
the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can
ensure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Even if we or our collaborators obtain orphan drug designation for a product
candidate, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Exclusive marketing rights in the United States may be limited if we or
our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">34 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if a product obtains orphan drug exclusivity, that
exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug
with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Furthermore, the FDA can waive orphan exclusivity if we or our collaborators are
unable to manufacture sufficient supply of the product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Similarly, in Europe, a medicinal product may receive orphan designation under Article 3 of
Regulation (EC) 141/2000. This applies to products that are intended for a life-threatening or chronically debilitating condition and either (1)&nbsp;such condition affects no more than five in 10,000 persons in the EU when the application is made,
or (2)&nbsp;the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment. Moreover, in order to obtain orphan designation in the EU it is necessary to
demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a method exists, the product will be of significant benefit to those affected by the
condition. In the EU, orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and applicants can benefit from specific regulatory assistance and scientific advice. Products receiving orphan
designation in the EU can receive 10 years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. An orphan product can also obtain an additional two years of market exclusivity in
the EU for pediatric studies. However, the <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan
designation&#151;for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the first applicant consents to a second orphan medicinal product application; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the first applicant cannot supply enough orphan medicinal product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If we or our collaborators do not receive or maintain orphan drug designation for product candidates for which we seek such designation, it could limit our ability to realize revenues from such product candidates.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may seek fast-track designation for some or all of our product candidates, but we may not receive such designation, and even if we do, it may
not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that such product candidates will receive marketing approval. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may seek fast-track designation and review for some or all of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition or disease, and nonclinical or clinical
data demonstrate the potential to address an unmet medical need, the product may qualify for FDA fast track designation, for which sponsors must apply. The FDA has broad discretion whether or not to grant this designation. Thus, even if we or our
collaborators believe a particular product candidate is eligible for this designation, the FDA may decide not to grant it. Moreover, even if we do receive fast track designation, we or our collaborators may not experience a faster development
process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from the clinical development program. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">35 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If the product candidates that we or our collaborators may develop receive regulatory approval in the
United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for such product candidate and adversely affect our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such
product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or our collaborators&#146; ability to develop, manufacture, promote and sell product candidates
internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell
product candidates in the EU and many other jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve
additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the
intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country
may have a negative effect on the regulatory approval process in others. If we or our collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a
particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize any product candidates we or our collaborators develop and may adversely
affect the prices for such product candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United&nbsp;States and certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our
product candidates, restrict or regulate post-approval activities and affect our or our collaborators&#146; ability to profitably sell any product candidates that obtain marketing approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the United States.
Among the provisions of the Affordable Care Act of importance to our product candidates, the Affordable Care Act establishes an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic
agents; increases in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, extends manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed
care organizations, expands eligibility criteria for Medicaid programs, expansion of the entities eligible for discounts under the Public Health program, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug
Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% commencing January&nbsp;1,
2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D, and creates a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">At this time, we are unsure of the full impact that the Affordable Care Act will have on our business. There have been judicial and political challenges to certain aspects of the Affordable Care Act. For example,
since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">36 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
loosen certain requirements mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act.
While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. Tax legislation enacted on December&nbsp;22, 2017 entitled &#147;an Act
to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018, Pub.L. 115&#150;97,&#148; or the Tax Cuts and Jobs Act of 2017, includes a provision repealing, effective January&nbsp;1,
2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred
to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care <FONT
STYLE="white-space:nowrap">Act-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance
providers based on market share. Further, the Bipartisan Budget Act of 2018, among other things, amends the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the
&#147;donut hole.&#148; More recently, in July 2018, the CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act
risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Congress may consider other legislation to repeal or repeal and replace other elements of the
Affordable Care Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&nbsp;2,
2011, the Budget Control Act of 2011 was signed into law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a
targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal
year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to
providers from three to five years. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of
the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product
pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products, some of which are included in the Trump administration&#146;s budget proposal
for fiscal year 2019. Additionally, the Trump administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the
negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has
begun the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. Although a number of these, and other potential, proposed measures will require authorization
through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical product and medical device pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">37 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and medical devices to purchase and which suppliers will be included in their prescription drug and other healthcare programs.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to
Try Act, was signed into law. The law, among other things, provides a federal, or the framework for certain patients with life-threatening diseases or conditions to access certain investigational new drug products that have completed a Phase 1
clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program.
There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect
that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we or our
collaborators may receive for any approved or cleared product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. We cannot predict the likelihood, nature or
extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to new requirements or policies, or if we or our
collaborators are not able to maintain regulatory compliance, any of our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Even if we obtain regulatory approval for any products that we develop alone or with collaborators, such products will remain subject to ongoing
regulatory requirements, which may result in significant additional expense. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if products we develop alone or with collaborators receive
regulatory approval, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, distribution, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information,
among other things. Any regulatory approvals received for such products may also be subject to limitations on the approved indicated uses for which they may be marketed or to the conditions of approval, or contain requirements for potentially costly
post-marketing testing and surveillance studies. For example, the holder of an approved BLA in the United States is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. FDA guidance
advises that patients treated with some types of gene therapy undergo <FONT STYLE="white-space:nowrap">follow-up</FONT> observations for potential adverse events for as long as 15 years. Similarly, in the EU, pharmacovigilance obligations are
applicable to all medicinal products. In addition to those, holders of a marketing authorization for gene or cell therapy products must detail, in their application, the measures they envisage to ensure
<FONT STYLE="white-space:nowrap">follow-up</FONT> of the efficacy and safety of these products. In cases of particular concern, marketing authorization holders for gene or cell therapy products in the EU may be required to design a risk management
system with a view to identifying, preventing or minimizing risks and may be obliged to carry out post-marketing studies. In the United States, the holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval
for certain changes to the approved product, product labeling or manufacturing process. Similar provisions apply in the EU. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other
potentially applicable federal and state laws. Similarly, in the EU any promotion of medicinal products is highly regulated and, depending on the specific jurisdiction involved, may require prior vetting by the competent national regulatory
authority. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">38 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review
and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, our collaborators or a regulatory agency discovers
previously unknown problems with a product such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of that product, a
regulatory agency may impose restrictions relative to that product, the manufacturing facility or us or our collaborators, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, if any of our product candidates are approved, our product labeling, advertising, promotion and distribution will be subject to regulatory requirements
and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s
approved labeling. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we or our collaborators fail to comply with applicable regulatory requirements following approval of any potential products we may
develop, authorities may: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">issue an untitled enforcement letter or a warning letter asserting a violation of the law; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seek an injunction, impose civil and criminal penalties, and impose monetary fines, restitution or disgorgement of profits or revenues;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">suspend or withdraw regulatory approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">suspend or terminate any ongoing clinical trials or implement requirements to conduct post-marketing studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our collaborators;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrict the labeling, marketing, distribution, use or manufacturing of products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seize or detain products or otherwise require the withdrawal or recall of products from the market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refuse to approve pending applications or supplements to approved applications that we or our collaborators submit; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refuse to permit the import or export of products; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refuse to allow us or our collaborators to enter into government contracts. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty
described above may inhibit our or our collaborators&#146; ability to commercialize products and our ability to generate revenues. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the
FDA&#146;s policies, and policies of foreign regulatory agencies, may change, and additional regulations may be enacted that could prevent, limit or delay regulatory approval of product candidates. For example, in December 2016, the 21st Century
Cures Act, or the Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of biologics and spur innovation, but its ultimate implementation is unclear. We cannot predict the likelihood, nature or
extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry.
Namely, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">39 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the
FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these requirements will be
implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose restrictions on the FDA&#146;s ability to engage in oversight and implementation activities in the
normal course, our business may be negatively impacted. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements, or if we or our collaborators are unable to maintain regulatory
compliance, marketing approval that has been obtained may be lost and we may not achieve or sustain profitability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Even if any product we develop
alone or with collaborators receives marketing approval, such product may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The commercial success of any potential therapeutic products we develop alone or with collaborators will depend upon their degree of market
acceptance by physicians, patients, third-party payors and others in the medical community. Even if any potential therapeutic products we develop alone or with collaborators receive marketing approval, they may nonetheless fail to gain sufficient
market acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any product we develop alone or with collaborators, if approved for commercial sale, will depend on a number of
factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the efficacy and safety of such product as demonstrated in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the prevalence and severity of any side effects; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the clinical indications for which the product is approved by FDA, the EMA or other regulatory authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a
product&#146;s approved labeling; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">public attitudes regarding genome editing technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our and any collaborators&#146; ability to educate the medical community about the safety and effectiveness of the product; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies, as well as their willingness to accept a
therapeutic intervention that involves the editing of the patient&#146;s genome; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the potential and perceived advantages compared to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">convenience and ease of administration compared to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any restrictions on the use of such product together with other treatments or products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">market introduction of competitive products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">publicity concerning such product or competing products and treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability to offer such product for sale at a competitive price; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">40 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the strength of marketing and distribution support; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">sufficient third-party coverage and adequate reimbursement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If any products we develop alone or with collaborators do not achieve an adequate level of acceptance, we may not generate significant product revenues, and we may not become profitable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any products we develop alone or
with collaborators, the commercialization of such products may not be successful if and when they are approved. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not have a sales or
marketing infrastructure and have no experience in the sale, marketing or distribution of biopharmaceutical or other commercial products. To achieve commercial success for any approved products for which we retain sales and marketing
responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate
in sales activities with our collaborators for, certain product candidates if and when they are approved. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are risks involved with both
establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, restricted or closed distribution channels may make it difficult to distribute products to segments of the patient
population, and the lack of complementary medicines to be offered by sales personnel may put us at a competitive disadvantage relative to companies with more extensive product lines. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Recruiting and training a sales force or reimbursement specialists are expensive and time consuming and could delay any product launch. If the commercial launch of a product for which we recruit a sales force and
establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we cannot retain or
reposition our commercialization personnel. Factors that may inhibit our efforts to commercialize products on our own include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unforeseen costs and expenses associated with creating an independent commercialization organization; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our inability to recruit, train, retain and effectively manage adequate numbers of effective sales, marketing, customer service and other support personnel,
including for reimbursement or medical affairs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we choose to enter into arrangements with third parties to perform sales, marketing, commercial support or distribution services,
we may not be successful in entering into such arrangements or may be unable to do so on terms that are favorable to us. Entering into such third-party arrangements may subject us to a variety of risks, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product revenues or profitability to us being lower than if we were to market and sell any products we or our collaborators may develop ourselves;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our inability to exercise direct control over sales and marketing activities and personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">failure of the third parties to devote necessary resources and attention to, or other inability to, sell and market any products we or our collaborators may
develop; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">41 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">potential disputes with third parties concerning sales and marketing expenses, calculation of royalties and sales and marketing strategies; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unforeseen costs and expenses associated with sales and marketing. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If we do not establish effective commercialization capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any of our product candidates that may receive
approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If the market opportunities for any products we develop alone or with collaborators are smaller than our estimates, or if we are unable
to successfully identify enough patients, our revenues may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We focus some of our research and product development on
treatments for rare genetic diseases. Our and our collaborators&#146; projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with product
candidates we may develop, are based on estimates. These estimates may prove to be incorrect, and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may
turn out to be lower than expected, and patients may not be amenable to treatment with products that we may develop alone or with collaborators, or may become increasingly difficult to identify or gain access to, any of which would decrease our
ability to realize revenue from any such products for such diseases. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The successful commercialization of potential products will depend in part on
the extent to which governmental authorities and health insurers establish coverage, and the adequacy of reimbursement levels and pricing policies, and failure to obtain or maintain coverage and adequate reimbursement for any potential products that
may receive approval, could limit marketability of those products and decrease our ability to generate revenue. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The availability of coverage and
adequacy of reimbursement by government healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors is essential for most patients to be able to afford prescription medications such as the potential
therapeutic products we develop alone or with collaborators. The ability to achieve acceptable levels of coverage and reimbursement for any potential products that may be approved by governmental authorities will have an effect on our and our
collaborators&#146; ability to successfully commercialize such products. Even if products we develop alone or with collaborators obtain coverage by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT
STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. If coverage and reimbursement in the United States, the EU or elsewhere is not available for any products we develop alone or with collaborators that may be
approved, or any reimbursement that may become available is decreased or eliminated in the future, we and our collaborators may be unable to commercialize such products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved drugs and biologics. In the United States, third-party payors, including private and governmental payors, such
as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors
and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug
therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for any product that we develop alone or with
collaborators. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. As a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">42 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
result, the coverage determination process is often a time-consuming and costly process that will require us or our collaborators to provide scientific and clinical support for the use of any
potential products that may be approved to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement
change frequently, in some cases on short notice. Obtaining coverage and adequate reimbursement for products we develop alone or with collaborators may be particularly difficult because of the higher prices often associated with drugs administered
under the supervision of a physician. In certain instances, payors may not separately reimbursement for the product itself, but only for the treatments or procedures in which such product is used. A decision by a third-party payor not to cover or
separately reimburse for products that we develop alone or with collaborators or procedures using such products, could reduce physician utilization of any such products that may receive approval. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Third-party payors are increasingly challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage
and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. If approved, it is possible that a third-party payor may consider any products that we develop alone or with
collaborators as substitutable and only offer to reimburse patients for the less expensive product. Pricing of existing third-party therapeutics may limit the amount we will be able to charge for any products that may receive approval even if we or
our collaborators show improved efficacy or improved convenience of administration such products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that
are too low to enable us to realize an appropriate return on our investment in the product. If reimbursement is not available or is available only at limited levels, we or our collaborators may not be able to successfully commercialize any of the
products that we develop, even if approved, and we may not be able to obtain a satisfactory financial return on them. Moreover, increasing efforts by governmental and&nbsp;third-party&nbsp;payors in the United States and abroad to cap or reduce
healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any products we develop alone or with collaborators
that may receive approval. We expect to experience pricing pressures in connection with the sale of any products that may receive approval due to the trend toward managed health care, the increasing influence of health maintenance organizations and
additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being
erected to the entry of new products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Outside the United States, international operations are generally subject to extensive governmental price controls
and other market regulations, and we believe the increasing emphasis on&nbsp;cost-containment&nbsp;initiatives in Europe and elsewhere have and will continue to put pressure on the pricing and usage of any products we develop alone or with
collaborators that may receive approval. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical
products, but monitor and control company profits. Additional international price controls or other changes in pricing regulation could restrict the amount that we or our collaborators are able to charge for products that we develop that may receive
approval. Accordingly, in markets outside the United States, the reimbursement for such products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are successful in achieving regulatory approval to commercialize any biologic product candidate we develop alone or with collaborators, it may face
competition from biosimilar products. In the United States, our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">43 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
product candidates are regulated by the FDA as biologic products subject to approval under the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or the BPCIA, created an
abbreviated pathway for the approval of biosimilar and interchangeable biologic products following the approval of an original BLA. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar
biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product may not be submitted until four years
following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years after the reference product was first licensed by the FDA. During this
<FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own
preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate
impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial
prospects for biological product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that any of our product candidates that are approved as biological products under a BLA should
qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider such product
candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been
the subject of recent litigation. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our or our collaborators&#146; reference products in a way that is similar to traditional generic substitution
for <FONT STYLE="white-space:nowrap">non-biologic</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars
referencing any products that we develop alone or with collaborators that may be approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Additional risks related to the identification, development and commercialization of our food and agricultural product candidates </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The regulatory landscape that may govern any potential food or agricultural products that we or our collaborators may develop is uncertain and may adversely
impact the development and commercialization activities of our food and agriculture platform. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, the United States Department
of Agriculture, or the USDA, regulates, among other things, the introduction (including the importation, interstate movement or release into the environment) of organisms and products altered or produced through genetic engineering determined to be
plant pests or for which there is reason to believe are plant pests. Such organisms and products are considered &#147;regulated articles.&#148; However, a petitioner may submit a request for a determination by the USDA of &#147;nonregulated
status&#148; for a particular article. A petition for determination of nonregulated status must include detailed information, including relevant experimental data and publications, field trial reports and a description of the genotypic differences
between the regulated article and the nonmodified recipient organism, among other things. Neither we nor, to our knowledge, our collaborators have obtained a determination from the USDA that any product candidates are not &#147;regulated
articles&#148; under these regulations. We cannot predict whether the USDA, advocacy groups or other third parties will contend that these products are regulated articles. The USDA&#146;s regulations also require that companies obtain a permit or
file a notification before engaging in the introduction (including the importation, interstate movement or release into the environment such as in field trials) of &#147;regulated articles.&#148;
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">44 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Additionally, a change in the way the USDA interprets its regulations, or a change in its regulations, could subject our or our collaborators&#146; products to more burdensome regulations,
thereby substantially increasing the time and costs associated with developing product candidates. Complying with the USDA&#146;s Part 340 regulations, including permitting requirements, is a costly, time-consuming process and could delay or prevent
the commercialization of any potential food or agricultural products we or our collaborators may develop. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any potential food or agricultural products
that we or our collaborators develop may also be subject to extensive FDA food product regulations. Under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act, or the FDCA, any substance that becomes or is reasonably expected to
become a component of food is a food additive and is therefore subject to FDA premarket review and approval, unless the substance is generally recognized, among qualified experts, as having been adequately shown to be safe under the conditions of
its intended use (generally recognized as safe, or GRAS), or unless the use of the substance is otherwise excluded from the definition of a food additive, and any food that contains an unsafe food additive is considered adulterated under section
402(a)(2)(C) of the FDCA. The FDA may classify some or all of the potential food or agricultural products that we or our collaborators may develop as containing a food additive that is not GRAS or otherwise determine that such products contain
significant compositional differences from existing plant products that require further review. Such classification would cause these potential products to require <FONT STYLE="white-space:nowrap">pre-market</FONT> approval, which could delay the
commercialization of these products. In addition, the FDA is currently evaluating its approach to the regulation of gene-edited plants. For example, on January&nbsp;19, 2017, the FDA issued a notice in the Federal Register requesting public comment
on the use of genome editing techniques to produce new plant varieties that are used for human or animal food or foods that are derived from such new plant varieties produced using genome editing. Among other things, the notice asked for data and
information in response to questions about the safety of foods from gene-edited plants, such as whether categories of gene-edited plants present food safety risks different from other plants produced through traditional plant breeding. If the FDA
enacts new regulations or policies with respect to gene-edited plants, such policies could result in additional compliance costs and delay or even prevent the commercialization of any of our product candidates, which could negatively affect our
profitability. Any delay in the regulatory consultation process, or a determination that any potential products we or our collaborators may develop do not meet regulatory requirements by the FDA or other regulators, could cause a delay in, or
prevent, the commercialization of our products, which may lead to reduced acceptance by the public and an increase in competitor products that may directly compete with ours, or could otherwise negatively impact our business, prospects and results
of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On May 4, 2018, the USDA issued a proposed rule implementing the National Bioengineered Food Disclosure Standard, with a proposed
compliance date of January 1, 2020. Under this proposed rule, the label of a bioengineered, or BE, food must include a disclosure that the food is a BE food or contains a BE ingredient, with certain exceptions. This proposed rule defines BE food as
&#147;a food that contains genetic material that was has been modified through in vitro recombinant deoxyribonucleic acid, or DNA, techniques and for which the modification could not otherwise be obtained through conventional breeding or found in
nature,&#148; except in the case of an incidental additive present in food at an insignificant level and that does not have any technical or functional effect in the food. If this proposed rule is passed and products developed by our collaborators
based on our ARCUS technology are required to be labeled &#147;BE,&#148; consumer perception of these products may be adversely affect. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the EU,
genetically modified foods, or GM foods, can only be authorized for sale on the market once they have been subject to rigorous safety assessments. The procedures for evaluation and authorization of GM foods are governed by Regulation (EC) 1829/2003
on GM food and feed and Directive 2001/18/EC on the release of genetically modified organisms, or GMOs, into the environment. If the GMO is not to be used in food or feed, then an application must be made under Directive 2001/18/EC. If the GMO is to
be used in food or feed (but it is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">45 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
not grown in the EU) then a single application for both food and feed purposes under Regulation 1829/2003 should be made. If the GMO is used in feed or food and it is also grown in the EU, an
application for both cultivation and food/feed purposes needs to be carried out under Regulation (EC) 1829/2003. A different EU regulation, Regulation (EC) 1830/2003, regulates the labeling of products that contain GMOs that are placed on the EU
market. Directive 2001/18/EC was amended by Directive (EU) 2015/412 which gives EU Member States more flexibility to allow, restrict or prohibit growing GMOs in their territory, on a range of environmental grounds, even if such crops were previously
authorized at EU level. Under Directive 2015/412, EU Member State restrictions or prohibitions can only cover cultivation, and not the free circulation and import of genetically modified seeds and plant propagation material, and should be in
conformity with the internal market rules of the EU Treaties. In March 2018, the Commission adopted Commission Directive (EU) 2018/350 amending Directive 2001/18/EC as regards the environmental risk assessment of GMOs. This measure aims to bring the
assessment of the environmental risk of GM foods in the EU up to date with developments in scientific knowledge and technical progress. Member States have to transpose the Directive by September&nbsp;29, 2019. Further EU level legislation on GM
foods includes Directive 2009/41/EC on contained use of genetically modified micro-organisms and Regulation (EC) 1946/2003 on transboundary movements of GMOs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We cannot predict whether or when any governmental authority will change its regulations with respect to any potential food or agricultural products that we develop alone or with collaborators. Advocacy groups have
engaged in publicity campaigns and filed lawsuits in various countries against companies and regulatory authorities seeking to halt biotechnology approval activities or influence public opinion against genetically engineered products. In addition,
governmental reaction to negative publicity concerning genetically edited agricultural products could result in greater regulation of genetic research and derivative products or regulatory costs that render our or our collaborators&#146; development
of potential food or agricultural products cost prohibitive. Our collaborators may use or integrate our products or technology into other products in ways that could subject those collaborators or products to additional regulation. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The overall agricultural industry is susceptible to agricultural price changes, and we may be exposed to risks from changes in commodity prices.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Changes in the prices of agricultural products could result in changes in demand for and prices of food and agricultural products that we or our
collaborators may develop. We may be susceptible to these changes as a result of factors beyond our control, such as general economic conditions, seasonal fluctuations, weather conditions, demand, food safety concerns, product recalls and government
regulations, subsidies or market export tariffs. If demand for agricultural products that we or our collaborators may develop is negatively impacted, our potential revenues under collaboration agreements for such products may decline, which could
adversely affect our results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The successful commercialization of any food or agricultural products we develop will depend in part
on our collaborators&#146; ability to produce high-quality plants and seeds cost-effectively on a large scale and to accurately forecast demand for such potential products, and they may be unable to do so. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The production of commercial-scale quantities of food or agricultural products or seeds for them requires the multiplication of the plants or seeds through a
succession of plantings and seed harvests. The cost-effective production of high-quality, high-volume quantities of such products or seeds may depend in part on our collaborators&#146; abilities to scale production processes to produce plants and
seeds in sufficient quantity to meet demand. Our collaborators&#146; existing or future plant and seed production techniques may not enable timely meeting of large-scale production goals cost-effectively for any potential food or agricultural
products that we and our collaborators may develop. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, because of the length of time it takes to produce commercial quantities of marketable
plants and seeds, our collaborators will need to make seed production decisions well in advance of food product sales. The </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">46 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
ability to accurately forecast demand can be adversely affected by a number of factors outside of their control, including changes in market conditions, environmental factors, such as pests and
diseases, and adverse weather conditions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The commercial success of any consumer-centric food or agricultural products that we or our
collaborators may develop is reliant on the needs of food manufacturers and the recognition of shifting consumer preferences. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The commercial
success of any consumer-centric products depends in part on the ability of the food manufacturer to accurately determine the shifting needs and desires of the ultimate consumer. We will not control the marketing, distribution labeling or any other
aspects of the sale and commercialization of the manufacturers&#146; food products. Consumer preferences may be a significant driver in the success of food manufacturers in their efforts to sell food and agricultural products, including products
that we or our collaborators may develop. While current trends indicate that consumer preferences may be moving towards &#147;healthier&#148; options, we cannot predict whether such trends will continue or which types of food products will be
demanded by consumers in the future. Additionally, as health and nutritional science continues to progress, consumer perception of what foods, nutrients and ingredients are considered &#147;healthy&#148; may shift. We and our collaborators may not
be dynamic enough in responding to consumer trends and creating products that will be demanded by consumers in the future. In addition, if consumer demand is lower than our estimates or those of our collaborators, our ability to realize revenues
from potential food or agricultural products may be limited. Failure by our collaborators to successfully recognize consumer trends could lower demand for potential food or agricultural products that we or our collaborators may develop, which could
harm our business, results of operations and financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Some of the potential food products we develop alone or with collaborators may
be distributed into markets or countries in which they have not received regulatory approval, which may result regulatory challenges or lawsuits. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The scale of the agricultural industry may make it difficult to monitor and control the distribution of any potential food products that we develop alone or with
collaborators. As a result, such products may be sold inadvertently within jurisdictions where they are not approved for distribution. Such sales may lead to regulatory challenges or lawsuits against us, which could result in significant expenses
and divert our management&#146;s attention, which could harm our business, results of operations and financial condition. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our
reliance on third parties </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have entered into significant arrangements with collaborators and expect to depend on collaborations with third
parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have sought in the past, and anticipate that we will continue to seek in the future, third-party collaborators for the research, development and commercialization of certain product candidates and the research
and development of certain technologies. For example, we are party to the Servier Agreement, pursuant to which we are focused on research and development of allogeneic chimeric antigen receptor T cell therapies for up to six oncology targets that
utilize or incorporate our genome editing technologies, and we are also party to a collaboration with Gilead focused on research and development of therapeutic product candidates for the treatment of Hepatitis B using ARCUS nucleases. In addition,
our food and agriculture platform is based on a consumer-centric model, whereby our research and development activities and potential revenues are based on the needs and commercial success of our collaborators. For example, we are a party to a
commercial license agreement with Cargill focused on targeting and modifying certain genes related to saturated oil production in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">47 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
canola plants. Our likely collaborators for other product research and development arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical and biotechnology
companies biotechnology and food, beverage, nutrition and agricultural biotechnology companies, and our likely collaborators for other technology research and development arrangements include universities and other research institutions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Working with collaborators poses several significant risks. We will likely have limited control over the amount and timing of resources that our collaborators
dedicate to the product candidates or technologies we may seek to develop with them. A variety of factors may impact resource allocation decisions of collaborators, such as study or trial results, changes in the collaborator&#146;s strategic focus,
turnover in personnel responsible for the development activities, financial capacity or external factors such as a business combination or change in control that diverts resources or creates competing priorities. Collaboration agreements may not
lead to development or commercialization of product candidates or the development of technologies in the most efficient manner or at all. Resource allocation and other developmental decisions made by our collaborators may result in the delay or
termination of research programs, studies or trials, repetition of or initiation of new studies or trials or provision of insufficient funding or resources for the completion of studies or trials or the successful marketing and distribution of any
product candidates that may receive approval. Collaborators could independently develop, or develop with third parties, product candidates or technologies that compete directly or indirectly with our product candidates or technologies if the
collaborators believe that competitive products or technologies are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. Collaborators may not properly obtain, maintain,
enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. Disputes may arise between
us and our collaborators that result in the delay or termination of the research, development or commercialization activities or that result in costly litigation or arbitration that diverts management attention and resources. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in
these arrangements. If our collaborations do not result in the successful development and commercialization of product candidates or technologies, or if one of our collaborators terminates its agreement with us, we may not receive any future funding
or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates or technologies could be delayed, and we may need additional resources to develop such
product candidates or technologies. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and may need to raise additional
capital to pursue further development or commercialization of the applicable product candidates or technologies. These events could delay development programs and negatively impact the perception of our company in business and financial communities.
Failure to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator or reputational damage that could impact our relationships with other collaborators in the relatively
small industry communities in which we operate. Moreover, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus apply to the activities of our collaborators. If our existing
collaboration agreements or any collaborative or strategic relationships we may establish in the future are not effective and successful, it may damage our reputation and business prospects, delay or prevent the development and commercialization of
product candidates and inhibit or preclude our ability to realize any revenues. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">48 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our
research, development and commercialization plans. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our research and product development programs and the potential commercialization of any
product candidates we develop alone or with collaborators will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and potential
commercialization of current and future product candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number
of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our
assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include, among other things and as
applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, by the USDA, the FDA or similar
regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and
technologies and industry and market conditions generally. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Current or future collaborators may also consider alternative product candidates or
technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering
into future agreements on certain terms or for certain development activities with potential collaborators. For example, we have granted exclusive rights or options to Servier and Gilead for certain targets, and during the terms of our respective
collaboration agreements with them we will be restricted from granting rights to other parties to use our ARCUS technology to pursue potential products that address those targets. Similarly, our collaboration agreements have in the past and may in
the future contain <FONT STYLE="white-space:nowrap">non-competition</FONT> provisions that could limit our ability to enter into strategic collaborations with future collaborators. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional
collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional
collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization
timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization
activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We expect to rely
on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements,
or otherwise perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct preclinical
studies and future clinical trials for our product candidates. Nevertheless, we will be responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">49 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
protocol, legal and regulatory requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we intend to design the trials for our product candidates either alone or with collaborators, third parties may conduct all of the trials. As a result,
many important aspects of our research and development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control
over the management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes and difficulties in
coordinating activities. Outside parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with
other entities, some of which may be our competitors. We also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties, which may reduce our trade secret protection and allow
our potential competitors to access and exploit our proprietary technology. For any violations of laws and regulations during the conduct of our preclinical studies and future clinical trials, we could be subject to warning letters or enforcement
action that may include civil penalties up to and including criminal prosecution. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For example, we will remain responsible for ensuring that each of our
clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as Good Clinical Practices, or GCPs, for conducting,
monitoring, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we, our collaborators,
our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and FDA or comparable foreign regulatory authorities may require us to perform additional clinical
trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results of such completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain
timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If our CROs or other third parties do not
successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory
requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we
develop. If we are required to repeat, extend the duration of or increase the size of any trials we conduct, it could significantly delay commercialization and require significantly greater expenditures. As a result of any of these factors, our
financial results and the commercial prospects for any product candidate that we or our collaborators may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We expect to rely on third parties to supply raw materials or manufacture product supplies that are necessary for the conduct of preclinical studies, clinical
trials and manufacturing of our product candidates, and failure by third parties to provide us with sufficient quantities of products, or to do so at acceptable quality levels or prices and on a timely basis, could harm our business.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are dependent on third parties for the supply of various biological materials, such as cells, cytokines and antibodies, and the manufacture
of product supplies, such as media, plasmids, mRNA and AAV viral vectors, that are necessary to produce our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging an
alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers may involve substantial costs and is likely
to result in a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">50 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional
studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive
manner, or at all. If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured product supplies and there can be no assurance that we will be able to establish such
relationships to provide such supplies on commercially reasonable terms or at acceptable quality levels, if at all. If we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays
or incur additional costs in procuring such materials. In addition, manufactured product supplies are subject to stringent manufacturing processes and rigorous testing. Delays in the completion and validation of facilities and manufacturing
processes of these materials could adversely affect the ability to complete studies or trials and commercialize any product candidates that may receive approval. Furthermore, if our suppliers or manufacturers encounter challenges relating to
employee turnover, the supply and manufacturing of our materials could be delayed or adversely affected as such parties seek to hire and train new employees. These factors could cause the delay of studies or trials, regulatory submissions, required
approvals or commercialization of product candidates that we or our collaborators may develop, cause us to incur higher costs and prevent us from commercializing products successfully. Furthermore, if our suppliers or manufacturers fail to meet
contractual requirements, and we are unable to secure one or more replacements capable of production at a substantially equivalent cost, our or our collaborators&#146; studies or trials may be delayed and we could lose potential revenue. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may rely on third parties for at least a portion of the manufacturing process of product candidates, and failure by those parties to adequately perform
their obligations could harm our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not currently own any facility that may be used as our clinical-scale manufacturing and
processing facility and expect that we may rely on outside vendors for at least a portion of the manufacturing process of product candidates that we or our collaborators may develop. The facilities used by our contract manufacturers to manufacture
product candidates must be approved by the FDA or other foreign regulatory agencies pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. To the extent that we or our
collaborators engage third parties for manufacturing services, we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing providers for compliance with cGMP requirements for manufacture of the
product candidates. We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that
even minor changes in the process will result in products that are safe and effective. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or
other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality
control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any of our or our collaborators&#146; potential products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">51 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to intellectual property </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our ability to compete may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantage.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our commercial success depends upon obtaining and maintaining proprietary rights to our intellectual property estate, including rights relating
to ARCUS and to our product candidates, as well as successfully defending these rights against third-party challenges and successfully enforcing these rights to prevent third-party infringement. We will only be able to protect ARCUS and product
candidates from unauthorized use by third parties to the extent that valid and enforceable patents or effectively protected trade secrets cover them. Our ability to obtain and maintain patent protection for ARCUS and our product candidates is
uncertain due to a number of factors, including that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not have been the first to invent the technology covered by our pending patent applications or issued patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not be the first to file patent applications covering product candidates, including their compositions or methods of use, as patent applications in the
United States and most other countries are confidential for a period of time after filing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our compositions and methods may not be patentable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any or all of our pending patent applications may not result in issued patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">others may independently develop identical, similar or alternative technologies, products or compositions or methods of use thereof;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">others may design around our patent claims to produce competitive technologies or products that fall outside of the scope of our patents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages or may be successfully challenged
by third parties; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">others may identify prior art or other bases upon which to challenge and ultimately invalidate our patents or otherwise render them unenforceable.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if we have or obtain patents covering ARCUS or any product candidates or compositions, we and our collaborators may still be
barred from making, using and selling such product candidates or technologies because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar
or identical to ours, which could materially affect our ability to successfully develop any product candidates or to successfully commercialize any approved products alone or with collaborators. In addition, because patent applications can take many
years to issue, there may be currently pending applications unknown to us that may later result in issued patents that we or our collaborators may infringe. These patent applications may have priority over patent applications filed by us.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">52 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our
owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held
unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Furthermore,
we cannot guarantee that any patents will be issued from any pending or future owned or licensed patent applications. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide us with meaningful
protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. In addition, third parties may be able to develop products that are similar to, or better than, ours in a way that is not covered by the
claims of our patents, or may have blocking patents that could prevent us from marketing our products or practicing our own patented technology. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is
generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Without patent protection for current or future product candidates, we may be open to competition
from generic versions of such potential products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates
are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to those we or our collaborators may develop. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Obtaining and maintaining a patent portfolio entails significant expense, including periodic maintenance fees, renewal fees, annuity fees and various other
governmental fees on patents and patent applications. These expenditures can be at numerous stages of prosecuting patent applications and over the lifetime of maintaining and enforcing issued patents. We may or may not choose to pursue or maintain
protection for particular intellectual property in our portfolio. If we choose to forgo patent protection or to allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. Furthermore, we
employ reputable law firms and other professionals to help us comply with the various procedural, documentary, fee payment and other similar provisions we are subject to and, in many cases, an inadvertent lapse can be cured by payment of a late fee
or by other means in accordance with the applicable rules. There are situations, however, in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Legal action that may be required to enforce our patent rights can be expensive and may involve the diversion of significant management time. There can be no
assurance that we will have sufficient financial or other resources to file and pursue infringement claims, which typically last for years before they are concluded. In addition, these legal actions could be unsuccessful and result in the
invalidation of our patents, a finding that they are unenforceable or a requirement that we enter into a licensing agreement with or pay monies to a third party for use of technology covered by our patents. We may or may not choose to pursue
litigation or other actions against those that have infringed on our patents, or have used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to successfully protect or enforce
our intellectual property rights, our competitive position could suffer, which could harm our results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we fail to comply with our
obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our
business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into
additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">53 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
obligations on us. We may need to outsource and rely on&nbsp;third parties&nbsp;for many aspects of the development, sales and marketing of any products covered under our&nbsp;current and future
license&nbsp;agreements. Delay or failure by these&nbsp;third parties&nbsp;could adversely affect the continuation of our&nbsp;license&nbsp;agreements with our licensors. If we fail to comply with any of our obligations under these agreements, or we
are subject to a bankruptcy, our licensors may have the right to terminate the license, in which event we would not be able to market any products covered by the license. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, disputes may arise regarding the payment of the royalties due to licensors in connection with our exploitation of the rights we license from them. Licensors may contest the basis of royalties we
retained and claim that we are obligated to make payments under a broader basis. In addition to the costs of any litigation we may face as a result, any legal action against us could increase our payment obligations under the respective agreement
and require us to pay interest and potentially damages to such licensors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In some cases, patent prosecution of our licensed technology is controlled
solely by the licensor. If such licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we license from such licensor, we could lose our rights to such intellectual property or the exclusivity of
such rights, and our competitors could market competing products using such intellectual property. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we
or our collaborators may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. In other cases, we control the prosecution of patents resulting from licensed technology. In the event we
breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For example, our license
agreement with Duke University, or Duke, which we refer to as the Duke License, imposes various payment, royalty and other obligations on us in order to maintain the license.<B><I> </I></B>For example, if we fail to make royalty payments or
milestone payments required under the Duke License, Duke may terminate the agreement. If we or our affiliates obtain a license from a third party to practice the Duke technology, we must use commercially reasonable efforts to secure a covenant not
to sue Duke, or any of its faculty, students, employees or agents, for any research and development efforts conducted at Duke that resulted in the creation of any of its inventions or intellectual property rights arising therefrom. Additionally,
because development of the Duke technology was funded in part by the U.S. government, it is subject to certain government rights and obligations, including the requirement that any products sold in the United States based upon such technology be
substantially manufactured in the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, our cross-license agreement with Cellectis, or the Cellectis License, imposes various
obligations on us in order to maintain the license.<B><I> </I></B>In particular, if we participate in or provide assistance to a third party challenging the validity, enforceability and/or patentability of any claim of any patent licensed to us by
Cellectis under this agreement, Cellectis may terminate the agreement. The Cellectis License does not provide exclusive rights to use the licensed intellectual property and technology or rights in all relevant fields in which we may wish to develop
or commercialize our technology and products in the future. As a result, we are not able to prevent competitors from developing and commercializing competitive products and technology that may use this technology. Additionally, we do not have the
right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from Cellectis. Therefore, we cannot be certain that these patents and patent
applications will be prepared, filed, prosecuted, maintained and defended in a manner consistent with the best interests of our business. If Cellectis or other licensors fail to prosecute, maintain, enforce and defend the patents subject to such
licenses, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are the subject of such licensed rights could be
adversely affected. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">54 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we fail to comply with our obligations under the Duke License or the Cellectis License, or arrangements with
any other licensors, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product candidate that is covered by these agreements, which could materially
adversely affect the value of any such product candidate. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms,
or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Disputes may arise
regarding intellectual property subject to a license agreement, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope of rights granted under the license agreement and other interpretation-related issues; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the amounts of royalties, milestones or other payments due to our licensors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sublicensing of patent and other rights under our collaborative development relationships; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property by our
licensors and us and our collaborators; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the priority of invention of patented technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Such disputes may be costly to resolve and may divert management&#146;s attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities. If disputes over
intellectual property that we have licensed from third parties prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we or our collaborators may be unable to successfully develop and commercialize the affected
product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Some of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property has been discovered through government
funded programs and thus may be subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such
regulations may limit our exclusive rights and our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain intellectual property rights that have been <FONT STYLE="white-space:nowrap">in-licensed</FONT> pursuant to the Duke License have been generated through the
use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole
Act of 1980, or the Bayh-Dole Act. These U.S. government rights include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any
governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of
these inventions to a third party if it determines that (1)&nbsp;adequate steps have not been taken to commercialize the invention, (2)&nbsp;government action is necessary to meet public health or safety needs or (3)&nbsp;government action is
necessary to meet requirements for public use under federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). The U.S. government also has the right to take title to these inventions if the
licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to
certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these
inventions be manufactured substantially in the United States, and the Duke License requires that we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">55 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
comply with this requirement. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that
reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture the products substantially in the United States or that under the circumstances domestic manufacture is
not commercially feasible. This preference for U.S. industry may limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by such intellectual property. To the extent any of our
owned or licensed future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates, thereby potentially
extending the term of marketing exclusivity for such product candidates, our business may be harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, a patent that covers
an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA.
Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration
Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review
process. In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply
prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or
if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The
resulting reduction of years of revenue from applicable products could be substantial. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Patents and patent applications involve highly complex
legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The patent positions of
biopharmaceutical and biotechnology companies and other actors in our fields of business can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in
some patents covering biopharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards
of the United States Patent and Trademark Office, or the USPTO, and its foreign counterparts are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if
issued, may be challenged, invalidated or circumvented. U.S.&nbsp;patents and patent applications may also be subject to interference or derivation proceedings, and U.S.&nbsp;patents may be subject to reexamination proceedings, post-grant review
and/or<I>&nbsp;inter partes</I>&nbsp;review in the USPTO. International patents may also be subject to opposition or comparable proceedings in the corresponding international patent office, which could result in either loss of the patent or denial
of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, derivation, reexamination, post-grant review, <I>inter partes</I> review and opposition
proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">56 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, even if not challenged, our patents and patent applications may not adequately protect our
technology and any product candidates or products that we develop alone or with collaborators or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patent
applications we hold with respect to product candidates or potential products is threatened, it could dissuade companies from collaborating with us to develop, and could threaten our or their ability to successfully commercialize, such product
candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO in order to determine who was the
first to invent any of the subject matter covered by such patent claims. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, changes in, or different interpretations of, patent laws in the
United States and other countries may permit others to use our discoveries or to develop and commercialize our technology and product candidates or products without providing any compensation to us, or may limit the scope of patent protection that
we are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S.&nbsp;laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the patent applications we hold or have <FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect to our current and future research and
development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our technology or any products and product candidates that we or our
collaborators may develop, it could dissuade companies from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our or our collaborators&#146; ability to commercialize
future product candidates. Any such outcome could have a material adverse effect on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Third parties may assert claims against us
alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the
development and commercialization of product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our commercial success depends in part upon our ability to develop, manufacture, market and sell product candidates without alleged or actual infringement,
misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical, biotechnology and
agricultural biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding international patent offices. The various markets in which we plan
to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual&nbsp;property-dependent&nbsp;industries, including the biotechnology, agricultural
biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous United States, EU and other internationally issued patents and pending patent applications,
which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates, and as the biotechnology, agricultural biotechnology and pharmaceutical industries expand and more patents are issued, the
risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties. For example, we are aware of certain patents held by third parties relating to the modification of T cells,
including the production of CAR T cells. Although conducting clinical trials and other development activities with respect to our CAR T product candidates is not considered an act of infringement in the United States, if and when any of our CAR T
product candidates may be approved by the FDA, those third parties may seek to enforce their patents by filing a patent infringement lawsuit against us. As a result of any patent infringement claims, or in
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">57 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
order to avoid any potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require payment of substantial royalties or fees, or
require us to grant a cross-license under our intellectual property rights, similar to the cross license we granted Cellectis as part of our patent litigation settlement. These licenses may not be available on reasonable terms or at all. Even if a
license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we or our collaborators
could be prevented from commercializing one or more product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. We or our collaborators might also
be forced to redesign or modify our technology or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be
impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, if a patent infringement suit is brought against us, our collaborators or our third-party service providers, our development, manufacturing or sales
activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. In addition, defending such claims has in the past and may in the future cause us to incur substantial expenses and, if successful,
could cause us to pay substantial damages if we are found to be infringing a third party&#146;s patent rights. These damages potentially include increased damages and attorneys&#146; fees if we are found to have infringed such rights willfully. Some
claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies
that focus solely on extracting royalties and settlements by enforcing patent rights may target us. In addition, if the breadth or strength of protection provided by the patents and patent applications we own or in-license is threatened, it could
dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have been and may in the
future be subject to third-party claims and similar adversarial proceedings or litigation in other jurisdictions regarding our infringement of the patent rights of third parties. Even if such claims are without merit, a court of competent
jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our or our collaborators&#146; ability to further develop or commercialize the applicable product
candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover
aspects of our technologies, compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those technologies, compositions, formulations, methods of treatment, prevention
or use or other technologies, effectively blocking our or our collaborators&#146; ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we or
our collaborators obtain a license. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more
effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays
or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability
to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we or
one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering our technology or a product candidate, the defendant could counterclaim that our patent is invalid or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">58 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
unenforceable. In patent litigation in the United States and Europe, defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an
alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness <FONT STYLE="white-space:nowrap">or&nbsp;non-enablement.</FONT> Third parties might allege unenforceability of our patents because during
prosecution of the patent an individual connected with such prosecution withheld relevant information, or made a misleading statement. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is
unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution, but that an adverse third party may identify and
submit in support of such assertions of invalidity. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or product
candidates. Our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights. Even if resolved in our
favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, because of
the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such
litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Developments in patent law could have a negative impact on our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">From time to time, the United States Supreme Court, or the Supreme Court, other federal courts, the United&nbsp;States Congress, or Congress, the USPTO and similar international authorities may change the standards
of patentability, and any such changes could have a negative impact on our business. For example, the America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change
introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a
patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours
even if we made the invention before it was made by the third party. Circumstances could prevent us from promptly filing patent applications on our inventions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The AIA limited where a patentee may file a patent infringement suit and provided opportunities for third parties to challenge any issued patent in the USPTO. Those provisions apply to all of our U.S. patents,
regardless of when issued. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO
proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures
to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. These provisions could increase the uncertainties and costs surrounding the prosecution of our or
our licensors&#146; patent applications and the enforcement or defense of our or our licensors&#146; issued patents. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">59 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, the Supreme Court has ruled on several patent cases in recent years either narrowing the scope of
patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing
uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of our patents and patent applications. Depending on decisions by Congress, the federal courts and
the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European
patent system is relatively stringent in the type of amendments that are allowed during prosecution, but the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit
our ability to obtain new patents in the future that may be important for our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we were unable to protect the confidentiality of our
trade secrets and enforce our intellectual property assignment agreements, our business and competitive position would be harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to
patent protection, because we operate in the highly technical field of development of product candidates and products using genome editing, we rely significantly on trade secret protection in order to protect our proprietary technology and
processes. Trade secrets are difficult to protect. Our policy is to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other
advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#146;s
relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, we may be unsuccessful in executing such an agreement with each
party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may
bring against us, to determine the ownership of what we regard as our intellectual property. In addition, these agreements may be held unenforceable and may not effectively assign intellectual property rights to us. If our trade secrets and other
unpatented or unregistered proprietary information are disclosed, we are likely to lose such trade secret protection. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, certain provisions in
our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology,
or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, agreements with third parties typically restrict the ability of such third parties to publish data potentially relating to our trade secrets. Our
academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified period of time in order to secure our intellectual property rights arising from the arrangement. In
other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and product development activities that may require us to share trade secrets under
the terms of our research and development collaborations or similar agreements. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such
measures may not provide adequate protection for our proprietary information. For example, our security measures may not prevent an employee or consultant with authorized access from misappropriating our trade secrets and providing them to a
competitor, and the recourse we have available against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult,
expensive and time </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">60 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Furthermore, our proprietary information may be
independently developed by others in a manner that could prevent legal recourse by us. Competitors could purchase any products we may develop and commercialize and attempt to reverse engineer and replicate some or all of the competitive advantages
we derive from our development efforts, willfully infringe our intellectual property rights or design around our protected technology. In addition, our key employees, consultants, suppliers or other individuals with access to our proprietary
technology and <FONT STYLE="white-space:nowrap">know-how</FONT> may incorporate that technology and <FONT STYLE="white-space:nowrap">know-how</FONT> into projects and inventions developed independently or with third parties. As a result, disputes
may arise regarding the ownership of the proprietary rights to such technology or <FONT STYLE="white-space:nowrap">know-how,</FONT> and any such dispute may not be resolved in our favor. If any of our confidential or proprietary information,
including our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed and such disclosure or misappropriation could have a material
adverse effect on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may
not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Filing, prosecuting and
defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in
the United States, assuming that rights are obtained in the United States. <FONT STYLE="white-space:nowrap">In-licensing</FONT> patents covering product candidates in all countries throughout the world may similarly be prohibitively expensive, if
such opportunities are available at all. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third
parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We generally apply for patents in those countries where we intend to make, have made, use, offer for sale or sell products and where we assess the risk of
infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. If
we fail to timely file a patent application in any such country or major market, we may be precluded from doing so at a later date. Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop
their own products and may export otherwise infringing products to territories where we have patent protection, but where our ability to enforce our patent rights is not as strong as in the United States. These products may compete with any products
that we or our collaborators may develop, and our patents or other intellectual property rights may not be effective or sufficient to prevent such competition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The laws of some other countries do not protect intellectual property rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment
of the human body more than U.S. law does. Patent protection must ultimately be sought on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process
with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly
developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biopharmaceuticals or biotechnologies. As a result, many companies have encountered significant difficulties in
protecting and defending intellectual property rights in certain jurisdictions outside the United States. Such issues may make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other
intellectual property rights. For example, many other countries, including countries in the EU, have </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">61 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including
government agencies or government contractors. In these countries, patents may provide limited or no benefit. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to
grant a license to a third party, which could materially diminish the value of those patents and could limit our potential revenue opportunities. Accordingly, our and our licensors&#146; efforts to enforce intellectual property rights around the
world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, proceedings to
enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, subject our patents to the risk of being invalidated or interpreted narrowly, subject our
patent applications to the risk of not issuing or provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful,
while the damages and other remedies we may be ordered to pay such third parties may be significant. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be successful in obtaining or maintaining necessary rights to product
components and processes for our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have
rights, through licenses from third parties and under patents that we own, to the intellectual property to develop the product candidates we are currently developing alone or with collaborators. Because our programs may involve additional product
candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. In
addition, product candidates may require specific formulations to work effectively and efficiently, and these rights may be held by others. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods
of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies, or
companies that have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive to develop or commercialize product candidates. These
established companies may have a competitive advantage over us due to their size and greater cash resources and clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately
acquire the rights to the intellectual property surrounding product candidates that we may seek to acquire. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For example, we sometimes collaborate with
academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in
technology resulting from the strategic alliance. Regardless of such right of first negotiation, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us, and the institution may license such
intellectual property rights to third parties, potentially blocking our ability to pursue our development and commercialization plans. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition,
companies that perceive us to be a competitor may be unwilling to assign or license to us intellectual property rights that we require in order to successfully develop and commercialize potential products. We also may be unable to obtain such a
license or assignment on terms that would allow us to make an appropriate return on our investment. In either event, our business and prospects for growth could suffer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">62 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If our trademarks and trade names are not adequately
protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We may not be able to protect our rights to our trademarks and trade names, which we need to build name recognition
among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In
addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are
unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce
or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights and other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our
financial condition or results of operations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our organization, structure and operations </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of September&nbsp;30, 2018, we had 115 employees. We will need to significantly expand our organization, and our future financial performance, ability to develop
and commercialize product candidates alone or with collaborators and ability to compete effectively will depend in part on our ability to effectively manage any future growth. We may have difficulty identifying, hiring and integrating new personnel.
Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history than we do. If we are unable to continue to attract and
retain high-quality personnel and consultants, the rate and success at which we can identify and develop product candidates, enter into collaborative arrangements and otherwise operate our business will be limited. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate
additional employees, consultants and contractors. Management may need to divert a disproportionate amount of its attention away from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and
devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively
manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development
resources from other projects, such as the development of product candidates. If we are not able to effectively manage the expansion of our operations, it may result in weaknesses in our infrastructure, increase our expenses more than expected, give
rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity. Our future financial performance, ability to successfully commercialize any of our product candidates and our ability to compete effectively
will depend, in part, on our ability to effectively manage any future growth. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may engage in transactions that could disrupt our business, cause
dilution to our stockholders or reduce our financial resources. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the future, we may enter into transactions to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> rights to product candidates, products or technologies or to acquire other businesses. If we do identify suitable candidates, we may not be able to enter
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">63 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
into such transactions on favorable terms, or at all. Any such acquisitions or <FONT STYLE="white-space:nowrap">in-licenses</FONT> may not strengthen our competitive position, and these
transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or <FONT STYLE="white-space:nowrap">in-license,</FONT> which may negatively impact our financial condition and restrict
our operations, or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities
of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our
existing business in an effective, timely and nondisruptive manner. Such transactions may also divert management attention from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, increase our
expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or <FONT STYLE="white-space:nowrap">in-licenses</FONT> or the effect that they might have on our operating
results. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our future success depends on our ability to retain our Chief Executive Officer, Chief Scientific Officer, Chief Technology Officer and
other key executives and to attract, retain and motivate qualified personnel. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are highly dependent on the research and development
experience, technical skills, leadership and continued service of certain members of our management and scientific teams, including Matthew Kane, our Chief Executive Officer, Derek Jantz, our Chief Scientific Officer, and Jeff Smith, our Chief
Technology Officer. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time upon thirty days&#146; written notice. We maintain a
$1&nbsp;million &#147;key man&#148; life insurance policy for our benefit on each of the lives of Drs. Jantz and Smith, but not on the lives of any of our other team members. The loss of the services of any of these persons could impede the
achievement of our research, development and commercialization objectives. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Recruiting and retaining qualified scientific, clinical, manufacturing and,
if we retain commercialization responsibility for any product candidate we develop alone or with collaborators, sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on
acceptable terms or at all given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research
institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by
employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The inability to recruit, integrate, motivate and retain additional skilled and qualified personnel,
or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance
initiatives and corporate governance practices, including establishing and maintaining proper and effective internal control over financial reporting. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the Securities Exchange Act of 1934, as amended, or the Exchange
Act, including the reporting requirements thereunder, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, or Nasdaq, and other applicable securities
rules and regulations, including requirements related to the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount
of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, make </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">64 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
some activities more difficult, time consuming or costly, and increase demand on our systems and resources. When we no longer qualify as an emerging growth company, legal, accounting and other
expenses are expected to further increase. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will be required to
furnish a report by our management on our internal control over financial reporting beginning with our second annual report following the completion of our initial public offering. However, while we remain an emerging growth company, we will not be
required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 of the Sarbanes-Oxley Act within the prescribed period,
we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. We may need to hire more employees in the future or engage outside consultants to comply with these
requirements, which will further increase our costs and expenses. If we fail to implement the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in the required timeframe, we may be subject to sanctions or investigations by regulatory
authorities, including the SEC and Nasdaq. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective, our investors may lose confidence in the accuracy and completeness of our financial reports, the
market price of our common stock could decline, and we could be subject to sanctions or investigations by regulatory authorities. Failure to implement or maintain an effective internal control system could also restrict our future access to the
capital markets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our business and operations would suffer in the event of system failures or security breaches. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Despite the implementation of security measures, our computer systems, as well as those of third parties with which we have relationships, are vulnerable to damage
from computer viruses, unauthorized access, natural and manmade disasters, terrorism, war and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure, accident or security breach to date,
if such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of trial data from completed, ongoing or planned
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to data or
applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other
data relating to individuals, and U.S. federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data. In the ordinary course of our business, we and third parties
with which we have relationships will continue to collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial
subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators&#146; security measures, our information technology and
infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance or other disruptions. A number of proposed and enacted federal, state and international laws and
regulations obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors
or other organizations with which we have formed strategic relationships. Although, to our knowledge, neither we nor any such third parties have experienced any material security breach, and even though we may have contractual protections with such
third parties, any such breach could compromise our or their networks and the information stored there could be accessed, publicly disclosed, lost </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">65 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or stolen. Any such access, disclosure, notifications, <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to such a security breach or other loss of information could result in
legal claims or proceedings, liability under laws that protect the privacy of personal information and significant costs, including regulatory penalties, fines and legal expenses, and such an event could disrupt our operations, cause us to incur
remediation costs, damage our reputation and cause a loss of confidence in us and our or such third parties&#146; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We or third parties with whom we have relationships may be adversely affected by natural or manmade disasters, and our business continuity and
disaster recovery plans may not adequately protect us from a serious disaster. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Natural or manmade disasters could severely disrupt our
operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our
facilities, that damaged our infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time, and our research and development activities
could be setback or delayed. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our
disaster recovery and business continuity plans, which could have a material adverse effect on our business, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in
us and our or third parties&#146; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not carry insurance for all categories of risk that our business may encounter. If we obtain marketing approval for any product candidates that we or our
collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. We do not carry specific biological
or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the
event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and clinical trials or regulatory approvals for any of our product candidates could be suspended. We also expect
that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or
similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors, our board committees or as our executive officers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insurance coverage is becoming increasingly expensive, and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient
amounts to protect us against losses. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any
expenses or losses we may suffer. A successful liability claim or series of claims brought against us could require us to pay substantial amounts and cause our share price to decline and, if judgments exceed our insurance coverage, could adversely
affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">66 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial
condition and stock price. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Global credit and financial markets have experienced extreme volatility and disruptions in the past several years,
including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, and similar deterioration in the credit and
financial markets and confidence in economic conditions may occur in the future. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or unpredictable and unstable market conditions. If
the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable
terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service
providers, manufacturers or others with whom we have strategic relationships may not survive any difficult economic times, which could directly affect our ability to attain our operating goals. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of September&nbsp;30, 2018, we had cash and cash equivalents of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. While we are
not aware of any downgrades, material losses or other significant deterioration in the fair value of our cash and cash equivalents since September&nbsp;30, 2018, deterioration of the global credit and financial markets could negatively impact our
current portfolio of cash equivalents or our ability to meet our financing objectives. Furthermore, our stock price may decline due in part to the volatility of the stock market and any general economic downturn. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we or any of our contract manufacturers or other suppliers fail to comply with environmental, health and safety laws and regulations, we could become
subject to fines or penalties or incur significant costs. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We and any of our contract manufacturers and suppliers are subject to numerous
federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated
materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and
radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event
of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs
relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we
cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general
liability insurance policies (under which we currently have an aggregate of approximately $10&nbsp;million in coverage) specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.
Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals for any product candidate we develop alone or
with collaborators could be suspended, which could have a material adverse effect on our business and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">67 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we may incur substantial costs in order to comply with current or future environmental, health and
safety laws, regulations and permitting requirements, and any third-party contract manufacturers and suppliers we engage will also be subject to such current and future regulations and requirements. These current or future laws, regulations and
permitting requirements may impair our research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements, either by us or by any third-party contract manufacturers and suppliers we engage, also
may result in substantial fines, penalties or other sanctions or business disruption. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our business operations, including our current and future
relationships with third parties, will expose us to penalties for potential misconduct or improper activity, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Complex laws constrain our business and the financial arrangements and relationships through which we conduct our operations, including how we may research, market,
sell and distribute product candidates alone or with collaborators. We are exposed to the risk of fraud or other misconduct by our employees, consultants and collaborators and, if we or our collaborators commence clinical trials and proceed to
commercialization, our principal investigators and commercial partners, as well as healthcare professionals, third-party payors, patient organizations and customers. For example, misconduct by these parties could include intentional failures to
comply with FDA regulations or the regulations applicable in the EU and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and
regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive
laws and regulations intended to prevent fraud, misconduct, kickbacks, false and/or misleading statements, corruption of government officials, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of
pricing, discounting, marketing, promotion, sales commission and customer incentive programs and other business arrangements. Such misconduct also could involve the improper use or misrepresentation of information obtained in the course of clinical
trials, creating fraudulent data in preclinical studies or clinical trials, illegal misappropriation of study materials or other property, or improper interactions with the FDA or other regulatory authorities, which could result in regulatory
sanctions and cause serious harm to our or our collaborators&#146; reputations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Ensuring that our internal operations and current and future business
arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none
occurred. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and
administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, additional reporting requirements and oversight if subject to a
corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits
and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to similar penalties, such
as criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly and
time-consuming and may require significant personnel resources. Therefore, even if </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">68 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
we are successful in defending against any such actions that may be brought against us, our business may be impaired. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We intend to adopt, prior to the completion of this offering, a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we
take to detect and prevent such activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with applicable laws
or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could result in the imposition of any of the penalties discussed above and have a significant impact on our business and financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>The recently passed Tax Cuts and Jobs Act of 2017 could adversely affect our business and financial condition. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On December&nbsp;22, 2017, President Trump signed into law new legislation, known as the Tax Cuts and Job Act of 2017, or the Tax Act, that significantly revises the Internal Revenue Code of 1986, as amended, or
the Code. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense
to 30% of adjusted taxable income (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one-time taxation of offshore
earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation
expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions).
Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act is uncertain, and our business and financial condition could be adversely affected. In addition, it is unknown if and to what extent various states
will conform to the Tax Act. The impact of the Tax Act on holders of our common stock is likewise uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the
potential tax consequences of investing in or holding our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are subject to complex tax rules relating to our business, and any
audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to income and <FONT STYLE="white-space:nowrap">non-income</FONT> taxes in the United States. Income tax accounting often involves complex issues, and
judgment is required in determining our provision for income taxes and other tax liabilities. We recently formed a subsidiary in Australia and may operate in other <FONT STYLE="white-space:nowrap">non-US</FONT> jurisdictions in the future. We could
become subject to income and <FONT STYLE="white-space:nowrap">non-income</FONT> taxes in <FONT STYLE="white-space:nowrap">non-US</FONT> jurisdictions as well. In addition, many jurisdictions have detailed transfer pricing rules, which require that
all transactions with <FONT STYLE="white-space:nowrap">non-resident</FONT> related parties be priced using arm&#146;s length pricing principles within the meaning of such rules. The application of withholding tax, goods and services tax, sales taxes
and other <FONT STYLE="white-space:nowrap">non-income</FONT> taxes is not always clear and we may be subject to tax audits relating to such withholding or <FONT STYLE="white-space:nowrap">non-income</FONT> taxes. We believe that our tax positions
are reasonable and our tax reserves are adequate to cover any potential liability. We are currently not subject to any tax audits. However, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal
Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor,
which may have a significant impact on our results and operations and future cash flow. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">69 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be able to utilize all, or any, of our net operating loss carryforwards. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have incurred substantial losses during our history, do not expect to become profitable in the near future, and we may never achieve profitability. As of
December&nbsp;31, 2017, we had U.S. federal and state net operating loss carryforwards of approximately $20.1&nbsp;million and $19.4&nbsp;million, respectively. Our federal net operating loss carryforwards begin to expire in 2030, and the state net
operating loss carryforwards begin to expire in 2025. In addition, we have U.S. federal and state research and development tax credits of $1.7&nbsp;million and an amount less than $0.1&nbsp;million as of December&nbsp;31, 2017, respectively,
available to offset future U.S. federal and state income taxes, which begin to expire in 2027 and 2030, respectively. Unused losses generated in taxable years ending after December&nbsp;31, 2017 will not expire and may be carried forward
indefinitely, but will be deductible only to the extent of 80% of current year taxable income (computed without regard to the deduction for the net operating losses) in any given year. It is uncertain if and to what extent various states will
conform to the newly enacted federal tax law. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2017, we have a valuation allowance for the full amount of our net deferred tax
assets as the realization of the net deferred tax assets is not determined to be more likely than not. In addition, Sections&nbsp;382 and 383 of the Code limit a corporation&#146;s ability to utilize its net operating loss carryforwards and certain
other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period. State net operating loss carryforwards
(and certain other tax attributes) may be similarly limited. A Section&nbsp;382 ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change, and any increased
liabilities could adversely affect the corporation&#146;s business, results of operations, financial condition and cash flow. We have not yet determined if any prior change in the ownership of our equity or any change in such ownership in connection
with this offering, would trigger a Section 382 ownership change. It is possible that such a Section 382 ownership change has already occurred in prior periods. Furthermore, additional ownership changes may occur in the future as a result of events
over which we will have little or no control, including purchases and sales of our equity by our 5% stockholders, the emergence of new 5% stockholders, additional equity offerings or redemptions of our stock or certain changes in the ownership of
any of our 5% stockholders. As a result, <FONT STYLE="white-space:nowrap">our&nbsp;pre-2018</FONT> net operating loss&nbsp;carryforwards (and research tax credits) may expire prior to being used, and our net operating loss carryforwards and tax
credits generated in 2018 and thereafter will be subject to a percentage limitation, upon an ownership change. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain
profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Risks related to this offering and owning our common stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>An active trading market for our common stock
may not develop, and you may not be able to sell your shares at or above the initial public offering price. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to this offering, there has
been no public market for shares of our common stock. Although we anticipate that our common stock will be approved for listing on Nasdaq, an active trading market for our common stock may never develop or be sustained following this offering. The
lack of an active trading market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable, reduce the market value of your shares, impair our ability to raise capital and impair our
ability to attract, motivate and retain our employees through equity incentive awards. The initial public offering price of our common stock will be determined through negotiations between us and the underwriters, and it may not be indicative of the
market price of our common stock in an open market after this offering. Consequently, you may not be able to sell your common stock at or above the initial public offering price and may lose a portion or all of your investment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">70 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We expect that our common stock price will fluctuate significantly, which could result in substantial
losses for purchasers of shares in this offering. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our stock price is likely to be volatile. You should invest in our common stock only if you
can withstand a significant loss and wide fluctuations in the market value of your investment. The market price for our common stock may be influenced by many factors, including those discussed in this &#147;Risk factors&#148; section and the
following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">inconsistent trading volume levels of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">announcements or expectations regarding debt or equity financing efforts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">sales of common stock by us, our insiders or our other stockholders; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">actual or anticipated fluctuations in our financial condition and operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">results from or delays in our studies or trials, or those of our collaborators, competitors or companies perceived to be similar to us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delay, failure or discontinuation of any of our product development and research programs, or those of our collaborators, competitors or companies perceived to
be similar to us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">announcements about new research programs or product candidates from us or our collaborators, our competitors or companies perceived to be similar to us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">announcements by us, our collaborators, our competitors or companies perceived to be similar to us relating to significant acquisitions, strategic partnerships
or alliances, joint ventures, collaborations or capital commitments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">actual or anticipated changes in our growth rate relative to our competitors or companies perceived to be similar to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fluctuations in the valuation of our collaborators, our competitors or companies perceived to be comparable to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a lack of, limited or withdrawal of coverage by security analysts, or positive or negative recommendations by them; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">actual or expected changes in estimates as to financial results, development timelines or recommendations by securities analysts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">publication of research reports about us, genome editing or the biopharmaceutical and agricultural biotechnology industries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments or changing views regarding the use of genomic products, including those that involve genome editing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to effectively manage our growth; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the recruitment or departure of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the results of any efforts by us to identify, develop, acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;additional</FONT> product candidates,
products or technologies; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">71 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unanticipated serious safety concerns related to the use of any of our product candidates, or those of our competitors or companies perceived to be similar to
us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the termination of a collaboration agreement, licensing agreement or other strategic arrangement or the inability to establish additional strategic arrangements
on favorable terms, or at all; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory actions with respect to any of our product candidates, or those of our competitors or companies perceived to be similar to us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory or legal developments in the United States and other countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in physician, hospital, healthcare provider or agricultural practices that may make our or our collaborators&#146; products less useful;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in the structure of healthcare payment systems; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">significant lawsuits, such as products liability, patent or stockholder litigation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">general economic, industry and market conditions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance. These factors may have a material
adverse effect on the market price and liquidity of our common stock, which may limit or prevent you from readily selling your shares of common stock and may affect our ability to obtain financing or enter into desired strategic relationships.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We could be subject to securities class action litigation. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical
companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The initial public offering price of our common stock will be substantially higher than the net tangible book value per share of our common stock. Therefore, if you
purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. Based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, representing the difference between our pro forma as adjusted net tangible book value per share, after giving effect to this offering, and the assumed initial public offering price. As of September&nbsp;30, 2018, there
were&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares subject to outstanding options with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. To the extent these
outstanding options are ultimately exercised, you will incur further dilution. In addition, purchasers of common stock in this offering will have contributed approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate price paid by all purchasers
of our stock but will own only approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our common stock outstanding after this offering. For a further description of the dilution that you will experience immediately after this offering, see
&#147;Dilution.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">72 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be sold
into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the
market price of our common stock. After this offering and after giving effect to the conversion of all outstanding shares of our convertible preferred stock
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock upon the closing of this offering, we will
have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if the underwriters exercise their option to
purchase additional shares in full, in each case based on the 81,390,126 shares of our common stock outstanding as of September&nbsp;30, 2018, assuming the conversion of all outstanding shares of our preferred stock. Of these shares,
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase
additional shares in full, we are selling in this offering may be resold in the public market immediately, unless purchased by our affiliates. The remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
are currently restricted under securities laws or as a result of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other agreements, but will be able to be sold after this offering as described in the &#147;Shares eligible for future sale&#148;
section of this prospectus. Approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be available for sale in the public market beginning 180 days after the date of this prospectus following the
expiration of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between our stockholders and the underwriters. JP Morgan Securities LLC, Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC may release these stockholders from their <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters at any time and without notice, except for officers and directors, for whom notice of such waiver would be provided two business days before the effective date thereof, which
would allow for earlier sales of shares in the public market. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, as of September&nbsp;30, 2018, up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for
sale in the public market to the extent permitted by the provisions of various vesting schedules, <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the
Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Moreover, after this offering, holders of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will have rights, subject to conditions, to
require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register
all&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. Once we register these
shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in &#147;Underwriting.&#148; If
substantial portions of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>After this offering, our executive officers, directors and significant stockholders will have the ability to directly or indirectly influence all matters submitted to stockholders for approval.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our executive officers, directors, current 5% or greater stockholders and affiliated entities will beneficially own
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of our common stock after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares and assuming that group does not participate in this
offering. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate
action might be taken even if other stockholders, including those who purchase shares in this offering, oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other
stockholders may view as beneficial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">73 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them
effectively. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our management will have broad discretion in the application of the net proceeds from this offering, and we could spend the
proceeds in ways that do not improve our results of operations or enhance the value of our common stock. We expect that we will use the net proceeds from this offering to advance and expand our clinical and preclinical development programs and for
working capital and other general corporate purposes, which may include the costs of establishing a manufacturing facility, as set forth under &#147;Use of proceeds.&#148; However, our use of these proceeds may differ substantially from our current
plans. The failure by our management to apply these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.
These investments may not yield a favorable return to our investors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We do not currently intend to pay dividends on our common stock.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not intend to pay any dividends to holders of our common stock for the foreseeable future. We currently intend to invest our future
earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future, and the success of an investment in our common stock will depend upon any future appreciation in its value.
Consequently, you may need to sell all or part of your common stock after price appreciation, which may never occur, as the only way to realize any future gains on your investment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>If securities or industry analysts do not publish research or reports about us and our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading
volume could decline. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The trading market for our common stock will be influenced by the research and reports that industry or securities
analysts publish about us and our business. We do not currently have, and may never obtain, research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our stock
would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock
performance, or if our preclinical studies and clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports
on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Provisions in our amended and restated certificate of incorporation and restated bylaws that will become effective upon the closing of this offering or
Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and therefore depress the trading price of our common stock. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Provisions in our amended and restated certificate of incorporation and our restated bylaws, which will become effective upon the closing of this offering, may discourage, delay or prevent a merger, acquisition or
other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to
pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate
or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board
of directors; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">74 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death
or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences
and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the required approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the shares entitled to vote at an election of directors to
adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, our chief executive officer (or our
president, in the absence of a chief executive officer) or a majority of our board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at
a stockholders&#146; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of us.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the General Corporation
Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess
of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our amended and restated certificate
of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our
stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and
restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1)&nbsp;any derivative action or
proceeding brought on our behalf, (2)&nbsp;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&nbsp;any action asserting a claim arising pursuant to any
provision of the General Corporation Law of the State of Delaware, our amended and restated certificate of incorporation or our amended and restated bylaws, (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our amended
and restated certificate of incorporation or our amended and restated bylaws, or (5) any action asserting a claim governed by the internal affairs doctrine. Our amended and restated certificate of incorporation will further provide that the federal
district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a
judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">75 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of
Delaware. The Court of Chancery and federal district courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the
action, and such judgments or results may be more favorable to us than to our stockholders. Some companies that adopted a similar federal district court forum selection provision are currently subject to a suit in the Court of Chancery by
stockholders who assert that the provision is not enforceable. If a court were to find either choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur
additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less
attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. We will remain an emerging growth company
until the earlier of (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion or more, (2)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this
offering, (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years, or (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC which
means the market value of our common shares that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June&nbsp;30th. For so long as we remain an emerging growth company, we are permitted and
intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">being permitted to present only two years of audited financial statements and only two years of related &#147;Management&#146;s discussion and analysis of
financial condition and results of operations&#148; disclosure in this prospectus; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or
a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports, proxy statements and registration statements; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have taken advantage of reduced reporting burdens in this prospectus. In particular, in this prospectus, we
have provided only two years of audited financial statements and corresponding &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure, and we have not included all of the executive
compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock
less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended
transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to take
advantage of this extended transition period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">76 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_3"></A>Special note regarding forward-looking statements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus contains forward-looking statements. All statements other than statements of present and historical facts contained in this prospectus, including
statements regarding our future results of operations and financial position, business strategy, prospective products, planned preclinical or greenhouse studies and clinical or field trials, regulatory approvals, research and development costs, and
timing and likelihood of success, as well as plans and objectives of management for future operations, may be forward-looking statements. Without limiting the foregoing, the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148;
&#147;expect,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;potential,&#148; the negative thereof and similar words and
expressions are intended to identify forward-looking statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Forward-looking statements are based on our management&#146;s beliefs and assumptions
and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking
statements due to various factors, including, but not limited to, those identified under &#147;Risk factors&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and elsewhere in this
prospectus. These risks and uncertainties include factors relating to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the initiation, cost, timing, progress and results of research and development activities, preclinical or greenhouse studies and clinical or field trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our or our collaborators&#146; ability to identify, develop and commercialize product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our or our collaborators&#146; ability to advance product candidates into, and successfully complete, clinical or field trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the potential for <FONT STYLE="white-space:nowrap">off-target</FONT> editing or other adverse events, undesirable side effects or unexpected characteristics
associated with any of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our or our collaborators&#146; ability to obtain and maintain regulatory approval of future product candidates, and any related restrictions, limitations and/or
warnings in the label of an approved product candidate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the success of our existing collaboration agreements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to enter into new collaboration arrangements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to achieve our anticipated operating efficiencies as we commence manufacturing operations at our new facility; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to obtain funding for our operations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">public perception about genome editing technology and its applications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our or our collaborators&#146; ability to successfully commercialize any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rate and degree of market acceptance of any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory developments in the United States and international jurisdictions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">potential manufacturing problems associated with any of our product candidates; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">77 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">potential liability lawsuits and penalties related to our technology, our product candidates and our current and future relationships with third parties;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to attract and retain key scientific and management personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to effectively manage the growth of our operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately under those arrangements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our use of proceeds from this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our financial performance; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expected fluctuations of our stock price. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All
forward-looking statements speak only as of the date of this prospectus, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">78 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_4"></A>Industry and other data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We obtained the industry, statistical and market data in this prospectus from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by
third parties. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type
appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are
cautioned not to give undue weight to such data. While we believe that each of these studies and publications is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors,
including those described in &#147;Risk factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">79 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_5"></A>Use of proceeds </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds to us from the issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering will be
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters&#146; option to purchase additional shares from us is exercised in full, we estimate that our net proceeds
will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the
net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million in the number of shares we are offering would increase (decrease) the net proceeds to us from this
offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed initial public offering price stays the same and after deducting the underwriting discounts and commissions and estimated offering expenses
payable by us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our
common stock and to facilitate our future access to the public equity markets. We anticipate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance and expand our clinical and
preclinical development programs and for working capital and other general corporate purposes, which may include the costs of establishing a manufacturing facility. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve.
We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in additional businesses, technologies, products or assets, although currently we have no specific agreements, commitments or
understandings in this regard. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend on the
uses set forth above. Predicting the cost necessary to develop our technology and product candidates can be difficult, and we anticipate that we will need additional funds to complete our development programs. The amounts and timing of our actual
expenditures and the extent of our preclinical studies and clinical trials and other development efforts may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from
preclinical studies and any clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our management will retain
broad discretion over the allocation of the net proceeds from this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Based on our current operating plan and planned use of the net proceeds
from this offering and our existing cash and cash equivalents, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital
resources sooner than we currently expect. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income
earned on invested cash balances or a combination of one or more of these sources. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pending our use of the net proceeds from this offering, we intend to
invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">80 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_6"></A>Dividend policy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash
dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business
prospects and other factors our board of directors deems relevant, and subject to any restrictions applicable to us contained in any future financing instruments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">81 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_7"></A>Capitalization </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth our cash and cash equivalents and capitalization as of September&nbsp;30, 2018: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on a pro forma basis to reflect: </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the automatic conversion of all outstanding shares of our convertible preferred stock into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock upon the closing of this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the filing and effectiveness of our amended and restated certificate of incorporation, which will occur upon the closing of this offering; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on a pro forma as adjusted basis to give further effect to our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pro forma as adjusted information below is illustrative only, and our capitalization following the closing of this offering will be adjusted based on the actual
initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus and the
&#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; section and other financial information contained in this prospectus. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As&nbsp;of&nbsp;September&nbsp;30,&nbsp;2018</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro&nbsp;forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro&nbsp;forma</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>as&nbsp;adjusted(1)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;amounts)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Convertible preferred stock; $0.0001 par value per share:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, actual; no shares issued or outstanding,
pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Common stock; $0.000005 par value per share: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
authorized;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, pro forma and pro forma as adjusted; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</FONT></P></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Treasury stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total stockholders&#146; (deficit) equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total assets, total
stockholders&#146; (deficit) equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price per
share remains the same and after deducting estimated underwriting discounts and commissions. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">82 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The number of shares of our common stock on a pro forma and pro forma as adjusted basis set forth in the table
above is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding as of September&nbsp;30, 2018 and does not include: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon exercise of stock options outstanding under
our 2006 Plan and our 2015 Plan as of September&nbsp;30, 2018, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019 Plan, which will
become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under our 2019 Plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019 ESPP, which will
become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under our 2019 ESPP. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">83 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_8"></A>Dilution </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share of our common stock and
the pro forma as adjusted net tangible book value per share of our common stock after this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of September&nbsp;30, 2018, we had a historical
net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of such date. Our historical net tangible book value per share represents total tangible assets less total liabilities,
divided by the number of shares of our common stock outstanding as of September&nbsp;30, 2018. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our pro forma net tangible book value as of
September&nbsp;30, 2018 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Pro forma net tangible book value represents the amount of our total tangible assets less total
liabilities, after giving effect to the automatic conversion of all shares of our convertible preferred stock outstanding as of September&nbsp;30, 2018 into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with this offering. Pro forma net tangible book value per share represents our pro forma net tangible book value divided
by the total number of shares outstanding as of September&nbsp;30, 2018, after giving effect to the pro forma adjustment described above. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After giving
further effect to the receipt of the net proceeds from our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2018 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This amount represents an immediate increase in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate
dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors participating in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after this
offering from the amount of cash that a new investor paid for a share of common stock. The following table illustrates this dilution: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assumed&nbsp;initial&nbsp;public&nbsp;offering&nbsp;price&nbsp;per&nbsp;share</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Historical net tangible book value (deficit) per share as of September&nbsp;30, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma increase per share attributable to the conversion of our convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net tangible book value per share as of September&nbsp;30, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Increase in the pro forma net tangible book value per share attributable to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma as adjusted net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Dilution per share to new investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and
other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the
cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and dilution in pro forma net tangible book
value per share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting estimated underwriting discounts and commissions. An increase of 1.0&nbsp;million shares in the number of shares </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">84 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
offered by us would increase our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and decrease the
dilution to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the assumed initial public offering price remains the same and after deducting estimated underwriting
discounts and commissions. A decrease of 1.0 million shares in the number of shares offered by us would decrease our pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and increase the dilution to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the assumed initial
public offering price remains the same and after deducting estimated underwriting discounts and commissions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters exercise their option
to purchase additional shares of our common stock in full, the pro forma as adjusted net tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the increase in pro forma net tangible
book value per share would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, in each case based on the initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, after deducting estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes, as of September&nbsp;30, 2018, on the pro forma as adjusted basis described above, the total number of shares of common stock
purchased from us on an as converted to common stock basis, the total consideration paid or to be paid and the average price per share paid or to be paid by existing stockholders and by new investors in this offering at an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the underwriting discounts and commissions and estimated offering
expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares&nbsp;purchased</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total&nbsp;consideration</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Average&nbsp;price<BR>per&nbsp;
share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Existing stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters exercise their option to purchase additional shares of our common stock in full, the percentage of shares of
common stock held by existing stockholders will decrease to approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering, and the number of shares held by new investors will increase
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of
the price range set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase, would increase the
percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase or decrease of 1.0&nbsp;million shares in the
number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase,
would increase the percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming the assumed initial public offering price per share remains the same and after deducting the underwriting discounts and commissions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">85 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The foregoing tables and calculations (other than the historical net tangible book value calculation) are based
on the number of shares of our common stock outstanding as of September&nbsp;30, 2018, after giving effect to the automatic conversion of all outstanding shares of our convertible preferred stock into common stock in connection with this offering,
and exclude: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon exercise of stock options outstanding under our 2006
Plan and our 2015 Plan as of September&nbsp;30, 2018, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019 Plan, which will
become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under our 2019 Plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019 ESPP, which will
become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under our 2019 ESPP. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent that these outstanding stock options are exercised, new stock options are issued or we issue additional shares of common stock in the future, there
will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.
If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">86 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_9"></A>Selected consolidated financial data </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes included elsewhere in
this prospectus and &#147;Management&#146;s discussion and analysis of financial condition and results of operations.&#148; We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2016 and 2017 and the
consolidated balance sheet data as of December&nbsp;31, 2016 and 2017 from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that should be
expected in any future period. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Statements of Operations Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Impairment of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss and net loss attributable to common stockholders&#151;basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share attributable to common stockholders&#151;basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of common stock outstanding&#151;basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,825,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,956,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma weighted-average shares of common stock outstanding&#151;basic and diluted (unaudited)(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See Note 10 to our audited consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical basic and
diluted net loss per share of common stock and the weighted-average number of shares used in the computation of the per share amounts. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">87 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Working capital(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">55,129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">98,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">103,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stockholders&#146; (deficit) equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(26,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We define working capital as current assets less current liabilities. See our consolidated financial statements included elsewhere in this prospectus for further details
regarding our current assets and current liabilities. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">88 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_10"></A>Management&#146;s discussion and analysis of financial condition and results of
operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>You should read the following discussion and analysis of financial condition and operating results together with the section captioned
&#147;Selected consolidated financial data&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. As a
result of many factors, such as those set forth in the section of the prospectus captioned &#147;Risk factors&#148; and elsewhere in this prospectus, our actual results may differ materially from those anticipated in these forward-looking
statements. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a leading
genome editing company dedicated to improving life. We have developed a groundbreaking proprietary genome editing platform to treat human diseases and create healthy and sustainable food and agricultural solutions: we call this platform
&#147;ARCUS.&#148; The versatility and breadth of ARCUS support the ability to develop further product platforms in a variety of applications. We are initially focusing on three innovative and high value areas where we believe our technology
addresses the limitations of other genome editing technologies: cancer immunotherapy (allogeneic CAR T cells), <I>in vivo</I> gene corrections and food and agriculture. We expect to enter the clinic with our gene-edited allogeneic CAR T cell lead
candidate targeting CD19 in the first quarter of 2019. We believe our team, whom we call Precisioneers, has the deepest scientific experience and capabilities of all genome editing companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Since our formation in 2006, we have devoted substantially all of our resources to developing ARCUS, conducting research and development activities, recruiting skilled personnel, developing manufacturing processes,
establishing our intellectual property portfolio and providing general and administrative support for these operations. We have financed our operations primarily with proceeds from the sale of our convertible preferred stock
and&nbsp;upfront&nbsp;payments from licensing arrangements. Through September&nbsp;30, 2018, we have raised approximately $136&nbsp;million in gross proceeds from the sale of convertible preferred stock, and we received an upfront payment of
$105&nbsp;million under the Servier Agreement, as described below. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since our inception, we have incurred significant operating losses and have not
generated any revenue from the sale of products. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our
product candidates or the product candidates of our collaborators for which we may receive milestone payments or royalties. Our net losses for the years ended December&nbsp;31, 2016 and 2017 were $8.3&nbsp;million and $21.1&nbsp;million,
respectively. As of December&nbsp;31, 2017, we had an accumulated deficit of $39.1&nbsp;million. We do not expect to generate revenue from sales of any products for the foreseeable future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our total operating expenses were $15.8&nbsp;million and $28.5&nbsp;million for the years ended December&nbsp;31, 2016 and 2017, respectively. We expect our operating expenses to increase substantially in
connection with the expansion of our product development programs. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one of our product candidates or the
product candidates of our collaborators for which we may receive milestone payments or royalties. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization
capability to support product sales, marketing and distribution. In addition, following the closing of this offering, we expect to incur additional costs associated with operating as a public company. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of these anticipated expenditures, we will need additional financing to support our continuing operations. Until such time as we can generate
significant revenue from product sales, if ever, we expect to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">89 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
finance our cash needs through a combination of public or private equity or debt financings or other sources, which may include current and new collaborations with third parties. Adequate
additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot
assure you that we will ever generate significant revenue to achieve profitability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because of the numerous risks and uncertainties associated with the
development of therapeutic and agricultural products, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales,
we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be required to raise additional capital on terms that are unfavorable to us or we may be unable to continue our
operations at planned levels and be forced to reduce or terminate our operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently conduct our operations through two reportable segments:
Therapeutics and Plant Sciences. Our Therapeutics segment is focused on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. Our Plant Sciences segment focuses on applying
ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Collaborations </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Servier </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2016, we entered into the Servier
Agreement, pursuant to which we have agreed to develop allogeneic chimeric antigen receptor T cell therapies for up to six unique antigen targets selected by Servier. Upon selection of an antigen target by Servier, we have agreed to perform
early-stage research and development on individual T cell modifications for the selected target, develop the resulting therapeutic product candidates through Phase 1 clinical trials and prepare clinical supply of such product candidates for use in
Phase 2 clinical trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We received an upfront payment of $105.0&nbsp;million under the Servier Agreement. We have the ability to receive total
payments, including the upfront payment, option fees and milestone payments, in the aggregate across all six targets, of up to approximately $1.6&nbsp;billion, as well as the payment of tiered royalties ranging from the <FONT
STYLE="white-space:nowrap">mid-single</FONT> digit percentages to the low double digit percentages on world-wide net sales. We also have the right to participate in the development and commercialization of any licensed products resulting from the
collaboration through a 50/50 <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-promotion</FONT> option in the United States, subject to our payment of an option fee, which is exercisable after
Servier&#146;s commercial option exercise. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We recognized $4.8&nbsp;million and $5.8&nbsp;million in revenues under the Servier Agreement during 2016 and
2017, respectively. The amount recorded as deferred revenue was $100.2&nbsp;million and $94.4&nbsp;million as of December&nbsp;31, 2016 and 2017, respectively. No development or sales-based milestones were received for the fiscal years ended
December&nbsp;31, 2016 and 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cargill </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2015, we entered into a commercial license agreement, as subsequently amended, with Cargill that is focused on targeting and modifying certain genes
related to saturated oil production in canola plants license for an initial license fee, certain research funding and the right to receive royalties based on future sales. We refer to this agreement as the Cargill Agreement. Under the terms of the
Cargill Agreement, we granted Cargill an exclusive research license under certain nucleases and technology, for 24 months, which term was subsequently extended through November 2018, and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
license under certain <FONT STYLE="white-space:nowrap">know-how</FONT> for the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">90 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
length of the term for which we are eligible to receive royalties. Cargill may maintain certain exclusive rights by paying a one-time option fee. We recognized $1.6&nbsp;million and
$0.4&nbsp;million in revenue during 2016 and 2017, respectively, under the Cargill Agreement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Components of our results of operations
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. We record revenue from collaboration agreements, including amounts related to upfront payments, annual fees for licenses
of our intellectual property and research and development funding. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our
product candidates. These include the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expenses incurred under agreements with third parties, including CROs and other third parties that conduct preclinical research and development activities and
clinical trials on our behalf; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">costs of developing and scaling our manufacturing process and manufacturing drug products for use in our preclinical studies and future clinical trials,
including the costs of CMOs that will manufacture our clinical trial material for use in our preclinical studies and potential future clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">costs of outside consultants, including their fees and related travel expenses; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">license payments made for intellectual property used in research and development activities; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically
identifiable to research activities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expense research and development costs as incurred. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We track external research and development costs, including the costs of laboratory supplies and services, outsourced research and development, clinical trials,
contract manufacturing, laboratory equipment and maintenance and certain other development costs, by product candidate when the costs are specifically identifiable to a product candidate. Internal and external costs associated with infrastructure
resources, other research and development costs, facility related costs and depreciation and amortization that are not identifiable to a specific product candidate are included in the platform development, early-stage research and unallocated
expenses category in the table below. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">91 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes our research and development expenses by product candidate or development program:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;
31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Increase</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Direct research and development expenses by product candidate:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">CD19&nbsp;external development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Platform development, early-stage research and unallocated expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Employee-related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory supplies and services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outsourced research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory equipment and maintenance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Facility related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development activities are central to our business model. We expect that our research and development expenses will
continue to increase substantially for the foreseeable future and will comprise a larger percentage of our total expenses as we initiate a Phase 1/2a clinical trial for CD19 and continue to discover and develop additional product candidates.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot determine with certainty the duration and costs of future clinical trials of&nbsp;CD19&nbsp;or any other product candidate we may develop or
if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration,
costs and timing of clinical trials and development of&nbsp;CD19&nbsp;and any other our product candidate we may develop will depend on a variety of factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope, rate of progress, expense and results of clinical trials of CD19, as well as of any future clinical trials of other product candidates and other
research and development activities that we may conduct; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">uncertainties in clinical trial design and patient enrollment rates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability and
commercial viability; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">significant and changing government regulation and regulatory guidance; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing and receipt of any marketing approvals; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing
associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical
development of a product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on
the completion of clinical development. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">92 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>General and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, operations and
administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses;
and facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs that are not specifically attributable to research activities. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research
activities and development of product candidates. Following this offering, we also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory
<FONT STYLE="white-space:nowrap">and&nbsp;tax-related&nbsp;services</FONT> associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interest income </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest income consists of interest
income earned on our cash and cash equivalents. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income taxes </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Since our inception in 2006, we have generated cumulative federal and state net operating loss and R&amp;D credit carryforwards for which we have not recorded any net tax benefit due to the uncertainty around
utilizing these tax attributes within their respective carryforward periods. As of December&nbsp;31, 2017, we had federal and state net operating loss carryforwards of $20.1&nbsp;million and $19.4&nbsp;million, respectively, which may be available
to offset future taxable income. The U.S. federal and state net operating loss carryforwards begin to expire in 2030 and 2025, respectively. As of December&nbsp;31, 2017, we also had federal research and development tax credit carryforwards of
$1.7&nbsp;million, which begin to expire in 2027. As of December 31, 2017, we also have federal contribution carryforwards of less than $0.1&nbsp;million, which begin to expire in 2020. We have recorded a full valuation allowance against our net
deferred tax assets at each balance sheet date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;22, 2017, the Tax Cuts and Jobs Act was signed into United States law. The Tax Cuts and
Jobs Act includes a number of changes to existing tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, effective as of January&nbsp;1, 2018,
as well as a limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017 (though any
such net operating losses may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of our deferred tax assets and liabilities recorded as of December&nbsp;31, 2017, and a corresponding reduction
in our valuation allowance. As a result, no income tax expense or benefit was recognized as of the enactment date of the Tax Cuts and Jobs Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">93 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Results of operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Comparison of years ended December&nbsp;31, 2016 and 2017 </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes our results of
operations for the years ended December&nbsp;31, 2016 and 2017, together with the changes in those items in dollars: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Impairment of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Revenue </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue for the
year ended December&nbsp;31, 2016 was $7.0&nbsp;million, compared to $6.5&nbsp;million for the year ended December&nbsp;31, 2017. The decrease of $0.5&nbsp;million in revenue during the year ended December&nbsp;31, 2017 was the result of a decrease
of $1.2&nbsp;million in license fees and research funding from Cargill and a $0.3&nbsp;million decrease in license fees from a biopharmaceutical manufacturer whose contract ended in 2016, partially offset by an increase in $1.0&nbsp;million in the
amount of revenue recognized from the Servier Agreement. The $105.0&nbsp;million upfront payment from Servier contained multiple deliverables that were bundled into a single unit of accounting and is being recognized as revenue ratably over the
estimated performance period of 9.5 years. The year ended December&nbsp;31, 2017 was the first full year of operation for the Servier Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue
from the Servier Agreement was $4.8 million and $5.8 million for the years ended December&nbsp;31, 2016 and 2017, respectively. Revenue from the Cargill Agreement was $1.6 million and $0.4 million for the years ended December&nbsp;31, 2016 and 2017,
respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">94 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Research and development expenses </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Direct research and development expenses by program:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">CD19&nbsp;external development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Platform development, early-stage research and unallocated expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Employee-related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory supplies and services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outsourced research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory equipment and maintenance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Facility related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses for the year ended December&nbsp;31, 2016 were $9.7&nbsp;million, compared to $20.3&nbsp;million
for the year ended December&nbsp;31, 2017. The increase of $10.6&nbsp;million was primarily due to a $3.5&nbsp;million increase in direct research and development expenses related to our&nbsp;CD19 program as we incurred a $2.5&nbsp;million increase
in lab supplies and $1.0&nbsp;million in payments to CMOs for the production of clinical trial material and increases in platform development and early-stage research expenses of $7.1&nbsp;million for this same period. Contributing to this increase
was a $3.7&nbsp;million increase in employee-related costs as our research and development headcount grew to support our technology platform development and manufacturing capabilities. Lab supplies and services increased $1.2&nbsp;million and
laboratory equipment and maintenance increased $0.1&nbsp;million to support our increased research and development efforts, excluding our CD19 program. Outsourced research and development increased $0.9&nbsp;million due to an increase in payments to
external scientific service providers and consultants for work performed on our development programs, excluding our CD19 program. Facility related costs increased $0.4&nbsp;million as a result of our leasing additional space in our Durham, N.C.
facility. Depreciation and amortization increased $0.6&nbsp;million due to an increase in lab equipment purchases and leasehold improvements. Other research and development expenses increased $0.3&nbsp;million. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>General and administrative expenses </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">General and
administrative expenses were $6.2&nbsp;million for the year ended December&nbsp;31, 2016, compared to $8.0&nbsp;million for the year ended December&nbsp;31, 2017. The increase of $1.8&nbsp;million was primarily due to an increase of
$0.6&nbsp;million in employee-related costs as we increased our general and administrative headcount. Also contributing to the increase in general and administrative expenses were $0.5&nbsp;million in facility related costs, including equipment,
$0.3&nbsp;million in information technology costs, $0.2&nbsp;million in consulting fees and $0.2&nbsp;million in depreciation and amortization. These increases were partially offset by a decrease of $0.3&nbsp;million in legal fees as we incurred
legal fees in connection with the Servier agreement in 2016 that did not recur in 2017. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Interest income </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest income was $0.6&nbsp;million for the year ended December&nbsp;31, 2016 compared to $0.9&nbsp;million for the year ended December&nbsp;31, 2017. The
increase of $0.3&nbsp;million of interest income generated on our cash and cash </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">95 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
equivalent balances for the year ended December&nbsp;31, 2017 compared to the year ended December&nbsp;31, 2016 was the result of higher interest rates and having higher cash balances invested in
2017 compared to 2016. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Segment results </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following tables summarize segment revenues and segment operating loss for the years ended December&nbsp;31, 2016 and 2017 (see Note 14 to our consolidated
financial statements included elsewhere in this prospectus for additional information regarding our segments): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Revenue:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total segment revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Segment operational cash expenditures:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total segment operational cash expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,761</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Allocation of centralized research and development operational cash expenditures:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,948</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total allocation of centralized research and development operational cash expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Segment operating income (loss):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total segment operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(14,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We evaluate the operating performance of each segment based on segment operating loss. Segment operating loss is derived by
deducting operational cash expenditures from revenue. Operational cash expenditures are cash disbursements made that are specifically identifiable to the reportable segment (including specifically identifiable research and development and property,
equipment and software expenditures) plus an allocation of centralized research and development expenditures for early stage research, nuclease development and the purchase of general laboratory supplies. These expenditures are allocated to the
segments based on headcount. The reportable segment and centralized research and development operational cash expenditures include cash disbursements for compensation, lab supplies, purchases of property, equipment and software and procuring
services from CROs, CMOs and research organizations. We do not allocate general operational expenses or <FONT STYLE="white-space:nowrap">non-cash</FONT> income statement amounts to our reportable segments. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Therapeutics segment </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue for the year ended
December&nbsp;31, 2016 was $5.4&nbsp;million, compared to $6.1&nbsp;million for the year ended December&nbsp;31, 2017. The increase of $0.7&nbsp;million was attributable to a $1.0&nbsp;million increase in the amount of revenue recognized from the
Servier Agreement, partially offset by a $0.3&nbsp;million decrease in license fees from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">96 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
a biopharmaceutical manufacturer whose contract ended in 2016, as described above in &#147;&#151;Revenue.&#148; Segment operational cash expenditures for the year ended December&nbsp;31, 2016
were $5.8&nbsp;million, compared to $11.1&nbsp;million for the year ended December&nbsp;31, 2017. The increase of $5.3&nbsp;million was due to increases in lab supply and property, equipment and software expenditures, payments made to service
providers for research and development and contract manufacturing services, and an increase in employee headcount and related costs. Segment operating loss increased $8.6&nbsp;million from $3.3&nbsp;million for the year ended December&nbsp;31, 2016
to $11.9&nbsp;million for the year ended December&nbsp;31, 2017 primarily due to the factors discussed above. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Plant Sciences segment </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue for the year ended December&nbsp;31, 2016 was $1.6&nbsp;million, compared to $0.4&nbsp;million for the year ended December&nbsp;31, 2017. The decrease of
$1.2&nbsp;million is the result of lower license fee and research funding revenue from the Cargill Agreement, as described above in &#147;&#151;Revenue.&#148; Segment operational cash expenditures for the year ended December&nbsp;31, 2016 were
$0.8&nbsp;million, compared to $1.7&nbsp;million for the year ended December&nbsp;31, 2017. The increase of $0.9&nbsp;million was primarily due to an increase in employee headcount and related costs. Segment operating income of less than
$0.1&nbsp;million for the year ended December&nbsp;31, 2016 compared to segment operating loss $2.4&nbsp;million for the year ended December&nbsp;31, 2017 represented an increase in segment operating loss of $2.5&nbsp;million primarily due to the
factors discussed above. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Liquidity and capital resources </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of
our product candidates. We expect that our research and development and general and administrative costs will continue to increase, including in connection with conducting preclinical studies and clinical trials for our product candidates,
contracting with CMOs and building out internal capacity to have product manufactured to support preclinical studies and clinical trials, expanding our intellectual property portfolio and providing general and administrative support for our
operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily with
proceeds from the sale of our convertible preferred stock and upfront&nbsp;payments from licensing arrangements. Since inception, we have received a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront&nbsp;payment of $105.0&nbsp;million under
the Servier Agreement and raised a total of $135.7&nbsp;million through September&nbsp;30, 2018 in gross proceeds from the sale of shares of our convertible preferred stock. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Cash flows </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our cash and cash equivalents totaled $93.4&nbsp;million and $62.8&nbsp;million as of
December&nbsp;31, 2016 and 2017, respectively. We had no indebtedness as of December&nbsp;31, 2016 or 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes our sources
and uses of cash for the periods presented: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by (used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,169</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(30,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">97 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cash flows for the year ended December&nbsp;31, 2017 </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Operating activities </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in operating activities
for the year ended December&nbsp;31, 2017 was $24.2&nbsp;million, primarily consisting of our net loss of $21.1&nbsp;million as we incurred expenses associated with research activities on our CD19 program and research activities on other
applications for our technology and incurred general and administrative expenses. In addition, we had a loss of $0.1&nbsp;million on the disposal of assets and <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $2.0&nbsp;million for
depreciation and stock-based compensation expense and the impairment of intangible assets. Net cash used in operating activities was also impacted by $5.1&nbsp;million in changes in operating assets and liabilities, including $6.2&nbsp;million in
deferred revenue and $0.6&nbsp;million in prepaid expenses and other current assets, partially offset by changes of $0.9&nbsp;million in accounts payable, $0.7&nbsp;million in accrued expenses and other current liabilities and $0.1&nbsp;million in
other assets. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Investing activities </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash
used in investing activities for the year ended December&nbsp;31, 2017 was $5.5&nbsp;million, which was attributable to purchases of property, equipment and software of $5.6&nbsp;million, partially offset by $0.1&nbsp;million from the proceeds from
the disposal of equipment. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Financing activities </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in financing activities for the year ended December&nbsp;31, 2017 was $0.9&nbsp;million, consisting of repurchases of common stock of
$1.0&nbsp;million, partially offset by less than $0.1&nbsp;million in proceeds from stock option exercises. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cash flows for the year ended
December&nbsp;31, 2016 </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Operating activities </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities for the year ended December&nbsp;31, 2016 was $92.3&nbsp;million, primarily consisting of a $106.3&nbsp;million in payments under the Servier Agreement and the Cargill
Agreement, the majority of which was a $105&nbsp;million upfront payment received under the Servier Agreement. These payments were partially offset by our net loss of $8.3&nbsp;million as we incurred expenses associated with research activities
related to our CD19 program and other applications for our technology and incurred general and administrative expenses. In addition, we had a loss of less than $0.1&nbsp;million on the disposal of assets and
<FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.8&nbsp;million for depreciation and stock-based compensation expense. Net cash provided by operating activities was also impacted by $0.4&nbsp;million in changes in operating assets and
liabilities including $0.1&nbsp;million in accounts payable and $0.8&nbsp;million in accrued expenses and other liabilities, partially offset by a change of $0.4&nbsp;million in prepaid expenses and other current assets and less than
$0.1&nbsp;million in other assets. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Investing activities </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net cash used in investing activities for the year ended December&nbsp;31, 2016 was $2.1&nbsp;million, which was attributable to purchases of property, equipment and software of $1.8&nbsp;million and acquired
intellectual property of $0.3&nbsp;million. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Financing activities </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net cash used in financing activities for the year ended December&nbsp;31, 2016 was $12.4&nbsp;million, which consisted of a distribution to Series A preferred stockholders of $12.4&nbsp;million, partially offset
by less than $0.1&nbsp;million in proceeds from stock option exercises. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">98 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Funding requirements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our operating expenses have increased substantially in 2017 and 2018 and are expected to increase substantially in the future in connection with our ongoing activities, particularly as we advance our preclinical
activities <FONT STYLE="white-space:nowrap">including&nbsp;pre-IND&nbsp;enabling</FONT> <FONT STYLE="white-space:nowrap">studies,&nbsp;scale-up&nbsp;of</FONT> manufacturing processes and engagement with CMOs and initiation of human clinical trials.
In addition, following the closing of this offering, we expect to incur additional costs associated with operating as a public company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Specifically,
our costs and expenses will increase as we: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pursue the preclinical and clinical development of our CD19 program as well as product candidates for the treatment of Hepatitis B using ARCUS nucleases under
the Gilead Agreement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pursue the preclinical and clinical development of other product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">further scale up our internal manufacturing processes and capabilities and contract with CMOs to support our preclinical studies and clinical trials of our
product candidates and make other capital expenditures to support our operations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to other products, product candidates or technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">maintain, expand and protect our intellectual property portfolio; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">hire additional personnel in research, manufacturing and regulatory and clinical development as well as management personnel; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expand our operational, financial and management systems and increase personnel, including personnel to support our operations as a public company.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents, will enable us
to fund our operating expenses and capital expenditure requirements through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have based these estimates on assumptions that may prove to be
imprecise, and we could utilize our available capital resources sooner than we expect. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because of the numerous risks and uncertainties associated with
research, development and commercialization of pharmaceutical and agricultural products, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors,
including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the progress, costs and results of our preclinical development and initial clinical trials for our CD19 program; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the progress, costs and results of our additional research and preclinical development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs and timing of internal process development and manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> activities and contract with CMOs
associated with our CD19 program and other programs we advance through preclinical and clinical development; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope, progress, results and costs of any product candidates that we may derive from ARCUS or any other product candidates we may develop alone or with
collaborators; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">99 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products, product candidates or technologies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against
any intellectual property-related claims; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidates for
which we or our collaborators obtain marketing approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Until such time, if ever, that we can generate product revenue sufficient to
achieve profitability, we expect to finance our cash needs through a combination of public or private equity or debt financings, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements and marketing and/or
distribution arrangements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity<B> </B>financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding,
collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, product development and research programs or
product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development
or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Contractual obligations and commitments </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following is a summary of our significant contractual obligations
as of December&nbsp;31, 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Payments&nbsp;due&nbsp;by&nbsp;period</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Less&nbsp;than</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1 year</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1&#151;3</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>years</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3-5</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>years<STRIKE></STRIKE></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>More&nbsp;than<BR>5&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating lease obligation(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents future minimum lease payments under our operating leases for office and lab space in Durham, North Carolina that expire in July 2024. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On March&nbsp;29, 2018, we entered into an operating lease agreement for office and lab space in Research Triangle Park, North Carolina. We began occupying the
space in May 2018 and the total lease payments will be $3.6&nbsp;million over the seven-year lease term (see Note 15 to our consolidated financial statements included elsewhere in this prospectus for additional information on this agreement).
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;2, 2018, we entered into a long-term lease agreement for approximately 17,300 square feet of laboratory space located in Research
Triangle Park, North Carolina. The lease term is seven years and two months and lease payments begin nine months after execution of the lease. Total lease payments will be approximately $3.5&nbsp;million over the lease term. The landlord is required
to provide us a maximum allowance of $70.58 per square foot for improvements done on the premises, which will be subject to landlord adjustments as outlined in the lease (see Note 15 to our consolidated financial statements included elsewhere in
this prospectus for additional information on this agreement). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We enter into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical
research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for
services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the table above as the amount and timing of such payments are not known.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On January&nbsp;1, 2018, we entered into a research, collaboration and license agreement with the University of Pennsylvania, or Penn, that includes
three knockout programs and up to three gene knockin or gene repair programs. We will provide funding to Penn and receive a license to certain technology invented under the agreement. The research funding payments will be expensed as incurred.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we have entered into the Duke License under which we are obligated to make aggregate future milestone payments of up to $0.2&nbsp;million
upon the achievement of specified corporate milestones as well as <FONT STYLE="white-space:nowrap">low-single</FONT> digit percent royalty payments based on future net sales of applicable products and generally
<FONT STYLE="white-space:nowrap">mid-teen</FONT> percent royalties based on sublicensing revenue. See the section entitled &#147;Business&#151;License and collaboration agreements&#148; appearing elsewhere in this prospectus for more information
regarding our payment obligations under the Duke License. We have not included future payments under this agreement in the table above since the payment obligations under this agreement are contingent upon future events, such as the achievement of
specified milestones or generating product sales, and we are unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Critical accounting policies and use of estimates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our management&#146;s discussion and analysis of financial
condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial
statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial
statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this prospectus,
we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Revenue recognition </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our revenues are generated primarily through collaborative research, license,
development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (1)&nbsp;licenses, or options to obtain licenses, to use our technology, (2)&nbsp;research and
development activities to be performed on behalf of the collaborative partner, and (3)&nbsp;in certain cases, services in connection with the manufacturing of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical material. Payments we
receive under these arrangements typically include one or more of the following: <FONT STYLE="white-space:nowrap">non-refundable,</FONT> upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and
development, regulatory, and sales milestone payments; and royalties on future product sales. We classify payments received under these agreements as revenues within our consolidated statements of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">101 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2016, we entered into the Servier Agreement for research, development, manufacturing of product for
clinical trials and commercialization of products using our genome editing technology for the treatment of certain diseases (see Note&nbsp;13 to our consolidated financial statements included elsewhere in this prospectus). Consideration we received,
or may receive, under this collaboration and license agreement includes upfront nonrefundable payments, payments based upon the achievement of certain milestones and royalties on any resulting net product sales. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue is recognized when all of the following conditions are met: (1)&nbsp;persuasive evidence of an arrangement exists, (2)&nbsp;delivery has occurred or
services have been rendered, (3)&nbsp;fees are fixed or determinable, and (4)&nbsp;collection of fees is reasonably assured. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We analyze our
collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification 808, Collaborative Arrangements, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This requires that we determine whether elements of the collaboration are deemed to be within
the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of Accounting Standards Codification <FONT STYLE="white-space:nowrap">605-25,</FONT> Revenue Recognition&#151;Multiple-Element
Arrangements, or ASC 605. To date, we have no arrangements that are within the scope of ASC 808. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When evaluating multiple element arrangements under ASC
605, we determine whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of
accounting when the delivered element has standalone value to the customer. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of
accounting. If the arrangement constitutes a single combined unit of accounting, we determine the revenue recognition method for the combined unit of accounting and recognize the revenue over the period from inception through the date the last
deliverable within the single unit of accounting is delivered. Our arrangements do not include a general right of return relative to delivered elements. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in our accompanying consolidated balance sheets. Our deferred
revenue includes nonrefundable upfront license fees. The deferred revenue is recognized into revenue on a proportional or straight-line basis over the estimated period of our substantive performance obligations or the period the rights granted are
in effect. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset or another performance obligation. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In arrangements that include license rights and other noncontingent deliverables, these deliverables do not have standalone value because the noncontingent
deliverables are dependent on the license rights, are not sold separately and cannot be resold. In addition, when noncontingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate
earnings process. As such, we account for the license and the noncontingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of nonrefundable upfront payments is deferred and recognized over
the applicable relationship period, which historically has been the estimated period of our substantive performance obligations or the period the rights granted are in effect. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We will recognize clinical and development, regulatory, and sales milestone payments as revenue when earned if they are substantive and we have no ongoing performance obligations related to the milestone payment. A
milestone payment is considered substantive if it (1)&nbsp;is commensurate with either our performance to achieve </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">102 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the milestone or the enhanced value of the delivered item as a result of a specific outcome from our performance to achieve the milestone, (2)&nbsp;relates solely to past performance,&nbsp;and
(3)&nbsp;is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Royalties earned on product sales, if any, are recognized based on contractual terms of the agreement when reported sales are reliably measurable and collectibility
is reasonably assured, provided that there are no performance obligations then remaining. To date, none of our product candidates have been approved and, therefore, we have not earned any royalty revenue from product sales. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event an agreement was to be terminated and we have no further performance obligations at that time, we would recognize as revenue any portion of the <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront payment and other payments that had not previously been recorded as revenue and were classified as deferred revenue at the date of such termination. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Accrued research and development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As part of
the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to
identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of
our service providers invoice us in arrears for services performed, on <FONT STYLE="white-space:nowrap">a&nbsp;pre-determined&nbsp;schedule</FONT> or when contractual milestones are met; however, some require advance payments. We make estimates of
our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to the
following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">CROs and other third parties in connection with performing research and development activities, conducting preclinical studies and clinical trials on our behalf;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">vendors in connection with preclinical development activities; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">CMOs and other vendors in connection with product manufacturing and development and distribution of preclinical supplies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that
conduct and manage preclinical studies and clinical trials and CMOs that manufacture product for our research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, we estimate the time period over
which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense
accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary
and may cause us to report amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">103 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Stock-based compensation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We measure stock options and other stock-based awards granted to our employees, directors, consultants and advisors based on the fair value on the date of the grant and recognize compensation expense for those
awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For stock-based
awards granted <FONT STYLE="white-space:nowrap">to&nbsp;non-employees,&nbsp;compensation</FONT> expense is recognized over the period during which services are rendered by <FONT STYLE="white-space:nowrap">such&nbsp;non-employees&nbsp;until</FONT>
completed. At the end of each financial reporting period prior to the completion of the service, the fair value of these awards <FONT STYLE="white-space:nowrap">is&nbsp;re-measured&nbsp;using</FONT> the then-current fair value of our common stock
and updated assumption inputs in the Black-Scholes option-pricing model. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate the fair value of each stock option grant on the date of grant
using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period
that approximates the expected term of our stock options and our expected dividend yield. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Determination of fair value of common stock
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board of
directors as of the date of each option grant, with input from<B> </B>management, taking into consideration our most recently available third-party valuations of common stock at the time of the grants, as well as our board of directors&#146;
assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Third-party valuations, or valuation reports, were
performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide,<I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common stock valuation reports were prepared using a market approach, utilizing either the guideline M&amp;A or guideline public company methodologies. Under
the guideline M&amp;A methodology, a set of mergers and acquisitions within the biotechnology and pharmaceutical industries for similar stage companies were reviewed and an applicable equity value was selected to apply to the company. Under the
guideline public company methodology, the market capitalizations of similar public companies were analyzed and an applicable capitalization for the company was selected on the basis of qualitative and quantitative factors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For each valuation report, an option pricing allocation method, or OPM, was selected to allocate the total equity value across the various securities outstanding at
the time of the valuation. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a
company&#146;s securities changes. These third-party valuations resulted in a valuation of our common stock of $0.55 and $0.94 per share as of December&nbsp;31, 2016 and 2017, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition to considering the results of the valuation reports, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date,
including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the prices at which we sold shares of preferred stock and the superior rights and preferences of the preferred stock relative to our common stock at the time of
each grant; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the progress of our research and development programs, including the status and results of preclinical studies for our product candidates;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">104 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our stage of development and commercialization and our business strategy; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">external market conditions affecting the biopharmaceutical industry and trends within that industry; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our financial position, including cash on hand, and our historical and forecasted performance and operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the lack of an active public market for our common stock and our convertible preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company in light of prevailing market conditions; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The assumptions underlying these valuations represented management&#146;s best estimate, which involved inherent uncertainties and the application of
management&#146;s judgment. As a result, if we had used different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Once a public trading market for our common stock has been established in connection with the closing of this offering, it will no longer be necessary for our board
of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted market price of
our common stock. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recent accounting pronouncements not yet adopted </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A description of recent accounting pronouncements not yet adopted that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 1 to our consolidated financial
statements included elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined
under SEC rules. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Quantitative and qualitative disclosures about market risk </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash and cash equivalents of
$62.8&nbsp;million, or 86.4% of our total assets at December&nbsp;31, 2017. Interest income earned on these assets was $0.9&nbsp;million for the year ended December&nbsp;31, 2017. Our interest income is sensitive to changes in the general level of
interest rates, primarily U.S. interest rates. At December&nbsp;31, 2017, our cash equivalents consisted of money market funds and repurchase agreements that were collateralized by deposits in the form of government securities and obligations. Such
interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. We had no debt outstanding as of December&nbsp;31, 2017. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Emerging growth company status </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an &#147;emerging
growth company,&#148; as defined in the JOBS Act, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section&nbsp;107 of the JOBS Act exempts
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">105 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. We have elected to
take advantage of the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
The JOBS Act also exempts us from having to provide an auditor attestation of internal control over financial reporting under Sarbanes-Oxley Act Section&nbsp;404(b). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We will remain an &#147;emerging growth company&#148; until the earliest of (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more, (2)&nbsp;the last day
of the fiscal year following the fifth anniversary of the completion of our IPO, (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years or (4)&nbsp;the date on which we are deemed
to be a large accelerated filer under the rules of the SEC, which generally is when we have more than $700&nbsp;million in market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> and we have been a public company for
at least 12 months and have filed one annual report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">106 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_11"></A>Business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a leading genome editing company dedicated to improving life. We have developed a
groundbreaking proprietary genome editing platform to treat human diseases and create healthy and sustainable food and agricultural solutions: we call this platform &#147;ARCUS.&#148; The versatility and breadth of ARCUS support our ability to
develop product platforms in a variety of applications. We are initially focusing on three innovative and high value areas where we believe our technology addresses the limitations of other genome editing technologies: cancer immunotherapy
(allogeneic CAR T cells), <I>in vivo</I> gene corrections and food and agriculture. We expect to commence a Phase 1/2a clinical trial with our lead gene-edited allogeneic CAR T cell candidate targeting CD19 in the first quarter of 2019. We believe
our team, whom we call Precisioneers, has the deepest scientific experience and capabilities of all genome editing companies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our genome editing
platform&#151;ARCUS </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Genome editing is a biotechnology process that removes, inserts or repairs a portion of DNA at a specific location in a
cell&#146;s genome. Our proprietary genome editing platform, ARCUS, is a collection of protein engineering methods that were developed specifically to re-program the DNA recognition properties of I-CreI. In nature, I-CreI is an endonuclease found in
the genome of algae, <I>Chlamydomonas reinhardtii</I>, which evolved for the purpose of carrying out a complex gene insertion edit. I-CreI is responsible for modifying a specific location in the algae&#146;s genome by inserting a gene using a very
precise cellular repair mechanism called homology directed repair, or HDR. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe I-CreI has a number of attributes that are beneficial for genome
editing applications, such as: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Specificity</B>. Complex applications of genome editing technology, especially those involving the human body, require a very high level of endonuclease
specificity to limit the likelihood that the endonuclease will recognize and cut any genetic sequence other than its intended target. I-CreI recognizes and cuts a DNA sequence that is 22 base pairs in length through a large number of complex
molecular interactions with the bases. I-CreI physically couples the functions of DNA binding with DNA cutting, and acts through a slow catalytic mechanism and low turnover rate, remaining inactive in the absence of its DNA target site.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Efficiency</B>. Most applications of genome editing technology require that a sufficient portion of the targeted cells are edited to achieve the desired
result. The activity level of the endonuclease is one factor that can affect how many cells are edited. Given its slow catalytic activity, I-CreI is able to achieve a high level of on-target editing while rarely cutting off-target.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Delivery</B>. Size and structural simplicity affect the ease with which endonucleases can be delivered to cells for editing. I-CreI is very small relative to
other genome editing endonucleases. As such, it is compatible with many different delivery mechanisms, and its small size and simple structure facilitate the simultaneous delivery of multiple engineered endonucleases to introduce more than one edit
to a cell. Both of these properties significantly broaden the spectrum of potential applications for I-CreI-based genome editing endonucleases. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Type of cut</B>. I-CreI creates four base 3&#146; overhangs when it cuts its DNA site, which increases the likelihood that the cell will repair the DNA cut
through HDR. HDR is a mechanism of DNA repair whereby the cell uses a second DNA molecule with a sequence similar to that of the cut DNA molecule to guide the repair process. Since HDR uses a template of similar genetic information to guide the
repair process, it is the more precise mechanism of cellular repair compared to the other mechanism, non-homologous end joining, or NHEJ, which prioritizes speed over accuracy, making it prone to leaving insertions and/or deletions of DNA bases at
the </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">107 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
cut site. As such, the DNA cuts created by I-CreI can be exploited to efficiently insert or repair DNA as well as DNA. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Programmability</B>. I-CreI recognizes its DNA target site through a complex network of contacts between the endonuclease and the DNA bases which makes the
enzyme very challenging to re-program for new editing applications involving different DNA sequences. This engineering challenge represents a very high barrier to entry and has enabled us to secure a strong intellectual property position and control
over what we believe to be a superior genome editing technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To apply <FONT STYLE="white-space:nowrap">I-CreI</FONT> to genome
editing in other cells or organisms, we must modify it to recognize and cut a different DNA sequence for each new application we pursue. Since the <FONT STYLE="white-space:nowrap">I-CreI</FONT> endonuclease evolved to recognize its target sequence
in the algae genome with a very high degree of selectivity, it is difficult to <FONT STYLE="white-space:nowrap">re-design</FONT> it to bind and cut a different DNA sequence. Using the ARCUS process, we create customized endonucleases for particular
applications. We call these custom endonucleases &#147;ARCUS nucleases.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are able to redirect the ARCUS nucleases to a new location in a genome
without compromising its editing abilities. In addition to changing the parts of the enzyme involved in recognizing a target DNA site, we can modify the active site of the enzyme and parts of the enzyme involved in anchoring it to the DNA. These
modifications allow us to control how tightly the enzyme binds to DNA or how quickly it cuts, both of which play an important role in determining the efficiency with which the endonuclease cuts its intended target site or any potential off-target
sites. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe ARCUS nucleases are the smallest and easiest to deliver genome editing endonucleases. Like I-CreI, ARCUS nucleases produce DNA cuts
with 3&#146; overhangs that promote HDR, facilitating gene insertions and gene repairs in addition to gene knockouts. We believe that these attributes will enable us to translate ARCUS into a wide array of products that have the potential to address
the limitations of other genome editing technologies and improve life. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We leverage ARCUS to build platforms designed to rapidly generate new products in
a given field. We are currently developing products from three such platforms: cancer immunotherapy (allogeneic CAR T cells), <I>in vivo</I> gene corrections, and food and agriculture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>Cancer immunotherapy (allogeneic CAR T cells).</B> We believe that we have developed the world&#146;s leading allogeneic gene-edited CAR T cell platform with the potential to overcome certain limitations of
autologous CAR T cell therapies and significantly increase patient access to these cutting-edge treatments. The allogeneic approach involves the use of donor-derived cells which can be selected using specific criteria to define &#147;healthy&#148; T
cells. We expect the allogeneic approach will lessen the product-to-product variability seen in autologous therapies, which are derived from the patient&#146;s own cells. Additionally, donor-derived cells could be used in any patient, eliminating
the &#147;one patient: one product&#148; burden of autologous CAR T cell therapies. We are also initially developing product candidates for well-validated CAR T cell targets. Our most advanced program, PBCAR0191, is an allogeneic CAR T cell therapy
targeting the well-validated tumor target CD19 and being developed for Acute Lymphoblastic Leukemia, or ALL, and Non-Hodgkin Lymphoma, or NHL. In February 2016, we entered into an agreement with Les Laboratories Servier, or Servier, pursuant to
which we have agreed to develop allogeneic CAR T cell therapies for up to six unique antigen targets selected by Servier, one of which is CAR. An IND for PBCAR0191 was submitted to the U.S. Food and Drug Administration, or the FDA, in October 2018.
We have used the qualities of ARCUS to create a one-step cell engineering process for allogeneic CAR T cells that we believe will rapidly yield a consistent cell product at a significantly lower cost than autologous CAR T cell therapies. Due to our
one-step editing method and the decision early in the development of the platform to invest in process development, our manufacturing process today is scaled as opposed to scalable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">108 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>In vivo </I></B><B>gene corrections.</B> Our goal is to cure genetic diseases by correcting the DNA errors
responsible for causing them. We are advancing a deep portfolio of diverse programs toward <I>in vivo</I> efficacy and toxicity studies. We are generating a significant large animal dataset that we believe will be the most comprehensive of any in
the field. The potential of ARCUS for <I>in vivo</I> genome editing is highlighted in our July 2018 publication in <I>Nature Biotechnology</I>, which we believe is the first peer-reviewed publication of <I>in vivo</I> genome editing data in
non-human primates. The publication reported high-efficiency editing of the PCSK9 gene in non-human primates using ARCUS and, even at the highest dose, the treatment was observed to be well tolerated. Because this therapeutic effect is due to
modifications to the DNA itself, the benefit of the treatment appears to be permanent. In September 2018, we announced a collaboration with Gilead Sciences Inc. to co-develop an ARCUS-based cure for chronic Hepatitis B infection. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Food and agriculture.</B> This platform, which we operate through our wholly owned subsidiary, Elo Life Systems, or Elo, is an integrated suite of gene discovery
and plant engineering technologies that allows us to generate pre-breeding material for food producers. We believe we have the most in-depth experience in crop genome editing in the industry. Over the last decade, we have developed highly efficient
methods to improve delivery and functionality of ARCUS nucleases to edit DNA in plants. By combining the power of our ARCUS technology platform with target discovery, transformation and high throughput evaluation, we are enabling our partners to
address emerging opportunities in food and agriculture. Our differentiated collaboration-based business model enables us to remain capital efficient throughout the product-development cycle while generating revenue through various revenue-sharing
models. Since 2014, Elo and Cargill have been engaged in a collaboration to produce ARCUS-optimized canola varieties and have achieved significantly lower levels (less than 4.5%) of saturated fatty acids compared to the current levels (7%). These
edited varieties are currently being evaluated in greenhouse and field trials. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our team </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We believe that our team, whom we call Precisioneers, has the deepest scientific experience and capabilities of all genome editing companies. Derek Jantz, Ph.D., our Chief Scientific Officer and a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Precision, and Jeff Smith, Ph.D., our Chief Technology Officer and also a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Precision, have been working with genome editing technology for more than
15 years. They are pioneers in the genome editing field and developed our ARCUS genome editing platform to address what they perceived as limitations in the existing genome editing technologies. Our Chief Executive Officer, Matthew Kane, also a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Precision, has almost 20 years&#146; experience in life sciences, most of which has been working in genome editing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have selectively expanded our team of Precisioneers to include individuals with extensive industry experience and expertise in the discovery, development, manufacture and commercialization of cell and gene
therapies and the creation of innovative solutions to myriad problems affecting food systems. Over half of our team of Precisioneers have advanced degrees, including 42 with Ph.D. degrees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are a purpose driven organization, and we have carefully promoted a culture that values innovation, accountability, respect, adaptability and perseverance. We strive to ensure that our open, collaborative
culture empowers Precisioneers to be their best selves and do their best work. We strongly believe that our shared values will help our team navigate and overcome any challenges we may experience as we pursue our mission of improving life through
genome editing. Our culture has helped build a world-class team with industry-leading experience in genome editing and continually attracts new talent to further build our capabilities. Our team is a group of motivated individuals that value the
opportunity to contribute their time and talents toward the pursuit of improving life. Precisioneers appreciate high-quality research and are moved by the opportunity to translate their work into treatments and solutions that will impact human
health. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">109 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our strategy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are dedicated to improving life. Our goal is to broadly translate the potential of genome editing into permanent genetic solutions for significant unmet needs. Our strategy to achieve this goal includes the
following key elements: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Create a fully integrated genome editing company capable of delivering solutions that address unmet needs in human health.&nbsp;&nbsp;&nbsp;&nbsp;</B>We
believe that, to be a leader in the field of genome editing and maximize the impact of our ARCUS genome editing platform, we must be able to control those elements of our business that may provide us with certain strategic advantages or operational
efficiencies. We intend to continue to invest in comprehensive research, development and commercial capabilities that provide control and oversight of our product candidates from discovery through commercialization. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Accelerate advancement of our first four cancer immunotherapy product candidates.&nbsp;&nbsp;&nbsp;&nbsp;</B>We believe that we have developed the
world&#146;s leading allogeneic CAR&nbsp;T cell manufacturing platform and the first that is capable, today, of producing drug product at scale. We have selected four validated CAR&nbsp;T cell targets that we believe offer the greatest chance of
clinical success for our initial product candidates, which we intend to rapidly advance into clinical development. In October&nbsp;2018, we submitted an IND to the FDA for our leading CAR&nbsp;T cell product candidate targeting CD19.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Advance </B><B><I>in vivo</I></B><B> genetic correction programs for the liver and eye.</B>&nbsp;&nbsp;&nbsp;&nbsp;We have achieved high-efficiency and
tolerability in <I>in vivo </I>genome editing in a <FONT STYLE="white-space:nowrap">non-human</FONT> primate, as published in <I>Nature Biotechnology</I> in July 2018. To our knowledge, we are the first company to complete this milestone, which we
believe to be critical to successful <I>in vivo </I>genome editing therapeutic development. We intend to build on this early success by diligently advancing a diverse portfolio of preclinical <I>in vivo </I>gene correction programs through
additional large animal studies, focusing initially on gene targets occurring in the liver and eye. Based on the results from these large animal studies, we intend to advance a subset of these programs to human clinical trials.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Build a human health focused food business.</B>&nbsp;&nbsp;&nbsp;&nbsp;We believe that rapidly changing consumer preferences and food insecurity resulting
from population growth and climate change will drive significant demand for genome-edited food products. We are building a fully integrated discovery and development platform that combines genome editing, gene discovery, plant transformation and
high-throughput testing to enable accelerated innovation in the food industry. We employ a business model that is focused on collaborating with critical stakeholders within the supply chain from the outset of any given project. We believe that this
approach will enable us to successfully respond to growing unmet needs within food supply to build a human health focused business in a capital-efficient manner. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Continue investing in the optimization of ARCUS and enabling technologies.&nbsp;&nbsp;&nbsp;&nbsp;</B>We believe that a key to our future success is the
quality of the genome editing tools that we produce. Since our founding, we have devoted ourselves to continuously refining the precision and efficiency of our core genome editing platform. We intend to continue this investment in ARCUS while
surrounding it with enabling technologies and expertise to retain what we believe is a leadership position in the field. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Create an environment that is a destination of choice for premier talent within the life science industry.</B>&nbsp;&nbsp;&nbsp;&nbsp;We believe that we
currently have the deepest and strongest skill set within the genome editing industry and credit much of our past success to our commitment to our team and culture. Our future success will depend on our ability to continue to attract and retain
world-class talent within our markets of interest. We intend to consciously invest in fostering an environment within our company that is both challenging and supportive and inspires our team to broadly translate genome editing into permanent
genetic solutions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Expand the breadth of our operations through additional product platforms and strategic relationships.</B>&nbsp;&nbsp;&nbsp;&nbsp;We believe that the ARCUS
genome editing platform has broad utility beyond our current </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">110 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
areas of focus. We intend to invest in the development of additional product platforms and seek collaborations with companies with expertise in areas outside of our current target markets to
maximize the value of our company.</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview of genome editing </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Deoxyribonucleic acid, or DNA, carries the genetic instructions for all basic functions of a living cell. These instructions are encoded in four different molecules, called bases, which are strung together in
specific sequences to form genes. Each gene is responsible for a specific function in a cell, and the complete set of genes in a cell, which can consist of tens of thousands of genes and billions of individual bases, is known as a genome. The
complete genome sequence has been determined for many organisms, including humans. This allows scientists to identify specific genes and determine how their unique sequences contribute to a particular cellular function. Studying variations in gene
sequences further informs an understanding of why a cell behaves a certain way, which can greatly enhance understanding of what causes and how to treat aberrant behavior that leads to disease. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Genome editing is a biotechnology process that removes, inserts or repairs a portion of DNA at a specific location in a cell&#146;s genome. Early applications of genome editing focused on advancing genetic
research. As genome editing technologies have advanced, their application is moving beyond understanding disease to treating or preventing disease by editing DNA. Genome editing is accomplished by delivering a DNA cutting enzyme, called an
endonuclease, to a targeted segment of genetic code. Once the endonuclease cuts the DNA, the cell has to repair the break to survive and will do so in one of two ways, as shown below. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g10x21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are two mechanisms of DNA repair, <FONT STYLE="white-space:nowrap">non-homologous</FONT> end joining, or NHEJ, and homology
directed repair, or HDR. As shown in A) above, NHEJ is a pathway that repairs breaks in DNA without a template. NHEJ is the less precise method of repair that prioritizes speed over accuracy, making it prone to leaving insertions and/or deletions of
DNA bases at the cut site. These insertions or deletions can disrupt the gene sequence and can be used to inactivate or &#147;knock out&#148; the function of the gene. Accordingly, genome editing technologies can be used to permanently knock out a
gene in a cell or organism by creating a break in the DNA sequence of that gene. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">111 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As shown in B) above, HDR is a mechanism of DNA repair whereby the cell uses a second DNA molecule with a
sequence similar to that of the cut DNA molecule to guide the repair process. Since HDR uses a &#147;template&#148; of similar genetic information to guide the repair process, it is the more precise mechanism of cellular repair. HDR results in the
sequence of the template being copied permanently into the genome at the site of the DNA cut. If we provide a template DNA molecule directly to the edited cell and the cell repairs itself using HDR, a new gene can be incorporated or &#147;knocked
in&#148; at a precise location in the genome. Alternatively, the use of HDR can &#147;repair&#148; a DNA mutation by correcting it to the proper functioning sequence when repairing the break. Thus, genome editing endonucleases can be used to
introduce a variety of different changes to the genetic code of a cell or organism including gene knockout, gene insertion and gene repair. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are
several genome editing technologies, including ARCUS, <FONT STYLE="white-space:nowrap">zinc-finger</FONT> nucleases, or ZFNs, <FONT STYLE="white-space:nowrap">TAL-effector</FONT> nucleases, or TALENs, and CRISPR/Cas9. These technologies differ from
one another principally in the properties of the endonuclease that they each employ. The different endonucleases have fundamentally different mechanisms of recognizing and cutting their DNA targets, which gives each technology advantages and
disadvantages depending on how each is used. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Important attributes to consider in evaluating the suitability of a genome editing technology for a
particular application include the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Specificity.&nbsp;&nbsp;&nbsp;&nbsp;</B>The overall objective of genome editing is to cut and modify a <I>single site </I>in a genome with little or no
editing at <FONT STYLE="white-space:nowrap">off-target</FONT> locations. In the three billion base pairs human genome, any DNA sequence greater than 16 base pairs in length is statistically expected to occur only once. Thus, an endonuclease that can
specifically identify a DNA sequence of at least 16 base pairs should be able to &#147;find&#148; and cut a single site in the genome. All of the different genome editing endonucleases can recognize target sites of at least this length. However, the
ability to discriminate between closely related DNA sequences can vary from one technology to another and also among different endonucleases used in the same technology platform. Less specific endonucleases are prone to introducing <FONT
STYLE="white-space:nowrap">off-target</FONT> edits because the endonuclease may recognize and cut DNA sites that differ from the intended DNA sequence. <FONT STYLE="white-space:nowrap">Off-target</FONT> editing can alter cell function in unintended
ways that can lead to undesirable side effects. In applications of genome editing technology where safety is a concern, high endonuclease specificity is a critical attribute. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Efficiency.</B>&nbsp;&nbsp;&nbsp;&nbsp;Genome editing typically involves large numbers of cells growing in isolation or in a tissue or organism. Each cell in
the population that is exposed to the editing endonuclease may or may not become edited and, among the edited cells, the genetic changes can vary from cell to cell. For most applications, a low frequency of &#147;properly&#148; edited cells is not
sufficient to achieve the desired outcome. Thus, a critical attribute of a genome editing endonuclease is its ability to cut its intended DNA site efficiently to ensure that a sufficient number of cells in the population are edited. Factors that
contribute to editing efficiency include the activity level of the endonuclease, the accessibility of the DNA target site in the genome and the amount of endonuclease delivered to the cell. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Delivery.&nbsp;&nbsp;&nbsp;&nbsp;</B>Before a genome editing process begins, the endonuclease must be delivered to the cell to be edited. Endonucleases can be
delivered in a variety of different forms depending on the intended application. Most frequently, genome editing endonucleases are delivered to a cell in the form of a genetic construct, either DNA or mRNA (messenger ribonucleic acid), that is
translated into the endonuclease by the cell&#146;s natural genetic translation mechanisms. The DNA or mRNA can be delivered to the cell using several different strategies depending on the application. For <I>ex vivo</I> applications involving the
editing of isolated cells outside of the organism, DNA or mRNA encoding the editing endonuclease is typically delivered using chemical, electrical or virus-based approaches. For <I>in vivo</I> applications involving the editing of cells inside a
living organism, delivery options are typically more limited and virus-based approaches predominate. In general, the difficulty of delivering an endonuclease to cells depends on its size and number of components. Large
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">112 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
and/or multi-component endonucleases are more challenging to deliver and compatible with fewer delivery strategies whereas endonucleases that are smaller and/or a single component can generally
be more broadly applied. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Type of cut.&nbsp;&nbsp;&nbsp;&nbsp;</B>The type of cut made by an endonuclease can influence the repair mechanism employed by the edited cell, which in turn
impacts the type of gene edits that can be accomplished. DNA consists of two parallel strands of bases. Genome editing endonucleases typically cut both strands to initiate a genome editing event. However, the type of double-strand cut made differs
among endonucleases. Some endonucleases create &#147;blunt&#148; ends in which both strands of the DNA are cut in the exact same location. Other endonucleases create staggered cuts in which one strand overhangs the other. This results in the
formation of a short stretch of single-stranded DNA bases. If the top strand overhangs the bottom strand, it is referred to as a 3&#146; overhang. Conversely, if the bottom strand overhangs the top, it is referred to as a 5&#146; overhang. Since the
first step in the HDR process requires a 3&#146; single strand of DNA, cells are more likely to repair cuts that leave 3&#146; overhangs using HDR. Cellular repair using HDR facilitates more complex genetic edits, such as gene addition or gene
repair. Accordingly, the type of cut made by the genome editing technology impacts its potential applications. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Programmability.</B>&nbsp;&nbsp;&nbsp;&nbsp;To actively target and cut a certain portion of a genome, endonucleases must be programmable with respect to DNA
sequence specificity. Each genome editing application requires a custom-made endonuclease that recognizes and cuts DNA at a particular location of interest. Thus, it is necessary to engineer the endonuclease to recognize a new DNA target site for
each new application. The extent to which an endonuclease can be engineered to recognize new DNA sequences and the difficulty of accomplishing such engineering are properties that differ among genome editing technologies. A primary driver of genome
editing technology development over the last two decades has been increasing the ease of programmability of the endonucleases to increase the accessibility of the technology. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our approach to genome editing </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are pioneers in the field
of genome editing and have extensive experience with a breadth of genome editing technologies. Our Precision platform was developed to address limitations of other editing technologies that could impair their deployment for therapeutic applications.
We looked to nature for examples of genome editing and found the <FONT STYLE="white-space:nowrap">I-CreI</FONT> endonuclease from the algae <I>Chlamydomonas reinhardtii</I>. Unlike ZFN, TALEN or CRISPR/Cas9,
<FONT STYLE="white-space:nowrap">I-CreI</FONT> is a natural enzyme that evolved to edit a large, complex genome. In nature, it is responsible for modifying a specific location in the algae genome by inserting a gene using the HDR process.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that <FONT STYLE="white-space:nowrap">I-CreI</FONT> has a number of attributes that make it attractive for the development of novel genome
editing endonucleases, such as: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Specificity.&nbsp;&nbsp;&nbsp;&nbsp;</B>Complex applications of genome editing technology, especially those involving the human body, require a very high
level of endonuclease specificity to limit the likelihood that the endonuclease will recognize and cut any genetic sequence other than its intended target. We believe that several attributes of <FONT STYLE="white-space:nowrap">I-CreI</FONT>
naturally inhibit <FONT STYLE="white-space:nowrap">off-target</FONT> cutting. <FONT STYLE="white-space:nowrap">I-CreI:</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><U>Recognizes and cuts a DNA sequence that is 22 base pairs in length</U>.&nbsp;&nbsp;&nbsp;&nbsp;A sequence of this length is statistically expected to occur
only once in a large genome. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><U>Recognizes its DNA target site through a large number of complex molecular interactions with the bases</U>.<B></B>&nbsp;&nbsp;&nbsp;&nbsp;Relative to other
endonucleases, an unusually high percentage of the <FONT STYLE="white-space:nowrap">I-CreI</FONT> protein surface area is dedicated to specific contacts with the DNA bases. This method of site recognition enhances
<FONT STYLE="white-space:nowrap">I-CreI&#146;s</FONT> ability to discriminate among similar sequences of DNA, reducing the likelihood that it will cut DNA sequences that differ even slightly from the intended DNA sequence.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">113 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><U>Physically couples the functions of DNA binding and DNA cutting</U>.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>The region of
<FONT STYLE="white-space:nowrap">I-CreI</FONT> that is responsible for DNA site recognition also contains the region that cuts the DNA, or the active site. Due to this structure, the active site is not in a position to cut unless the enzyme is
seated properly on the correct DNA sequence. ZFN, TALEN and CRISPR/Cas9 are multi-domain endonucleases in which the <FONT STYLE="white-space:nowrap">DNA-binding</FONT> and <FONT STYLE="white-space:nowrap">DNA-cutting</FONT> functions reside in
different regions of the enzyme.<B> </B> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g60a59.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><U>Remains inactive in the absence of its DNA target site</U>.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>When <FONT STYLE="white-space:nowrap">I-CreI</FONT> is not bound to
its proper DNA target site, it folds up on itself such that its active site is blocked from external interaction. In this form, <FONT STYLE="white-space:nowrap">I-CreI</FONT> is inert. This structural configuration provides a type of natural
&#147;on/off switch&#148; that reduces <FONT STYLE="white-space:nowrap">I-CreI&#146;s</FONT> activity away from the target site. Other genome editing endonucleases lack this type of natural control over the enzyme&#146;s cutting activity.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><U>Cuts slowly and with low turnover</U>.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Relative to other genome editing endonucleases and to enzymes in general, <FONT
STYLE="white-space:nowrap">I-CreI</FONT> has a very slow mechanism of action. <FONT STYLE="white-space:nowrap">I-CreI</FONT> takes a relatively long time to cut its DNA target site and, after doing so, remains bound to the cut DNA ends. These
properties greatly reduce the likelihood that <FONT STYLE="white-space:nowrap">I-CreI</FONT> will cut any other<I> </I>DNA site after making its initial <FONT STYLE="white-space:nowrap">on-target</FONT> cut. We believe that this translates directly
to a reduction in the frequency of <FONT STYLE="white-space:nowrap">off-target</FONT> cutting without sacrificing <FONT STYLE="white-space:nowrap">on-target</FONT> editing efficiency. In contrast, other editing endonucleases have very high rates of
catalysis and turnover because their natural function is defending bacteria from viruses. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Efficiency.</B>&nbsp;&nbsp;&nbsp;&nbsp;Most applications of genome editing technology require that a sufficient portion of the targeted cells are edited to
achieve the desired result. The activity level of the endonuclease is one factor that can affect how many cells are edited. The slow catalytic mechanism of <FONT STYLE="white-space:nowrap">I-CreI</FONT> imparts specificity but does not impact its <FONT
STYLE="white-space:nowrap">on-target</FONT> efficiency for genome editing purposes because genome editing involves cutting only a single site in a cell. As such, <FONT STYLE="white-space:nowrap">I-CreI</FONT> is able to achieve a high level of <FONT
STYLE="white-space:nowrap">on-target</FONT> editing while rarely cutting <FONT STYLE="white-space:nowrap">off-target.</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Delivery.&nbsp;&nbsp;&nbsp;&nbsp;</B>Size and structural simplicity affect the ease with which endonucleases can be delivered to cells for editing. <FONT
STYLE="white-space:nowrap">I-CreI</FONT> is very small relative to other genome editing endonucleases. It is approximately one quarter to one sixth of the size of the ZFN, TALEN and CRISPR/Cas9 endonucleases. Unlike those endonucleases, <FONT
STYLE="white-space:nowrap">I-CreI</FONT> can be delivered as a single gene. As such, it is compatible with many different delivery mechanisms. Additionally, <FONT STYLE="white-space:nowrap">I-CreI&#146;s</FONT> size and structure facilitate the
simultaneous delivery of multiple engineered endonucleases to introduce more than one edit to a cell. Both of these properties significantly broaden the spectrum of potential applications for <FONT STYLE="white-space:nowrap">I-CreI-based</FONT>
genome editing endonucleases. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Type of cut.&nbsp;&nbsp;&nbsp;&nbsp;</B>A genome editing technology that facilitates cellular repair through HDR enables applications that require a gene
insertion or gene repair. Unlike other editing endonucleases, <FONT STYLE="white-space:nowrap">I-CreI</FONT> creates four base 3&#146; overhangs when it cuts its DNA site, which increases the likelihood that the cell will repair the DNA cut through
HDR. As such, the DNA cuts created by <FONT STYLE="white-space:nowrap">I-CreI</FONT> can be exploited to efficiently insert or repair DNA, consistent with the natural role of <FONT STYLE="white-space:nowrap">I-CreI</FONT> in catalyzing the targeted
insertion of a gene in algae. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Programmability.</B>&nbsp;&nbsp;&nbsp;&nbsp;As described above, <FONT STYLE="white-space:nowrap">I-CreI</FONT> recognizes its DNA target site through a
complex network of contacts between the endonuclease and the DNA bases. While this confers significant specificity advantages, it also makes the enzyme very challenging to re-program for new editing applications involving different DNA
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">114 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
sequences. Indeed, the challenges associated with <FONT STYLE="white-space:nowrap">re-programming</FONT> <FONT STYLE="white-space:nowrap">I-CreI</FONT> have, historically, hampered its adoption
by the genome editing community in favor of more easily engineered endonucleases. This engineering challenge represents a very high barrier to entry and has enabled us to secure a strong intellectual property position and control over what we
believe to be a superior genome editing technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other than the key programming challenge, we believed that the differentiated
properties of <FONT STYLE="white-space:nowrap">I-CreI</FONT> cited above made it an ideal &#147;scaffold&#148; for the development of novel genome editing tools. Moreover, we believed those properties were differentiated enough from other editing
technologies to merit substantial investment in overcoming the key challenge of programmability. To that end, we invested 15 years of research effort to develop a robust, proprietary protein engineering method that now enables us to consistently <FONT
STYLE="white-space:nowrap">re-program</FONT> <FONT STYLE="white-space:nowrap">I-CreI</FONT> to direct it to targeted sites in a genome. We call our approach &#147;ARCUS.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Our ARCUS genome editing platform </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ARCUS is a collection of protein engineering methods that we developed
specifically to <FONT STYLE="white-space:nowrap">re-program</FONT> the DNA recognition properties of <FONT STYLE="white-space:nowrap">I-CreI.</FONT> The natural <FONT STYLE="white-space:nowrap">I-CreI</FONT> endonuclease recognizes and cuts a DNA
sequence in the genome of algae. To apply <FONT STYLE="white-space:nowrap">I-CreI</FONT> to genome editing in other cells or organisms, we must modify it to recognize and cut a different DNA sequence for each new application we pursue. Since the <FONT
STYLE="white-space:nowrap">I-CreI</FONT> endonuclease evolved to recognize its target sequence in the algae genome with a very high degree of selectivity, it is difficult to <FONT STYLE="white-space:nowrap">re-design</FONT> it to bind and cut a
different DNA sequence. Using the ARCUS process, we create customized endonucleases for particular applications. We call these custom endonucleases &#147;ARCUS nucleases.&#148; Our process is proprietary and core components are claimed in an
extensive international patent portfolio. Moreover, since the ARCUS process involves a sophisticated blend of protein engineering art and science, each ARCUS nuclease we create is novel and, we believe, patentable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ARCUS process involves a combination of computer-based, or <I>in silico</I>, protein modeling and an experimental method called directed evolution that allows
us to change a substantial portion of the amino acid building blocks in the <FONT STYLE="white-space:nowrap">I-CreI</FONT> endonuclease. We use this process to <FONT STYLE="white-space:nowrap">re-direct</FONT> the endonuclease to a new location in
the genome without compromising its editing abilities. In addition to changing the parts of the enzyme involved in recognizing a target DNA site, we can modify the active site of the enzyme and parts of the enzyme involved in anchoring it to the
DNA. These modifications allow us to control how tightly the enzyme binds to DNA and how quickly it cuts, both of which play an important role in determining the efficiency with which the endonuclease cuts its intended target site or any potential <FONT
STYLE="white-space:nowrap">off-target</FONT> sites. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The natural <FONT STYLE="white-space:nowrap">I-CreI</FONT> target site is pseudo-palindromic,
meaning the first half of the sequence is approximately a mirror image of the second half of the sequence. Palindromic DNA sites are rare in most genomes so it was necessary for us to develop additional technology that would overcome this limitation
on the diversity of DNA sites that we can target. To this end, the ARCUS process involves the production of <I>two</I> <FONT STYLE="white-space:nowrap">re-programmed</FONT> <FONT STYLE="white-space:nowrap">I-CreI</FONT> proteins for each target
site. These two different proteins are then linked together into a single protein that can be expressed from a single gene. This approach, called a &#147;single-chain endonuclease,&#148; represents a major advancement in <FONT
STYLE="white-space:nowrap">I-CreI</FONT> engineering because it enables our ARCUS nucleases to recognize and cut <I>non</I>-palindromic target sites using an endonuclease that, like natural <FONT STYLE="white-space:nowrap">I-CreI,</FONT> is very
small and easy to deliver to cells. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">115 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The graphic below depicts the molecular structure of natural <FONT STYLE="white-space:nowrap">I-CreI</FONT> in
comparison to an engineered ARCUS nuclease called &#147;M1PCSK9.&#148; The regions of the structures colored in pink or cyan represent the amino acid building blocks that are responsible for contacting the DNA target site and determining the
sequence of DNA bases that the endonuclease recognizes and cuts. The DNA target sites recognized by the two endonucleases are shown below the structures. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g36a15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since creating an ARCUS nuclease requires such extensive reengineering of <FONT STYLE="white-space:nowrap">I-CreI,</FONT> it is,
generally, an iterative process that involves multiple cycles of design and testing. We can typically produce a first-generation ARCUS nuclease in seven weeks. First-generation nucleases are suitable for research and development, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies or other <FONT STYLE="white-space:nowrap">non-therapeutic</FONT> applications. For therapeutic applications requiring the lowest possible <FONT
STYLE="white-space:nowrap">off-targeting,</FONT> however, we are rarely satisfied with generation one and each endonuclease undergoes extensive optimization. To this end, we thoroughly interrogate the nuclease with respect to its <FONT
STYLE="white-space:nowrap">on-</FONT> and <FONT STYLE="white-space:nowrap">off-target</FONT> cutting properties using ultra-sensitive tests that we developed specifically for use with ARCUS. These results then inform our design of a
second-generation nuclease with the goal of optimizing <FONT STYLE="white-space:nowrap">on-target</FONT> efficiency while minimizing <FONT STYLE="white-space:nowrap">off-target</FONT> cutting. Therapeutic ARCUS nucleases typically require two to
four cycles of design and testing, often resulting in <FONT STYLE="white-space:nowrap">off-target</FONT> cutting frequencies that are below the limit of detection with our most sensitive assays. This process can take six months or longer and has
resulted in development of &#147;therapeutic-grade&#148; editing endonucleases. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ARCUS process is robust and reproducible. It enables us to create
engineered variants of the <FONT STYLE="white-space:nowrap">I-CreI</FONT> endonuclease that recognize and cut DNA sites that bear little resemblance to <FONT STYLE="white-space:nowrap">I-CreI&#146;s</FONT> natural target site. Importantly, however,
ARCUS retains the attributes of <FONT STYLE="white-space:nowrap">I-CreI</FONT> that we believe make it highly suitable as a genome editing endonuclease for complex commercial applications. We believe that ARCUS nucleases are exquisitely specific as
a result of the natural structure of <FONT STYLE="white-space:nowrap">I-CreI</FONT> and the intricate design process we employ to create them. To our knowledge, ARCUS nucleases are the smallest and easiest to deliver genome editing endonucleases.
Like <FONT STYLE="white-space:nowrap">I-CreI,</FONT> ARCUS nucleases produce DNA cuts with 3&#146; overhangs that promote HDR, facilitating gene insertions and gene repairs in addition to gene knockouts. We believe that these attributes will enable
us to translate ARCUS into a wide array of products that have the potential to address the limitations of other genome editing technologies and improve life. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">116 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our product development platform approach </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We believe that ARCUS is a leading genome editing platform for therapeutic, food and agricultural applications. Realizing the potential of ARCUS, however, requires supporting technologies and capabilities. To
facilitate the potential commercial deployment of ARCUS in different fields, we surround it with ancillary technologies, domain expertise and infrastructure specific to that area of development. We leverage ARCUS to build platforms designed to
rapidly generate new products in a given field. We are currently developing products from three such platforms: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Cancer immunotherapy (allogeneic CAR T cells).&nbsp;&nbsp;&nbsp;&nbsp;</B>Our most advanced product platform is constructed for the large-scale production of
allogeneic CAR T cells for cancer immunotherapy. Our lead therapeutic product candidate, PBCAR0191, is a gene-edited anti-CD19 CAR T cell therapy for the treatment of Acute Lymphocytic Leukemia, or ALL, and
<FONT STYLE="white-space:nowrap">Non-Hodgkin</FONT> Lymphoma, or NHL, for which we submitted an IND to the FDA in October 2018. We are also developing product candidates in this platform against other validated targets, including CD20, <FONT
STYLE="white-space:nowrap">b-cell</FONT> maturation antigen, or BCMA, and <FONT STYLE="white-space:nowrap">CLL-1.</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>In vivo </I></B><B>gene correction.</B>&nbsp;&nbsp;&nbsp;&nbsp;We believe that ARCUS can be used to treat genetic disorders by directly correcting the
causative defect in a patient&#146;s DNA. This approach, long considered the &#147;Holy Grail&#148; of the genome editing field, requires exquisite levels of editing specificity and the ability to deliver editing endonucleases efficiently to
different tissues in the body. As such, we believe that ARCUS is well-positioned to lead this emerging field of genetic medicine. We have several programs targeting the eye and liver and have already achieved <I>in vivo </I><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in large animals, including a <FONT STYLE="white-space:nowrap">non-human</FONT> primate model for a program targeting the liver. We intend to advance certain
of these programs into preclinical development with the goal of submitting an IND to the FDA for our lead <I>in vivo</I> gene correction product candidate in 2020. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Food and agriculture.&nbsp;&nbsp;&nbsp;&nbsp;</B>Our third product platform is built for the creation of novel products that enhance the nutrition and
diversity of the food supply. This platform, which we operate through our wholly owned subsidiary, Elo Life Systems, or Elo, is an integrated suite of gene discovery and plant engineering technologies that allows us to generate <FONT
STYLE="white-space:nowrap">pre-breeding</FONT> material for food producers. Unlike conventional plant biotechnology companies who focus on traits that are valued by the farmer, Elo is focused on a rapidly emerging trend in Western consumers toward
healthier eating. Elo partners directly with food companies to develop healthier ingredients through highly focused genetic optimization. These ingredients, in turn, should translate to healthier food products and improved world nutrition.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our cancer immunotherapy (allogeneic CAR T cells) platform </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g59c35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are leveraging the properties of ARCUS in an integrated platform for the development and large-scale production of CAR T cell
immunotherapies. A key to the success of this platform is a proprietary, <FONT STYLE="white-space:nowrap">one-step</FONT> method for modifying the genetics of T cells from a healthy donor to make them detect and kill cancer cells. This method allows
us to manufacture CAR T cell product candidates rapidly, at large scale and with greater consistency than currently marketed CAR T cell therapies. As such, we believe that our allogeneic CAR T cell platform will greatly increase patient access to
these cutting-edge treatments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">117 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>CAR T cell therapies </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">CAR T cell therapy is a form of cancer immunotherapy that uses a patient&#146;s immune system to kill cancer cells. T cells are a component of the immune system that can distinguish pathogen-infected or tumor cells
from healthy cells and kill them. Recognition of pathogen-infected cells or tumor cells occurs through a protein called a T cell receptor, or TCR, that is expressed on the surface of T cells. Tumor cells, however, have evolved numerous ways to evade
<FONT STYLE="white-space:nowrap">TCR-mediated</FONT> killing by T cells. In CAR T cell therapy, T cells are engineered <I>ex vivo</I> to express a protein called a chimeric antigen receptor, or CAR, that recognizes specific tumor cells and allows
the T cells to function independently of the TCR, thus circumventing tumor cells&#146; evasion of the TCR. CAR T cell therapy has been shown in clinical trials to be an effective treatment for patients that have not responded to traditional cancer
treatments, and there are now two FDA approved CAR T cell products available to treat certain types of leukemia and lymphoma. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The most common form of
CAR T cell therapy, which includes the two approved therapies, is referred to as &#147;autologous&#148; CAR T cell therapy because the CAR T cells are generated using T cells taken directly from the cancer patient. T cells are harvested from the
patient, genetically engineered <I>ex vivo</I> to express a CAR, and then injected back into the patient. While autologous CAR T cell therapy has been shown to be effective for treating certain tumor types, it has several significant drawbacks:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Patient eligibility.</B>&nbsp;&nbsp;&nbsp;&nbsp;Many patients may not be eligible for the treatment because of low T cell numbers and poor T cell quality or
because the risk of undergoing the process to harvest T cells is too great. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Consistency.</B>&nbsp;&nbsp;&nbsp;&nbsp;Since each autologous therapy is, by definition, unique, it is difficult to define standards of safety and efficacy or
to thoroughly assess the quality of the product prior to infusion into the patient. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Delay in treatment.&nbsp;&nbsp;&nbsp;&nbsp;</B>Because the process to make CAR T cells can take several weeks, there is a significant delay in treating what
can often be very aggressive tumors. If manufacturing complications such as contamination, mislabeling or low yield are encountered, the patient may not survive long enough to attempt manufacturing a second time. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Cost.&nbsp;&nbsp;&nbsp;&nbsp;</B>The CAR T cell manufacturing process is complex and expensive. In the case of an autologous therapy, the process must be
performed, in its entirety, for each patient. As such, scaling of the manufacturing process is exceedingly difficult, and the cost of product manufacturing has resulted in high treatment costs per patient. This high cost of treatment, along with the
practical complexities described above, limits the availability of autologous CAR T cell therapies to patients. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">118 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that the use of allogeneic, or donor-derived, CAR T cells will address many of the challenges
associated with autologous CAR T cell therapy. An allogeneic approach allows selection of donors using specific criteria to define &#147;healthy&#148; T cells, which we expect will lessen the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-to-product</FONT></FONT> variability seen in autologous therapies. Donor-derived cells could be used in any patient, eliminating the &#147;one patient: one product&#148; burden of autologous CAR T cell therapies.
Because healthy donors would provide the starting material, patients that were too sick or otherwise unqualified for an autologous approach may benefit from an allogeneic CAR T cell therapy. Additionally, patients receiving an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> allogeneic treatment would not have to wait for the manufacture of a personalized autologous treatment, which could be further delayed by manufacturing
difficulties. By scaling the manufacturing of CAR T cells and optimizing the manufacturing process for a specific pool of donors, we believe that allogeneic CAR T cells can be manufactured at costs that are significantly lower than autologous CAR T
cells and that will, over time, approach the manufacturing costs for conventional biologic drugs. These potential advantages of an allogeneic approach should allow for a safer, more predictable product with defined quality standards and
significantly increase patient access. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g11s18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The major challenge to producing allogeneic CAR T cells is that donor-derived T cells still express their own TCR. Because the
TCR enables T cells to recognize cells that are foreign to the donor, they may induce graft versus host disease, or GvHD, if introduced to the patient in their natural form. This is a dangerous condition in which the donor T cells indiscriminately
attack cells in the body of the patient. Accordingly, expression of the TCR must be eliminated in donor cells before the cells can be engineered into CAR T cells and administered to a patient. An allogeneic CAR T cell therapy therefore requires the
use of a genome editing technology like ARCUS to knock out TCR genes in the DNA to produce &#147;universal&#148; donor cells that are designed to be incapable of eliciting GvHD. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We and others have shown that genome editing can be used to eliminate expression of the TCR on donor cells, and there are several companies working on gene-edited allogeneic CAR T cell therapies. However, there are
a number of challenges associated with manufacturing gene-edited allogeneic CAR T cells, including the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>T cell phenotype.</B>&nbsp;&nbsp;&nbsp;&nbsp;T cells actually comprise several subtypes of different cells. Some subtypes of T cells are directly responsible
for killing virus-infected or tumor cells, while other subtypes serve a helper function. Some subsets retain a &#147;memory&#148; function and can be recalled later if the target tumor reappears, and some subsets even decrease the killing activity
of T cells. These subsets are distinguished by the unique combination of proteins they express on their cell surface, which is described as their &#147;phenotype.&#148; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">119 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
Understanding what phenotypes of T cells are best for a CAR T cell therapy is important, as is the ability to maintain the stability of those phenotypes throughout the manufacturing process.
Depending on growth conditions, phenotypes of T cells may change over the course of a manufacturing run, and the final product may not be the desired mix of T cell subtypes. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Consistency.&nbsp;&nbsp;&nbsp;&nbsp;</B>In most CAR&nbsp;T cell therapies, the CAR is introduced into the T&nbsp;cell using a viral vector, usually a
lentiviral vector. Lentiviral vectors are vectors derived from the <FONT STYLE="white-space:nowrap">HIV-1</FONT> virus, which is a member of the viral subfamily of the lentivirus. This lentiviral vector inserts the CAR randomly or semi-randomly into
the T cell genome. When introduced in this manner, CAR expression typically varies significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cell-to-cell</FONT></FONT> depending on the number of CARs that were delivered
and where in the T cell genome they were inserted. This variability can cause CAR T cells to be inconsistent from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cell-to-cell</FONT></FONT> within the same CAR&nbsp;T cell batch. Too
little expression could make the CAR T cell unable to activate and kill when it identifies a cancer cell. Too much expression could lead the CAR T cell to become hyper-stimulated, which can lead to an inactive state known as &#147;exhaustion.&#148;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Scalability.</B>&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing scale drives the cost and availability of the final <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> product. If an allogeneic CAR T cell therapy cannot be manufactured at large scale, it has few advantages over an autologous therapy. While generating allogeneic CAR T cells at lab
scale (a few million cells) is straightforward, manufacturing them at a clinically relevant scale (billions of cells) is a major challenge that is impacted by, among other things, the efficiency of CAR gene insertion, the efficiency of <FONT
STYLE="white-space:nowrap">on-</FONT> and <FONT STYLE="white-space:nowrap">off-target</FONT> genome editing, starting donor T cell phenotype and the duration of the manufacturing process. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our approach to allogeneic CAR T cells </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have used
the qualities of ARCUS to create a <FONT STYLE="white-space:nowrap">one-step</FONT> cell engineering process for allogeneic CAR T cells that we believe will yield a well-defined cell product in a cost-effective manner. To produce an allogeneic CAR T
cell, it is necessary to make two edits to the DNA of T cells from a healthy donor. First, it is necessary to knock out the gene that encodes the TCR to prevent the donor-derived T cells from eliciting GvHD in the patient. The TCR is actually a
complex of several different components encoded by different genes, and knocking out any one of them is generally sufficient to prevent the TCR from functioning. Second, it is necessary to add, or knock in, a gene that encodes the CAR to give the T
cells the ability to recognize and kill cancer cells. Precision developed a proprietary, <FONT STYLE="white-space:nowrap">one-step</FONT> method for achieving both genetic changes simultaneously. This method, aspects of which are protected by seven
issued U.S. patents, involves the use of ARCUS to target the insertion of a CAR gene directly into the gene that encodes the alpha subunit of the TCR. This approach adds the DNA encoding the CAR while simultaneously disrupting the DNA encoding the
TCR, essentially replacing one gene with the other. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">One-step</FONT> engineered allogeneic CAR T cells
</B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g20j13.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">120 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that our <FONT STYLE="white-space:nowrap">one-step</FONT> engineering approach, and the differentiated
attributes of the ARCUS nucleases used to implement it, will overcome many of the critical challenges associated with allogeneic CAR&nbsp;T cell production as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>T cell phenotype.</B>&nbsp;&nbsp;&nbsp;&nbsp;Because it is well established that T cell phenotype has a profound impact on the efficacy of CAR&nbsp;T cell
therapy, we have established a T cell platform that is designed to maximize the percentage of cells with ideal phenotypes. Our process starts with carefully screening donors to identify individuals with high percentages of &#147;young&#148;
(na&iuml;ve or central memory) T cells that should yield the most potent cell product. To this end, we have developed our own set of analytics for screening candidate donors and have put significant effort into identifying individuals with the
desired T cell profiles. We then use proprietary growth strategies and media to maintain the selected phenotype throughout the CAR T manufacturing process. Importantly, our <FONT STYLE="white-space:nowrap">one-step</FONT> genome editing approach
helps minimize cell processing time, which helps prevent the CAR T cells from differentiating during the process. We believe our <FONT STYLE="white-space:nowrap">10-day</FONT> allogeneic manufacturing process is the shortest in the industry.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Consistency.</B>&nbsp;&nbsp;&nbsp;&nbsp;By targeting the insertion of the CAR gene to a defined location in the DNA of the cell, we are able to produce
populations of T cells that are identical at the DNA level. This makes the cells in our CAR&nbsp;T cell drug formulation less heterogeneous as compared to manufacturing processes that use lentiviral vectors. Importantly, our genome editing process
gives us greater control over the amount of CAR that is expressed on the surface of each CAR T cell, which determines how easily the CAR T cell is activated once it encounters a cancer cell. This allows us to &#147;fine-tune&#148; the CAR T cells to
ensure that they respond appropriately to the cancer but do not become hyper-activated or exhausted. The below comparison demonstrates the difference in consistency achieved by using lentivirus delivery compared with targeted delivery through an
ARCUS nuclease. CAR T cells produced using ARCUS exhibit reduced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cell-to-cell</FONT></FONT> variability as well as more controlled levels of CAR gene expression depending on whether
the calls are tuned for high expression or low expression. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g12p10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Scalability.</B>&nbsp;&nbsp;&nbsp;&nbsp;To realize the potential benefits of allogeneic CAR T cell therapy, it will be important to manufacture as many cells
as possible in each batch in accordance with GMP. Scaling efficiently requires <FONT STYLE="white-space:nowrap">scale-up</FONT> at every step in the process and, as with all drug manufacturing, process development takes significant time and capital.
We made the decision early in the development of our CAR&nbsp;T cell platform to invest in process development and manufacturing rather than initiating clinical trials with a process that would not fully support development and commercialization. We
did this, in part, because we believed that several attributes of ARCUS, such as high specificity and high knockin efficiency, would allow us to scale manufacturing more effectively than our competitors. As a consequence of our early investment and
the <FONT STYLE="white-space:nowrap">one-step</FONT> editing method enabled by ARCUS, our manufacturing process today is <I>scaled</I> as opposed to <I>scalable</I>. We are manufacturing our lead anti-CD19 allogeneic CAR&nbsp;T cell product
candidate at multi-billion </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">121 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
cell scale consistently, and our best manufacturing runs have yielded over one hundred doses of drug product at a dose of 1e6 CAR T cells/kg, which is the middle dose in our forthcoming Phase
1/2a clinical trial. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In order to maximize the potential of our CAR&nbsp;T cell platform, we have developed extensive <FONT
STYLE="white-space:nowrap">in-house</FONT> capabilities to support the entire process, from discovery to manufacturing, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">A fully human antibody platform for the production of novel CAR binding domains. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">A proprietary collection of costimulatory signaling domains that, if incorporated into a CAR, induce the cell to multiply in response to exposure to cancer
cells. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">A high-throughput method for screening new CARs to evaluate their cancer killing activity and target specificity. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">ARCUS for knocking genes out or in to optimize the genetics of our CAR T cells. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">An <FONT STYLE="white-space:nowrap">in-house</FONT> adeno-associated virus, or AAV, platform for the production of
<FONT STYLE="white-space:nowrap">CAR-encoding</FONT> AAV vectors. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">An <FONT STYLE="white-space:nowrap">in-house</FONT> mRNA platform for the production of ARCUS-encoding mRNA. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">An <FONT STYLE="white-space:nowrap">in-house</FONT> animal facility with real-time tumor imaging capabilities. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Proprietary cytometry panels, potency assays and other bioanalytics for product quality control and release. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Proprietary manufacturing process for large-scale production of GMP CAR T cells. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">In-house</FONT> GMP manufacturing expect to be completed in the first half of 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our cancer immunotherapy (allogeneic CAR&nbsp;T cells) pipeline </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We plan to leverage our CAR&nbsp;T cell platform to develop product candidates against validated CAR&nbsp;T cell targets in the near term. By focusing on vetted targets, we seek to avoid many technical hurdles
associated with early clinical development and can validate our allogeneic platform in patients with fewer variables. This approach also allows us to leverage the abundance of available public resources for these targets, including CARs, cell and
animal models, and clinical protocols. In parallel to advancing product candidates for validated CAR&nbsp;T cell targets, we are performing early-stage research on more challenging solid tumor targets for which the quality and efficiency of the
genome editing is expected to be critical for success. Therefore, we expect that we will gradually shift from a focus on validated liquid tumor targets to more challenging solid tumor targets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">122 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The first four product candidates in our CAR&nbsp;T cell development pipeline are: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>PBCAR0191</B>.&nbsp;&nbsp;&nbsp;&nbsp;PBCAR0191 is an allogeneic anti-CD19 CAR&nbsp;T cell product candidate for ALL and NHL. CD19 is a protein that is
expressed on the surface of B cells. It is a well-validated target for CAR&nbsp;T cell therapy and the two currently marketed autologous CAR&nbsp;T cell products (Yescarta and Kymriah) also target CD19. In February 2016, we entered into the Servier
Agreement and we have agreed to develop allogeneic CAR T cell therapies for up to six unique antigen targets selected by Servier, one of these antigen targets is CD19. We submitted an IND to the FDA for our allogeneic PBCAR0191 in October 2018. As
shown below, PBCAR0191 was observed to prolong survival in mouse models of leukemia <FONT STYLE="white-space:nowrap">(Nalm-6</FONT> model) and lymphoma (Raji <FONT STYLE="white-space:nowrap">Sub-Q</FONT> model). Moreover, the gene edited cells were
observed to not elicit GvHD, as measured by weight loss and survival, in a xenotransplantation model in which <FONT STYLE="white-space:nowrap">un-edited</FONT> human T cells are exceedingly toxic. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="56%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Nalm-6 Leukemia Model</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Raji Sub-Q Lymphoma Model</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><B>


<IMG SRC="g367280g36u48.jpg" ALT="LOGO">
</B></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><B>


<IMG SRC="g367280g62i20.jpg" ALT="LOGO">
</B></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g97t94.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">123 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>PBCAR1201</B>.&nbsp;&nbsp;&nbsp;&nbsp;PBCAR1201 is an allogeneic anti-CD20 CAR T cell product candidate for Chronic Lymphocytic Leukemia. Like CD19, CD20 is a
protein expressed on the surface of B cells. It is an established target for cancer treatment and several CD20-targeted therapies, such as the monoclonal antibody Rituxan, have long histories of clinical success. We have selected a development
candidate for our anti-CD20 CAR T cell product and have observed tumor cell killing in <I>in vivo</I> preclinical animal studies. We anticipate submitting an IND to the FDA on PBCAR1201 in 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>PBCARBCMA1</B>.&nbsp;&nbsp;&nbsp;&nbsp;PBCARBCMA1 is an allogeneic anti-BCMA CAR T cell product candidate for Multiple Myeloma. BCMA is a protein that is
expressed on the surface of mature B cells called &#147;plasma cells&#148; that are responsible for the disease. It is a validated target for CAR T cell and autologous therapies, such as bluebird bio&#146;s bb2121 program, have yielded promising
results in early clinical studies. We have selected a development candidate for our anti-BCMA product and have observed tumor cell killing in <I>in vivo </I>preclinical animal studies. We anticipate submitting an IND to the FDA on PBBCMA1 in 2020.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>PBCARCLL1</B>.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>PBCARCLL1 is an allogeneic
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-CLL-1</FONT></FONT> CAR T cell product candidate for Acute Myeloid Leukemia, or AML. <FONT STYLE="white-space:nowrap">CLL-1</FONT> is a protein that is expressed on myeloid
cells, including many AML cancer cells. It is less well-validated than the other targets that we are developing products against but we believe that it is worth investigation due to promising preclinical data and the very high unmet need in AML. We
are currently screening CAR vectors to identify a development candidate to move into <I>in vivo </I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies. We anticipate submitting an IND to the FDA
on PBCARCLL1 in 2020. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our </B><B><I>in vivo</I></B><B> gene correction platform </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g40d80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect
<I>in vivo </I>genome editing to be a significant focus of our operations long-term because the differentiated attributes of ARCUS are particularly advantageous for this type of application. <I>In vivo</I> gene correction involves the delivery of
ARCUS nucleases directly into a patient&#146;s cells to treat disease at the level of the underlying DNA. <I>In vivo </I>genome editing is more complex and challenging than <I>ex vivo</I> approaches like CAR T cells due to the need to safely deliver
ARCUS directly to cells in the body. We believe that <I>in vivo</I> applications are particularly well suited to ARCUS because they require extremely low levels of <FONT STYLE="white-space:nowrap">off-target</FONT> editing and efficient delivery.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Due to the demands of <I>in vivo</I> editing, we are taking a highly disciplined approach to managing our project portfolio that emphasizes studies in
large animals, using both viral and <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery technologies. We believe that there is a remarkable lack of large animal data in the genome editing field and that demonstrating safety and efficacy in
large animals is an important gating step prior to beginning human clinical studies. Thus, we are advancing an extensive and diverse portfolio of programs toward <I>in vivo</I> efficacy and toxicity studies and are generating a large animal dataset
that, we believe, will be the most comprehensive of any in the field. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Treatment of genetic disease </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Genetic diseases are caused by errors in the DNA that lead to misfunction of a cell or tissue. While the underlying cause of a particular genetic disease can often
be complex and variable, DNA errors generally fall into two categories: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function.</FONT></FONT> Genetic diseases are most frequently caused by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">124 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> errors in which a particular gene is mutated at the DNA level in such a way that it is either <FONT
STYLE="white-space:nowrap">non-functional</FONT> or less functional than it should be. In these cases, treating the disease requires <I>adding</I> the function that the cell or tissue is otherwise lacking. Gain of function genetic disorders are the
result of DNA errors that cause a gene to acquire a new, harmful function that leads to disease. In these cases, it is necessary to remove the unwanted function to treat the disorder. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Genetic disease is a very active area of therapeutic development, and the therapies that are available or in development are, to a large extent, as variable and specialized as the diseases themselves. There are,
however, two gene therapy platform approaches that are being broadly applied to the treatment of multiple genetic disorders. For the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT>
diseases, <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy can often be an effective treatment. AAV is a <FONT STYLE="white-space:nowrap">non-integrating</FONT> virus that can be used to deliver DNA to a wide range of different cell
types in a patient. The virus can be engineered to deliver a functional copy of a gene that is otherwise missing or under-performing in the cell. This approach can, in some cases, restore normal function to the cell and alleviate the symptoms of the
disease. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">While a number of <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapies appear to be showing great promise in clinical trials, the
approach is subject to a number of limitations. Many patients have antibodies in their blood that recognize and inactivate the AAV virus before it can deliver the DNA into the patient&#146;s cells. In addition, among patients who do <I>not</I> have
antibodies upon initial treatment with the virus, most will develop antibodies following the first dose. Therefore, in most cases, it is only possible to dose a patient one time. Most importantly, although
<FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy can be an effective treatment, it is probably not a permanent <I>cure</I> because <FONT STYLE="white-space:nowrap">AAV-delivered</FONT> genes do not generally persist for more than a few
years in the body. While the duration of virus persistence varies from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cell-to-cell</FONT></FONT> and from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">patient-to-patient,</FONT></FONT> it is not believed to be permanent and symptoms of the disease can return once the virus is no longer present in the body. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A second platform gene therapy approach, RNA interference, or RNAi, has been shown to be an effective treatment strategy for many <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gain-of-function</FONT></FONT> genetic disorders. These therapies usually take the form of a small-interfering RNA, or siRNA, which is a short piece of synthetic RNA that can &#147;silence&#148; or partially inactivate a
deleterious gene if it is delivered to a cell in sufficient quantities. Therapeutic siRNA is most frequently used to silence genes with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function</FONT></FONT> mutations that
are expressed in the liver. This is because the siRNA molecules can be delivered efficiently to liver cells following IV infusion using a variety of different delivery approaches. Like <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy,
the primary limitation of RNAi approaches is that they lack permanence. siRNA drugs have a limited lifetime and, therefore, must be administered repeatedly for the life of the patient in order to be effective. While longer half-life siRNA drugs are
showing persistence for up to six months, we believe there is a need for therapeutic options that untether the patient from regular drug treatments by addressing the underlying cause of the disease. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our approach to </I></B><B>in vivo</B><B><I> gene correction </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our goal is to cure genetic diseases by correcting the DNA errors responsible for causing them. In principle, <I>in vivo</I> genome editing can likely be used to cure any genetic disorder. In practice, however,
<I>in vivo</I> genome editing is limited by several challenges that, we believe, are best addressed using ARCUS: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Specificity.&nbsp;&nbsp;&nbsp;&nbsp;</B><I>In vivo </I>genome editing requires an extremely high degree of precision to minimize the occurrence of any
unwanted <FONT STYLE="white-space:nowrap">off-target</FONT> editing. <FONT STYLE="white-space:nowrap">Off-target</FONT> changes to the DNA could, potentially, have significant safety implications that may not manifest themselves until well after
administration of the therapy. As enumerated above, we believe that the differentiated attributes of ARCUS enable us to create endonucleases that have a very high degree of specificity and minimal levels of
<FONT STYLE="white-space:nowrap">off-target</FONT> editing to address this significant safety concern. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">125 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Delivery.</B>&nbsp;&nbsp;&nbsp;&nbsp;Gene delivery technologies suitable for the delivery of genome editing endonucleases to tissues <I>in vivo</I> have not
been developed for all tissues. Delivery challenges are particularly pronounced for editing applications that require promoting DNA repair by HDR because it is necessary to deliver both the nuclease and the DNA &#147;donor&#148; template for HDR. We
have focused our initial development efforts on genetic disorders of the eye and liver, two tissues for which we believe we have good options for delivery and in which we have shown ARCUS to be effective in preclinical studies. We believe the small
size of our ARCUS nucleases and their ability to efficiently promote HDR will enable us to address a greater variety of genetic diseases requiring more complex delivery strategies. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Efficiency.</B>&nbsp;&nbsp;&nbsp;&nbsp;Genome editing efficiency is a critical parameter for <I>in vivo </I>therapeutic efficacy because the requisite edit
must be achieved in a sufficient number of cells to have therapeutic benefit. Efficiency is best measured <I>in vivo</I> in animals because it is affected by multiple parameters including delivery, endonuclease activity and the accessibility of the
DNA target site in the organism. Moreover, we believe that only large<I> </I>animals such as <FONT STYLE="white-space:nowrap">non-human</FONT> primates accurately model these different parameters and are representative of the human condition. As
such, we have placed a good deal of emphasis on large animal studies and have demonstrated, we believe, therapeutic levels of editing efficiency using ARCUS in the most relevant models. This gives us greater confidence that ARCUS will translate from
the lab bench to the clinic. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The potential of ARCUS for <I>in vivo</I> genome editing is highlighted in a July 2018 publication in
<I>Nature Biotechnology</I> that describes a research project performed as part of a collaboration between our company and Dr.&nbsp;Jim Wilson&#146;s Orphan Disease Center at the University of Pennsylvania.
<FONT STYLE="white-space:nowrap">Co-authors</FONT> of the publication include Derek Jantz and Jeff Smith, two of our <FONT STYLE="white-space:nowrap">co-founders.</FONT> This publication is, to our knowledge, the first peer-reviewed publication of
<I>in vivo</I> genome editing data in <FONT STYLE="white-space:nowrap">non-human</FONT> primates. The publication reported well tolerated, long-term, high-efficiency editing of the PCSK9 gene in <FONT STYLE="white-space:nowrap">non-human</FONT>
primates using ARCUS. A single IV administration of an AAV vector encoding a PCSK9-specific ARCUS nuclease was able to efficiently knock out the gene in the livers of Rhesus macaques, a species of monkey, resulting in up to approximately 85% reduced
levels of PCSK9 protein in the blood. This reduction in PCSK9 then resulted in significantly reduced levels of <FONT STYLE="white-space:nowrap">LDL-C,</FONT> commonly known as &#147;bad cholesterol,&#148; in the blood of treated animals. Because
this therapeutic effect is due to modifications to the DNA itself, the benefit of the treatment appears to be permanent. The first animals that were treated have maintained reduced levels of PCSK9 and <FONT STYLE="white-space:nowrap">LDL-C</FONT>
since they were treated in February 2017. Importantly, even at the highest dose the treatment was observed to be well tolerated. These peer reviewed data exemplify the power of ARCUS for <I>in vivo</I> editing at therapeutically meaningful levels of
efficiency. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>LDL Serum Levels </B></FONT></P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g24b05.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">126 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that establishing collaborations with other groups that have domain expertise and access to the most
relevant animal models will be important to advancing our <I>in vivo</I> editing platform, and we have entered into a number of collaborations and licensing agreements with third parties to help us advance our <I>in vivo</I> editing portfolio. In
particular, in September 2018 we announced a sponsored research agreement with the Orphan Disease Center at the University of Pennsylvania. This organization, led by Dr.&nbsp;Jim Wilson, is dedicated to curing rare genetic diseases and has access to
unique expertise and resources, including AAV vector production and <FONT STYLE="white-space:nowrap">non-human</FONT> primate models. Several of our liver-directed projects are being conducted in collaboration with Dr.&nbsp;Wilson under this
agreement. In September 2018, we also announced a partnership with Gilead to <FONT STYLE="white-space:nowrap">co-develop</FONT> an ARCUS-based treatment for chronic Hepatitis B infection. Infection by the Hepatitis B Virus is in many ways analogous
to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function</FONT></FONT> genetic disorder. In this case, the deleterious DNA that needs to be eliminated is the genome of the virus itself. To this end, Precision and
Gilead are working together to develop an ARCUS-based drug that specifically targets and eliminates virus DNA from infected liver cells. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that
our proprietary ARCUS genome editing platform, strong collaborations and a disciplined approach to preclinical development that emphasizes large animal studies will help position us to unlock the enormous potential of therapeutic <I>in vivo</I>
editing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our food and agriculture platform </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g03d00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Technology-centric solutions to meet changing demands in food and agriculture </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Improvements in food and agriculture have been central to the development of the modern world. The total global food and agriculture market, estimated to be at $5
trillion (2015), is heavily influenced by population growth, highly urbanized population, access to disposable income and changing consumer behavior. With the global population projected to reach 8.5 billion by 2030, demand for basic food and
nutrition needs has already put a lot of pressure on traditional food production systems. In response, the agriculture industry is currently in the process of a slow, but massive, repositioning effort to reinvent its capital-intensive
infrastructure, complex business structures and product pipelines. The food and agriculture industry has also seen significant shifts in consumer preferences where consumers are actively transitioning to high quality and healthier foods and
beverages, while rejecting artificial ingredients, sugar and salt, creating a demand for natural and holistic ingredients built on a sustainable supply chain. Traditional approaches to agricultural innovation are slow, siloed, rely heavily on <FONT
STYLE="white-space:nowrap">non-scalable</FONT> academic advancements and continue to use inefficient crop improvement practices. It is our belief that the current pressures on the food and agriculture industry from imminent threats like food
insecurity, nutritional insecurity, new pests and diseases, the impact of climate change, and an ever-increasing incidence of diet related illnesses, can only be met by addressing the unmet needs at a systems level, through technology and creative
business models. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Elo Life Systems: Innovation-focused technology platform and business model </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Elo Life Systems is our wholly owned subsidiary, dedicated to addressing the needs of consumers and consumer-facing industries in the food and agriculture sector.
By combining the power of our technology </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">127 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
platform with a differentiated collaboration-based business model, we are enabling our partners to address emerging opportunities in food and agriculture. Further, our business model enables us
to remain capital efficient throughout the product-development cycle while generating revenue through various revenue-sharing models; the industry partners gain access to our technology platform and our continuously improving knowledgebase.
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g25i86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Elo&#146;s technology platform </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> food and agriculture platform is built to support rapid innovation across multiple crop species. With our ARCUS genome
editing platform as our cornerstone technology, we have integrated complementary tools and technologies both upstream and downstream of this pipeline. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1" COLOR="#FFFFFF">ARCUSTM and other Complementary technologies
Target Discovery Bioinformatics tools OMICS &amp; analytics Automated workflows Target discovery pipeline Target Validation ARCUS Gene delivery Edit screening Target Validation pipeline Product Characterization Multicrop transformation Protoplast
screens Regeneration Greenhouse trials End-to-End Food and Agriculture Platform </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g07t67.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are one of the first to apply genome editing technology
to crop plants and we believe we have the most <FONT STYLE="white-space:nowrap">in-depth</FONT> experience in crop genome editing in the industry. Over the last decade, we have developed highly efficient methods to improve delivery and functionality
of ARCUS nucleases in plants to edit DNA. These nucleases have been successfully validated in collaborative projects with major food and agriculture companies like Cargill, BASF, Bayer CropScience and DuPont Pioneer
<FONT STYLE="white-space:nowrap">Hi-bred.</FONT> A comparison of the three breeding </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">128 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
approaches (below) elucidates the value of ARCUS as the preferred genome editing platform for crop improvement. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Traditional breeding</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Mutagenesis breeding</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Precise breeding</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Can specific gene(s) be targeted to generate a desired phenotype?</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Yes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Yes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Yes</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>How is it done?</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Crossing and selecting plants over several generations</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Chemical or radiation induced random mutations in the genome. Select one with a desired mutation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Precisely edit a gene of interest by targeting a specific DNA sequence encoding that gene </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>How many unintended genes perturbed or mutated?</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Very high</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">High</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Few to none</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Product development timelines</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">10-20</FONT> years</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">7-10</FONT> years</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">3-5</FONT> years</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="7" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Capabilities from discovery to development </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Elo&#146;s food and agriculture platform serves as an attractive proposition for companies in the industry for the following reasons: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Robust target discovery.&nbsp;&nbsp;&nbsp;&nbsp;</B>Elo&#146;s multiscale biology-based computational workflow is built on the principles of machine learning
and therefore scalable and highly adaptable across crops. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Scalable target validation.&nbsp;&nbsp;&nbsp;&nbsp;</B>ARCUS nucleases have been successfully used in multiple crops of commercial importance like cotton,
rice, canola, maize, petunia and alfalfa. The nucleases optimized specifically for applications in plants using our proprietary methods show a high degree of editing efficiency with minimal <FONT STYLE="white-space:nowrap">off-site</FONT> targeting.
Further the small size of the nuclease enables a differentiated technical advantage by improving nuclease delivery efficiencies into cells. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Access to other complementary technologies and expertise.&nbsp;&nbsp;&nbsp;&nbsp;</B>Our platform integrates expertise across traditional (molecular breeding)
and novel <FONT STYLE="white-space:nowrap">(next-gen</FONT> sequencing) complementary technologies. This holistic approach enables us to rapidly integrate historical datasets into our discovery pipeline and help springboard innovative programs
leading to novel products. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Multi-crop expertise and experience.</B>&nbsp;&nbsp;&nbsp;&nbsp;We are a solutions-focused company that partners with key players in the food and agriculture
space to improve crops through technology. For this reason, we have built capabilities that are broadly applicable to improving a diverse portfolio of crops like canola, soybean, rice, stevia, cucumber, watermelon, alfalfa and sorghum.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">129 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have used ARCUS to implement genome edits in a variety of plants as shown by the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g98e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are building our platform to serve as an integrated accelerator for all critical stages of product development- from target
gene discovery to generation of <FONT STYLE="white-space:nowrap">pre-breeding</FONT> material. In the advanced stages, collaborators will assume responsibilities of navigating the project through the final stages of development and into
commercialization. We classify our stages of food product development as Discovery, Greenhouse, Field 1, Field 2 and Field 3. In Discovery, we identify the trait and genetic targets of interest. In Greenhouse, we attempt to edit the intended target
and produce initial plant material in a controlled environment. In Field 1, we grow a small number of plants in the field to characterize and confirm the desired phenotype. In Field 2, we grow a larger number of plants at multiple sites to further
confirm the desired phenotype in various geographies. In Field 3, we grow a commercial-scale pilot quantity and perform customer testing. </FONT></P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g15w60.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1" COLOR="#FFFFFF">ELO LIFE SYSTEMS COLLABORATOR DISCOVERY Bioinformatics and OMICS Legacy/Field
knowledge Model crop testing PROOF OF CONCEPT Laboratory based Target confirmation Target optimization Event generation Event and characterization GREENHOUSE Event and trait characterization Pre-regulatory data Greenhouse studies Greenhouse trials
FIELD 1 and 2 Field testing Trait integration Regulatory submission Product development FIELD 3 PRE LAUNCH Product development Regulatory approval Seed bulk-up Pre-marketing PRODUCT LAUNCH Seed bulk-up Storage Marketing </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">Ultra-low</FONT> saturated fatty acid canola oil (in collaboration with Cargill Inc.) </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Canola oil is the third largest vegetable oil by volume after palm and soybean oil. In the United States, canola oil is one of the most widely consumed oils, second
only to soybean oil. With worldwide production at 30&nbsp;million metric tons in 2017, the global canola oil is estimated to be a $20&nbsp;billion industry. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Cargill is one of the world&#146;s largest growers and processors of canola. Since 2014, Elo and Cargill are engaged in a collaboration to produce ARCUS-optimized canola varieties and have achieved significantly
lower levels (less than 4.5%) of saturated fatty acids compared to the current levels (7%). This oil with the desirable premium trait, is intended for the quick-service restaurants and food ingredients industries, and products made with
it&#151;particularly fried foods&#151;may be able to use <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">front-of-package</FONT></FONT> nutrient content claims on saturated fat levels, such as &#147;Low in Saturated Fat&#148; or
&#147;No Saturated Fat,&#148; depending on their overall nutritional profile. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This program has generated canola varieties with up to an approximately
38% decrease in total saturated fats compared to unedited varieties. These edited varieties are currently being evaluated in greenhouse and field trials. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">130 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Low-calorie sweeteners from stevia and monk fruit </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The $2&nbsp;billion <FONT STYLE="white-space:nowrap">low-calorie</FONT> sweetener market is the fastest growing segment in the sweetener industry given the recent data connecting excessive consumption of high
fructose corn syrup and cane sugar has been linked to diabetes, metabolic syndrome and heart disease. Changing consumer preferences over the last few years are expected to contribute to a greater than 4% CAGR growth from 2017 to 2027 for natural,
high intensity sweeteners like stevia and monk fruit. We expect this market to grow rapidly as the food and beverage industry reacts to increased taxation on beverages sweetened with cane sugar and transitions to natural alternatives. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Over the past decade, stevia has emerged as a preferred <FONT STYLE="white-space:nowrap">low-calorie</FONT> sugar substitute. However, stevia is subject to a number
of disadvantages, including undesirable aftertaste, complex biology, unsustainable production practices and supply chain issues. Self-incompatibility, or a genetic condition that prevents self-fertilization and promotes outcrossing for flowering
plants, has been identified as one of the main limitations in stevia improvement. We believe changing that property of stevia will not only address the issues limiting the food industry from fully embracing stevia into their product development
pipeline, but will introduce new breeding strategies to expeditiously improve the crop. At Elo, we are currently developing self-compatible stevia varieties to help advance global stevia production, address current issues within the stevia supply
chain. Our stevia products will allow us to develop varieties suitable for cultivation in the United States, the largest and fastest growing market for <FONT STYLE="white-space:nowrap">low-calorie</FONT> sweeteners. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The food and beverage industry sees a high-intensity sweetener from monk fruit as a possible solution to issues with stevia. The monk fruit compound, Mogroside V,
is approximately 300 times sweeter than cane sugar and has been identified as an excellent alternative to cane sugar and stevia. We are currently engaged in studying the mogroside biosynthetic pathway in monk fruit and other related crops with the
goal of scaling up Mogroside V as a viable option for the industry. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Plant-based proteins </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Shifting consumer preferences across the globe towards plant-based proteins have been greatly influenced by reports correlating animal protein to lifestyle
diseases, such as diabetes and heart disease, sustainability and climate change. This demand for plant-based proteins, projected to grow to a $10.5&nbsp;billion global industry by 2020, cannot be met by the pulse and legume industries that use
traditional breeding methods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are developing novel strains of pulse crops with improved agronomic performance, improved nutritional profiles and
enhanced sensory qualities to facilitate rapid integration into the food industry. By creating new varieties of pulses and legumes, we are creating new opportunities for the food industry to incorporate the raw materials into their product pipeline.
We have embarked on a pulse improvement program which will be heavily aided by our multi-omics-based target discovery platform and our expertise in multi-crop transformation. We aim for the resulting products to make a significant contribution
towards the increasing demand for sustainable plant-based proteins as a healthful alternative to animal protein. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Manufacturing </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently contract with third parties for the manufacturing of materials used in the production of our product candidates. To date, our third-party manufacturers
have met our manufacturing requirements. We believe that there are alternate sources of supply that can satisfy our requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The manufacturing
process for our cancer immunotherapy (allogeneic CAR T cells) platform utilizes a <FONT STYLE="white-space:nowrap">one-step</FONT> cell engineering method in which a CAR gene is targeted directly into the T cell receptor alpha constant, or TRAC,
locus. We believe this approach greatly streamlines the manufacturing process. Commercial raw </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">131 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
materials and reagents for this production are readily available. Our manufacturing strategy for our <I>in vivo </I>gene correction platform and our food and agricultural platform is to
internally control process development and manufacturing to safeguard the proprietary nature of our technology and facilitate our ability to function as an integrated life sciences company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are building strong internal scientific process development and manufacturing capabilities, including investing in building a cGMP-compliant manufacturing facility to support our therapeutic product development
platforms. We believe that having internal manufacturing capacity and expertise will be a competitive advantage that enables enhanced control over process development timelines, costs and intellectual property. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are in the planning stages of building a cGMP-compliant manufacturing facility. We have leased approximately 17,300 feet of space for our manufacturing facility
at a location approximately seven miles from our headquarters in Durham, North Carolina. We expect to have a modular, three suite cleanroom setup, for CAR T cell, mRNA and AAV production, to process development for our cancer immunotherapy
(allogeneic CAR T cells) platform. We expect that our manufacturing facility will leverage single use, disposable, closed system operations aligned to our technology platforms to ensure both flexibility and cost effectiveness. The initial scope will
be for preclinical through Phase 1/2a manufacturing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>License and collaboration agreements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Servier </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2016, we entered into the Servier
Agreement, pursuant to which we have agreed to develop allogeneic chimeric antigen receptor T cell therapies for up to six unique antigen targets selected by Servier. Upon selection of an antigen target by Servier, we perform early-stage research
and development on individual T cell modifications for the selected target, develop the resulting therapeutic product candidates through Phase 1 clinical trials and prepare clinical supply of such product candidates for use in Phase 2 clinical
trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We received an upfront payment of $105.0&nbsp;million under the Servier Agreement. At Phase 2 readiness for any product candidate covered by the
Servier Agreement, Servier may exercise a commercial option to proceed with development and commercialization of the product candidate, subject to option fees. We have the ability to receive total payments, including the upfront payment, option fees
and milestone payments, in the aggregate across all six targets that may be selected by Servier, of up to approximately $1.6&nbsp;billion, as well as the payment of tiered royalties ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT>
digit percentages to the low double digit percentages on world-wide net sales of any products developed under the Servier Agreement, subject to customary potential reductions. Servier&#146;s obligation to pay royalties to us expires on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis upon the later of
(1)&nbsp;the expiration of the last to expire valid claim of all Precision patents covering a licensed product, (2)&nbsp;expiration of all regulatory exclusivity with respect to a licensed product in the applicable country of sale, and (3)&nbsp;the
expiration of a certain number of years following the first commercial sale of a licensed product in a country. We also have the right to participate in the development and commercialization of any licensed products resulting from the collaboration
through a 50/50 <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-promotion</FONT> option in the United States, subject to our payment of an option fee, which is exercisable after Servier&#146;s
commercial option exercise. So long as Servier holds a commercial license with respect to any particular licensed product, we may not develop, manufacture or commercialize any engineered human T cells with chimeric antigen receptors for use in
humans directed to the same antigen target as the target of that licensed product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless terminated earlier, the Servier Agreement expires upon the
first to occur of (1)&nbsp;the expiration of the period in which Servier may nominate antigen targets, if there are no targets nominated by Servier, (2)&nbsp;the expiration of the period in which Servier may exercise a commercial option on a
licensed product candidate, if no commercial options have been exercised by Servier, or (3)&nbsp;the expiration of the last to expire royalty term </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">132 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
for the licensed products and satisfaction of all of Servier&#146;s payment obligations under the agreement. Servier has the right to terminate the agreement for convenience, either in its
entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, by providing advance
notice to us. We may terminate immediately upon notice to Servier if Servier (itself or through the use of certain affiliates or a third party) or any sublicensee initiates or participates in a patent challenge against our patents licensed by
Servier under the agreement. In addition, the Servier Agreement may be terminated (a)&nbsp;by either party for the other party&#146;s material breach that remains uncured as specified in the agreement, (b)&nbsp;by either party upon the occurrence of
certain insolvency-related events of the other party and (c)&nbsp;upon mutual agreement of the parties in the event either party suffers an event of force majeure as specified in the agreement. If Servier terminates the agreement for our uncured
material breach of provisions in the agreement that restrict development, manufacture or commercialization of engineered human T cells with chimeric antigen receptors for use in humans directed to a target selected by Servier, certain licenses we
grant to Servier will become royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> perpetual and irrevocable with respect to the licensed product candidates and licensed products directed to the target that was the subject of such
breach, and Servier will be deemed to have previously exercised its commercial option for any then-existing licensed product candidates directed to such target. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Gilead </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In September 2018, we and Gilead entered into a collaboration and license agreement, which we
refer to as the Gilead Agreement, to develop genome editing tools using ARCUS to target viral DNA associated with the Hepatitis B virus. Pursuant to the terms of the agreement, Gilead received an exclusive license to exploit the resulting synthetic
nucleases and products that use them to treat the Hepatitis&nbsp;B virus in humans, and we are entitled to receive up to approximately $40&nbsp;million in research funding over an initial three year term and milestone payments of up to an aggregate
of $445&nbsp;million. We are also entitled to receive tiered royalties ranging from the high single digit percentages to the <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on world-wide net sales of the products developed through the
collaboration, subject to customary potential reductions. Gilead&#146;s obligation to pay royalties to us expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, upon the latest to occur of certain events related to patents, regulatory exclusivity or first commercial sale of the product. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless terminated earlier, the Gilead Agreement will continue, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">licensed-product-by-licensed-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of
a defined royalty term for each licensed product and country. Gilead has the right to terminate the Gilead Agreement for convenience by providing advance notice to us as specified in the Gilead Agreement. Gilead may also terminate the agreement
during the collaboration term if we enter into certain change of control transactions with a third party that is clinically developing or commercializing products in the field of the Hepatitis B virus. In addition, either party may terminate the
Gilead Agreement (1)&nbsp;for material breach by the other party and a failure to cure such breach within the time period specified in the Gilead Agreement and (2)&nbsp;upon the occurrence of certain insolvency-related events of the other party.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Duke University </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2006, we
entered into the Duke License, pursuant to which Duke granted us an exclusive (subject to certain <FONT STYLE="white-space:nowrap">non-commercial</FONT> rights reserved by Duke), sublicensable, worldwide license under certain patents related to
certain meganucleases and methods of making such meganucleases owned by Duke to develop, manufacture, use and commercialize products and processes that are covered by such patents, in all fields and in all applications. The patents that we license
pursuant to the Duke License have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. See &#147;Risk factors&#151; Risks related to intellectual property&#151;Some of our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> intellectual property has been discovered </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">133 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
through government funded programs and thus may be subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a
preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers.&#148; </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Duke License, in addition to upfront licensing fees, we are also required to pay Duke (1)&nbsp;a total of $0.3&nbsp;million in milestone payments, a
portion of which we paid upon the completion of our Series A financing, a further portion of which we paid upon our first signed partnership in excess of $1&nbsp;million, and the remainder of which we will be required to pay upon successful
commercialization of seed traits and human therapeutics, (2)&nbsp;royalties in the low single digit percentages on net sales of licensed products and licensed processes sold by us and our affiliates, subject to certain reductions in certain
circumstances, with certain annual minimum royalties, and (3)&nbsp;certain percentages of sublicensing revenue received under sublicenses granted to third parties, which are creditable against annual minimum royalties and are subject to certain
reductions in certain circumstances. For sublicenses of <FONT STYLE="white-space:nowrap">non-commercial</FONT> products, the percentage of sublicensing revenue payable to Duke is in the <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages
for sublicense revenues owed from royalties received and low double-digits for sublicense revenues owed from non-royalty payments. For sublicenses of commercial products created by us and derivatives thereof, the percentage is determined by the
highest negotiated royalty rate in such sublicense. If the highest negotiated royalty rate between us and our sublicensee exceeds a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit percentage, the percentage of sublicensing revenue payable
to Duke will be high single digit, decreasing to low single digit as the highest negotiated royalty rate in such sublicense increases. The Duke License will expire upon the expiration of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">last-to-expire</FONT></FONT> patent that is licensed to us. We may terminate the Duke License by providing advance written notice as specified in the Duke License. Either party may terminate the Duke License in the event
of the other party&#146;s uncured material breach or for the other party&#146;s fraud, willful misconduct or illegal conduct with respect to the subject matter of the Duke License. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Cellectis S.A. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In January 2014, we entered into a cross-license agreement with Cellectis S.A., which we
refer to as the Cellectis License, in connection with a settlement of litigation matters (1)&nbsp;between Cellectis and us and (2)&nbsp;among Cellectis, Duke and us. Cellectis granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
sublicensable, worldwide, fully paid, royalty-free license to certain modified <FONT STYLE="white-space:nowrap">I-Crel</FONT> homing endonuclease patents and Cellectis patents asserted in the litigation, to make, use and commercialize modified <FONT
STYLE="white-space:nowrap">I-Crel</FONT> homing nucleases and products developed using such nucleases, in all fields. The license we received from Cellectis is subject to the rights of a preexisting license agreement that Cellectis entered into with
a third party, and the license granted to us excludes any rights exclusively granted by Cellectis under such preexisting license, which preexisting license is limited to certain specific applications unrelated to the fields of human therapeutics and
plant agriculture, for so long as the rights under the preexisting license remain exclusive. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We granted Cellectis a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable, worldwide, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free license to certain modified <FONT STYLE="white-space:nowrap">I-Crel</FONT> homing endonuclease
patents and our patents asserted in the litigation matters (1)&nbsp;between Cellectis and us and (2)&nbsp;among Cellectis, Duke and us to make, use and commercialize modified <FONT STYLE="white-space:nowrap">I-Crel</FONT> homing nucleases and
products developing using such nucleases, in all fields except those for which we did not receive rights from Cellectis due to the preexisting license. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Cellectis License will expire upon the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid
claim of all of the patents licensed to or from each of the parties to the agreement. Either party may terminate any of the licenses granted under the agreement (1)&nbsp;in the event of the other party&#146;s material breach, subject to an
opportunity to cure within the time period specified in the Cellectis License, or (2)&nbsp;if the other party directly or indirectly challenges a patent licensed to it by the other party. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">134 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Competition </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a diversified life sciences company, we compete in multiple different fields. The biotechnology, pharmaceutical and agricultural biotechnology industries are
characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. We principally compete with others developing and utilizing genome editing technology in the human health
and plant sciences sectors, including companies such as Cellectis S.A., CRISPR Therapeutics, AG, Editas Medicine, Inc., Intellia Therapeutics, Inc. and Sangamo Therapeutics, Inc. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We compete with many biotechnology and pharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions. We expect that our operations focused on CAR T
cell product development and commercialization will face substantial competition from those focusing on immunotherapy solutions. Several companies, including Novartis Pharmaceuticals Corp. and Gilead Sciences, Inc., have obtained FDA approval for
autologous cell therapies, and a number of companies, including Cellectis S.A., Celgene Corp., Allogene Therapeutics and CRISPR Therapeutics AG, are pursuing allogeneic cell therapies. We expect that our operations focused on developing products for
<I>in vivo</I> treatment of genetic disease will face substantial competition from others focusing on gene therapy treatments, especially those that may focus on conditions that our product candidates target. Moreover, any human therapeutics
products that we may develop will compete with existing standards of care for the diseases and conditions that our product candidates target and other types of treatments, such as small molecule, antibody or protein therapies. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of our current or potential competitors in the therapeutics space, either alone or with their collaboration partners, have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than we do. In addition to competing on the bases of safety, efficacy, timing of development and
commercialization, convenience, cost, availability of reimbursement and rate of adoption of potential product candidates, we may also compete with these competitors in recruiting and retaining qualified personnel, establishing clinical sites,
establishing relationships with collaborators or other third parties, registering patients for clinical trials and acquiring technologies complementary to, or necessary for, our product development platforms. Our commercial opportunity could be
reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also
may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also compete with participants in the agricultural biotechnology space, including Pairwise Plants, LLC, Caribou Biosciences, Inc., Corteva Agriscience, Tropic
Biosciences UK LTD, Calyxt, Inc. and Cibus. Competition for improving plant genetics comes from conventional and advanced plant breeding techniques, as well as from the development of genetically modified traits. Competition for providing more
nutritious ingredients for food companies comes from chemical-based ingredients, additives and substitutes, which are developed by various companies. We also face less direct competition from trait research and development companies and agricultural
research universities and institutions. We compete with respect to many aspects of the product development cycle in the plant sciences space, such as computational capabilities for identifying relevant gene targets, access to germplasm and enabling
technologies and entry into strategic relationships to facilitate product development and commercialization. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of our current or potential
competitors in the agricultural biotechnology space, either alone or with others, have significantly greater financial resources and expertise in research and development, manufacturing, testing and marketing approved products than we do. Mergers
and acquisitions in the plant science, specialty food ingredient and agricultural biotechnology, seed and chemical industries may result in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">135 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through strategic
relationships with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for, our food
and nutrition platform. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Intellectual property </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our success depends in part on our abilities to (1)&nbsp;obtain and maintain proprietary protection for ARCUS, (2)&nbsp;defend and enforce our intellectual property
rights, in particular, our patent rights, (3)&nbsp;preserve the confidentiality of our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, and (4)&nbsp;operate without infringing valid and enforceable intellectual property rights of
others. We seek to protect our proprietary position by, among other things, exclusively licensing U.S. and certain foreign patent applications, and filing U.S. and certain foreign patent applications, related to ARCUS, existing and planned programs,
and improvements that are important to the development of our business, where patent protection is available. We also rely on trademarks, trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and
confidential information and pursue licensing opportunities to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to
protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and others who may have access to proprietary information,
under which they are bound to assign to us inventions made during the term of their employment or term of service. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our
premises and physical and electronic security of our information technology systems. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot be sure that patents will be granted with respect to any
patent applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or which have been granted to us, or patents that may be licensed or granted to us in the future, will not be
challenged, invalidated or circumvented or that such patents will be commercially useful in protecting our technology. Moreover, trade secrets can be difficult to protect. While we have confidence in the measures we take to protect and preserve our
trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. For more information regarding the
risks related to our intellectual property, see &#147;Risk factors&#151;Risks related to our intellectual property.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our patent portfolio consists
of a combination of issued patents and pending patent applications that are owned by us or licensed by us from third parties. As of September&nbsp;30, 2018, we have an exclusive license from Duke University under 12 issued United States patents and
two pending U.S. patent applications. In addition, as of September&nbsp;30, 2018, we own 14 issued United States patents, 12 pending non-provisional U.S. patent applications, and seven pending PCT international patent applications. We also
exclusively license from Duke or own many corresponding patents and patent applications outside the United States, as described below. We intend to pursue, when possible, additional patent protection, including composition of matter, method of use
and process claims, related to ARCUS. We also intend to obtain rights to existing delivery technologies through one or more licenses from third parties. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>ARCUS platform patent families </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We license one patent
family from Duke and own two patent families that are directed to the core technologies employed in our ARCUS platform for nuclease design. Thus, each of our product candidates is protected by one or more patents in these families. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">136 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The first family, licensed from Duke, includes 12 issued United States patents, eight issued European patents,
three issued Japanese patents, and one issued patent in each of Australia and Canada. This family also includes one pending patent application in each of the United States, Europe, Japan and Canada. Patents in this family include claims directed to
(1)&nbsp;recombinant meganucleases having altered cleavage specificity, altered heterodimer formation, and/or altered DNA binding affinity, (2)&nbsp;methods for cleaving target recognition sites in DNA using such meganucleases, and (3)&nbsp;methods
for producing genetically modified eukaryotic cells using such meganucleases. Patents in this family have a standard expiration date of October&nbsp;18, 2026, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The second family, which we own, includes four issued United States patents, two issued patents in each of Europe and Japan, and one issued Australian patent. This family also includes one pending patent
application in each of the United States, Europe, Japan and Australia. Patents in this family include claims directed to (1)&nbsp;recombinant single-chain meganucleases, and (2)&nbsp;methods for producing isolated genetically modified eukaryotic
cells using such meganucleases. Patents in this family have a standard expiration date of October&nbsp;31, 2028, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
third family, which we own, includes one issued patent in each of the United States and Europe, and two issued Australian patents. This family also includes two pending patent applications in the United States and one pending patent application in
Europe. Patents in this family include claims directed to methods of cleaving DNA at specific 4 base pair sites using a recombinant meganuclease. Patents in this family have a standard expiration date of July&nbsp;14, 2029, subject to potential
extensions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Immunotherapy patent families </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own nine patent families that are directed to immunotherapy, including CAR T cell therapies. Some of these are applicable to immunotherapies and/or CAR T cells
directed to killing a variety of different types of infected or cancerous cells. Others are directed to specific indications in which cells expressing particular antigens are targeted. Each of our immunotherapy product candidates is protected by one
or more patents in these families. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The first family includes seven issued United States patents, and pending patent applications in each of the United
States, Europe, Australia, Canada, China, Israel, Japan, Mexico and South Korea. Patents in this family include claims directed to (1)&nbsp;populations of genetically-modified human T cells in which 20%-65% of the cells have reduced expression of an
endogenous TCR and express an anti-cancer antigen CAR from DNA inserted into the cells&#146; TCR alpha constant region (TRAC) gene, (2)&nbsp;methods for using such populations of genetically modified human T cells for cancer immunotherapy,
(3)&nbsp;pharmaceutical compositions comprising such populations of genetically modified human T cells, (4)&nbsp;genetically modified human T cells which have reduced expression of an endogenous TCR and express an anti-cancer antigen CAR from DNA
inserted into the cells&#146; TRAC gene, (5)&nbsp;methods for using such genetically modified human T cells for cancer immunotherapy, and (6)&nbsp;pharmaceutical compositions comprising such genetically modified human T cells. Patents in this family
have a standard expiration date of October&nbsp;5, 2036, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The second family includes pending patent applications in each
of the United States, Europe, Australia, Canada and Japan. Patent applications in this family include claims directed to (1)&nbsp;first-generation recombinant meganucleases that cleave a target in the TRAC gene, (2)&nbsp;nucleic acids and vectors
encoding such recombinant meganucleases, (3)&nbsp;methods for producing genetically modified eukaryotic cells, including CAR T cells, using such meganucleases, and (4)&nbsp;methods of using such genetically modified eukaryotic cells for cancer
immunotherapy. Patents in this family, if issued, will have a standard expiration date of October&nbsp;5, 2036, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
third family includes a pending provisional patent application in the United States. That provisional patent application includes claims directed to (1)&nbsp;second-generation engineered meganucleases that cleave a specific
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">137 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
target in the TRAC gene, (2)&nbsp;nucleic acids and vectors encoding such recombinant meganucleases, (3)&nbsp;methods for producing genetically modified eukaryotic cells, including CAR T cells,
using such meganucleases, (4)&nbsp;genetically modified eukaryotic cells or populations of cells prepared by such methods, (5)&nbsp;pharmaceutical compositions comprising such cells or populations of cells, and (6)&nbsp;methods of treating diseases
using such cells, populations of cells or pharmaceutical compositions to treat diseases, including cancer immunotherapy. Patents in this family, if issued, will likely have a standard expiration date of April&nbsp;12, 2039, subject to potential
extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The fourth family includes a pending PCT international patent application. That PCT patent application includes claims directed to
(1)&nbsp;nucleic acids encoding <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> domains having certain amino acid sequences, (2)&nbsp;recombinant DNA constructs and vectors comprising such nucleic acids, (3)&nbsp;nucleic acids and vectors
encoding such recombinant meganucleases, (4)&nbsp;genetically modified cells comprising such nucleic acids, (5)&nbsp;methods for producing such genetically modified cells, (6)&nbsp;pharmaceutical compositions comprising such cells, and
(7)&nbsp;methods of immunotherapy using such cells. Patents in this family, if issued, will have a standard expiration date of October&nbsp;4, 2037, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The fifth family includes a pending PCT international patent application. That PCT patent application includes claims directed to (1)&nbsp;methods of reducing cytotoxicity associated with DNA transfection in
primary eukaryotic cells, (2)&nbsp;methods for increasing the number of gene-edited primary eukaryotic cells following DNA transfection, (3)&nbsp;methods for increasing gene editing frequency in primary eukaryotic cells following DNA transfection,
(4)&nbsp;methods for increasing the number of primary eukaryotic cells comprising targeted insertion of an exogenous sequence of interest into the genome following DNA transfection, (5)&nbsp;methods for increasing insertion frequency of an exogenous
sequence of interest into the genome in primary eukaryotic cells following DNA transfection, (6)&nbsp;methods for high throughput screening of primary human T cells expressing a CAR or exogenous TCR, (7)&nbsp;methods for high throughput screening of
primary human T cells expressing a CAR or exogenous TCR, and (8)&nbsp;genetically modified primary eukaryotic cells produced by the methods. Patents in this family, if issued, will have a standard expiration date of April&nbsp;30, 2038, subject to
potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The sixth family includes pending patent applications in the United States, Europe, Australia, Canada and Japan. Patent
applications in this family include claims directed to (1)&nbsp;recombinant meganucleases that recognize and cleave a recognition sequence within the human <FONT STYLE="white-space:nowrap">beta-2</FONT> microglobulin gene, (2)&nbsp;nucleic acids and
vectors encoding such recombinant meganucleases, (3)&nbsp;methods for producing genetically modified eukaryotic cells, including CAR T cells, using such meganucleases, (4)&nbsp;populations of genetically modified eukaryotic cells in which 80% of the
cells have reduced expression of an endogenous TCR and 80% of the cells have reduced expression of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beta-2-microglobulin,</FONT></FONT> (5) pharmaceutical compositions comprising such
populations of genetically modified eukaryotic cells, and (6)&nbsp;methods for using such genetically modified eukaryotic cells for cancer immunotherapy. Patents in this family, if issued, will have a standard expiration date of December&nbsp;22,
2036, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The seventh family includes a pending PCT international patent application. That PCT patent application includes
claims directed to (1)&nbsp;nucleic acids encoding an engineered antigen receptor (e.g., a CAR) and an inhibitory molecule (e.g., an RNA interfering with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beta-2-microblobulin</FONT></FONT> expression), (2) genetically modified eukaryotic cells comprising such nucleic acids, (3)&nbsp;methods for producing such genetically modified
eukaryotic cells using such nucleic acids and an engineered nuclease that promotes insertion of such nucleic acids, (4)&nbsp;genetically modified eukaryotic cells expressing an engineered antigen receptor and having expression of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beta-2-microglobulin</FONT></FONT> or MHC Class&nbsp;I molecules reduced by <FONT STYLE="white-space:nowrap">10%-95%,</FONT> (5) pharmaceutical compositions comprising such genetically
modified eukaryotic cells, and (6)&nbsp;methods for using such genetically modified eukaryotic cells for immunotherapy. Patents in this family, if issued, will have a standard expiration date of May&nbsp;8, 2038, subject to potential extensions.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">138 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The eighth family includes a pending PCT international patent application. That PCT patent application includes
claims directed to (1)&nbsp;engineered meganucleases that recognize and cleave a recognition sequence in an upstream intron of the human TRAC gene, (2)&nbsp;nucleic acids and vectors encoding such engineered meganucleases, (3)&nbsp;methods for
producing genetically modified T cells using such nucleic acids or vectors, (4)&nbsp;genetically modified T cells in which an exogenous sequence is inserted into an upstream of the human TRAC gene and endogenous TCR expression is reduced,
(5)&nbsp;populations of such genetically modified T cells, (6)&nbsp;pharmaceutical compositions comprising such genetically modified T cells, and (7)&nbsp;methods of treating disease using such genetically modified T cells and pharmaceutical
compositions, including cancer immunotherapy. Patents in this family, if issued, will have a standard expiration date of June&nbsp;27, 2038, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The ninth family includes a pending United States provisional patent application. That provisional patent application includes claims directed to (1)&nbsp;nucleic acids and vectors encoding certain modified human
epidermal growth factor receptor, or EGFRs, (2) genetically modified cells and populations of cells, including T cells and CAR T cells, expressing such modified EGFRs, (3)&nbsp;methods for producing such genetically modified cells using such nucleic
acids or vectors encoding such modified EGFRs, (4)&nbsp;pharmaceutical compositions comprising such genetically modified cells, (5)&nbsp;methods for isolating such genetically modified cells, (6)&nbsp;methods of treating disease using such
genetically modified cells and pharmaceutical compositions, including cancer immunotherapy, and (7)&nbsp;methods of depleting such genetically modified cells in a subject using anti-modified EGFR antibodies. Patents in this family, if issued, will
likely have a standard expiration date of October&nbsp;3, 2038, subject to potential extensions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Hepatitis B virus gene therapy patent families
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own two patent families that are directed to gene therapy for Hepatitis B Virus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The first family includes a pending PCT international patent application. That PCT patent application includes claims directed to (1)&nbsp;engineered meganucleases that recognize and cleave recognition sites in the
Hepatitis B virus (HBV) genome, (2)&nbsp;nucleic acids and vectors encoding such engineered meganucleases, (3)&nbsp;pharmaceutical compositions comprising such nucleic acids or meganucleases, and (4)&nbsp;methods for treating HBV infection using
such meganucleases, nucleic acids and/or pharmaceutical compositions. Patents in this family, if issued, will have a standard expiration date of October&nbsp;13, 2037, subject to potential extensions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The second family includes a pending United States provisional patent application. That provisional patent application includes claims directed to (1)&nbsp;second
generation engineered meganucleases that recognize and cleave recognition sites in the Hepatitis B virus, or HBV genome, (2)&nbsp;nucleic acids and vectors encoding such engineered meganucleases, (3)&nbsp;pharmaceutical compositions comprising such
nucleic acids or meganucleases, and (4)&nbsp;methods for treating HBV infection using such meganucleases, nucleic acids and/or pharmaceutical compositions. Patents in this family, if issued, will likely have a standard expiration date of
April&nbsp;12, 2039, subject to potential extensions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Hemophilia A gene therapy patent families </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own two patent families that are directed to gene therapy for Hemophilia A. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The first family includes a pending PCT international patent application. That PCT patent application includes claims directed to (1)&nbsp;engineered meganucleases that recognize and cleave recognition sites in a
mutant Factor VIII gene, (2)&nbsp;nucleic acids and vectors encoding such engineered meganucleases, (3)&nbsp;pharmaceutical compositions comprising such nucleic acids or meganucleases, and (4)&nbsp;methods for treating Hemophilia A using such
meganucleases, nucleic acids and/or pharmaceutical compositions. Patents in this family, if issued, will have a standard expiration date of May&nbsp;3, 2037, subject to potential extensions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">139 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The second family includes a pending United States provisional patent application. That provisional patent
application includes claims directed to (1)&nbsp;engineered meganucleases that recognize and cleave <FONT STYLE="white-space:nowrap">non-methylated</FONT> recognition sites in a mutant Factor VIII gene, (2)&nbsp;nucleic acids and vectors encoding
such engineered meganucleases, (3)&nbsp;pharmaceutical compositions comprising such nucleic acids or meganucleases, and (4)&nbsp;methods for treating Hemophilia A using such meganucleases, nucleic acids and/or pharmaceutical compositions. Patents in
this family, if issued, will likely have a standard expiration date of November&nbsp;1, 2038, subject to potential extensions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other patent
families </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own a pending PCT international patent application directed to engineered meganucleases and methods of treatment targeting the PCSK9
gene, which is associated with familial hypercholesterolemia. Patents in this family, if issued, will have a standard expiration date of April&nbsp;20, 2038, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We own pending patent applications in the United States, Europe, Australia, Canada and Japan directed to engineered meganucleases and methods of treatment targeting the rhodopsin gene, which is associated with
retinitis pigmentosa. Patents in this family, if issued, will have a standard expiration date of September&nbsp;8, 2036, subject to potential extensions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own pending patent applications in the United States, Europe, Australia, Canada and Japan directed to engineered meganucleases and methods of treatment targeting
the dystrophin gene, which is associated with Duchenne Muscular Dystrophy. Patents in this family, if issued, will have a standard expiration date of March&nbsp;12, 2035, subject to potential extensions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own pending patent applications in the United States and Europe directed to engineered meganucleases and methods of treatment targeting genomic trinucleotide
repeats, which are associated with several trinucleotide repeat disorders. Patents in this family, if issued, will have a standard expiration date of May&nbsp;2, 2036, subject to potential extensions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We license from Duke a pending patent application in the United States directed to engineered fusion proteins comprising engineered meganuclease domains and
effector domains which may be useful in controlling gene expression. Patents in this family, if issued, will have a standard expiration date of April&nbsp;27, 2029, subject to potential extensions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own one patent and one pending patent application in the United States, and one pending patent application in Europe, directed to engineered meganucleases which
target amplifiable genetic loci and may be useful in producing cells with amplified transgenes. Patents in this family will have a standard expiration date of June&nbsp;1, 2032, subject to potential extensions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own pending patent applications in the United States and Europe directed to self-limiting viral vectors (e.g., AAV vectors) which encode engineered meganucleases
which eliminate the vector after gene delivery. Patents in this family, if issued, will have a standard expiration date of June&nbsp;20, 2036, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We own, through our Elo Life Systems subsidiary, an issued United States patent directed to engineered meganucleases which target a genetic locus in maize and methods for genetically modifying that locus in maize.
That patent has a standard expiration date of March&nbsp;2, 2029, subject to potential extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own, through our Elo Life Systems subsidiary, a
pending United States provisional patent application directed to engineered meganucleases which target the deoxyhypusine synthase gene and methods for genetically modifying that gene in plants. Patents in this family, if issued, will likely have a
standard expiration date of November&nbsp;20, 2038, subject to potential extensions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">140 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For any individual patent, the term depends on the applicable law in the country in which the patent is granted.
In most countries where we have filed patent applications or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications, patents have a term of 20 years from the application filing date or earliest claimed <FONT
STYLE="white-space:nowrap">non-provisional</FONT> priority date. In the United States, the patent term is 20 years but may be shortened if a patent is terminally disclaimed over another patent that expires earlier. The term of a U.S. patent may also
be lengthened by a patent term adjustment to address administrative delays by the USPTO in granting a patent. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, the term of a patent
that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug or biologic may be eligible for patent term extension in order to restore the period of a patent term lost during the premarket FDA regulatory review process. The Hatch-Waxman
Act permits a patent term extension of up to five years beyond the natural expiration of the patent. The patent term restoration period is generally equal to the portion of the FDA regulatory review period for the approved product that occurs after
the date the patent issued, subject to certain exceptions. Only one patent may be extended for a regulatory review period for any product, and the application for the extension must be submitted prior to the expiration of the patent. In the future,
we may decide to apply for restoration of patent term for one of our currently owned or licensed patents to extend its current expiration date, depending on the expected length of the clinical studies and other factors involved in the filing of the
relevant BLA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> If we are required to and unable to obtain an exclusive license to any such third party <FONT
STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors. In addition, we may
need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us. We or our licensors are subject
to and may also become a party to similar proceedings or priority disputes in Europe or other foreign jurisdictions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our registered trademark portfolio
currently contains two registered trademarks, specifically ARC nuclease and ARCUS, in the United States.&nbsp;In addition, there are two pending applications in the United States for the marks ELO Life Systems and Precision Breeding
Technologies.&nbsp;Finally, our international portfolio contains seven registered trademarks around the world for ARC nuclease and ARCUS. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Licensed intellectual property </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Duke University
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2006, we exclusively licensed from Duke families of patents and patent applications related to certain meganucleases and methods of making
such nucleases owned by Duke. The patent family covered by the Duke License comprises the core patents covering ARCUS described above. See &#147;&#151;License and collaboration agreements&#151;Duke University&#148; above for additional information
regarding the Duke License. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Cellectis S.A. </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
January 2014, we entered into the Cellectis License, which relates to certain modified <FONT STYLE="white-space:nowrap">I-Crel</FONT> homing endonuclease patents and patents that had been subject to litigation between us and Cellectis. The patents
to which we have rights under the cross-license include at least eight issued patents in each of the United States and Australia, seven issued patents in Europe, two issued patents in Canada and one issued patent in Japan. These patents have
standard expiration dates prior to January&nbsp;29, 2034, subject to potential extensions. See &#147;&#151;License and collaboration agreements&#151;Cellectis S.A.&#148; above for additional information regarding the Cellectis License. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">141 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Government regulation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality
control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biological product candidates such as
those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct
studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of
substantial time and financial resources. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>U.S. biologics regulation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s Good Laboratory Practice requirements, or GLPs;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before clinical trials may begin;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approval by an IRB or ethics committee at each clinical site before the trial is commenced; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its
intended purpose; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">satisfactory completion of an FDA Advisory Committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which the
proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity and potency, and of selected clinical investigation
sites to assess compliance with GCPs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is
a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes
results of animal and <I>in vitro</I> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or
literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT
STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns
or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">142 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United
States,&nbsp;certain human clinical trials involving recombinant or synthetic nucleic acid molecules&nbsp;had historically been subject to review by the Recombinant DNA Advisory Committee, or the RAC, of the NIH Office of Biotechnology Activities,
or the OBA, pursuant to the NIH Guideline.&nbsp;On August&nbsp;17, 2018, the NIH issued a notice in the Federal Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the
applicable NIH Guidelines to modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products, and requesting public comment on its proposed modifications.&nbsp;During the public comment period, which
closes October&nbsp;16, 2018, the NIH has announced that it will no longer accept new human gene transfer protocols for review as a part of the protocol registration process or convene the RAC to review individual clinical protocols. These trials
will remain subject to the FDA&#146;s oversight and other clinical trial regulations, and oversight at the local level will continue as set forth in the NIH Guidelines.&nbsp;Specifically, under the NIH Guidelines, supervision of human gene transfer
trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and
identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or
sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with
GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study,
the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent
protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must
monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial
is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or
not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration
of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Phase 1&#151;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are
designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Phase 2&#151;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary
efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical
trials. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">143 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Phase 3&#151;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant
evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to
provide an adequate basis for product approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Phase 4&#151;In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more
information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to approval of the BLA. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for
manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the
identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>BLA submission and review by the FDA </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical
studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored
clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a substantial user fee to FDA,
and the sponsor of an approved BLA is also subject to an annual program fee. These fees are typically increased annually. A waiver of user fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on BLAs for
products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Once a BLA has
been submitted, the FDA&#146;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing.
Priority review designation will direct overall attention and resources to the evaluation of applications for products that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of
serious conditions. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is
safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical
insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing
processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to
assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">144 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After the FDA evaluates a BLA and conducts inspections of
manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with
specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are
inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may
recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not
satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which
such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to
enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries,
and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if
compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase IV post-market studies and
surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government
requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs. For example, in
December 2016, the 21st Century Cures Act was signed into law. The Act is intended, among other things, to modernize the regulation of drugs and biologics and to spur innovation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Expedited development and review programs </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A sponsor may seek approval of its product candidate under
programs designed to accelerate FDA&#146;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a
serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the
complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any
required user fees upon submission of the first section of the application. A fast track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the
FDA accepts the application for filing. Priority review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious disease or
condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of 10 months after FDA accepts </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">145 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit,
or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity,
rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#146;s clinical benefit in
relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional
materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted
clinical benefit of the product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the Food and Drug Administration Safety and Innovation Act, or the FDASIA, which was enacted and signed
into law in 2012, established the breakthrough therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or
biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such
as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with
the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the
nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead
for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate,
which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the
benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions
of the application and the payment of applicable user fees before the FDA may initiate a review. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Fast Track designation, priority review and
breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Orphan drug designation and
exclusivity </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition,
defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the
cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">146 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed
publicly by the FDA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for
the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for
seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability
of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same
disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan
designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its
product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. We
plan to seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Post-approval requirements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any products manufactured or distributed by us pursuant to FDA approvals are
subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion
of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products.
Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with
cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information;
imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">147 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fines, warning letters or holds on post-approval clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product seizure or detention, or refusal to permit the import or export of products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">mandated modification of promotional materials and labeling and the issuance of corrective information; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about
the product; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and
in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these
requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the
product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe that such <FONT
STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict
manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Biosimilars and
exclusivity </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Affordable Care Act, signed into law in 2010, includes a subtitle called the BPCIA, which created an abbreviated approval
pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The FDA has issued several guidance documents outlining an approach to review and
approval of biosimilars. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the
reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product
must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be
alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more
complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first
licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT>
period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical data and data from adequate and
well-controlled clinical trials to demonstrate </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">148 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether
products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT>
exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written
Request&#148; for such a study. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have
sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a
result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Genetically engineered food products
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, the FDA and the USDA are primarily responsible for overseeing food regulation and safety, although many other federal
agencies also play a role in food regulation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">USDA has jurisdiction over certain genetically engineered crops through the Animal and Plant Health
Inspection Services, or APHIS. Under the Plant Protection Act and APHIS&#146; Part 340 regulations, USDA requires anyone who wishes to import, transport interstate, or release into the environment a &#147;regulated article&#148; to apply for a
permit or, in some cases, notify APHIS that the introduction will be made. Regulated articles are defined as &#147;any organism which has been altered or produced through genetic engineering &#133; which USDA determines is a plant pest or has reason
to believe is a plant pest.&#148; Regulated articles may be subject to extensive regulation, including both permitting requirements and inspections. However, APHIS may make a determination of nonregulated status for a product following the
submission of a petition requesting such a determination. The petition process can be a multi-year process that varies based on a number of factors, including APHIS&#146;s familiarity with similar products, the type and scope of the environmental
review conducted, and the number and types of public comments received. APHIS conducts a comprehensive science-based review of the petition to assess, among other things, plant pest risk, environmental considerations pursuant to the National
Environmental Policy Act of 1969, or NEPA, and any potential impact on endangered species. If, upon the completion of the review, APHIS grants the petition, the product is no longer deemed a &#147;regulated article&#148; and the petitioner may
commercialize the product, subject to any conditions set forth in the decision. In January 2017, APHIS proposed significant amendments to its Part 340 regulatory framework that would, among other things, clarify the types of genetically engineered
plants subject to regulation thereunder. In November 2017, however, APHIS withdrew its proposed rule and stated that it would &#147;begin a fresh stakeholder engagement aimed at exploring alternative policy approaches.&#148; That process appears to
remain ongoing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On May&nbsp;4, 2018, the USDA issued a proposed rule implementing the National Bioengineered Food Disclosure Standard, with a proposed
compliance date of January&nbsp;1, 2020. Under this proposed rule, the label of a bioengineered, or BE, food must include a disclosure that the food is a BE food or contains a BE ingredient, with certain exceptions. This proposed rule defines BE
food as &#147;a food that contains genetic material that was has been modified through in vitro recombinant deoxyribonucleic acid, or DNA, techniques and for which the modification could not otherwise be obtained through conventional breeding or
found in nature,&#148; except in the case of an incidental additive present in food at an insignificant level and that does not have any technical or functional effect in the food. The USDA&#146;s proposed rule may change significantly prior to
being finalized. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA&#146;s oversight of food safety and security is primarily carried out by the Center for Food Safety and Applied Nutrition. To
execute its responsibilities, the FDA conducts inspections and collects and analyzes </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">149 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
product samples. Foods are typically not subject to premarket review and approval requirements, with limited exceptions, such as the requirement for premarket review and approval of food
additives. Under Section&nbsp;201(s) and 409 of the FDCA, any substance that is reasonably expected to become a component of food is considered a &#147;food additive&#148; that is subject to premarket approval by the FDA, unless it is already
subject to a food additive regulation. Ingredients that are GRAS are exempt from the definition of food additive and from the premarket approval requirements. Under section 201(s), and FDA&#146;s implementing regulations, the use of a food substance
may be GRAS either through a determination by qualified experts or, for a substance used in food before 1958, through experience based on common use in food. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Manufacturers of GRAS substances may voluntarily provide the FDA with a notification of GRAS determination, which includes, among other things, a description of the substance, the applicable conditions of use, the
dietary exposure and an explanation of how the substance was determined to be safe for the intended use. Upon review of such a notification, the FDA may respond with a &#147;no questions&#148; letter stating that while it has not made its own GRAS
determination, it has no questions at the time regarding the applicant&#146;s own GRAS determination. Alternatively, manufacturers may self-affirm that a given substance is GRAS without the voluntary FDA notification. A company may market a new food
ingredient based on its independent determination that the substance is GRAS; however, the FDA can disagree with this determination and take enforcement action. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA regulates foods made with genetically modified organisms under the approach summarized in its 1992 &#147;Statement of Policy: Foods Derived from New Plant Varieties.&#148; Under this policy, updated in
2017, the FDA regulates foods derived from genetically modified plant varieties consistent with the framework for <FONT STYLE="white-space:nowrap">non-genetically</FONT> modified foods. Under this framework, the FDA offers a voluntary consultation
process to determine whether a food derived from a genetically modified plant variety raises any safety or other regulatory issues, such as whether any substance in the food from the plant may require premarket approval as a food additive.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other U.S. healthcare laws and compliance requirements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the United States, our activities are potentially subject to regulation under various federal and state healthcare laws including, among others, the federal Anti-Kickback Statute, the federal False Claims Act
and HIPAA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable
under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. A person does not need to have knowledge of the statute or specific intent to violate it to have
committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False
Claims Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which can be
enforced through civil whistleblower or qui tam actions, prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the
U.S. government. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that
prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">150 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including
private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment
for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations,
impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule,
such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health
information. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, the federal Physician Payments Sunshine Act, and its implementing regulations, require that certain manufacturers of drugs,
devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to certain payments or other
transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the
physicians and teaching hospitals and to report annually to CMS certain ownership and investment interests held by physicians and their immediate family members. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Moreover, analogous state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations may apply to our activities, such as state anti-kickback and false claims laws, which may apply to our business
practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including
private insurers, or by the patients themselves, state laws that require pharmaceutical and device companies to comply with the industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government,
or otherwise restrict payments that may be made to healthcare providers and other potential referral sources, state laws and regulations that require manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures and pricing information, state and local laws which require the registration of pharmaceutical sales representatives and state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, such
as the EU General Data Protection Regulation 2016/679, governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Efforts to ensure that current and future business arrangements with third parties complies with applicable healthcare laws and
regulations involves substantial costs. If a business is found to be in violation of any of these or any other health regulatory laws that may apply to it, it may be subject to significant penalties, including the imposition of significant civil,
criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, additional reporting requirements and oversight if
subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, and
curtailment or restructuring of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">151 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Coverage, pricing and reimbursement </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Significant uncertainty exists as to the coverage and reimbursement status for newly approved therapeutics. In the United States and markets in other countries, sales of any products for which we receive regulatory
approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state
healthcare programs, private managed care providers, health insurers and other organizations. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. A payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s
determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Moreover, the coverage provided may be more limited than the purposes for which the product is approved by the FDA. It is
also possible that a third-party payor may consider a product as substitutable and only offer to reimburse patients for the less expensive product. Adequate third-party payor reimbursement may not be available to enable us to maintain price levels
sufficient to realize an appropriate return on our investment in product development. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more
products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Healthcare reform </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States and some foreign
jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate
post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the
Affordable Care Act, enacted in March 2010, has substantially changed healthcare financing and delivery by both governmental and private insurers. Among other things the Affordable Care Act included the following provisions: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these
entities according to their market share in some government healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts, which through subsequent legislative amendments, will be increased to 70%, starting in 2019, off negotiated prices of applicable brand drugs to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expansion of eligibility criteria for Medicaid programs; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">152 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expansion of the entities eligible for discounts under the 340B Drug Discount Program; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with
funding for such research; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
implanted, or injected; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a licensure framework for follow on biologic products. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, President Trump
has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or
part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017
includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health
coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the
implementation of certain Affordable Care <FONT STYLE="white-space:nowrap">Act-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans,
the annual fee imposed on certain health insurance providers based on market share. Further, the Bipartisan Budget Act of 2018, among other things, amends the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most
Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; More recently, in July 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health
insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&nbsp;2, 2011, the Budget Control Act of
2011 was signed into law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at
least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on
April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012
was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription
drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products, some of which are included in the Trump administration&#146;s budget proposal for fiscal year 2019.
Additionally, the Trump administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain
federal </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">153 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and
Human Services has begun the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. Although a number of these, and other potential, proposed measures will require
authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level,
legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product and medical device pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly
using bidding procedures to determine what pharmaceutical products and medical devices to purchase and which suppliers will be included in their prescription drug and other healthcare programs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to
access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical
trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Facilities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently occupy approximately 49,000 square
feet of office and laboratory space at our corporate headquarters in Durham, North Carolina under a lease that expires in 2024. This lease provides us the option to lease an additional 20,000 square feet of office space. We also occupy approximately
15,500 square feet of laboratory and office space in Research Triangle Park, North Carolina under a lease that expires in 2025, and we occupy approximately 17,300 square feet of laboratory and office space in Research Triangle Park, North Carolina
under a lease that expires in 2026. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Employees </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of September&nbsp;30, 2018, we had 115 full-time Precisioneers, over half of whom have advanced
degrees, including 42 with&nbsp;Ph.D. degrees. Of these full-time employees, 80 are engaged in research and development activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider
our relationships with our employees to be good. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Legal proceedings </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are not currently party to any material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">154 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_12"></A>Management </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Executive officers and directors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth the name, age and position of each of our
executive officers and directors as of September&nbsp;30, 2018. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="68%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Age</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Position</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Executive officers</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">President, Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Derek Jantz, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Chief Scientific Officer and Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Abid Ansari</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Vice President, Finance and Operations</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Michael Dombeck</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Vice President, Business Development</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fayaz Khazi, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Chief Executive Officer, Elo Life Systems</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Michael Nicholson, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Chief People Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jeff Smith, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Chief Technology Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David Thomson, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Chief Development Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Robert Adelman, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Tony Yao, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="7" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Member of the audit committee. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Member of the compensation committee. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Member of the nominating and corporate governance committee. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Executive officers </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Matthew Kane</I>, a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Precision, has served as our President and Chief Executive Officer and a director since our inception in 2006. Mr.&nbsp;Kane has nearly 20 years of experience in the life sciences industry, most of
which has been spent specifically working in genome editing. Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> Precision, Mr.&nbsp;Kane was with Suros Surgical Systems. Mr.&nbsp;Kane received a B.S. in mechanical engineering and an M.S.
in biomedical engineering from the Rose-Hulman Institute of Technology and an M.B.A. from Duke University. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that Mr.&nbsp;Kane is qualified to
serve on our board of directors because of the perspective and experience he provides as one of our founders and as our President and Chief Executive Officer, as well as his many years of experience within the life sciences and agricultural
biotechnology industries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Derek Jantz</I>, <I>Ph.D.</I>, a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Precision, has been our Chief
Scientific Officer since August 2013 and has served on our board of directors since January 2006. He previously served as our Vice President of Scientific Development from our inception to August 2013. Dr.&nbsp;Jantz is the <FONT
STYLE="white-space:nowrap">co-inventor</FONT> of several of our foundational patents and other intellectual property. As a protein engineer, he was an early developer of zinc finger technology and has spent most of his research career designing
proteins for genome editing applications. Dr.&nbsp;Jantz received a B.A. in biology from the University of Colorado at Boulder and a Ph.D. in biophysics from the Johns Hopkins University School of Medicine. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">155 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that Dr.&nbsp;Jantz&#146;s extensive experience in genome editing and as an inventor of ARCUS, in
addition to his perspective as one of our founders and senior executives, qualifies him to serve on our board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Abid Ansari</I> has
served as our Vice President, Finance&nbsp;&amp; Operations since July 2016. Prior to joining us, Mr.&nbsp;Ansari served as Senior Director, Deal Finance and M&amp;A from November 2013 to July 2016 and Senior Director, Head of Portfolio Analysis
Group from September 2011 to November 2013 for GlaxoSmithKline plc. Before that, he served for five years in commercial and capital finance roles at MedImmune, LLC and three years as a plant controller at Uniqema (previously a division of Imperial
Chemical Industries Plc). Mr.&nbsp;Ansari received a B.S. in chemical engineering and an M.B.A. from Purdue University. Mr.&nbsp;Ansari is also a Certified Public Accountant. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Michael Dombeck</I> has served as our Vice President, Business Development since April 2015. Prior to joining us, Mr.&nbsp;Dombeck was a Director in the R&amp;D Strategy and Portfolio Management group of
GlaxoSmithKline plc beginning in April 2012 and a manager in the Portfolio and Business Analysis group from September 2009 to April 2012. Mr.&nbsp;Dombeck&#146;s prior experience also includes market research and portfolio planning for Talecris
Biotherapeutics, business development for DarPharma, Inc., business development and corporate strategy consulting for Campbell Alliance and <FONT STYLE="white-space:nowrap">co-founding</FONT> Cempra Pharmaceuticals. Mr.&nbsp;Dombeck received a B.S.,
M.B.A. and Master of Public Policy from Duke University. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Fayaz Khazi</I>, <I>Ph.D.</I>, has served as the CEO of our food-focused subsidiary, Elo
Life Systems, since May 2018 and, prior to that, served as President of Elo Life Systems beginning in May 2017. From May 2014 to April 2017, Dr.&nbsp;Khazi served as the CEO of Key Gene USA. Dr.&nbsp;Khazi also held several executive leadership
positions at Intrexon Corporation directing translation programs in the food, human health and agricultural biotechnology sectors, including serving as Vice President, Business Analytics and Strategy from January 2012 to January 2014, and also
serving as Intrexon&#146;s founding Director of Translational Medicine. Dr.&nbsp;Khazi received a B.Sc. from the University of Agricultural Sciences, Bangalore, and a Ph.D. in biological sciences from Auburn University. He trained as a Howard Hughes
Medical Institute post-doctoral fellow and a senior researcher at the Children&#146;s Hospital of Philadelphia, where he studied the genotoxicity of gene therapy vectors and developed <I>in vivo</I> genome-editing technologies to treat genetic
diseases. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Michael Nicholson, Ph.D.,</I> has held a number of leadership positions with us, and has served as Chief People Officer since January 2018.
Prior to that, Dr.&nbsp;Nicholson served as our Vice President of Research and Development from November 2016 to December 2017, Executive Director of Scientific Operations from June&nbsp;2015 to October 2016 and Director of Cell Biology from July
2008 to May 2015. Dr.&nbsp;Nicholson received a B.S. in chemistry from the College at Brockport, State University of New York and a Ph.D. in molecular biology and genetics from the Johns Hopkins University School of Medicine. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Jeff Smith</I>, <I>Ph.D.</I>, a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Precision, has served as our Chief Technology Officer since August 2013
and, before that, served as our Chief Science Officer beginning at our inception. Dr.&nbsp;Smith received his graduate degree from the Johns Hopkins University School of Medicine while developing and characterizing custom nucleases for genome
engineering. Continuing his work in protein engineering first as a postdoctoral fellow and then as a senior research associate at Duke University Medical Center, Dr.&nbsp;Smith helped create the foundation for ARCUS. Dr.&nbsp;Smith received a B.A.
in biology and chemistry from Franklin&nbsp;&amp; Marshall College and a Ph.D. in biochemistry, cellular and molecular biology from the Johns Hopkins University School of Medicine. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>David Thomson, Ph.D.</I>, has served as our Chief Development Officer since June 2017. Prior to joining us, he served as&nbsp;Senior Vice President Research and Nonclinical Development for Shire plc beginning in
May 2016 until May&nbsp;2017 where he was responsible for the strategy and operational direction of the Global Research and Nonclinical Development Organization, including transitioning programs from research into clinical development and support of
programs through commercialization. Prior to that, he served as Senior Vice </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">156 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
President and Global Head, Research and Development Operations for Shire from February 2015 to May 2016. From May 2014 to January 2015, Dr.&nbsp;Thomson served as the Director of the
Biomanufacturing Research Institute and Technology Enterprise and a Professor in the Department of Pharmaceutical Sciences of North Carolina Central University. From September 2012 to April 2014, Dr.&nbsp;Thomson served as Vice President, Shire
Human Genetic Therapies and later Senior Vice President, Global Head of Research and Nonclinical Development for Shire plc.&nbsp;He received a B.Sc. in chemistry from the University of Strathclyde and a Ph.D. in organic chemistry from the University
of Toronto, and he completed post-doctoral work at Yale University. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Robert Adelman, M.D.</I>, has served on our board of directors since April 2015. Since 2011, Dr.&nbsp;Adelman has been Managing Partner of
venBio Partners LLC, a venture capital firm Dr.&nbsp;Adelman founded in 2011. Dr.&nbsp;Adelman currently serves on the board of directors of Metacrine, Inc., ALX Oncology and TP Therapeutics, Inc. Prior to founding venBio, Dr.&nbsp;Adelman had a
seven-year tenure as a Private Equity Partner at OrbiMed Advisors LLC. Dr.&nbsp;Adelman has also previously <FONT STYLE="white-space:nowrap">co-founded</FONT> a number of biotechnology companies and practiced surgery in New York and New Jersey.
Dr.&nbsp;Adelman received a B.A. in biochemistry from the University of California at Berkeley and a M.D. from Yale University, and he completed his residency at Cornell University Medical Center. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that Dr.&nbsp;Adelman&#146;s medical background and experience in the venture capital industry, particularly with biotechnology and pharmaceutical
companies, qualify him to serve as a member of our board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Tony Yao, M.D., Ph.D.,</I> has served on our board of directors since May
2018. Since April 2012, Dr.&nbsp;Yao has served as a portfolio manager at ArrowMark Partners, where he leads the healthcare team and manages the healthcare portfolio. Dr.&nbsp;Yao currently serves on the board of directors of 4D Molecular
Therapeutics, Inc. and NexImmune, Inc. Dr.&nbsp;Yao began his investment career in February 2002 as an analyst and later an assistant portfolio manager at Janus Capital Group. Dr.&nbsp;Yao received a B.Sc. in biochemistry from Brown University and a
M.D. and Ph.D. in immunology from Stanford University. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that Dr.&nbsp;Yao&#146;s medical background and experience in private equity
investing, particularly with healthcare companies, qualify him to serve as a member of our board of directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Board composition and election of
directors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The primary responsibility of our board of directors is to provide oversight, strategic guidance, counseling and direction to our
management. Our board of directors meets on a regular basis and additionally as required. Our board of directors currently consists of four directors. The members of our board of directors were elected in compliance with the provisions of our
amended and restated certificate of incorporation in effect at such time and an amended and restated voting agreement, which we refer to as our voting agreement, among us and certain of our stockholders. Our voting agreement will terminate upon the
closing of this offering and none of our stockholders will have any special rights regarding the election or designation of members of our board of directors following the closing of this offering. See &#147;Certain relationships and related party
transactions&#151;Voting agreement&#148; for a discussion of our voting agreement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Director independence </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors currently consists of four members. Our board of directors has determined that, of our four
directors,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;do not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is defined under the applicable listing rules of The Nasdaq Stock Market LLC, or the Nasdaq rules. There are no family
relationships among any of our directors or executive officers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">157 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Classified board of directors </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In accordance with our amended and restated certificate of incorporation that will go into effect upon the closing of this offering, our board of directors will be divided into three classes with staggered,
three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Effective upon the
closing of this offering, our directors will be divided among the three classes as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual meeting of stockholders following this offering; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Class&nbsp;II directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual meeting of stockholders following this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the third annual meeting of stockholders following this offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws that will go into effect upon the closing of this offering will provide that the authorized number of directors may be changed
only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT
STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company. Our
directors may be removed only for cause by the affirmative vote of the holders of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> our outstanding voting stock entitled to vote in the election of directors. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Role of the board in risk oversight </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">One of the key
functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of
directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing
strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to
govern the process by which risk assessment and management are undertaken. Our audit committee also monitors compliance with legal and regulatory requirements. Our nominating and corporate governance committee monitors the effectiveness of our
corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our compensation committee assesses and monitors whether any of our compensation policies and programs has the
potential to encourage excessive risk-taking. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, our entire board of directors is regularly informed through committee reports about such
risks. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Board committees </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors
has established three standing committees&#151;audit, compensation, and nominating and corporate governance&#151;each of which operates under a charter that has been approved by our board of directors. Upon our listing on The Nasdaq Global Market,
each committee&#146;s charter will be available under the Corporate Governance section of our website at www.precisionbiosciences.com. The reference to our website address does not constitute incorporation by reference of the information contained
at or available through our website, and you should not consider it to be a part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">158 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Audit committee </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our audit committee&#146;s responsibilities include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">appointing, approving the compensation of and assessing the independence of our registered public accounting firm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related
disclosures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">coordinating our board of directors&#146; oversight of our internal control over financial reporting, disclosure controls and procedures and code of business
conduct and ethics; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing procedures for the receipt, retention and treatment of complaints we receive regarding financial controls, accounting or auditing matters and other
matters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">discussing our risk management policies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">meeting independently with our internal auditing staff, if any, independent registered public accounting firm and management; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing on a periodic basis our investment policy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and approving or ratifying any related person transactions; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">preparing the audit committee report required by SEC rules. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The members of our audit committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serves as the chairperson of the committee. All members of our audit committee
meet the requirements for financial literacy under the Nasdaq rules. Our board of directors has determined
that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;meet the independence
requirements of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3&nbsp;under</FONT> the Exchange Act and the applicable Nasdaq rules. Our board of directors has determined
that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined
under the applicable Nasdaq rules. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Compensation committee </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our compensation committee&#146;s responsibilities include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and approving, or recommending for approval by the board of directors, the compensation of our CEO and our other executive officers;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">overseeing and administering our cash and equity incentive plans; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and making recommendations to our board of directors with respect to director compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and discussing annually with management our &#147;Compensation discussion and analysis,&#148; to the extent required; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">preparing the annual compensation committee report required by SEC rules, to the extent required. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The members of our compensation committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serves as the chairperson of the committee. Our board of directors has
determined that each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">159 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is independent under the applicable Nasdaq rules, including the Nasdaq rules specific to
membership on our compensation committee, and is <FONT STYLE="white-space:nowrap">a&nbsp;&#147;non-employee&nbsp;director&#148;</FONT> as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> promulgated under the Exchange Act.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Nominating and corporate governance committee </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our nominating and corporate governance committee&#146;s responsibilities include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">identifying individuals qualified to become board members; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recommending to our board of directors the persons to be nominated for election as directors and to each board committee; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developing and recommending to our board of directors corporate governance guidelines, and reviewing and recommending to our board of directors proposed changes
to our corporate governance guidelines from time to time; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">overseeing a periodic evaluation of our board of directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The members of our nominating and corporate governance committee are &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
..&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serves as the chairperson of the committee. Our board of directors has determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are independent under the applicable Nasdaq rules. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Compensation committee interlocks and insider participation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">No member of our compensation committee is or has been our current or former officer or employee. None of our executive officers served as a director or a member of a compensation committee (or other committee
serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our compensation committee during the fiscal year ended December&nbsp;31, 2017. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Code of ethics and code of conduct </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have adopted a
written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions. Upon our listing on The Nasdaq Global Market, our code of business conduct and ethics will be available under the Corporate Governance section of our website at www.precisionbiosciences.com. In addition, we intend to post on our website
all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained
at or available through our website, and you should not consider it to be a part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">160 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_13"></A>Executive compensation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This section discusses the material components of our 2017 compensation program for our principal executive officer and next two most highly compensated executive officers who are named in the Summary compensation
table below. These &#147;named executive officers&#148; and their positions are: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane, President and Chief Executive Officer; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Fayaz Khazi, Chief Executive Officer, Elo Life Systems; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">David Thomson, Chief Development Officer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This
discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of
this offering may differ materially from the currently planned programs summarized in this discussion. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Summary compensation table </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth information concerning the compensation of our named executive officers for the year ended December&nbsp;31, 2017: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name and principal position</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Salary&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Bonus&nbsp;($)(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Option<BR>awards&nbsp;($)(2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>All&nbsp;other<BR>compensation($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">124,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">501,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em"><FONT STYLE="font-family:arial" SIZE="2">President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fayaz Khazi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">216,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(4)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">184,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">126,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">114,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(5)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">642,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em"><FONT STYLE="font-family:arial" SIZE="2">CEO, Elo Life Systems</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David Thomson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">181,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(7)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">550,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em"><FONT STYLE="font-family:arial" SIZE="2">Chief Development Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The amounts reported represent bonuses based upon our board&#146;s assessment of the achievement of company and individual performance objectives for 2017, which were paid in
January 2018, as well as other additional bonuses paid during 2017 that were generally payable to our other employees. With respect to Drs. Khazi and Thomson, the amounts reported also include <FONT STYLE="white-space:nowrap">one-time</FONT> signing
bonuses of $85,000 and $70,000, respectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The amounts reported reflect the grant date fair value of stock options granted during 2017 computed in accordance with Accounting Standards Codification 718,
Compensation&#151;Stock Compensation, or ASC 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of the option awards in Note 7 to our consolidated
financial statements included in this prospectus. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The amount reported includes 401(k) matching contributions by us of $8,848 and tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> of $15 in connection with nondiscriminatory
wellness reimbursements. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Dr.&nbsp;Khazi joined our company in May 2017. The amount reported represents the base salary that he earned for the portion of 2017 that he was employed. Dr.&nbsp;Khazi&#146;s
annual base salary for 2017 was $325,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The amount reported represents relocation and housing expenses of $104,670 in connection with Dr.&nbsp;Khazi&#146;s hiring and $9,723 of tax
<FONT STYLE="white-space:nowrap">gross-ups</FONT> in connection therewith and premiums of $392 we paid for supplemental disability insurance for Dr.&nbsp;Khazi. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Dr.&nbsp;Thomson joined our company in June 2017. The amount reported represents the base salary that he earned for the portion of 2017 that he was employed.
Dr.&nbsp;Thomson&#146;s annual base salary for 2017 was $350,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The amount reported represents relocation and housing expenses of $12,787 in connection with Dr.&nbsp;Thomson&#146;s hiring and $2,904 of tax
<FONT STYLE="white-space:nowrap">gross-ups</FONT> in connection therewith and premiums of $1,271 we paid for supplemental disability insurance for Dr.&nbsp;Thomson. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>2017 salaries </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our named executive officers receive a base salary to compensate them for services
rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">161 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
reflecting the executive&#146;s skill set, experience, role and responsibilities. None of our named executive officers is currently party to an employment agreement or other agreement or
arrangement that provides for automatic or scheduled increases in base salary. The following table shows the annual base salaries for 2017 and 2018 of our named executive officers: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name&nbsp;and&nbsp;principal&nbsp;position</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017&nbsp;Base<BR>salary&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2018&nbsp;Base<BR>salary&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fayaz Khazi</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">CEO, Elo Life Systems</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">325,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">335,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David Thomson</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Chief Development Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">355,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2017 bonuses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
addition to base salaries, our named executive officers were eligible to receive a cash bonus based on company and individual performance for 2017. Pursuant to the employment agreements entered into with our named executive officers, Mr.&nbsp;Kane
is eligible to receive an annual bonus of up to 30% of his base salary; Dr.&nbsp;Khazi is eligible to receive an annual bonus of up to 40% of his base salary (to a maximum of $130,000); and Dr.&nbsp;Thomson is eligible to receive an annual bonus of
up to 35% of his base salary. In January 2018, we paid performance bonuses of $122,500 to Mr.&nbsp;Kane, $97,500 to Dr.&nbsp;Khazi and $105,000 to Dr.&nbsp;Thomson with respect to 2017. In addition, as described in the footnotes to the Summary
compensation table, Drs. Khazi and Thomson received signing bonuses of $85,000 and $70,000, respectively, in connection with joining our company in 2017. Our executive officers also received certain additional bonuses during 2017 of less than $5,000
that were generally payable to our other employees. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Equity compensation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our equity award program is the primary vehicle for offering long-term incentives to our executives. We believe that equity awards provide our executives with a strong link to our long-term performance, create an
ownership culture and help to align the interests of our executives and our stockholders. To date, we have used stock option grants for this purpose because we believe they are an effective means by which to align the long-term interests of our
executive officers with those of our stockholders. The use of options also can provide tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity awards are an important retention
tool for our executive officers, as well as for our other employees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We award stock options broadly to our employees, including to our <FONT
STYLE="white-space:nowrap">non-executive</FONT> employees. Grants to our executives and other employees are made at the discretion of our board of directors and are not made at any specific time period during a year. The grants of stock options to
Drs. Khazi and Thomson in 2017 were made in connection with each executive&#146;s joining our company in 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We granted the following stock options to
our named executive officers during 2017 under our 2015 Plan, which is described below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Named&nbsp;executive&nbsp;officers</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017&nbsp;Stock&nbsp;options<BR>granted</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fayaz Khazi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David Thomson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">162 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, we intend to adopt our 2019 Plan to facilitate the grant of cash and equity
incentives to directors, employees (including our named executive officers) and consultants of our company and to enable our company to obtain and retain services of these individuals, which we believe are essential to our long-term success.
Following the effective date of our 2019 Plan, we will not make any further grants under our 2015 Plan. However, our 2015 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. For additional information
about our 2019 Plan, see &#147;&#151;Incentive plans&#148; below. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Retirement plans </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently maintain the Precision BioSciences, Inc. 401(k) Plan, a defined contribution retirement savings plan, or the 401(k) Plan, for the benefit of our
employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. The Code allows eligible
employees to defer a portion of their compensation, within prescribed limits, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis through contributions to the 401(k) Plan. We have historically matched participants&#146; elective salary
deferral contributions to the 401(k) Plan up to 50% of the first 6% of the employee&#146;s salary deferred. Matching contributions made by us vest 25% each year and are fully vested after four years. We believe that providing a vehicle for <FONT
STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) Plan, and making matching contributions, adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our
named executive officers, in accordance with our compensation policies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Employee benefits and perquisites </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our named executive officers are eligible to participate in our employee benefit plans and programs, which include medical, dental and vision benefits, health and
flexible spending accounts, life, short-term, long-term and supplemental individual disability, and supplemental insurance and wellness and tuition reimbursement to the same extent as our other full-time employees generally, subject to the terms and
eligibility requirements of those plans. We also provide Mr.&nbsp;Kane and Drs. Khazi and Thomson, along with certain other executive officers and senior employees, with certain supplemental disability insurance benefits. We also provide relocation
benefits to our named executive officers as determined in our board&#146;s discretion. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Outstanding equity awards at 2017 fiscal <FONT
STYLE="white-space:nowrap">year-end</FONT> </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes the number of shares of common stock underlying outstanding equity
incentive plan awards for each of our named executive officers as of December&nbsp;31, 2017. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Option awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>securities<BR>underlying<BR>unexercised<BR>options</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>(#)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>exercisable</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>securities<BR>underlying<BR>unexercised<BR>options</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>(#)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>unexercisable</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Option<BR>exercise<BR>price</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>($)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Option<BR>expiration<BR>date</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">688,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5/17/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3/23/2027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fayaz Khazi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4/30/2027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David Thomson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6/29/2027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Award vests as to 25% of the underlying shares on March&nbsp;24, 2018 with respect to Mr.&nbsp;Kane, March&nbsp;24, 2018 with respect to Dr.&nbsp;Khazi and May&nbsp;31, 2018 with
respect to Dr.&nbsp;Thomson and in equal installments at the end of each three-month period over the following 36 months, subject to the named executive officer&#146;s continued employment with us. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">163 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Employment agreements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have entered into employment agreements with each our named executive officers that set forth the terms and conditions of each executive&#146;s employment with us. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each employment agreement establishes an annual base salary for each named executive officer, which is subject to our discretionary review and adjustment in
accordance with our policies, procedures and practices as they may exist from time to time provided that no named executive officer&#146;s base salary may be decreased unless the decrease is an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">across-the-board</FONT></FONT> decrease of all senior management employees of our company. See &#147;Summary compensation table&#151;2017 salaries&#148; above for the base salaries in effect for 2017 and 2018. Each of our
named executive officers is also eligible to receive an annual bonus. Mr.&nbsp;Kane is eligible to receive an annual bonus of up to 30% of his base salary, Dr.&nbsp;Khazi is eligible to receive an annual bonus of up to 40% of his base salary (to a
maximum of $130,000), and Dr.&nbsp;Thomson is eligible to receive an annual bonus of up to 35% of his base salary. The named executive officers are eligible to participate in all medical, dental and disability insurance, the 401(k), personal leave
and other employee benefit plans and programs for which the named executive officer is eligible, subject to the terms and conditions of such plans and programs. Each employment agreement further provides for the reimbursement of reasonable and
necessary business expenses actually incurred by the named executive officer in performing services for us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each named executive officer&#146;s
employment agreement and employment are terminable by either the named executive officer or us without cause on <FONT STYLE="white-space:nowrap">30-days&#146;</FONT> notice. In the event that a named executive officer&#146;s employment is terminated
by us without cause or for disability or by the executive for good reason, in each case as defined in the employment agreements, then in addition to any accrued amounts and subject to such named executive officer&#146;s timely delivering an
effective release of claims in our favor, he will be entitled to receive (1)&nbsp;payment of an amount equal to six months of the named executive officer&#146;s base salary in the case of Mr.&nbsp;Kane or nine months in the case of Drs. Khazi and
Thomson, except in the case of termination for disability, in which case the amount will be three months for either Dr.&nbsp;Khazi or Dr.&nbsp;Thomson, paid in substantially similar installments on same payroll applicable to him immediately prior to
his separation from service, subject to certain exceptions, (2)&nbsp;payment of any bonus that has been earned but not yet paid as of the date of termination, and (3)&nbsp;reimbursement for additional costs the executive incurs for continued
coverage under our group health insurance under the Consolidated Budget Reconciliation Act of 1985, or COBRA, for the applicable severance period or, if sooner, until comparable coverage is available in connection with subsequent employment. Upon
termination of employment by us for cause or due to death or by the named executive officer other than for good reason, he will not be entitled to any additional compensation beyond any earned but unpaid salary. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the foregoing, the employment agreements provide that, in the event a named executive officer&#146;s employment is terminated by us without cause or
by the named executive officer for good reason within 12&nbsp;months for Mr.&nbsp;Kane or six months for Drs. Khazi or Thomson after the occurrence of a change in control, as defined in the employment agreements, then, subject to his timely
executing a release of claims, the period for which he is entitled to receive his monthly salary and reimbursement for continued group health insurance coverage under COBRA described above shall increase from six or nine months, as applicable, to
12&nbsp;months. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the employment agreement with Mr.&nbsp;Kane and a separate proprietary information, inventions,
<FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement with each of Drs. Khazi and Thomson, each named executive officer has agreed to refrain from competing with us or
soliciting our employees, in each case, while employed and following the termination of his employment for any reason for a period of two years for Mr.&nbsp;Kane or 12 months for Drs. Khazi and Thomson, and has acknowledged our ownership rights in
any intellectual property and assigned any such ownership rights to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">164 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, we are evaluating entering into amended and restated employment agreements with
our named executive officers. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Incentive plans </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following summarizes the material terms of the long-term incentive compensation plan in which our named executive officers will be eligible to participate
following the consummation of this offering and our 2015 Plan and 2006 Plan under which we have previously made periodic grants of equity and equity-based awards to our named executive officers and other key employees. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2019 Incentive award plan </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to adopt and ask
our stockholders to approve our 2019 Plan to be effective upon the effectiveness of the registration statement of which this prospectus forms a part, under which we may grant cash and equity-based incentive awards to eligible service providers in
order to attract, retain and motivate the persons who make important contributions to our company. The material terms of our 2019 Plan are summarized below. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Eligibility and administration </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our employees, consultants and directors, and employees and consultants of our
subsidiaries, will be eligible to receive awards under our 2019 Plan. Our 2019 Plan will be administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of our directors and/or officers
(referred to collectively as the plan administrator below), subject to the limitations imposed under our 2019 Plan, Section&nbsp;16 of the Exchange Act, stock exchange rules and other applicable laws. The plan administrator will have the authority
to take all actions and make all determinations under our 2019 Plan, to interpret our 2019 Plan and award agreements and to adopt, amend and repeal rules for the administration of our 2019 Plan as it deems advisable. The plan administrator will also
have the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under our 2019 Plan, including any vesting and vesting acceleration provisions, subject to the conditions
and limitations in our 2019 Plan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Shares available for awards </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">An aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will initially be available for issuance under our 2019 Plan.
The number of shares initially available for issuance will be increased by an annual increase on January&nbsp;1 of each calendar year beginning
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and ending in and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, equal to
the least of (1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, (2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of the shares of common stock outstanding on the final day of the immediately
preceding calendar year and (3)&nbsp;a smaller number of shares determined by our board of directors. No more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock may
be issued under our 2019 Plan upon the exercise of incentive stock options, or ISOs. Shares issued under our 2019 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If an award under our 2019 Plan, our 2015 Plan or our 2006 Plan expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without
having been fully exercised or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under our 2019 Plan. Awards granted under our 2019 Plan in substitution for any options or other stock
or stock-based awards granted by an entity before the entity&#146;s merger or consolidation with us or our acquisition of the entity&#146;s property or stock will not reduce the shares available for grant under our 2019 Plan, but will count against
the maximum number of shares that may be issued upon the exercise of ISOs, as applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">165 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the maximum aggregate grant date fair value as determined in accordance with ASC 718 (or any
successor thereto), of awards granted to <FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director</FONT> for services as a director pursuant to our 2019 Plan during any fiscal year may not exceed
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (or, in the fiscal year of any director&#146;s initial service,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ). The plan administrator may, however, make exceptions to such limit on director compensation in extraordinary circumstances, subject to the
limitations in our 2019 Plan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Awards </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our 2019
Plan provides for the grant of stock options, including ISOs, and nonqualified stock options, or NSOs, stock appreciation rights, or SARs, restricted stock, dividend equivalents, restricted stock units, or RSUs, and other stock or cash based awards.
Certain awards under our 2019 Plan may constitute or provide for payment of &#147;nonqualified deferred compensation&#148; under Section&nbsp;409A of the Code. All awards under our 2019 Plan will be set forth in award agreements, which will detail
the terms and conditions of awards, including any applicable vesting and payment terms and post-termination exercise limitations. A brief description of each award type follows. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Stock Options and SARs. Stock options provide for the purchase of shares of our common stock in the future at an exercise price set on the grant date. ISOs, by
contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding periods and other requirements of the Code are satisfied. SARs entitle their holder, upon exercise, to receive
from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The plan administrator will determine the number of shares covered by each option and SAR, the exercise price of each option
and SAR and the conditions and limitations applicable to the exercise of each option and SAR. The exercise price of a stock option or SAR will not be less than 100% of the fair market value of the underlying share on the grant date (or 110% in the
case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The term of a stock option or SAR may not be longer than ten years (or five years in the
case of ISOs granted to certain significant stockholders). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Restricted Stock and RSUs. Restricted stock is an award of nontransferable shares of our common stock that remain forfeitable unless and until specified
conditions are met and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be
accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. The plan administrator may provide that the delivery of the shares underlying RSUs will be
deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to restricted stock and RSUs will be determined by the plan administrator, subject to the conditions and limitations contained in our 2019 Plan.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Other Stock or Cash Based Awards. Other stock or cash based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or
partially by referring to, or otherwise based on, shares of our common stock or other property. Other stock or cash based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as
standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. The plan administrator will determine the terms and conditions of other stock or cash based awards, which may include any purchase price,
performance goal, transfer restrictions and vesting conditions. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">166 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Performance criteria </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The plan administrator may select performance criteria for an award to establish performance goals for a performance period. Performance criteria under our 2019 Plan may include, but are not limited to, the
following:&nbsp;net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, <FONT STYLE="white-space:nowrap">and&nbsp;non-cash&nbsp;equity-based</FONT> compensation expense); gross or net sales or
revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or
operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on
assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per
share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating
to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service;
employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity,
profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured
in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the company&#146;s performance or the performance of a subsidiary, division, business segment or business unit
of the company or a subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. When determining performance goals, the plan
administrator may provide for exclusion of the impact of an event or occurrence which the plan administrator determines should appropriately be excluded, including, without
<FONT STYLE="white-space:nowrap">limitation,&nbsp;non-recurring&nbsp;charges</FONT> or events, acquisitions or divestitures, changes in the corporate or capital structure, events unrelated to the business or outside of the control of management,
foreign exchange considerations, and legal, regulatory, tax or accounting changes. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Certain transactions </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with certain corporate transactions and events affecting our common stock, including a change in control, or change in any applicable laws or
accounting principles, the plan administrator has broad discretion to take action under our 2019 Plan to prevent the dilution or enlargement of intended benefits, facilitate the transaction or event or give effect to the change in applicable laws or
accounting principles. This includes canceling awards for cash or property, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares subject to
outstanding awards and/or with respect to which awards may be granted under our 2019 Plan and replacing or terminating awards under our 2019 Plan. In addition, in the event of
<FONT STYLE="white-space:nowrap">certain&nbsp;non-reciprocal&nbsp;transactions</FONT> with our stockholders, the plan administrator will make equitable adjustments to our 2019 Plan and outstanding awards as it deems appropriate to reflect the
transaction. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Plan amendment and termination </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
board of directors may amend or terminate our 2019 Plan at any time; however, no amendment, other than an amendment that increases the number of shares available under our 2019 Plan, may materially and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">167 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
adversely affect an award outstanding under our 2019 Plan without the consent of the affected participant, and stockholder approval will be obtained for any amendment to the extent necessary to
comply with applicable laws. Further, the plan administrator cannot, without the approval of our stockholders, amend any outstanding stock option or SAR to reduce its price per share. Our 2019 Plan will remain in effect until the tenth anniversary
of its effective date, unless earlier terminated by our board of directors. No awards may be granted under our 2019 Plan after its termination. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Foreign participants, claw-back provisions, transferability and participant payments </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The plan administrator may modify awards granted to participants who are foreign nationals or employed outside the United States or establish subplans or procedures to address differences in laws, rules,
regulations or customs of such foreign jurisdictions. All awards will be subject to any company claw-back policy as set forth in such claw-back policy or the applicable award agreement. Except as the plan administrator may determine or provide in an
award agreement, awards under our 2019 Plan are <FONT STYLE="white-space:nowrap">generally&nbsp;non-transferrable,&nbsp;except</FONT> by will or the laws of descent and distribution, or, subject to the plan administrator&#146;s consent, pursuant to
a domestic relations order, and are generally exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under our 2019 Plan, and exercise price obligations arising in connection with the
exercise of stock options under our 2019 Plan, the plan administrator may, in its discretion, accept cash, wire transfer or check, shares of our common stock that meet specified conditions, a promissory note, a &#147;market sell order,&#148; such
other consideration as the plan administrator deems suitable or any combination of the foregoing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2015 Stock incentive plan </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors and stockholders have approved our 2015 Plan, under which we may grant stock options, restricted stock, RSUs and other stock-based awards to
employees, officers, directors, consultants, advisors, advisory board members and other service providers.&nbsp;A total of 11,250,000&nbsp;shares of our common stock have been authorized for issuance under our 2015 Plan. As of the date of this
prospectus, awards of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stock options are outstanding under our 2015 Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Following the effectiveness of our 2019 Plan, we will not make any further grants under our 2015 Plan. However, our 2015 Plan will continue to govern the terms and conditions of the outstanding awards granted under
it. Shares of our common stock subject to awards granted under our 2015 Plan that are forfeited, lapse unexercised or are settled in cash and which following the effective date of our 2019 Plan are not issued under our 2015 Plan will be available
for issuance under our 2019 Plan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Administration </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our 2015 Plan is administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of our directors (referred to
collectively as our board of directors below) to the extent permitted by applicable law. Our board of directors has the authority to grant awards under our 2015 Plan and to adopt, amend, and repeal such administrative rules, guidelines, and
practices relating to our 2015 Plan as it shall deem advisable. Our board of directors may correct any defect, supply any omission, or reconcile any inconsistency in our 2015 Plan or any award thereunder in the manner and to the extent it deems
expedient to carry our 2015 Plan into effect. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Types of awards </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our 2015 Plan provides for the grant of stock options, including NSOs and ISOs, restricted stock, RSUs and other stock-based awards to employees, officers, directors, consultants, advisors, advisory board members
or other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">168 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
service providers, except that stock options intended to qualify as ISOs under the Code may only be granted to employees. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Certain adjustments </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of certain changes in capitalization, or any dividend or distribution to
holders of our common stock other than an ordinary cash dividend, the number and class of securities available under our 2015 Plan and the number and class of securities and exercise price per share of each outstanding option will be equitably
adjusted by us (or substituted awards may be made, if applicable) in the manner determined by our board of directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Change in control
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless otherwise specifically provided in an award agreement, our board of directors may take any one or more of the following actions as to all (or
any portion of) outstanding options on such terms as our board of directors determines in connection with a change in control, as defined in our 2015 Plan: (1)&nbsp;provide for the assumption or substitution of the award; (2)&nbsp;upon written
notice to a participant, provide for the termination of all unexercised options unless exercised within a specific period; (3)&nbsp;provide that outstanding options will become exercisable prior to or upon such change in control; (4)&nbsp;in the
event of a change in control in which holders of our common stock will receive cash payment for shares surrendered, make or provide for a cash payment to participants based on the excess, if any of (a)&nbsp;the change in control consideration times
the number of shares subject to outstanding options less (b)&nbsp;the aggregate exercise price of the outstanding options, in exchange for termination of such options; (5)&nbsp;provide that, in connection with our liquidation or dissolution, awards
shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof); or (c)&nbsp;any combination of the foregoing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Plan amendment and termination </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors may amend, suspend or terminate our 2015 Plan at any
time; provided, however, that if at any time the approval of our stockholders is required as to any modification or amendment under Section&nbsp;422 of the Code or any successor provision with respect to ISOs, our board may not effect such
modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to our 2015 Plan will apply to, and be binding on the holders of, all awards outstanding under our 2015 Plan at the time the amendment is
adopted, provided our board determines that such amendment does not materially and adversely affect the rights of participants under our 2015 Plan. Our 2015 Plan will remain in effect until the tenth anniversary of its effective date, unless earlier
terminated by our board of directors. No awards may be granted under our 2015 Plan after its termination. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Transferability of awards </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except as our board may otherwise expressly determine or provide in an award, awards under our 2015 Plan may not be sold, assigned, transferred, pledged or
otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an ISO, pursuant to a qualified domestic relations order,
and, during the life of the participant, shall be exercisable only by the participant. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2006 Stock incentive plan </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors previously adopted and our stockholders approved our 2006 Plan in May 2006. Our 2006 Plan expired in accordance with its terms in May 2016
and no further stock awards may be granted under </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">169 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
our 2006 Plan. Any awards granted under our 2006 Plan remain subject to the terms of our 2006 Plan and applicable award agreements, until such outstanding awards that are stock options are
exercised, or until they terminate or expire by their terms. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Administration </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our 2006 Plan is administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of our directors (referred to collectively as our board of directors below) to
the extent permitted by applicable law. Prior to the expiration of our 2006 plan, our board of directors had the authority to grant awards under our 2006 Plan, and our board of directors has the authority to adopt, amend, and repeal such
administrative rules, guidelines, and practices relating to our 2006 Plan as it shall deem advisable. Our board of directors may correct any defect, supply any omission, or reconcile any inconsistency in our 2006 Plan or any award thereunder in the
manner and to the extent it deems expedient to carry our 2006 Plan into effect. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Types of awards </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our 2006 Plan provided for the grant of stock options, including NSOs and ISOs, restricted stock, RSUs and other stock-based awards to employees, officers,
directors, consultants and advisors, except that stock options intended to qualify as ISOs under the Code were only permitted to be granted to employees. As of the date of this
prospectus,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;awards of stock options are outstanding under our 2006 Plan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Certain adjustments </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of certain changes in capitalization, or any dividend or distribution to
holders of our common stock other than an ordinary cash dividend, the number and class of securities available under our 2006 Plan and the number and class of securities and exercise price per share of each outstanding option will be equitably
adjusted by us (or substituted awards may be made, if applicable) in the manner determined by our board of directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Reorganization </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors may take any one or more of the following actions as to all (or any portion of) outstanding awards on such terms as our board of directors
determines in connection with a reorganization, as defined in our 2006 Plan: (1)&nbsp;provide for the assumption or substitution of the award, (2)&nbsp;upon written notice to a participant, provide for the termination of all unexercised options
unless exercised within a specific period, (3)&nbsp;provide that outstanding options will become exercisable prior to or upon such reorganization, (4)&nbsp;in the event of a reorganization in which holders of our common stock will receive cash
payment for shares surrendered, make or provide for a cash payment to participants equal to (a)&nbsp;the reorganization consideration times the number of shares subject to outstanding options minus (b)&nbsp;the aggregate exercise price of the
outstanding options, in exchange for termination of such options, (5)&nbsp;provide that, in connection with our liquidation or dissolution, awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price
thereof) and (6)&nbsp;any combination of the foregoing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Transferability of awards </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Except as our board may otherwise have expressly determined or provided in an award, awards under our 2006 Plan may not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are
granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an ISO, pursuant to a qualified domestic relations order, and, during the life of the participant, shall be
exercisable only by the participant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">170 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2019 Employee stock purchase plan </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We intend to adopt and ask our stockholders to approve our 2019 ESPP to be effective upon the effectiveness of the registration statement of which this prospectus forms a part. The material terms of our 2019 ESPP
are summarized below. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Shares available for awards; administration </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A total of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will initially be reserved for issuance under our 2019 ESPP. In
addition, the number of shares available for issuance under our 2019 ESPP will be annually increased on January&nbsp;1 of each calendar year beginning
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and ending in and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, by an
amount equal to the least of (1)&nbsp;&nbsp;&nbsp;&nbsp;% of the shares outstanding on the final day of the immediately preceding calendar year and (2)&nbsp;such smaller number of shares as is determined by our board of directors, provided that no
more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock may be issued under our 2019 ESPP. The foregoing numbers are subject to adjustment in certain events, as
described below. Our board of directors or a committee of our board of directors will have authority to interpret the terms of our 2019 ESPP and determine eligibility of participants. We expect that the compensation committee will be the initial
administrator of our 2019 ESPP. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Eligibility </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
employees are eligible to participate in our 2019 ESPP if they are customarily employed by us or a participating subsidiary for more than twenty hours per week and more than five months in any calendar year. However, an employee may not be granted
rights to purchase stock under our 2019 ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our stock. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Grant of rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our 2019 ESPP is intended to qualify under
Section&nbsp;423 of the Code and stock will be offered under our 2019 ESPP during offering periods. The length of the offering periods under our 2019 ESPP will be determined by the plan administrator and may be up to twenty-seven months long.
Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates for each offering period will be the final trading day in the offering period. Offering periods under our 2019 ESPP will
commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our 2019
ESPP permits participants to purchase common stock through payroll deductions of up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of their eligible compensation, which includes a participant&#146;s gross base
compensation for services to us, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The plan administrator will establish a maximum number
of shares that may be purchased by a participant during any offering period, which, in the absence of a contrary designation, will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.
In addition, no employee will be permitted to accrue the right to purchase stock under our 2019 ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market
value per share of our common stock as of the first day of the offering period). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On the first trading day of each offering period, each participant will
automatically be granted an option to purchase shares of our common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the
offering period. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">171 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
market value of our common stock on the first trading day of the offering period or on the purchase date. Participants may voluntarily end their participation in our 2019 ESPP at any time at
least one week prior to the end of the applicable offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s
termination of employment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A participant may not transfer rights granted under our 2019 ESPP other than by will or the laws of descent and distribution.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Certain transactions </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of certain <FONT
STYLE="white-space:nowrap">non-reciprocal</FONT> transactions or events affecting our common stock known as &#147;equity restructurings,&#148; the plan administrator will make equitable adjustments to our 2019 ESPP and outstanding rights. In the
event of certain unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> events or transactions, including a change in control, the plan administrator may provide for (1)&nbsp;either the replacement of outstanding rights with other rights
or property or termination of outstanding rights in exchange for cash, (2)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3)&nbsp;the adjustment in the
number and type of shares of stock subject to outstanding rights, (4)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights
under ongoing offering periods or (5)&nbsp;the termination of all outstanding rights. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Plan amendment </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The plan administrator may amend, suspend or terminate our 2019 ESPP at any time. However, stockholder approval will be obtained for any amendment that increases
the aggregate number or changes the type of shares that may be sold pursuant to rights under our 2019 ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in our 2019 ESPP or changes our 2019 ESPP in
any manner that would cause our 2019 ESPP to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT
STYLE="white-space:nowrap">Non-employee</FONT> director compensation policy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Historically, our directors have not received compensation for their
service on our board of directors. We intend to approve and implement a compensation program for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that will become effective upon the effectiveness of the registration statement of
which this prospectus is a part. The terms of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director program are not yet known and will be described in this prospectus once they are determined. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">172 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_14"></A>Certain relationships and related party transactions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following includes a summary of transactions since January&nbsp;1, 2015, to which we have been a party in which the amount involved exceeded or will exceed
$120,000, and in which any of our directors or executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or
indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#147;Executive compensation.&#148; We also describe below certain other transactions with our
directors, executive officers and stockholders. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Preferred stock financings </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Series A preferred stock financing </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2015 and May 2015, we issued and sold to investors in a
private placement 25,650,000 shares of our Series A preferred stock at a price per share of $1.00, for aggregate consideration of $25.65&nbsp;million. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes the Series A preferred stock purchased by directors, executive officers, beneficial owners of more than 5% of our capital stock or
any member of the immediate family of any of the foregoing persons. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Participants</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Series&nbsp;A</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>preferred&nbsp;stock</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Total&nbsp;purchase</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>price</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>5% or greater stockholders and directors</B>(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amgen Investments Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund IV LP(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">RA Capital Healthcare Fund, L.P.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">venBio Global Strategic Fund L.P.(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Additional details regarding these stockholders and their equity holdings are provided in this prospectus under the caption &#147;Principal stockholders.&#148;
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Ben Auspitz, a former member of our board of directors, is a partner at <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners. Mr.&nbsp;Auspitz does not hold voting or
dispositive power over the shares held by <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund IV LP. See &#147;Principal stockholders&#148; below for more information. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Robert Adelman, M.D., a member of our board of directors, is a partner at venBio Global Strategic Fund L.P. See &#147;Principal stockholders&#148; below for more information.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Series B preferred stock financing </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">From May 2018 to July 2018, we issued and sold to investors in a private placement 21,956,095 shares of our Series B preferred stock at a price per share of $5.01, for aggregate gross proceeds of approximately
$110.0&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">173 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes the Series B preferred stock purchased by directors, executive officers,
beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Participants</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Series&nbsp;B</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>preferred&nbsp;stock</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Total&nbsp;purchase</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>price</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>5% or greater stockholders and directors</B>(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amgen Investments Ltd.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">499,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund IV LP(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">873,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,374,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">RA Capital Healthcare Fund, L.P.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">399,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,000,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">venBio Global Strategic Fund, L.P.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">998,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Tony Yao(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">47,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Additional details regarding these stockholders and their equity holdings are provided in this prospectus under the caption &#147;Principal stockholders.&#148;
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Series B preferred stock was purchased by Amgen Ventures LLC, an affiliate of Amgen Investment Ltd. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Ben Auspitz, a former member of our board of directors, is a partner at <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners. Mr.&nbsp;Auspitz does not hold voting or
dispositive power over the shares held by <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund IV LP. See &#147;Principal stockholders&#148; below for more information. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Robert Adelman, M.D., a member of our board of directors, is a partner at venBio Global Strategic Fund, L.P. See &#147;Principal stockholders&#148; below for more information.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Tony Yao, M.D., Ph.D. is a current member of our board of directors. Dr.&nbsp;Yao is associated with the ArrowMark Funds (as defined below). See &#147;Principal
stockholders&#148; below for more information. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Investors&#146; rights agreement </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are party to an amended and restated investors&#146; rights agreement, which we refer to as our investors&#146; rights agreement, with each holder of our
convertible preferred stock and certain holders of our common stock (Derek Jantz, Matthew Kane and Jeff Smith), which includes each holder of more than 5% of our capital stock and each of our directors (or, in some cases, entities affiliated
therewith). Our investors&#146; rights agreement imposes certain affirmative obligations on us and also grants certain rights to the holders, including certain registration rights with respect to the registrable securities held by them that will
survive this offering. See &#147;Description of capital stock&#151;Registration rights&#148; for additional information. This right of first offer does not apply to this offering and will terminate by its terms in connection with the closing of this
offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Voting agreement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a party to an
amended and restated voting agreement with certain of our stockholders, pursuant to which the following directors were elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: Matthew Kane,
Derek Jantz, Robert Adelman and Tony Yao. Our voting agreement will terminate by its terms in connection with the closing of this offering, and members previously elected to our board of directors pursuant to this voting agreement will continue to
serve as directors until they resign, are removed or their successors are duly elected by the holders of our common stock. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Board
composition and election of directors.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are party to an amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement with each holder of our convertible
preferred stock and certain holders of our common stock (Derek Jantz, Matthew Kane and Jeff Smith), which includes each holder of more than 5% of our capital stock and certain of our directors (or, in some cases, entities affiliated therewith),
pursuant to which we have a right of first refusal in respect of certain </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">174 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
sales of securities by Drs. Jantz and Smith and Mr.&nbsp;Kane. To the extent we do not exercise such right in full, the holders of our convertible preferred stock are granted certain rights of
first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of such sale. The right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement will terminate by its terms in connection with the closing of this
offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Director and officer indemnification and insurance </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have agreed to indemnify each of our directors and executive officers against certain liabilities, costs and expenses and have purchased directors&#146; and officers&#146; liability insurance. See
&#147;Description of capital stock&#151;Limitations on liability and indemnification matters.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Employment agreements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have entered into employment agreements with our certain of our executive officers, including our named executive officers. For more information regarding the
agreements with our named executive officers, see &#147;Executive compensation&#151;Employment agreements.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Stock option grants to executive
officers and directors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have granted stock options to our executive officers as more fully described in &#147;Executive compensation.&#148;
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other transactions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2017, in connection
with a repurchase program approved by our board of directors, we repurchased 1,282,226 shares of common stock from J. Christopher Rhodes, a beneficial owner of more than 5% of our common stock, for aggregate proceeds of approximately $0.7 million.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Chelsea Lynam, Mr. Kane&#146;s wife, serves as our Manager, Facilities Planning &amp; Design. Ms. Lynam received total compensation of $186,545 from the
beginning of 2018 through September 30, 2018 in respect of base salary, bonus and the grant date fair value of options to purchase 45,000 shares of our common stock that were granted in April 2018. Ms. Lynam also participates in other employee
benefit plans and arrangements that are made generally available to other employees.</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Policies and procedures for related person transactions
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors has adopted a written related person transaction policy, to be effective upon the closing of this offering, setting forth the
policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities
Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a related person
had, has or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest as well as indebtedness,
guarantees of indebtedness and our employment of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the
transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the
effectiveness of this policy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">175 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_15"></A>Principal stockholders </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth information with respect to the beneficial ownership of our common stock as of September&nbsp;30, 2018 by: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each of our named executive officers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each of our directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">all of our executive officers and directors as a group. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The number of shares beneficially owned by each stockholder is determined under rules promulgated by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has
sole or shared voting power or investment power. Each stockholder&#146;s percentage ownership is based on 81,390,126 shares of common stock outstanding as of September&nbsp;30, 2018, assuming the conversion of all outstanding shares of preferred
stock into 47,606,095 shares of our common stock upon the closing of this offering. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to
options or other rights held by such person that are currently exercisable or will become exercisable within 60 days of September&nbsp;30, 2018 are considered outstanding, although these shares are not considered outstanding for purposes of
computing the percentage ownership of any other person. Unless otherwise noted, the address of all listed stockholders is c/o Precision BioSciences, 302 East Pettigrew St., Suite <FONT STYLE="white-space:nowrap">A-100,</FONT> Durham, North Carolina
27701. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless otherwise noted, subject to community property laws where applicable. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number of
shares<BR>beneficially&nbsp;owned</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage&nbsp;of&nbsp;shares<BR>beneficially&nbsp;owned</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name&nbsp;of&nbsp;beneficial&nbsp;owner</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Before</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>offering</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>After</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>offering</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B></B><B><I>5% or Greater Stockholders</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">venBio Global Strategic Fund, L.P.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,998,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jeff Smith, Ph.D.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,915,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund IV LP(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,873,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B></B><B><I>Named Executive Officers and Directors</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,585,601</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fayaz Khazi, Ph.D.(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">131,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David Thomson, Ph.D.(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">156,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Robert Adelman, M.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,998,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Derek Jantz, Ph.D.(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,915,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Tony Yao, M.D., Ph.D.(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,996,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">All executive officers and directors as a group (10 persons)(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,589,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Less than 1%. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 8,000,000 shares of Series A preferred stock and 998,004 shares of Series B preferred stock. VenBio Global Strategic GP, L.P., or venBio GP, is the sole general
partner of venBio Global Strategic Fund, L.P., or venBio, and venBio Global Strategic GP, Ltd., or venBio GP Ltd., is the sole general partner of venBio GP. Robert Adelman, one of our directors, and Corey Goodman are directors of venBio GP Ltd. and
share voting and dispositive control over the shares held by venBio. The mailing address of venBio Global Strategic Fund, L.P. is c/o venBio Partners, LLC, 1700 Owens Street, Suite 595, San Francisco, CA 94158. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of (a) 8,208,231 shares of common stock and (b) 707,638 shares of common stock underlying options exercisable within 60 days of September&nbsp;30, 2018.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">176 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 7,000,000 shares of Series A preferred stock and 873,253 shares of Series B preferred stock. The general partner of <FONT STYLE="white-space:nowrap">F-Prime</FONT>
Capital Partners Healthcare Fund IV LP is <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Advisors Fund IV LP. <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Advisors Fund IV LP is solely
managed by Impresa Management LLC, the managing member of its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC. Each of the entities listed above
expressly disclaims beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein. The mailing address of <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund IV LP is 245
Summer Street, Boston, MA 02210. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of (a) 3,847,616 shares of common stock held directly by Mr.&nbsp;Kane, (b) 17,222 shares of common stock held by Chelsea Lynam, Mr.&nbsp;Kane&#146;s wife, (c) 707,638
shares of common stock underlying options held by Mr.&nbsp;Kane exercisable within 60 days of September&nbsp;30, 2018 and (d) 13,125 shares of common stock underlying options held by Ms.&nbsp;Lynam exercisable within 60 days of September&nbsp;30,
2018. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 131,250 shares of common stock underlying options exercisable within 60 days of September&nbsp;30, 2018. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 156,250 shares of common stock underlying options exercisable within 60 days of September&nbsp;30, 2018. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of (a) 8,208,231 shares of common stock and (b) 707,638 shares of common stock underlying options exercisable within 60 days of September&nbsp;30, 2018.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 9,500 of Series B preferred stock held directly by Dr.&nbsp;Yao and 200,000 shares of Series B preferred stock held by ArrowMark Fundamental Opportunity Fund, L.P.,
244,572 shares of Series B preferred stock held by ArrowMark Life Science Fund, 10,000 of Series B preferred stock held by CF Ascent LLC, 149,451 of Series B preferred stock held by Iron Horse Investments, LLC, or Iron Horse, 39,920 of Series B
preferred stock held by Lookfar Investments, LLC, 624,759 of Series B preferred stock held by Meridian Growth Fund, or Meridian Growth, 558,855 of Series B preferred stock held by Meridian Small Cap Growth Fund, or Meridian Small Cap, 149,451 of
Series B preferred stock held by THB Iron Rose, LLC, or THB Iron Rose, 9,500 of Series B preferred stock held by THB Iron Rose, LLC Life Science Portfolio, or THB Iron Rose Life Science, which are referred to collectively as the ArrowMark Funds.
ArrowMark Colorado Holdings LLC, or ArrowMark Colorado, is investment advisor to ArrowMark Funds. Dr.&nbsp;Yao, one of our directors, is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the
shares held by ArrowMark Life Science Fund and THB Iron Rose Life Science. Mr.&nbsp;Yao may be considered the beneficial owner of the shares held by ArrowMark Life Science Fund and THB Iron Rose Life Science and disclaims beneficial ownership of
such shares, except to the extent of any pecuniary interest therein. The principal business address of the ArrowMark Funds is 100 Fillmore Street, Suite 325, Denver, Colorado 80206. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of (a) 21,725,382 shares of common stock, (b) 3,869,755 shares of common stock underlying options exercisable within 60 days of September&nbsp;30, 2018, (c) 8,000,000
shares of Series A preferred stock and (d) 2,994,012 of Series B preferred stock. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">177 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_16"></A>Description of capital stock </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Capital structure </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following description of our capital
stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated
bylaws that will go into effect upon the closing of this offering. Copies of these documents will be filed with the SEC as exhibits to our registration statement, of which this prospectus forms&nbsp;a part. The descriptions of our common stock and
preferred stock reflect changes to our capital structure that will occur upon the closing of this offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>General </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the completion of this offering, our authorized capital stock will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, par value $0.000005 per share,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, par value $0.0001 per share, all of which will be undesignated. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Common stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of September&nbsp;30, 2018, assuming
the conversion of all outstanding shares of our convertible preferred stock into 47,606,095 shares of our common stock upon the closing of this offering, we had outstanding 81,390,126 shares of common stock held of record by 121 stockholders.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative
voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as
may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and
other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered
by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of
shares of any series of preferred stock that we may designate and issue in the future. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Preferred stock </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of September&nbsp;30, 2018, there were 47,606,095 shares of our convertible preferred stock outstanding. Upon the closing of this offering, all outstanding
shares of our convertible preferred stock will convert into 47,606,095 shares of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of our amended and restated
certificate of incorporation that will go into effect upon the closing of this offering, our board of directors will be authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of
directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">178 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and
preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could
have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred
stock outstanding, and we have no present plans to issue any shares of preferred stock. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Options </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of September&nbsp;30, 2018, options to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock were outstanding under our 2015 Plan, of which&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;options were vested as of that date, and options to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock were outstanding under our 2006 Plan, all of which options were vested as of that date. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Registration rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our investors&#146; rights
agreement grants the parties thereto certain registration rights in respect of the &#147;registrable securities&#148; held by them, which securities include (1)&nbsp;the shares of our common stock issued upon the conversion of shares of our
convertible preferred stock, (2)&nbsp;the shares of our common stock issued to certain of our founders, and (3)&nbsp;any shares of our common stock issued as a dividend or other distribution with respect to the shares described in the foregoing
clauses&nbsp;(1) and (2). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Demand registration rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Upon the closing of this offering, certain holders of our registrable securities are entitled to demand registration rights. Under the terms of our investors&#146; rights agreement, we will be required, upon the
request of holders of at least 60% of our outstanding registrable securities issued or issuable upon conversion of our convertible preferred stock, to file&nbsp;a registration statement with an anticipated offering amount of at least
$15.0&nbsp;million and use our best efforts to effect the registration of these shares for public resale. We are required to effect up to three registrations pursuant to this provision of our investors&#146; rights agreement. A demand for
registration may not be made until six months after the effective date of the registration statement for which this prospectus forms a part. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Short form registration rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the closing of
this offering, the holders of our registrable securities are also entitled to short form registration rights. Pursuant to our investors&#146; rights agreement, if we are eligible to file a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> upon the request of holders of at least 25% of our outstanding registrable securities to sell registrable securities with an anticipated aggregate offering amount of at least $1.0&nbsp;million
net of certain expenses related to the offering, we will be required to use our best efforts to effect a registration of such shares. We are required to effect up to two registrations in any <FONT STYLE="white-space:nowrap">12-month</FONT> period
and no more than one registration in any four-month period pursuant to this provision of our investors&#146; rights agreement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Piggyback
registration rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The holders of our registrable securities are also entitled to piggyback registration rights. If we register any of our
securities either for our own account or for the account of other security holders, the holders of our outstanding registrable securities are entitled to include their shares in the registration (other than a demand registration or a registration
pursuant to a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> or <FONT STYLE="white-space:nowrap">S-8).</FONT> Subject to certain </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">179 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
exceptions contained in our investors&#146; rights agreement, we and the underwriters may limit the number of shares included in an underwritten offering if the underwriters determine that
marketing factors require a limitation of the number of shares to be underwritten. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Expenses and indemnification </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant
to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a single counsel for the selling security
holders and blue sky fees and expenses. Our investors&#146; rights agreement also includes customary indemnification and procedural terms. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Termination of registration rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The registration
rights will expire on the earlier of (1)&nbsp;the date that is five years after the closing of this offering or (2)&nbsp;with respect to each stockholder following the closing of this offering, at such time as such stockholder holds 1% or less of
our outstanding common stock and can sell all of its registrable securities without volume limitations pursuant to Rule&nbsp;144 of the Securities Act during any three-month period. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Anti-takeover provisions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some provisions of Delaware law and our amended and restated certificate of
incorporation and our amended and restated bylaws that will go into effect upon the closing of this offering could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a
proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their
best interests or in our best interests, including transactions that provide for payment of a premium over the market price for our shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These
provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of
directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these
proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Undesignated preferred stock </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ability of our board of directors, without action by our stockholders, to issue up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the
success of any attempt to effect a change in control of our company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Stockholder meetings </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated bylaws
will provide that a special meeting of stockholders may be called only by the chairman of our board of directors, our chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our
board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">180 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Requirements for advance notification of stockholder nominations and proposals </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated bylaws will establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the
nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Elimination of stockholder action by written consent </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of
incorporation will eliminate the right of stockholders to act by written consent without a meeting. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Staggered board </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors will be divided into three classes. The directors in each class will serve for a three-year term, with one class being elected each year by
our stockholders. For more information on our classified board, see &#147;Management&#151;Board composition and election of directors.&#148; This system of electing and removing directors may tend to discourage a third party from making a tender
offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Removal of directors </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation will provide that no member
of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting
power of the outstanding shares of stock entitled to vote in the election of directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Stockholders not entitled to cumulative voting
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation will not permit stockholders to cumulate their votes in the election of directors.
Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors will be able to elect all of the directors standing for election, if they choose, other than any directors that
holders of our convertible preferred stock may be entitled to elect. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Choice of forum </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the Court of
Chancery of the State of Delaware will be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our
directors, officers, employees or agents to us or our stockholders, (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or
bylaws, (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws, or (5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. This provision would not apply to
suits brought to enforce a duty or liability created by the Exchange Act. Our amended and restated certificate of incorporation will also provide that any person or entity holding, purchasing or otherwise acquiring any interest in shares of our
capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our amended and restated certificate of
incorporation is inapplicable or unenforceable if it is challenged in a proceeding or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">181 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
otherwise. Our amended and restated certificate will further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a
cause of action arising under the Securities Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Amendment of charter provisions </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision
prohibiting cumulative voting, would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote thereon. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#147;interested stockholders&#148; from engaging in a &#147;business
combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder
was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of
interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested
stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Limitations on liability and indemnification matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation,
which will go into effect upon the closing of this offering, will limit our directors&#146; liability to the fullest extent permitted under Delaware law, which prohibits our amended and restated certificate of incorporation from limiting the
liability of our directors for the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any breach of the director&#146;s duty of loyalty to us or our stockholders; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any transaction from which the director derived an improper personal benefit. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent
permitted by Delaware law, as so amended. This limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated bylaws, which will go into effect upon the closing of this offering, will provide that we will indemnify our directors and
officers to the fullest extent permitted under Delaware law and that we shall have the power to indemnify our employees and agents to the fullest extent permitted by law. Our amended and restated bylaws will also permit us to secure insurance on
behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether we would have the power to indemnify such person against such expense, liability or loss under the
General Corporation Law of the State of Delaware. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have also entered into separate indemnification agreements with our directors and executive
officers, in addition to indemnification provided for in our amended and restated bylaws. These agreements, among other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">182 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by such persons in any action or proceeding arising out
of this person&#146;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and indemnification agreements are
necessary to attract and retain qualified persons as directors and executive officers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The above description of the limitation of liability and
indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which
will be filed as an exhibit to this registration statement to which this prospectus forms a part. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The limitation of liability and indemnification
provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duties. They may also reduce the likelihood
of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards
against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions,
we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or
officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Listing </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to apply to list our common stock on The Nasdaq Global Market under the symbol
&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Transfer agent and registrar
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The transfer agent and registrar for our common stock will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">183 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_17"></A>Shares eligible for future sale </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Immediately prior to this offering, there was no public market for our common stock, and no predictions can be made about the effect, if any, that market sales of
our common stock or the availability of such shares for sale will have on the market price prevailing from time to time. Nevertheless, future sales of our common stock in the public market, or the perception that such sales may occur, could
adversely affect the market price of our common stock and could impair our ability to raise capital through future sales of our securities. See &#147;Risk factors&#151;Risks related to this offering and owning our common stock&#151;A significant
portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing
well.&#148; Furthermore, although we intend to apply to have our common stock listed on the Nasdaq Global Market, we cannot assure you that there will be an active public trading market for our common stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the closing of this offering, based on the number of shares of our common stock outstanding as of September&nbsp;30, 2018 and after giving effect to the
automatic conversion of all outstanding shares of our convertible preferred stock into 47,606,095 shares of our common stock upon the closing of this offering, and assuming no exercise of options after September&nbsp;30, 2018, we will have an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding
(or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock if the underwriters exercise in full their option to purchase additional shares). Of these shares of our common
stock, all of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares sold in this offering
(or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise in full their option to purchase additional shares) will be freely tradable without restriction or
further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act, whose sales would be subject to the Rule&nbsp;144 resale restrictions
described below, other than the holding period requirement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be &#147;restricted securities,&#148; as that term is defined in Rule&nbsp;144 under the Securities
Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. We
expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
described below. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, we estimate that approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock will be available for sale in the public market, subject in some cases to applicable volume limitations under Rule&nbsp;144. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We and each of our directors and executive officers and holders of substantially all of our
outstanding capital stock, who will collectively own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock upon the closing of this offering (after giving effect to the
automatic conversion of all outstanding shares of our convertible preferred stock into shares of our common stock upon the closing of this offering), have agreed not to sell or transfer any common stock or securities convertible into, exchangeable
for, exercisable for or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of J.P. Morgan Securities LLC, Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such
<FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. For a further description of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, see
&#147;Underwriting.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">184 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Rule 144 </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Affiliate resales of restricted securities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially
owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period
that does not exceed the greater of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock immediately after this offering; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the average weekly trading volume in shares of our common stock on the Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on
Form&nbsp;144 with respect to such sale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Affiliate resales under Rule 144 are also subject to the availability of current public
information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on
Form&nbsp;144 with the SEC and Nasdaq concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales of restricted securities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours at the time of sale, and has not been an affiliate
at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares subject only to the availability of current public
information about us. If such person has held our shares for at least one year, such person can resell under Rule&nbsp;144(b)(1) without regard to any Rule&nbsp;144 restrictions, including the <FONT STYLE="white-space:nowrap">90-day</FONT> public
company requirement and the current public information requirement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the
manner of sale, volume limitation or notice filing provisions of Rule&nbsp;144. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Rule 701 </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In general, under Rule 701, any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with
a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of
the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to
comply with the current public information and holding period requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The SEC has indicated that Rule 701 will apply to typical options granted by
an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange
Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Equity plans </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to file one or more
registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares of our common stock subject to outstanding options and shares of our common stock issued or issuable under
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">185 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
our incentive plans. We expect to file the registration statement covering shares offered pursuant to our incentive plans shortly after the date of this prospectus, permitting the resale of such
shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Registration rights </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the closing of this
offering, the holders of 67,870,173 shares of our common stock (including shares of our common stock issuable upon the conversion of all outstanding shares of our convertible preferred stock upon the closing of this offering) or their transferees
will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the
Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of capital stock&#151;Registration rights&#148; for additional information. Shares covered by a registration
statement will be eligible for sale in the public market upon the expiration or release from the terms of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">186 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_18"></A>Material U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following discussion is a summary of the material U.S. federal income tax consequences
to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax
effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S. Internal
Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect as of
the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This discussion is
limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not
address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment income or the alternative
minimum tax. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">U.S. expatriates and former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated
investment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">banks, insurance companies, and other financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">brokers, dealers or traders in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that accumulate earnings to avoid U.S. federal
income tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons deemed to sell our common stock under the constructive sale provisions of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by qualified
foreign pension funds; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons who own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below); and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons subject to special tax accounting rules as a result of any item of gross income with respect to the stock being taken into account in an applicable
financial statement. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">187 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax
treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships (or other entities treated as a partnership for
U.S. federal income tax purposes) holding our common stock and the partners in such partnerships or other entities should consult their tax advisors regarding the U.S. federal income tax consequences to them. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.
FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Definition of a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT>
Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a corporation, or an entity treated as a corporation, created or organized under the laws of the United States, any state thereof, or the District of Columbia;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning
of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Distributions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As described in the section entitled &#147;Dividend policy,&#148; we do not anticipate declaring
or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the
extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be
applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in our common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under
&#147;&#151;Sale or other taxable dispositions of common stock.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the discussion below on effectively connected income, dividends paid to
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder timely furnishes a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT>
(or other applicable documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate,
may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits
under any applicable income tax treaty. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">188 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must timely furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form), certifying that the dividends are effectively
connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any such
effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits
tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors
regarding any applicable tax treaties that may provide for different rules. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Sales or other taxable dispositions of common stock </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable
disposition of our common stock unless: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is attributable); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States for 183 days or more during the
taxable year of the disposition and certain other requirements are met; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or USRPHC, for U.S.
federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a
net income basis at the regular graduated rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax
treaty) on such effectively connected gain, as adjusted for certain items. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Gain described in the second bullet point above will be subject to U.S.
federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is
not considered a resident of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Generally, a corporation is a U.S. real
property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade
or business. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our
other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities
market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">189 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding
potentially applicable income tax treaties that may provide for different rules. </B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Information reporting and backup withholding </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or
reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in
connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, proceeds of the sale or other taxable disposition of our common stock within the United States, or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or
information reporting, if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption.
Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information
reporting. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax
authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Backup withholding is not an
additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required
information is timely furnished to the IRS. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Additional withholding tax on payments made to foreign accounts </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on
certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends
on, or gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code),
unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial
United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign
entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of
the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain
information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions
that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">190 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies
to payments of dividends on our common stock, and will apply to payments of gross proceeds from the sale or other disposition of such stock on or after January&nbsp;1, 2019. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">191 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_19"></A>Underwriting </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Barclays Capital Inc. are
acting as joint <FONT STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of
the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this
prospectus, the number of shares of common stock listed next to its name in the following table: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Goldman Sachs&nbsp;&amp; Co. LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jefferies LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Barclays Capital Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The
underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters propose to offer the common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus and to
certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price. After the initial offering of the shares to the public, if all of the shares of common stock are not sold at the initial public offering price, the
underwriters may change the offering price and the other selling terms. Sales of shares made outside of the United States may be made by affiliates of the underwriters. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The underwriters have an option to buy up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock from us to cover sales of shares by the underwriters which
exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional
shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on
which the shares are being offered. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the
underwriters to us per share of common stock. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters
assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Without</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>option&nbsp;to<BR>purchase<BR>additional<BR>shares</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>exercise</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>With&nbsp;full</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>option&nbsp;to<BR>purchase<BR>additional<BR>shares</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>exercise</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Per Share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">192 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing
fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses relating to the
clearance of this offering with the Financial Industry Regulatory Authority, Inc. in an amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in
the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and
selling group members that may make Internet distributions on the same basis as other allocations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We<I> </I>have agreed that, subject to certain
exceptions, we will not (1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise
dispose of, directly or indirectly, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock,
or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (2)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares
of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent
of J.P. Morgan Securities LLC, Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC for a period of 180 days after the date of this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
directors and executive officers, and substantially all of our securityholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each of
these persons or entities, with limited exceptions, for a period of 180&nbsp;days after the date of this prospectus, may not, without the prior written consent of J.P. Morgan Securities LLC, Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC
(1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of,
directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be
beneficially owned by such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2)&nbsp;enter into any swap or
other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such other securities, whether any such transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery
of common stock or such other securities, in cash or otherwise, or (3)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable
for our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to apply to have our common stock approved for listing on The Nasdaq Global Market under the symbol
&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, the
underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while
this offering is in progress. These stabilizing transactions may include making short sales of the common stock, which involves the sale by the underwriters </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">193 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short
sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short
positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this
determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A
naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the
extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have
advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if
the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the
underwriting discount received by them. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These activities may have the effect of raising or maintaining the market price of the common stock or
preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities,
they may discontinue them at any time. The underwriters may carry out these transactions on The Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations
between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the information set forth in this prospectus and otherwise available to the representatives; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our prospects and the history and prospects for the industry in which we compete; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an assessment of our management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our prospects for future earnings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the general condition of the securities markets at the time of this offering; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">other factors deemed relevant by the underwriters and us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Neither we nor the underwriters can assure investors that an active trading market will develop for our common shares, or that the shares will trade in the public market at or above the initial public offering
price. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other relationships </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters and
their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">194 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services.
Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for which they received or will receive customary
fees and expenses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors
and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of
their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of ours (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with
us, including long or short positions in our debt or equity securities or loans. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express
independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Selling restrictions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other than in the United States, no
action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under
circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the
offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is
unlawful. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the European Economic Area </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, (each, a &#147;Relevant Member State&#148;), with effect from and including the date on which the
Prospectus Directive is implemented in that Relevant Member State, no offer of shares may be made to the public in that Relevant Member State other than: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters; or
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the
Prospectus Directive and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Company that it is a &#147;qualified
investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">195 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the case of any shares being offered to a financial intermediary as that term is used in Article 3(2) of the
Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT>
basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified
investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any shares in any Relevant Member State means the
communication in any form and by means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant
Member State. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the United Kingdom </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as
defined in the Prospectus Directive)&nbsp;(1) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the
&#147;Order&#148;) and/or (2)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as
&#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any
action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Canada </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares may be
sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the
Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in
accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Securities legislation
in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are
exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s
province or territory for particulars of these rights or consult with a legal advisor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts, or NI <FONT STYLE="white-space:nowrap">33-105,</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">196 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Switzerland </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does
not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the
offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Neither this document nor any other offering or marketing
material relating to the offering, the Company or the shares has been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the
Swiss Financial Market Supervisory Authority FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or the CISA. The investor protection afforded to acquirers of interests
in collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the Dubai International
Financial Centre (&#147;DIFC&#148;) </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial
Services Authority, or the DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to
which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this
document you should consult an authorized financial advisor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to its use in the DIFC, this document is strictly private and confidential and
is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold
directly or indirectly to the public in the DIFC. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the United Arab Emirates </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial
Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities
in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and
Commodities Authority or the Dubai Financial Services Authority. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Australia </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">197 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the purposes of the
Corporations Act and does not purport to include the information required of a disclosure document under Chapter 6D.2 of the Corporations Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">does not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or invitation to arrange the issue or sale, or an
issue or sale, of interests to a &#147;retail client&#148; (as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, or Exempt
Investors, available under section 708 of the Corporations Act. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares may not be directly or indirectly offered for subscription
or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where
disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you
are an Exempt Investor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As any offer of shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations
Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By
applying for the shares you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances where
disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Japan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares have not been and will not be registered pursuant to
Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan
(which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in
Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and
ministerial guidelines of Japan in effect at the relevant time. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Hong Kong </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (1)&nbsp;to &#147;professional
investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance or (2)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in
the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been
or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except
if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities
and Futures Ordinance and any rules made under that Ordinance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">198 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Singapore </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation
for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other
than (1)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (2) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and
in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (3)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of
which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited
investor, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">where no consideration is or will be given for the transfer; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">where the transfer is by operation of law; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">as specified in Section&nbsp;276(7) of the SFA; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Bermuda </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Shares may be
offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons
(including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Saudi Arabia </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This document may not be distributed in the Kingdom of Saudi
Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or the CMA, pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended, or the CMA Regulations. The CMA does
not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the
securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorised financial adviser. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">199 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the British Virgin Islands </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of the
Company. The Company may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British
Virgin Islands. This prospectus has not been, and will not be, registered with the Financial Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the shares for the purposes of the
Securities and Investment Business Act, 2010 or the Public Issuers Code of the British Virgin Islands. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in China
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus does not constitute a public offer of shares, whether by sale or subscription, in the People&#146;s Republic of China, or the PRC.
The shares are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, no
legal or natural persons of the PRC may directly or indirectly purchase any of the shares or any beneficial interest therein without obtaining all prior PRC&#146;s governmental approvals that are required, whether statutorily or otherwise. Persons
who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective
investors in Korea </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and
the decrees and regulations thereunder, or the FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to
any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange
Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in
connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws
and regulations of Korea. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Malaysia </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be registered with the Securities Commission of Malaysia, or the Commission, for the
Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not
be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (1)&nbsp;a closed end fund approved by the
Commission, (2)&nbsp;a holder of a Capital Markets Services Licence, (3)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the shares may only be acquired at a consideration of not less than RM250,000 (or its
equivalent in foreign currencies) for each transaction, (4)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value
of the primary residence of the individual, (5)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">200 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
annum in the preceding 12 months, (6)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the
preceding 12 months, (7)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts, (8)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million
(or its equivalent in foreign currencies), (9) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010, (10) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services
and Securities Act 2010, and (11)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (1)&nbsp;to (11), the distribution of the shares is made by a holder of a Capital Markets Services
Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer
for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Taiwan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares have
not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which
constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give
advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in South Africa
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Due to restrictions under the securities laws of South Africa, the shares are not offered, and the offer shall not be transferred, sold, renounced
or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(1) the offer,
transfer, sale, renunciation or delivery is to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">persons whose ordinary business is to deal in securities, as principal or agent; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the South African Public Investment Corporation; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">persons or entities regulated by the Reserve Bank of South Africa; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">authorised financial service providers under South African law; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">financial institutions recognised as such under South African law; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(f)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund or
collective investment scheme (in each case duly registered as such under South African law); or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(g)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any combination of the person in (a)&nbsp;to (f); or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No &#147;offer to the public&#148; (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or
<FONT STYLE="white-space:nowrap">re-enacted),</FONT> or the South African Companies Act, in South Africa is being made in connection with </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">201 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the issue of the shares. Accordingly, this document does not, nor is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act)
prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. Any issue or offering
of the shares in South Africa constitutes an offer of the shares in South Africa for subscription or sale in South Africa only to persons who fall within the exemption from &#147;offers to the public&#148; set out in section 96(1)(a) of the South
African Companies Act. Accordingly, this document must not be acted on or relied on by persons in South Africa who do not fall within section 96(1)(a) of the South African Companies Act (such persons being referred to as &#147;SA Relevant
Persons&#148;). Any investment or investment activity to which this document relates is available in South Africa only to SA Relevant Persons and will be engaged in South Africa only with SA relevant persons. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">202 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_20"></A>Legal matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The validity of the shares of common stock offered hereby and certain other legal matters will be passed upon for us by Smith, Anderson, Blount, Dorsett, Mitchell&nbsp;&amp; Jernigan, LLP, Raleigh, North Carolina,
and certain other legal matters will be passed upon for us by Latham&nbsp;&amp; Watkins LLP. Certain legal matters in connection with this offering will be passed upon for the underwriters by Cooley LLP, New York, New York. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_21"></A>Experts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The financial statements
included in this prospectus have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are included in reliance upon the report of such
firm given upon their authority as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc367280_22"></A>Where you can find more information
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. Upon completion of this offering, we will be required to file periodic reports, proxy statements, and other information with the SEC pursuant to the Exchange Act. You may read and copy this information at the Public Reference
Room of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the public reference room by calling the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC also maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address
of that site is www.sec.gov. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">203 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="index"></A>Ind<A NAME="toc367280_23"></A>ex to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin367280_1">Report of independent registered public accounting firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin367280_2">Consolidated balance sheets</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin367280_3">Consolidated statements of operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin367280_4">Consolidated statements of changes in stockholders&#146; deficit</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin367280_5">Consolidated statements of cash flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin367280_6">Notes to consolidated financial statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin367280_1"></A>Report of independent registered public accounting firm </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the stockholders and the Board of Directors of Precision BioSciences, Inc. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Opinion on the Financial Statements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have audited the accompanying consolidated balance sheets of Precision
BioSciences, Inc. (the &#147;Company&#148;) as of December 31, 2017 and 2016, the related consolidated statements of operations, changes in stockholders&#146; deficit and cash flows, for each of the two years in the period ended December 31, 2017,
and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and
the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Basis for Opinion </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States
of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on
the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">/s/ Deloitte &amp; Touche LLP </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Raleigh, North Carolina </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">October 18, 2018 </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have served as the Company&#146;s auditor since 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin367280_2"></A>Precision BioSciences, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Consolidated balance sheets </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(In thousands, except share and per share amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">979</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">94,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">64,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property, equipment, and software&#151;net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets&#151;net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">98,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities and Stockholders&#146; Deficit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,209</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred revenue&#151;noncurrent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">94,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88,596</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred rent&#151;noncurrent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">103,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Commitments and contingencies (Note 9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stockholders&#146; deficit:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series A convertible preferred stock; $0.0001 par value&#151;25,650,000 shares authorized; 25,650,000 shares issued and
outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Common stock; $0.000005 par value&#151;100,000,000 shares authorized; 35,132,923 shares issued and outstanding at December&nbsp;31, 2016;
35,215,548 shares issued and 33,485,443 shares outstanding at December&nbsp;31, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Treasury stock (at cost, 0 and 1,730,105 shares of common stock at December&nbsp;31, 2016 and 2017, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(26,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities and stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">98,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:36px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><I>See notes to consolidated financial statements </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin367280_3"></A>Precision BioSciences, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of operations </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(In thousands, except share and per share amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Impairment of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss and net loss attributable to common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share attributable to common stockholders-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of common stock outstanding-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,825,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,956,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net loss per share attributable to common stockholders-basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma weighted-average shares of common stock outstanding-basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:120px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>See notes to consolidated financial statements </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin367280_4"></A>Precision BioSciences, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of changes in stockholders&#146;&nbsp;deficit </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(In thousands, except<BR>share amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Series A convertible</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>preferred
stock</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Common stock</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Additional</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">paid-in&nbsp;capital</FONT></B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated<BR>deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Treasury<BR>stock</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>stockholders&#146;</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>equity&nbsp;(deficit)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance&#151;January 1, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,650,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,352,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,473</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,758</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Return of capital to Series A preferred stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stock option exercises</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">705,411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Issuance of restricted common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance&#151;December 31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,650,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,132,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Repurchase of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stock option exercises</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">82,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance&#151;December&nbsp;31, 2017</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,650,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,215,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(26,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="32" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:120px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><I>See notes to consolidated financial statements </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin367280_5"></A>Precision BioSciences, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of cash flows </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(In thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss on disposal of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Impairment of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by (used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,169</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Acquired intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds from disposal of equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchases of property, equipment, and software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,815</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,565</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Return of capital to Series A preferred stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Repurchases of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds from stock option exercises</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(30,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Supplemental disclosures of noncash financing and investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property, equipment and software additions included in accounts payable and accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:96px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>See notes to consolidated financial statements
</I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin367280_6"></A>Precision BioSciences, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 1:
Description of business and summary of significant accounting policies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Description of business and basis of presentation </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Precision BioSciences, Inc. (the &#147;Company&#148;) was incorporated on January&nbsp;26, 2006 under the laws of the State of Delaware and is based in Durham,
North Carolina. The Company is focused on utilizing its proprietary genome editing platform to help overcome cancers, cure genetic diseases and enable the development of safer, more productive food sources. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s 100% owned subsidiary, Precision PlantSciences, Inc., was incorporated on January&nbsp;4, 2012. Precision PlantSciences, Inc. amended its
certificate of incorporation on January&nbsp;16, 2018 to change its name to ELO Life Systems, Inc. The accompanying consolidated financial statements include the accounts of the Company and ELO Life Systems, Inc. Intercompany balances and
transactions have been eliminated in consolidation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since its inception, the Company has devoted substantially all of its efforts to research and
development activities, recruiting skilled personnel, developing manufacturing processes, establishing our intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of
risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and
companies and the technical risks associated with the successful research, development and clinical manufacturing of its and its collaborators&#146; product candidates. The Company&#146;s success is dependent upon its ability to continue to raise
additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations and, ultimately, attain profitable operations.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Use of estimates </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of
consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the amounts reported in the
consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ from those estimates. Significant estimates include recording revenue for multiple element
arrangements, determination of the fair value of share-based compensation grants and estimating services expended by third-party service providers used to recognize research and development expense. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Basis of presentation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These financial statements
have been prepared in accordance with GAAP. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal
course of business. To date, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. During the year ended December&nbsp;31, 2017, the Company
incurred a net loss of $21.1 million and, as of December&nbsp;31, 2017, has a $39.1 million accumulated deficit. The Company has financed operations to date primarily through the issuance of preferred stock (see Note 6) and with proceeds from its
development and commercial license agreement with Les Laboratoires Servier (&#147;Servier&#148;) (see Note 13). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Management believes that existing cash and cash equivalents will allow the Company to continue its operations for
at least a year from the issuance date of these consolidated financial statements. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise
additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Cash and cash equivalents </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company considers all highly liquid investments with an original maturity
of three months or less at the date of purchase to be cash equivalents. As of December&nbsp;31, 2016 and 2017, the Company held cash equivalents composed of money market funds and repurchase agreements that were collateralized by deposits in the
form of government securities and obligations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Concentrations of credit risk </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. All of the Company&#146;s cash and cash equivalents are held at
financial institutions that management believes to be of high credit quality. The Company may maintain cash deposits in financial institutions in excess of government insured limits. The Company regularly invests excess cash deposits in money market
funds and repurchase agreements. The Company believes that the credit risk arising from the holdings of these financial instruments is mitigated by the fact that these securities are of short duration, government backed and of high credit rating.
The Company has not experienced any losses on cash and cash equivalents to date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue from two development and license agreements accounted for 69%
and 22% of revenue during 2016 and 89% and 6% of revenue during 2017. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Property, equipment and software </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property, equipment, and software are stated at cost, net of depreciation and amortization. Depreciation and amortization are calculated using the straight-line
method over the estimated useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depreciation and amortization periods for the Company&#146;s significant property, equipment and software categories are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Computer hardware and software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3 years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Lab equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">5 to 7 years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3 to 5 years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Lesser&nbsp;of&nbsp;remaining&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp;life</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Repairs and maintenance are charged to operations as incurred, and expenditures for additions and improvements that extend the
useful life of the asset are capitalized. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Impairment of long-lived assets </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Long-lived assets, such as property, equipment and software and intangible assets, subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. An impairment loss is assessed when future undiscounted cash flows are less than the assets&#146; carrying value and recognized when the carrying value of the asset exceeds fair value. Fair value is calculated by
estimating the undiscounted future cash flows expected to be generated by the asset as well as other valuation techniques. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value of the asset.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Revenue recognition </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s
revenues are generated primarily through collaborative research, license, development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i)&nbsp;licenses, or
options to obtain licenses, to the Company&#146;s technology, (ii)&nbsp;research and development activities to be performed on behalf of the collaborative partner, and (iii)&nbsp;in certain cases, services in connection with the manufacturing of
pre-clinical and clinical material. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical
and development, regulatory, and sales milestone payments; and royalties on future product sales. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue is recognized when all of the following
conditions are met: (i)&nbsp;persuasive evidence of an arrangement exists, (ii)&nbsp;delivery has occurred or services have been rendered, (iii)&nbsp;fees are fixed or determinable and (iv)&nbsp;collection of fees is reasonably assured. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company analyzes its collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification <I>808, Collaborative
Arrangements</I> (&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the
commercial success of such activities. This requires the Company to determine whether elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore
within the scope of Accounting Standards Codification <I>605-25, Revenue Recognition&#151;Multiple-Element Arrangements</I> (&#147;ASC 605&#148;). To date, the Company has no arrangements that are within the scope of ASC 808. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When evaluating multiple element arrangements under ASC 605, the Company determines whether the arrangement should be divided into separate units of accounting and
how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has stand-alone value to the customer. Any delivered elements
that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. The Company determines the revenue recognition method for the combined unit of accounting and
recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. The Company&#146;s arrangements do not include a general right of return relative to delivered elements.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets.
The Company&#146;s deferred revenue includes nonrefundable up-front </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
license fees. The deferred revenue is recognized into revenue on a proportional or straight-line basis over the estimated period of the Company&#146;s substantive performance obligations or the
period the rights granted are in effect. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or a license to use an asset or some other performance
obligation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In arrangements that include license rights and other noncontingent deliverables, these deliverables do not have stand-alone value because
the noncontingent deliverables are dependent on the license rights, are not sold separately and cannot be resold. In addition, when noncontingent deliverables are sold with up-front license rights, the sale of license rights do not represent the
culmination of a separate earnings process. As such, the Company accounts for the license and the noncontingent deliverables as a single unit of accounting. In such instances, the license revenue in the form of nonrefundable up-front payments is
deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company&#146;s substantive performance obligations or the period the rights granted are in effect. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company will recognize clinical and development, regulatory, and sales milestone payments as revenue when earned if they are substantive and the Company has no
ongoing performance obligations related to the milestone payment. A milestone payment is considered substantive if it i)&nbsp;is commensurate with either the Company&#146;s performance to achieve the milestone or the enhanced value of the delivered
item as a result of a specific outcome from the Company&#146;s performance to achieve the milestone; ii)&nbsp;relates solely to past performance;&nbsp;and iii)&nbsp;is reasonable relative to all of the deliverables and payment terms, including other
potential milestone consideration, within the arrangement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Royalties earned on product sales, if any, are recognized based on contractual terms of the
agreement when reported sales are reliably measurable and collectibility is reasonably assured, provided that there are no performance obligations then remaining. To date, none of the Company&#146;s product candidates have been approved or
commercialized, and therefore, the Company has not earned any royalty revenue from product sales. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event that an agreement was to be terminated
and the Company had no further performance obligations at that time, the Company would recognize as revenue at the date of such termination any portion of the non-refundable upfront payment and other payments that had not previously been recorded as
revenue and were classified as deferred revenue at the date of such termination. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development
activities including salaries, benefits, share-based compensation, allocations for rent and facility costs, depreciation, preclinical manufacturing expenses, costs of services provided by contract research organizations (&#147;CROs&#148;) in
connection with preclinical trials and contract manufacturing organizations (&#147;CMOs&#148;) engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service
providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Nonrefundable advance payments for goods or services to be received in the
future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-10 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company is required to estimate accrued research and development expenses resulting from its obligations under
contracts with CROs, CMOs, research organizations, service providers, vendors and consultants in connection with research and development activities. The financial terms of these contracts are subject to negotiations and vary from contract to
contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#146;s objective is to reflect the appropriate research and development expenses in
its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. There may be instances in which payments made to the Company&#146;s vendors will exceed the level of services provided
and result in a prepayment of the expense. In accruing fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or
the level of effort varies from the Company&#146;s estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Accrued amounts are disclosed in Note 5. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#146;s understanding of the status and timing of services performed relative to the actual
status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to prior estimates of accrued research
and development expenses. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Common stock valuation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Due to the absence of an active market for the Company&#146;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical
Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair
value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined based upon a variety of factors, including the illiquid nature of the common stock, the Company&#146;s financial position and
historical financial performance, the status of technological developments within the Company&#146;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#146;s competition and
the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net loss per share </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Basic net loss per share is
computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common
stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&nbsp;31, 2016 and 2017 since all
potential shares of common stock instruments are anti-dilutive as a result of the net loss. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s convertible preferred stock contractually
entitles the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are
not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-11 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive shares of common stock are
not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&nbsp;31, 2016 and 2017. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Share-based compensation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Employees</I></B>&#151;The Company determines the fair value of stock
options issued to employees as of the grant date. Share-based compensation expense equal to the grant-date fair value of the stock options is recognized over the requisite service period, which is equal to the vesting period. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Nonemployees</I></B>&#151;For nonemployees, the Company also determines the fair value of stock options as of the grant date. Share-based compensation expense
equal to the grant-date fair value of the stock options is recognized over the requisite service period, which is equal to the vesting period. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income taxes </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax assets and liabilities are
determined based on the temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to
reverse. In estimating future tax consequences, all expected future events are considered other than the enactment of changes in the tax law or rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on
examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50%
likelihood of being realized upon ultimate settlement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge
to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Recent accounting pronouncements not yet adopted </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
Company is an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may take advantage of reduced reporting requirements that are otherwise applicable to public companies.
Section&nbsp;107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use
the extended transition period for complying with new or revised accounting standards; and as a result of this election, its financial statements may not be comparable to companies that comply with public company effective dates. The JOBS Act also
exempts the Company from having to provide an auditor attestation of internal controls over financial reporting under Sarbanes-Oxley Act Section&nbsp;404(b). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company will remain an &#147;emerging growth company&#148; until the earliest of (a)&nbsp;the last day of the fiscal year in which it has total annual gross revenues of $1.07 billion or more, (b)&nbsp;the last
day of the fiscal year following </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-12 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the fifth anniversary of the completion of its IPO, (c)&nbsp;the date on which it has issued more than $1.0 billion in nonconvertible debt during the previous three years or (d)&nbsp;the date on
which it is deemed to be a large accelerated filer under the SEC, which generally is when it has more than $700 million in market value of our stock held by non-affiliates, been a public company for at least 12 months and have filed one annual
report on Form 10-K. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update (&#147;ASU&#148;),
No.&nbsp;2014-09, Revenue (Topic 606): Revenue from Contracts with Customers (&#147;ASU 2014-09&#148;), which will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. The new
standard and the subsequent amendments, which are codified in ASC 606, will be effective for the Company beginning on January&nbsp;1, 2019. The Company is in the process of evaluating the impact of the adoption of ASC&nbsp;606 on its consolidated
financial statements. The Company will continue to assess the potential impact that ASC&nbsp;606 may have on its financial position and results of operations as it relates to the Company&#146;s February 2016 development and commercial license
agreement with Servier (see Note 13 to the consolidated financial statements). The Company&#146;s initial assessment is that revenue recognition under the February 2016 development and commercial license agreement with Servier for the up-front
payment and certain development milestones related to early-stage activities that are nonsubstantive, less fees to exercise the codevelopment and copromotion option may not be materially different under ASC 606 as compared to ASC 605. Further, the
Company&#146;s initial assessment of revenue for development milestones that are considered substantive under this agreement is that they be recognized over time when the amount of the milestone can be reasonably be estimated without a significant
reversal under ASC 606. The actual quantitative effects of the adoption of ASU 2014-09 is subject to change pending the Company&#146;s final assessment in the first quarter of 2019. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In February 2016, the FASB issued ASU No.&nbsp;2016-02, <I>Leases (Topic 842)</I>, in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance
sheets for those leases previously classified as operating leases under GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use
the underlying asset for the lease term. ASU 2016-02 is effective for the Company for annual periods beginning after December&nbsp;15, 2019 and early adoption is permitted. The Company is evaluating the impact of adoption of this standard on the
consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2016, the FASB issued ASU No.&nbsp;2016-09, <I>Compensation&#151;Stock Compensation: Improvements to
Employee Share-Based Payment Accounting</I> (&#147;ASU 2016-09&#148;), which amends ASC 718, <I>Compensation&#151;Stock Compensation</I>. The amendments simplify several aspects of the accounting for share-based payment transactions, including the
income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification in the consolidated statements of cash flows. ASU 2016-09 is effective for the Company for annual periods beginning after
December&nbsp;15, 2017 and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements. The Company plans to elect to account for the impact of
pre-vesting forfeitures as they occur rather than applying an estimated forfeiture rate and to adopt this standard using the modified retrospective adoption method. No material changes are expected to the Company&#146;s consolidated financial
statements as a result of the adoption of this standard. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2017, the FASB issued ASU No.&nbsp;2017-09, <I>Compensation-Stock Compensation</I>, or
ASU 2017-09. The new guidance is an update to ASC 718 and simplifies the modification accounting for share-based payment awards. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-13 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
ASU 2017-09 is effective for annual periods beginning after December&nbsp;15, 2017. The Company is evaluating the impact of the adoption of this standard but does not believe it will have a
material effect on the Company&#146;s consolidated financial statements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 2: Prepaid expenses and other current assets </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prepaid expenses and other current assets consisted of the following as of December&nbsp;31 (in thousands): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred rent asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Noncustomer receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">979</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 3: Property, equipment and software </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Property, equipment and software consisted of the following as of December&nbsp;31 (in thousands): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Construction in progress</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total property, equipment and software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property, equipment and software&#151;net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation expense, including amortization of leasehold improvements and software, was $0.6 million and $1.4 million for the years
ended December&nbsp;31, 2016 and 2017, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 4: Intangible assets </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Acquired patents </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company licensed patents from Duke University (&#147;Duke&#148;) as part of a
license agreement in exchange for consideration including an upfront payment of $0.2 million and reimbursement of legal fees to maintain and defend the patents. The patents are being amortized on a straight-line basis over 273 months, which is the
expected useful life of the patents. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company licensed limited-use patents for a fee of $0.3 million and a term of 36 months to test the
licensors&#146; intellectual property in association with the Company&#146;s technology platform. The Company performed an evaluation of its intangible assets for purposes of determining possible impairment as of December&nbsp;31, 2017 and
determined that, based on its research experiments with the licensor&#146;s intellectual property, it will not pursue further development of the intellectual property. As a result, the Company recognized an impairment charge of $0.1 million for the
year ended December&nbsp;31, 2017. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-14 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net, consisted of the following as of December&nbsp;31 (in thousands): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">License cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">431</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">431</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: impairments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Amortization expense of the intangible assets was $0.1 million for the years ended December&nbsp;31, 2016 and 2017. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 5: Accrued expenses and other current liabilities </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accrued expenses and other current liabilities consisted of the following as of December&nbsp;31 (in thousands): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">416</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">983</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Tax withholding for return of capital to Series A preferred stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">219</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 6: Stockholders&#146; deficit </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Capital structure </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2015, the Company amended and restated its certificate of incorporation and
authorized 125,650,000 shares, of which 100,000,000 shares were designated as $0.000005 par value common stock and 25,650,000 shares were designated as $0.0001 par value Series A preferred stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2018, the Company amended and restated its certificate of incorporation and authorized 177,606,100 shares, of which 130,000,000 shares were designated as
$0.000005 par value common stock, 25,650,000 shares were designated as $0.0001 par value Series A preferred stock, and 21,956,100 shares were designated as $0.0001 par value Series B preferred stock. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Preferred Stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2015, the Company issued
25,650,000 shares of Series A preferred stock for gross proceeds of $25.7 million and incurred stock issuance costs of $0.3 million. The Series A preferred stock shares were sold for $1.00 per share (the &#147;Series A Original Issue Price&#148;).
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon issuance, the Series A preferred stock accrued dividends at $0.06 per share annually, could be converted into common stock on a share-for-share
basis, and had liquidation preference over the common stock. In December 2016, the Company paid $12.4 million (net of transaction expenses) based on fair value as a return of capital&nbsp;to the Series A preferred stockholders to remove the
preferred stock&#146;s liquidation and dividend preferences and certain conversion rights. The Company recorded the return of capital as a decrease in paid-in capital. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-15 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">From May 2018 to July 2018, the Company issued 21,956,100 shares of its Series B preferred stock and received
approximately $110.0 million in gross proceeds, less $0.2 million in aggregate offering costs. The Series B preferred stock shares were sold for $5.01 per share (the &#147;Series B Original Issue Price&#148;, together with the Series A Original
Issue Price, the &#147;Original Issue Price&#148;). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The rights and privileges of the Series A and Series B preferred stockholders include the following:
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Conversion</I>&#151;Each share of Series A and Series B preferred stock may be converted at any time, at the option of the holder, into shares of
common stock. Each share of the Series A and Series B preferred stock will be automatically converted into shares of common stock, at the applicable conversion rate then in effect, upon the earlier of (i)&nbsp;the closing of an initial public
offering of the Company&#146;s common stock at a price of at least $6.01 per share and with net proceeds of at least $50.0 million, subject to adjustment as set forth in the Company&#146;s amended and restated certificate of incorporation (a
&#147;Qualified IPO&#148;), (ii)&nbsp;in connection with any stock split, stock dividend, combination or other similar events and (iii)&nbsp;in accordance with anti-dilution provisions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The conversion rate of the Series A and Series B preferred stock is determined by dividing the Original Issue Price by the conversion price for each series of stock. The initial conversion price for the Series A
and Series B preferred stock is the Original Issue Price of $1.00 per share and $5.01 per share, respectively, subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other
adjustments as set forth in the Company&#146;s amended and restated certificate of incorporation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Voting Rights</I>&#151;Preferred stock and common
stock vote together as one class on an as-converted basis. Holders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are
then convertible. The Company cannot perform any of the following actions without a vote of approval from at least 60% of outstanding preferred stockholders: execute a liquidation event, amend the Company&#146;s certificate of incorporation in a
manner detrimental to Series A and Series B preferred stockholders, create or amend any securities to be senior to the Series A and Series B preferred stockholders, issue or increase the amount of common shares, or change the size of the board of
directors. The Company&#146;s board of directors is currently comprised of four directors: two designated by the common stockholders and two designated by the preferred stock stockholders. The remaining three directors, none of whom may have any
affiliation with any class of stockholder, will be designated by the four common and preferred designees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Dividends</I>&#151;No classes of stock are
entitled to receive dividends unless preferred stockholders first receive dividends on outstanding shares in an amount at least equal to the amount of dividends payable to the other classes of stock. The preferred shares do not accrue dividends.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Liquidation</I>&#151;Upon liquidation, dissolution, or winding-up of the Company, Series A and Series B preferred stockholders do not receive a
liquidation preference in priority to holders of common stock. Assets available for distribution will be allocated ratably among the preferred, on a fully converted basis, and the common stockholders based on their pro rata holdings. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Redemption</I>&#151;The Series A and Series B preferred stock can only be redeemed at the option of the holder for cash or other assets upon the occurrence of
specific events following a &#147;Deemed Liquidation Event&#148; (as defined in the Company&#146;s amended and restated certificate of incorporation) involving the sale, transfer, lease or other disposition of all or substantially all of the
Company&#146;s assets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-16 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A Deemed Liquidation Event that would give rise to a preferred stockholder&#146;s right of redemption cannot be
triggered without approval of the Company&#146;s board of directors, because under applicable legal and contractual requirements, the Company&#146;s board of directors is required to approve (a)&nbsp;any closing of the sale, transfer, lease or other
disposition, of all or substantially all of the Company&#146;s assets, (b)&nbsp;any consummation of the merger or consolidation of the Company with or into another entity and (c)&nbsp;the Company&#146;s participation in any closing of the transfer
(whether by merger, consolidation, or otherwise), in which the Company is a constituent party to a person or group of affiliated persons, of the Company&#146;s securities, in which, after such closing, such person or group of affiliated persons
would hold a majority of the outstanding voting stock of the Company (or the surviving or acquiring entity). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The holders of the Series A and Series B
preferred stock do not have the ability to control whether the Company will redeem the preferred stock or cause the preferred stock to become redeemable (including through a Deemed Liquidation Event) through representation on the Company&#146;s
board of directors, voting rights or other rights, and there is no event not solely within the Company&#146;s control that contractually could cause the holders of the Series A and Series B preferred stock to obtain such control. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Common stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2017, the Company&#146;s board
of directors authorized the repurchase of up to 9,090,909 shares of its common stock at a price of $0.55 per share in a solicited offer to non-employees. The Company accounts for its common stock repurchases as treasury stock under the cost method.
In April 2017, the Company repurchased 1,730,105 shares of common stock at a cost of $1.0 million pursuant to this repurchase program. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Voting, dividend
and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The rights and privileges of the holders of common stock include the following: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Voting</I>&#151;Each holder of
outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock
and preferred stock voting together as a single class. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Dividends</I>&#151;Subject to preferred stockholders&#146; right to receive at least an equal
amount of dividends payable to the other classes of stock in the event of a dividend, the holders of common stock shall be entitled to receive dividends out of funds legally available at such times and in such amounts as the Company&#146;s board of
directors may determine in its sole discretion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Liquidation</I>&#151;Upon liquidation, dissolution, or winding-up of the Company, the common
stockholders are entitled to receive assets available for distribution ratably with the preferred stockholders, on a fully converted basis, based on their pro rata holdings. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Redemption</I>&#151;The common stock is not redeemable at the option of the holder. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 7: Stock options
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of its stock option plans, the Company&#146;s board of directors may grant stock options to employees, directors and service
providers. The Company issued stock options under the 2006 Stock Incentive Plan (&#147;2006 plan&#148;) until April 2015, when the 2015 Stock Incentive Plan (&#147;2015 plan&#148;) was adopted. The 2006
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-17 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
plan expired in 2016; there are no remaining shares available to be granted under the 2006 plan and there were 3,671,488 and 3,327,044 stock options outstanding under the 2006 Plan as of
December&nbsp;31, 2016 and 2017, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon adoption of the 2015 plan, there were 11,250,000 shares of common stock reserved for issuance. There
were 6,291,555 and 2,910,250 shares of common stock available for future grants under the 2015 plan as of December&nbsp;31, 2016 and 2017, respectively, and 4,979,000 and 8,234,625 stock options outstanding as of December&nbsp;31, 2016 and 2017,
respectively. In May 2018, the Company amended the 2015 plan to increase the number of shares of common stock reserved for issuance to 17,530,000. The Company&#146;s board of directors determines the terms of stock options granted under the 2015
plan, including option exercise prices and vesting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company recorded $0.2 million and an amount less than $0.1 million in employee and nonemployee
share-based compensation expense, respectively, during the year ended December&nbsp;31, 2016 and $0.4 million and an amount less than $0.1 million in employee and nonemployee share-based compensation expense, respectively, during the year ended
December&nbsp;31, 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation expense related to stock options is included in the following line items in the consolidated statements
of operations for the year ended December&nbsp;31 (in thousands): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">160</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Determining the appropriate fair value model and the related assumptions requires judgment. The fair value of each option grant is
estimated using a Black-Scholes option-pricing model on the date of grant as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nonemployees</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Employees</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nonemployees</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Employees</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Estimated dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average expected stock price volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">75.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72.64%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70.28%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73.35%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.35%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.51%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.99%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected life of options (in years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average fair value per option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term.
The expected life represents the average time that stock options that vest are expected to be outstanding. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company does not have sufficient history
of exercising stock options to estimate the expected term of employee stock options and thus continues to calculate expected life based on the midpoint between the vesting date and the contractual term which is in accordance with the simplified
method. The expected term for share-based compensation granted to nonemployees is the contractual life. The risk-free rate is based on the United States Treasury yield curve during the expected life of the option. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-18 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes activity in the Company&#146;s stock option plans during the years ended
December&nbsp;31, 2016 and 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Outstanding&nbsp;option<BR>shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise
price</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,093,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,355,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(705,411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited/canceled</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(93,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,650,488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,766,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(82,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited/canceled</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(772,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of December&nbsp;31, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,561,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes certain information about stock options granted under the stock option plans which are vested or
expected to vest as of December&nbsp;31, 2016 and 2017, by incorporating an estimated forfeiture rate: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of&nbsp;options</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>remaining&nbsp;
contractual<BR>life (in years)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise
price</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Expected&nbsp;to&nbsp;be&nbsp;exercisable</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,460,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Currently exercisable</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,788,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Expected&nbsp;to&nbsp;be&nbsp;exercisable</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,266,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Currently exercisable</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,566,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="14" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes certain information about stock options outstanding under the stock option plans as of
December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exercise price</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of&nbsp;options</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>outstanding</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>remaining&nbsp;life</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of&nbsp;options&nbsp;exercisable</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.0006 &#151; $0.0058</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">898,714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">898,714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.0145</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,772,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,772,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.1900</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,849,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,117,036</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.5600</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,650,488</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,788,524</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-19 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exercise price</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of&nbsp;options<BR>outstanding</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>remaining&nbsp;life</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of&nbsp;options&nbsp;exercisable</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.0006 &#151; $0.0058</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">554,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">554,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.0145</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,772,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,772,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.1900</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,453,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,896,711</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$0.5600</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,781,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">342,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,561,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,566,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There was approximately $0.7 million and $1.5 million of total unrecognized compensation cost related to unvested stock options as
of December&nbsp;31, 2016, and 2017, respectively, which is expected to be recognized over a weighted-average period of 3.19 and 3.03 years, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Note 8: Retirement plan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In January 2011, the Company established a defined contribution 401(k) retirement
savings plan (the &#147;Retirement Plan&#148;) to all full-time employees. Employee contributions to the Retirement Plan can be 100% of annual compensation up to the prescribed annual maximum under the Internal Revenue Code. Administrative fees of
less than $0.1 million were paid by the Company for the years ended December&nbsp;31, 2016 and 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Retirement Plan includes a discretionary
matching employer contribution equal to 100% of participants&#146; deferral contributions up to a certain percentage amount to be determined by the Company on an annual basis. The Company made contributions of $0.1 million and $0.2 million to the
Retirement Plan during the years ended December&nbsp;31, 2016 and 2017, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 9: Commitments and contingencies </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Litigation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company is subject to various legal
matters and claims in the ordinary course of business. Although the results of legal proceedings and claims cannot be predicted with certainty, in the opinion of management, there are currently no such known matters that will have a material effect
on the consolidated financial condition, results of operations or cash flows of the Company. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Leases </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2010, the Company entered into an agreement to lease office and laboratory space in Durham, North Carolina under a lease that is classified as an operating
lease. The lease was amended in July 2015 to extend the term through July&nbsp;31, 2021 and expanded to provide for additional space. As part of the amended lease, the landlord completed leasehold improvements on the new space. The new lease terms
did not commence until the work was completed on January&nbsp;1, 2016. The lease was amended again in 2016 to expand into additional space and extend the lease term until July&nbsp;31, 2024. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-20 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following is a schedule of future minimum lease payments for all leases as of December&nbsp;31, 2017 (in
thousands): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating&nbsp;leases</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2021</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2023 and beyond</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Future minimum lease payments due under certain operating lease arrangements contain fixed rent increases and rent abatements over
the term of the lease. Rent expense on these operating leases is recognized over the term of the lease on a straight-line basis. The excess of rent expense over lease payments made has been reported in deferred rent and deferred rent-noncurrent in
the consolidated balance sheets. Rent expense was $0.5 million and $0.8 million during the years ended December&nbsp;31, 2016 and 2017, respectively, and apportioned between the &#147;Research and development&#148; and &#147;General and
administrative&#148; lines items in the consolidated statements of operations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Supply agreements </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company enters into contracts in the ordinary course of business with CMOs for the manufacture of clinical trial materials. These agreements provide for
termination at the request of either party with less than one-year notice and are, therefore, cancelable contracts and, if canceled, are not anticipated to have a material effect on the consolidated financial condition, results of operations or cash
flows of the Company. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 10: Net loss per share and unaudited pro forma net loss per share </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net loss per share </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Basic and diluted net loss per
share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Numerator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Denominator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of common stock outstanding&#151;basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,825,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,956,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share attributable to common stockholders&#151;basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect
would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-21 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company excluded the following potential common shares from the computation of diluted net loss per share
attributable to common stockholders because including them would have had an anti-dilutive effect: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Preferred stock (as converted to common stock)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,650,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,650,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding stock options converted to common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,699,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,891,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,349,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,541,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Unaudited pro forma net loss per share </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the year ended December&nbsp;31, 2017 has been prepared to give effect to adjustments arising upon the completion
of a Qualified IPO. The unaudited pro forma net loss attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders gives effect to the automatic conversion
of all outstanding shares of convertible preferred stock into shares of common stock as if the proposed initial public offering had occurred on the later of January&nbsp;1, 2017 or the issuance date of the convertible preferred stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The unaudited pro forma basic and diluted weighted-average shares of common stock outstanding used in the calculation of unaudited pro forma basic and diluted net
loss per share attributable to common stockholders for the year ended December&nbsp;31, 2017 has been prepared to give effect, upon a Qualified IPO, to the automatic conversion of all outstanding shares of convertible preferred stock into common
stock as if the proposed initial public offering had occurred on the later of January&nbsp;1, 2017 or the issuance date of the convertible preferred stock. Unaudited pro forma basic and diluted net loss per share attributable to common stockholders
was calculated as follows (in thousands, except share and per share amounts): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Numerator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Denominator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of common stock outstanding&#151;basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,956,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma adjustment to reflect automatic conversion of convertible preferred stock to common stock upon the completion of the proposed
initial public offering (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma weighted-average shares of common stock outstanding&#151;basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-22 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 11: Income taxes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company recorded a less than $0.1 million current period state tax benefit for the year ended December&nbsp;31, 2016 and no income tax expense due to the operating losses incurred for the years ended
December&nbsp;31, 2016 and 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Significant components of the Company&#146;s deferred tax assets and deferred tax liabilities are as follows as of
December&nbsp;31 (in thousands): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Noncurrent deferred tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contribution carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Tax credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total deferred tax assets, noncurrent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Noncurrent deferred tax liability:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total deferred tax liabilities, noncurrent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2016 and 2017, the Company has provided a valuation allowance for the full amount of the net deferred tax
assets as the realization of the net deferred tax assets is not determined to be more likely than not. The net increase in the valuation allowance for the year ended December&nbsp;31, 2017 of $3.6 million is comprised of an increase in the valuation
allowance recorded against the deferred tax assets, primarily deferred revenue for the year. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-23 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The reasons for the difference between actual income tax benefit for the years ended December&nbsp;31, 2016 and
2017 and the amount computed by applying the statutory federal income tax rate to losses before income tax benefit are as follows (dollars in thousands): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%&nbsp;of&nbsp;pretax<BR>earnings</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%&nbsp;of&nbsp;pretax<BR>earnings</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense at statutory rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">State income taxes, net of federal tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(417</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-deductible expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,039</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in federal tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(23.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in state tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax (benefit) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">At December&nbsp;31, 2016, the Company had federal and state net operating loss (&#147;NOL&#148;) carryforwards of approximately
$19.1 million and $18.3 million, respectively. As of December&nbsp;31, 2017, the Company had federal and state NOL carryforwards of approximately $20.1 million and $19.4 million, respectively. The federal NOL carryforwards begin to expire in 2030
and the state NOL carryforwards begin to expire in 2025. At December&nbsp;31, 2016, the Company had federal and state research and development (&#147;R&amp;D&#148;) tax credits of $0.5 million and an amount less than $0.1 million which begin to
expire in 2027 and 2030, respectively. At December&nbsp;31, 2017, the Company had federal and state R&amp;D tax credits of $1.7 million and an amount less than $0.1 million, which begin to expire in 2027 and 2030, respectively. At December&nbsp;31,
2016 and 2017, the Company had federal contribution carryforwards of amounts less than $0.1 million, which begin to expire in 2020. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s
ability to utilize its NOL and R&amp;D credit carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section&nbsp;382 of the Internal Revenue Code of 1986, as
amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an
&#147;ownership change,&#148; as defined by Section&nbsp;382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by
certain stockholders or public groups. The Company has not completed a study to assess whether one or more ownership changes have occurred since the Company became a loss corporation under the definition of Section&nbsp;382. If the Company has
experienced an ownership change, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of the Company&#146;s stock at the time of the ownership change by
the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Until a study
is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from
deferred tax assets with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any possible limitation will have an impact on the results of operations of the Company.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-24 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company reflects in the accompanying consolidated financial statements the benefit of positions taken in a
previously filed tax return or expected to be taken in a future tax return only if it is considered &#145;more-likely-than-not&#146; that the position taken will be sustained by the appropriate taxing authority. As of December&nbsp;31, 2017 and
2016, the Company had no unrecognized income tax benefits. The Company&#146;s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying
consolidated statements of operations. As of December&nbsp;31, 2016 and 2017, the Company had no such accruals. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;22, 2017, the Tax Cuts
and Jobs Act was enacted into law, which reduced the federal corporate income tax rate to 21% for tax years beginning after December&nbsp;31, 2017. As a result of the newly enacted tax rate, the Company adjusted its deferred tax assets as of
December&nbsp;31, 2017 by applying the new 21% rate, which resulted in a decrease to the deferred tax assets and a corresponding decrease to the valuation allowance of approximately $5 million. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The SEC staff issued Staff Accounting Bulletin No.&nbsp;118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (&#147;SAB 118&#148;), which allows the
Company to record provisional amounts during a measurement period which is similar to the measurement period used when accounting for business combinations. Provisional amounts have been recorded related to the deferred rate change. The Company will
continue to assess the impact of the recently enacted tax law on its business and consolidated financial statements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 12: Fair value
measurements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying amounts of the Company&#146;s financial instruments, including accounts receivable, accounts payable, and accrued expenses
and other current liabilities, approximate their respective fair values due to their short-term nature. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring
basis and to minimize the use of unobservable inputs when determining their fair value. The three tiers are defined as follows: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 1&#151;Observable
inputs based on unadjusted quoted prices in active markets for identical assets or liabilities </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 2&#151;Inputs, other than quoted prices in active
markets, that are observable either directly or indirectly </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 3&#151;Unobservable inputs for which there is little or no market date, which require
the Company to develop its own assumptions </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company classifies investments in money market funds within Level 1 as the prices are available from
quoted prices in active markets. Investments in repurchase agreements are classified within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2016 and 2017, the Company held cash equivalents which is composed of money market funds and repurchase agreements that were purchased
through repurchase intermediary banks and collateralized by deposits in the form of government securities and obligations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-25 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following represents assets measured at fair value on a recurring basis by the Company (in thousands):
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31, 2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Fair&nbsp;value</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level 2</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Repurchase agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31, 2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Fair&nbsp;value</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level 2</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Repurchase agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,596</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 13: Collaboration and license agreements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On February 16, 2015, the Company entered into a commercial license agreement, as subsequently amended, with Cargill Inc. (&#147;Cargill&#148;) that is focused on targeting and modifying certain genes related to
saturated oil production in canola plants for an initial license fee, certain research funding and the right to receive royalties based on future sales (the &#147;Cargill Agreement&#148;). Under the terms of the Cargill Agreement, the Company
granted Cargill an exclusive research license under certain nucleases and technology, for 24 months, which term was subsequently extended through November 2018, and a non-exclusive license under certain know-how for the length of the term for which
the Company is eligible to receive royalties. Cargill may maintain certain exclusive rights by paying a one-time option fee. The Company recognized $1.6 million and $0.4 million in revenue during 2016 and 2017, respectively, under the Cargill
Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On February&nbsp;24, 2016, the Company entered into a development and commercial license agreement, as subsequently amended, with Servier
that establishes a collaboration between the Company and Servier to develop allogeneic chimeric antigen receptor T cell therapies for up to six unique antigen targets selected by Servier. The Company granted Servier a development license and will
perform early-stage R&amp;D on the selected targets and develop the resulting therapeutic products through Phase 1 clinical trials and prepare clinical supply for use in Phase 2 clinical trials. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company received an upfront payment of $105.0 million under the Servier Agreement. At Phase 2 readiness for any product candidate covered by the Servier
Agreement, Servier may exercise a commercial option to proceed with development and commercialization of the product candidate, subject to option fees. The Company has the ability to receive total payments, including the upfront payment, option fees
and milestone payments, in the aggregate across all six targets that may be selected by Servier, of up to approximately $1.6&nbsp;billion, as well as the payment of tiered royalties ranging from the mid-single digit percentages to the low double
digit percentages on worldwide net sales of any products developed under the Servier Agreement, subject to customary potential reductions. The Company also has the right to participate in the development and commercialization of any licensed
products resulting from the collaboration through a 50/50 codevelopment and copromotion option in the United States, subject to the payment of an option fee, which is exercisable after Servier&#146;s commercial option exercise. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-26 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has determined that the targets are not separable and consist of one technology platform. As a result,
the up-front payment for the development license and certain development milestones related to early-stage activities that are nonsubstantive, less fees to exercise the codevelopment and copromotion, were bundled into a single unit of accounting and
are recognized as revenue over the estimated performance period of 9.5 years, which includes the period of time Servier has to nominate targets for development and the estimated time for the Company to complete early-stage product development
activities. The Company recognized $4.8 million and $5.8 million in revenues during 2016 and 2017, respectively. The amount recorded as deferred revenue was $100.2 and $94.4 million as of December&nbsp;31, 2016 and 2017, respectively. No development
or sales-based milestones were received for the fiscal years ended December&nbsp;31, 2016 and 2017. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 14: Segment reporting </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has developed a genome editing platform and performs related research for human therapeutic and agricultural applications. The Company&#146;s Chief
Operating Decision Maker (&#147;CODM&#148;) evaluates the Company&#146;s financial performance based on two reportable segments: Therapeutics and Plant Sciences. The Therapeutics segment is focused on the development of products in the field of
immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Plant Sciences segment is focused on applying ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies.
The CODM reviews segment performance and allocates resources based upon segment revenue and segment operating loss of the Therapeutics and Plant Sciences reportable segments. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Segment operating loss is derived by deducting operational cash expenditures, net, from GAAP revenue. Operational cash expenditures are cash disbursements made that are directly attributable to the reportable
segment (including directly attributable research and development and property, equipment, and software expenditures) plus an allocation of centralized research and development expenditures for early stage research, nuclease development and the
purchase of general laboratory supplies. These expenditures are allocated to the segments based on headcount. The reportable segment and centralized research and development operational cash expenditures include cash disbursements for compensation,
lab supplies, purchases of property, equipment, and software and procuring services from CROs, CMOs, and research organizations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain cost items are
not allocated to the Company&#146;s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company&#146;s executive, business development, finance, operations, human resources and
legal functions. The Company does not allocate non-cash income statement amounts to its reportable segments, such as share based compensation, depreciation and amortization, intangible asset impairment charges and losses on disposal of assets.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-27 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the
Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is the financial information with respect to the
Company&#146;s reportable segments (in thousands): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Revenue:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total segment revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Segment operational cash expenditures:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total segment operational cash expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,761</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Allocation of centralized research and development operational cash expenditures:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,948</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total allocation of centralized research and development operational cash expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Segment operating loss:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Therapeutics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plant Sciences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total segment operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(14,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Adjustments to reconcile segment operating loss to consolidated loss from operations:</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Corporate general and administrative cash expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Impairment of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss on disposal of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile cash expenditures to GAAP expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total consolidated loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Note 15: Subsequent events </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On January&nbsp;1, 2018, the Company entered into a research, collaboration and license agreement with the University of Pennsylvania (&#147;Penn&#148;) that
includes three gene knockout programs and up to three gene knockin or gene repair programs. The Company will provide funding to Penn and receive a license to certain technology invented under the agreement. The research funding payments will be
expensed as incurred. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On January&nbsp;24, 2018, the Company amended its Durham, North Carolina lease to provide for additional space in two different
areas of the building. The first area is for 7,106 square feet and was occupied by the Company in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-28 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Precision BioSciences, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
May of 2018 and will be leased through July&nbsp;31, 2024. The Company will pay $1.1 million over the lease term, which includes a rent abatement. The landlord also provided a $0.2 million
allowance for improvements. The second area is for 2,848 square feet and was occupied by the Company in September 2018 and will be leased through July&nbsp;31, 2024. The Company will pay $0.3 million over the lease term, which includes a rent
abatement. The landlord also provided a $0.1 million allowance for improvements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;6, 2018, the Company further amended its Durham, North
Carolina lease to provide for additional space of 1,626 square feet, which was occupied by the Company in September of 2018 and will be leased through July&nbsp;31, 2024. The Company will pay $0.3 million over the lease term. The landlord also
provided an allowance of an amount less than $0.1 million for improvements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On March&nbsp;29, 2018, the Company entered into a long-term lease agreement
for approximately 15,558 square feet of laboratory and office space in Research Triangle Park, North Carolina. The lease term is seven years and begins six months after the landlord delivers the premises to the Company, which was May&nbsp;15, 2018.
Total lease payments at lease inception were $3.2 million over the lease term. The Company has the option to accept an improvement allowance from the landlord, which ranges up to a maximum of $70.00 per square foot for improvements done on the
premises. In September of 2018, the Company opted to accept the maximum level of improvement allowance offered by the landlord, which resulted in an incremental increase in rent. This increased the total lease payments due over the lease term to
$3.6 million. The Company also has the ability to expand into other areas of the facility. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">From May 2018 to July 2018, the Company issued 21,956,100
shares of the Series B preferred stock and received approximately $110.0 million in gross proceeds, less $0.2 million in aggregate offering costs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On
September&nbsp;10, 2018, the Company and Gilead Sciences, Inc. (&#147;Gilead&#148;) entered into a collaboration and license agreement (the &#147;Gilead Agreement&#148;) to develop genome editing tools to target viral DNA associated with Hepatitis
B. Pursuant to the terms of the agreement, Gilead will receive an exclusive license to exploit the resulting synthetic nucleases and products that use them to treat Hepatitis B in humans, and the Company is entitled to receive up to approximately
$40 million in research funding over an initial three year term and milestone payments of up to an aggregate of $445 million. The Company is also entitled to receive tiered royalties ranging from the high single digit percentages to the mid-teen
percentages on world-wide net sales of the products developed through the collaboration, subject to customary potential reductions. Gilead is responsible for obtaining regulatory approvals and, upon termination of the collaboration, will assume sole
responsibility for the development and commercialization of such gene editing therapies and products. Precision will provide technology transfer of its development know-how prior to Gilead assuming responsibility and manufacture clinical supplies
for use by Gilead at a price based on Precision&#146;s costs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;2, 2018, the Company entered into a long-term lease agreement for
approximately 17,296 square feet of laboratory space located in Research Triangle Park, North Carolina. The lease term is seven years and two months and lease payments begin nine months after execution of the lease. Total lease payments will be
approximately $3.5 million over the lease term. The landlord will provide the Company a maximum allowance of $70.58 per square foot for improvements done on the premises, which will be subject to landlord adjustments as outlined in the lease.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has evaluated subsequent events through October 18, 2018, the date these consolidated financial statements were issued and has determined
that there were no events which have occurred that would require adjustment to or disclosure in these consolidated financial statements other than those disclosed above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-29 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:48px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
</I></B></FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g367280g02p15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:50px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Common stock </I></B></FONT></P> <P STYLE="margin-top:90px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="6"><B>Prospectus </B></FONT></P> <P STYLE="font-size:90px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P.&nbsp;Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="5"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Barclays</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:90px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019
</FONT></P> <P STYLE="font-size:48px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Part II </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Information not required in prospectus </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;13.
Other expenses of issuance and distribution. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table indicates the expenses to be incurred in connection with the offering described in
this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority,
Inc., or FINRA, filing fee and the Nasdaq listing fee. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Securities and Exchange Commission registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Nasdaq listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Blue sky fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transfer agent fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Miscellaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*&nbsp;&nbsp;&nbsp;&nbsp;To</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">be filed by amendment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;14. Indemnification of
directors and officers. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal
liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in
intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of the General Corporation Law of the State of Delaware or obtained an improper personal benefit. Our amended and
restated certificate of incorporation will provide that none of our directors shall be personally liable to us or to our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing
such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the
request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of such
position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, in any criminal action or proceeding, had no reasonable cause to believe his or her
conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated bylaws will provide that we will indemnify each person who was or is a party or threatened to be made a party to any
threatened, pending or completed action, suit or proceeding (other than an action by or in the right of our company) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed
to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an
&#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in
connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action
or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of incorporation and amended and restated bylaws will provide that we will indemnify any Indemnitee who was or is a
party to an action or suit by or in the right of our company to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our
request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such
capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the
Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have
been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any
Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an
Indemnitee under certain circumstances. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have entered into indemnification agreements with each of our directors and executive officers. These
indemnification agreements may require us, among other things, to indemnify our directors and executive officers for expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any
action or proceeding arising out of his or her service as one of our directors or executive officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or
omissions in their capacities as directors or officers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In any underwriting agreement we enter into in connection with the sale of common stock being
registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, or the Securities Act, against certain
liabilities. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;15. Recent sales of unregistered securities. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Set forth below is information regarding shares of capital stock issued by us within the past three years. Also included is the consideration received by us for such shares and information relating to the section
of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Issuances of Capital Stock. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2015 and May 2015, we issued
25,650,000 shares of Series A Preferred Stock to certain accredited investors at a price of $1.00 per share for aggregate proceeds of approximately $26.65&nbsp;million. From May 2018 to July 2018, we issued 21,956,095 shares of Series B Preferred
Stock to certain accredited investors at a price of $5.01 per share for aggregate proceeds of approximately $110.0&nbsp;million. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Equity Grants and Issuances under Stock Incentive Plans. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since
September 2015, we have granted stock option and restricted stock awards to purchase an aggregate of 6,542,250 shares of our common stock to employees, consultants and directors under our 2015 Stock Incentive Plan with exercise or purchase prices
ranging between $0.19 and $4.76 per share, and we have issued 478,713 shares of restricted common stock to employees, consultants and directors under our 2015 Stock Incentive Plan. In addition, since September 2015, we have also issued 1,766,243
shares of restricted common stock to employees, consultants and directors in connection with the exercise of stock options granted under our 2006 Stock Incentive Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The issuances of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated thereunder, or Rule
701 promulgated under Section&nbsp;3(b) of the Securities Act, as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. Individuals who purchased
securities as described above represented their intention to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were affixed to the share certificates
issued in such transactions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions or any public offering.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;16. Exhibits and financial statement schedules. </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<BR>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Description</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Underwriting Agreement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Amended and Restated Certificate of Incorporation of the Registrant, to be effective upon the closing of this offering</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;3.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Registrant, as currently in effect</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;3.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Amended and Restated Bylaws of the Registrant, to be effective upon the closing of this offering</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;4.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Specimen Common Stock Certificate</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Amended and Restated Investors&#146; Rights Agreement among the Registrant and certain of its stockholders, dated May&nbsp;25, 2018</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Opinion of Smith, Anderson, Blount, Dorsett, Mitchell&nbsp;&amp; Jernigan, LLP</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.1*&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Development and Commercial License Agreement by and between Les Laboratoires Servier and the Registrant, dated February&nbsp;24,&nbsp;2016, as amended</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<BR>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Description</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.2&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">License Agreement by and between Duke University and the Registrant, dated April&nbsp;17, 2006, as amended</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.3&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Patent Cross-License Agreement by and between Cellectis SA and the Registrant, dated January&nbsp;23, 2014</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.4&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Collaboration and License Agreement by and between Gilead Sciences, Inc. and the Registrant, dated September&nbsp;10, 2018</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.5*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Lease Agreement between the Registrant and Venable Center, LLC, dated April&nbsp;5,&nbsp;2010, as amended</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.6*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Lease Agreement between Elo Life Systems, Inc. and <FONT STYLE="white-space:nowrap">ARE-NC</FONT> Region No.&nbsp;17, LLC, dated March&nbsp;29, 2018</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.7*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Lease Agreement between Registrant and Durham TW Alexander, LLC, dated October&nbsp;2, 2018</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2006 Stock Incentive Plan, as amended, and form of award agreements thereunder</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2015 Stock Incentive Plan, as amended, and form of award agreements thereunder</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.10*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2019 Incentive Award Plan, and form of award agreements thereunder</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.11*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">2019 Employee Stock Purchase Plan</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.12*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between the Registrant and Matthew Kane, dated June&nbsp;14,&nbsp;2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.13*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between the Registrant and Derek Jantz, dated July&nbsp;23,&nbsp;2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.14*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between the Registrant and Fayaz Khazi, dated May&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.15*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between the Registrant and David Thomson, dated July&nbsp;3, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.16*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Indemnification Agreement between the Registrant and its directors and officers</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.17*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Plan</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Subsidiaries of the Registrant</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">23.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Consent of Deloitte&nbsp;&amp; Touche LLP</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">23.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Consent of Smith, Anderson, Blount, Dorsett, Mitchell&nbsp;&amp; Jernigan, LLP (included as part of Exhibit&nbsp;5.1)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">24.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Power of Attorney (included on signature page)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">To be filed by amendment. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule 406 under the Securities Act of 1933, as
amended, and have been filed separately with the Securities and Exchange Commission. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Financial Statement Schedules. Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the
consolidated financial statements or notes thereto. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;17. Undertakings. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the
underwriter to permit prompt delivery to each purchaser. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The undersigned hereby undertakes that: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance
upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
effective. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Signatures </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on this&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">PRECISION BIOSCIENCES, INC.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Power of attorney and signatures </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We, the undersigned officers and directors of Precision BioSciences, Inc., hereby severally constitute and appoint Matthew Kane and Abid Ansari, and each of them singly (with full power to each of them to act
alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead,
and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to
Rule&nbsp;462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and
purposes as he might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or any of them, or their or his substitute or
substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, this registration
statement has been signed by the following persons in the capacities indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Signature</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Title</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Matthew Kane</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">President, Chief Executive Officer and Director</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2"><I>(Principal Executive Officer)</I></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;
2019</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Abid Ansari</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Vice President, Finance and Operations</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2"><I>(Principal Financial and Accounting Officer)</I></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Robert Adelman, M.D.</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Derek Jantz, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Tony Yao, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid"></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT (the &#147;<U>Agreement</U>&#148;) is made as of the 25<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day of May, 2018, by and among Precision BioSciences, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), the investors listed on <U>Schedule</U><U></U><U>&nbsp;A</U> hereto, each of
which is herein referred to as an &#147;<U>Investor</U>&#148; and collectively as the &#147;<U>Investors</U>&#148;, and the holders of Common Stock (as defined below) listed on <U>Schedule B</U> hereto, each of which is herein referred to as a
&#147;<U>Common Holder</U>&#148; and collectively as the &#147;<U>Common Holders</U>&#148;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, certain of the Investors (the &#147;<U>Existing Investors</U>&#148;) and the Common Holders hold shares of the Series A Stock
(as defined below) and/or shares of Common Stock issued upon conversion thereof and variously possess registration rights, information rights, right of first offer, and other rights pursuant to an Investors&#146; Rights Agreement dated as of
April&nbsp;29, 2015 between the Company and such Investors and the Common Holders, as amended by the Omnibus Amendment to Investors Rights Agreement, Voting Agreement and ROFR and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement dated as of
December&nbsp;21, 2016 (as amended, the &#147;<U>Prior Agreement</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Existing Investors are holders of at
least 58% of the Registrable Securities (as defined in the Prior Agreement) of the Company and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted
to them under the Prior Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, certain of the Investors are parties to that certain Series B Preferred Stock
Purchase Agreement of even date herewith between the Company and such Investors (the &#147;<U>Purchase Agreement</U>&#148;), under which the Company&#146;s and such Investors&#146; obligations are conditioned upon the execution and delivery of this
Agreement by such Investors, Existing Investors holding at least 58% of the Registrable Securities, the Common Holders and the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the Company, the Existing Investors and the Common Holders hereby agree that the Prior Agreement shall be amended and
restated in its entirety by this Agreement, and the parties to this Agreement further agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For
purposes of this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>1934 Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Act</U>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Affiliate</U>&#148; means, with respect to any Person, any other Person who or which, directly or indirectly, controls, is
controlled by, or is under common control with such specified Person, including, without limitation, any general partner, limited partner, member, managing member, employee, officer, director or manager of such Person, or with
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to <FONT STYLE="white-space:nowrap">F-Prime</FONT> (as defined below) or any Affiliate of <FONT STYLE="white-space:nowrap">F-Prime</FONT> only, any trust for the benefit of any of the
foregoing or trust for the benefit of any Affiliate of the foregoing, or any venture capital, hedge or private equity style fund now or hereafter existing that is controlled by one or more general partners or managing members of, or is under common
investment management with, such Person. For purposes of this definition, the term &#147;control&#148; when used with respect to any Person means the power to direct the management or policies of such Person, directly or indirectly, whether through
ownership of voting securities, by contract or otherwise, and the terms &#147;controlling&#148; and &#147;controlled&#148; shall have meanings correlative to the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Board</U>&#148; means the Company&#146;s Board of Directors, as constituted from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Common Holder Registrable Securities</U>&#148; means (i)&nbsp;the 22,330,742 shares of Common Stock or Common Stock issuable upon
the exercise of options held by the Common Holders, and (ii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to,
or in exchange for or in replacement of such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Common Stock</U>&#148; means the Company&#146;s Common Stock, par value
$0.000005 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Form</U><U></U><U>&nbsp;S</U><U><FONT STYLE="white-space:nowrap">-3</FONT></U>&#148; means such form
under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the
SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Free Writing Prospectus</U>&#148; means a free-writing prospectus, as defined in Rule 405. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Holder</U>&#148; means any Person owning or having the right to acquire Registrable Securities or any assignee thereof in
accordance with <U>Section</U><U></U><U>&nbsp;2.10</U> of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Initial Offering</U>&#148; means the
Company&#146;s first firm commitment underwritten public offering of its Common Stock under the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>Key Employee</U>&#148;
means the employees of the Company listed on <U>Schedule B</U> attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) &#147;<U>Person</U>&#148; shall mean any individual,
corporation, partnership, trust, limited liability company, association or other entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) &#147;<U>Preferred Directors</U>&#148; shall
have the meaning given to it in the Restated Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) &#147;<U>Preferred Stock</U>&#148; shall mean the Series A Stock and the
Series B Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) &#147;<U>Register</U>,&#148; &#147;<U>registered</U>,&#148; and
&#147;<U>registration</U>&#148; refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or
document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) &#147;<U>Registrable Securities</U>&#148; means (i)&nbsp;the Common Stock issuable or issued upon conversion of the
Preferred Stock, and any Common Stock issued as (or issuable upon conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, in exchange for or in replacement of such
Preferred Stock, and (ii)&nbsp;the Common Holder Registrable Securities,<U> provided</U>, <U>however</U>, that such Common Holder Registrable Securities shall not be deemed Registrable Securities and the Common Holders shall not be deemed Holders
for the purposes of Sections 2.1, 2.11 and 4.6 and any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or
in exchange for, or in replacement of, the shares referenced in (i)&nbsp;and (ii) above, excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which such Person&#146;s rights under
<U>Section</U><U></U><U>&nbsp;2</U> of this Agreement are not assigned. In addition, the number of shares of Registrable Securities outstanding shall equal the aggregate of the number of shares of Common Stock outstanding that are, and the number of
shares of Common Stock issuable pursuant to then exercisable or convertible securities that are, Registrable Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q)
&#147;<U>Required Holders</U>&#148; shall mean the written consent or affirmative vote of the holders of at least sixty percent (60%) of the Registrable Securities issued or issuable upon conversion of the Preferred Stock, given in writing or by
vote at a meeting, consenting or voting (as the case may be) together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) &#147;<U>Restated Certificate</U>&#148; shall mean the Company&#146;s Third Amended and Restated Certificate of Incorporation, as further
amended and/or restated from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(s) &#147;<U>Rule 144</U>&#148; shall mean Rule 144 under the Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(t) &#147;<U>Rule 405</U>&#148; shall mean Rule 405 under the Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(u) &#147;<U>SEC</U>&#148; shall mean the Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) &#147;<U>Series A Stock</U>&#148; means the Company&#146;s Series&nbsp;A Preferred Stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(w) &#147;<U>Series B Stock</U>&#148; means the Company&#146;s Series&nbsp;B Preferred Stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Registration Rights</U>. The Company covenants and agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1 <U>Request for Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to the conditions of this <U>Section</U><U></U><U>&nbsp;2.1</U>, if the Company shall receive at any time after the earlier of
(i)&nbsp;December&nbsp;31, 2021 or (ii)&nbsp;six&nbsp;(6) months after the effective date of the Initial Offering, a written request from the Required Holders (for purposes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this <U>Section</U><U></U><U>&nbsp;2.1</U>, the &#147;<U>Initiating Holders</U>&#148;) that the Company file a registration statement under the Act covering the registration of Registrable
Securities with an anticipated aggregate offering price of at least (A) $150,000,000 if such request is received after the date set forth in clause (i)&nbsp;above, but prior to the Initial Offering or (B) $15,000,000 if such request is received
after the Initial Offering and the Company is not eligible to register the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> then the Company shall, within twenty (20)&nbsp;days of the receipt thereof, give written notice
of such request to all Holders, and subject to the limitations of this <U>Section</U><U></U><U>&nbsp;2.1</U>, use its best efforts to effect, within ninety (90)&nbsp;days after the date of the request by the Initiating Holders, the registration
under the Act of all Registrable Securities that the Holders request to be registered in a written request received by the Company within twenty (20)&nbsp;days of the mailing of the Company&#146;s notice pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1(a)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U>, and the Company shall include such information in the written notice referred to in
<U>Section</U><U></U><U>&nbsp;2.1(a)</U>. In such event the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such
Holder&#146;s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company (which underwriter or underwriters shall be reasonably acceptable to those
Initiating Holders holding a majority of the Registrable Securities then held by all Initiating Holders). Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;2.1</U>, if the underwriter advises the Company that marketing
factors require a limitation on the number of securities underwritten (including Registrable Securities), then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of
shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities pro rata based on the number of Registrable Securities held by all such Holders (including the Initiating Holders). In no event shall
any Registrable Securities be excluded from such underwriting unless all other securities are first excluded. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, the Company shall not be required to effect a registration pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i) in any particular jurisdiction in which the Company would be required to execute a general
consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Act; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii) after the Company has effected three (3)&nbsp;registrations pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U>, and such
registrations have been declared or ordered effective; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii) during the period starting with the date sixty&nbsp;(60) days prior to
the Company&#146;s good faith estimate of the date of the filing of, and ending on a date one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hundred eighty&nbsp;(180) days following the effective date of, a <FONT STYLE="white-space:nowrap">Company-initiated</FONT> registration subject to <U>Section</U><U></U><U>&nbsp;2.2</U> below,
<U>provided</U> that the Company is actively employing in good faith its best efforts to cause such registration statement to become effective; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iv) if the Initiating Holders propose to dispose of Registrable Securities that may be registered on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> pursuant to <U>Section</U><U></U><U>&nbsp;2.3</U> hereof; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(v) if the Company
shall furnish to Holders requesting a registration statement pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U> a certificate signed by the Company&#146;s Chief Executive Officer stating that in the good faith judgment of the Board, it would be
materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, then the Company
shall have the right to defer such filing for a period of not more than ninety (90)&nbsp;days after receipt of the request of the Initiating Holders; <U>provided</U> that such right shall be exercised by the Company not more than once in any
twelve&nbsp;(12) month period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2 <U>Company Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the
Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities (other than (i)&nbsp;a registration relating to a request pursuant to
<U>Section</U><U></U><U>&nbsp;2.1</U> of this Agreement or (ii)&nbsp;a registration relating solely to the sale of securities of participants in a Company employee benefit or stock ownership plan, a registration relating to a corporate
reorganization or transaction under Rule&nbsp;145 of the Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of
such registration. Upon the written request of each Holder given within twenty (20)&nbsp;days after mailing of such notice by the Company in accordance with <U>Section</U><U></U><U>&nbsp;4.5</U> of this Agreement, the Company shall, subject to the
provisions of <U>Section</U><U></U><U>&nbsp;2.2(c)</U> of this Agreement, use its best efforts to cause to be registered under the Act all of the Registrable Securities that each such Holder requests to be registered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Right to Terminate Registration</U>. The Company shall have the right to terminate or withdraw any registration initiated by it under
this <U>Section</U><U></U><U>&nbsp;2.2</U> prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be borne by the Company in
accordance with <U>Section</U><U></U><U>&nbsp;2.6</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Underwriting Requirements</U>. In connection with any offering
involving an underwriting of shares of the Company&#146;s capital stock, the Company shall not be required under this <U>Section</U><U></U><U>&nbsp;2.2</U> to include any of the Holders&#146; Registrable Securities in such underwriting unless they
accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by the Company (or by other Persons entitled to select </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the underwriters) and enter into an underwriting agreement in customary form with such underwriters. If the total amount of securities, including Registrable Securities, requested by stockholders
to be included in such offering exceeds the amount of securities to be sold (other than by the Company) that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to
include in the offering only that number of such securities, including Registrable Securities, that the underwriters determine in their sole discretion will not jeopardize the success of the offering. In the event that the underwriters determine
that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned pro rata among the selling Holders based on the
number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i)&nbsp;any Registrable Securities be excluded
from such offering unless all other stockholders&#146; securities have been first excluded from the offering, (ii)&nbsp;the amount of securities of the selling Holders included in the offering be reduced below twenty-five percent (25%) of the total
amount of securities included in such offering, unless such offering is the Initial Offering, in which case the selling Holders may be excluded if the underwriters make the determination described above and no other stockholder&#146;s securities are
included in such offering or (iii)&nbsp;notwithstanding (ii) above, any Registrable Securities which are not Common Holder Registrable Securities be excluded from such underwriting unless all Common Holder Registrable Securities are first excluded
from such offering. For purposes of the preceding sentence concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital, hedge or private equity style fund, partnership or
corporation, the affiliated venture capital, hedge or private equity style funds, partners, members, retired partners and stockholders of such Holder, or the estates and family members of any such partners, members and retired partners and any
trusts for the benefit of any of the foregoing Persons, or, with respect to <FONT STYLE="white-space:nowrap">F-Prime</FONT> or an Affiliate of <FONT STYLE="white-space:nowrap">F-Prime</FONT> only, any trust for the benefit of any of the foregoing or
trust for the benefit of any Affiliate of the foregoing, shall be deemed to be a single &#147;selling Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate amount of Registrable
Securities owned by all such related entities and individuals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3 <U>Form S</U><U><FONT STYLE="white-space:nowrap">-3</FONT>
Registration</U>. In case the Company shall receive, at any time after the first anniversary of the Initial Offering<U>,</U> from the Holders of at least twenty-five percent (25%) of the Registrable Securities (for purposes of this
<U>Section</U><U></U><U>&nbsp;2.3</U>, the &#147;<U><FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders</U>&#148;) a written request or requests that the Company effect a registration on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) use its best efforts to effect, as soon as practicable, such registration and all such qualifications and compliances as may be so
requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders&#146; Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other
Holders joining in such request as are specified in a written request given within fifteen (15)&nbsp;days after receipt of such written notice from the Company; <U>provided</U>, <U> </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>however</U>, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i) if <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is not available for such offering by the Holders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters&#146; discounts or commissions) of less than $1,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii) if the Company shall furnish to all Holders requesting a registration statement pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U> a
certificate signed by the Company&#146;s Chief Executive Officer stating that in the good faith judgment of the Board, it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective
or remain effective for as long as such registration statement otherwise would be required to remain effective, then the Company shall have the right to defer such filing for a period of not more than ninety (90)&nbsp;days after receipt of the
request of the <FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders; <U>provided</U> that such right shall be exercised by the Company not more than once in any twelve&nbsp;(12) month period; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iv) if the Company has, within the twelve (12)&nbsp;month period preceding the date of such request, already effected at least two
(2)&nbsp;registrations on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U> or if the Company has, within the four (4)&nbsp;month period preceding the date of such request, already effected
at least one (1)&nbsp;registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service
of process in effecting such registration, qualification or compliance; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(vi) if the Company, within thirty (30)&nbsp;days of receipt of
the request of such <FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders, gives notice of its bona fide intention to effect the filing of a registration statement with the SEC within one hundred twenty (120)&nbsp;days of receipt of such
request (other than a registration effected solely to qualify an employee benefit plan or to effect a business combination pursuant to Rule 145), <U>provided</U> that the Company is actively employing in good faith its best efforts to cause such
registration statement to become effective; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(vii) during the period starting with the date thirty&nbsp;(30) days prior to the
Company&#146;s good faith estimate of the date of the filing of and ending on a date ninety (90)&nbsp;days following the effective date of a <FONT STYLE="white-space:nowrap">Company-initiated</FONT> registration subject to
<U>Section</U><U></U><U>&nbsp;2.2</U> of this Agreement, <U>provided</U> that the Company is actively employing in good faith its best efforts to cause such registration statement to become effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If the <FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U> and the Company shall include such information in the written notice referred to in
<U>Section</U><U></U><U>&nbsp;2.3(a)</U>. The provisions of <U> </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;2.1(b)</U> of this Agreement shall be applicable to such request (with the substitution of <U>Section</U><U></U><U>&nbsp;2.3</U> for references to
<U>Section</U><U></U><U>&nbsp;2.1</U>). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Subject to the foregoing, the Company shall file a registration statement covering the
Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the <FONT STYLE="white-space:nowrap">S-3</FONT> Initiating Holders. Registrations effected pursuant to this
<U>Section</U><U></U><U>&nbsp;2.3</U> shall not be counted as requests for registration effected pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.4 <U>Obligations of the Company</U>. Whenever required under this <U>Section</U><U></U><U>&nbsp;2</U> to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep
such registration statement effective for a period of up to one hundred twenty (120)&nbsp;days or, if earlier, until the distribution contemplated in the Registration Statement has been completed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Act in order to enable the disposition of all securities covered by such registration statement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) furnish to the selling Holders such number of copies of a prospectus, including a preliminary prospectus and any Free Writing Prospectus,
in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky
laws of such jurisdictions as shall be reasonably requested by the Holders, <U>provided</U> that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of
process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) relating thereto is required to be delivered under the Act of the happening of any event as a result of which the
prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the
light of the circumstances then existing, and, at the request of any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder, the Company will, as soon as reasonably practicable, file and furnish to all such Holders a supplement or amendment to such prospectus or Free Writing Prospectus (to the extent prepared
by or on behalf of the Company) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements
therein not misleading in light of the circumstances under which they were made; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) cause all such Registrable Securities registered
pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> to be listed on a national exchange or trading system and on each securities exchange and trading system on which similar securities issued by the Company are then listed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this
<U>Section</U><U></U><U>&nbsp;2</U>, the Company shall be entitled to postpone or suspend, for a reasonable period of time, the filing, effectiveness or use of, or trading under, any registration statement if the Company shall determine that any
such filing or the sale of any securities pursuant to such registration statement would in the good faith judgment of the Board: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i)
impede, delay or interfere with any material pending or proposed financing, acquisition, corporate reorganization or other similar transaction involving the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii) impair the consummation of any pending or proposed material offering or sale of any class of securities by the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii) require disclosure of material nonpublic information that, if disclosed at such time, would be harmful to the interests of the Company
and its stockholders; <U>provided</U>, <U>however</U>, that during any such period all executive officers and directors of the Company are also prohibited from selling securities of the Company (or any security of any of the Company&#146;s
subsidiaries or affiliates). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of the suspension of effectiveness of any registration statement pursuant to this
<U>Section</U><U></U><U>&nbsp;2.4</U>, the applicable time period during which such registration statement is to remain effective shall be extended by that number of days equal to the number of days the effectiveness of such registration statement
was suspended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.5 <U>Information from Holder</U>. It shall be a condition precedent to the obligations of the Company to take any action
pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the
intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder&#146;s Registrable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.6 <U>Expenses of Registration</U>. All expenses <U>(</U>other than underwriting discounts and commissions<U>)</U> incurred in connection with
registrations, filings or qualifications pursuant to <U> </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Sections</U><U></U><U>&nbsp;2.1</U>, <U>2.2</U> and <U>2.3</U> of this Agreement, including, without limitation, all registration, filing and qualification fees, printers&#146; and accounting
fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders shall be borne by the Company. Notwithstanding the foregoing, the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>Section</U><U></U><U>&nbsp;2.3</U> of this Agreement if the registration request is subsequently withdrawn at the request of the Holders of a
majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless in the
case of a registration requested under <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>Section</U><U></U><U>&nbsp;2.3</U>, the Holders of a majority of the Registrable Securities to be registered agree to forfeit their right to one demand registration
pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>Section</U><U></U><U>&nbsp;2.3</U>, as the case may be; <U>provided</U>, <U>however</U>, that if at the time of such withdrawal, the Holders have learned material adverse information concerning
the Company different from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse information, then the Holders shall not be
required to pay any of such expenses and shall retain their rights pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>Section</U><U></U><U>&nbsp;2.3</U> of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.7 <U>Delay of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.8 <U>Indemnification</U>. In the event any Registrable Securities are included in a registration statement under this
<U>Section</U><U></U><U>&nbsp;2</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder,
severally and not jointly, the partners, members, officers, directors and stockholders of each Holder, legal counsel and accountants for each Holder, any underwriter (as defined in the Act) for such Holder and each Person, if any, who controls such
Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act, any state securities laws or any rule or
regulation promulgated under the Act, the 1934 Act or any state securities laws, insofar as such losses, claims, damages, or liabilities (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon
any of the following statements, omissions or violations (collectively, a &#147;<U>Violation</U>&#148;): (i)&nbsp;any untrue or alleged untrue statement of a material fact contained in such registration statement, including any preliminary
prospectus, final prospectus, or Free Writing Prospectus contained therein or any amendments or supplements thereto, any issuer information (as defined in Rule 433 of the Act) filed or required to be filed pursuant to Rule 433(d) under the Act or
any other document incident to such registration prepared by or on behalf of the Company or used or referred to by the Company, (ii)&nbsp;the omission or alleged omission of a material fact required to be stated in such registration statement, or
necessary to make the statements therein not misleading or (iii)&nbsp;any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any
state securities laws, and the Company will reimburse each such Holder, underwriter, controlling Person or other aforementioned Person for any legal or other expenses reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incurred by them in connection with investigating or defending any such loss, claim, damage, liability, action or proceeding as such expenses are incurred; <U>provided</U>, <U>however</U>, that
the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;2.8(a)</U> shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, action or proceeding if such settlement is effected without the consent of
the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, action or proceeding to the extent that it arises out of or is based upon a Violation that
occurs in reliance upon, and in conformity with, written information furnished expressly for use in connection with such registration by any such Holder, underwriter, controlling Person or other aforementioned Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of the Act, legal counsel and accountants for the Company, any underwriter, any other Holder selling securities in such registration
statement and any controlling Person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing Persons may become subject, under the Act, the 1934 Act, any state
securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws, insofar as such losses, claims, damages or liabilities (or actions or proceedings, whether commenced or threatened, in respect thereof)
arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with
such registration; and each such Holder will reimburse any Person intended to be indemnified pursuant to this <U>Section</U><U></U><U>&nbsp;2.8(b)</U> for any legal or other expenses reasonably incurred by such Person in connection with
investigating or defending any such loss, claim, damage, liability, action or proceeding as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;2.8(b)</U> shall
not apply to amounts paid in settlement of any such loss, claim, damage, liability, action or proceeding if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld), and <U>provided</U> that in
no event shall any indemnity under this <U>Section</U><U></U><U>&nbsp;2.8(b)</U> exceed the net proceeds from the offering received by such Holder, except in the case of fraud or willful misconduct by such Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this <U>Section</U><U></U><U>&nbsp;2.8</U> of notice of the commencement of any
action or proceeding (including any governmental action or proceeding) for which a party may be entitled to indemnification, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
<U>Section</U><U></U><U>&nbsp;2.8</U>, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>, <U>however</U>, that an indemnified party (together with all other indemnified parties that may be
represented without conflict by one counsel) shall have the right to retain one (1)&nbsp;separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action or proceeding, if prejudicial to
its ability to defend such action or proceeding, shall relieve such indemnifying party of any liability to the indemnified party under this <U>Section</U><U></U><U>&nbsp;2.8</U> but only to the extent of such prejudice; <U>provided</U>,
<U>however</U>, that the omission to so deliver written notice to the indemnifying party will not relieve such indemnifying party of any liability that it may have to any indemnified party otherwise than under this
<U>Section</U><U></U><U>&nbsp;2.8</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;2.8</U> is held by a
court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall
contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the
indemnified party on the other hand in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations; <U>provided</U>, <U>however</U>, that
(i)&nbsp;no contribution by any Holder, when combined with any amounts paid by such Holder pursuant to <U>Section</U><U></U><U>&nbsp;2.8(b)</U>, shall exceed the net proceeds from the offering received by such Holder and (ii)&nbsp;no Person guilty
of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided</U> <U>further</U> that in no event shall
a Holder&#146;s liability pursuant to this <U>Section</U><U></U><U>&nbsp;2.8(d)</U>, when combined with the amounts paid or payable by such Holder pursuant to <U>Section</U><U></U><U>&nbsp;2.8(b)</U>, exceed the proceeds from the offering received
by such Holder (net of any expenses paid by such Holder). The relative fault of the indemnifying party and the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification
and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this <U>Section</U><U></U><U>&nbsp;2.8</U> shall survive the completion of any offering of Registrable Securities in a registration statement under this <U>Section</U><U></U><U>&nbsp;2</U> and otherwise shall survive
the termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.9 <U>Reports Under the 1934 Act</U>. With a view to making available to the Holders the benefits of
Rule&nbsp;144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form <FONT STYLE="white-space:nowrap">S-3,</FONT>
the Company agrees to: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) make and keep public information available, as those terms are understood and defined
in Rule&nbsp;144, at all times after the effective date of the registration statement filed by the Company for the Initial Offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
use best efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act (at any time after the Company has become subject to such reporting requirements); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of Rule&nbsp;144 (at any time after ninety (90)&nbsp;days after the effective date of the first registration statement filed by the Company), the Act and the 1934
Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (at any time after it so qualifies),
(ii)&nbsp;a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (iii)&nbsp;such other information as may be reasonably requested to avail any Holder of any rule or
regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to use such form). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.10 <U>Assignment of
Registration Rights</U>. The rights to cause the Company to register Registrable Securities pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such
securities that after such transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations), <U>provided</U>: (a)&nbsp;the Company is,
within a reasonable time prior to such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or
assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including, without limitation, the provisions of <U>Section</U><U></U><U>&nbsp;2.12</U> of this Agreement; and (c)&nbsp;such transferee or assignee
is not a person deemed by the Board, in its reasonable judgment, to be a competitor or potential competitor of the Company; <U>provided</U>, <U>however</U>, that for purposes of this <U>Section</U><U></U><U>&nbsp;2.10</U> &#147;competitor&#148; of
the Company shall not include Gilead Sciences, Inc. (&#147;<U>Gilead</U>&#148;) or any other entity that is wholly-owned, either directly or indirectly, by Gilead as of the date of this Agreement.<U> </U>Notwithstanding the limitation set forth in
the foregoing sentence respecting the minimum number of shares which must be transferred, any Holder that (i)&nbsp;is a partnership, limited liability company or corporation may transfer such Holder&#146;s Registration rights to (A)&nbsp;entities
affiliated directly or indirectly with such partnership <U>(</U>or its manager<U>)</U>, limited liability company or corporation, (B)&nbsp;any partner (or retired partner or incoming partner), member (or retired member) or stockholder of such
partnership, limited liability company or corporation, (C)&nbsp;the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or stockholder, (D)&nbsp;the estate of any such partner (or
retired partner), member (or retired member) or stockholder<U>, </U>(E)&nbsp;any custodian or trustee for the benefit of any such partner (or retired partner), member (or retired member) or stockholder or the spouse, siblings, lineal descendants or
ancestors of any such partner (or retired partner), member (or retired member) or stockholder, as the case may be and (F)&nbsp;any Affiliate, or (ii)&nbsp;holds shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in its capacity as trustee, manager or custodian of a trust, may transfer such Holder&#146;s rights to cause the Company to register Registrable Securities to a replacement trustee, manager or
custodian of the relevant trust, in each case, without restriction as to the number or percentage of shares acquired by any such transferee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.11 <U>Limitations on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the <U>Required </U>Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (a)&nbsp;to include any of such securities in any
registration filed under <U>Section</U><U></U><U>&nbsp;2.1</U>, <U>Section</U><U></U><U>&nbsp;2.2</U> or <U>Section</U><U></U><U>&nbsp;2.3</U> of this Agreement, unless under the terms of such agreement, such holder or prospective holder may include
such securities in any such registration only to the extent that the inclusion of such securities will not reduce the amount of the Registrable Securities of the Holders that are included or (b)&nbsp;to demand registration of their securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.12 <U>&#147;</U><U>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT></U><U>&#148;</U><U> Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on
the date of the final prospectus relating to the Initial Offering and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180)&nbsp;days) (i)&nbsp;lend, offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock, in each case, held immediately before the effective date of the registration statement for such offering, or (ii)&nbsp;enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause&nbsp;(i) or (ii)&nbsp;above is to be settled by delivery of Common Stock or other
securities, in cash or otherwise. The foregoing provisions of this <U>Section</U><U></U><U>&nbsp;2.12</U> shall apply only to the Initial Offering, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement,
and shall only be applicable to the Holders if all officers and directors are subject to the same restrictions and the Company uses best efforts to obtain a similar agreement from all stockholders individually owning greater than one percent (1%) of
the Company&#146;s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with the Initial Offering are intended
<FONT STYLE="white-space:nowrap">third-party</FONT> beneficiaries of this <U>Section</U><U></U><U>&nbsp;2.12</U> and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further
agrees to execute such agreements as may be reasonably requested by the underwriters in the Initial Offering that are consistent with this <U>Section</U><U></U><U>&nbsp;2.12</U> or that are necessary to give further effect thereto. Any discretionary
waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply to all Holders subject to such agreements pro rata based on the number of shares subject to such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to enforce the foregoing covenant, the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with
respect to the Registrable Securities of each Holder (and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares or securities of every other Person subject to the foregoing restriction) until the end of such period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates representing all shares or
securities of the Company of each Holder (and the shares or securities of every other Person subject to the restriction contained in this <U>Section</U><U></U><U>&nbsp;2.12</U>): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD AFTER THE EFFECTIVE DATE
OF THE ISSUER&#146;S REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER&#146;S
PRINCIPAL OFFICE. SUCH <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.13
<U>Termination of Registration Rights</U>. No Holder shall be entitled to exercise any right provided for in this <U>Section</U><U></U><U>&nbsp;2</U>: (a) after five (5)&nbsp;years following the consummation of a firm commitment underwritten public
offering of shares of Common Stock of the Company at a price per share to the public of at least $6.01 (adjusted for stock splits, stock dividends, recapitalizations and similar events, including any such events to be effected in connection with
such offering) resulting in aggregate proceeds to the Company (net of the underwriting discounts or commissions and offering expenses) of not less than $50,000,000 (a &#147;<U>Qualified IPO</U>&#148;) or (b)&nbsp;as to any Holder, such time
following a Qualified IPO at which both (i)&nbsp;such Holder (together with its Affiliates) holds one percent (1%) or less of the Company&#146;s outstanding Common Stock and (ii) all Registrable Securities held by such Holder (together with any
Affiliate of the Holder with whom such Holder must aggregate its sales under Rule&nbsp;144) can be sold in any three&nbsp;(3) month period without registration or volume limitations in compliance with Rule&nbsp;144. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Covenants of the Company</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Delivery of Financial Statements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall deliver to each Investor (or transferee of an Investor): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i) as soon as practicable, but in any event within one hundred twenty (120)&nbsp;days after the end of each fiscal year of the Company, a
consolidated income statement for such fiscal year, a consolidated balance sheet of the Company and consolidated statement of stockholders&#146; equity as of the end of such year, and a consolidated statement of cash flows for such year, such <FONT
STYLE="white-space:nowrap">year-end</FONT> financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (&#147;<U>GAAP</U>&#148;), audited and certified by independent public accountants of
nationally recognized standing selected by the Company; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii) as soon as practicable, but in any event within forty-five
(45)&nbsp;days after the end of each of the first three (3)&nbsp;quarters of each fiscal year of the Company, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an unaudited consolidated income statement and statement of cash flows for such fiscal quarter and for the current fiscal year to date, and an unaudited balance sheet as of the end of such fiscal
quarter (the &#147;<U>Quarterly Financial Statements</U>&#148;), all prepared in accordance with GAAP (except that such financial statements may (A)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and
(B)&nbsp;not contain all notes thereto that may be required in accordance with GAAP). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company shall deliver to each Investor (or
transferee of an Investor) that holds at least 1,000,000 shares of Registrable Securities (appropriately adjusted for any stock split, dividend, combination or other recapitalization) (a &#147;<U>Major Investor</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i) as soon as practicable, but in any event at least thirty (30)&nbsp;days prior to the end of each fiscal year, an operating budget and
business plan (the &#147;<U>Business Plan</U>&#148;) for the next fiscal year, approved by the Board and prepared on a quarterly basis, as well as a summary of the Business Plan together with any update of the Business Plan as such update is
prepared, including consolidated balance sheets, income statements and statements of cash flows for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii) concurrently with the delivery of the Quarterly Financial Statements, a comparison of the Quarterly Financial Statements against the
Business Plan, as then updated and in effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii) such other information relating to the financial condition, business or corporate
affairs of the Company as the Major Investor may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this subsection&nbsp;(ii) to provide information that (A)&nbsp;it deems in good
faith to be a trade secret or similar confidential information or (B)&nbsp;the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2 <U>Inspection</U>. The Company shall permit each Major Investor, at such Major Investor&#146;s expense, and after reasonable notice
provided by such Major Investor, to visit and inspect the Company&#146;s properties, to examine its books of account and records and to discuss the Company&#146;s affairs, finances and accounts with its officers, all at such reasonable times as may
be requested by the Major Investor; <U>provided</U>, <U>however</U>, that the Company shall not be obligated pursuant to this <U>Section</U><U></U><U>&nbsp;3.2</U> to provide access to any information that (A)&nbsp;it deems in good faith to be a
trade secret or similar confidential information or (B)&nbsp;the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.3 <U>Observer Rights</U>.<U> </U>As long as F-Prime Capital Partners Healthcare Fund IV LP, together with its Affiliates
(&#147;F-Prime&#148;), owns not less than 1,500,000 shares of Preferred Stock (as adjusted for stock dividends, combinations, splits or the like), the Company shall invite a representative of <FONT STYLE="white-space:nowrap">F-Prime</FONT> (the
&#147;<U>F-Prime Investor Observer</U>&#148;) to attend all meetings of its Board in a nonvoting observer capacity. As long as Brace Pharmaceuticals LLC, together with its Affiliates (&#147;Brace&#148;), owns not less than 1,500,000 shares of
Preferred Stock (as adjusted for stock dividends, combinations, splits or the like), the Company shall invite a representative of Brace (the &#147;<U>Brace Investor Observer</U>&#148;) to attend all meetings of its Board in a nonvoting capacity. As
long as Cowen Healthcare Investments II LP and CHI EF II LP, together with their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Affiliates (&#147;<U>Cowen</U>&#148;), owns not less than 1,500,000 shares of Preferred Stock (as adjusted for stock dividends, combinations, splits or the like), the Company shall invite a
representative of Cowen (the &#147;<U>Cowen Investor Observer</U>&#148; and together with the <FONT STYLE="white-space:nowrap">F-Prime</FONT> Investor Observer and the Brace Observer, the &#147;<U>Investor Observers</U>&#148; and each an
&#147;<U>Investor Observer</U>&#148;) to attend all meetings of its Board in a nonvoting observer capacity. The initial <FONT STYLE="white-space:nowrap">F-Prime</FONT> Investor Observer shall be Ben Auspitz. The initial Brace Investor Observer shall
be Todd Brady. In this respect, the Company shall give each Investor Observer copies of all notices and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; <U>provided</U>,
<U>however</U>, that such representative shall agree to hold in confidence and trust and to act as a fiduciary with the same standard of care as a member of the Board with respect to all information so provided; and <U>provided</U> <U>further</U>,
that the Company reserves the right to exclude any Investor Observer from any meeting, or any portion thereof, and/or to exclude some or all of the materials to be sent to such Investor Observer, if the Board determines in good faith that attendance
at such meeting, or portion thereof, and/or providing such materials or any portion thereof, could materially and adversely affect the Company, whether by way of adversely affecting the attorney-client privilege between the Company and its counsel,
or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.4 <U>Termination of Information</U><U>,</U><U> Inspection </U><U>and Observer </U><U>Covenants</U>. The covenants set
forth in <U>Sections</U><U></U><U>&nbsp;3.1</U>, <U>3.2</U> and <U>3.3</U> shall terminate and be of no further force or effect upon the earlier to occur of (a)&nbsp;the consummation of a Qualified IPO, (b)&nbsp;when the Company first becomes
subject to the periodic reporting requirements of Sections&nbsp;12(g) or 15(d) of the 1934 Act and (c)&nbsp;the consummation of a Liquidation Event, as that term is defined in the Restated Certificate, whichever event shall first occur. The
confidentiality provisions under <U>Section&nbsp;3.3</U> will survive any such termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.5 <U>Right of First Offer</U>. Subject to
the terms and conditions specified in this <U>Section</U><U></U><U>&nbsp;3.5</U>, the Company hereby grants to each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). A Major
Investor shall be entitled to apportion the right of first offer hereby granted it among itself and its partners and Affiliates in such proportions as it deems appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each time the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable for any shares of, its
capital stock (&#147;<U>Shares</U>&#148;), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall deliver a notice in accordance with <U>Section</U><U></U><U>&nbsp;4.5</U> (&#147;<U>Notice</U>&#148;) to the Major
Investors stating (i)&nbsp;its bona fide intention to offer such Shares, (ii)&nbsp;the number of such Shares to be offered and (iii)&nbsp;the price and terms upon which it proposes to offer such Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) By written notification received by the Company within thirty (30)&nbsp;calendar days after the giving of Notice, each Major Investor may
elect to purchase, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of Registrable Securities issued and held by such Investor (assuming full conversion and
exercise of all convertible and exercisable securities then outstanding, but excluding unexercised options) bears to the total number of shares of Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock of the Company then outstanding (assuming full conversion and exercise of all convertible and exercisable securities then outstanding, but excluding unexercised options). At the expiration
of such thirty (30)&nbsp;calendar day period, the Company shall promptly, in writing, notify each Major Investor that elects to purchase all the shares available to it (a &#147;<U>Fully-Exercising Investor</U>&#148;) of any other Major
Investor&#146;s failure to do likewise. During the fifteen (15)&nbsp;calendar day period commencing after the Company has given such notice to the Fully-Exercising Investors, each <FONT STYLE="white-space:nowrap">Fully-Exercising</FONT> Investor may
elect to purchase that portion of the Shares for which Major Investors were entitled to subscribe, but which were not subscribed for by the Major Investors, that is equal to the proportion that the number of shares of Registrable Securities issued
and held by such <FONT STYLE="white-space:nowrap">Fully-Exercising</FONT> Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all <FONT
STYLE="white-space:nowrap">Fully-Exercising</FONT> Investors who wish to purchase some of the unsubscribed shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If all Shares that
Major Investors are entitled to obtain pursuant to <U>Section</U><U></U><U>&nbsp;3.5(b)</U> of this Agreement are not elected to be obtained as provided in <U>Section</U><U></U><U>&nbsp;3.5(b)</U> of this Agreement, the Company may, during the sixty
(60)&nbsp;day period following the expiration of the period provided in <U>Section</U><U></U><U>&nbsp;3.5(b)</U> of this Agreement, offer the remaining unsubscribed portion of such Shares to any Person or Persons at a price not less than that, and
upon terms no more favorable to the offeree than those, specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within thirty (30)&nbsp;days of
the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Investors in accordance herewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The right of first offer in this <U>Section</U><U></U><U>&nbsp;3.5</U> shall not be applicable to (i)&nbsp;Shares issued as a dividend or
distribution on Preferred Stock or upon conversion of the Preferred Stock; (ii)&nbsp;Shares issued pursuant to a transaction described in Article IV.B Section&nbsp;4(d)(i) of the Restated Certificate; (iii)&nbsp;Shares issued or granted to
employees, directors, consultants and other service providers for the primary purpose of soliciting or retaining their services pursuant to this Corporation&#146;s equity incentive or option plans or any other plan or agreement approved by the Board
(including the approval of at least one Preferred Director); (iv) Common Stock issued to the public in a firm commitment underwritten public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended;
(v)&nbsp;Shares issued pursuant to the conversion or exercise of convertible or exercisable securities outstanding as of the date of this Agreement or excluded from the rights of first offer pursuant to this Section&nbsp;3.5(d); (vi) Shares issued
in connection with a bona fide business acquisition by the Company, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise, provided that such issuance is approved by the Board (including the approval of at least
one Preferred Director); (vii) Shares issued pursuant to any equipment leasing arrangement, real estate, bank financing or similar arrangement, which arrangement is approved by the Board (including the approval of at least one Preferred Director);
(viii) Shares issued to persons or entities with which this Corporation has business or partnering relationships, provided such issuances are approved by the Board (including the approval of at least one Preferred Director) and are primarily for <FONT
STYLE="white-space:nowrap">non-equity</FONT> financing purposes; (ix)&nbsp;the issuance of shares of Series B Stock to Additional Purchasers pursuant to Section&nbsp;1.3 of the Purchase Agreement or (x)&nbsp;shares of Common Stock issued in a
Qualified IPO. In addition to the foregoing, the right of first offer in this <U>Section</U><U></U><U>&nbsp;3.5</U> shall not be applicable with respect to any Investor in any subsequent offering of </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares if (i)&nbsp;at the time of such offering, the Investor is not an &#147;accredited investor,&#148; as that term is then defined in Rule 501(a) of the Act and (ii)&nbsp;such offering of
Shares is otherwise being offered only to accredited investors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The rights provided in this <U>Section</U><U></U><U>&nbsp;3.5</U> may
not be assigned or transferred by any Major Investor; <U>provided</U>, <U>however</U>, that a Major Investor that is a venture capital, hedge or private equity style fund may assign or transfer such rights to its Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The covenants set forth in this <U>Section</U><U></U><U>&nbsp;3.5</U> shall terminate and be of no further force or effect upon the
consummation of (i)&nbsp;a Qualified IPO or (ii)&nbsp;a Liquidation Event, as that term is defined in the Restated Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6
<U>Insurance</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Key-Person Insurance</U>. The Company has as of the date hereof term life insurance on the life of Derek Jantz
in an amount of at least $1,000,000. Such policies are owned by the Company and name the Company as loss payee. The Company will use its best efforts to cause such term life insurance policies be maintained until such time as the Board determines
that such insurance should be discontinued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Directors&#146; and Officers&#146; Insurance</U>. The Company has as of the date
hereof directors&#146; and officers&#146; liability insurance in an amount equal to $3,000,000. The Company will use its best efforts to cause such insurance policy be maintained until such time as the Board determines that such insurance should be
discontinued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.7 <U>Proprietary Information and Inventions Agreements</U>. The Company shall require all employees and consultants with
access to confidential information to execute and deliver a Proprietary Information and Inventions Agreement in substantially the form approved by the Board or a consulting agreement containing substantially similar proprietary rights assignment and
confidentiality provisions.<U> </U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.8 <U>Matters Requiring Director Approval</U><U>.</U> So long as the holders of Preferred Stock are
entitled to elect a Preferred Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board, including at least one Preferred Director: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, or other entity unless it is wholly owned by the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) make, or permit any subsidiary to make, any loan
or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan
approved by the Board; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) incur, guarantee, directly or indirectly, or permit any subsidiary to incur, guarantee, directly or
indirectly, any indebtedness (including operating and capital leases) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater than $5,000,000 except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any &#147;associate&#148;
(as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the 1934 Act) of any such Person, except for transactions contemplated by this Agreement, the Purchase Agreement, that certain Amended and Restated Voting Agreement
executed as of even date herewith, and that certain Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement executed as of even date herewith or transactions made in the ordinary course of business
and pursuant to reasonable requirements of the Company&#146;s business and upon fair and reasonable terms that are approved by a majority of the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) hire, terminate, or materially change the compensation of the executive officers, including approving any option grants or stock awards to
executive officers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) materially change the principal business of the Company, enter new lines of business, or exit the current line of
business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) create any subsidiary of the Corporation; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of
money or assets greater than $5,000,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.9 <U>Board Matters</U><U>.</U> Unless otherwise determined by the vote of a majority of the
directors then in office, the Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors and any person with contractual board observer rights for all reasonable <FONT
STYLE="white-space:nowrap">out-of-pocket</FONT> travel and other expenses incurred (consistent with the Company&#146;s travel policy, if any) in support of the Company or in connection with the performance of duties as directors, including, without
limitation, attending meetings of the Board or committees thereof. Promptly after the date hereof, the Board will form compensation, audit and nominating and corporate governance committees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.10 <U>Successor Indemnification</U><U>.</U> If the Company or any of its successors or assignees consolidates with or merges into any other
Person or entity and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of
the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company&#146;s Bylaws, its Certificate of Incorporation, or elsewhere, as the case
may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.11 <U>Confidentiality</U><U>.</U> Each Investor agrees, severally and not jointly, to use the same degree of care as such
Investor uses to protect its own confidential information for any information obtained pursuant to this Agreement or otherwise as a stockholder of the Company which the Company identifies in writing as being proprietary or confidential and such
Investor acknowledges that it will not, unless otherwise required by law or the rules of any national securities exchange, association or marketplace, disclose such information without the prior written consent of the Company except such information
that (a)&nbsp;was in the public domain prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the time it was furnished to such Investor, (b)&nbsp;is or becomes (through no willful improper action or inaction by such Investor) generally available to the public, (c)&nbsp;was in its
possession or known by such Investor without restriction prior to receipt from the Company, (d)&nbsp;was rightfully disclosed to such Investor by a third party without restriction or (e)&nbsp;was independently developed without any use of the
Company&#146;s confidential information. Notwithstanding the foregoing, each Investor that is a limited partnership or limited liability company may disclose such proprietary or confidential information to any former partners or members who retained
an economic interest in such Investor, current or prospective partner of the partnership or any subsequent partnership under common investment management, limited partner, general partner, member or management company of such Investor (or any
employee or representative of any of the foregoing) (each of the foregoing Persons, a &#147;<U>Permitted Disclosee</U>&#148;) or legal counsel, accountants or representatives for such Investor. Furthermore, nothing contained herein shall prevent any
Investor or any Permitted Disclosee from (i)&nbsp;entering into any business, entering into any agreement with a third party, or investing in or engaging in investment discussions with any other company (whether or not competitive with the Company),
<U>provided</U> that such Investor or Permitted Disclosee does not, except as permitted in accordance with this <U>Section</U><U></U><U>&nbsp;3.11</U>, disclose or otherwise make use of any proprietary or confidential information of the Company in
connection with such activities, or (ii)&nbsp;making any disclosures required by law, rule, regulation or court or other governmental order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.12 <U>Bad Actor Status</U><U>.</U> The Company will notify the Investors promptly in writing in the event the Company has knowledge that a
&#147;Bad Actor&#148; disqualifying event described in Rule 506(d)(1)(i) to (viii)&nbsp;of the Securities Act (a &#147;<U>Disqualification Event</U>&#148;) becomes applicable to the Company, except for a Disqualification Event as to which Rule
506(d)(2)(ii)-<U>(</U>iv) or (d)(3) is applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.13 <U>Employee Agreements</U>. The Company will cause (i)&nbsp;each person now or
hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights
assignment agreement; and (ii)&nbsp;each Key Employee to enter into a one (1)&nbsp;year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board, <U>provided</U>, <U>however</U>, that any employee that has
entered into an employment agreement with the Company that contains provisions regarding the subject matter in the foregoing clauses (i) and (ii) shall not be required to enter into a nondisclosure and proprietary rights assignment agreement or
enter into a noncompetition and nonsolicitation agreement. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between
the Company and any employee, without the consent of at least one Preferred Director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.14 <U>Employee Stock</U><U>.</U> Unless otherwise
approved by the Board, including at least one Preferred Director, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company&#146;s capital stock after the date hereof
shall be required to execute restricted stock or option agreements, as applicable, providing for (i)&nbsp;vesting of shares over a four (4)&nbsp;year period, with the first twenty-five percent (25%) of such shares vesting following twelve
(12)&nbsp;months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months, and (ii)&nbsp;a market <FONT STYLE="white-space:nowrap">stand-off</FONT> provision substantially similar to that in <U>Section</U><U></U><U>&nbsp;2.12</U>. In addition, unless otherwise
approved by the Board, including at least one Preferred Director, the Company shall retain a &#147;right of first refusal&#148; on employee transfers until the Initial Offering and shall have the right to repurchase unvested shares at cost upon
termination of employment of a holder of restricted stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.15 <U>Indemnification Matters</U>. The Company hereby acknowledges that one
(1)&nbsp;or more of the directors nominated to serve on the Board by the Investors (each a &#147;<U>Fund Director</U>&#148;) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the
Investors and certain of their affiliates (collectively, the &#147;<U>Fund Indemnitors</U>&#148;).&nbsp;The Company hereby agrees (a)&nbsp;that it is the indemnitor of first resort (<I>i.e.</I>, its obligations to any such Fund Director are primary
and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses
incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the
Restated Certificate (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c)&nbsp;that it irrevocably waives, relinquishes and releases the Fund
Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.&nbsp;The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of
any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of
such advancement or payment to all of the rights of recovery of such Fund Director against the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.16 <U>Right to Conduct
Activities</U><U>.</U> The Company hereby agrees and acknowledges that (A)&nbsp;each of ArrowMark Colorado Holdings, LLC (together with its Affiliates &#147;<U>AP</U>&#148;), venBio Partners, LLC (together with its Affiliates,
&#147;<U>venBio</U>&#148;), Osage University Partners II (together with its Affiliates, &#147;<U>Osage</U>&#148;), G LTP LLC, G HSP LLC, G ERP LLC and G JBD LLC (together with their Affiliates, &#147;<U>DUMAC</U>&#148;), RA Capital Healthcare Fund,
L.P. (together with its Affiliates, &#147;<U>RA Capital</U>&#148;), Franklin Strategic Series &#150; Franklin Biotechnology Discovery Fund and Franklin Templeton Investment Funds &#150; Franklin Biotechnology Discovery Fund (together with their
Affiliates, &#147;<U>Franklin</U>&#148;), Agent Capital Fund I LP (together with its Affiliates, &#147;<U>Agent Capital</U>&#148;), Vivo Panda Fund, L.P. (together with its Affiliates, &#147;<U>Vivo Panda</U>&#148;), Brace and <FONT
STYLE="white-space:nowrap">F-Prime</FONT> (collectively with AP, venBio, Osage, DUMAC, RA Capital, Franklin, Agent Capital, Vivo Panda and Brace, the &#147;<U>Investments Funds</U>&#148;) is a professional investment fund, and as such invests in
numerous portfolio companies, some of which may be deemed competitive with the Company&#146;s business (as currently conducted or as currently propose to be conducted) and (B)&nbsp;that Gilead is a public company with numerous business lines and an
active investment and acquisition program (together, the &#147;<U>Other Gilead Business</U>&#148;).&nbsp;The Company hereby agrees that, to the extent permitted under applicable law, none of the Investment Funds nor Gilead or any of its Affiliates
(together, the &#147;<U>Gilead Group</U>&#148;) shall be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by any Investment Fund or the Gilead Group in any entity competitive with the Company,
(ii)&nbsp;actions taken by any partner, officer or other representative of any Investment Fund the Gilead Group to assist any such competitive company, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company or
(iii)&nbsp;with respect to the Gilead Group, the Gilead Group engaging in Other Gilead Business; <U>provided</U>, <U>however</U>, that the foregoing shall not relieve (x)&nbsp;any of the Investors from liability associated with the unauthorized
disclosure by the Investors (or any of their affiliates) of the Company&#146;s confidential information obtained pursuant to this Agreement, or (y)&nbsp;any director or officer of the Company from any liability associated with his or her fiduciary
duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.17 <U>Termination of Certain Covenants</U><U>.</U> The covenants set forth in <U>Sections 3.7</U>, <U>3.8</U>,
<U>3.12</U>, <U>3.13</U>, <U>3.14</U>, shall terminate and be of no further force or effect upon the consummation of (a)&nbsp;a Qualified IPO or (ii)&nbsp;a Liquidation Event, as that term is defined in the Restated Certificate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1
<U>Successors and Assigns</U>. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any
shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or
by reason of this Agreement, except as expressly provided in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2 <U>Governing Law</U>. This Agreement shall be interpreted
under the laws of the State of Delaware without reference to Delaware conflicts of law provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3 <U>Counterparts; Facsimile</U>.
This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.4 <U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.5 <U>Notices</U>. All notices and other
communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by confirmed electronic mail or facsimile if sent during normal
business hours of the recipient; if not, then on the next business day, (c)&nbsp;five (5)&nbsp;days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1)&nbsp;day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices and other communications shall be sent to the Company and to the other parties at the addresses set forth on the signature pages
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereto (or at such other addresses as shall be specified by notice given in accordance with this <U>Section</U><U></U><U>&nbsp;4.5</U>). If notice is given to the Company, a copy (which shall not
constitute notice) shall also be sent to Smith, Anderson, Blount, Dorsett, Mitchell&nbsp;&amp; Jernigan, L.L.P., Wells Fargo Capitol Center, 150 Fayetteville St., Suite 2300, Raleigh, NC 27601, Attention: Michael P. Saber, Facsimile No. (919) <FONT
STYLE="white-space:nowrap">821-6800;</FONT> and if notice is given to the Investors, a copy (which shall not constitute notice) shall also be given to Tannenbaum Helpern Syracuse&nbsp;&amp; Hirschtritt LLP, 900 Third Avenue, New York, NY 10022,
Attention: James Rieger, Facsimile No. (212) <FONT STYLE="white-space:nowrap">371-1084.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.6 <U>Entire Agreement; Amendments and
Waivers</U>. This Agreement (including the Exhibits hereto, if any) constitutes the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof, and supersedes all other agreements between or among
any of the parties with respect to the subject matter hereof and thereof, including the Prior Agreement. Any term of this Agreement (other than <U>Section</U><U></U><U>&nbsp;3.1</U>, <U>Section</U><U></U><U>&nbsp;3.2</U>, <U>Section&nbsp;3.3</U>,
<U>Section 3.4</U> and <U>Section&nbsp;3.16</U>) may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of
(a) the Company and (b) the Required Holders. The provisions of <U>Section 3.1</U> and <U>Section 3.2</U> may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent
of the Company and the Major Investors holding at least sixty percent (60%) of the Registrable Securities then held by all of the Major Investors. The provisions of <U>Section 2.10</U>, <U>Section 3.4</U>, <U>Section 3.15</U> and <U>Section 3.16</U>
may be amended or waived only with the written consent of (a) the Company and (b) if such amendment or waiver adversely affects venBio, AP, Brace, F-Prime, Franklin, Osage, DUMAC, RA Capital, Agent Capital, Vivo Panda and/or Gilead, such adversely
affected party. The provisions of <U>Section 3.3</U> may be amended or waived only with the written consent of the Company and, if such amendment or waiver adversely affects F-Prime, Cowen and/or Brace, such adversely affected party. Notwithstanding
the foregoing, this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, modification,
termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 3.5 (Right of First Offer) with respect to a particular transaction shall be deemed to apply to all Investors in the same
fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). Further, this Agreement may not be amended, and no provision
hereof may be waived, in each case, in any way which would adversely affect the rights of the Common Holders hereunder in a manner disproportionate to any adverse effect such amendment or waiver would have on the rights of the Investors hereunder,
without also obtaining the written consent of the Common Holders holding a majority of the shares of Common Stock then held by all Common Holders who are then providing services to the Company as officers or employees in good standing. Any amendment
or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities, each future holder of all such Registrable Securities and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.7 <U>Waiver of Rights of First Offer</U>. Pursuant to Sections 3.5 and 4.6 of the Prior Agreement, the Investors having rights of first offer
under the Prior Agreement hereby waive, on behalf of all parties having such rights thereunder, all rights they may have under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5 of the Prior Agreement with respect to the issuance and sale of the Series B Stock pursuant
to the Purchase Agreement and the Common Stock issuable to the purchasers of the Series B Stock pursuant to the Purchase Agreement, including, without limitation, their right to receive notice pursuant to Section&nbsp;3.5(a) of the Prior Agreement
and their right of first offer pursuant to Section&nbsp;3.5 of the Prior Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.8 <U>Severability</U>. Whenever possible, each
provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.9 <U>Aggregation of Stock</U>. All shares of Registrable Securities held or acquired by affiliated entities (including affiliated venture
capital, hedge and private equity style funds or venture capital, hedge or private equity style funds under common investment management) or Persons shall be aggregated together for the purpose of determining the availability of any rights under
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.10 <U>Additional Investors</U>. Notwithstanding <U>Section</U><U></U><U>&nbsp;4.6</U>, no consent shall be necessary to
add additional Investors as signatories to this Agreement and to update <U>Schedule</U><U></U><U>&nbsp;A</U> accordingly, <U>provided</U> that such Investors have purchased Series B Stock pursuant to the subsequent closing provisions of Section 1.3
of the Purchase Agreement. <U>Schedule A</U> shall be updated without any action of the Investors to reflect such additional Investors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.11 <U>WAIVER OF JURY TRIAL</U>. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF THIS AGREEMENT, THE OTHER AGREEMENTS TO BE EXECUTED IN CONNECTION WITH THE EXECUTION OF THIS AGREEMENT, THE REGISTRABLE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL
DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THE TRANSACTIONS CONTEMPLATED HEREBY, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON
LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS
WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRECISION BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">302 E. Pettigrew Street, Suite <FONT STYLE="white-space:nowrap">A-100</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Durham, NC 27701</TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>COMMON HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>DEREK JANTZ</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Derek Jantz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Derek Jantz</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>MATTHEW KANE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew Kane</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>JEFF SMITH</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeff Smith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeff Smith</TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ADAGE CAPITAL PARTNERS, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Adage Capital Partners, GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Adage Capital Advisors, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Lehan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dan Lehan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">COO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">200 Clarendon Street </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, MA 02116</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>AGENT CAPITAL FUND I LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agent Capital Fund I GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Geeta Vemuri</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Geeta Vemuri</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Address:</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">810 Memorial Drive, Suite 107</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cambridge, <FONT STYLE="white-space:nowrap">MA-02139</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ALEXANDRIA VENTURE INVESTMENTS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Alexandria Real Estate Equities, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Aaron Jacobson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Aaron Jacobson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SVP &#150; Venture Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Address:</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">385 E. Colorado Blvd., Suite 299</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pasadena, CA 91101</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>AMGEN VENTURES, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David A. Piacquad</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: David A. Piacquad</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: SVP, Business Development</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">c/o Amgen Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">One Amgen Center Drive</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thousand Oaks, CA 91320</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Corporate Secretary</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MERIDIAN GROWTH FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Address:</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MERIDIAN SMALL CAP GROWTH FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Address:</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARROWMARK LIFE SCIENCE FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">AMP Life Science GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARROWMARK FUNDAMENTAL OPPORTUNITY FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ArrowMark Partners GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LOOKFAR INVESTMENTS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CF ASCENT LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THB IRON ROSE, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THB IRON ROSE, LLC LIFE SCIENCE PORTFOLIO</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IRON HORSE INVESTMENTS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tony Yao</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Tony Yao</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Fillmore
Street, Suite 325</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80206</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>BRACE PHARMACEUTICALS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vinzenz Ploerer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vinzenz Ploerer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">155 Gibbs Street, Suite 406</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Rockville, MD 20850</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CORMORANT PRIVATE HEALTHCARE FUND I, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cormorant Private Healthcare GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bihua Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bihua Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">200 Clarendon Street, 5nd Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, MA 02116</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cormorant Global Healthcare GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bihua Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bihua Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">200 Clarendon Street, 5nd Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, MA 02116</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CRMA SPV, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cormorant Asset Management, LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-in-Fact</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bihua Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bihua Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO/CIO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">P.O. Box 309</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Ugland House</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Grand Cayman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">KY1-1104</FONT> Cayman Islands</TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>COWEN HEALTHCARE INVESTMENTS II LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cowen Healthcare Investments II GP LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Raidy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kevin Raidy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen Advisors, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">599
Lexington Avenue, 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">New York, NY 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attention: Kevin Raidy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CHI EF II LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cowen Healthcare Investments II GP LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Raidy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kevin Raidy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen Advisors, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">599
Lexington Avenue, 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">New York, NY 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attention: Kevin Raidy</TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>G LTP LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Seth M. Posternak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seth M. Posternak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannine M. Lall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Controller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">280 S. Mangum Street, Suite 210</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Durham, NC 27701-3675</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>G HSP LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Seth M. Posternak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seth M. Posternak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannine M. Lall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Controller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">280 S. Mangum Street, Suite 210</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Durham, NC 27701-3675</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>G JBD LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Seth M. Posternak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seth M. Posternak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannine M. Lall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Controller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">280 S. Mangum Street, Suite 210</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Durham, NC 27701-3675</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>G ERP LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>G ERP LLC, acting through the Duke University Defined Benefit Plan Master Trust</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>By: DUMAC, Inc., as authorized agent of the trustee of the master trust</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Seth M. Posternak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seth M. Posternak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannine M. Lall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Controller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc. Authorized Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">280 S. Mangum Street, Suite 210</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Durham, NC 27701-3675</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">F-PRIME</FONT> CAPITAL PARTNERS HEALTHCARE FUND IV LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Advisors Fund IV LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Impresa Holdings LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Impresa Management LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mary Bevelock Pendergast</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mary Bevelock Pendergast</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1 Main Street, 13<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Cambridge, MA 02142</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FRANKLIN TEMPLETON INVESTMENT FUNDS &#150; FRANKLIN BIOTECHNOLOGY DISCOVERY FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Franklin Advisers, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Evan McCulloch</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Evan McCulloch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Franklin Templeton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: Wendy Lam</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">One Franklin Parkway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">San Mateo, CA 94403</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FRANKLIN STRATEGIC SERIES &#150; FRANKLIN BIOTECHNOLOGY DISCOVERY FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Franklin Advisers, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Evan McCulloch</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Evan McCulloch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Franklin Templeton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: Wendy Lam</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">One Franklin Parkway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">San Mateo, CA 94403</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>GILEAD SCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robin L. Washington</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robin L. Washington</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">EVP, Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">333 Lakeside Drive</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Foster City, CA 94404</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: Andrew Dickinson, SVP, Corporate Dev.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">With copy to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">333 Lakeside
Drive</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Foster City, CA 94404</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: General Counsel</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LEERINK HOLDINGS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy A. G. Gerhold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Timothy A. G. Gerhold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">One Federal Street, 37<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, MA 02110</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LEERINK PARTNERS <FONT STYLE="white-space:nowrap">CO-INVESTMENT</FONT> FUND, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey A. Leerink</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jeffrey A. Leerink</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">One Federal Street, 37<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, MA 02110</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: General Counsel</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LONGEVITY FUND 1 LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Longevity Funds LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura H. Deming</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Laura Deming</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">555 Bryant St, Palo Alto CA 94301</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LONGEVITY FUND 2 LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Longevity Funds 2 LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura H. Deming</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Laura Deming</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">555 Bryant St, Palo Alto CA 94301</TD></TR>
</TABLE></DIV> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Millman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Millman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">404 Beacon Street, #4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02115</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>OCV FUND I, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">OCV I GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Yung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Yung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">M Principal</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">4700 Wilshire Blvd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Los Angeles, CA 90010</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: Mark Yung</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>OSAGE UNIVERSITY PARTNERS II, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Osage University GP II, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William Harrington</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">William Harrington</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">50 Monument Road, Suite 201</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Bala Cynwyd, PA 19004</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PONTIFAX GLOBAL FOOD AND AGRICULTURE TECHNOLOGY FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Pontifax Global Food and Agriculture Technology GP LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Adrenalin Properties Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ben Belldegrun</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ben Belldegrun</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">2025 S. Westgate Avenue, First Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Los Angeles, CA 90025</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RA Capital Management, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">20 Park Plaza, Suite 1200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, MA 02116</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: Compliance</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>REV CAPITAL II, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric I. Richman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Eric I. Richman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">9740 Sorrel Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Potomac, MD 20854</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>RFS PARTNERS, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RFS&nbsp;&amp; Associates, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Raymond F. Schinazi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Raymond F. Schinazi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">1860 Montreal Road</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tucker, GA 30084</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: Bill Ollinger</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>RIDGEBACK CAPITAL INVESTMENTS LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ridgeback Capital Management LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher A. Nonas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Christopher A. Nonas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ridgeback Capital Management LP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">75
Ninth Ave., 5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">New York, NY 10011</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>TODDMAN PTY LTD (ATF MH JORGENSEN FAMILY TRUST)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Max Jorgensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Max Jorgensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Unit 1411/22 Refinery Parade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Farm, Queensland 4005</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australia</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Todd Jorgensen</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>VENBIO GLOBAL STRATEGIC FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">venBio Global Strategic GP, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">venBio Global Strategic GP, Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Adelman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Adelman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">venBio Partners LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1700 Owens
Street, Suite 595</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">San Francisco, CA 94158</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>VIVO PANDA FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vivo Panda, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mahendra Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mahendra Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Address:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">505 Hamilton Avenue, Suite 207</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Palo Alto, CA 94301</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>RECISION</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146;
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">200 Clarendon Street, 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,497,006</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agent Capital Fund I LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">810 Memorial Drive, Suite 107</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">399,202</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexandria Venture Investments, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">385 E. Colorado Blvd., Suite 299</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pasadena, CA 91101</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">598,803</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amgen Investments Ltd.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Amgen Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Amgen Center Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thousand Oaks, CA 91320</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Corporate Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amgen Ventures LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Amgen Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Amgen Center Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thousand Oaks, CA 91320</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Corporate Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">499,002</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Fundamental Opportunity Fund, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Life Science Fund</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">244,572</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baxalta US Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Baxter Parkway</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deerfield, IL 60015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brace Pharmaceuticals LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">155 Gibbs Street, Suite 406</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,996,008</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CF Ascent LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHI EF II LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Cowen Advisors, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue, 19th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention: Tim Anderson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">135,805</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">200 Clarendon Street, 5nd Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">223,653</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Private Healthcare Fund I, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">200 Clarendon Street, 5nd Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">739,720</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen Healthcare Investment II LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Cowen Advisors, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue, 19th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention: Tim Anderson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,860,203</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRMA SPV, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P.O. Box 309</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ugland House</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grand Cayman</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KY1-11004</FONT> Cayman Islands</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34,631</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund IV LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Fidelity Biosciences</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1 Main Street, 13th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Mary Bevelock Pendergast</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">873,253</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franklin Strategic Series &#150; Franklin Biotechnology Discovery Fund</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention: Wendy Lam</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Franklin Parkway</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">San Mateo, CA 94403</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">750,193</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franklin Templeton Investment Funds &#150; Franklin Biotechnology Discovery Fund</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention: Wendy Lam</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Franklin Parkway</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">San Mateo, CA 94403</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,245,815</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G ERP LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o DUMAC, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">280 South Mangum Street, Suite 210</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27701-3675</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">45,995</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">15,607</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G HSP LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o DUMAC, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">280 South Mangum Street, Suite 210</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27701-3675</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">61,493</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">20,866</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G JBD LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o DUMAC, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">280 South Mangum Street, Suite 210</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27701-3675</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">105,507</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">35,801</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G LTP LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o DUMAC, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">280 South Mangum Street, Suite 210</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27701-3675</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">287,005</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">97,387</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">333 Lakeside Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foster City, CA 94404</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Andrew Dickinson, SVP, Corporate Dev.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">With copy to:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">333 Lakeside Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foster City, CA 94404</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">998,004</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iron Horse Investments, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">149,451</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Holdings LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Federal Street, 37th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02110</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">149,701</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Federal Street, 37th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02110</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">149,701</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Longevity Fund 1 LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">555 Bryant Street, #517</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Laura Deming</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">49,900</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Longevity Fund 2 LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">555 Bryant Street, #517</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Laura Deming</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">49,900</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lookfar Investments, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">39,920</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meridian Growth Fund</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">624,759</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meridian Small Cap Growth Fund</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">558,855</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Millman</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">404 Beacon Street, #4</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02115</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">49,900</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCV Fund I, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4700 Wilshire Blvd.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Los Angeles, CA 90010</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Mark Yung</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,360,289</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50 Monument Road, Suite 201</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bala Cynwyd, PA 19004</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">399,202</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pontifax Global Food and Agriculture Technology Fund, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025 S. Westgate Avenue, First Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Los Angeles, CA 90025</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Ben Belldegrun</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,996,008</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o RA Capital Management, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20 Park Plaza, Suite 1200</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Compliance</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">399,202</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REV Capital II, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Erick I. Richman</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9740 Sorrel Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Potomac, MD 20854</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">99,800</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RFS Partners, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Bill Ollinger</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1860 Montreal Road</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tucker, GA 30084</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">119,761</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ridgeback Capital Investments LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Ridgeback Capital Management LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75 Ninth Avenue, 5th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10011</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">499,002</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">THB Iron Rose, LLC Life Science Portfolio</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">THB Iron Rose, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">149,451</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toddman Pty Ltd (ATF MH Jorgensen Family Trust)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unit 1411/22 Refinery Parade</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Farm, Queensland 4005</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australia</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Todd Jorgensen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">19,955</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">venBio Global Strategic Fund L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">venBio Partners LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1700 Owens Street, Suite 595</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94158</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Robert Adelman</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">998,004</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vivo Panda Fund, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vivo Capital</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">505 Hamilton Avenue, Suite 207</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">598,803</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tony Yao</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ArrowMark Partners</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,650,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,956,095</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF COMMON HOLDERS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek Jantz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,208,231</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">738,888</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Kane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,847,616</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">738,888</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,208,231</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">738,888</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
AGREEMENT made and entered into this 17<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of April (&#147;EFFECTIVE DATE&#148;), by and between DUKE UNIVERSITY, a nonprofit educational and research institution organized under the laws of
North Carolina (&#147;DUKE&#148;), having its principal office at Durham, North Carolina 27710, and Precision BioSciences, Inc., a Delaware corporation (&#147;PRECISION&#148;) with offices at 2211 Hillsborough Road, #4087, Durham, NC 27705. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, DUKE owns certain PATENT RIGHTS (as hereinafter defined) relating to Duke Office of Science and Technology File [***], entitled
&#147;[***]&#148; (&#147;INVENTION&#148;), and has the right to grant licenses under said PATENT RIGHTS; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, DUKE desires to
have the PATENT RIGHTS developed and commercialized to benefit the public and is willing to grant a license hereunder; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
LICENSEE desires to obtain licenses under PATENT RIGHTS and upon the terms and conditions hereinafter set forth; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
INVENTION was made with US government support and, notwithstanding anything to the contrary in this AGREEMENT, the US government has certain rights in the INVENTION under the 37 C.F.R. &#167; 401. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1 - DEFINITIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes
of this AGREEMENT, and solely for that purpose, the terms and phrases set forth below and elsewhere in this AGREEMENT in capital letters shall be defined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.01 &#147;AFFILIATE&#148; shall mean any corporation or <FONT STYLE="white-space:nowrap">non-corporate</FONT> entity which controls, is
controlled by or is under the common control with a party hereto. A corporation or a <FONT STYLE="white-space:nowrap">non-corporate</FONT> entity, as applicable, shall be regarded as in control of another corporation if it owns or directly or
indirectly controls at least fifty percent (50%) of the voting stock of the other corporation, or in the absence of ownership of at least fifty percent (50%) of the voting stock of a corporation, or in the case of a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> entity, if it possesses directly or indirectly, the power to direct or cause the direction of the management and policies of such corporation or
<FONT STYLE="white-space:nowrap">non-cooperate</FONT> entity, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.02 &#147;FIELD OF USE&#148; shall mean all applications of
the PATENT RIGHTS in all fields of use. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.03 &#147;INVENTOR&#148; means any individual who is identified as an inventor on one or more of
the PATENT RIGHTS (in accordance with applicable patent law) and whose contribution as an inventor to such PATENT RIGHTS was made as result of his/her association with DUKE such that the individual is obligated to assign his/her rights in such
PATENT RIGHTS to DUKE. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]
Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.04 &#147;PATENT RIGHTS&#148; shall mean the patents, patent applications listed in
APPENDIX A (such patent applications hereinafter collectively referred to as &#147;PATENT APPLICATION&#148;) and any patent hereafter issuing on any such PATENT APPLICATIONS, together with all divisions, continuations,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> (but only to the extent that the subject matter claimed in each such
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part</FONT></FONT> application is described in and enabled by the disclosure of said PATENT APPLICATIONS), <FONT STYLE="white-space:nowrap">re-examinations,</FONT>
reissues, substitutions, or extensions thereof and patents issuing therefrom in the United States and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. Notwithstanding the foregoing or anything else to the contrary in this AGREEMENT,
PATENT RIGHTS shall not include those patents and/or patent applications which, during the term of this AGREEMENT, cease to be PATENT RIGHTS pursuant to Section&nbsp;6.01. It is understood and agreed that subject matter that is PATENTABLY DISTINCT
(defined below) from the subject matter described within the PATENT APPLICATIONS is not within the scope of the PATENT RIGHTS even though that PATENTABLY DISTINCT subject matter may fall within the scope of one or more claims of said PATENT
APPLICATIONS. PATENTABLY DISTINCT improvements relating to the subject matter of PATENT APPLICATIONS shall not be considered PATENT RIGHTS. As used herein, &#147;PATENTABLY DISTINCT&#148; subject matter is subject matter that is novel and unobvious
over subject matter described within said PATENT APPLICATIONS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.05 &#147;PATENT RIGHTS EXPENSES&#148; shall mean all patent-related
expenses (including, but not limited to, filing fees, maintenance fees, and reasonable fees and expenses of patent counsel) incurred in connection with the PATENT RIGHTS, including but not limited to all reasonable expenses incurred in connection
with the assembly and copying of files for transfer to and from as the case may be LICENSEE&#146;s legal counsel in connection with LICENSEE&#146;s assuming responsibility for PATENT RIGHTS or transferring some of all of that responsibility back to
DUKE (as the case may be) pursuant to Section&nbsp;6. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.06 &#147;VALID CLAIM&#148; shall mean (i)&nbsp;an issued and unexpired claim
within the PATENT RIGHTS, that has not been permanently revoked or held invalid or unenforceable by a decision of a court or other governmental agency of competent jurisdiction and that has not been dedicated to the public or admitted to be invalid
or unenforceable through reissue, disclaimer or otherwise, or (ii)&nbsp;a claim of a pending patent application that was filed in good faith, has not been pending for more than [***] (including in parent applications), and which has not been
abandoned or finally disallowed without the possibility of appeal or refilling of such application contained in the PATENT RIGHTS in the country in which any such product or part thereof is made, used or sold. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.07 &#147;LICENSED PRODUCT&#148; shall mean any product or part thereof which: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) is covered in whole or in part by any VALID CLAIM contained in the PATENT RIGHTS in the country in which any such product or part thereof
is made, used or sold; and/or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) is manufactured by using a process which is covered in whole or in part by a VALID CLAIM contained in
the PATENT RIGHTS in the country in which such product or part thereof is used or sold; or </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) in its use, practices a VALID CLAIM contained in the PATENT RIGHTS in the country in
which any such product or part thereof is made, used, or sold. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.08 &#147;LICENSED PROCESS&#148; shall mean any process which is covered
in whole or in part by any VALID CLAIM contained in the PATENT RIGHTS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.09 &#147;LICENSED PRODUCTS&#148; shall mean the following terms,
collectively: LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES, and a LICENSED PROCESS and LICENSED SERVICE shall be included within such term notwithstanding such process or service is not literally a &#147;product&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 &#147;LICENSED SERVICE&#148; shall mean any service provided by LICENSEE (and/or SUBLICENSEES, as the case may be) to a THIRD PARTY that
is covered in whole or in part by any VALID CLAIM contained in the PATENT RIGHTS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 &#147;MATERIALS&#148; shall mean samples of the
materials covered under Patent Rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12 &#147;NET SALES&#148; shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) in the case of LICENSED PRODUCTS, LICENSEE&#146;S (and/or those of its AFFILIATES, as the case may be) revenues received from sale and/or
lease of LICENSED PRODUCTS; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) in the case of LICENSED PROCESSES, LICENSEE&#146;S (and/or those of its AFFILIATES, as the case may
be) revenues received from sale and/or lease of LICENSED PROCESSES; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***]: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***]<U> </U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***]<U> </U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***]<U> </U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13
&#147;SUBLICENSE&#148; and &#147;SUBLICENSE AGREEMENT&#148; shall mean, and include without limitation, any relationship/agreement in which a THIRD PARTY gains any rights&#151;temporary or otherwise&#151;to any of the rights granted by DUKE to
LICENSEE under this AGREEMENT (including, but not limited to, LICENSEE&#146;s licensee(s) and/or sublicensee(s), hereinafter, such THIRD PARTIES referred as &#147;SUBLICENSEES&#148;, but not including LICENSEE&#146;s AFFILIATES), including, but not
limited to those granted via options, rights of first refusal, material transfer agreements, sublicenses (implied or expressed), and the like. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 &#147;SUBLICENSE REVENUES&#148; shall mean any and all upfront fees, license fees, royalties, option fees, milestone payments, and other
amounts payable to LICENSEE (and/or its AFFILIATES, as the case may be) under a SUBLICENSE to any of the licenses granted by DUKE to LICENSEE under this AGREEMENT, [***] </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15 &#147;TERRITORY&#148; shall mean the world. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16 &#147;THIRD PARTY&#148; means any individual or other entity other than DUKE and/or LICENSEE or its AFFILIATES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17 Where appropriate, words denoting a singular number only shall include the plural and vice versa. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18 Certain other defined terms shall have the meanings given them elsewhere in this AGREEMENT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2 - LICENSE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.01 DUKE hereby
grants to LICENSEE and its AFFILIATES and LICENSEE and its AFFILIATES hereby accept from DUKE, subject to the terms and conditions of this AGREEMENT, the exclusive right and sublicenseable license for the FIELD OF USE in the TERRITORY to practice
under the PATENT RIGHTS (a)&nbsp;to develop, make, have made, import, use, lease, offer for sale, sell, and distribute LICENSED PRODUCTS for the FIELD OF USE in the TERRITORY, (b)&nbsp;to develop, make, have made, import, use, practice, lease, offer
for sale, sell, and distribute LICENSED PROCESSES in/for the FIELD OF USE in the TERRITORY, until the end of the term for which the PATENT RIGHTS are granted unless this AGREEMENT shall be sooner terminated according to the terms hereinafter
provided. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.02 Notwithstanding anything to the contrary in this AGREEMENT, it is understood and agreed that DUKE encourages LICENSEE
(and/or its AFFILLIATES and/or SUBLICENSEE(S), as the case may be) to secure rights under any THIRD PARTY intellectual property rights required to practice the PATENT RIGHTS and/or to exercise any and all of the rights practiced or exercised by
LICENSEE or such AFFILIATES and/or SUBLICENSEE(S) (as the case may be) and that DUKE shall have no responsibility in securing any such rights. Further, if LICENSEE (and/or any of its AFFILIATES) secures any such rights to THIRD PARTY intellectual
property rights in order to practice the technology and/or to exercise any or all the rights granted herein, then LICENSEE (and/or such AFFILIATES and/or SUBLICENSEE, as the case may be) shall use its commercially reasonable efforts to secure from
any such THIRD PARTY a covenant not to sue DUKE, or any of its faculty, students, employees or agents, for any research and development efforts conducted at DUKE that resulted in the creation of any of its inventions and/or any licensing thereof,
and any intellectual property or other rights arising therefrom, including, but not limited to, PATENT RIGHTS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.03 All SUBLICENSES shall
be subject to the terms and conditions of this AGREEMENT, shall be no less favorable to or protective of DUKE than this AGREEMENT except as expressly stated in this AGREEMENT, and shall not be further sublicenseable without the express written
approval of DUKE, such approval not to be unreasonably withheld. DUKE shall be a third party beneficiary of each SUBLICENSE. In the event of any termination of this Agreement, all SUBLICENSES shall survive such termination provided that the
SUBLICENSEES are in compliance with the terms and conditions of the SUBLICENSE and the SUBLICENSEES comply with all terms of this Agreement related to such SUBLICENSE including the payment of all amounts that would be due DUKE under this Agreement
if it had not terminated. In such case, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
DUKE shall not be obligated to perform any of the obligations of LICENSEE under such SUBLICENSE. However, DUKE shall have all of the rights afforded LICENSEE under any such SUBLICENSE including
but not limited to enforcement of the SUBLICENSE, collection of payments, receipt of reports indemnification by SUBLICENSEE, termination for breach by SUBLICENSEE etc. LICENSEE will ensure that said rights to DUKE are included in any executed
SUBLICENSE. LICENSEE shall use commercially reasonable efforts to enforce the terms of the SUBLICENSE agreements. LICENSEE further agrees to provide DUKE with a copy of all SUBLICENSES [***] prior to execution of each subject SUBLICENSE with the
ability to review and comment, such comments to be reasonably considered by LICENSEE. LICENSEE will provide DUKE with an executed copy of SUBLICENSE within [***] of the effective date of such SUBLICENSE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.04 In the event that LICENSEE shall receive <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration for any SUBLICENSE, DUKE shall
nonetheless be entitled to its applicable portion of sublicense fees in cash with respect to such <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration. In the event that DUKE and LICENSEE cannot agree on the value of such <FONT
STYLE="white-space:nowrap">on-cash</FONT> consideration, such value shall be determined by an independent THIRD PARTY selected in good faith by LICENSEE and DUKE. If LICENSEE and DUKE cannot mutually agree upon an independent THIRD PARTY within
thirty (30)&nbsp;business days, then DUKE and LICENSEE shall each select an independent THIRD PARTY within thirty (30)&nbsp;business days, and those two independent third parties shall in good faith select a mutually agreeable THIRD PARTY within
thirty (30)&nbsp;days thereafter. The expense of such independent THIRD PARTY being borne equally by DUKE and LICENSEE. In the event on a dispute concerning the valuation of the THIRD PARTY consideration, no payment of the fees with respect thereto
shall be made until the dispute is resolved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.06 Notwithstanding anything to the contrary in this AGREEMENT, DUKE shall have the right to practice under the PATENT RIGHTS for its own
internal, <FONT STYLE="white-space:nowrap">non-commercial,</FONT> educational, research and clinical purposes without restriction and without payment of royalties and other fees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.07 The licenses granted under this AGREEMENT will not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise
as to any data, technology, patents, patent applications or other property rights held by DUKE (solely or jointly) not specifically set forth herein, regardless of whether such property rights are dominant or subordinate to any of the PATENT RIGHTS
DUKE represents that it is the sole owner of the Patent Rights, that it has the authority to grant the licenses granted hereunder, and that it has not knowingly taken any actions that would adversely affect the validity of the PATENT RIGHTS. DUKE
does not warrant the validity or enforcement of the PATENT RIGHTS licensed hereunder and makes no representations whatsoever with regard to the scope of the PATENT RIGHTS or that the practice of the PATENT RIGHTS does not infringe the rights of any
third party. Notwithstanding anything to the contrary in this Section&nbsp;2, LICENSEE shall have the right to continue to use the lab notebooks and technical data related to the PATENT RIGHTS developed by employees or agents of LICENSEE while
working at DUKE, provided however, that DUKE employees and students shall not be considered agents of LICENSEE. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.08 DUKE hereby discloses to LICENSEE and LICENSEE acknowledges that the research leading
to the PATENT RIGHTS was funded in part by the U.S. Government, and the parties agree that, notwithstanding any use of descriptive terms such as &#147;exclusive&#148; herein this AGREEMENT, the U.S. Government has certain rights in the PATENT RIGHTS
as set forth in 37 CFR 401. LICENSEE agrees to comply with all obligations resulting from such government rights, including, but not limited to, the requirement that any products sold in the United States based upon such technology be substantially
manufactured in the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.09 The license granted hereunder shall be subject to Public Law
<FONT STYLE="white-space:nowrap">96-517</FONT> and Public Law <FONT STYLE="white-space:nowrap">98-260.</FONT> Any right granted in this AGREEMENT which is greater than that permitted under Public Law <FONT STYLE="white-space:nowrap">96-517</FONT>
and Public Law <FONT STYLE="white-space:nowrap">98-260</FONT> shall be modified as may be required to conform to the provisions of those laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE
3 - LICENSE FEE, ROYALTIES AND OTHER FEES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.01 In consideration of the rights granted to LICENSEE pursuant to this AGREEMENT and
subject to the terms and conditions of this AGREEMENT, LICENSEE agrees to pay or otherwise compensate DUKE as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) LICENSEE shall pay to DUKE [***], which shall be due and payable within [***] of the EFFECTIVE DATE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Royalty on NET SALES</U>. At the times and in the manner set forth hereinafter, LICENSEE and it AFFILIATES shall pay to DUKE a [***]
royalty on NET SALES of LICENSED PRODUCTS or LICENSED PROCESSES, by LICENSEE, and/or its AFFILIATES. Such royalty shall be at the rate of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) [***] of NET SALES for LICENSED PRODUCTS; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) [***] of NET SALES for LICENSED PROCESSES; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:15%; font-size:10pt; font-family:Times New Roman">provided that where in order to manufacture, sell, use, practice or otherwise dispose of LICENSED PRODUCTS or LICENSED PROCESSES it is [***]
for LICENSEE to obtain a license under any patent rights from a THIRD PARTY (including in settlement of a claim contemplated by Article 7.01) and by reason of an agreement with such THIRD PARTY a royalty on LICENSEE NET SALES (or similarly defined
amount) is payable to such THIRD PARTY the royalties shall be reduced as follows. The royalty payable pursuant to this Article 3.01(c) shall be reduced by [***] of the amounts paid to third parties provided that under no circumstances will the
royalty payable to DUKE on NET SALES of LICENSED PRODUCTS or LICENSED PROCESSES reduce to less than [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) MINIMUM ROYALTY. [***] </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>SUBLICENSE FEE</U>. LICENSEE shall pay to DUKE a sublicense fee (&#147;SUBLICENSE FEE&#148;) which is equal to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) [***] of all SUBLICENSE REVENUES from royalties; plus, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) [***] of all SUBLICENSE REVENUES from <FONT STYLE="white-space:nowrap">non-royalty</FONT> sublicense revenue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SUBLICENSE FEES shall be creditable against the MINIMUM ROYALTIES on NET SALES in Section 3.01(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>MILESTONE PAYMENTS</U>. LICENSEE shall pay to DUKE, MILESTONE PAYMENTS as set forth in APPENDIX C. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.02 Notwithstanding reports, correspondence or other communications from LICENSEE, it is understood that DUKE shall, in accordance with its
policies and procedures, apply any amounts received from LICENSEE under the terms of this AGREEMENT as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Application of amounts
received under (a)&nbsp;above shall in no respect alter the aggregate amount due to DUKE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.03 Notwithstanding anything to the contrary in
this AGREEMENT, all payments due hereunder shall be paid in full, without deduction of taxes or other fees which may be imposed by any government and which shall be paid by LICENSEE on behalf of LICENSEE, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.04 LICENSEE agrees to achieve the milestones set forth in APPENDIX B. If these milestones are not met, DUKE may, in its sole discretion after
providing LICENSEE a thirty (30)&nbsp;day notification during which period LICENSEE fails to achieve the applicable milestone(s), terminate the exclusive licenses granted hereunder. In the event of any such termination, all SUBLICENSES shall survive
such termination provided that the SUBLICENSEES are in compliance with the terms and conditions of the SUBLICENSE and the SUBLICENSEES comply with all terms of this Agreement related to such SUBLICENSE including the payment of all amounts that would
be due DUKE under this Agreement if it had not terminated. In such case, DUKE shall not be obligated to perform any of the obligations of LICENSEE under such SUBLICENSE subject to the same terms and conditions as described in section 2.03. For any
rights that LICENSEE may be permitted to retain, LICENSEE will still be responsible to DUKE for any royalty payments and payments with respect to <FONT STYLE="white-space:nowrap">non-royalty</FONT> income. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.05 All payments due from LICENSEE pursuant to this AGREEMENT shall be due and payable in
accordance with the terms and conditions of this AGREEMENT, and if a payment due pursuant to this AGREEMENT is not paid within [***] of the payment due date, then a late payment fee equal to [***] shall be added to the payment due; [***]. The
payment of such [***] late fees shall not foreclose DUKE from exercising any other rights it may have as a consequence of the lateness of any payment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.06 No multiple royalties on NET SALES shall be payable to DUKE on a single LICENSED PRODUCT or LICENSED PROCESS, because its manufacture,
use, lease, sale or practice are or shall be covered by more than one of the PATENT RIGHTS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.07 All payments due to DUKE under this
AGREEMENT shall be paid in United States Dollars in Durham, North Carolina, or at such place as DUKE may reasonably designate consistent with the laws and regulations controlling in any foreign country. If any currency conversion shall be required
in connection with such payments due hereunder, such conversion shall be made by using the exchange rate prevailing at Wachovia Bank (N.A.) (or its successor, as the case may be) on the last business day of the reporting period to which such
payments relate. If payments are made by wire, electronic or other transfer form for which a fee is charged (&#147;PAYMENT TRANSFER FEES&#148;), LICENSEE shall be responsible for the full amount of such fees and shall promptly reimburse DUKE for
DUKE&#146;s payment of such reasonable PAYMENT TRANSFER FEES within thirty (30)&nbsp;days of invoice of the same from DUKE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.08 All
payments due to DUKE under this AGREEMENT shall cite &#147;[***]&#148;, and shall be made payable to &#147;Duke University.&#148; Such payments, as well as reports due to DUKE shall be sent to DUKE at the following address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>For delivery via the U.S. Postal Service: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Duke University Office of Science and Technology </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Attention: Financial Administrator </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Box 90083 Duke University </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Durham, NC 27708 USA </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>For
delivery via nationally/internationally recognized courier: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Duke University Office of Science and Technology </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Attention: Financial Administrator </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2020 West Main Street, Suite 10 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Durham, NC 27705 USA </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>For
payment via wire transfer: </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>BANK:</B>
<B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>ABA#</B>
<B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>SWIFT CODE: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>BENEFICIARY: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>ACCOUNT NO.: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>ATTENTION: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4 - DUE DILIGENCE REQUIREMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.01 LICENSEE shall use commercially reasonable efforts to bring LICENSED PRODUCTS and/or LICENSED PROCESSES to market through a thorough,
vigorous and diligent program for exploitation of the PATENT RIGHTS, and to continue active, diligent marketing efforts for LICENSED PRODUCTS and/or LICENSED PROCESSES throughout the term of this AGREEMENT. The development and commercialization
schedule set forth on attached APPENDIX B (hereinafter &#147;COMMERCIALIZATION SCHEDULE&#148;) is hereby agreed upon as a reasonable one to be followed. Variations from the schedule set forth in the COMMERCIALIZATION SCHEDULE must be expressly
approved by DUKE in writing, such approval not to be unreasonably withheld. If any of the targets set forth in the COMMERCIALIZATION SCHEDULE are not reached within the stated time periods set out in APPENDIX B, or within those amended periods of
time approved in writing by Duke, then it will be considered a material breach by the LICENSEE, and will be handled according to Section&nbsp;10 herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.02 During the term of this AGREEMENT, LICENSEE will submit [***] progress reports to DUKE as set forth in Section&nbsp;5. DUKE shall have the
right to request [***] to discuss such information with representatives of LICENSEE at mutually acceptable times and places. It is agreed that should any of DUKE&#146;s personnel be required by LICENSEE to consult with LICENSEE outside of Durham,
North Carolina, LICENSEE will reimburse reasonable travel and living expenses incident thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5 - REPORTS AND RECORDS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.01 LICENSEE shall keep full, true and accurate books of accounts and other records containing all particulars which may be necessary to
properly ascertain and verify the amounts payable to DUKE hereunder and shall require its AFFILIATES and/or SUBLICENSEES, as the case may be, to do the same. Said books of account shall be kept at LICENSEE&#146;s (and/or AFFILIATE&#146;s and/or
SUBLICENSEES&#146;) principal place of business or the principal place of business of the appropriate division of LICENSEE (and/or AFFILIATE&#146;s and/or SUBLICENSEE) to which this AGREEMENT relates. Said books of LICENSEE and its AFFILIATES and
the supporting data shall be open at all reasonable times for [***] following the end of the calendar year to which they pertain, to the inspection of an independent certified public accountant engaged by DUKE for the purpose of verifying the
LICENSEE&#146;s and/or AFFILIATE&#146;S royalty statement or compliance in other respects with this AGREEMENT. [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.02 LICENSEE shall
report the status of development of each LICENSED PRODUCT and LICENSED PROCESS [***] to DUKE by [***]. Such report shall provide information at least sufficient to meet DUKE&#146;s government reporting requirements and additionally shall include
descriptions of LICENSEE&#146;s (and/or AFFILIATE&#146;s and/or SUBLICENSEES&#146;s plans and commercially reasonable estimated timeframes for testing, development, governmental approvals and marketing/sale of each LICENSED PRODUCT or LICENSED
PROCESS. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment
requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.03 After the first commercial sale of a LICENSED PRODUCT or LICENSED PROCESS and in
addition to the reports required, LICENSEE shall render to DUKE prior to [***] a written account of the NET SALES of LICENSED PRODUCTS and LICENSED PROCESSES, subject to royalty under this AGREEMENT and made during the prior [***] period ending
[***], and shall simultaneously pay to DUKE the royalties due on such NET SALES in United States dollars. Reports tendered shall include the calculation of royalties by product by country in substantially the format provided in APPENDIX D hereto.
Further, LICENSEE shall render to DUKE prior to [***] a written account of the portion of SUBLICENSE REVENUES due to DUKE for the prior [***] period [***] and shall simultaneously pay to DUKE such amounts due in United States dollars. MINIMUM
ROYALTIES which are due DUKE for any calendar year, shall be paid by LICENSEE along with the written report due on [***]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6 - PATENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.01 Patent Prosecution </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
LICENSEE shall, apply for, prosecute, and maintain the PATENT RIGHTS during the term of this AGREEMENT. LICENSEE will keep DUKE advised as to all developments with respect to any PATENT APPLICATIONS, and/or applicable continuation, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part</FONT></FONT> and reissue application(s) promptly. DUKE will have (i)&nbsp;the right to review LICENSEE&#146;s pending PATENT APPLICATIONS that are within the PATENT
RIGHTS, and to make recommendations regarding the prosecution of such PATENT APPLICATIONS, (ii)&nbsp;the right to receive such applications and other documentations at such time as to allow a reasonable period for review thereof prior to any
applicable deadline for filing or responding, and (iii)&nbsp;the right to request amendments of any such patent application to include claims or arguments as may be appropriate for obtaining a patent claiming commercially relevant inventions. Upon
request by DUKE and/or its agents, LICENSEE shall promptly inform DUKE in writing which <FONT STYLE="white-space:nowrap">non-US</FONT> countries, if any, in which LICENSEE will seek patent protection. DUKE may elect to seek patent protection in
countries not so designated by LICENSEE, in which case DUKE shall notify LICENSEE in writing of such election, and from the date of such filing of such PATENT APPLICATIONS by DUKE shall not be considered PATENT RIGHTS (and/or PATENT APPLICATIONS)
and LICENSEE shall be deemed to have forfeited all rights under this AGREEMENT to such PATENT APPLICATIONS and resulting patents. (APPENDIX A shall be deemed to be so amended.) It is understood and agreed that all final decisions with respect to
prosecution of PATENT RIGHTS are reserved to DUKE except as expressly stated in this AGREEMENT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.02 Patent Costs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If LICENSEE
decides to discontinue the prosecution or maintenance of a subject PATENT APPLICATION or patent falling within the scope of PATENT RIGHTS, LICENSEE will give DUKE timely written notice at least [***] in advance of the effective date of
LICENSEE&#146;s decision and DUKE will be free to continue prosecution or maintain any such application/patent, and to maintain any protection issuing thereon in the U.S. and in any foreign country at DUKE&#146;s sole expense. In such instances,
from the date of DUKE&#146;s receipt of such </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written notice from LICENSEE, such patent and/or PATENT APPLICATION shall no longer be considered to fall within the definition of PATENT RIGHTS (APPENDIX A shall be deemed to be so amended) and
LICENSEE shall forfeit all rights under this AGREEMENT to the subject issued patent(s) and/or subject PATENT APPLICATION and patent(s) arising from such PATENT APPLICATION. Accordingly, DUKE shall be free, at its sole discretion to license said
patent(s) and patent application(s) to any THIRD PARTY or otherwise dispose of such patent(s) and patent applications(s) as it deems appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.03 It is understood that ownership of such PATENT RIGHTS shall not be affected by LICENSEE&#146;s assuming such responsibility for
prosecution and maintenance of such PATENT RIGHTS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.04 LICENSEE agrees to mark the LICENSED PRODUCTS and LICENSED PROCESS, and/or their
containers, labels, and/or other packaging, in such a manner as to conform to the patent laws and practices of the country of manufacture or sale, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7 - INFRINGEMENT OF THIRD-PARTY RIGHTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.01 In the event that DUKE or LICENSEE is charged with infringement of a patent by a THIRD PARTY or is made a party in a civil action as a
result of the activity of LICENSEE and/or its AFFILIATE and/or a SUBLICENSEE (and not from the activity of DUKE or its AFFILIATES other than the granting of this license to LICENSEE) as a result (directly or indirectly) under the licenses granted
hereunder to LICENSEE, LICENSEE: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) [***]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) [***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.02 DUKE will give LICENSEE reasonable assistance, [***] in the defense of any such infringement charge or lawsuit, as may be reasonably
required. [***]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8 - INFRINGEMENT OF PATENT RIGHTS BY THIRD PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.01 Each party to this AGREEMENT is obligated to inform the other promptly in writing of any alleged infringement of which it becomes aware
and of any available evidence of infringement by a THIRD PARTY of any patents within the PATENT RIGHTS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.02 If during the term of this
AGREEMENT, LICENSEE becomes aware of any alleged infringement by a THIRD PARTY, LICENSEE shall have the right, but not the obligation, to either: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) settle the infringement suit by sublicensing the alleged infringer or by other means; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) prosecute at its own expense any infringement of the PATENT RIGHTS. In the event LICENSEE prosecutes such infringement of PATENT RIGHTS,
LICENSEE may, for such purposes, request to use the name of DUKE as party plaintiff. DUKE, at its sole discretion, may agree to become a party plaintiff, and all costs associated therewith shall be borne by LICENSEE. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.03 In the event that LICENSEE undertakes the enforcement and/or defense of the PATENT
RIGHTS by litigation, including any declaratory judgment action, [***]. Any recovery of damages by LICENSEE as a result of such action shall be applied [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.04 In the event LICENSEE does not undertake action to prevent the infringing activity within [***] of having been made aware and notified
thereof, DUKE shall have the right, but not the obligation, to prosecute at its own expense any such infringements of the PATENT RIGHTS and, in furtherance of such right, DUKE may use the name of LICENSEE as a party plaintiff in any such suit
without expense to LICENSEE. [***]. Any recovery of damages by DUKE for any infringement shall be applied [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.05 In any infringement
suit instituted by either party to enforce the PATENT RIGHTS pursuant to this AGREEMENT, the other party hereto shall, at the request and expense of the party initiating such suit, reasonably cooperate in all respects and, to the extent reasonably
possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.06 LICENSEE has the sole right in accordance with the terms and conditions herein to sublicense any LICENSED PRODUCT or LICENSED PROCESS to
an alleged infringer under the PATENT RIGHTS in the TERRITORY in order to avoid infringement in the future. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.07 Any of the foregoing
notwithstanding, if at any time during the term of this AGREEMENT any of the PATENT RIGHTS are held invalid or unenforceable in a decision which is not appealable or is not appealed within the time allowed, LICENSEE shall have no further obligations
to DUKE with respect to its future use or sale of any LICENSED PRODUCT and LICENSED PROCESS covered solely by such PATENT RIGHTS, including the obligation of paying royalties. For avoidance of doubt it is understood and agreed that in such event,
LICENSEE shall not have any damage claim or any claim for refund or reimbursement against DUKE for any amounts previously paid to DUKE under this AGREEMENT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 9 - GOVERNMENT CLEARANCE, PUBLICATION, EXPORT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.01 Insofar as such clearance is required, LICENSEE agrees to use its commercially reasonable efforts to have the LICENSED PRODUCTS and/or
LICENSED PROCESSES cleared for marketing in those countries in which LICENSEE intends to sell LICENSED PRODUCTS and/or LICENSED PROCESSES, by the responsible government agencies requiring such clearance. To accomplish said clearances at the earliest
possible date, LICENSEE agrees to file or have filed, according to the usual practice of LICENSEE, any necessary data with said government agencies as quickly as commercially reasonable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.02 It is understood and agreed that the right of publication/presentation of the inventions described in the PATENT RIGHTS shall reside in
the INVENTORS, faculty, staff, and students of DUKE. LICENSEE shall also have the right to publish and/or <FONT STYLE="white-space:nowrap">co-author</FONT> any publication/presentation on the inventions described in PATENT RIGHTS in accordance with
academic custom. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential
treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.03 This AGREEMENT is subject to all of the United States laws and regulations controlling
the export of technical data, computer software, laboratory prototypes and other commodities and technology. It is understood that DUKE is subject to United States laws and regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control Act, as amended and the Export Administration Act of 1979), and that its obligations hereunder are contingent on compliance with applicable United States export laws and
regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by LICENSEE that LICENSEE shall not export data or commodities to certain
foreign countries without prior approval of such agency. DUKE neither represents that a license shall not be required nor that, if required, it shall be issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10 - DURATION AND TERMINATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.01 This AGREEMENT shall become effective upon the EFFECTIVE DATE, and unless sooner terminated in accordance with any of the provisions
herein, shall remain in full force and effect for the life of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> of the patents included in the PATENT RIGHTS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.02 Subject to the provisions of this AGREEMENT, LICENSEE will have caused a material breach in accordance with this Section&nbsp;10 if
LICENSEE fails to meet any of the development/commercialization milestones set forth in APPENDIX B unless DUKE expressly approves such variations in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.03 LICENSEE may terminate this AGREEMENT by giving DUKE written notice at least [***] prior to the effective date of such termination. It is
understood that LICENSEE shall remain responsible for the timely payment of all amounts due DUKE under this AGREEMENT through the effective date of the termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.04 Either party may immediately terminate this AGREEMENT for fraud, willful misconduct, or illegal conduct of the other party, in all such
cases with respect to the subject matter of this AGREEMENT, upon written notice of same to that other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.05 If either party fails
to fulfill any of its material obligations under this AGREEMENT including, but not limited to, lack of payment or failure to meet the provisions of ARTICLE 3, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party may terminate this
AGREEMENT, upon written notice to the breaching party, as provided below. Such notice must contain a full description of the event or occurrence constituting a breach of the AGREEMENT. The party receiving notice of the breach will have the
opportunity to cure that breach within [***] of receipt of notice. If the breach is not cured within that time, the termination will be effective as of [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.06 If during the term of this AGREEMENT, LICENSEE shall become insolvent whether by the voluntary act of LICENSEE or otherwise, or if
LICENSEE shall cease to exist as an active business, this AGREEMENT shall immediately terminate. In the event the LICENSEE shall become bankrupt or if the business of LICENSEE shall be placed in the hands of a receiver or trustee, this LICENSE shall
terminate unless otherwise prohibited by law or judicial action. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.07 Notwithstanding anything to the contrary in this AGREEMENT, neither expiration nor any
termination of this AGREEMENT shall remove any financial obligations to DUKE which LICENSEE incurred under this AGREEMENT prior to and as of the effective date of any expiration or termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.08 On or before the effective date of any early termination of this AGREEMENT pursuant to Sections 10.02 &#150; 10.06, LICENSEE shall cease
the manufacture, use, practice, lease, and sale, offering, distribution, and other commercialization of LICENSED PRODUCTS and LICENSED PROCESSES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.09 Within [***] of any early termination of this AGREEMENT, LICENSEE shall destroy all LICENSED PRODUCTS for which a royalty has not been
paid to DUKE in a safe and legal manner. LICENSEE shall also provide DUKE with a written statement signed by an authorized representative of LICENSEE certifying the destruction of all such LICENSED PRODUCTS for which a royalty has not been paid to
DUKE in a safe and legal manner. Further, LICENSEE shall certify that they have destroyed all confidential information provided by DUKE under Article 11 or return all copies of such information to DUKE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 11 - CONFIDENTIALITY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.01 DUKE
and LICENSEE each agree to treat any confidential information disclosed to it by the other party under this AGREEMENT with reasonable care and to avoid disclosure of such information to any other person, firm or corporation, except AFFILIATES bound
by the obligations of confidentiality and restricted use set forth in this Article 11, and either party shall be liable for unauthorized disclosure or failure to exercise such reasonable care. Further, the receiving party will not use the disclosing
party&#146;s confidential information other than for the benefit of the parties hereto and relating to this AGREEMENT. These obligations of <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and restricted use shall remain in effect for each
subject disclosure of confidential information for a period of time of [***] from such disclosure, however, neither party shall have an obligation, with respect to confidential information disclosed to it, or any part thereof, which: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) is already known to the receiving party at the time of the disclosure; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) becomes publicly known without the wrongful act or breach of this AGREEMENT by the receiving party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) is rightfully received by the receiving party from a THIRD PARTY on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) is subsequently and independently developed by employees of the receiving party who had no knowledge of the information, as verified by
written records; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) is approved for release by prior written authorization of the party disclosing the information; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) is disclosed pursuant to any judicial or government request, requirement or order, provided that the party so disclosing takes reasonable
steps to provide the other party sufficient prior notice in order to contest such request, requirement or order and provided that such disclosed confidential information otherwise remains subject to the obligations of confidentiality set forth in
this Article 11. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential
treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.02 DUKE and LICENSEE agree that any information to be treated as confidential information
under this Article 11 must be disclosed in writing or other tangible medium and must be clearly marked &#147;CONFIDENTIAL&#148;. Confidential information disclosed orally must be summarized and reduced to writing or other tangible medium and
communicated to the other party within [***] of such disclosure, and the other party agrees that such disclosed information shall be deemed confidential. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.03 Notwithstanding the foregoing, LICENSEE shall have the right to use and disclose any confidential information related to the PATENT
RIGHTS (a)&nbsp;to the extent necessary to obtain regulatory approval for, or to sell, a LICENSED PRODUCT or LICENSED PROCESS and (b)&nbsp;to investors, prospective investors, employees, consultants and agents with a need to know, collaborators,
prospective collaborators and other THIRD PARTIES in the chain of manufacturing and distribution provided that LICENSEE obtains from such parties written confidentiality agreements, the provisions of which are at least as restrictive and protective
of DUKE&#146;s confidential information as those provided in this Article 11. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.04 Notwithstanding anything to the contrary in this
AGREEMENT, all information relating to filing, prosecution, maintenance, defense, infringement, and the like regarding the PATENT RIGHTS (no matter how disclosed) shall be considered the confidential information of DUKE until published by the
applicable patent office and subject to the obligations of restricted use and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> set forth in this Article 11. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 12 - NOTICES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.01 It shall be a
sufficient giving of any notice, request, report, statement, disclosure or other communication hereunder if the party giving the same shall </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) hand deliver such communication; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) mail such a communication, postage prepaid, first class, certified mail; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) send such communication, shipping prepaid by national/international courier service </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">to the party to receive such communication at the address given below or as otherwise given as provided in this ARTICLE 12, in the case of
payments and/or reports due in accordance with this AGREEMENT or such other address as may hereafter be designated by notice in writing by the appertaining party. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DUKE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">LICENSEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>For delivery via the U.S. Postal Service</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Science and Technology</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke
University</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agreement Coordinator</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Box 90083</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27708 USA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences, Inc.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Matthew Kane</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2211 Hillsborough Rd #4087</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27705 USA</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For delivery via nationally/internationally</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>recognized courier</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office of Science and Technology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(same as above)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke University</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agreement Coordinator</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2020 West Main Street, Suite 10</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27705 USA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">cc:&#8194;&#8201;&#8202;<I>(if of a legal nature)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Office of University Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WilmerHale</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Duke University</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: Michael J. Bevilacqua</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2400 Pratt Street, Suite 4000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">60 State Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Durham, North Carolina 27710</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02109 USA</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.02 The date of giving any such notice, request, report, statement, disclosure or other communications, and
the date of making any payment hereunder required (provided such payment is received), shall be the actual date of receipt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 13 - ASSIGNMENT
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.01 This AGREEMENT shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto.
However, LICENSEE may not assign its rights in this AGREEMENT without approval by DUKE, such approval not to be unreasonably withheld. Notwithstanding the foregoing, a change of control transaction, merger, consolidation or sale of substantially all
of the business of LICENSEE related to this Agreement shall not be deemed an assignment for purposes of this clause and no consent of DUKE shall be required for such transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 14 - INDEMNITY, INSURANCE, REPRESENTATIONS, STATUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.01 DUKE, and its trustees, officers, employees, faculty members, students, and agents (collectively, &#147;DUKE Indemnitees&#148;) will be
indemnified, defended by counsel reasonably acceptable to DUKE, and held harmless by LICENSEE and AFFILIATES and SUBLICENSEES, as the case may be, from and against any claim, liability, cost, expense, damage, deficiency, loss or obligation, of any
kind or nature (including, without limitation, reasonable attorneys&#146; fees and other costs and expenses of defense) (collectively, &#147;CLAIMS&#148;) based upon, arising out of, or otherwise relating to this AGREEMENT including, but not limited
to, (i)&nbsp;any action relating to product liability, and (ii)&nbsp;any CLAIM that a LICENSED PRODUCT and/or LICENSED PROCESS and/or practice of any of the PATENT RIGHTS infringes the intellectual property of a THIRD PARTY. However, the foregoing
indemnity shall not apply to CLAIMS to the extent that they are (x)&nbsp;caused by the gross negligence of DUKE, DUKE employees, DUKE faculty members, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
students, and/or agents acting solely within the performance of their respective responsibilities at DUKE, (y)&nbsp;caused by a material breach of this AGREEMENT by DUKE, and/or (z)&nbsp;pertain
solely to claims that the activities of DUKE employees, faculty members, students, and/or agents in their performance of their respective responsibilities at DUKE (excluding any research or other responsibilities such individuals may have as a
result of an association each may have with LICENSEE and/or AFFILIATES and/or SUBLICENSEES) infringe the intellectual property of a THIRD PARTY. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.02 DUKE MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OF ANY KIND. IN PARTICULAR, THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THE USE OF THE PATENT RIGHTS DOES NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS. IN ADDITION, NOTHING IN THIS AGREEMENT SHALL BE DEEMED TO BE A REPRESENTATION OR WARRANTY BY
DUKE OF THE VALIDITY OF ANY OF THE PATENT RIGHTS OR THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE, OF THE PATENT RIGHTS DUKE SHALL HAVE NO OBLIGATION, EXPRESS OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR OTHERWISE ASSUME
RESPONSIBILITY FOR THE PRODUCTION, MANUFACTURE, TESTING, MARKETING OR SALE OF ANY LICENSED PRODUCT OR LICENSED PROCESS. (FOR AVOIDANCE OF DOUBT, IT IS UNDERSTOOD AND AGREED THAT ANY SUCH ACTIVITY DESCRIBED IN THE PRECEDING SENTENCE BY ONE OR MORE OF
THE INVENTORS OR ANY OTHER DUKE TRUSTEE, FACULTY MEMBER, EMPLOYEE, STUDENT, AND/OR AGENT SHALL BE DEEMED TO BE OUTSIDE THEIR RESPECTIVE CAPACITY AS A DUKE TRUSTEE, FACULTY MEMBER, EMPLOYEE, STUDENT, AND/OR AGENT, AS THE CASE MAY BE.) FURTHER, DUKE
SHALL HAVE NO LIABILITY WHATSOEVER TO LICENSEE, ITS AFFILIATES, SUBLICENSEES, OR ANY THIRD PARTIES FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY OTHER
LIABILITY INCURRED BY OR IMPOSED UPON LICENSEE OR ANY OTHER PERSON OR ENTITY, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
the production, use, practice, offering, lease, or sale of any LICENSED PRODUCT or LICENSED PROCESS; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) the use of the PATENT RIGHTS; or
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) any advertising or other promotional activities with respect to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.03 Neither party hereto is an agent of the other party for any purpose whatsoever. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 15 - USE OF A PARTY&#146;S NAME </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.01 Neither party will, without the prior written consent of the other party: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) use in any publication, advertising, publicity, press release, promotional activity or otherwise, any trade-name, personal name, trademark,
trade device, service mark, symbol, image, icon, or any abbreviation, contraction or simulation thereof owned by the other party; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) use the name or image of any employee, faculty member, student, or agent of the other
party in any publication, publicity, advertising, press release, promotional activity or otherwise; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) represent, either directly or
indirectly, that any product or service of the other party is a product or service of the representing party or that it is made in accordance with or utilizes the information or documents of the other party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 16 - SEVERANCE AND WAIVER </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.01
Each clause of this AGREEMENT is a distinct and severable clause and if any clause is deemed illegal, void or unenforceable, the validity, legality or enforceability of any other clause or portion of this AGREEMENT will not be affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.02 The failure of a party in any instance to insist upon the strict performance of the terms of this AGREEMENT will not be construed to be
a waiver or relinquishment of any of the terms of this AGREEMENT, either at the time of the party&#146;s failure to insist upon strict performance or at any time in the future, and such terms will continue in full force and effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 17 - TITLES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.01 All titles and
article headings contained in this AGREEMENT are inserted only as a matter of convenience and reference. They do not define, limit, extend or describe the scope of this AGREEMENT or the intent of any of its provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 18 - SURVIVAL OF TERMS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.01 The
provisions of ARTICLES 2.04, 2.09, 3 (as regards financial obligations described therein incurred during the term of this Agreement), 5 (as regards obligations for reports and payments due to Duke for activities occurring during the term of this
Agreement), 6, 7, 8, (to the extent, but only to the extent, that such infringement occurs during the term of this Agreement and excluding Section&nbsp;8.06 which shall only apply during the term of this Agreement), .11, 12, 13, 14, 15, 16, 18, 19
shall survive the expiration or termination of this AGREEMENT. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 19 - GOVERNING LAW </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.01 This AGREEMENT shall be construed as having been entered into in the State of North Carolina and shall be interpreted in accordance with
and its performance governed by the laws of the State of North Carolina. Notwithstanding the foregoing, questions affecting the construction and effect of any patent in PATENT RIGHTS shall be determined by the law of the country in which the patent
was granted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 20 - ENTIRE UNDERSTANDING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.01 This AGREEMENT represents the entire understanding between the parties, and supersedes all other agreements, express or implied, between
the parties concerning the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument subscribed to by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this AGREEMENT on the dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DUKE UNIVERSITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Precision BioSciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rose Ritts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Rose Ritts, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Executive Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Office of Licensing and Ventures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4/17/2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4/17/2006</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><I>Read and Understood by the INVENTORS</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Homme Hellinga</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Homme Hellinga, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4/24/2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeff Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jeff Smith, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4/17/2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Derek Jantz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Derek Jantz, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4/17/2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Milestones </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMMERCIALIZATION SCHEDULE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(year
one starts the day the license is executed by DUKE) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX C </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Milestone payments </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amount&nbsp;due&nbsp;DUKE</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1) Closing of Series A Financing in excess of $1&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2) First signed partnership with guaranteed payments in excess of $1&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3) First commercial seed trait brought to market by PBI or partner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4) First human therapeutic brought to market by PRI or partner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX D </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
per the attached XL file titled &#147;standard royrpt format&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX E </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX F </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDMENT to License Agreement (the &#147;Amendment&#148;), dated as of May&nbsp;31, 2007, is entered into by and between Duke
University, a nonprofit educational and research institution organized under the laws of North Carolina (&#147;Duke&#148;) and Precision BioSciences, Inc., a Delaware corporation (&#147;Precision&#148;, and collectively with Duke, the
&#147;Parties&#148;). All capitalized terms used herein and not otherwise defined shall have the meaning given to them in the License Agreement (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties entered into that certain License Agreement, dated April&nbsp;17, 2006 (the &#147;License Agreement&#148;), whereby
Precision licensed certain PATENT RIGHTS from Duke; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties wish to amend the License Agreement to [***] the royalty
payments and sublicense fees payable to Duke under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the mutual covenants and
agreements contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Section
3.01(c) shall be deleted in its entirety and replaced with the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(i)&#8195;&#8194;Royalty on NET SALES. At the times and in the manner set forth
hereinafter, LICENSEE and it AFFILIATES shall pay to DUKE a [***] royalty on NET SALES of LICENSED PRODUCTS or LICENSED PROCESSES, by LICENSEE, and/or its AFFILIATES. Such royalty shall be at the rate of:</P></TD></TR>
</TABLE></DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of NET SALES for LICENSED PRODUCTS; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of NET SALES for LICENSED PROCESSES. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where in order to manufacture, sell, use, practice or otherwise dispose of LICENSED PRODUCTS or LICENSED
PROCESSES it is [***] for LICENSEE to obtain a license under any patent rights from a THIRD PARTY (including in settlement of a claim contemplated by Article 7.01) and by reason of an agreement with such THIRD PARTY a royalty on LICENSEE NET SALES
(or similarly defined amount) is payable to such THIRD PARTY, the royalty payable pursuant to this Article 3.01(c) shall be reduced by [***] of the amounts paid to third parties provided that under no circumstances will the royalty payable to DUKE
on NET SALES of LICENSED PRODUCTS or LICENSED PROCESSES reduce to less than [***]. </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the development, manufacture, importation, use, lease, sale or distribution of LICENSED PRODUCTS or
LICENSED PROCESSES utilizes or incorporates technology owned by LICENSEE (the &#147;LICENSEE TECHNOLOGY&#148;), the royalty payable pursuant to this Article 3.01(c) shall be reduced by [***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Article 3.01 (c), the royalties payable to DUKE on NET SALES of LICENSED PRODUCTS or LICENSED
PROCESSES shall not be lower than [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The following language shall be added to the end of Section&nbsp;3.01(e): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Where the development, manufacture, importation, use, lease, sale or distribution of LICENSED PRODUCTS or LICENSED PROCESSES utilizes or
incorporates LICENSEE TECHNOLOGY, the SUBLICENSE FEE payable pursuant to Article 3.01(e)(i) shall be reduced to [***] or the SUBLICENSE FEE payable pursuant to Article 3.01(e)(ii) shall be reduced to [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have each caused this Amendment to be executed by its duly authorized representative. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DUKE UNIVERSITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PRECISION BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rose Ritts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rose Ritts, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Office of Licensing&nbsp;&amp; Ventures</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Duke University&nbsp;&amp; DUMC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]
Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 T.W. Alexander Drive, Bldg #7 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P.O. Box 12292 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Research Triangle
Park, NC 27709 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;10, 2007 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Science
and Technology </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke University </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agreement Coordinator
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Box 90083 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27708 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Whom This May Concern: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the License
Agreement, dated as of April&nbsp;17, 2006, by and between Duke University and Precision BioSciences, Inc. (&#147;PB&#148;) (as amended, the &#147;License Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is a clarification of the definition of the term &#147;Patent Rights,&#148; which is set forth in paragraph 1.04 of the License Agreement. Specifically,
the term &#147;Patentably Distinct,&#148; as used therein, is not intended by the parties to the License Agreement to apply to any of the patents and/or patent application(s) listed in Appendix A of the License Agreement, including any and all
divisionals, continuations, and/or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> (only to the extent set forth in paragraph 1.04 of the License Agreement) which constitute any of the Patent
Rights licensed to PB thereunder and which may be sublicensed by PB to a third party pursuant to the terms of the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign both
copies this letter where indicated below and return one copy to PB at the address set forth above. Thank you for your assistance with this matter. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Matthew Kane</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledge and Agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DUKE UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rose Ritts</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Rose Ritts, Ph.D.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Executive Director, Duke Office of Licensing&nbsp;&amp; Ventures </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 T.W. Alexander Drive, Bldg #7 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P.O. Box 12292 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Research Triangle
Park, NC 27709 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February13, 2009 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Science and
Technology </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke University </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agreement Coordinator </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Box 90083 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27708 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Whom This May Concern: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the License
Agreement, dated as of April&nbsp;17, 2006, by and between Duke University (&#147;Duke&#148;) and Precision BioSciences, Inc. (&#147;Precision&#148;) as amended on May&nbsp;31, 2007, and as clarified by letter agreement on December&nbsp;10, 2007,
(collectively, the &#147;Duke License Agreement&#148;). Precision proposes to enter into an agreement (the &#147;[***] License Agreement&#148;) with [***] (&#147;[***]&#148;) pursuant to which Precision would grant to [***] among other things a
sublicense under the rights and licenses granted to Precision under the Duke License Agreement. In connection with Precision&#146;s proposal to enter into the [***] License Agreement, Duke and Precision wish to clarify certain terms and conditions
of the Duke License Agreement, as follows. Terms not defined herein have the meaning ascribed to them in the Duke License Agreement, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2.03 of the Duke License Agreement states that &#147;All SUBLICENSES shall be subject to the terms
and conditions of this AGREEMENT, shall be no less favorable to or protective of DUKE than this AGREEMENT except as expressly stated in this AGREEMENT, and shall not be further sublicenseable without the express written approval of DUKE, such
approval not to be unreasonably withheld.&#148; The parties hereby agree that the express written approval requirement shall not apply to the following types of sublicenses entered into by a sublicensee of Precision (a &#147;Precision
Sublicensee&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sublicenses of a Licensed Product or Licensed Products by a Precision Sublicensee to a third party, under which
such third party may make, use, sell, offer for sale, import, distribute or otherwise exploit such Licensed Product or Licensed Products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sublicenses by a Precision Sublicensee to a third party for such third party to practice the Patent Rights in
order to perform work on the Precision Sublicensee&#146;s behalf; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Further sublicenses of any sublicense entered into in accordance with either of
<FONT STYLE="white-space:nowrap">sub-sections</FONT> (a)&nbsp;or (b) above. </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">II.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2.03 of the Duke License Agreement further states that &#147;In the event of any termination of
this Agreement, all SUBLICENSES shall survive such termination provided that the SUBLICENSEES are in compliance with the terms and conditions of the SUBLICENSE and the SUBLICENSEES comply with all terms of this Agreement related to such SUBLICENSE
including the payment of all amounts that would be due DUKE under this Agreement if it had not terminated.&#148; The parties hereby agree that in the event of any termination of the Duke License Agreement (including without limitation termination
under Section&nbsp;3.04 of the Duke License Agreement), the requirement that a Precision Sublicensee comply with the terms of Precision&#146;s sublicense to the Precision Sublicensee (the &#147;Primary Sublicense&#148;) and the Duke License
Agreement shall mean the following with respect to payment obligations: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">III.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereby agree that Section&nbsp;2.03 of the Duke License Agreement (as regards the survival of
sublicenses) survives termination of the Duke License Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Remainder of Page Intentionally Left Blank </B></P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and return a copy of this letter to us to acknowledge our mutual agreement on this matter. Thank
you for your assistance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRECISION BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and Agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DUKE UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rose Ritts</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Rose Ritts, PhD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Director Office of Licensing&nbsp;&amp; Ventures</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Duke University&nbsp;&amp; DUMC</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 East Pettigrew Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dibrell
Building, Suite <FONT STYLE="white-space:nowrap">A-100</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Durham, NC 27701 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;17, 2012 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Licensing and Ventures </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke University </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agreement Coordinator </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Box 90083 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27708 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Whom This May Concern: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the License
Agreement, dated as of April&nbsp;17, 2006, by and between Duke University (&#147;Duke&#148;) and Precision BioSciences, Inc. (&#147;Precision&#148;) as amended on May&nbsp;31, 2007, and as clarified by letter agreements on December&nbsp;10, 2007
and February&nbsp;13, 2009 (collectively, the &#147;Duke License Agreement&#148;). Precision proposes to enter into the agreement attached hereto as Exhibit A (the &#147;Plantco License Agreement&#148;) with Precision PlantSciences, Inc.
(&#147;Plantco&#148;), a wholly-owned subsidiary of Precision formed to conduct business exclusively in the plant field, pursuant to which Precision would grant to Plantco among other things a sublicense under the rights and licenses granted to
Precision under the Duke License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Precision&#146;s proposal to enter into the Plantco License Agreement, Duke and Precision
wish to clarify certain terms and conditions of the Duke License Agreement, as follows. Terms not defined herein have the meaning ascribed to them in the Duke License Agreement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;1.14 of the Duke License Agreement states that &#147;&#145;SUBLICENSE REVENUES&#146; shall mean
any and all upfront fees, license fees, royalties, option fees, milestone payments, and other amounts payable to LICENSEE (and/or its AFFILIATES, as the case maybe) under a SUBLICENSE to any of the licenses granted by DUKE to LICENSEE under this
AGREEMENT.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereby agree that as long as Plantco remains an AFFILIATE of Precision, [***]. [***]. The foregoing
is illustrated for convenience by the example chart set forth below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Example: SUBLICENSE FEES while Precision and
Plantco are AFFILIATES </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Example 1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Example 2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Example 3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]
Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereby agree that at such time as Plantco no longer remains an AFFILIATE of Precision, Duke will be
entitled in accordance with the Duke License Agreement to [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2.03 of the Duke License Agreement states that &#147;All SUBLICENSES shall be subject to the terms
and conditions of this AGREEMENT, shall be no less favorable to or protective of DUKE than this AGREEMENT except as expressly stated in this AGREEMENT, and shall not be further sublicenseable without the express written approval of DUKE, such
approval not to be unreasonably withheld.&#148; Without limiting anything set forth in the letter agreement between the parties dated February&nbsp;13, 2009, the parties hereby agree that the express written approval requirement shall not apply to
any SUBLICENSES entered into by Plantco or, to the extent described in such letter agreement, Plantco&#146;s sublicensees; provided, however, that Plantco provides Duke with a copy of any SUBLICENSES entered into by Plantco [***] prior to execution
of each subject SUBLICENSE with the ability to review and comment, such comments to be reasonably considered by Plantco, and Plantco provides Duke with an executed copy of such SUBLICENSE within [***] of the effective date of such SUBLICENSE.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 7 of the Duke License Agreement provides LICENSEE with certain rights and obligations with respect to
infringement of THIRD PARTY rights. Duke agrees that for so long as Plantco remains an AFFILIATE of Precision, each instance of the term &#147;LICENSEE&#148; in Article 7 of the Duke License Agreement shall be deemed to mean &#147;LICENSEE and/or
Precision PlantSciences, Inc., as applicable.&#148; For clarity, as long as Plantco remains an AFFILIATE of Precision, in accordance with Section&nbsp;7.01(b) of the Duke License Agreement, [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 8 of the Duke License Agreement provides LICENSEE with certain rights to enforce the PATENT RIGHTS
against potential infringers. Duke agrees that to the extent that LICENSEE grants a SUBLICENSEE such enforcement rights, each instance of the term &#147;LICENSEE&#148; in Article 8 of the Duke License Agreement shall be deemed to mean &#147;LICENSEE
and/or SUBLICENSEE, as applicable&#148; and that Duke will cooperate with any such SUBLICENSEE as set forth in Section&nbsp;8,05 of the Duke License Agreement as if such SUBLICENSEE were a party to the Duke License Agreement. For clarity, if such
SUBLICENSEE enforces the PATENT RIGHTS and there is a balance remaining from recovery of damages by SUBLICENSEE, in accordance with Section&nbsp;8.03 of the Duke License Agreement, [***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke acknowledges that Precision will be assigning to Plantco (as an AFFILIATE of Precision) the following SUBLICENSES in accordance with their terms:
(i)&nbsp;License Agreement between [***] and Precision dated [***], (ii) Research and Commercial Option Agreement between [***] and Precision dated [***], and (iii)&nbsp;Research and Commercial Option Agreement between [***] and Precision dated
[***], each as amended from time to time (collectively, the &#147;Existing Plant Sublicenses&#148;). In support thereof, Duke acknowledges and agrees that the Plantco License Agreement constitutes a valid SUBLICENSE under and is consistent with the
terms of the Duke License Agreement as modified herein, and the Existing Plant Sublicenses, upon such assignment, </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall continue to constitute valid SUBLICENSES under the Duke License Agreement consistent with the terms thereof as so modified. Duke further acknowledges and agrees that in the event of any
termination of the Duke License Agreement, the Existing Plant Sublicenses shall survive such termination in accordance with Section&nbsp;2.03 of the Duke License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to any confidentiality or nondisclosure obligations to any third parties or legal restrictions, Precision agrees to provide Duke with a copy of any
proposed amendment to the Plantco License Agreement prior to the execution thereof with the ability to review and comment for a reasonable period (but not to exceed [***], such comments to be reasonably considered by Precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and return a copy of this letter to us to acknowledge our mutual agreement on this matter. Thank you for your assistance. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRECISION BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane 1/18/2012</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and Agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DUKE UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rose Ritts 1/17/2012</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Rose Ritts, PhD</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Executive Director Office of Licensing&nbsp;&amp; Ventures Duke University&nbsp;&amp; DUMC </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLANTCO LICENSE AGREEMENT </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRECISION BIOSCIENCES, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 East Pettigrew Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dibrell
Building, Suite <FONT STYLE="white-space:nowrap">A-100</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Durham, NC 27701 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;6, 2013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Licensing and Ventures </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke University </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agreement Coordinator </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Box 90083 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27708 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Whom This May Concern: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the License
Agreement, dated as of April&nbsp;17, 2006, by and between Duke University (&#147;Duke&#148;) and Precision BioSciences, Inc. (&#147;Precision&#148;) as amended on May&nbsp;31, 2007, and as clarified by letter agreements on December&nbsp;10, 2007,
February&nbsp;13, 2009, and January&nbsp;17, 2012 (collectively, the &#147;Duke License Agreement&#148;). Duke and Precision now wish to acknowledge and agree that the milestones listed in the COMMERCIALIZATION SCHEDULE in APPENDIX B of the Duke
License Agreement have been achieved and fully satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and return a copy of this letter to us to acknowledge our mutual agreement on this
matter. Thank you for your assistance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRECISION BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and Agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DUKE UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rose Ritts</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Rose Ritts, PhD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Director Office of Licensing&nbsp;&amp; Ventures</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Duke University&nbsp;&amp; DUMC</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRECISION BIOSCIENCES, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 East Pettigrew Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dibrell
Building, Suite <FONT STYLE="white-space:nowrap">A-100</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Durham, NC 27701 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;13, 2013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Licensing and Ventures </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duke University </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Agreement Coordinator </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Box 90083 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27708 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Whom This May Concern: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the License
Agreement, dated as of April&nbsp;17, 2006, by and between Duke University (&#147;Duke&#148;) and Precision BioSciences, Inc. (&#147;Precision&#148;) as amended on May&nbsp;31, 2007, and as clarified by letter agreements on December&nbsp;10, 2007,
February&nbsp;13, 2009, January&nbsp;17, 2012, and December&nbsp;6, 2013 (collectively, the &#147;Duke License Agreement&#148;). As Precision has discussed with Duke, Precision&#146;s business model may from time to time include the creation and
licensing of products such as a modified cell line, a mouse with a modified genome, or a therapeutic, each created, in part, through use of Precision&#146;s meganuclease technology and licensed to customers for commercial applications. Because the
financial dynamics of these transactions are more akin to sales of a product than a typical technology &#147;sublicense&#148;, the parties wish to modify the financial provisions of the Duke License Agreement to facilitate Precision&#146;s efforts
to execute on this new business model. The parties anticipate that Precision&#146;s success in such execution will greatly benefit Duke by operation of the Duke License Agreement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Terms not defined herein have the meaning ascribed to them in the Duke License Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Duke and Precision agree that SUBLICENSES to make, use, sell, offer for sale, import, distribute or otherwise
exploit LICENSED PRODUCTS created by Precision and/or its AFFILIATES (including derivatives thereof), where such SUBLICENSE includes the right to use a LICENSED PRODUCT (or derivative) and where the applicable SUBLICENSE includes a negotiated
royalty rate that may equal [***], shall constitute &#147;Commercial Product Sublicenses&#148; and shall be subject to the remaining terms of this letter agreement. For clarity, but without limiting the foregoing, a SUBLICENSE that satisfies the
foregoing royalty rate criteria and that includes a LICENSED PRODUCT (or derivative) constituting [***], shall be considered Commercial Product Sublicenses. [***]<U>.</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Duke and Precision agree that Commercial Product Sublicenses shall, in lieu of the SUBLICENSE FEES set forth in
Section&nbsp;3.01(e) of the Duke License Agreement, bear a SUBLICENSE FEE equal to the applicable percent of SUBLICENSE REVENUES from such Commercial Product Sublicenses as set forth in the following chart: </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Highest Negotiated</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Royalty
Rate in</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Commercial Product</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sublicense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3.01(e)(i)</B><br><B>SUBLICENSE FEE = ___ Percent of</B><br><B>SUBLICENSE</B><br><B>REVENUES from</B><br><B>royalties</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3.01(e)(ii) SUBLICENSE</B><br><B>FEE = ___ Percent of</B><br><B>SUBLICENSE</B><br><B>REVENUES from
<FONT STYLE="white-space:nowrap">non-</FONT></B><br><B>royalties</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Duke and Precision agree that all Commercial Product Sublicenses shall be entered into on terms consistent with
and shall be subject to the terms and conditions of the Duke License Agreement, except that the second and eighth sentences of Section&nbsp;2.03 of the Duke License Agreement shall not apply to Commercial Product Sublicenses, and notwithstanding the
first sentence of Section&nbsp;2.03 of the Duke License Agreement, Commercial Product Sublicenses shall be freely sublicenseable without the express written approval of Duke. Except as specifically modified in this letter agreement, all provisions
of the Duke License Agreement applicable to SUBLICENSES shall apply to Commercial Product Sublicenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and return a copy of
this letter to us to acknowledge our mutual agreement on this matter. Thank you for your assistance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRECISION BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and Agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DUKE UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rose Ritts</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Rose Ritts, PhD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Director Office of Licensing&nbsp;&amp; Ventures</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Duke University&nbsp;&amp; DUMC</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]
Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PATENT CROSS-LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Patent Cross-License Agreement (<B>&#147;Agreement&#148;</B>) is made as of January&nbsp;23, 2014 (<B>&#147;Effective Date&#148;</B>) by
and between the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Cellectis SA</B>, a French corporation with its principal place of business at 8, rue de la Croix Jarry,
75013 Paris, France (<B>&#147;Cellectis&#148;</B>); and <B>Precision BioSciences, Inc.</B>, a Delaware corporation with its principal place of business at 302 East Pettigrew Street, Dibrell Building, Suite
<FONT STYLE="white-space:nowrap">A-100,</FONT> Durham, North Carolina 27701 (<B>&#147;Precision&#148;</B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cellectis and Precision are
each referred to herein as a <B>&#147;Party&#148;</B> and collectively as the <B>&#147;Parties</B>.<B>&#148;</B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Precision owns or controls certain patents and patent applications covering Engineered
<FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganuclease (defined below) technology that is useful for modifying the genome of cells, including for biomanufacturing purposes and certain other uses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Cellectis owns or controls certain patents and patent applications covering Engineered
<FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganuclease technology that is useful for modifying the genome of cells, including for biomanufacturing purposes and certain other uses; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Parties are entering into a Settlement Agreement (the <B>&#147;Settlement Agreement</B>&#148;), and Precision is entering
into a Stipulation of Dismissal with Lonza Group Ltd. and certain of its Affiliates, pursuant to which the Parties have agreed to settle certain disputes between them, including the Pending Litigations (defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> this Agreement shall have no force or effect until such time as the Parties have signed the Settlement Agreement and satisfied
the obligations set forth in Article 2 and Article 3 of the Settlement Agreement with respect to filing the Stipulations of Dismissal and the Stipulation of Dismissal With Prejudice of the Lonza Litigation set forth in such Articles; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Parties have agreed to enter into this Agreement to establish cross-licenses to the Licensed Precision Patents and
Licensed Cellectis Patents (each defined below), as consideration for one another and in further consideration for each Party&#146;s entry into the Settlement Agreement, which cross-licenses shall provide each Party with certain <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> patent rights with respect to Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganuclease technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the mutual covenants, representations, warranties and other terms and conditions contained herein
and in the Settlement Agreement, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1. DEFINITIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to other terms defined elsewhere herein, the following terms, as used in this Agreement, shall have the meanings indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Affiliate&#148; </B>shall mean any corporation, firm, partnership, entity or other person that
directly or indirectly controls, is controlled by, or is under common control with a Party; where &#147;control&#148; means the capacity to designate, appoint or otherwise determine the board of directors or other governing authority of such person,
whether by law or in fact, or whether by ownership of more than fifty percent (50%) of the equity or other ownership interests of such person (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Control&#148; </B>with respect to a Party&#146;s rights in or to a Patent, means that the Party owns
the Patent, or has the right to grant licenses or immunities from suit (other than pursuant to the rights granted in this Agreement) to the other Party, or bring or release claims or actions for infringement of such Patent as to the other Party,
each without violating the terms of any agreement or other arrangement with any Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Design&#148; </B>shall mean, with respect to any person or entity, the design of Engineered <FONT
STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases by such person or entity, whether for itself or for or on behalf of any Third Party; provided, however, that &#147;Design&#148; does not include [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganuclease&#148; </B>shall mean a [***].
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Exclusive Field&#148; </B>shall have the meaning set forth in Article 2.1.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Existing Licensee&#148; </B>shall mean a licensee under the licenses (the &#147;<B>Existing
Licenses</B>&#148;) in effect prior to the Effective Date granting to a Third Party any rights under any of the Licensed Cellectis Patents (with respect to licenses granted by Cellectis) or Licensed Precision Patents (with respect to licenses
granted by Precision). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Field&#148; </B>shall mean any and all fields of use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensee&#148; </B>shall mean: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to Licensed Cellectis Patents, Precision and its Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to Licensed Precision Patents, Cellectis and its Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensor&#148; </B>shall mean: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to Licensed Cellectis Patents, Cellectis and its Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to Licensed Precision Patents, Precision and its Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Cellectis Patents&#148; </B>shall mean any Patent Controlled by Cellectis or its Affiliates
that contains one or more claims claiming a priority date prior to the Effective Date; which Patent also (i)&nbsp;was the basis of any claim asserted in the Pending Litigations (collectively, &#147;<B>Litigated Cellectis Patents</B>&#148;) or (ii)
[***]. Without limiting the foregoing, the Licensed Cellectis Patents shall include the Patents of the families of patents listed in <B>Exhibit A</B>, as may be updated from time to time by Cellectis during the Term (including an annual update on
the anniversary date of the Effective Date, if applicable, and an update if Cellectis later discovers a Patent that should have been listed in <B>Exhibit A</B>). For the further sake of clarity, an application listed on <B>Exhibit A</B> that, at any
time, falls within the foregoing definition of Licensed Cellectis Patents later shall no longer be a Licensed Cellectis Patent if, subsequently during its prosecution </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
as an application and on issuance as a patent, it no longer satisfies the requirements of this definition. For further clarity, practice of the subject matter of a patent that does not meet the
foregoing definition is not authorized under this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Product&#148; </B>shall mean any product [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Patents&#148; </B>shall mean: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">when the Licensee is Precision or its Affiliates: Licensed Cellectis Patents </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">when the Licensee is Cellectis or its Affiliates: Licensed Precision Patents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Precision Patents&#148; </B>shall mean any Patent Controlled by Precision or its Affiliates
that contains one or more claims claiming a priority date prior to the Effective Date, which Patent also (i)&nbsp;was the basis of any claim asserted in the Pending Litigations (collectively, &#147;<B>Litigated Precision Patents</B>&#148;) or (ii)
[***]. Without limiting the foregoing, the Licensed Precision Patents shall include the Patents listed in <B>Exhibit B</B>, as may be updated from time to time by Precision during the Term (including an annual update on the anniversary date of the
Effective Date, if applicable, and an update if Precision later discovers a Patent that should have been listed in <B>Exhibit B</B>). For the further sake of clarity, an application listed on <B>Exhibit B</B> that, at any time, falls within the
foregoing definition of Licensed Precision Patents later shall no longer be a Licensed Precision Patent if, subsequently during its prosecution as an application and on issuance as a patent, it no longer satisfies the requirements of this
definition. For further clarity, practice of the subject matter of a patent that does not meet the foregoing definition is not authorized under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Litigated Patents&#148; </B>shall mean the Litigated Cellectis Patents and Litigated Precision
Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Ongoing Proceedings&#148; </B>shall mean the proceedings listed in <B>Exhibit E</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Patent&#148; </B>shall mean the rights and interests in and to any and all issued patents and pending
patent applications (including inventors certificates and utility models) in any country or jurisdiction, including any and all provisionals, <FONT STYLE="white-space:nowrap">non-provisionals,</FONT> substitutions, continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals and other continuing applications, supplementary protection certificates, renewals and letters patent on any of the foregoing, and any and
all reissues, reexaminations, extensions, confirmations, registrations and patents of addition, as well as any patent resulting from any post-grant proceeding provided under Title 35 of the U.S. Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Pending Litigations&#148; </B>shall mean the litigation cases pending as of the Effective Date, under
the docket numbers set forth on <B>Exhibit C</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Term&#148; </B>shall mean the time period from the Effective Date until the date on which the last
Valid Claim within the Licensed Patents ceases to be in effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Territory&#148; </B>shall mean any and all countries throughout the world in which Licensed Patents
are in force or are pending during the Term. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Third Party&#148; </B>shall mean any and all persons, other than Cellectis and its Affiliates, and
Precision and its Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Valid Claim&#148; </B>shall mean any claim contained in an issued and unexpired Licensed Patent, which
claim has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency or competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be
invalid or unenforceable through abandonment, reissue, disclaimer or otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2. CROSS-LICENSES </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-exclusive</FONT> License to Precision in the Field; <FONT
STYLE="white-space:nowrap">Non-exclusive</FONT> License to Cellectis in the Field </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Subject to the terms and conditions of this Agreement, Cellectis, on behalf of itself and its
Affiliates, hereby grants to Precision and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (pursuant to Article 2.1.4), fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free license under the
Licensed Cellectis Patents to make, have made, use, lease, transfer, sell, offer for sale, export, import and otherwise exploit Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases or Products within the Field (except within the
Exclusive Field, as specified in Article 2.1.2) in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties acknowledge that, prior to the Effective Date, Cellectis has entered into an Existing
License pursuant to which Cellectis has granted certain exclusive license rights under certain of the Licensed Cellectis Patents within the field listed in <B>Exhibit F</B> (the <B>&#147;Exclusive Agreement&#148;</B>) to the counterparty to such
Existing License (the <B>&#147;Cellectis Exclusive Licensee&#148;</B>). The Parties agree that, during the period in which any such exclusive rights under those Licensed Cellectis Patents that have actually been granted by Cellectis to a Cellectis
Exclusive Licensee in such field pursuant to the Exclusive Agreement remain exclusive and in full force and effect, the license granted to Precision pursuant to Article 2.1.1 shall not include any rights within the scope of such exclusive license
granted by Cellectis to such Cellectis Exclusive Licensee (the <B>&#147;Exclusive Field</B>&#148;), solely as and to the extent necessary for Cellectis to be in compliance with such exclusive rights grants to such Cellectis Exclusive Licensee.
Likewise, during such period the license granted to Cellectis pursuant to Article 2.1.3 shall not include any rights within the Exclusive Field. At such time as any such exclusive rights granted by Cellectis under the Exclusive Agreement cease, in
whole or in part, to be exclusive or to be in full force and effect (a <B><FONT STYLE="white-space:nowrap">&#147;Non-exclusivity</FONT> Event&#148;</B>), effective automatically without any further action required by either of the Parties, such
rights, to the full extent that they are no longer licensed exclusively to a Cellectis Exclusive Licensee under the Exclusive Agreement and would otherwise be part of the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights granted under
this Agreement, shall be removed from the Exclusive Field and included under each of the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license granted to Precision in the Field pursuant to Article 2.1.1 and the
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license granted to Cellectis in the Field pursuant to Article 2.1.3. Within thirty (30)&nbsp;days of Cellectis&#146;s first awareness of the occurrence of a
<FONT STYLE="white-space:nowrap">Non-exclusivity</FONT> Event, Cellectis shall notify Precision in writing of the scope of rights that are the subject of such <FONT STYLE="white-space:nowrap">Non-exclusivity</FONT> Event, and the Parties promptly
shall update <B>Exhibit F</B> in order to properly reflect the additional scope of <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights that has been granted to Precision and Cellectis, if applicable. Beginning within a reasonable time of
the Effective Date, Cellectis shall use reasonable efforts to cause all license rights granted under the Licensed Cellectis Patents that are included within the Exclusive Agreement to be amended to be
non-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
exclusive. Without limiting the foregoing, Cellectis shall not, except as required by the terms of the Exclusive Agreement as of the Effective Date, amend the Exclusive Agreement in a manner that
would reduce or restrict Precision&#146;s rights under this Agreement without the prior written consent of Precision. The Parties agree that it shall not be a breach of this Agreement if Cellectis is unable to secure any such amendment to the
Exclusive Agreement, notwithstanding its reasonable efforts to achieve same, and Cellectis makes no representations or warranties that it will be able to amend the Exclusive Agreement in the foregoing manner or any other manner. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Subject to the terms and conditions of this Agreement, Precision, on behalf of itself and its
Affiliates, hereby grants to Cellectis and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (pursuant to Article 2.1.4), fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free license under the
Licensed Precision Patents to make, have made, use, lease, transfer, sell, offer for sale, export, import and otherwise exploit Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases or Products within the Field (except within the
Exclusive Field, as specified in Article 2.1.2) in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party and its Affiliates (the <B>&#147;Sublicensor&#148;</B>) may grant sublicenses (<B>&#147;First
Tier Sublicenses&#148;</B>) under the license grants in this Article 2.1 solely (a)&nbsp;to an Existing Licensee; or (b)&nbsp;to a Third Party (subject to the restrictions in Article 5.5) (together with an Existing Licensee, a
<B>&#147;Sublicensee&#148;</B>), in each case pursuant to an agreement with such Sublicensee wherein the license grant to the Sublicensee under the Sublicensor&#146;s own Licensed Patents is at least as broad in scope of rights granted as the
license granted to the Sublicensee under the other Party&#146;s Licensed Patents. However, for the sake of clarity, the remaining terms and conditions of any such Sublicense to a Sublicensee need not be the same for the Sublicensor&#146;s own
Licensed Patents as compared to the other Party&#146;s Licensed Patents being licensed to the Sublicensee. Any First Tier Sublicense may be further sublicenseable by Sublicensee only pursuant to the foregoing restrictions, as applied to the
Sublicensee. Notwithstanding the foregoing, except pursuant to an Existing License in which rights to Design Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases were granted under a Party&#146;s own Licensed Patents as of the
Effective Date, neither Party nor any of its Sublicensees may grant any Sublicensee a sublicense under the other Party&#146;s Licensed Patents to Design Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases. Subject to the
foregoing, all sublicenses to Existing Licensees executed or otherwise automatically incorporated into an Existing License within the period of forty-five (45)&nbsp;days after the Effective Date shall be deemed to be effective as of the Effective
Date, and the Parties acknowledge that, as of the Effective Date and as part of the Settlement Agreement, each Party&#146;s Existing Licensees are released by the other Party as set forth in the Settlement Agreement. Moreover, notwithstanding any
other provision of this Agreement, the Parties agree that, as of the Effective Date of this Agreement, Cellectis shall have been deemed to have granted a First Tier Sublicense under the Licensed Precision Patents to Lonza Group Ltd. and/or certain
of its Affiliates under the terms of this Agreement, pursuant to a sublicense granted by Cellectis to such Lonza entities, and the Parties acknowledge that the ongoing litigation against such Lonza entities shall be dismissed pursuant to the terms
of the Settlement Agreement. The foregoing sublicense to such Lonza entities may be executed at any time after the Effective Date and shall have retroactive effect to the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Retained Rights. </B>Each Party expressly retains any rights not expressly granted to the other Party under
this Article 2 (or otherwise under this Agreement). Nothing in this Agreement shall be construed to effect a transfer or change in ownership with respect to either Party&#146;s Patents or other intellectual property rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Duke Patents. </B>Precision represents and warrants, and Cellectis understands, that the licenses and rights
granted by Precision or its Affiliates to Cellectis and its Affiliates under any Patent owned by Duke University (&#147;<B>Duke</B>&#148;, and such Patents, the &#147;<B>Duke IP</B>&#148;) are granted subject to the terms and conditions of the
License Agreement entered into by Precision and Duke on April&nbsp;17, 2006, as amended from time to time, including but not limited to Duke&#146;s right to practice under the Duke IP for its own internal,
<FONT STYLE="white-space:nowrap">non-commercial,</FONT> educational, research and clinical purposes, and subject to the rights of the United States Government and applicable limitations under 37 C.F.R. 401, Public Law
<FONT STYLE="white-space:nowrap">96-517</FONT> and Public Law <FONT STYLE="white-space:nowrap">98-620</FONT> resulting from the United States Government&#146;s funding of research leading to creation of the Duke IP. Duke shall be a third party
beneficiary of this Agreement to the extent its terms and conditions apply or relate to the Duke IP. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Other Licenses. </B>No right or license under or to any invention, information, <FONT
STYLE="white-space:nowrap">know-how</FONT> or other intellectual property or Patent is granted or shall be granted by implication or estoppel. All such rights or licenses are or shall be granted only as expressly provided in the terms of this
Agreement. Neither Party shall be obligated to provide the other Party with: (i)&nbsp;any information other than that disclosed in the Licensed Patents, or (ii)&nbsp;any technical assistance, including
<FONT STYLE="white-space:nowrap">hands-on</FONT> technical support by such Party&#146;s personnel, relating to the practice of the Licensed Patents or manufacture or use of Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights in Bankruptcy. </B>If applicable, the Parties agree that all intellectual property rights licensed
hereunder, including any Patents of a Party in any country covered by the license grants under this Agreement, are part of the &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the Bankruptcy Code subject to the protections
afforded the <FONT STYLE="white-space:nowrap">non-terminating</FONT> Party under Section&nbsp;365(n) of the U.S. Bankruptcy Code, and any similar law or regulation in any other country. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Registration of Licenses. </B>Each Party agrees to cooperate with the other Party regarding registration of
the licenses granted under this Agreement, solely as may be required under the law in order to preserve or maintain any rights of such other Party under this Agreement, including by executing and recording with the appropriate authorities an
appropriate short-form statement of license, if so required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Party Releases. </B>The Parties acknowledge that, as of the Effective Date and as part of the Settlement
Agreement, each Party&#146;s Existing Licensees are released by the other Party as set forth in the Settlement Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3.
INVALIDITY CHALLENGES. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>During the Term of this Agreement, except as required by law (e.g., compelled by subpoena) or in
response to an infringement allegation in a court of competent jurisdiction, a Party to this Agreement shall not directly or indirectly commence, participate in or provide assistance to a Third Party with respect to a proceeding in any court or
other administrative body of any sort (including any patent office in any country) related to (i)&nbsp;the validity, enforceability and/or patentability of any claim of any Litigated Patent Controlled by the other Party or its Affiliates, or
(ii)&nbsp;an interference, derivation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition, post-grant review or other form of patent challenge of any claim of any Litigated Patent Controlled by the other Party or its Affiliates. For
the sake of clarity, notwithstanding the foregoing, a Party may participate as required in an interference proceeding initiated by the USPTO or in response to a subpoena, or as otherwise required by law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>During the Term of this Agreement, except as required by law (e.g., compelled by subpoena) or in
response to an infringement allegation in a court of competent jurisdiction, a Party to this Agreement shall not directly or indirectly commence, participate in or provide assistance to a Third Party with respect to a proceeding in any court or
other administrative body of any sort (including any patent office in any country) related to (i)&nbsp;the validity, enforceability and/or patentability of any claim of any other Licensed Patents Controlled by the other Party or its Affiliates, or
(ii)&nbsp;an interference, derivation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition, post-grant review or other form of patent challenge of any claim of any other Licensed Patents Controlled by the other Party or its
Affiliates. For the sake of clarity, notwithstanding the foregoing, a Party may participate as required in an interference proceeding initiated by the USPTO or in response to a subpoena, or as otherwise required by law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For clarity, the existence of the Ongoing Proceedings shall not be deemed to be a breach of or default
under this Agreement by a Party, so long as such Party carries out all required acts specified in the Settlement Agreement and does not participate in or provide assistance to a Third Party with respect to any such Ongoing Proceeding in relation to
the other Party&#146;s Patents after the Effective Date. For further clarity, a Party&#146;s participation after the Effective Date in a proceeding solely to defend the validity or enforceability of any Licensed Patents Controlled by such Party or
its Affiliates (e.g., to defend a <FONT STYLE="white-space:nowrap">re-examination)</FONT> shall not be deemed to be a breach of or default under this Agreement by such Party. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4. CONSIDERATION; LICENSE REQUEST. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration. </B>The Parties acknowledge that each of the licenses and rights granted by each Party to the
other Party, along with the benefits exchanged through the Settlement Agreement, individually and collectively, constitute good, valuable, and sufficient consideration for each and all of the other licenses, rights, and entry into the Settlement
Agreement contemplated hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Precision License Request. </B>From time to time during the Term, if Precision desires to obtain exclusive
rights under the Licensed Cellectis Patents to make, have made, use, lease, transfer, sell, offer for sale, export or import Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases or products made using Engineered <FONT
STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases within the Field or any particular field in the Territory, Precision shall provide Cellectis with a written notice requesting a license to Precision that would grant such rights to Precision (a
&#147;<B>Precision License Request</B>&#148;). Upon Cellectis&#146;s receipt of a Precision License Request, provided that Cellectis has no obligation to a Third Party or under applicable law that would conflict with such Precision License Request
(e.g., Cellectis has not previously granted rights to a Third Party with respect to the subject matter of the Precision License Request that are inconsistent in any way with the rights requested by Precision, as determined by Cellectis), Cellectis
will discuss with Precision, using its best efforts in good faith for up to [***], commercially reasonable terms under which the rights that are the subject of the Precision License Request may </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
be made available to Precision for licensing. However, Cellectis (at its sole discretion and for any reason) may decline to grant the rights requested by Precision under any Precision License
Request, and Cellectis is not obligated under any circumstances to grant such rights, and nothing in this Agreement or elsewhere shall be interpreted otherwise. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cellectis License Request. </B>From time to time during the Term, if Cellectis desires to obtain exclusive
rights under the Licensed Precision Patents to make, have made, use, lease, transfer, sell, offer for sale, export or import Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases or products made using Engineered <FONT
STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases within the Field or any particular field in the Territory, Cellectis shall provide Precision with a written notice requesting a license to Cellectis that would grant such rights to Cellectis (a
&#147;<B>Cellectis License Request</B>&#148;). Upon Precision&#146;s receipt of a Cellectis License Request, provided that Precision has no obligation to a Third Party or under applicable law that would conflict with such Cellectis License Request
(e.g., Precision has not previously granted rights to a Third Party with respect to the subject matter of the Cellectis License Request that are inconsistent in any way with the rights requested by Cellectis, as determined by Precision), Precision
will discuss with Cellectis, using its best efforts in good faith for up to [***], commercially reasonable terms under which the rights that are the subject of the Cellectis License Request may be made available to Cellectis for licensing. However,
Precision (at its sole discretion and for any reason) may decline to grant the rights requested by Cellectis under any Cellectis License Request, and Precision is not obligated under any circumstances to grant such rights, and nothing in this
Agreement or elsewhere shall be interpreted otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5. INTELLECTUAL PROPERTY </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensed Cellectis Patents. </B>Cellectis (or its Affiliate, as applicable) will have the sole right and
responsibility, at Cellectis&#146; discretion and at Cellectis&#146; expense, to file, prosecute, and maintain Patent protection in the Territory for all Licensed Cellectis Patents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensed Precision Patents. </B>Precision (or its Affiliate, as applicable) will have the sole right and
responsibility, at Precision&#146;s discretion and at Precision&#146;s expense, to file; prosecute, and maintain Patent protection in the Territory for all Licensed Precision Patents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Infringement of Licensed Cellectis Patents. </B>Cellectis will have the sole and exclusive right
(but not the obligation) to initiate an infringement or other appropriate suit (including defense of declaratory judgment actions) in the Territory with respect to infringements or suspected infringements of any of the Licensed Cellectis Patents and
to any and all recoveries obtained in connection therewith. Cellectis will have the sole and exclusive right to select counsel for any suit referred to in this Article 5.3 initiated by Cellectis and will pay all expenses of the suit, including
attorneys&#146; fees and court costs. Notwithstanding the foregoing, for a period of [***] beginning on the Effective Date, neither Cellectis nor its Affiliates shall initiate any infringement action against any Third Party under the Licensed
Cellectis Patents. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Infringement of Licensed Precision Patents. </B>Precision will have the sole and exclusive right
(but not the obligation) to initiate an infringement or other appropriate suit (including defense of declaratory judgment actions) in the Territory with respect to infringements or suspected infringements of any of the Licensed Precision Patents and
to any and all recoveries obtained in connection therewith. Precision will have the sole and exclusive right to select counsel for any suit referred to in this Article 5.4 initiated by Precision and will pay all expenses of the suit, including
attorneys&#146; fees and court costs. Notwithstanding the foregoing, for a period of [***] beginning on the Effective Date, neither Precision nor its Affiliates shall initiate any infringement action against any Third Party under the Licensed
Precision Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Interference</FONT> with Enforcement Activities. </B>Without limiting
the obligations set forth in the final sentence of Article 5.3 and the final sentence of Article 5.4, Cellectis or Precision (or their Affiliates), as applicable, (the &#147;<B>Enforcing Party</B>&#148;) shall provide written notice (an
&#147;<B>Intent to Enforce Notice</B>&#148;) to the other Party (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Enforcing</FONT> Party</B>&#148;) at least [***] prior to (i)&nbsp;providing a Third Party (the &#147;<B>Purported
Infringer</B>&#148;) with written notice of infringement of the Licensed Cellectis Patents or Licensed Precision Patents, as applicable, or (ii)&nbsp;commencing any action against a Purported Infringer to enforce the Licensed Cellectis Patents or
Licensed Precision Patents, as applicable. Upon receipt of such Intent to Enforce Notice, [***]. For any avoidance of any doubt, a Party may not enforce the other Party&#146;s Licensed Patents. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6. CONFIDENTIALITY </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>During the term of this Agreement and for a period of three (3)&nbsp;years following its termination or
expiration, the Parties shall keep strictly confidential and not publish, or disclose to any Third Party any of the terms of this Agreement, without the prior written approval of the other Party, provided, however, that either Party may disclose the
terms and conditions of this Agreement (a)&nbsp;to the extent such terms must be disclosed in response to a valid order of a court or other governmental body, or are otherwise required to be disclosed by law or regulation (provided, however, in such
event that the receiving Party shall first have given reasonable prior notice to the disclosing Party and shall have made a reasonable effort to obtain a protective order requiring that the information so disclosed be limited to information
necessarily responsive to the order issued), or (b)&nbsp;to a Third Party bound by an obligation of confidentiality in connection with the Party&#146;s merger, consolidation, change of control, sublicense, or sale of all or substantially all of its
assets with or to such Third Party, or an equity or debt investment in such Party by such Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding the foregoing, the Parties will issue the joint press release set forth on <B>Exhibit
D</B> concerning the Parties&#146; entry into the Agreement. A Party shall not be required to seek the permission of the other Party to repeat or disclose any information as to the terms of this Agreement that has already been publicly disclosed by
such Party in accordance with the foregoing or by the other Party, or any similar or comparable information. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7. WARRANTIES AND INDEMNITY </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual Representations and Warranties. </B>Each Party represents, warrants and covenants to the other Party
that: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) at the Effective Date it has the full power to enter into this Agreement and to perform its
obligations hereunder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) at the Effective Date it is a corporation duly organized, validly existing and in good standing
under the laws of its jurisdiction of incorporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) at the Effective Date the execution, delivery and performance of
this Agreement have been duly authorized by all necessary corporate actions of such Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) at the Effective Date this
Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against it in accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors, and
(ii)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) at the
Effective Date (i)&nbsp;it has never approved or commenced any proceeding, or made any election contemplating, the winding up or cessation of its business or affairs or the assignment of material assets for the benefit of creditors, and no such
proceeding is pending or (to its knowledge) threatened; and (ii)&nbsp;no steps have been taken, and no event has occurred, that gives any Third Party a right to enforce any lien or security right over any of the Licensed Patents Controlled by such
Party or any of its Affiliates; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) at the Effective Date and at all times during the Term it has the full right, power
and authority to enter into this Agreement and grant the rights, licenses, releases and immunities granted hereunder, without the need for any licenses, releases, consents, approvals or immunities not yet granted or obtained, and without conflicting
with rights granted to any Third Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the execution, delivery and performance by it of this Agreement and its
compliance with the terms and provisions of this Agreement does not at the Effective Date and will not during the Term (i)&nbsp;conflict with or result in a violation or breach of any of the terms, conditions or provisions of its certificate or
articles of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other comparable corporate charter documents); (ii) conflict with or result in a violation or breach of any term or provision of any law or order applicable to it; or
(iii)&nbsp;(A) conflict with or result in a violation or breach of, (B)&nbsp;constitute (with or without notice or lapse of time or both) a default under, (C)&nbsp;require it to obtain any consent, approval or action of, make any filing with or give
any notice to any person as a result or under the terms of, or (D)&nbsp;result in the creation or imposition of any lien or other similar interest upon it or any of the Licensed Patents Controlled by such Party or any of its Affiliates under, any
contract, instrument or license to which it is a party or by which any of its assets and properties is bound; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) at the
Effective Date there are no actions, claims, demands, suits, citations, summons, subpoenas, inquiries or investigations of any nature, civil, criminal, regulatory or otherwise, in law or in equity, or arbitral proceedings or any proceedings by or
before any governmental authority, pending or, to its knowledge, threatened </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
against, relating to or affecting it or any of the Licensed Patents Controlled by such Party or any of its Affiliates (with the exception of normal prosecution at the United States Patent and
Trademark Office and equivalent foreign patent offices or customary actions with the relevant regulatory authorities) which (A)&nbsp;could reasonably be expected to result in the issuance of an order restraining, enjoining or otherwise prohibiting
or making illegal the consummation of any of the transactions contemplated by this Agreement or otherwise result in a diminution of the benefits contemplated by this Agreement to the other Party; or (B)&nbsp;if determined adversely to it, could
reasonably be expected to result in any injunction or other equitable relief against it that would interfere in any material respect with its ability to perform its duties and obligations under this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) at all times during the Term it shall not grant to any Third Party any rights that conflict with the rights and licenses
granted to the other Party under this Agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) at all times during the Term it shall promptly notify the other
Party in writing upon becoming aware of any actual action, suit or proceeding by any Third Party which, if adversely determined, would have a material adverse effect upon the other Party&#146;s rights under this Agreement with respect to the
Licensed Patents Controlled by such Party or any of its Affiliates. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cellectis Representations, Warranties and Covenants.</B> Cellectis represents, warrants and covenants that:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Cellectis is the owner of the entire right, title and interest in and to the Licensed Cellectis
Patents (including the inventions claimed therein); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Exhibit A</B> contains a true, complete and accurate list of
all Licensed Cellectis Patents Controlled by Cellectis or any of its Affiliates as of the Effective Date (other than patent applications having a priority date prior to the Effective Date that are not yet published), with the understanding that
applications listed in <B>Exhibit A</B> are subject to ongoing prosecution and possible amendment of claims; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Cellectis
and its Affiliates have not assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Licensed Cellectis Patents in a manner that conflicts with any rights granted to Precision hereunder. Cellectis and its
Affiliates have not granted to any Third Party a right to assert or cause to be asserted any claim of infringement based on any of the Licensed Cellectis Patents against a licensee of the Licensed Cellectis Patents (including Precision); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) to the best of its knowledge and belief, Cellectis shall at all times operate under this Agreement (including the licenses
granted to Cellectis under Licensed Precision Patents) in compliance with all applicable laws and governmental regulations and guidelines; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) as of the Effective Date, subject only to the exclusive licenses granted to the Cellectis Exclusive Licensee in the
Exclusive Agreement, Cellectis has not granted any exclusive licenses to any Third Party under any of the Licensed Cellectis Patents in the Field; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Cellectis shall maintain in effect any applicable <FONT
STYLE="white-space:nowrap">in-licenses</FONT> pursuant to which Cellectis or any of its Affiliates Controls any Licensed Cellectis Patents, subject to the terms of any such <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Precision Representations, Warranties and Covenants. </B>Precision represents, warrants and covenants that:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Precision is either the owner of or otherwise Controls the entire right, title and interest in and
to the Licensed Precision Patents (including the inventions claimed therein); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)<B> Exhibit B</B> contains a true,
complete and accurate list of all Licensed Precision Patents Controlled by Precision or any of its Affiliates as of the Effective Date (other than patent applications having a priority date prior to the Effective Date that are not yet published),
with the understanding that applications listed in <B>Exhibit B</B> are subject to ongoing prosecution and possible amendment of claims; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Precision and its Affiliates have not assigned, transferred, conveyed or otherwise encumbered its right, title and interest
in the Licensed Precision Patents in a manner that conflicts with any rights granted to Cellectis hereunder. Precision and its Affiliates have not granted to any Third Party a right to assert or cause to be asserted any claim of infringement based
on any of the Licensed Precision Patents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) to the best of its knowledge and belief, Precision shall at all times
operate under this Agreement (including the licenses granted to Precision under Licensed Cellectis Patents) in compliance with all applicable laws and governmental regulations and guidelines; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) as of the Effective Date, Precision has not granted any exclusive licenses to any Third Party under any of the Licensed
Precision Patents in the Field; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Precision shall maintain in effect any applicable
<FONT STYLE="white-space:nowrap">in-licenses</FONT> pursuant to which Precision or any of its Affiliates Controls any Licensed Precision Patents, subject to the terms of any such <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISCLAIMER. </B>EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN ARTICLES 7.1, 7.2 AND 7.3 OF THIS AGREEMENT. NO
PARTY MAKES ANY OTHER REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND ALL SUCH REPRESENTATIONS OR WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED, INCLUDING ANY WARRANTY REGARDING ENGINEERED <FONT STYLE="white-space:nowrap">I-CREI</FONT>
MEGANUCLEASES OR THEIR USE, SAFETY, EFFICACY, OR PERFORMANCE, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY FOR FITNESS FOR ANY PARTICULAR PURPOSE OR A WARRANTY OR REPRESENTATION THAT ANY ACT OR ANYTHING MADE, USED, SOLD, OR OTHERWISE DISPOSED OF
UNDER THE LICENSE GRANTED IN THIS AGREEMENT IS OR WILL BE FREE FROM INFRINGEMENT OF PATENTS, COPYRIGHTS, AND OTHER RIGHTS OF THIRD PARTIES OR ANY OTHER EXPRESS OR IMPLIED LEGAL OR CONTRACTUAL WARRANTY. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">NEITHER PARTY (INCLUDING ITS AFFILIATES AND SUBLICENSEES) SHALL BE LIABLE UNDER THIS AGREEMENT FOR ANY SPECIAL, INCIDENTAL, OR CONSEQUENTIAL
DAMAGES OR FOR LOSS OF PROFIT OR LOST REVENUE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS ARTICLE 7.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT (A)&nbsp;THE INDEMNIFICATION RIGHTS OF A PARTY OR DAMAGES AVAILABLE FOR A
PARTY&#146;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 6, OR (B)&nbsp;EITHER PARTY&#146;S LIABILITY FOR ITS (OR ITS AFFILIATES&#146;) BREACH OF ARTICLE 2, ARTICLE 3 OR THE COVENANTS IN ARTICLES 5.4 OR 5.5, OR (C)&nbsp;EITHER PARTY&#146;S (OR
ITS AFFILIATES&#146; OR SUBLICENSEES&#146;) LIABILITY FOR INFRINGEMENT (WHETHER DIRECT, PARTIAL OR CONTRIBUTORY INFRINGEMENT OR INDUCEMENT TO INFRINGE), VIOLATION OR MISAPPROPRIATION OF ANY INTELLECTUAL PROPERTY (WHETHER PATENT, TRADE SECRET OR
OTHERWISE) CONTROLLED BY THE OTHER PARTY. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Precision agrees to indemnify Cellectis and its Affiliates, and their respective officers, employees,
directors, and agents (the &#147;<B>Cellectis Indemnitees</B>&#148;) from and against any and all liability, demands, claims, damages and losses actually incurred by a Cellectis Indemnitee arising out of or in connection with any claim, suit,
demand, investigation or proceeding brought by a Third Party based on (a)&nbsp;the manufacture, use, sale, or other exploitation of Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases and their derivatives by Precision or its
Affiliates, sublicensees, contractors, agents or customers under the licenses granted by Cellectis to Precision in this Agreement, or (b)&nbsp;any breach of any representation, warrant, covenant and/or obligation of Precision in this Agreement. The
foregoing indemnification shall not apply to the extent that any liability, demands, claims, damages and losses are due to a breach of any of Cellectis&#146; representations, warranties, covenants and/or obligations under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Cellectis agrees to indemnify Precision and its Affiliates, and their respective officers, employees,
directors, and agents (the &#147;<B>Precision Indemnitees</B>&#148;) from and against any and all liability, demands, claims, damages and losses actually incurred by a Precision Indemnitee arising out of or in connection with any claim, suit,
demand, investigation or proceeding brought by a Third Party based on (a)&nbsp;the manufacture, use, sale, or other exploitation of Engineered <FONT STYLE="white-space:nowrap">I-Crel</FONT> Meganucleases and their derivatives by Cellectis or its
Affiliates, sublicensees, contractors, agents or customers under the licenses granted by Precision to Cellectis in this Agreement, or (b)&nbsp;any breach of any representation, warrant, covenant and/or obligation of Cellectis in this Agreement. The
foregoing indemnification shall not apply to the extent that any liability, demands, claims, damages and losses are due to a breach of any of Precision&#146;s representations, warranties, covenants and/or obligations under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The obligation to indemnify pursuant to this Article 7 shall be contingent upon timely notification by
the indemnitee to the indemnitor of any claims, suits or service of process; the tender by the indemnitee to the indemnitor of full control over the conduct and disposition of any claim, demand or suit; and reasonable cooperation by the indemnitee
in the defense of the claim, demand or suit. No indemnitor will be bound by or liable with respect to any settlement or admission entered or made by any indemnitee without the prior written consent of the indemnitor. The indemnitee will have the
right to retain its own counsel to participate in its defense in any proceeding hereunder. The indemnitee shall pay for its own counsel except to the extent it is determined that (a)&nbsp;one or more legal defenses may be available to it which are
different from or additional to those available to the indemnitor, or (b)&nbsp;representation of both Parties by the same counsel would be inappropriate due to actual or potential differing interests between them. In any such case and to such
extent, the indemnitor shall be responsible to pay for the reasonable costs and expenses of one separate </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
counsel retained to participate in the defense of the indemnitee, provided that such expenses are otherwise among those covered by the indemnitor&#146;s indemnity obligations under this Article
7. Notwithstanding the foregoing, if the indemnitor reasonably believes that any of the exceptions to its obligation of indemnification of the indemnitee set forth in Articles 7.5 or 7.6 may apply, the indemnitor shall promptly notify the
indemnitee, which shall then have the right to be represented in any such action or proceeding by separate counsel at the indemnitee&#146;s expense; provided, that the indemnitor shall be responsible for payment of such expenses if the indemnitee is
ultimately determined to be entitled to indemnification from the indemnitor. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8. DURATION &#150; TERMINATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Agreement shall come into effect at the Effective Date and shall continue for the duration of the Term, unless sooner terminated as
provided in Article 8.3 and Article 8.4 hereinafter. Notwithstanding the foregoing, the Agreement shall have no force or effect until such time as the Parties have signed the Settlement Agreement and satisfied the obligations set forth in Article 2
and Article 3 of the Settlement Agreement with respect to the filing the Stipulations of Dismissal and the Stipulation of Dismissal With Prejudice of the Lonza Litigation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may terminate any license granted to it under this Agreement for any reason or no reason,
upon thirty (30)&nbsp;days written notice to the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Failure by either Party to comply with any of its respective material obligations and conditions
contained in this Agreement (including Article 3) shall entitle the other Party to give to the Party in default notice. If such default is not cured within [***] after receipt of such notice by the Party alleged to be in default, the notifying Party
shall be entitled (without prejudice of any of its other rights conferred on it by this Agreement) to terminate (a)&nbsp;this Agreement in its entirety, or (b)&nbsp;any or all licenses granted to the Party in default, each by giving a written
termination notice, which shall take effect immediately. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The right of either Party to terminate this Agreement or any
licenses granted hereunder as set forth in this Article 8.3 shall not be affected in any way by its waiver of, or failure to take action with respect to any previous default. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If, other than in the Ongoing Proceedings, either Party or one of its Affiliates (the
&#147;<B>Challenging Party</B>&#148;) directly or indirectly commences or participates in any interference, derivation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition, post-grant review or other form of patent challenge related
to the validity, enforceability and/or patentability of, or challenges the validity or enforceability of, any Licensed Patent Controlled by the other Party (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Challenging</FONT> Party</B>&#148;) to
this Agreement before any tribunal or patent office, or intentionally provides assistance to a Third Party for any such purposes, except as required by law, then the <FONT STYLE="white-space:nowrap">Non-Challenging</FONT> Party may terminate this
Agreement in its entirety or any or all licenses granted to the Challenging Party under this Agreement immediately upon written notice to the Challenging Party. Notwithstanding anything to the contrary herein, no act or omission committed by a
Challenging Party that otherwise would fall within the scope of the immediately preceding sentence shall give rise to a right for the <FONT STYLE="white-space:nowrap">Non-Challenging</FONT> Party to elect the </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
foregoing remedy if such act or omission is an act or omission that is expressly exempted from the prohibitions set forth in Section&nbsp;3.1 or Section&nbsp;3.2. For the sake of clarity,
notwithstanding the foregoing and without triggering the provisions of this paragraph, a Party may participate as required in an interference proceeding initiated by the USPTO. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon any termination of this Agreement in its entirety, all licenses granted hereunder shall terminate
and all rights granted thereunder shall revert to the applicable Licensor. Notwithstanding the foregoing, in the event any Party&#146;s license under any Licensed Patent is terminated, other than pursuant to (i)&nbsp;such Party&#146;s breach of
Article 3, (ii) such Party&#146;s voluntary termination of a license pursuant to Article 8.2, or (iii)&nbsp;the operation of Article 8.4, then in each such event the terminating Party shall grant, and hereby grants, effective only in the event of
such a termination, to each then-existing (as of the effective date of such termination) Sublicensee (including without limitation the Existing Licensees under the Existing Licenses, as applicable) of the terminated Party&#146;s rights hereunder,
the right, exercisable by written notice to the terminating Party within [***] after such termination, to obtain a direct license from the terminating Party under the relevant Licensed Patents on terms substantially similar in scope, grant and
financial compensation, to those of the sublicense; provided, that (i)&nbsp;such sublicense was properly granted in compliance with the terms of this Agreement, and (ii)&nbsp;the sublicensee is in material compliance with the terms of such
sublicense and the applicable provisions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any rights and obligations accrued prior to termination or expiration of this Agreement shall not be
affected by such termination or expiration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The provisions of Articles 1 (to the extent required to support surviving rights and obligations), 2.2,
2.3, 2.4, 5.1, 5.2, 5.3, 5.4, 6, 7, 8.5, 8.6, 8.7, 9 and 10 shall survive the expiration or termination of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE
9. MISCELLANEOUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>No amendment to this Agreement shall be valid unless embodied in a writing executed by each of the
Parties hereto. No waiver of any of the provisions of this Agreement shall be valid unless embodied in a writing executed by the Party against whom the waiver is sought to be enforced. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement, together with the Settlement Agreement, constitutes the entire understanding and
agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements, understanding or arrangements, whether written or oral. Notwithstanding the foregoing, the Confidentiality Agreement dated November&nbsp;16,
2011 and Supplement to Confidentiality Agreement dated September&nbsp;1, 2012 between Cellectis and Precision shall remain in full force and effect in accordance with its terms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any notice of communication authorized or required to be given hereunder or for the purpose hereof shall
be deemed duly given by either Party if sent by prepaid registered post or by any other method of delivery capable of providing reasonable proof of receipt thereof and sent to the other party hereto, as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>If to Cellectis</U>:</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Name: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Title: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Address: 8, rue de la Croix Jarry </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; text-indent:4%; font-size:10pt; font-family:Times New Roman">75013 Paris, France </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>If to Precision</U>:</B> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Name:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Title:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Address:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;302 East Pettigrew Street </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dibrell Building, Suite <FONT STYLE="white-space:nowrap">A-100</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Durham, North Carolina, USA 27701 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>It is expressly agreed that the relationship between the Parties is that of independent contractors and
shall not constitute a partnership, franchise, joint venture, agency, employment or other similar relationship. Neither Party shall have any express or implied right or authority to make any statements, representations or commitments of any kind, or
to take any action, which shall be binding on the other, without the prior consent of the other Party to do so, with the understanding that each Party has the right to grant sublicenses under the other Party&#146;s Licensed Patents pursuant to the
terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In performing this Agreement, each Party shall comply with all applicable laws to the best of its
knowledge and belief. If any provision of this Agreement is held by any competent authority to be invalid or unenforceable in whole or in part, this Agreement shall continue to be valid as to the other provisions thereof and the remainder of the
affected provision; provided that if the absence of such provision causes a material adverse change in either the risks or benefits of this Agreement to either Party, the Parties shall negotiate in good faith a commercially reasonable substitute or
replacement for the invalid or unenforceable provision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Captions and paragraph headings are for convenience only and shall not form an interpretative part of
this Agreement. Unless otherwise specifically provided, all references to an Article incorporate all sections or subsections thereunder. This Agreement has been prepared jointly and shall not be strictly construed against either party hereto. The
plural shall be substituted for the singular number in any place in which the context may require such substitution. The word &#147;including&#148; will not be construed as limiting the immediately preceding general term or statement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement may not be assigned by either Party without the prior written consent of the other Party.
Notwithstanding the foregoing, such other Party&#146;s consent shall not be required for any assignment to an entity that succeeds to all or substantially all of the assigning Party&#146;s business or assets relating to this Agreement, whether by
sale, </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
merger, operation of law or otherwise provided that, in any such event, the intellectual property rights of the acquiring party to such transaction (if other than one of the Parties to this
Agreement) shall not be included in the licenses granted hereunder or otherwise be subject to this Agreement. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective permitted successors and assigns.
In any case, the assignor shall guarantee the compliance of the terms of the Agreement by the assignee. Further, each Party agrees that any assignment of any of the Licensed Patents by either Party shall be subject to the terms and conditions of
this Agreement, and no Licensed Patent may be assigned without the simultaneous assignment of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties will execute and deliver, or cause to be executed or delivered, such further documents and
do or cause to be done such further acts and things as may be required to carry out the intent and purpose of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except as otherwise provided herein, all legal and other costs and expenses incurred in connection with
this Agreement and the transactions contemplated hereby are to be paid by the Party incurring such costs and expenses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All written materials, correspondence, technical information, notices and oral assistance supplied by
either Party hereto shall be in the English language. The English language version of this Agreement will be controlling on the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except as and to the extent set forth in Article 2.3, this Agreement is solely for the benefit of the
Parties and their respective successors and permitted assigns, and no other person or entity has any right, benefit, priority or interest under or because of the existence of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Precision and Cellectis have each consulted counsel of their choice regarding this Agreement, and each
acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and shall be construed accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party shall ensure that its Affiliates comply with all terms and conditions of this Agreement,
including those that are stated to be applicable to such Affiliates, and each Party shall remain responsible and be directly and primarily liable for any <FONT STYLE="white-space:nowrap">non-compliance</FONT> of its Affiliates with such terms and
conditions. Without limiting the foregoing, to the extent that any Affiliate of a Licensee exercises rights under the licenses granted hereunder, the applicable Licensee shall ensure that such Affiliate complies, in relation to such activities, with
all covenants and obligations that are imposed on such Licensee under this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10. GOVERNING LAW </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement is acknowledged to have been made in and shall be construed in accordance with the laws of the State of Delaware, U.S.A., without regard to
conflict of laws principles which would dictate the application of the law of a different jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 11. DISPUTE SETTLEMENT </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties shall attempt in good faith to settle any disputes between the Parties relative to the
interpretation of this Agreement or intellectual property licensed from one Party to the other hereunder. In the event that the Parties fail to resolve a dispute within [***] of written notice of such a dispute from one disputing Party to the other
disputing Party, the dispute shall be referred at the written request of either Party to a committee that consists of the Chief Executive Officer or President of Precision and the Chief Executive Officer or President of Cellectis (&#147;<B>Executive
Committee</B>&#148;). The written request shall contain a description of the dispute, including the factual and legal basis for the Parties&#146; respective positions with respect to the dispute and the relief sought by the Party making the request.
The Executive Committee members shall diligently attempt to resolve the dispute, including, if they deem it necessary, meeting directly in order to provide full consideration of the dispute. The Executive Committee members shall have [***] to
attempt to do so before any Party can seek to resolve the dispute through the following provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If the Executive Committee is unable to resolve the dispute within the [***] specified above, then the
dispute, at the written request of either Party made within [***] following the end of that [***] period during which the Executive Committee attempted to resolve it, shall be subject to <FONT STYLE="white-space:nowrap">non-binding</FONT> mediation
by a neutral mediator selected by the Parties, with such mediation administered by the International Chamber of Commerce in accordance with its commercial mediation procedures. Any such mediation may be initiated by a Party by written notice (the
&#147;<B>Mediation Notice</B>&#148;) to the other Party specifying the subject of the requested mediation. The dispute shall be mediated by one mediator, to be mutually selected by the Parties. If the Parties fail to agree on the mediator within
[***] following the date of the Mediation Notice, then the recommended individuals named by the Parties shall select a third individual to act as the mediator. The mediator shall not be any employee, director, shareholder or agent of any Party or an
Affiliate of any Party, or otherwise involved (whether by contract or otherwise) in the affairs of any Party. The mediation shall be conducted in the English language in New York City, New York. The mediation shall be completed within [***] of
selection of the mediator. The costs of mediation (exclusive of the expense of a Party in preparing for and participating in the mediation, all of which shall be borne by such Party) shall be shared equally by the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All disputes with respect to this Agreement that are not otherwise resolved pursuant to the foregoing
Articles 11.1 and 11.2 shall be brought and heard in the federal district court in Delaware, USA, as the sole and exclusive jurisdiction. The Parties agree that none of their communications resulting from Articles 11.1 or 11.2 shall be discoverable
or admissible as evidence for any purpose in any such litigation resulting from this paragraph; including any communications of an oral or written nature from a mediator pursuant to Article 11.2. The Parties each consent to the in personam
jurisdiction and venue of such courts. The Parties agree that service of process upon them in any such action may be made if delivered in person, by courier service, by telegram, by facsimile or by first class mail, and shall be deemed effectively
given upon receipt. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing herein shall be construed to prevent either Party from obtaining, in case of urgency, equitable
relief, including injunction or specific performance, in the event of a breach or threatened breach of the provisions of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties have caused this Agreement to be executed on their behalf by their
respective duly authorized officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CELLECTIS SA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PRECISION BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andr&eacute; Choulika</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andr&eacute; Choulika</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman and CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">January&nbsp;23, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;A:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensed Cellectis Patents</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit B:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensed Precision Patents</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit C:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pending Litigations</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit D:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joint Press Release</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit E:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ongoing Proceedings</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit F:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive Field granted to Cellectis Exclusive Licensee</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBITS TO PATENT CROSS-LICENSE AGREEMENT </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A: LICENSED CELLECTIS PATENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="10" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="16" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="13" VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="12" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="8" VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="7" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="4" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="8" VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="8" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="11" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#a6a6a6"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#a6a6a6"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="9" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="9" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2" BGCOLOR="#a6a6a6"></TD>
<TD HEIGHT="16" COLSPAN="2" BGCOLOR="#a6a6a6"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="5" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="5" VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#a6a6a6"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" BGCOLOR="#a6a6a6"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>APPLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>GRANT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="6" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="10" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom" BGCOLOR="#a6a6a6">&nbsp;&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#a6a6a6"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B: <U>LICENSED PRECISION PATENTS</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issue&nbsp;Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issue&nbsp;Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issue&nbsp;Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issue&nbsp;Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issue&nbsp;Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issue&nbsp;Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C: <U>PENDING LITIGATIONS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cellectis S.A. v. Precision BioSciences, Inc., No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">5:08-CV-00119-H</FONT></FONT></FONT> (E.D.N.C.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cellectis S.A. v. Precision BioSciences, Inc. and Precision PlantSciences, Inc., No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1:11-CV-00173-SLR</FONT></FONT></FONT> (D. Del.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cellectis S.A. v. Precision BioSciences, Inc., No. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:11-CV-00890-SLR</FONT></FONT></FONT> (D. Del.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cellectis
S.A. v. Precision BioSciences, Inc., No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:12-CV-00204-SLR</FONT></FONT></FONT> (D. Del.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cellectis S.A. v. Precision BioSciences, Inc., No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:12-CV-01662-SLR</FONT></FONT></FONT> (D. Del.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences, Inc. and Duke University v. Cellectis S.A., Cellectis bioresearch and Cellectis bioresearch Inc., No. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:13-CV-00247-SLR</FONT></FONT></FONT> (D.&nbsp;Del.) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D: <U>JOINT PRESS RELEASE</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRESS RELEASE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Precision
BioSciences and Cellectis SA Announce Cross-License and Settlement Agreement for </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gene Editing Technology </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Enables Broad Commercialization of Highly Specific Engineered Meganuclease Technology </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RESEARCH TRIANGLE PARK, North Carolina, USA and PARIS, France, <B>January XX, 2014</B> &#151; Precision BioSciences, Inc. and Cellectis SA (Alternext: ALCLS),
today announced that they have reached an agreement to settle patent litigation involving engineered <FONT STYLE="white-space:nowrap">I-CreI</FONT> meganuclease technology. As part of the settlement, the companies will cross-license certain genome
engineering patents and drop their <FONT STYLE="white-space:nowrap">on-going</FONT> lawsuits and patent challenges. This agreement provides clear freedom to operate for both companies in the engineered <FONT STYLE="white-space:nowrap">I-CreI</FONT>
meganuclease genome engineering field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Engineered meganucleases are one of the preferred genome engineering technology for most high-value applications.
Their small size and exquisite specificity make them safer and easier to deliver than alternative gene editing tools. In addition, current embodiments of the technology are versatile enough to edit any gene in a genome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to have reached this agreement with our colleagues at Cellectis,&#148; said Matthew Kane, Precision BioSciences&#146; CEO, &#147;and are
very much looking forward to focusing fully on the commercial development of highly needed products utilizing our Directed Nuclease Editor genome engineering technology.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This agreement with our colleagues of Precision Biosciences sets the value of innovation of a proven and effective genome engineering tool:
meganucleases,&#148; stated Dr.&nbsp;Andre Choulika, Chairman and CEO of Cellectis, &#147;This natural technology has tremendous advantages and has now the full potential to be developed in a number important applications such as agricultural
biology and bioproduction.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Precision BioSciences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences&#146; mission is to continually provide, improve, and enable the world&#146;s most powerful genome engineering technology.
Precision&#146;s proprietary <I>Directed Nuclease Editor&#153; </I>(DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences&#146; vision is to be the conduit through which the world&#146;s greatest genome
engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the world&#146;s largest biopharmaceutical and agbiotech firms. Internally, Precision is developing <FONT
STYLE="white-space:nowrap">DNE-based</FONT> products for biologics manufacturing and human therapeutics. For additional information, please visit <U>www.precisionbiosciences.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cellectis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Founded in Paris in 1999, Cellectis is a
life science group focusing on oncology. We develop next generation <FONT STYLE="white-space:nowrap">T-Cell</FONT> CAR allogeneic adoptive immunotherapy for leukemia and solid tumors. The strength of our company is based of 14 years of expertise in
cell line engineering with a leading TALENT?&#148; based genome-engineering technology and Pulsagile a proprietary vector electroporation system. The Company has a strong partnership with University College London (UCL) on UCART19, the first
allogeneic <FONT STYLE="white-space:nowrap">T-Cell</FONT> CAR technology to enter clinical development in CLL/ALL in 2015. We have also a strong pipeline of products addressing series of liquid and solid tumors. Cellectis&#146; application sectors
are human health, agricultural biotechnology, <FONT STYLE="white-space:nowrap">bio-energies</FONT> and genome customization gene editing tools and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit our website: www.cellectis.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cellectis: Philippe Valachs, phone: +33
(0)1 81 69 16 00 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> media@cellectis.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Precision BioSciences: Chelsea Lynam, phone: +1 919 <FONT STYLE="white-space:nowrap">314-5512</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>cheisea.lynam@precisionbiosciences.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclaimer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release and the information
contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E: <U>ONGOING PROCEEDINGS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Reexaminations of Cellectis Owned or Licensed Patents </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Reexaminations of Precision Owned or Licensed Patents </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reexam Control No. [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent Owner: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Party Requester: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>European Oppositions to Cellectis Owned or Licensed Patents </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proprietor: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opponent: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proprietor: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opponent: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proprietor: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opponent: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>European Oppositions to Precision Owned or Licensed Patents </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Patent No. [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proprietor: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opponent: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Status: [***] </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F: <U>EXCLUSIVE FIELD GRANTED TO CELLECTIS EXCLUSIVE LICENSEE</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and
Exchange Commission. Omitted portions have been filed separately with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initials PB: /s/ MK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initials CLS: /s/ AC</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GILEAD
SCIENCES, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of September&nbsp;10, 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COLLABORATION MANAGEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Steering Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Research and Development Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Provisions Applicable to Joint Committees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEVELOPMENT AND REGULATORY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration R&amp;D Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance of the Collaboration R&amp;D Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Following Expiry of the Collaboration Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Supply of the Licensed Products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Records and JSC Reporting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GRANT OF RIGHTS AND COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grants to Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grants to Precision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublicensing and Subcontracting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retention of Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exclusivity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preservation of Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements and
[***] <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PAYMENTS AND RECORDS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments during the Collaboration Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development and Regulatory Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mode of Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTELLECTUAL PROPERTY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maintenance and Prosecution of Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Enforcement of Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infringement Claims by Third Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invalidity or Unenforceability Defenses or Actions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Term Extensions in the Territory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-DISCLOSURE</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted Disclosures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Announcements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return of Confidential Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REPRESENTATIONS AND WARRANTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Representations and Warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Representations and Warranties of Precision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Covenants of Precision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DISCLAIMER OF WARRANTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INDEMNITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification of Precision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification of Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Claim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Control of Defense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special, Indirect, and Other Losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TERM AND TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination by Either Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Termination Rights by Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Termination Rights by Precision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rights in Bankruptcy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remedies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued Rights; Surviving Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ii - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Force Majeure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Export Control</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dispute Resolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">English Language</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments and Waivers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits of Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Further Assurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relationship of the Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Descriptive Headings; Certain Interpretations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SCHEDULES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 1.45</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Duke IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 1.112</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Precision Existing Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 1.113</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Precision HBV Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 2.1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial JSC Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 2.2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial JRDC Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 3.8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Template Report</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 5.1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invoicing Template</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 6.2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARCUS Patents and Precision Patents (To be added when first delivered to Gilead pursuant to
Section&nbsp;6.2.8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Press Release(s)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;8.2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Precision IP Subject to U.S. Federal Government Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- iii - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Collaboration and License Agreement (the &#147;<B>Agreement</B>&#148;) is made<B> </B>and entered into effective as of September&nbsp;10,
2018 (the &#147;<B>Effective Date</B>&#148;) by and between Gilead Sciences, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 333 Lakeside Drive, Foster City, California
94404 (&#147;<B>Gilead</B>&#148;), and Precision Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 302 East Pettigrew St., Suite <FONT
STYLE="white-space:nowrap">A-100,</FONT> Durham, North Carolina 27701 (&#147;<B>Precision</B>&#148;). Gilead and Precision are sometimes referred to herein individually as a &#147;<B>Party</B>&#148; and collectively as the
&#147;<B>Parties</B>.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Precision has developed a proprietary genome editing platform, the ARCUS Technology (as defined herein), and controls certain
intellectual property rights with respect to using the ARCUS Technology to create fully synthetic nucleases derived from homing endonucleases<I>;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Gilead and Precision desire to collaborate on a research and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development
program to construct, optimize and develop one or more gene editing therapy(ies) that incorporates or otherwise uses one or more nucleases made using the ARCUS Technology and that targets the hepatitis B virus DNA, as further described below, in
accordance with the terms and conditions set forth below; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>following the end of the collaboration, Gilead
wishes to assume sole responsibility for the development and commercialization of such gene editing therapies and products containing such gene editing therapies, as further described below, in accordance with the terms and conditions set forth
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specifically provided herein, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Acquirer</B>&#148; means, with respect to a Party, collectively (a)&nbsp;any Third Party that
acquires a Party after the Effective Date (whether by transfer or sale of all or any portion of such Party&#146;s assets, equity or business, or by a Change of Control or similar business combination transaction or otherwise) and (b)&nbsp;the
Affiliates of such Third Party, but excluding such Party and such Party&#146;s Affiliates existing immediately prior to the closing of such acquisition of such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Act</B>&#148; means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the
rules, regulations, guidelines, guidance documents and requirements promulgated thereunder, as may be in effect from time to time. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Action</B>&#148; means any claim or threatened
claim, action, suit, arbitration, inquiry, audit, proceeding or investigation (including any investigation by, before or otherwise involving any governmental authority or Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Active Component</B>&#148; means a component that confers a therapeutic effect on a standalone
basis or on an incremental or synergistic basis, excluding, for clarity and without limitation, [***] and compounds that potentiate nucleases but which themselves do not confer a therapeutic effect on such basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person that directly or indirectly
Controls, is directly or indirectly Controlled by, or is under direct or indirect common Control with, such first Person. For purposes of this definition, a Person shall be deemed, in any event, to Control another Person if it (a)&nbsp;owns or
Controls, directly or indirectly, or has the ability to direct or cause the direction or Control of, more than fifty percent (50%) of the voting equity of such other Person, or (b)&nbsp;has the ability to direct, cause the direction of or Control
the management or policies of such other Person, whether through direct or indirect ownership of voting equity, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affordable Basis</B>&#148;<B> </B>means sale or other disposition of the Licensed Product by Gilead
or its Affiliate or Sublicensee [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Agreement</B>&#148; has the meaning set forth in the
preamble hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Alliance Manage</B>r&#148; has the meaning set forth in Section&nbsp;2.3.5.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Applicable Law</B>&#148; means any applicable federal, state, local or foreign constitution,
treaty, law, statute, ordinance, rule, regulation, interpretation, guidance document, directive, policy, order, writ, award, decree, injunction, judgment, stay or restraining order of any governmental authority or Regulatory Authority, the terms of
any permit, and any other ruling or decision of, agreement with or by, or any other requirement of, any governmental authority or Regulatory Authority having proper jurisdiction over the matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ARC Nuclease</B>&#148; means any fully synthetic nuclease derived from a homing endonuclease and
made using the ARCUS Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ARCUS Assigned IP</B>&#148; [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ARCUS IP</B>&#148; means the ARCUS Technology and the ARCUS Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ARCUS Patents</B>&#148; means any and all Patents Controlled by Precision or any of its Affiliates
as of the Effective Date or at any time during the Term that claim or cover ARCUS Technology, excluding Patents that claim or cover ARCUS Assigned IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ARCUS Technology</B>&#148; means the proprietary genome editing platform Controlled by Precision,
known as ARCUS&#153;, relating to the design, creation, selection and optimization of fully synthetic enzymes derived from homing endonucleases, including any modifications or improvements to such platform, excluding ARCUS Assigned IP. For the sake
of clarity, ARCUS Technology does not include the sequence(s) (including amino acid sequences and mRNA sequences) of any Gilead ARC Nuclease, the use of any Gilead ARC Nuclease, or the formulation of any Gilead ARC Nuclease or the Licensed Products.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Bayh-Dole Act</B>&#148; means the Patent and
Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">200-212,</FONT> as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B>&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Biosimilar Product</B>&#148; means, with respect to a Licensed Product in a country or
jurisdiction specified below, any product sold by a Third Party that (a)(i) in the United States, is subject to a license by the FDA under Section&nbsp;351(k) of the PHSA as a product that is &#147;biosimilar&#148; (as defined in
Section&nbsp;351(i)(2) of the PHSA) to, or &#147;interchangeable&#148; (as defined in Section&nbsp;351(i)(3) of the PHSA) with, such Licensed Product, (ii)&nbsp;in the EU, has been licensed as a similar biological medicinal product by the EMA
pursuant to Directive 2001/83/EC, as may be amended, or any subsequent or superseding law, statute or regulation, or (iii)&nbsp;in any country outside the United States and the EU, has received Regulatory Approval in an abbreviated licensure
procedure as a biogeneric, biosimilar or interchangeable product from the applicable Regulatory Authority in such country or jurisdiction, in reliance upon the prior Regulatory Approval (or data therein) of such Licensed Product; and (b)&nbsp;is not
an Authorized Biosimilar Version of such Licensed Product; where &#147;<B>Authorized Biosimilar Version</B>&#148; means any product that (1)&nbsp;is sold under the BLA filed by Gilead or its Affiliate or Sublicensee for such Licensed Product, and
(2)&nbsp;is not sold under the product trademark under which such Licensed Product is sold by Gilead, its Affiliate or Sublicensee, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>BLA</B>&#148; means Biologics License Application as described in 21 C.F.R &#167;601.2, or
equivalent FDA application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means any day excluding Saturdays,
Sundays, December&nbsp;26 through December&nbsp;31, and any day that is a legal holiday under the Applicable Laws of the United States or that is a day on which banking institutions located in Durham, North Carolina or San Francisco, California, are
authorized or required by Applicable Law or other governmental action to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar
Quarter</B>&#148; means each successive period of three (3)&nbsp;calendar months commencing on January&nbsp;1, April&nbsp;1, July&nbsp;1 and October&nbsp;1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and
end on the day immediately prior to the first to occur of January&nbsp;1, April&nbsp;1, July&nbsp;1 or October&nbsp;1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar Year</B>&#148; means each successive period of twelve (12)&nbsp;calendar months
commencing on January&nbsp;1 and ending on December&nbsp;31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December&nbsp;31 of the year in which the Effective Date occurs and the last Calendar Year
of the Term shall commence on January&nbsp;1 of the year in which the Term ends and end on the last day of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cellectis Agreement</B>&#148; has the meaning set forth in Section&nbsp;4.6.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cellectis Patents</B>&#148; has the meaning set
forth in Section&nbsp;4.6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Change of Control</B>&#148; means, with respect to a Party,
(a)&nbsp;a merger or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged,
ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b)&nbsp;a transaction or series of related transactions in
which a Third Party, together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party, or (c)&nbsp;the sale or other transfer to a Third Party of all
or substantially all of such Party&#146;s business. For clarity, an initial public offering of capital stock of Precision that is effected pursuant to a registration statement or an offering statement filed with, and declared effective or qualified,
as the case may be, by the Securities and Exchange Commission under the Securities Act of 1933, as amended, shall not in and of itself constitute a Change of Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clinical Studies</B>&#148; means a Phase I Clinical Study, a Phase II Clinical Study, a Proof of
Concept Clinical Study, a Phase III Clinical Study, a Registrational Clinical Study and such other tests and studies in human subjects that are required by Applicable Law, or otherwise recommended by the Regulatory Authorities, to obtain or maintain
Regulatory Approvals for a Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>COGS</B>&#148; means in respect of each Licensed
Product, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Collaboration Budget</B>&#148; has the meaning set forth in
Section&nbsp;2.1.3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Collaboration Program</B>&#148; has the meaning set forth in
Section&nbsp;3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Collaboration R&amp;D Plan</B>&#148; has the meaning set forth in
Section&nbsp;3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Collaboration Term</B>&#148; has the meaning set forth in Section&nbsp;3.1.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Combination Product</B>&#148; means a Licensed Product that contains one or more Gilead ARC
Nuclease(s) as one component as well as one or more other Active Components that do not constitute a Gilead ARC Nuclease, whether <FONT STYLE="white-space:nowrap">co-formulated,</FONT> <FONT STYLE="white-space:nowrap">co-packaged</FONT> or otherwise
sold together for one price. <B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercially Reasonable Efforts</B>&#148; means:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.32.1&nbsp;&nbsp;&nbsp;&nbsp;with respect to the obligations of a Party under this Agreement relating to Development activities, of a
Licensed Product, the level of efforts and expenditure of resources typically devoted in the research-based biopharmaceutical industry by a company to Development, of a product of similar commercial potential at a similar stage in its development or
product life, in each case taking into account the Relevant Factors and as measured by the facts and circumstances at the time such efforts are due; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.32.2&nbsp;&nbsp;&nbsp;&nbsp;with respect to the level of obligations of a Party under this Agreement relating to other Exploitation
activities, the level of efforts and expenditure of resources typically devoted in the research-based biopharmaceutical industry by a company to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product of similar market potential at a similar stage in its development or product life, taking into account Relevant Factors and as measured by the facts and circumstances at the time such
efforts are due; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.32.3&nbsp;&nbsp;&nbsp;&nbsp;with respect to the obligations of a Party under this Agreement relating to any other
objective, reasonable, good-faith efforts typically devoted to similar objectives in the research-based pharmaceutical industry by a company, taking into account industry practices;<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided that</I>, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Competitive Infringement</B>&#148; means any alleged or threatened infringement of the Precision
Patents or Joint Collaboration Program Patents, as applicable, by a Third Party (including alleged or threatened infringement based on the development or commercialization of, or an application to market, a Licensed Product) that is based on the
manufacture, use or sale of a Gene Editing Therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Competitive Program</B>&#148; means
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Competitor</B>&#148; means any Person, other than the Parties and their Affiliates,
that is conducting any Competitive Program, for so long as such conduct continues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidential Information</B>&#148; has the meaning set forth in Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidentiality Agreement</B>&#148; means that certain Mutual Confidential Disclosure Agreement by
and between the Parties, dated September&nbsp;3, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Control</B>&#148; means (a)&nbsp;when
used with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by contract or otherwise,
(b)&nbsp;when used with respect to any security, the possession, directly or indirectly, of the power to vote, or to direct the voting of, such security or the power to dispose of, or to direct the disposition of, such security and (c)&nbsp;when
used with respect to any item of Information, Regulatory Documentation, material, Patent, or other IP Rights, possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to assign or grant a license,
sublicense or other right to or under such Information, Regulatory Documentation, material, Patent or other IP Rights to the extent that it does not violate the terms of any written agreement with any Third Party existing as of the date of such
assignment or such grant, as applicable; <I>provided that</I>,<I> </I>any such Third Party agreement entered into after the Effective Date and requiring additional payment will meet this definition of Control only if such agreement is entered into
in compliance with the requirements set forth in Section&nbsp;5.4.3. &#147;<B>Controlled</B>&#148; and &#147;<B>Controlling</B>&#148; have corresponding meanings. For clarity, in the case of clause (c), a Person may Control <FONT
STYLE="white-space:nowrap">in-licensed</FONT> IP Rights from a Third Party even if its license to such IP Rights is <FONT STYLE="white-space:nowrap">non-exclusive</FONT> or otherwise more limited than licenses granted in Sections 4.1 or 4.2,
provided that the rights granted under such <FONT STYLE="white-space:nowrap">in-licensed</FONT> IP Rights will be limited to the extent and scope of the license granted by the licensor Third Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B>&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B>Development</B>&#148; means all activities
related to discovery, identification, research, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing, test method development and stability testing, toxicology, formulation,
process development, manufacturing <FONT STYLE="white-space:nowrap">scale-up,</FONT> qualification and validation, quality assurance/quality control, clinical studies, including manufacturing in support thereof, statistical analysis and report
writing, the preparation and submission of applications for Regulatory Approvals, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority
as a condition or in support of obtaining or maintaining a Regulatory Approval. &#147;<B>Develop</B>&#148; and &#147;<B>Developing</B>&#148; have corresponding meanings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Dispute</B>&#148; has the meaning set forth in Section&nbsp;11.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Distributor</B>&#148; means any person appointed by Gilead or any of its Affiliates or its or
their Sublicensees, and that is not an Affiliate of any of them, to distribute, market and sell the Licensed Products in one or more countries in the Territory, in circumstances where the Person purchases its requirements of the Licensed Products
from Gilead or its Affiliates or its or their Sublicensees but does not make any royalty or other payment to Gilead or its Affiliates or its or their Sublicensees for (sub)license rights under Precision
<FONT STYLE="white-space:nowrap">Know-How</FONT> or Precision Patents with respect to such Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Divest</B>&#148; means, as it relates to a Competitive Program: (a)&nbsp;the sale of all right,
title and interest in such Competitive Program, including all technology, intellectual property and other assets relating solely thereto, to a Third Party, without the retention or reservation of any rights, license or interest (other than an
economic interest such as a right to receive payments) by the selling entity or its Affiliates; or (b)&nbsp;the complete termination and/or shut-down of such Competitive Program such that no technology, intellectual property or other asset solely
relating thereto is used by the terminating entity or its Affiliates for the conduct of such Competitive Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Dollars</B>&#148; or &#147;<B>$</B>&#148; means United States Dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Duke Agreement</B>&#148; means the License Agreement entered into by Precision and Duke University
(&#147;<B>Duke</B>&#148;) on April&nbsp;17, 2006, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Duke
IP</B>&#148; means all Patents and Information licensed to Precision under the Duke Agreement that constitute ARCUS Technology. The patent numbers and patent application numbers of the Patents that are included within the Duke IP as of the Effective
Date are set forth in <U>Schedule 1.45</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Effective Date</B>&#148; has the meaning set
forth in the preamble hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>EMA</B>&#148;<B> </B>means the European Medicines Agency and
any successor agency thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Europe</B>&#148; means the countries of the European Union as
constituted on the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Existing
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; means the Duke Agreement and the Cellectis Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exploit</B>&#148; means to make, have made, import, use, sell, or offer for sale, research,
develop, commercialize, register, manufacture, have manufactured, hold, or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market, or have sold or otherwise dispose of. &#147;<B>Exploitation</B>&#148; and
&#147;<B>Exploiting</B>&#148; have corresponding meanings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FDA</B>&#148; means the United States Food and
Drug Administration, or any successor agency thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field</B>&#148; means the diagnosis,
treatment and prevention of all diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>First Commercial Sale</B>&#148; means, on a
Licensed <FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the first invoiced commercial sale for monetary value for use
or consumption by the general public of a Licensed Product in any country in the Territory after the Marketing Approval for such Licensed Product has been obtained in such country. For the avoidance of doubt, sales prior to receipt of all Marketing
Approvals necessary to commence regular commercial sales, such as <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;named patient sales&#148; and &#147;compassionate use sales&#148;, shall not be construed as a First Commercial Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Formulation and Delivery Combination Patent</B>&#148; means a Patent that includes a use in
combination claim that covers the use of an ARC Nuclease in combination with a formulation or [***] developed by either Party outside the Collaboration Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FTE</B>&#148; has the meaning set forth in the definition of &#147;<B>FTE Rate</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FTE Rate</B>&#148; means a rate of [***] based on a total of [***] of work performed by one or
more full time employees (&#147;<B>FTE</B>&#148;), to be <FONT STYLE="white-space:nowrap">pro-rated</FONT> on a daily basis if necessary [***]; such rate to be restricted to scientific work and managerial activities related directly to the
Collaboration R&amp;D Plan and included in the Collaboration Budget or otherwise provided for in this Agreement. For the avoidance of doubt (a)&nbsp;such rate includes all benefits, travel, and overhead; and (b)&nbsp;in no event shall any one
(1)&nbsp;individual be counted as more than one (1)&nbsp;FTE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B>&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B>GAAP</B>&#148; means generally
accepted accounting principles, as applied in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gene Editing
Therapy</B>&#148; means any product that functions through a mechanism of action of targeting, editing, deleting or otherwise modifying an HBV Target. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Generally Applicable Utility</B>&#148; means, with respect to any Patent or Information, that the
utility of such Patent or Information is not limited to (a)&nbsp;the field of HBV, (b)&nbsp;any Gilead ARC Nuclease, or (c)&nbsp;any Active Component contained in a Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Generic Sublicensee</B>&#148; means a Sublicensee with respect to which Gilead&#146;s sublicense
is <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> is granted in accordance with Gilead&#146;s &#147;Developing World Access&#148; program as consistently applied by Gilead to its hepatitis B product lines or, if such program is not active,
then in accordance with Gilead&#146;s successor program with respect to its hepatitis B product lines and so applied, and is limited to the right to manufacture and sell a generic version of the Licensed Product in a country in which Gilead
generally provides services through its &#147;Developing World Access&#148; program, or if such program is not active, then in a country then listed by the World Bank&#146;s latest rankings in the &#147;low&#148; and &#147;lower middle&#148; income
group or equivalent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead</B>&#148; has the meaning set forth in
the preamble hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead ARC Nuclease</B>&#148; means any ARC Nuclease designed, created,
selected or optimized by Precision for Gilead, as disclosed or presented to Gilead pursuant to the Collaboration R&amp;D Plan, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead Dual IP</B>&#148; means the Gilead Dual <FONT STYLE="white-space:nowrap">Know-How</FONT>
and the Gilead Dual Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead Dual
<FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any and all Information to the extent Controlled by Gilead or its Affiliates that (a)&nbsp;is conceived, discovered, developed or otherwise made by or on behalf of Gilead or its
Affiliates or Sublicensees [***] or (b)(i) Gilead or its Affiliates elect to provide or disclose to Precision under this Agreement at any time during the Term other than in the case of this clause (b) [***] and (ii) [***]. For clarity, Gilead Dual <FONT
STYLE="white-space:nowrap">Know-How</FONT> does not include any Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead Dual
Patents</B>&#148; means (a)&nbsp;any and all Patents (i)&nbsp;that claim or cover Gilead Dual <FONT STYLE="white-space:nowrap">Know-How</FONT> and (ii)&nbsp;to the extent such Patents are Controlled by Gilead or its Affiliates at any time during the
Term; and (b)&nbsp;any and all Patents [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead Funding Commitment</B>&#148; has the
meaning set forth in Section&nbsp;5.1.1.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead
<FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any and all Information to the extent Controlled by Gilead or any of its Affiliates at any time during the Term that is necessary for Precision to conduct its Development activities
under the Collaboration R&amp;D Plan, excluding Gilead Dual <FONT STYLE="white-space:nowrap">Know-How,</FONT> ARCUS Assigned IP and Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How.</FONT> For clarity, Gilead <FONT
STYLE="white-space:nowrap">Know-How</FONT> does not include any Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Gilead
Patents</B>&#148;<B> </B>means any and all Patents that claim or cover the Gilead <FONT STYLE="white-space:nowrap">Know-How</FONT> that are Controlled by Gilead or its Affiliates at any time during the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Grant-Back Right</B>&#148; has the meaning set forth in Section&nbsp;4.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>HBV</B>&#148; means the hepatitis B virus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>HBV Target</B>&#148; means any HBV DNA, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IND</B>&#148; means (a)&nbsp;an investigational new drug application filed with the FDA for
authorization to commence Clinical Studies and its equivalent in other countries or regulatory jurisdictions, and (b)&nbsp;all supplements and amendments that may be filed with respect to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnification Claim Notice</B>&#148; has the meaning set forth in Section&nbsp;9.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnified Party</B>&#148; has the meaning set forth in Section&nbsp;9.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnifying Party</B>&#148; has the meaning set forth in Section&nbsp;9.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Information</B>&#148; means all technical,
scientific and other <FONT STYLE="white-space:nowrap">know-how</FONT> and information, trade secrets, ideas, inventions, discoveries, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques,
procedures, experiences, ideas, designs, drawings, assembly procedures, computer programs, specifications, data, results and other information, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
<FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, safety, manufacturing and quality control data and information, including study designs and protocols, assays and biological methodology, in each case (whether or not confidential,
proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initial Term</B>&#148; has the meaning set forth in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initiation</B>&#148; or &#147;<B>Initiate</B>&#148; means, with respect to a Clinical Study, the
first dosing of the [***] human subject in such Clinical Study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IP Assignee&#148; </B>has the
meaning set forth in Section&nbsp;6.1.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IP Assignor&#148; </B>has the meaning set forth in
Section&nbsp;6.1.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IP Rights</B>&#148; means any and all legal means of establishing rights
in and to ideas, inventions, discoveries, Information, data, databases, documentation, reports, materials, writings, designs, computer software, processes, principles, methods, techniques and other information, including Patents, trade secrets,
trademarks, service marks, trade names, registered designs, design rights, copyrights (including rights in computer software and database rights) and any rights or property similar to any of the foregoing in any part of the world, whether registered
or not, together with the right to apply for the registration of any such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint
Collaboration Program IP</B>&#148; means the Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Joint Collaboration Program Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; has the
meaning set forth in Section&nbsp;6.1.3(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Collaboration Program Patents</B>&#148; has
the meaning set forth in Section&nbsp;6.1.3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Committee</B>&#148; means the JSC, the
JRDC, or any subcommittee established to carry out the functions of the JSC or JRDC, including the Joint Tech Transfer Team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Research and Development Committee</B>&#148; or &#147;<B>JRDC</B>&#148; has the meaning set
forth in Section&nbsp;2.2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Steering Committee</B>&#148; or &#147;<B>JSC</B>&#148; has
the meaning set forth in Section&nbsp;2.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Tech Transfer Team</B>&#148; or
&#147;<B>JTTT</B>&#148; means the Subcommittee established by the JSC pursuant to Section&nbsp;2.1.3(f) to oversee, and provide guidance to the Parties regarding the implementation of the Technology Transfer Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Knowledge</B>&#148; means the actual knowledge
of Precision&#146;s Chief Executive Officer, Chief Science Officer, Vice President of Business Development and Director of Intellectual Property, with internal due inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Product</B>&#148; means any Gene Editing Therapy that incorporates one or more Gilead ARC
Nuclease(s), in any and all forms, presentations, delivery systems, dosages, and formulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Product Family</B>&#148; has the meaning set forth in Section&nbsp;5.4.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;[***] <B><FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; means any agreements
between Precision or its Affiliates and a Third Party entered into as a Third Party License to [***] subject to Section&nbsp;5.4.3(b) during the Term, in each case under which Precision has obtained rights to [***] for the Exploitation of the
Licensed Products and which are used to Exploit the Licensed Products for Gilead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.93</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Losses</B>&#148; has the meaning set forth in Section&nbsp;9.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.94</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Major Market</B>&#148; means any of [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.95</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacture</B>&#148; and &#147;<B>Manufacturing</B>&#148; means all activities related to the
manufacture, processing, filling, finishing, packaging, labeling, shipping, and holding of any Licensed Product, including process development, process qualification and validation, <FONT STYLE="white-space:nowrap">scale-up,</FONT> <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and commercial manufacture and analytic development, Licensed Product characterization, stability testing, quality assurance, and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.96</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Marketing Approval</B>&#148; means, with respect to a Licensed Product for a particular country,
the grant of a Regulatory Approval that is required in such country from the competent Regulatory Authority to market and sell such Licensed Product in such country, including a BLA in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.97</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Net Sales</B>&#148; means [***].<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.98</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party</B>&#148; means the Party that is
not the Prosecuting Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.99</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Other Infringement</B>&#148; means any alleged or threatened
infringement of the Precision Patents or Joint Collaboration Program Patents, as applicable, by a Third Party and such alleged or threatened infringement is not a Competitive Infringement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.100</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Party</B>&#148; and &#147;<B>Parties</B>&#148; has the meaning set forth in the preamble hereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.101</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Challenge</B>&#148; has the meaning set forth in Section&nbsp;5.4.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.102</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Challenge Criteria</B>&#148;<B> </B>shall have the meaning set forth in
Section&nbsp;5.4.8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.103</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patents</B>&#148; means (a)&nbsp;all national, regional and
international patents and patent applications, including provisional patent applications; (b)&nbsp;all patent applications filed from such patents, patent applications or provisional applications or from an application claiming
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
priority from either of these, including divisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> substitutions,
provisionals, converted provisionals, and continued prosecution applications; (c)&nbsp;any and all patents that have issued or in the future issue from the foregoing patent applications described in clauses (a)&nbsp;and (b), including utility
models, petty patents and design patents and certificates of invention; (d)&nbsp;any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues,
<FONT STYLE="white-space:nowrap">re-examinations</FONT> and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications described in clauses (a), (b), and (c); and (e)&nbsp;any
similar rights, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of addition to any such foregoing patent
applications and patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.104</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means an individual, corporation, partnership,
limited liability company, joint venture, association, trust, unincorporated organization or other entity or any governmental authority or Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.105</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase I Clinical Study</B>&#148; means a human clinical trial of any product conducted during
Phase 1 of a clinical investigation as defined in 21 C.F.R. 312.21(a) or corresponding foreign regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.106</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase Ib Clinical Study</B>&#148; means a Phase I Clinical Study within the HBV patient
population that is designed to establish an initial indication of efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.107</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase II
Clinical Study</B>&#148; means a human clinical trial of any product conducted during Phase 2 of a clinical investigation as defined in 21 C.F.R. 312.21(b) or corresponding foreign regulations, including any such trial conducted as an open label
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.108</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase III Clinical Study</B>&#148; means a human clinical trial of any
product on sufficient numbers of patients that is designed to demonstrate statistically that such product is safe and efficacious for its intended use and to define warnings, precautions and adverse reactions that are associated with such product in
the dosage range to be prescribed, as described in 21 C.F.R. 312.21(c) or corresponding foreign regulations, and that is intended to support Marketing Approval of such product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.109</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PHSA</B>&#148; means the United States Public Health Service Act, as may be amended, or any
subsequent or superseding law, statute or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.110</B>&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.111</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Precision</B>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.112</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Precision Existing Patents</B>&#148; means the Patents listed in <U>Schedule</U><U>
</U><U>1.112</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.113</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Precision HBV Patents</B>&#148; means any Precision Patent that, without
expanding the definition of Precision Patents, [***], including the Patents listed in <U>Schedule 1.113</U>, as such schedule may be updated by Precision during the Term in accordance with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.114</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Precision IP</B>&#148; means the Precision <FONT
STYLE="white-space:nowrap">Know-How,</FONT> the Precision Patents and, to the extent not included in the Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Precision Patents, the ARCUS Assigned IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.115</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Precision <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any and all
Information to the extent Controlled by Precision or any of its Affiliates: (a)&nbsp;as of the Effective Date or at any time during the Collaboration Term and resulting from the conduct of the Collaboration Program, in each case that is necessary or
reasonably useful for the Exploitation of any Licensed Product or any Gilead ARC Nuclease, or (b)&nbsp;at any time during the Term that Precision or its Affiliates elect to provide or disclose to Gilead under this Agreement, that is necessary or
reasonably useful for the Exploitation of any Licensed Product or any Gilead ARC Nuclease; and in each case ((a) and (b)) excluding Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How,</FONT> ARCUS Technology, and any [***]. For
clarity, Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> does not include any Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.116</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Precision Patents</B>&#148; means any and all Patents to the extent Controlled by Precision or
any of its Affiliates (a)&nbsp;as of the Effective Date or at any time during the Collaboration Term and resulting from the conduct of the Collaboration Program, in each case that are necessary or reasonably useful for the Exploitation of any
Licensed Product or any Gilead ARC Nuclease; (b)&nbsp;at any time during the Term that cover or claim Precision <FONT STYLE="white-space:nowrap">Know-How;</FONT> or (c)&nbsp;at any time during the Term that cover or claim any Licensed Product or
Gilead ARC Nuclease or are necessary for the Exploitation of Licensed Products or Gilead ARC Nucleases, in the case of Licensed Products under this clause (c)&nbsp;in the form in which such Licensed Products exist as of the end of the Collaboration
Term (and including any Regulatory Authority-required modifications made thereto after the Collaboration Term) and in any form supplied under the Supply Agreement but excluding in all cases of clause (c)&nbsp;any Patents that claim or cover any
formulation or [***] developed or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Precision or its Affiliates after the Effective Date outside the Collaboration Program unless such Patent is a<B> </B>Formulation and Delivery Combination
Patent, in which case only claims that cover the use, composition or production of such formulation or [***] apart from the combination shall be excluded; and in each of cases (a)&nbsp;through (c), including the Precision Existing Patents, but
excluding any Joint Collaboration Program Patents, ARCUS Patents and any [***].</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.117</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Proof of
Concept Clinical Study</B>&#148; [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.118</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Prosecuting Party</B>&#148; means the Party
preparing, filing, prosecuting, maintaining, enforcing or defending the relevant Patent(s), as applicable, in exercise of its rights under, and in accordance, with ARTICLE 6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.119</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Publications</B>&#148; has the meaning set forth in Section&nbsp;7.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.120</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Quality Agreement</B>&#148; has the meaning set forth in Section&nbsp;3.5.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.121</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Registrational Clinical Study</B>&#148; [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.122</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Approval</B>&#148; means, with respect to any jurisdiction, any and all approvals
(including pricing and reimbursement approvals), licenses, registrations or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorizations of any Regulatory Authority necessary or useful for the Exploitation of any Licensed Product in such jurisdiction, including, where applicable, (a)&nbsp;IND, Marketing Approval
applications and supplements and amendments thereto; (b)&nbsp;Marketing Approvals and <FONT STYLE="white-space:nowrap">pre-</FONT> and post-Marketing Approval marketing authorizations (including any prerequisite manufacturing approval or
authorization related thereto); (c) labeling approval; and (d)&nbsp;technical, medical and scientific licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.123</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Authority</B>&#148; means any applicable supra-national, federal, national, regional,
state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise having legal authority with respect to the Exploitation of Licensed Products in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.124</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Documentation</B>&#148; means any and all (a)&nbsp;applications, registrations,
licenses, authorizations and approvals (including all Regulatory Approvals), and <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical study authorization applications or notifications (including all supporting files, writings, data,
studies and reports) prepared for submission to a Regulatory Authority or research ethics committee with a view to the obtaining or maintaining of any Regulatory Approval, (b)&nbsp;correspondence to or with the FDA or any other Regulatory Authority
(including minutes and official contact reports relating to any communications with any Regulatory Authority), (c) pharmacovigilance databases, adverse drug experience reports and associated documents, and investigations of adverse drug experience
reports, (d)&nbsp;manufacturing records, and (e)&nbsp;nonclinical, clinical and other data contained or referenced in or supporting any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.125</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Exclusivity Period</B>&#148; means, with respect to each Licensed Product in any
country in the Territory, a period of exclusivity (other than Patent exclusivity) granted or afforded by Applicable Law or by a Regulatory Authority in such country that confers exclusive marketing rights with respect to such Licensed Product in
such country or prevents another Person from using, referencing or otherwise relying on data supporting the Marketing Approval for such Licensed Product without the prior written consent of the Marketing Approval holder, including regulatory data
exclusivity, new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, pediatric exclusivity and orphan drug designations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.126</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Relevant Factors</B>&#148; means all factors that are relevant to the Development, Manufacture or
Exploitation of a product, including its safety and efficacy, product profile, cost to develop, cost and availability of supply, the time required to complete Development, the competitiveness of the marketplace (including the proprietary position
and anticipated market share of the product), the patent position with respect to such product (including the ability to obtain or enforce, or have obtained or enforced, such patent rights), the Third Party patent landscape relevant to the product,
the regulatory structure involved, the likelihood of regulatory approval, the anticipated or actual profitability of the applicable product and other technical, commercial, legal, scientific, regulatory and medical considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.127</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Representatives</B>&#148; means, with respect to any Person, such Person&#146;s directors,
officers, managers, employees, counsel, accountants, financial advisors, lenders and other agents and representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.128</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Reversion IP</B>&#148; means any Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT>
that are Controlled by Gilead or any of its Affiliates as of the date of termination of this Agreement (in whole or in part, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and including, for clarity, Patents filed or issued at any later date covering or claiming applicable inventions conceived on or prior to such date) that are necessary for Precision to continue
the Development, Manufacture, use or Exploitation of Licensed Products in the form existing as of the date of termination of this Agreement (and including any Regulatory Authority-required modifications made thereto after such date), excluding any
Patent or <FONT STYLE="white-space:nowrap">Know-How</FONT> that covers or claims, or in the case of <FONT STYLE="white-space:nowrap">Know-How,</FONT> relates specifically to, (i)&nbsp;any Active Component of any Licensed Product that is not a Gilead
ARC Nuclease or (ii)&nbsp;any use of a Gilead ARC Nuclease in combination with any such other Active Component of such Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.129</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Reversion Patents</B>&#148; means, with respect to any particular Licensed Product, Patents
within Reversion IP that come to be Controlled by Gilead or any of its Affiliates as a result of activities conducted, under the Collaboration Program or in connection with this Agreement, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.130</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Royalty Term</B>&#148; means, with respect to each Licensed Product, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the period commencing on the date of First Commercial Sale of such Licensed Product by Gilead, its Affiliate or Sublicensee in such country until
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.131</B>&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B>Senior Officer</B>&#148; means, with respect to Gilead, its Chief Scientific Officer
or his or her designee, and with respect to Precision, its Chief Executive Officer or his or her designee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.132</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Subcommittee</B>&#148; means any Joint Committee other than the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.133</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicensee</B>&#148; means a Third Party to which Gilead has granted a sublicense under the
licenses granted to Gilead hereunder to Exploit a Licensed Product under Section&nbsp;4.3.1, but excluding Distributors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.134</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Supplied Product</B>&#148; has the meaning set forth in Section&nbsp;3.5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.135</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Supply Agreement</B>&#148; has the meaning set forth in Section&nbsp;3.5.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.136</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Technology Transfer</B>&#148; has the meaning set forth in Section&nbsp;3.6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.137</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Technology Transfer Plan</B>&#148; has the meaning set forth in Section&nbsp;3.6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.138</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Term</B>&#148; has the meaning set forth in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.139</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148; means all countries and territories of the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.140</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; means any Person other than Gilead, Precision and their respective
Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.141</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party Claims</B>&#148; has the meaning set forth in Section&nbsp;9.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.142</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;[***]&#148; has the meaning set forth in Section&nbsp;5.4.3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.143</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party License</B>&#148; has the meaning set forth in Section&nbsp;5.4.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.144</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>United States</B>&#148; or &#147;<B>U.S.</B>&#148; means the United States of America and its
territories and possessions (including the District of Columbia and Puerto Rico). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.145</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Valid Claim</B>&#148; means (a)&nbsp;a claim of
an issued and unexpired Patent included within the Precision Patents or Joint Collaboration Program Patents which has not been abandoned, cancelled or held permanently revoked, unenforceable or invalid by a decision of a court or other governmental
agency of competent jurisdiction unappealed within the time allowed for appeal, or which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise; [***]. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION
MANAGEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Steering Committee</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Formation. </B>Within [***] after the Effective Date, the Parties shall establish a joint steering committee
(the &#147;<B>Joint Steering Committee</B>&#148; or &#147;<B>JSC</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Membership. </B>The JSC
shall consist of two (2)&nbsp;representatives from each of the Parties, each with the requisite experience and seniority to enable such person to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of
the JSC. The initial JSC members from each Party are set forth on <U>Schedule 2.1.2</U>. From time to time, each Party may substitute one or more of its representatives to the JSC on written notice to the other Party. Each Party shall select from
its representatives a <FONT STYLE="white-space:nowrap">co-chairperson</FONT> for the JSC. From time to time, each Party may change the representative who will serve as its <FONT STYLE="white-space:nowrap">co-chairperson</FONT> on written notice to
the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Specific Responsibilities during the Collaboration Term. </B>During the Collaboration
Term,<B> </B>the JSC shall oversee the Collaboration Program, and shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;monitor and coordinate
the activities of the Parties under the Collaboration Program, including overseeing the JRDC, the JTTT, and any other Subcommittees and facilitating communications between the Parties with respect to the Development of the Licensed Products; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;except for the initial budget included in the Collaboration R&amp;D Plan that is to be executed by the Parties
contemporaneously with the execution of this Agreement, discuss and facilitate the Parties&#146; agreement on a reasonable budget (the &#147;<B>Collaboration Budget</B>&#148;) for the tasks to be completed in each
<FONT STYLE="white-space:nowrap">six-month</FONT> period of the Collaboration Term and for any adjustments to such tasks, subject to Section&nbsp;3.2.4; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;approve any amendments to the Collaboration R&amp;D Plan in accordance with Section&nbsp;3.2.2; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;review and discuss each Party&#146;s written reports, including the results of the Development activities,
provided to the JSC pursuant to Section&nbsp;3.8.3; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;approve subcontractors proposed to be used by Precision
for the purposes of performing &#147;material&#148; services (as the term &#147;material&#148; is used in Section&nbsp;4.3.2) in connection with the Collaboration Program, such approval not to be unreasonably withheld, conditioned or delayed,
pursuant to Section&nbsp;4.3.2; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;establish Subcommittees, including a Joint Tech Transfer Team,
as appropriate, to carry out its functions and to establish the rules governing and the responsibilities of the Joint Tech Transfer Team; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;resolve disputes that may arise in any Subcommittee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;without limiting clause (g)&nbsp;above, resolve disputes that may arise between the Parties or the JTTT regarding
the content of the Technology Transfer Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;discuss and consider optimal technologies or methodologies for
delivery, Manufacture and administration of Licensed Products, such as [***] and other potential Third Party Licenses pursuant to Section&nbsp;5.4.3(a), <I>provided however</I> that [***], and <I>provided further</I> that Precision shall timely
(A)&nbsp;provide Gilead through the JSC with such information with respect to any [***] that it intends to <FONT STYLE="white-space:nowrap">in-license</FONT> from a Third Party in reasonable detail to enable Gilead to understand the reasons for the
potential selection of such [***], (B) reasonably respond to Gilead&#146;s questions relating thereto and (C)&nbsp;consider in good faith Gilead&#146;s feedback with respect to such selection; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;perform such other functions as may be assigned to the JSC hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Specific Responsibilities following the Collaboration Term.</B> The JSC shall automatically be disbanded
immediately after the First Commercial Sale of the first Licensed Product. During the period after the Collaboration Term and prior to such First Commercial Sale, the JSC shall serve only (a)&nbsp;as a forum for sharing and discussing information
with respect to the Technology Transfer, Manufacture, Development and other Exploitation of the Licensed Products and (b)&nbsp;if the Technology Transfer has not been completed, to resolve disputes between the Parties or the JTTT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;Joint Research and Development Committee. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Formation. </B>Within [***] after the Effective Date, the Parties shall establish a joint research and
development committee (the &#147;<B>Joint Research and Development Committee</B>&#148; or &#147;<B>JRDC</B>&#148;). The JRDC shall consist of two (2)&nbsp;representatives from each of the Parties, each with the requisite experience and seniority to
enable such person to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the JRDC. The initial JRDC members from each Party are set forth on <U>Schedule 2.2.1</U>. From time to time, each Party may
substitute one or more of its representatives to the JRDC on written notice to the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Specific Responsibilities during the Collaboration Term.</B>
The JRDC shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;provide guidance to the Parties on the implementation of the Collaboration Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;propose amendments to the Collaboration R&amp;D Plan to the JSC for its review and approval in accordance with
Section&nbsp;3.2.2; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;discuss the Regulatory Documentation prepared by Gilead pursuant to
Section&nbsp;3.7.1(a); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;discuss the reports to be provided by Precision pursuant to Section&nbsp;3.7.1(b),
including the chemistry, manufacturing and control (CMC) reports; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;perform such other functions as may be
assigned to the JRDC hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, the JRDC shall not have the authority to modify the Collaboration R&amp;D Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Specific Responsibilities after the Collaboration Term and Disbandment</B>. The JRDC shall be disbanded and
have no further responsibilities or authority under this Agreement upon the expiry of the Collaboration Term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;General Provisions Applicable to Committees.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Meetings and Minutes</B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise agreed to by the Parties, the JSC shall meet quarterly during every twelve (12)&nbsp;month period
after the Effective Date until expiration of the Collaboration Term, and thereafter the JSC shall meet annually until disbanded pursuant to Section&nbsp;2.1.4, and the JRDC shall meet monthly during every twelve (12)&nbsp;month period after the
Effective Date until the expiration of the Collaboration Term; <I>provided that</I>, the JSC and the JRDC shall each meet in person once during each such twelve (12)&nbsp;month period after the Effective Date if mutually agreed. The location of such
in person meetings shall alternate between locations designated by Gilead and locations designated by Precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Alliance Manager for each Party shall be responsible for calling meetings with notice provided a reasonable
time in advance of such meeting. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items a reasonable time in advance of the applicable meeting; <I>provided that</I>,
under exigent circumstances requiring input by the Joint Committee, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for a
particular meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld, conditioned or delayed. At the conclusion of each
meeting, the Parties will decide which Party shall prepare and circulate for review and approval of the Parties minutes of each meeting within ten (10)&nbsp;Business Days after the meeting. The Parties shall agree on the minutes of each meeting
promptly, but in no event later than thirty (30)&nbsp;days after such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Procedural
Rules</B><B>.</B> Each Joint Committee shall have the right to adopt such standing rules as shall be necessary for its work, to the extent that such rules are not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inconsistent with this Agreement. A quorum of the Joint Committee shall exist whenever there is present at a meeting at least one (1)&nbsp;representative appointed by each Party. Subject to the
proviso in Section&nbsp;2.3.1(a), representatives of the Parties on a Joint Committee may attend a meeting either in person or by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the
other participants. Representation by proxy shall be allowed. Each Joint Committee shall take action by consensus of the representatives present at a meeting at which a quorum exists, with each Party having a single vote irrespective of the number
of representatives of such Party in attendance, or by a written resolution signed by at least one (1)&nbsp;representative appointed by each Party. Employees or consultants of a Party that are not representatives of such Party on a Joint Committee
may attend meetings of such Joint Committee with advance written notice to the other Party; <I>provided,</I> <I>however</I>, that such attendees (a)&nbsp;shall not vote or otherwise participate in the decision-making process of the Joint Committee,
and (b)&nbsp;are bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> equivalent to those set forth in ARTICLE 7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Decision-making and Dispute Resolution. </B>If the JRDC or any other Subcommittee cannot, or does not, reach
consensus on an issue arising within the scope of its responsibilities within a period of [***], then either Party may refer the matter to the JSC for resolution and a special meeting of the JSC may be called for such purpose. If during the
Collaboration Term, and thereafter for so long as the Technology Transfer has not been completed, the JSC cannot, or does not, reach consensus on an issue, including any dispute arising in the JRDC or a Subcommittee, within a period of [***] after
referral to the JSC, then the JSC shall refer such dispute to the Senior Officers for resolution. If such Senior Officers cannot resolve such dispute within [***] of it being referred to them, then, subject to the remaining provisions of this
Section&nbsp;2.3.3, and without limiting Gilead&#146;s diligence obligations under Sections 3.3 and 3.4 of this Agreement, Gilead shall have final decision-making authority with respect to such matter; <I>provided that</I>, Gilead may not exercise
such authority (i)&nbsp;to require Precision to license any particular IP Rights for use in the Collaboration Program beyond those already contemplated herein, (ii)&nbsp;to expand the scope of the Collaboration Program beyond HBV Targets,
(iii)&nbsp;to expand the scope of the definition of Precision IP, (iv)&nbsp;to accelerate the timelines for Precision Development activities, (v)&nbsp;to establish or modify the Collaboration Budget (for the avoidance of doubt, this clause
(v)&nbsp;shall not be construed to limit Gilead&#146;s right to modify the Collaboration R&amp;D Plan in a manner that requires the Parties to agree on a modified Collaboration Budget pursuant to Section&nbsp;3.2.4), (vi) to modify the Collaboration
R&amp;D Plan to add additional activities to the Collaboration R&amp;D Plan that Precision reasonably demonstrates would cause Precision&#146;s costs or resources for meeting the work plans and timelines set forth in the Collaboration R&amp;D Plan
to exceed the Collaboration Budget or the Gilead Funding Commitment, (vii)&nbsp;to dictate the content of the Technology Transfer Plan, or (viii)&nbsp;to select a [***] other than [***] for any Licensed Product. Notwithstanding the foregoing,
subject to the terms of this Agreement,<B><I> </I></B>Precision shall have final decision-making authority with respect to: (a)&nbsp;the design, creation, and optimization of ARC Nucleases to be proposed to Gilead as Gilead </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ARC Nucleases other than site selection for the HBV Target, which shall be within Gilead&#146;s final decision-making authority; (b)&nbsp;the selection of specific [***] for any Licensed Products
for [***] or such substitute [***] selected by the JSC; and (c)&nbsp;the selection of subcontractors for conducting activities assigned to Precision under the Collaboration R&amp;D Plan other than those subcontractors performing &#147;material&#148;
services in connection with the Collaboration R&amp;D Plan, which subcontractors shall be subject to approval of the JSC pursuant to Section&nbsp;4.3.2; <I>provided however,</I> that with respect to the foregoing (a), Precision shall timely
(A)&nbsp;provide Gilead with such information based on which Precision makes its decisions with respect to such design, creation, and optimization of ARC Nucleases under the Collaboration R&amp;D Plan in reasonable detail to enable Gilead to
understand the reasons for such decisions, (B)&nbsp;reasonably respond to Gilead&#146;s questions relating thereto and (C)&nbsp;consider in good faith Gilead&#146;s feedback with respect to such decisions. Following the Collaboration Term, the JSC
shall have no decision-making authority with respect to any matter arising under this Agreement and, for clarity, subject to the terms and conditions of this Agreement (including Section&nbsp;3.4 and Section&nbsp;4.5), Gilead shall have sole
decision-making authority with respect to any matter relating to the Technology Transfer, Manufacture, Development or Exploitation of the Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations on Authority. </B>Each Party shall retain the rights, powers, and discretion granted to it under
this Agreement and no such rights, powers, or discretion shall be delegated to or vested in a Joint Committee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. No
Joint Committee shall have the power to amend, modify, or waive compliance with this Agreement, which may only be amended or modified as provided in Section&nbsp;11.10 or compliance with which may only be waived as provided in Section&nbsp;11.10.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Alliance Manager.</B> Each Party shall appoint a person(s) who shall oversee contact between the Parties
for all matters between meetings of the Joint Committees and shall have such other responsibilities as the Parties may agree in writing after the Effective Date (each, an &#147;<B>Alliance Manager</B>&#148;). Each Party may replace its Alliance
Manager at any time by notice in writing to the other Party. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT AND REGULATORY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Collaboration Program</B><B>. </B>Subject to the terms and conditions of this Agreement, the Parties
shall collaborate on a research and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> program to construct, optimize and develop one or more Gene Editing Therapy(ies) made using the ARCUS Technology that targets the HBV Target (the
&#147;<B>Collaboration Program</B>&#148;) and conduct the Development activities set forth in the collaboration research and development plan described in Section&nbsp;3.2.1 (such plan, as amended from time to time, the &#147;<B>Collaboration
R&amp;D Plan</B>&#148;). The Collaboration Program shall commence on the Effective Date and will, unless otherwise mutually agreed by the Parties in writing, continue until the third anniversary of the Effective Date or, if earlier, the later of
(a)&nbsp;acceptance by the FDA or other competent foreign Regulatory Authority of [***] of the first IND filing for the first Licensed Product and (b)&nbsp;the satisfactory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completion (as mutually agreed upon by the Parties) of all tasks and activities required under the Collaboration R&amp;D Plan (&#147;<B>Initial Term</B>&#148;); <I>provided that</I>, if either
(a)&nbsp;or (b) has not occurred by the third anniversary of the Effective Date, Gilead, at its option, may extend the Initial Term (or then-current term, as the case may be) for one or more additional six (6)&nbsp;month periods until such time as
the later of (a)&nbsp;and (b) has occurred, by serving a written notice(s) to Precision; <I>provided that</I>, Gilead pays to Precision the funding payment for such additional period(s) in accordance with Section&nbsp;5.1 (the Initial Term together
with any such extensions, the &#147;<B>Collaboration Term</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2&nbsp;&nbsp;&nbsp;&nbsp;Collaboration R&amp;D Plan.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Initial Collaboration R&amp;D Plan. </B>The initial Collaboration R&amp;D Plan as agreed to by the Parties as
of the date hereof, including the applicable Collaboration Budget, has been signed and acknowledged by each Party and copies of such signed document have been exchanged between the Parties concurrently with the execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments. </B>During the Collaboration Term, either Party, directly or through its representatives on the
JRDC or the JSC, may propose any amendment to the Collaboration R&amp;D Plan, including in light of changed circumstances, and, if the Collaboration Term is extended pursuant to Section&nbsp;3.1, the Parties shall update the Collaboration R&amp;D
Plan to include such additional period(s). Any and all such amendments or updates shall be subject to approval by the JSC, subject to the dispute resolution procedures set forth in Section&nbsp;2.3.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Contents. </B>The Collaboration R&amp;D Plan shall include, without limitation: (a)&nbsp;the Development
activities to be conducted by each Party pursuant to the Collaboration Program; (b)&nbsp;Development goals; (c)&nbsp;the estimated timelines for such activities; (d)&nbsp;the anticipated costs of and resources for the Development activities, which
shall, with respect to Precision&#146;s Development activities under the Collaboration R&amp;D Plan, not exceed the Gilead Funding Commitment and shall reflect the FTE Rate and the payment schedule set forth in Section&nbsp;5.1.1; and (e)&nbsp;the
preliminary design parameters for <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies to be performed under the Collaboration R&amp;D Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Collaboration Budget.</B> With respect to each <FONT STYLE="white-space:nowrap">six-month</FONT> period of the
Collaboration Term, Precision shall propose to the JSC a Collaboration Budget for the performance of the activities in the Collaboration R&amp;D Plan including required FTEs at the FTE Rate, materials, Third Party services and any other cost items.
In addition, Precision will propose to the JSC an update to the Collaboration Budget to reflect any adjustments made to the Collaboration R&amp;D Plan by the JSC; <I>provided however,</I> that the first Collaboration Budget shall be included in the
initial Collaboration R&amp;D Plan to be executed by the Parties contemporaneously with the execution of this Agreement, as described in Section&nbsp;3.2.1. The Parties, through the JSC, shall use reasonable efforts to agree promptly on each
proposed Collaboration Budget. For the avoidance of doubt, the Collaboration Budget must be mutually agreed by Precision and Gilead prior to conducting the relevant activities in the Collaboration Program and will not be subject to final
decision-making authority of either Party under Section&nbsp;2.3.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Inconsistency. </B>If the terms of
the Collaboration R&amp;D Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Performance of the </B><B>Collaboration R&amp;D
Plan</B><B>.</B><B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B>Precision and Gilead shall each use Commercially Reasonable Efforts to carry out or to cause to be carried out the activities assigned to it under the Collaboration R&amp;D
Plan in good scientific manner, in compliance with all Applicable Law and in accordance with the timelines set forth therein, and shall, in particular, use Commercially Reasonable Efforts to perform the activities within the time periods set forth
in the Collaboration R&amp;D Plan. In the event of any delay in any payments required under Section&nbsp;5.1.1 beyond the due date for such payment, and without limiting any right of Precision under Section&nbsp;10.2, Precision may suspend
performance of its activities assigned to it under the Collaboration R&amp;D Plan for so long as such delay continues. Neither Party makes any representation, warranty or guarantee that the Development activities conducted under the Collaboration
R&amp;D Plan will be successful or that any particular result will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Development
Following Expiry of the </B><B>Collaboration Term</B><B>.</B> Following expiry of the Collaboration Term, Gilead, at its sole cost, shall be solely responsible for the Development and other Exploitation of the Licensed Products throughout the
Territory. Gilead shall provide to Precision an annual high-level summary (consistent with Section B of <U>Schedule 3.8.3</U>) prepared in good faith of its plans to Develop the Licensed Products. Gilead will use Commercially Reasonable Efforts to
Develop and otherwise Exploit a Licensed Product in each of the Major Markets, and to comply with such plans, in accordance with the terms of this Agreement and in compliance with all applicable Laws. If Gilead and its Affiliates and Sublicensees
have collectively permanently ceased all Development and other Exploitation of Licensed Products under this Agreement, Gilead shall deliver notice to Precision and such notice will be deemed a termination of this Agreement pursuant to
Section&nbsp;10.3.1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5&nbsp;&nbsp;&nbsp;&nbsp;Clinical Supply of the Licensed Products.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.5.1&nbsp;&nbsp;&nbsp;&nbsp;With respect to any Licensed Product developed under the Collaboration Program and specified in the Supply
Agreement (and any such additional Licensed Products as the parties may mutually agree), until the later of the completion of a [***] for a Licensed Product and the completion of the Technology Transfer for such Licensed Product, Precision shall be
solely responsible for manufacturing and supplying clinical supplies of such Licensed Product(s) (&#147;<B>Supplied Product</B>&#148;) for use by or on behalf of Gilead under this Agreement, and thereafter Gilead shall assume all manufacturing and
supply activities for such Licensed Product (including, for clarity, commercial manufacture and supply). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.5.2&nbsp;&nbsp;&nbsp;&nbsp;Within ninety (90)&nbsp;days of identifying the Gilead ARC Nucleases to be used in any Licensed Product, the
Parties shall discuss in good faith and enter into (a)&nbsp;a reasonable and customary supply agreement pursuant to which Precision shall manufacture and supply and Gilead shall purchase Supplied Products incorporating such Gilead ARC Nucleases, for
use in Clinical Studies and under which Gilead would purchase clinical requirements of such Licensed Products for a price equal to [***] of COGS (the &#147;<B>Supply Agreement</B>&#148;) and (b)&nbsp;a reasonable and customary quality agreement that
shall set forth the terms and conditions upon which Precision shall conduct its quality activities in connection with such supply (the &#147;<B>Quality Agreement</B>&#148;), in each case (a)&nbsp;and (b), in a form reasonably acceptable to Gilead
and Precision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In the event that by [***] prior to the expected date of the first IND filing for the first Licensed Product the Parties do not mutually agree to the Supply Agreement and the Quality Agreement,
Gilead shall have the right to require Precision to conduct an early Technology Transfer to Gilead or its designee so that Gilead or such designee can commence the Manufacture of the Licensed Products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6&nbsp;&nbsp;&nbsp;&nbsp;Technology Transfer.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6.1&nbsp;&nbsp;&nbsp;&nbsp;Upon Gilead&#146;s request, and no later than upon the expiration of the Collaboration Term, Precision shall
promptly disclose and transfer to Gilead such Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> and such Information that Precision Controls under the [***] <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or other Third Party
Licenses that are licensed to Gilead hereunder as is required pursuant to the Technology Transfer Plan; <I>provided that</I>, before the expiration of the Collaboration Term, Gilead shall only receive such Precision
<FONT STYLE="white-space:nowrap">Know-How</FONT> as is necessary or reasonably useful for Gilead to meet its obligations under the Collaboration R&amp;D Plan or as the Parties may otherwise reasonably agree in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6.2&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall, no later than upon the expiration of the Collaboration Term, agree to a technology transfer
plan with reasonable limitations on access to Precision personnel (including reasonable caps on hours of access) and facilities, for the full technology transfer of the Manufacture of the Licensed Products to any facility of Gilead or its designee,
approved in advance in writing by Precision (such approval not to be unreasonably withheld, conditioned or delayed, and will not be required for facilities located in [***], including the transfer of all Precision
<FONT STYLE="white-space:nowrap">Know-How</FONT> relating to the Manufacture of the Supplied Products and any such Information that Precision Controls under the [***] <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or other Third Party
Licenses that may be obtained under this Agreement, in a form reasonably acceptable to the Parties (&#147;<B>Technology Transfer Plan</B>&#148;). Any further transfer by Gilead or its designee following the initial Technology Transfer shall be
subject to the approval process set forth above in this Section&nbsp;3.6.2. The Parties agree that ARCUS Technology will not be transferred to Gilead or its designee under this Agreement. Any disputes regarding the content of the Technology Transfer
Plan shall be resolved in accordance with Section&nbsp;2.3.3. Following expiration of the Collaboration Term, Precision shall conduct such technology transfer to Gilead or its designee in accordance with the Technology Transfer Plan (the
&#147;<B>Technology Transfer</B>&#148;), under the oversight and guidance of the JTTT (if any). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6.3&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the foregoing, for a period of [***] following completion of the Technology Transfer Plan, upon Gilead&#146;s request made reasonably in advance of the commencement of anticipated Manufacture by Gilead, Precision shall provide Gilead or its
designee with such Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> relating to the Manufacture of the Supplied Products supplemental to the Technology Transfer Plan (i.e., items inadvertently omitted from the Technology Transfer Plan) as
is reasonably necessary for Gilead or its designee to commence the Manufacture of the Licensed Products as permitted by this Agreement and the Supply Agreement. For the avoidance of doubt, Gilead acknowledges that after the [***] period described in
this Section&nbsp;3.6.3, Precision shall have no obligation to provide Gilead any such additional support. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6.4&nbsp;&nbsp;&nbsp;&nbsp;In the event the Supply Agreement is entered into by the
Parties pursuant to Section&nbsp;3.5.2, the Supply Agreement shall remain in effect until the completion of the Technology Transfer and shall either cover the Parties&#146; respective rights and obligations with respect to the Technology Transfer or
the Parties will enter into a separate written technology transfer agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6.5&nbsp;&nbsp;&nbsp;&nbsp;All Technology Transfer
responsibilities, costs and expenses of Precision and its Affiliates will be set forth in the Collaboration R&amp;D Plan and Collaboration Budget and considered Development activities funded under Section&nbsp;5.1.1, except for such activities
conducted following filing of an IND for any Licensed Product. For any such <FONT STYLE="white-space:nowrap">post-IND</FONT> activities, (a)&nbsp;Precision will [***] and (b) [***]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Matters.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.7.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Regulatory Activities.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;As between the Parties, subject to Section&nbsp;3.7.1(b) and Section&nbsp;3.7.1(d), Gilead shall be responsible for
(i)&nbsp;preparing and filing all Regulatory Documentation, including the IND filing for the first Licensed Product, (ii)&nbsp;obtaining and maintaining all Regulatory Approvals for the Licensed Products and (iii)&nbsp;conducting communications with
the Regulatory Authorities for the Licensed Products. Gilead shall prepare and file all clinical Regulatory Documentation under the Collaboration Program, including the first IND filing for the first Licensed Product, in consultation with the JRDC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;As between the Parties, during the Collaboration Term, Precision shall be responsible for preparing all <FONT
STYLE="white-space:nowrap">non-clinical</FONT> and chemistry, manufacturing and control (CMC) reports, in each case, as reasonably required by Gilead, for inclusion in the first IND filing for the first Licensed Products. Precision shall prepare all
such reports, and provide Gilead with copies of any such reports, in each case, in a timely manner to permit Gilead to make such IND filing without delay, which shall then be discussed in consultation with the JRDC. Without limiting the foregoing,
Precision shall support Gilead as may be reasonably necessary in connection with Gilead&#146;s preparation of clinical Regulatory Documentation under the Collaboration Program during the Collaboration Term pursuant to Section&nbsp;3.7.1(a). The
responsibilities, costs and expenses of Precision and its Affiliates under this Section&nbsp;3.7.1(b) during the Collaboration Term will be set forth in the Collaboration R&amp;D Plan and Collaboration Budget and considered Development activities
funded under Section&nbsp;5.1.1. Thereafter, for any such activities, (i)&nbsp;Precision will [***] and (ii)&nbsp;Gilead shall [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;All Regulatory Documentation generated under this Agreement, including in the course of conducting the
Collaboration Program, shall be owned by Gilead and held in the name of Gilead (or its designee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Except as
otherwise provided in the Supply Agreement or the Quality Agreement, with respect to each Licensed Product (i)&nbsp;Gilead shall have sole </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsibility for attending all meetings (whether occurring in person, by telephone or other remote means) with applicable Regulatory Authorities; <I>provided that</I>, Gilead, where permitted
by Applicable Law, shall permit a reasonable number of Precision employees to attend (A)&nbsp;each <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting for the Licensed Product, (B)&nbsp;the end of phase 2 meeting for the Licensed Product with
the FDA, and (C)&nbsp;any other meeting with FDA or EMA (or other competent Regulatory Authority in the United Kingdom) if such meeting has one or more items on the agenda directed toward the safety or delivery of ARC Nucleases; and (ii)&nbsp;Gilead
shall have the sole right and responsibility to correspond with applicable Regulatory Authorities; <I>provided that</I>, Gilead, where permitted by Applicable Law, will provide draft communications with the FDA and EMA (or other competent Regulatory
Authority in the United Kingdom) to Precision for review and comment to the extent it relates to the Gilead ARC Nuclease, the ARCUS Technology, ARCUS Assigned IP or any [***] to the extent licensed or sublicensed by Precision to Gilead, and will
consider Precision&#146;s comments in good faith before submitting the communications to the FDA or EMA (or other competent Regulatory Authority in the United Kingdom). If either Party or its Affiliates or subcontractors receive any material written
correspondence or other communication from the Regulatory Authorities in the Major Markets regarding (x)&nbsp;in the case of Precision as the Party receiving such correspondence from the Regulatory Authorities, the Licensed Products or any
components thereof, or (y)&nbsp;in the case of Gilead as the Party receiving such correspondence from the Regulatory Authorities, the Gilead ARC Nuclease, any [***] <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Precision or the ARCUS
Technology or ARCUS Assigned IP, such Party shall provide the other Party with&nbsp;access to or copies of all such material written or electronic correspondence promptly after its receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.7.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Pharmacovigilance. </B>To the extent safety reporting is required by Applicable Law, upon the request of
either Party, the Parties shall enter into an agreement to cover the exchange of adverse event safety data in a mutually agreed format in order to monitor the safety of the Licensed Products and to meet reporting requirements with any applicable
Regulatory Authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8&nbsp;&nbsp;&nbsp;&nbsp;Records and JSC Reporting.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.8.1&nbsp;&nbsp;&nbsp;&nbsp;Precision shall, and shall ensure that its subcontractors shall, maintain records in sufficient detail and in good
scientific manner appropriate for patent and regulatory purposes, and in compliance with Applicable Law, which shall be complete and accurate and shall properly reflect all work done and results achieved in the performance of its Development
activities under the Collaboration Program which shall record only such activities and shall not include or be commingled with records of activities outside the scope of this Agreement. Such records shall be retained by Precision for at least [***]
after the expiration or termination of this Agreement, or for such longer period as may be required by Applicable Law. Upon the request of Gilead, Precision shall provide copies of the records it has maintained pursuant to this Section&nbsp;3.8.1 to
Gilead. Gilead shall maintain such records and the information disclosed therein in confidence in accordance with ARTICLE 7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.8.2&nbsp;&nbsp;&nbsp;&nbsp;Gilead shall have the right, during normal business hours and
upon reasonable notice not more than twice annually during the Collaboration Term without Precision&#146;s consent (not to be unreasonably withheld, conditioned or delayed), to inspect and copy all records of Precision maintained pursuant to
Section&nbsp;3.8.1, which may at Gilead&#146;s reasonable request, be at Precision&#146;s facilities, or as permitted by Precision&#146;s agreements with its subcontractors, at the facilities of any such subcontractor. Gilead shall maintain such
records and the information disclosed therein in confidence in accordance with ARTICLE 7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.8.3&nbsp;&nbsp;&nbsp;&nbsp;At each JSC
meeting during the Collaboration Term, each Party&#146;s members on the JSC shall provide a written report to the JSC of its activities with respect to the Collaboration Program conducted since the last JSC meeting, including a reasonable summary of
the results of such activities and the progress of the Collaboration Program. In addition, Precision will provide Gilead with a semi-annual report summarizing its activities under the Collaboration Program, which report shall be in the form set
forth on <U>Schedule 3.8.3</U> and shall include disclosure of Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> required by Section&nbsp;6.1.1 that has not been previously disclosed. The JSC may request of a Party any such additional
written reports describing its activities with respect to the Collaboration Program, as it determines necessary or useful in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.8.4&nbsp;&nbsp;&nbsp;&nbsp;Without limiting any other rights of Precision hereunder, in the event a Regulatory Authority requests, in
connection with a request to obtain regulatory approval for a product (other than a Licensed Product) containing an ARC Nuclease (other than a Gilead ARC Nuclease) that Precision provide clinical data Controlled by Gilead or any of its Affiliates or
Sublicensees relating to (a)&nbsp;the safety of (i)&nbsp;the ARCUS Technology generally, or (ii)&nbsp;ARCUS Assigned IP, or (b)&nbsp;if relevant to such other product, a Gilead ARC Nuclease or its delivery, Precision may request that Gilead provide
such information within Gilead&#146;s Control (and Gilead will use Commercially Reasonable Efforts to obtain and provide such information from its Sublicensees) to Precision solely for use in response to such Regulatory Authority&#146;s request with
respect to such other product and Gilead shall promptly provide such information for provision to such Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.8.5&nbsp;&nbsp;&nbsp;&nbsp;Without limiting any other rights of Gilead hereunder, in the event a Regulatory Authority requests, in
connection with a request to obtain Regulatory Approval for a Licensed Product, that Gilead provide clinical data Controlled by Precision or any of its Affiliates or sublicensees relating to (a)&nbsp;the safety of the Gilead ARC Nuclease or its
delivery, or (b)&nbsp;if relevant to a Licensed Product, a Gilead ARC Nuclease or its delivery, Gilead may request that Precision provide such information to Gilead solely for use in response to such Regulatory Authority&#146;s request with respect
to the Licensed Product and Precision shall promptly provide such information within Precision&#146;s Control (and will use Commercially Reasonable Efforts to obtain and provide such information from its sublicensees) for provision to such
Regulatory Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRANT OF RIGHTS AND COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Grants to </B><B>Gilead</B><B>.</B><B> </B>Subject to the terms and conditions of this Agreement and
continuing unless and until terminated pursuant to ARTICLE 10, Precision hereby grants to Gilead: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;a
worldwide, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except pursuant to Section&nbsp;11.3), exclusive license (or sublicense, as the case may be), with the right to grant sublicenses in accordance with
Section&nbsp;4.3, under the Precision IP, [***] (subject to Section&nbsp;4.1.3) and Precision&#146;s interest in the Joint Collaboration Program IP, to Exploit the Licensed Products (including the Gilead ARC Nucleases incorporated in or for
incorporation into a Licensed Product) in the Field in the Territory, including to perform its Development activities under the Collaboration R&amp;D Plan; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1.2&nbsp;&nbsp;&nbsp;&nbsp;a worldwide, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except pursuant to
Section&nbsp;11.3), <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, with the right to grant sublicenses in accordance with Section&nbsp;4.3, under the ARCUS IP, to the extent necessary for Gilead to Exploit the Licensed Products
(including the Gilead ARC Nucleases incorporated in or for incorporation into a Licensed Product) in the Field in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1.3&nbsp;&nbsp;&nbsp;&nbsp;The license under Section&nbsp;4.1.1 with respect to [***] shall be (A)&nbsp;effective only upon execution of the
applicable [***] license granted to Precision, and (B)&nbsp;exclusive solely as between the Parties. Any licenses granted by Precision under Section&nbsp;4.1.1 under any [***] license are subject to and limited by any limitation, restriction or
additional terms set forth in the agreement under which Precision or its Affiliates obtained rights under such [***] license from such Third Party. Precision shall (i)&nbsp;use Commercially Reasonable Efforts to ensure the terms of such license
(a)&nbsp;confer IP Rights sufficient to grant the license to Gilead under Section&nbsp;4.1.1, (b) do not result in any material expansion of Gilead&#146;s obligations under this Agreement, and (c)&nbsp;do not require Gilead to make any additional
representations or warranties or to provide any additional indemnities materially different from those set forth herein, and (ii)&nbsp;disclose to Gilead in writing all terms of such agreement which materially limit or otherwise materially impact
Gilead&#146;s rights or obligations with respect to such [***]. In connection with such disclosure of terms, and prior to entering into any such license, Precision shall provide Gilead reasonable opportunities to review and comment on the draft
during negotiations of the draft with the applicable Third Party (which may be reasonably redacted by Precision, including to redact provisions relating to financials, IP Rights not relevant to this Agreement, and targets not relevant to this
Agreement), reasonably consider any comments made by Gilead and provide to Gilead a copy of the unexecuted final version of such redacted agreement no later than [***]. Upon receipt of such unexecuted final version, Gilead may elect by written
notice to Precision to (1)&nbsp;accept inclusion of the IP Rights licensed to Precision under such agreement in the licenses granted to Gilead herein or (2)&nbsp;reject such inclusion in good faith, in which case, for clarity, Gilead may enter into
a license for such [***] or similar [***] directly with the applicable licensor in accordance with Section&nbsp;5.4.3(b). In the event Gilead elects to accept such license entered into by Precision, Gilead shall comply with the terms or obligations,
as disclosed to Gilead in writing in such unexecuted final version shared with Gilead pursuant to the above prior to Gilead&#146;s election pursuant to the immediately preceding sentence, that Precision is required to impose under any such agreement
for [***]. Precision shall make Commercially Reasonable Efforts to ensure that the license rights to [***] will include rights for Gilead to modify or improve such technology. Gilead acknowledges that, notwithstanding Precision making such
Commercially Reasonable Efforts, the license rights to [***] may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include rights for Gilead to modify or improve such technology, or if such rights are included, such rights may be subject to allocation of IP Rights in such modifications or improvements that
differ from those contained in this Agreement. For the sake of clarity, if Gilead has accepted its inclusion as set forth above, upon execution the [***] licensed by Precision under the [***] <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements will fall within the scope of licenses set forth in Section&nbsp;4.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Grants to
</B><B>Precision</B><B>.</B> Subject to the terms and conditions of this Agreement, Gilead (on behalf of itself and its Affiliates) hereby grants to Precision: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2.1&nbsp;&nbsp;&nbsp;&nbsp; a worldwide, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free,
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, with the right to grant sublicenses to subcontractors (that have been, if required, approved by Gilead) in accordance with Section&nbsp;4.3, under the Gilead Dual IP, Gilead Patents and
Gilead <FONT STYLE="white-space:nowrap">Know-How</FONT> (but Gilead shall not be required to disclose any <FONT STYLE="white-space:nowrap">Know-How</FONT> except as otherwise specifically provided herein), to perform, or have performed by such
subcontractors, its Development activities under the Collaboration R&amp;D Plan during the Collaboration Term; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2.2&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3&nbsp;&nbsp;&nbsp;&nbsp;Sublicensing and Subcontracting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3.1&nbsp;&nbsp;&nbsp;&nbsp;Gilead shall have the right: (a)&nbsp;to grant sublicenses under Section&nbsp;4.1 through multiple tiers of
sublicenses to any Affiliate or Third Party; and (b)&nbsp;to subcontract to any Affiliate or Third Party the performance of any of its obligations under this Agreement. Notwithstanding the foregoing, during the Collaboration Term Gilead shall not
grant any sublicenses to a Third Party with respect to any Development of a Licensed Product in or for a Major Market without Precision&#146;s prior written consent. Gilead shall provide Precision with written notice of any sublicense under this
Agreement within [***] after its execution. [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3.2&nbsp;&nbsp;&nbsp;&nbsp;Precision shall have the right: (a)&nbsp;to subcontract
any of its Development activities under the Collaboration Program to any Affiliate or Third Party; (b)&nbsp;to grant sublicenses under Section&nbsp;4.2.1 to its subcontractors; and (c)&nbsp;subject to the last sentence of this Section&nbsp;4.3.2, to
grant sublicenses under Section&nbsp;4.2.2 through multiple tiers of sublicenses to any Affiliates or Third Parties;<I> provided however</I>, Precision shall only subcontract activities or services under the Collaboration Program that are designated
as &#147;material&#148; in the Collaboration R&amp;D Plan to a vendor that has not been <FONT STYLE="white-space:nowrap">pre-approved</FONT> by Gilead in the Collaboration R&amp;D Plan after receiving written consent from Gilead, such consent not to
be unreasonably withheld, conditioned or delayed. Precision shall provide Gilead with written notice of any sublicense it grants under any issued or published Patents, or Patents that have otherwise been disclosed to Precision, in each case licensed
by Gilead to Precision under Section&nbsp;4.2.2 within [***] after Precision is aware that it has sublicensed such a Patent of Gilead&#146;s. In the event Gilead denies consent for such subcontracting, then if Precision requests a recommendation
from Gilead for an alternative subcontractor, Gilead shall provide to Precision the name and contact information of at least one subcontractor approved for the conduct of the applicable activity or service within
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
[***] of Precision&#146;s request for consent. Notwithstanding anything to the contrary in this Agreement, Precision&#146;s right to sublicense under clause (c)&nbsp;above shall be subject to
Gilead&#146;s prior written consent if [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3.3&nbsp;&nbsp;&nbsp;&nbsp;Each sublicense or subcontract agreement entered into by a
Party under this Section&nbsp;4.3 shall be consistent with the applicable terms and conditions of this Agreement, including the confidentiality provisions of ARTICLE 7 and the intellectual property provisions of ARTICLE 6, and the applicable Party
shall be fully responsible for any breach of this Agreement by any of its Affiliates, Sublicensees or subcontractors. In addition, to the extent required by the Cellectis Agreement, each sublicense granted by Gilead under any Precision Patent must
grant the same scope of rights for all Precision Patents<I> </I>and each sublicense granted by Gilead under any ARCUS Patent must grant the same scope of rights for all ARCUS Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Retention of Rights.</B> Subject to Section&nbsp;4.5, Precision retains the right to (a)&nbsp;practice
the Precision IP and its interest in the Joint Collaboration Program IP to exercise its rights and perform its obligations under this Agreement (in each case in a manner consistent with this Agreement), including the Collaboration Program, and under
any Supply Agreement or Quality Agreement, (b)&nbsp;conduct research related to the ARCUS Technology and ARCUS Assigned IP; and (c)&nbsp;practice and license ARCUS Patents, ARCUS Assigned IP, Precision Patents and Precision <FONT
STYLE="white-space:nowrap">Know-How</FONT> outside the scope of the licenses granted to Gilead under Section&nbsp;4.1.1. Gilead hereby retains the right to practice all intellectual property licensed by Gilead to Precision under this Agreement for
any and all purposes. Except as set forth herein, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any trademarks, patents or patent applications, Information, or other IP
Rights owned or Controlled by the other Party. Neither Party grants to the other Party any rights, licenses or covenants in or to any IP Rights, whether by implication, estoppel, or otherwise, other than the license rights that are expressly granted
under this Agreement. Each Party shall not, and shall not permit any of its Affiliates or Sublicensees to, practice any Patents or Information licensed to it by the other Party outside of the scope of the license granted to it under this Agreement
(other than such practices as would be otherwise permitted by applicable safe harbors under Applicable Law). Without limiting the foregoing, nothing in this Agreement shall be deemed to grant Gilead any right to access or receive any ARCUS
Technology or any right to design, create, select, or optimize any ARC Nucleases using the ARCUS Technology or to otherwise use the ARCUS Technology as a genome engineering tool. Except as expressly set forth in this Article 4, the foregoing
licenses from Precision to Gilead do not include any rights under the ARCUS Patents or ARCUS Technology. Neither Party grants hereunder any rights with respect to other products or therapies with which a Licensed Product may be combined. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5&nbsp;&nbsp;&nbsp;&nbsp;Exclusivity.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.5.1&nbsp;&nbsp;&nbsp;&nbsp;The Parties acknowledge both their possession of confidential or proprietary information and the highly
competitive nature of the industry in which they operate and, accordingly, agree that, in consideration of entering into this Agreement and the promises contained herein, in the Territory, [***] Precision shall not, during the Term [***] (a)
conduct, participate in, or enable or directly fund, [***] other than [***] in accordance with this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, or (b)&nbsp;license, authorize, or appoint or otherwise enable any Third Party (other than subcontractors to the extent permitted herein) to engage in any of the activities set forth
in clause (a)&nbsp;of this Section&nbsp;4.5.1. Notwithstanding the foregoing, in no event shall [***] be prohibited or otherwise restricted by this Section&nbsp;4.5.1 from engaging in, directly or indirectly, or funding or otherwise enabling, [***].
Each Party acknowledges and agrees that (A)&nbsp;this Section&nbsp;4.5 has been negotiated by the Parties, (B)&nbsp;the geographical and time limitations on activities set forth in this Section&nbsp;4.5 are reasonable, valid and necessary in light
of the Parties&#146; circumstances and necessary for the adequate protection of the business of Exploiting the Licensed Products and (C) [***]. If, notwithstanding the foregoing, a court of competent jurisdiction determines that the restrictions set
forth in this Section&nbsp;4.5 are too broad or otherwise unreasonable under Applicable Law, including with respect to duration, geographic scope or space, the court is hereby requested and authorized by the Parties to revise this Section&nbsp;4.5
to include the maximum restrictions allowable under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.5.2&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary
in this Agreement, the restrictions on Precision set forth in Section&nbsp;4.5.1 shall not apply to any Acquirer of Precision [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.5.3&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section&nbsp;4.5.1, [***] acquires a Competitor, continuation of the relevant Competitive
Program(s) shall not be a breach of this Agreement; <I>provided that</I> (i) [***], and (ii)&nbsp;[***]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Ex</B><B>isting <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>. <B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.6.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Cellectis Patents.</B> Gilead acknowledges and agrees that rights under certain ARCUS Patents and/or Precision
Patents are licensed to Precision by Cellectis S.A. (the &#147;<B>Cellectis Patents</B>&#148;) under that certain Patent Cross-License Agreement between Cellectis S.A. and Precision dated January&nbsp;23, 2014 (the &#147;<B>Cellectis
Agreement</B>&#148;), and, notwithstanding any exclusive license granted to Gilead under this Agreement, (a)&nbsp;Cellectis S.A. retains rights under the Cellectis Patents and is not restricted from granting rights to Third Parties under the
Cellectis Patents, (b)&nbsp;any licenses and rights granted by Precision to Gilead under the Cellectis Patents are granted only within the permissible scope of sublicenses granted under the Cellectis Agreement, and (c)&nbsp;pursuant to the Cellectis
Agreement, Cellectis S.A. retains <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights under certain ARCUS Patents and/or Precision Patents identified in the Cellectis Agreement, which may be further sublicensed by Cellectis S.A. without
Precision control or consent. Gilead acknowledges and agrees that any exercise of any right by Cellectis S.A, or by any Third Party through Cellectis S.A, under the Cellectis Agreement shall not constitute a breach of this Agreement by Precision.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.6.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Duke IP.</B> Gilead acknowledges and agrees that any licenses and rights granted by Precision to Gilead
under the Duke IP are granted subject to the terms and conditions of the Duke Agreement, including Duke&#146;s right to practice under the Duke IP for its own internal, <FONT STYLE="white-space:nowrap">non-commercial,</FONT> educational, research
and clinical purposes, and subject to the rights of the United States Government and applicable limitations under 37 C.F.R. &#167; 401, Public Law <FONT STYLE="white-space:nowrap">96-517</FONT> and Public Law
<FONT STYLE="white-space:nowrap">98-620</FONT> resulting from the United States Government&#146;s funding of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research leading to creation of the Duke IP. Without limiting the foregoing, Gilead agrees to comply with any obligations resulting from such government rights with respect to its practice of the
Duke IP (if any) under this Agreement. Duke shall be a third party beneficiary of the Agreement to the extent its terms and conditions apply or relate to the Duke IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Preservation of Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements and </B>[***] <B><FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements. </B>To the extent relating to the Gilead ARC Nucleases or the Licensed Products, Precision shall, and shall procure that its Affiliates shall, maintain all licenses to all [***], including the
Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements and any [***] <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, in full force and effect in accordance with their terms and conditions and keep Gilead reasonably
informed in this regard. Without limiting the foregoing and Section&nbsp;5.4.9, Precision shall not (a)&nbsp;commit any acts or permit the occurrence of any omissions that would cause breach or termination of any license to [***], including Existing
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or any [***] <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or (b)&nbsp;amend or otherwise modify or permit to be amended or modified, any license to [***], including the
Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or any [***] <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, in any way that would prejudice Gilead&#146;s rights under this Agreement or its ability to continue
to Exploit Licensed Products. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAYMENTS AND RECORDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;Payments during the Collaboration Program. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Payments. </B>In consideration of Precision&#146;s agreement to perform its Development activities under the
Collaboration R&amp;D Plan,<B> </B>Gilead shall pay Precision (a) [***] for the first six (6)&nbsp;month period of the Collaboration Term, (b) [***] for the second six (6)&nbsp;month period of the Collaboration Term and (c) [***] for each six month
period of the Collaboration Term thereafter (in aggregate, the &#147;<B>Gilead Funding Commitment</B>&#148;); <I>provided that</I>, (i)&nbsp;if the Collaboration Budget at any time is less than the Gilead Funding Commitment for any <FONT
STYLE="white-space:nowrap">six-month</FONT> period, then Precision shall hold the difference for use later in the Collaboration Term if required based on the Collaboration Budget (i.e. if the Collaboration Budget exceeds the Gilead Funding
Commitment for a six month period), and (ii)&nbsp;if the Collaboration Budget at any time exceeds the Gilead Funding Commitment for any <FONT STYLE="white-space:nowrap">six-month</FONT> period, then after application of any amounts held by Precision
under clause (i)&nbsp;Gilead shall pay Precision the difference in the then-current period as an advance from later portions of the Gilead Funding Commitment in the Collaboration Term. For clarity, the aggregate Collaboration Budget for the entire
Collaboration Term shall not exceed the aggregate Gilead Funding Commitment without the written consent of both Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Invoicing. </B>On the Effective Date,<B> </B>Precision shall issue to Gilead an invoice for the first [***]
tranche referred to in Section&nbsp;5.1.1 and Gilead shall pay such tranche to Precision within [***] of receipt of invoice by Gilead. Thereafter Precision shall issue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an invoice for each [***] tranche or [***] tranche, as applicable, referred to in Section&nbsp;5.1.1 at least [***] in advance of the relevant six (6)&nbsp;month period. All invoices described in
the immediately preceding sentence or this Section&nbsp;5.1.2 shall be due within [***] of receipt by Gilead. Invoices shall be in accordance with the template set forth on <U>Schedule 5.1.2</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;Development and Regulatory Milestones. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2.1&nbsp;&nbsp;&nbsp;&nbsp;In partial consideration of the rights granted under this Agreement and subject to Section&nbsp;5.2.2 below,
Gilead shall pay to Precision the following <FONT STYLE="white-space:nowrap">one-time</FONT> milestone payments after the achievement of the following corresponding milestone events with respect to the first Licensed Product to achieve the
applicable milestone in the Territory during the Term. Gilead shall notify Precision in writing no later than [***] following the achievement of a milestone event and shall pay to Precision the milestone payment corresponding to such milestone event
[***] of receipt of an invoice from Precision. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Development and Regulatory Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2.2&nbsp;&nbsp;&nbsp;&nbsp;Each milestone payment in Section&nbsp;5.2.1 shall be payable only upon the first
achievement of such milestone and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a different Licensed Product. The maximum aggregate amount payable by Gilead pursuant to Section&nbsp;5.2.1
is [***]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3&nbsp;&nbsp;&nbsp;&nbsp;Commercial Milestones. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3.1&nbsp;&nbsp;&nbsp;&nbsp;In partial consideration of the rights granted hereunder and subject to Section&nbsp;5.3.2 below, Gilead shall pay
to Precision the following <FONT STYLE="white-space:nowrap">one-time</FONT> milestone payments after the achievement of the following milestone events with respect to the first occurrence of the Licensed Products achieving the milestone in the
Territory during the Term (including any wind-down period following the end of the Term). Gilead shall notify Precision in writing no later than [***] following the end of the Calendar Quarter in which the commercial milestone event occurs and shall
pay to Precision the milestone payment corresponding to such milestone event within [***] of receipt of an applicable invoice from Precision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Commercial Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***] and less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***] and less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***] and less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum total</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3.2&nbsp;&nbsp;&nbsp;&nbsp;Each milestone payment in Section&nbsp;5.3.1 shall be payable only once upon the
first achievement of such milestone and no amounts shall be due for subsequent or repeated achievements of such milestone. The maximum aggregate amount payable by Gilead pursuant to Section&nbsp;5.3.1 is [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3.3&nbsp;&nbsp;&nbsp;&nbsp;For the avoidance of doubt, for the purposes of this Section&nbsp;5.3, all Net Sales of Licensed Products shall
be aggregated globally for all sales made by Gilead or any of its Affiliates or Sublicensees in any and all forms, presentations, delivery systems, dosages, and formulations for purposes of determining whether the above Net Sales thresholds have
been achieved. For clarity, all Licensed Products shall be aggregated for the purposes of this Section&nbsp;5.3 even if they do not have the same Active Components as one another. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4&nbsp;&nbsp;&nbsp;&nbsp;Royalties. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.1&nbsp;&nbsp;&nbsp;&nbsp;In partial consideration of the rights granted hereunder and subject to Sections&nbsp;5.4.2 through 5.4.8, during
the applicable Royalty Term, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, Gilead shall pay to Precision royalties on the Net Sales of such Licensed Product at the rates set forth below, as determined by the aggregate
annual global Net Sales of all Licensed Products in the Licensed Product Family for such Licensed Product: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Global Net Sales of the Applicable Licensed
Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion of Net Sales of such Licensed Product Family in the Territory in any given
Calendar Year that is less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion of Net Sales of such Licensed Product Family in the Territory in any given
Calendar Year that is equal to or greater than [***] and less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Global Net Sales of the Applicable Licensed
Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion of Net Sales of such Licensed Product Family in the Territory in any given
Calendar Year that is equal to or greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion of Net Sales of such Licensed Product Family in the Territory in any given
Calendar Year that is greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.2&nbsp;&nbsp;&nbsp;&nbsp;[***]: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Third Party Licenses. </B>With respect to the Exploitation of any Licensed Product under this Agreement, and
without prejudice to any other right of each Party, Gilead and Precision may obtain licenses from Third Parties for any rights for the Exploitation of any Licensed Product in accordance with the following provisions of this Section&nbsp;5.4.3 (each,
a &#147;<B>Third Party License</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If during the Collaboration Term, either Party considers that a
license(s) to additional technology, including [***], or IP Rights of a Third Party are necessary or reasonably useful to Develop, Manufacture or otherwise Exploit a Licensed Product under this Agreement, such Party may refer the matter to the JSC
for discussion. If the JSC concludes that such a Third Party License is required or reasonably useful, the Parties shall negotiate in good faith which Party shall enter into the Third Party License and the allocation between the Parties of
responsibility for the costs and expenses of obtaining such Third Party License, including any royalty reductions under the payments otherwise payable to Precision under Section&nbsp;5.4.1. Notwithstanding the foregoing, after the Collaboration
Term, if rights to Patents controlled by any Third Party cover or claim the applicable Licensed Product or its Manufacture, then Gilead may negotiate and obtain a Third Party License from such Third Party for Gilead, its Affiliates or Sublicensees
to Exploit such Licensed Product in such country in accordance with this Agreement. If, pursuant to this Section&nbsp;5.4.3(a), Gilead has obtained a Third Party License, and owes a royalty under such Third Party License for sales of a Licensed
Product in a particular country, then Gilead shall have the right to reduce the royalty payments otherwise payable to Precision under Section&nbsp;5.4 based on such sales by up to [***] of such payments under such Third Party License; <I>provided
that,</I> no royalty payment to Precision for a Licensed Product hereunder shall be reduced, pursuant to this Section&nbsp;5.4.3(a), to less than [***] of the royalty payment that would otherwise be due to Precision in the absence of a reduction
pursuant to this Section&nbsp;5.4.3(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section&nbsp;5.4.3(a) above, Precision shall be
responsible for obtaining any licenses from Third Parties to Gilead ARC Nuclease delivery technology, including [***], used in the Collaboration Program in the Licensed Products (&#147;[***]&#148;), [***], and following the execution of any such
Third Party License shall notify Gilead promptly of the same. Precision shall not incorporate or use any such [***] in the Manufacture </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 33 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Licensed Products unless Precision has the right to sublicense such [***] to Gilead consistent with Section&nbsp;4.1.3 and transfers such [***] to Gilead as set forth in
Section&nbsp;3.6.2. In the event Precision fails to obtain a Third Party License with respect to the [***] that Precision uses in the Collaboration Program in the Licensed Products, or fails to so transfer such [***], or if the terms of such
proposed Third Party License as disclosed under Section&nbsp;4.1.3 are not acceptable to Gilead, then Gilead may do so independently and may in such case [***].&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;For clarity, to the extent an agreement includes rights with respect to any active therapeutic ingredient, having
a different mode of action than the Gilead ARC Nuclease or a different active component than the Gilead ARC Nuclease, it is not a Third Party License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.4&nbsp;&nbsp;&nbsp;&nbsp;<B>No Valid Claim. </B>In the event that, at the time a Licensed Product is sold in a country, there is no Valid
Claim in such country with respect to such Licensed Product and the Regulatory Exclusivity Period has expired in such country with respect to the Licensed Product but the Royalty Term remains in effect, then for the purposes of calculating the
royalties owed based on the sale of such Licensed Product in such country under Section&nbsp;5.4.1 at that time, in such country the royalties that would otherwise be owed and payable under Section&nbsp;5.4.1 based on such sale shall be reduced by
[***]. The calculation of the royalty reduction under this Section&nbsp;5.4.4 shall be conducted separately for each Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Biosimilar Products. </B>On a Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, if in any country in the Territory during the Royalty Term for a Licensed Product a Biosimilar Product launches with respect to such
Licensed Product in such country, then the royalties that would otherwise be owed and payable under Section&nbsp;5.4.1 for the Net Sales of such Licensed Product in such country shall be reduced by [***], from the date of launch of such Biosimilar
Product in such country until the end of the Royalty Term for such Licensed Product in such country. In the event that Gilead does not learn of such launch until after royalties are paid, Gilead shall be entitled to such adjustment retroactively to
such launch date in the form of a credit against future royalty obligations of Gilead under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty Floor. </B>Under no circumstances will the application of the reductions in Section&nbsp;5.4.3,
Section&nbsp;5.4.4 and Section&nbsp;5.4.5 together ever result in a reduction of the royalties payable by Gilead to Precision to less than [***] of the amounts specified in Section&nbsp;5.4.1.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.7&nbsp;&nbsp;&nbsp;&nbsp;<B>Compulsory Licensing; Generic Sublicensees.</B> If a Regulatory Authority requires Gilead or any of its
Affiliates or Sublicensees to grant a compulsory license to a Third Party permitting such Third Party to make and sell a Licensed Product in a country in the Territory, or Gilead sublicenses to a Generic Sublicensee, then all amounts received from
the compulsory licensee in consideration for grant of the license and received from the Generic Sublicensee in consideration for the sublicense, including any royalties so received, shall be [***]. For the avoidance of doubt, the reductions in
Section&nbsp;5.4.3, Section&nbsp;5.4.4 and Section&nbsp;5.4.5 shall not apply to reduce amounts payable to Precision pursuant to this Section&nbsp;5.4.7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 34 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.8&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent Challenge.</B> [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.9&nbsp;&nbsp;&nbsp;&nbsp;<B>Payments under Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements and </B>[***] <B><FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements. </B>The Parties acknowledge and agree that, without limiting the right of Gilead to take a license to [***] set forth in Section&nbsp;5.4.3(b), Precision shall be solely responsible for, and
shall promptly discharge, any and all payments payable pursuant to the Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements and [***] <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements. Notwithstanding anything in this
Agreement to the contrary, in the event Precision terminates any of the Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements and therefore Gilead enters into a license directly with the licensor or otherwise makes payments pursuant
to any of the Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements in order to maintain its rights as a sublicensee under such Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4.10&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty Payments and Reporting.</B> Gilead shall calculate all amounts payable to Precision pursuant to
Section&nbsp;5.4.1 at the end of each Calendar Quarter. Gilead shall pay to Precision the royalty amounts due with respect to a given Calendar Quarter within [***] after the end of such Calendar Quarter. Each payment of royalties due to Precision
shall be accompanied by a statement of the amount of gross sales and Net Sales (including applicable deductions) of each Licensed Product, in each country of the Territory during the applicable Calendar Quarter (including such amounts expressed in
local currency and as converted to Dollars), a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter, and details on the determination of incremental royalty rates including the aggregation of Licensed Products
into Licensed Product Families. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Mode of Payment.</B> All payments to Precision under this Agreement
shall be made by deposit of Dollars in the requisite amount to the following bank account of Precision or such other account as Precision may from time to time designate by notice to Gilead: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ACCOUNT NAME:</B><B>
</B>[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Currency.</B>&nbsp;For the purpose of calculating any sums due under, or otherwise
reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), Gilead shall convert any amount expressed in a foreign currency into Dollars equivalents using its, its Affiliate&#146;s or
Sublicensee&#146;s standard conversion methodology consistent with GAAP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7&nbsp;&nbsp;&nbsp;&nbsp;Taxes. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7.1&nbsp;&nbsp;&nbsp;&nbsp;A Party making payments to the other Party under this Agreement shall make such payments without deduction or
withholding for taxes except to the extent that any such deduction or withholding is required by Applicable Law in effect at the time of payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 35 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7.2&nbsp;&nbsp;&nbsp;&nbsp;Any tax required to be withheld on amounts payable under this
Agreement shall promptly be paid by the applicable paying Party on behalf of the other Party to the appropriate governmental authority or Regulatory Authority, and such paying Party shall furnish the other Party with proof of payment of such tax
within [***]. Any such tax required to be withheld shall be an expense of and borne by such other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7.3&nbsp;&nbsp;&nbsp;&nbsp;The
Parties shall cooperate with respect to all documentation required by any taxing authority or reasonably requested by either Party to secure a reduction in the rate of applicable withholding taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7.4&nbsp;&nbsp;&nbsp;&nbsp;If the applicable paying Party had a duty to withhold taxes in connection with any payment it made to the other
Party under this Agreement but such paying Party failed to withhold, and such taxes were assessed against and paid by such paying Party, then the other Party shall indemnify and hold harmless such paying Party from and against such taxes (including
interest, but not including any related penalties). If such paying Party makes a claim under this Section&nbsp;5.7.4, it shall comply with the obligations imposed by Section&nbsp;5.7.2 as if such paying Party had withheld taxes from a payment to the
other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7.5&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, if Gilead assigns its rights and obligations hereunder to an
Affiliate or successor pursuant to Section&nbsp;11.3, and if such Affiliate or successor shall be required by applicable law to withhold any additional nonrecoverable taxes from or in respect of any amount payable under this Agreement as a result of
such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional taxes withheld so that, after making all required withholdings, Precision receives an amount equal to the sum it would have
received had no such assignment been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Records.</B> Gilead shall, and shall cause its
Affiliates and Sublicensees to, keep complete and accurate books and records pertaining to its gross sales and Net Sales of the Licensed Products, in sufficient detail to calculate all amounts payable hereunder and to verify compliance with its
obligations under this Agreement. Such books and records shall be retained by Gilead and its Affiliates and Sublicensee until the later of (a)&nbsp;three (3)&nbsp;years after the end of the period to which such books and records pertain, and
(b)&nbsp;the expiration of the applicable tax statute of limitations (or any extensions thereof), or for such longer period as may be required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Audit</B><B>.</B> At the request of Precision, Gilead shall, and shall cause its Affiliates and
Sublicensees to, permit an independent auditor designated by Precision and reasonably acceptable to the Gilead, at reasonable times and upon reasonable notice, to audit the books and records maintained by Gilead pursuant to Section&nbsp;5.8 to
ensure the accuracy of all reports and payments made hereunder. Such examinations may not (a)&nbsp;be conducted for any Calendar Quarter more [***] after the end of such Calendar Quarter, (b)&nbsp;be conducted more than [***] or (c)&nbsp;be repeated
for any Calendar Quarter. Except as provided below, the cost of this audit shall be borne by the Precision, unless the audit reveals a variance of more than [***] from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 36 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the reported amounts, in which case Gilead shall bear the cost of the audit. If such audit concludes that (x)&nbsp;the amount Gilead paid to the Precision for a given period exceeded the amount
that was payable to Precision, then Precision shall reimburse Gilead for such variance within [***] of the date on which such audit was completed by Precision, or (y)&nbsp;the amount Gilead paid to the Precision for a given period was less than the
amount that was payable to Precision, Gilead shall reimburse Precision for such variance within [***] after the date on which such audit is completed by Precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confi</B><B>dentiality.</B> The auditing party shall treat all information subject to review under
Sections&nbsp;5.8 and 5.9 in accordance with the confidentiality provisions of ARTICLE 7. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;Ownership of Intellectual Property. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Ownership of Arising IP; Disclosure.</B> As between the Parties, subject to Sections&nbsp;6.1.2 and 6.1.3, each
Party shall own and retain all right, title and interest in and to any and all Information that is conceived, discovered, developed or otherwise made by or on behalf of such Party or its Affiliates under this Agreement, and any and all Patents and
other IP Rights with respect thereto. Gilead shall promptly disclose to Precision in writing during the Collaboration Term and shall cause its Affiliates and make Commercially Reasonable Efforts to cause its Sublicensees to so disclose during the
Collaboration Term, the conception, discovery, development or making of any Gilead Dual <FONT STYLE="white-space:nowrap">Know-How</FONT> described in clause (a)&nbsp;of the definition of Gilead Dual <FONT STYLE="white-space:nowrap">Know-How,</FONT>
and shall make available to Precision, in the form that Gilead has available (including by providing copies thereof), all such Gilead Dual <FONT STYLE="white-space:nowrap">Know-How</FONT> in connection with each JSC meeting. During the Collaboration
Term, Precision shall disclose to Gilead in writing and shall cause its Affiliates and make Commercially Reasonable Efforts to cause its sublicensees to so disclose, the conception, discovery, development or making of any Precision <FONT
STYLE="white-space:nowrap">Know-How</FONT> described in clause (a)&nbsp;of the definition of Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> and shall make available to Gilead, in the form that Precision has available (including by
providing copies thereof), all such Precision <FONT STYLE="white-space:nowrap">Know-How,</FONT> in connection with each JSC Meeting and semi-annual report described in Section&nbsp;3.8.3. Within [***] following the end of the Collaboration Term,
each Party shall disclose to the other Party in writing any additional Gilead Dual <FONT STYLE="white-space:nowrap">Know-How</FONT> or Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> required to be disclosed by this Section&nbsp;6.1.1
that has not previously been disclosed pursuant to this Section&nbsp;6.1.1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Ownership of ARCUS Assigned
IP; </B>[***]<B>.</B><B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 37 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Ownership of Joint Collaboration Program IP.</B> As between
the Parties, each Party shall own an equal, undivided interest in any and all: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Information which is
conceived, discovered, developed or otherwise made jointly by or on behalf of Gilead or its Affiliates, on the one hand, and Precision or its Affiliates or subcontractors, on the other hand, in the performance of the Collaboration Program [***]
(&#147;<B>Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Patents that claim or cover the Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How</FONT>
(&#147;<B>Joint Collaboration Program Patents</B>&#148;) or any other IP Rights with respect to the Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the license granted under Sections&nbsp;4.1.1, the Parties&#146; obligations under Section&nbsp;4.5, and the payment obligations in ARTICLE 5, each
Party shall have the right to Exploit the Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Joint Collaboration Program Patents without a duty of seeking consent or accounting to the other Party; <I>provided
however,</I> that [***]. Each Party shall promptly disclose to the other Party in writing and shall cause its Affiliates to so disclose, the conception, discovery, development or making of any Joint Collaboration Program <FONT
STYLE="white-space:nowrap">Know-How</FONT> or Joint Collaboration Program Patents by or on behalf of such Party or its Affiliates and shall make available to the other Party, in whatever form such other Party may reasonably request (including by
providing copies thereof), all such Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How</FONT> within ten (10)&nbsp;Business Days of such generation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment Obligation.</B> Each Party shall cause all Persons who perform Collaboration Program activities for
such Party, including subcontractors, to be under an obligation to assign their rights in any IP Rights resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> and public institutions which have standard policies against such an assignment (in which case a suitable license, or right to obtain such a license, shall be
obtained). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1.5&nbsp;&nbsp;&nbsp;&nbsp;<B>IP Transfer.</B> The licenses and other rights granted in this Agreement are intended to be
and will be binding on any permitted assignee or other transferee of any right, title, or interest with respect to any IP Rights licensed hereunder. Without limiting the generality of the foregoing, and without limiting anything else in this
Agreement, if a Party (&#147;<B>IP Assignor</B>&#148;) assigns or otherwise transfers any right, title or interest to a Third Party (&#147;<B>IP Assignee</B>&#148;) with respect to any of the IP Rights licensed by IP Assignor to the other Party
hereunder, IP Assignor will cause the IP Assignee to agree in writing that such rights are subject to the licenses and other rights granted under or with respect to such IP Rights pursuant to this Agreement, and such assignment or other transfer
shall only be effective if such IP Assignee does so agree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1.6&nbsp;&nbsp;&nbsp;&nbsp;<B>United States Law. </B>The determination of
whether information and inventions are conceived, discovered, developed, or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other IP Rights) therein, shall, for purposes of this Agreement,
be made in accordance with Applicable Law in the United States as such law exists as of the Effective Date irrespective of where such conception, discovery, development or making occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 38 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;Maintenance and Prosecution of Patents. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Precision Patent</B><B>s. </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;6.2.4, Precision shall have the first right, but not the obligation, through the use of
internal or outside counsel, to prepare, file, prosecute, and maintain the Precision Patents worldwide, at [***] sole cost and expense [***]. Precision shall keep Gilead consulted in a timely fashion with respect to the strategy of such preparation,
filing, prosecution and maintenance, and in the event of a disagreement with respect to such strategy in relation to a Precision HBV Patent, Gilead shall have final decision-making authority in accordance with Section&nbsp;6.2.4 and subject to
Section&nbsp;6.2.5; <I>provided, however</I>, that Gilead may relinquish such final decision-making authority with respect thereto, in which case Gilead shall no longer be obligated to pay for such activities with respect to the applicable Patent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Precision decides not to prepare, file, prosecute, or maintain a Precision Patent pursuant
to Section&nbsp;6.2.1(a), Precision shall provide reasonable prior written notice to Gilead of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline for any action that may be taken with respect to
such Patent). Gilead shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Patent (unless Precision&#146;s decision to allow the lapse of any
provisional patent application, or abandonment of any patent application, is intended to be in favor of trade secret protection or in favor of a continuation), at [***] cost and expense. The rights and obligations of the Parties shall not otherwise
be affected by such assumption of control by Gilead. For the purpose of this ARTICLE 6, &#147;prosecution&#148; shall include any post-grant proceeding including supplemental examination, post grant review proceeding, inter parties review
proceeding, patent interference proceeding, opposition proceeding and <FONT STYLE="white-space:nowrap">re-examination.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Gilead acknowledges and agrees that Precision has no rights or responsibility for preparing, filing, prosecuting
or maintaining the Cellectis Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Precision decides to allow the lapse of any patent
application in favor of trade secret protection as described in Section&nbsp;6.2.1(b) or Section&nbsp;6.2.2(b), Precision shall first discuss such decision with Gilead in good faith (including the potential strategic rationale for not disclosing
Information in patent filings and preserving such Information as a trade secret). If, following such discussion, Precision proceeds with allowing any such lapse, Precision shall [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Prior to Precision filing a patent application that would constitute a Precision HBV Patent, [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 39 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Collaboration Program Patents.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Precision shall have the first right, but not the obligation, through the use of internal or outside counsel, to
prepare, file, prosecute, and maintain the Joint Collaboration Program Patents worldwide, with the cost and expense of such activities to be [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Precision decides not to prepare, file, prosecute, or maintain a Joint Collaboration Program
Patent pursuant to Section&nbsp;6.2.2(a), Precision shall provide reasonable prior written notice to Gilead of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline for any action that may be taken
with respect to such Patent), and Gilead shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Patent (unless Precision&#146;s decision to allow
the lapse of any provisional patent application, or abandonment of any patent application, is intended to be in favor of trade secret protection or in favor of a continuation), with the cost and expense of such activities to be [***]. In the event
Gilead chooses not to assume such control and direction, [***] for the cost and expense of such activities. [***] the costs and expenses of the filing, prosecution, and maintenance of any Joint Collaboration Program Patents shall by so choosing
relinquish all ownership rights in such Joint Collaboration Program Patents (but not its license rights) and, [***] all such costs and expenses, then such other Party shall be deemed the sole owner thereof and the relinquishing Party shall assign
its interest in such Joint Collaboration Program Patents to such other Party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Gilead Dual Patents.</B><B>
</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Gilead shall have the first right, but not the obligation, through the use of internal or outside
counsel, to prepare, file, prosecute, maintain and otherwise control the Gilead Dual Patents worldwide, at [***]. Gilead shall provide Precision with notice of the filing of, and a copy of, any patent applications for a Gilead Dual Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Gilead decides not to prepare, file, prosecute, or maintain a Gilead Dual Patent pursuant to
Section&nbsp;6.2.3(a), Gilead shall provide reasonable prior written notice to Precision of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline for any action that may be taken with respect to
such Gilead Dual Patent), and Precision shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of a Patent that covers the patentable subject matter of
the Gilead Dual <FONT STYLE="white-space:nowrap">Know-How</FONT> to the extent relating to ARCUS Technology, ARCUS Assigned IP or ARC Nucleases (unless Gilead&#146;s decision to allow the lapse of any provisional patent application, or abandonment
of any patent application, is intended to be in favor of trade secret protection or in favor of a continuation), at [***]. The rights and obligations of the Parties shall not otherwise be affected by such assumption of control by Precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation; Precision HBV Patents. </B>With respect to a Precision Patent, Joint Collaboration Program
Patent, or Gilead Dual Patent, the Prosecuting Party shall keep the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party reasonably informed of all steps with regard to such preparation, filing, prosecution, and maintenance, including by
providing the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 40 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party with a copy of material communications to and from any patent authority regarding such Patent, and by providing the drafts to the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT>
Party of any material filings or responses to be made to such patent authorities sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for the
<FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party to review and comment thereon; <I>provided that</I>, with respect to the Precision HBV Patents, and subject to Section&nbsp;6.2.1(a) and Section&nbsp;6.2.5, Precision shall obtain
Gilead&#146;s prior written approval for such activities, and in the event of a dispute Gilead shall have the final decision-making authority with respect to such matter. If Gilead does not provide a response<B> </B>within [***] after a request from
Precision with respect to a filing or response, approval shall be deemed to have been provided by Gilead. The Prosecuting Party shall consider in good faith any comments of the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party with
respect to such drafts of the Prosecuting Party and with respect to strategies for filing and prosecuting the applicable Precision Patent, Joint Collaboration Program Patent or Gilead Dual Patent; <I>provided that</I>,<I> </I>with respect to the
Precision HBV Patents (subject to Section&nbsp;6.2.1(a) and Section&nbsp;6.2.5) and Joint Collaboration Program Patents, Precision shall incorporate any and all good faith comments of Gilead, and with respect to Gilead Dual Patents, Gilead shall
consider in good faith any comments provided by Precision. Notwithstanding the foregoing, the Prosecuting Party shall promptly inform the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party of any adversarial patent office proceeding or
<I>sua sponte</I> filing, including a request for, or filing or declaration of, any interference, opposition, or reexamination relating to the applicable Precision Patents, Joint Collaboration Program Patents or Gilead Dual Patents. The Parties
shall thereafter consult and the Prosecuting Party shall consider in good faith all comments, requests and suggestions provided by the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party. Each Party shall provide the other Party all
reasonable assistance and cooperation in the patent prosecution efforts under this Section&nbsp;6.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. When a Party
assumes the responsibilities for the prosecution and maintenance of a Patent under Section&nbsp;6.2.1(b), 6.2.2(b) or 6.2.3(b), the other Party shall promptly transfer to such Party the patent prosecution files for such Patent and provide reasonable
assistance in the transfer of the prosecution responsibilities. The Party assuming such prosecution and maintenance responsibilities shall have the right to engage its own counsel to do so. In connection with the activities set forth in
Section&nbsp;6.2.1, 6.2.2, and 6.2.3 the Prosecuting Party shall consult with the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party as to the strategy for the prosecution and maintenance of the Precision Patents, Joint Collaboration
Program Patents and Gilead Dual Patents, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.5&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Research Agreement. </B>Each Party shall have the right to make an election under 35 U.S.C. 102(c) when
exercising its rights under this ARTICLE 6 without the prior written consent of the other Party; <I>provided that</I>, the electing Party shall notify the other Party in advance of any such election and shall consider comments provided by the other
Party with respect to such election in good faith. With respect to any such election, the Parties shall coordinate their activities with respect to any submissions, filings, or other activities in support thereof. The Parties acknowledge and agree
that this Agreement is a &#147;joint research agreement&#148; as defined in 35 U.S.C. 100(h). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 41 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.7&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Maintenance and Prosecution.</B> Except as set forth
in this Section&nbsp;6.2, neither Party shall have any rights to prepare, file, prosecute or maintain Patents owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by the other Party or its Affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2.8&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent Schedules.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Precision HBV Patents.</B> At least [***], Precision shall deliver to Gilead an updated <U>Schedule 1.113</U>
listing the Precision HBV Patents as of the date of such delivery. Such updated <U>Schedule 1.113</U> shall be incorporated into this Agreement upon receipt by Gilead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Schedule of ARCUS Patents and Precision Patents.</B> Without limiting clause (a), at least every [***]
commencing as of the first anniversary of this Agreement, Precision shall deliver to Gilead a <U>Schedule 6.2.8</U> listing all ARCUS Patents and all Precision Patents, including Precision HBV Patents, as of the date of such delivery. In addition,
without limiting clause (a)&nbsp;or limiting the foregoing obligation in this clause (b), within [***] of Precision delivering to Gilead each Gilead ARC Nuclease under this Agreement, Precision shall deliver to Gilead an updated <U>Schedule
6.2.8</U> which schedule shall list all ARCUS Patents and all Precision Patents, including Precision HBV Patents, as of the date of such delivery. In addition, within [***] of the conclusion of the Collaboration Term, Precision shall deliver to
Gilead an updated <U>Schedule 6.2.8</U>, which updated schedule shall list all ARCUS Patents and all Precision Patents, including Precision HBV Patents as of the date of such delivery. Such updated <U>Schedule 6.2.8</U> shall be incorporated into
this Agreement upon receipt by Gilead. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3&nbsp;&nbsp;&nbsp;&nbsp;Enforcement of Patents.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Precision Patents.</B><B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B><B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement of the
Precision Patents by a Third Party of which such Party becomes aware (including alleged or threatened infringement based on the development or commercialization of, or an application to market, a Licensed Product), subject in each case to any
confidentiality obligations of the applicable Party owed to the Third Party who made such Party aware of such infringement. Neither Party shall prosecute any Competitive Infringement of the Precision Patents prior to [***]. Thereafter, Gilead shall
have the first right, but not the obligation, to prosecute any Competitive Infringement of the Precision Patents, at [***] cost and expense, and Gilead shall retain control of the prosecution of such suit. At all times, Precision shall have the sole
right, but not the obligation, to prosecute any Other Infringement of the Precision Patents at [***] cost and expense, and Precision shall retain control of the prosecution of such suit.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 42 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Gilead decides not to prosecute any
Competitive Infringement of the Precision Patents following [***], Gilead shall provide reasonable prior written notice to Precision of such intention (which notice shall, where reasonably practical, be given no later than [***] prior to the next
deadline for any action that may be taken with respect to such Patent), and Precision shall thereupon have the option to assume the control and direction of the prosecution of the Competitive Infringement, at [***] cost and expense; <I>provided
that,</I> in deciding whether to exercise its option, and in prosecuting such infringement, Precision shall take into consideration Gilead&#146;s business reasons for deciding not to prosecute the infringement of such Precision Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event a Party prosecutes infringement of a Precision Patent against Competitive Infringement pursuant to
this Section&nbsp;6.3.1, the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party shall have the right to join as a party to such claim, suit, or proceeding and participate with its own counsel at [***] cost and expense; <I>provided</I>
<I>that</I> the Prosecuting Party shall retain control of the prosecution of such claim, suit, or proceeding. During any such claim, suit, or proceeding, the Prosecuting Party shall: (i)&nbsp;provide the
<FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party with drafts of all official papers and statements (whether written or oral) prior to their submission in such claim, suit, or proceeding, in sufficient time to allow the <FONT
STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party to review, consider and substantively comment thereon; (ii)&nbsp;reasonably consider taking action to incorporate the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party&#146;s
comments on all such official papers and statements; (iii)&nbsp;allow the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party the opportunity to participate in the preparation of witnesses and other participants in such claim, suit, or
proceeding; and (iv)&nbsp;not settle any such claim, suit, or proceeding except in a manner that it believes in good faith is in the best interests of the Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Gilead acknowledges and agrees that (i)&nbsp;Precision has no rights or responsibility for enforcing the Cellectis
Patents, and therefore all references to Precision Patents in this Section&nbsp;6.3.1 shall be deemed to exclude the Cellectis Patents for all purposes, (ii)&nbsp;prior to initiating enforcement actions against a Third Party with respect to certain
Precision Patents which were subject to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license granted by Precision to Cellectis S.A. pursuant to the Cellectis Agreement, Precision is required by the Cellectis Agreement to confirm that
Cellectis S.A. has not granted a license to such Third Party under such Precision Patents, and Gilead will cooperate with Precision in taking such actions as required by the Cellectis Agreement, and (iii)&nbsp;Duke retains discretion as to whether
to become a party plaintiff and has certain rights with respect to enforcement of Patents contained within the Duke IP in the event Precision does not enforce such Patents.<B><I> </I></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Collaboration Program Patents.</B><B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement of the Joint
Collaboration Program Patents by a Third Party of which such Party becomes aware (including alleged or threatened infringement based on the development, commercialization, or an application to market a Licensed Product), subject in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 43 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each case to any confidentiality obligations of the applicable Party owed to the Third Party who made such Party aware of such infringement. Gilead shall have the first right, but not the
obligation, to prosecute any Competitive Infringement of the Joint Collaboration Program Patents, at [***] cost and expense, and Precision shall have the first right, but not the obligation, to prosecute any Other Infringement of the Joint
Collaboration Program Patents, at [***] cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Gilead decides not to prosecute
any Competitive Infringement of the Joint Collaboration Program Patents, Gilead shall provide reasonable prior written notice to Precision of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline
for any action that may be taken with respect to such Patent), and Precision shall thereupon have the option to assume the control and direction of the prosecution of the Competitive Infringement, at [***] cost and expense; <I>provided that</I>, in
deciding whether to exercise its option, and in prosecuting such Competitive Infringement, Precision shall take into consideration Gilead&#146;s business reasons for deciding not to prosecute the infringement of such Joint Collaboration Program
Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; In the event that Precision decides not to prosecute any Other Infringement of the Joint
Collaboration Program Patents, Precision shall provide reasonable prior written notice to Gilead of such intention (which notice shall, where reasonably practical, be given no later than [***] prior to the next deadline for any action that may be
taken with respect to such Patent), and Gilead shall thereupon have the option to assume the control and direction of the prosecution of the Other Infringement, at [***] cost and expense; <I>provided that,</I> in deciding whether to exercise its
option, and in prosecuting such infringement, Gilead shall take into consideration Precision&#146;s business reasons for deciding not to prosecute the infringement of such Joint Collaboration Program Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;In the event a Party prosecutes infringement of a Joint Collaboration Program Patent pursuant to this
Section&nbsp;6.3.2 and (i)&nbsp;the Prosecuting Party finds it necessary or desirable for the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party to join the Prosecuting Party as a party to any such claim, suit or proceeding, the <FONT
STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party shall, at the Prosecuting Party&#146;s request, or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party otherwise desires to join such claim, suit or proceeding, the <FONT
STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party shall have the right to, join as a party to such claim, suit or proceeding and participate with its own counsel at [***] cost and expense; <I>provided</I> <I>that</I> the Prosecuting Party
shall retain control of the prosecution of such claim, suit or proceeding. During any such claim, suit, or proceeding with respect to the Joint Collaboration Program Patents in which the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party
has joined pursuant to this Section&nbsp;6.3.2, the Prosecuting Party shall: (A)&nbsp;provide the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party with drafts of all official papers and statements (whether written or oral) prior to
their submission in such claim, suit, or proceeding, in sufficient time to allow the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party to review, consider and substantively comment thereon; (B)&nbsp;reasonably consider taking action to
incorporate the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party&#146;s comments on all such official papers and statements; and (C)&nbsp;allow the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party the opportunity to
participate in the preparation of witnesses and other participants in such claim, suit, or proceeding.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 44 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Gilead Dual Patents.</B> Each Party shall promptly notify
the other Party in writing of any alleged or threatened infringement of the Gilead Dual Patents by a Third Party of which such Party becomes aware (including alleged or threatened infringement based on the development or commercialization, or an
application to market, a Licensed Product or any Licensed Product), subject in each case to any confidentiality obligations of the applicable Party owed to the Third Party who made such Party aware of such infringement. Gilead shall have the right,
but not the obligation, to prosecute any such infringement at [***] cost and expense and Gilead shall retain control of the prosecution of such suit. With respect to any such alleged or threatened infringement of the Gilead Dual Patents, if Gilead
finds it necessary or desirable for Precision to join Gilead as a party to any such action, Precision shall, at Gilead&#146;s request, join as a party to such suit and participate with its own counsel at [***] cost and expense; <I>provided</I>
<I>that</I>, Gilead shall retain control of the prosecution of such suit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation.</B> Each Party
agrees to cooperate fully with the other Party in any infringement action pursuant to this Section&nbsp;6.3. Where the Prosecuting Party brings such an action, the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party shall, where necessary,
furnish a power of attorney solely for such purpose or shall join in, or be named as a necessary party to, such action. Unless otherwise set forth herein, the Prosecuting Party shall have the right to settle such claim; <I>provided</I> <I>that</I>,
the Prosecuting Party shall not have the right to settle any Patent infringement litigation under this Section&nbsp;6.3 in a manner that diminishes or has a material adverse effect on the rights or interest of the
<FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party, or in a manner that imposes any costs or liability on, or involves any admission by, the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party, without the express written
consent of the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party. The Prosecuting Party shall provide the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party with copies of all pleadings and other material documents filed with
the court and shall consider reasonable input from the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party during the course of the proceedings. In connection with the activities set forth in Sections&nbsp;6.3.1 and 6.3.2, the Prosecuting
Party shall consult with the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party as to the strategy for the enforcement of the Precision Patents against a Competitive Infringement and Joint Collaboration Program Patents, as applicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Recovery. </B>Except as otherwise agreed by the Parties in connection with a cost sharing arrangement,
any recovery realized as a result of such litigation described in Section&nbsp;6.3.1, 6.3.2 and 6.3.3 (whether by way of settlement or otherwise) shall be [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Enforcement.</B> Except as set forth in this Section&nbsp;6.3, neither Party shall have any rights to
enforce Patents owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by the other Party or its Affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4&nbsp;&nbsp;&nbsp;&nbsp;Infringement Claims by Third Parties. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4.1&nbsp;&nbsp;&nbsp;&nbsp;If the Manufacture or use of a Licensed Product pursuant to this Agreement results in, or may result in, any
claim, suit, or proceeding by a Third Party alleging </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 45 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent infringement by either Party, its Affiliates, Sublicensees or subcontractors, such Party shall promptly notify the other Party thereof in writing. Gilead shall have the first right, but
not the obligation, to defend and control the defense of any such claim, suit, or proceeding alleging patent infringement against Gilead, its Affiliate or Sublicensee at [***] cost and expense, using counsel of its own choice. Precision may
participate in any such claim, suit, or proceeding with counsel of its choice at [***] cost and expense. Without limitation of the foregoing, if Gilead finds it necessary or desirable for Precision to join Gilead as a party to any such action, the
Parties shall cooperate to execute all papers and perform such acts as shall be reasonably required for Precision to join such action. If Gilead elects (in a written communication submitted to Precision within a reasonable amount of time after
notice of the alleged patent infringement) not to defend or control the defense of, or otherwise fails to initiate and maintain the defense of, any such claim, suit, or proceeding, within such time periods so that Precision is not prejudiced by any
delays, Precision may conduct and control the defense of any such claim, suit, or proceeding at [***] cost and expense. Each Party shall keep the other Party reasonably informed of all material developments in connection with any such claim, suit,
or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4.2&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any
recovery realized as a result of such litigation described in Section&nbsp;6.4 (whether by way of settlement or otherwise) shall be [***]. For avoidance of doubt, any recovery realized for infringement of any Precision Patent, Joint Collaboration
Program Patents or Gilead Dual Patents shall be subject to Section&nbsp;6.3.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4.3&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4.4&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Section&nbsp;6.4 shall be construed to limit any rights or obligations of the Parties under
ARTICLE 9. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5&nbsp;&nbsp;&nbsp;&nbsp;Invalidity or Unenforceability Defenses or Actions.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice</B>. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion
of invalidity or unenforceability of any of the Precision Patents, Joint Collaboration Program Patents or Gilead Dual Patents by a Third Party, in each case, of which such Party becomes aware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Precision Patents. </B>Gilead shall have the first right, but not the obligation, at [***] cost and expense, to
defend and control the defense of the validity and enforceability of the Precision Patents where such defense is pursuant to Gilead&#146;s indemnification obligations under Section&nbsp;9.1, in response to a claim brought against Gilead or its
Affiliates or Sublicensees by a Third Party, or where the other party to the action is engaging in Competitive Infringement. In all other cases of defense of Precision Patents, or if Gilead elects not to defend or control such defense, or otherwise
fails to initiate and maintain the defense, Precision shall control such defense. Precision may participate in any such claim, suit, or proceeding defended by Gilead with counsel of its choice at [***] cost and expense; <I>provided</I> <I>that</I>,
Gilead shall retain control of the defense in such claim, suit, or proceeding. With respect to any such action involving the validity or enforceability of the Precision Patents, if the defending Party finds it necessary or desirable for the other
Party to join the defending Party as a party to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 46 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such action, the other Party shall, at the defending Party&#146;s request, join the defending Party as a party to such suit and participate with its own counsel at [***] cost and expense;
<I>provided</I> <I>that,</I> the defending Party shall retain control of the defense in such claim, suit, or proceeding. If Precision elects not to defend or control the defense of the Precision Patents in a suit brought, or otherwise fails to
initiate and maintain the defense of any such claim, suit, or proceeding, then, subject to Precision&#146;s rights under Section&nbsp;6.3.1, Gilead may conduct and control the defense of any such claim, suit, or proceeding at [***] cost and expense.
With respect to any such action involving the validity or enforceability of the Precision Patents, if Gilead finds it necessary or desirable for Precision to join Gilead as a party to any such action, Precision shall, at Gilead&#146;s request, join
Gilead as a party to such suit and participate with its own counsel at [***] cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint
Collaboration Program Patents. </B>Gilead shall have the first right, but not the obligation, to defend and control the defense of the validity and enforceability of the Joint Collaboration Program Patents at [***] cost and expense. With respect to
any such action involving the validity or enforceability of the Joint Collaboration Program Patents, if Gilead finds it necessary or desirable for Precision to join Gilead as a party to any such action, Precision shall, at Gilead&#146;s request,
join Gilead as a party to such suit and participate with its own counsel at [***] cost and expense; <I>provided</I> <I>that,</I> Gilead shall retain control of the defense in such claim, suit, or proceeding. If Gilead elects not to defend or control
the defense of the Joint Collaboration Program Patents in a suit brought, or otherwise fails to initiate and maintain the defense of any such claim, suit, or proceeding, then, subject to Gilead&#146;s rights under Section&nbsp;6.3.1, Precision may
conduct and control the defense of any such claim, suit, or proceeding at [***] cost and expense. With respect to any such action involving the validity or enforceability of the Joint Collaboration Program Patents, if Precision finds it necessary or
desirable for Gilead to join Precision as a party to any such action, Gilead shall, at Precision&#146;s request, join Precision as a party to such suit and participate with its own counsel at [***] cost and expense; <I>provided</I> <I>that,</I>
Precision shall retain control of the defense in such claim, suit, or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Gilead Dual Patents.
</B>Gilead shall have the right, but not the obligation, to defend and control the defense of the validity and enforceability of the Gilead Dual Patents at [***] cost and expense. With respect to any such action involving the validity or
enforceability of the Gilead Dual Patents, if Gilead finds it necessary or desirable for Precision to join Gilead as a party to any such action, Precision shall, at Gilead&#146;s request, join Gilead as a party to such suit and participate with its
own counsel at [***] cost and expense; <I>provided</I> <I>that</I>, Gilead shall retain control of the defense in such claim, suit, or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation. </B>Each Party shall assist and cooperate with the other Party as such other Party may reasonably
request from time to time in connection with its activities set forth in this Section&nbsp;6.5, including by being joined as a party plaintiff in such action or proceeding, providing access to relevant documents and other evidence, and making its
employees available at reasonable business hours. In connection with any such defense or claim or counterclaim, the controlling Party shall consider in good faith any comments from the other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 47 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party and shall keep the other Party reasonably informed of any steps taken, and shall provide copies of all documents filed, in connection with such defense, claim, or counterclaim. In
connection with the activities set forth in Sections&nbsp;6.5.2 and 6.5.3, the Prosecuting Party shall consult with the <FONT STYLE="white-space:nowrap">Non-Prosecuting</FONT> Party as to the strategy for the defense of the Precision Patents and
Joint Collaboration Program Patents, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent Term Extensions in the Territory.</B> As
between the Parties, Gilead shall have the sole right to make decisions regarding, and to apply for, patent term extensions in the Territory, including in the United States with respect to extensions pursuant to 35 U.S.C. &#167;156 et. seq. and in
other jurisdictions pursuant to supplementary protection certificates, and in all jurisdictions with respect to any other extensions that are now or become available in the future, wherever applicable, in each case for the Precision HBV Patents and
any Joint Collaboration Program Patents, with respect to the Licensed Product(s), including whether or not to do so. Prior to Gilead making any such decisions, the patent counsel of each Party shall discuss and recommend for which, if any, of the
Precision HBV Patents and Joint Collaboration Program Patents in the Territory the Parties should seek any term extension, supplementary protection certificates, and equivalents thereof. Precision shall provide prompt and reasonable assistance, as
requested by Gilead, including by taking such action as patent holder as is required under any Applicable Law to obtain such extension or supplementary protection certificate. Further, and without limiting the foregoing, Precision shall not apply
for any patent term extension based on a Marketing Approval for any Gilead ARC Nuclease or Licensed Product without Gilead&#146;s prior written consent and further consultation with Gilead. With respect to Precision Patents that are not Precision
HBV Patents, Precision shall discuss with Gilead in good faith options for applying for patent term extensions on such Precision Patents based on a Marketing Approval for any Gilead ARC Nuclease or Licensed Product prior to deciding whether to apply
for any such extension. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-DISCLOSURE</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality Obligations.</B> At all times during the Term and for a period of [***] following the
expiration or termination of this Agreement in its entirety, or, with respect to Confidential Information of either Party comprising trade secrets of such Party that have been labeled by such disclosing Party or identified by such disclosing Party
to the other Party as being the disclosing Party&#146;s trade secrets, for so long as such Confidential Information is a trade secret of such Party, each Party shall, and shall cause its officers, directors, employees and agents to, keep
confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the
extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary or useful for the performance of, or the exercise of such Party&#146;s rights under, this Agreement. &#147;<B>Confid</B><B>enti</B><B>al
Information</B>&#148; of a Party means any technical, business, or other information provided by or on behalf of such Party to the other Party in connection with this Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 48 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether prior to, on, or after the Effective Date, including (a)&nbsp;the terms and conditions of this Agreement, (b)&nbsp;the ARCUS Technology and the ARCUS Assigned IP, (c)&nbsp;any unpublished
Patents, (d)&nbsp;information relating to the Licensed Products (including the Regulatory Documentation generated pursuant to the Collaboration Program), (e) any Development of Gilead ARC Nucleases or the Licensed Products, and any Information with
respect thereto developed by or on behalf of the disclosing Party or its Affiliates (including Gilead Dual <FONT STYLE="white-space:nowrap">Know-How</FONT> and Precision <FONT STYLE="white-space:nowrap">Know-How,</FONT> as applicable), and
(f)&nbsp;information regarding the scientific, regulatory or business affairs or other activities of either Party. All Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How</FONT> and the terms and conditions of this Agreement shall
be deemed to be the Confidential Information of both Parties, and both Parties shall be deemed to be the receiving Party and the disclosing Party with respect thereto. Except with respect to the Precision
<FONT STYLE="white-space:nowrap">Know-How</FONT> contained in the chemistry, manufacturing and control (CMC) section of any Regulatory Documentation, all Information contained in the Regulatory Documentation and the Gilead Dual <FONT
STYLE="white-space:nowrap">Know-How</FONT> shall be deemed to be the Confidential Information of Gilead. All ARCUS IP, ARCUS Assigned IP and Precision <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed to be the Confidential
Information of Precision. Notwithstanding the foregoing, the confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations under this Section&nbsp;7.1 with respect to any Confidential Information shall not include any information
that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1.1&nbsp;&nbsp;&nbsp;&nbsp;is or hereafter becomes part of the public domain by public use, publication, general knowledge or the
like through no wrongful act, fault or negligence on the part of the receiving Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1.2&nbsp;&nbsp;&nbsp;&nbsp;can be demonstrated by
documentation or other competent proof to have been in the receiving Party&#146;s possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information; <I>provided</I> <I>that</I>, the
foregoing exception shall not apply with respect to the Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1.3&nbsp;&nbsp;&nbsp;&nbsp;is subsequently received by the receiving Party from a Third Party who is not bound by any obligation of
confidentiality with respect to such information; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1.4&nbsp;&nbsp;&nbsp;&nbsp;can be demonstrated by documentation or other competent
evidence to have been independently developed by or for the receiving Party without use of or reference to the disclosing Party&#146;s Confidential Information; <I>provided</I> <I>that</I>, the foregoing exception shall not apply with respect to the
Joint Collaboration Program <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specific aspects or details of Confidential Information shall not be deemed
to be within the public domain or in the possession of the receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination
of Confidential Information shall not be considered in the public domain or in the possession of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the receiving
Party unless the combination and its principles are in the public domain or in the possession of the receiving Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Per</B><B>mitte</B><B>d Disclosures.</B> Each Party may disclose Confidential Information of the other
Party to the extent that such disclosure is: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2.1&nbsp;&nbsp;&nbsp;&nbsp;made by or on behalf of the receiving Party to the Regulatory
Authorities as required in connection with any filing, application or request for Regulatory Approval; <I>provided,</I> <I>however</I>, that reasonable measures shall be taken to assure confidential treatment of such information to the extent
practicable and consistent with Applicable Law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 49 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2.2&nbsp;&nbsp;&nbsp;&nbsp;made by or on behalf of the receiving Party in response to a
valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial and local governmental or regulatory body of competent jurisdiction or, if in the opinion of the receiving Party&#146;s legal
counsel and without limiting Section&nbsp;7.4, such disclosure is otherwise required by Applicable Law (including, for clarity, any disclosure required by Applicable Law on clinicaltrials.gov or disclosure required by reason of filing with
securities regulators); <I>provided,</I> <I>however</I>, that the receiving Party shall first have given notice to the disclosing Party and given the disclosing Party (a)&nbsp;a reasonable opportunity to quash any such order or to obtain a
protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of any such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the
order was issued and (b)&nbsp;a right to review and comment upon such disclosure, which comments shall be considered in good faith by the receiving Party; and <I>provided</I> <I>further</I> that the Confidential Information disclosed in response to
any such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court or governmental order; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2.3&nbsp;&nbsp;&nbsp;&nbsp;made by or on behalf of the receiving Party to a patent authority as may be reasonably necessary or useful for
purposes of obtaining or enforcing a Patent pursuant to the terms of this Agreement in a manner not inconsistent with Article 6; <I>provided, however</I>, that reasonable measures shall be taken to assure confidential treatment of such information,
to the extent such protection is available; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2.4&nbsp;&nbsp;&nbsp;&nbsp;made by the receiving Party or its Affiliates, sublicensees
or subcontractors to its or their agents, attorneys, auditors, advisors, consultants, contractors, existing or prospective collaboration partners, licensees, sublicensees, investors, insurers or acquirers in connection with the performance of its
obligations or exercise of its rights as contemplated by this Agreement; <I>provided, however</I>, that such persons shall be subject to obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> with respect to such
Confidential Information substantially similar to the obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> of the receiving Party pursuant to this ARTICLE 7 (with a duration of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> obligations as appropriate that is no less than [***] from the date of disclosure); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2.5&nbsp;&nbsp;&nbsp;&nbsp; made by or on behalf of the receiving Party where such disclosure is required by a Regulatory Authority
(including in filings with the Securities and Exchange Commission or other agency) of certain material developments or material information generated under this Agreement; <I>provided</I> <I>that</I>, to the extent permitted, the Party seeking such
disclosure first provides the other Party a copy of the proposed disclosure; and <I>provided, further,</I> that the receiving Party shall afford to the other Party an opportunity to review and comment, which period shall be no less than [***], and
the receiving Party shall accept any reasonable comments so provided; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 50 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2.6&nbsp;&nbsp;&nbsp;&nbsp;made by or on behalf of Precision to Duke solely as and to the
extent necessary to fulfill Precision&#146;s reporting obligations under the Duke Agreement as of the Effective Date so long as such information is disclosed subject to the confidentiality provisions of the Duke Agreement as of the Effective Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Use of N</B><B>ame.</B> Except as expressly provided herein, neither Party shall mention or
otherwise use the name, logo, or trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior
written approval of such other Party in each instance. The restrictions imposed by this Section&nbsp;7.3 shall not prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Public A</B><B>nnouncements.</B> The Parties have agreed upon the content of press release(s) which shall
be issued substantially in the form attached hereto as <U>Schedule</U><U></U><U>&nbsp;7.4</U>, the release of which the Parties shall coordinate in order to accomplish such release at a time following execution of the Agreement to be agreed upon by
the Parties. Neither Party shall issue any other public announcement, press release, or other public disclosure regarding this Agreement or its subject matter without the other Party&#146;s prior written consent, except for any such disclosure that
is, in the opinion of the disclosing Party&#146;s counsel, required by Applicable Law, any Regulatory Authority (including filings with the Securities and Exchange Commission or other agency) or the rules of a stock exchange on which the securities
of the disclosing Party are listed (or to which an application for listing has been submitted). In the event a Party is, in the opinion of its counsel, required by Applicable Law, any Regulatory Authority (including filings with the Securities and
Exchange Commission or other agency) or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, and notwithstanding anything to the contrary in
Section&nbsp;7.2, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] prior to the anticipated date of disclosure) so as to provide a reasonable
opportunity to comment thereon; <I>provided, however</I>, if a Party is required by Applicable Law, any Regulatory Authority (including filings with the Securities and Exchange Commission or other agency) or the rules of a stock exchange on which
the securities of the disclosing Party are listed (or to which an application for listing has been submitted) to disclose this Agreement, such Party shall prepare a proposed redacted version of this Agreement to request confidential treatment for
this Agreement, and the other Party may promptly (and in any event, no less than [***] after receipt of such proposed redactions) provide its comments, which comments shall be considered in good faith by the Party required to make such disclosure.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Publicatio</B><B>ns.</B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Precision shall not
publish any papers or make any oral presentations regarding results of, and other information regarding, activities pursuant to the Collaboration Program (such papers and oral presentations, including abstracts of any of the foregoing,
&#147;<B>Publicatio</B><B>ns</B>&#148;) if such papers or presentations disclose any Information relating specifically to HBV, any Gilead ARC Nuclease or the Licensed Product, except as required by Applicable Law, in which case Section&nbsp;7.2.2
shall apply <I>mutatis mutandis</I>. Notwithstanding the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 51 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foregoing, subject to the obligations set forth in Sections 7.1, 7.2, and 7.3, Precision may make Publications relating specifically to the ARCUS Technology or ARCUS Assigned IP, <I>provided
that</I> for any Publication that discloses Information relating to HBV, any Gilead ARC Nuclease or the Licensed Product, Precision shall (a)&nbsp;provide Gilead with a draft of such Publication at least [***] prior to submission to the publisher,
(b)&nbsp;remove any confidential or sensitive Information as requested by Gilead that Gilead reasonably deems to be of a confidential or sensitive nature, (c)&nbsp;delay the submission for publication of such Publication for an additional [***]
period to permit the applicable Party under Section&nbsp;6.2 to seek patent protection with respect to the content of such Information, and (d)&nbsp;consider in good faith any comments from Gilead with respect to the information contained therein
pertaining to Licensed Products, Gilead ARC Nucleases or HBV. Gilead may, in its discretion, publish any Publication; <I>provided that</I>, Gilead shall (i)&nbsp;provide Precision with a draft of such Publication at least [***] prior to submission
to the publisher, (ii)&nbsp;remove any confidential or sensitive Information of Precision related to ARCUS Technology, ARCUS Assigned IP or ARC Nucleases generally, as requested by Precision, (iii)&nbsp;delay the submission for publication of such
Publication for an additional [***] period to permit the applicable Party under Section&nbsp;6.2 the opportunity to seek patent protection with respect to the content of such Information, and (iv)&nbsp;give Precision a
<FONT STYLE="white-space:nowrap">pre-publication</FONT> right to review and comment upon such Publication, which comments shall be considered in good faith by Gilead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Re</B><B>turn o</B><B>f Confidenti</B><B>al Information.</B> Upon the effective date of the termination
of this Agreement for any reason, either Party may request in writing, and the other Party shall either, with respect to Confidential Information to which such first Party does not retain rights under the surviving provisions of this Agreement:
(a)&nbsp;promptly destroy all copies of such Confidential Information in the possession of the other Party and confirm such destruction in writing to the requesting Party; or (b)&nbsp;promptly deliver to the requesting Party, at the [***] cost and
expense, all copies of such Confidential Information in the possession of the other Party;<I> pro</I><I>vided</I><I>, however</I>, the other Party shall be permitted to retain one (1)&nbsp;copy of such Confidential Information for the sole purpose
of performing any continuing obligations hereunder or for archival purposes. Notwithstanding the foregoing, such other Party also shall be permitted to retain such additional copies of or any computer records or files containing such Confidential
Information that have been created solely by such Party&#146;s automatic archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures, to the extent created and retained in a manner consistent with such other Party&#146;s standard
archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures, but not for any other use or purpose. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section&nbsp;7.1.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Mutual Representations and Warranties.</B> Each Party represents and warrants to the other Party as of
the Effective Date that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1.1&nbsp;&nbsp;&nbsp;&nbsp;such Party is an entity duly organized, validly existing and in good standing under
the Applicable Law of the state or country (as applicable) of its organization, is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 52 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified to do business and is in good standing as a foreign entity in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and
failure to have such would prevent it from performing its obligations under this Agreement, and has full power and authority to enter into this Agreement and to carry out the provisions hereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1.2&nbsp;&nbsp;&nbsp;&nbsp;such Party is duly authorized, by all requisite action, to execute and deliver this Agreement and the execution,
delivery and performance of this Agreement by such Party does not require any shareholder action or approval, and the person executing this Agreement on behalf of such Party is duly authorized to do so by all requisite action; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1.3&nbsp;&nbsp;&nbsp;&nbsp;no consent, approval, order or authorization of, or registration, qualification, designation, declaration or
filing with, any governmental authority or Regulatory Authority is required on the part of such Party in connection with the valid execution, delivery and performance of this Agreement by it; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1.4&nbsp;&nbsp;&nbsp;&nbsp;such Party has not employed (and, to its knowledge, has not used a contractor or consultant that has employed)
and in the future shall not employ (or, to its knowledge , use any contractor or consultant that employs; <I>provided that</I>, such Party may reasonably rely on a representation made by such contractor or consultant) any person debarred by the FDA
(or subject to a similar sanction of a foreign equivalent), or any person which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of a foreign equivalent), in the conduct of its activities under this Agreement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1.5&nbsp;&nbsp;&nbsp;&nbsp;this Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with
its terms except as enforceability may be limited by (a)&nbsp;bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors&#146; rights; and (b)&nbsp;equitable principles of general applicability; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1.6&nbsp;&nbsp;&nbsp;&nbsp;the execution, delivery and performance by it of this Agreement and its compliance with the terms and
provisions of this Agreement does not and shall not conflict with or result in a breach of any of the terms or conditions of (a)&nbsp;any other contractual or other obligations of such Party, (b)&nbsp;the provisions of its operating documents or
bylaws, or (c)&nbsp;any order, writ, injunction or decree of any governmental authority or Regulatory Authority entered against it or by which it or any of its property is bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Representations and Warranties of Precision.</B> Precision further represents and warrants to
Gilead as of the Effective Date that: <I></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.1&nbsp;&nbsp;&nbsp;&nbsp;The Precision Existing Patents comprise all Precision Patents
existing as of the Effective Date, other than Cellectis Patents. Precision is the sole and exclusive owner of the entire right, title and interest in, or otherwise Controls, all Precision Existing Patents and all existing ARCUS IP. All Precision
Existing Patents owned by Precision, and to the Knowledge of Precision, all Precision Existing Patents <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Precision, are subsisting and have not been determined by any competent court or other
governmental authority to be invalid or unenforceable, in whole or in part. In respect of the Precision Existing Patents owned by Precision, to Precision&#146;s Knowledge, Precision and its Affiliates have presented all relevant references,
documents, or information to the relevant patent examiner at the relevant patent office as required by any applicable duty of candor. To Precision&#146;s Knowledge, each of the Precision Existing Patents properly identifies each and every inventor
of the claims thereof as determined in accordance with the laws of the jurisdiction in which such Precision Existing Patent is issued or such application is pending. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 53 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.2&nbsp;&nbsp;&nbsp;&nbsp;There are no pending claims or claims threatened in writing (or
to its Knowledge, otherwise threatened), judgments, or settlements against, or amounts with respect thereto, owed by Precision or any of its Affiliates relating to the ARCUS IP or the Precision IP. Except as was resolved in connection with the
Cellectis Agreement, no claim or litigation has been brought against Precision or its Affiliates, or, to Precision&#146;s Knowledge, threatened in writing by any Person alleging that (a)&nbsp;the ARCUS IP or the Precision IP is invalid or
unenforceable or misappropriates any intellectual property or proprietary right of any Person other than the Parties, or (b)&nbsp;the Exploitation of the ARCUS Technology as contemplated herein violates, infringes, or otherwise conflicts or
interferes with, or would violate, infringe, or otherwise conflict or interfere with, any intellectual property or proprietary right of any Person other than the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.3&nbsp;&nbsp;&nbsp;&nbsp;To Precision&#146;s Knowledge, (a)&nbsp;Precision has the right to use all ARCUS IP and Precision IP as necessary
to conduct the Development activities in the Collaboration R&amp;D Plan, and (b)&nbsp;the use of the ARCUS IP and the Precision IP in the Development of the Licensed Products as contemplated herein (i)&nbsp;is not subject to any other license or
agreement to which Precision or any of its Affiliates is a party other than the Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, (ii)&nbsp;does not infringe any Patent or other intellectual property or proprietary right of any
Person other than the Parties, or (iii)&nbsp;does not constitute or involve the misappropriation of trade secrets or other rights or property of any Person other than the Parties, but excluding, in each case ((i), (ii) and (iii)), any intellectual
property or proprietary right of any Person other than the Parties relating specifically to any HBV Target. For purposes of the representation and warranty in this Section&nbsp;8.2.3, &#147;Precision&#146;s Knowledge&#148; shall also require review
of the foregoing representation and warranty with Precision&#146;s external patent counsel within [***] prior to execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.4&nbsp;&nbsp;&nbsp;&nbsp;Neither Precision nor any of its Affiliates has previously entered into any agreement, whether written or oral,
with respect to, or otherwise assigned, transferred, licensed, conveyed, or otherwise encumbered its right, title, or interest in or to the ARCUS IP, the Precision IP or the Gilead ARC Nucleases (including by granting any covenant not to sue with
respect thereto), or any Patent or other intellectual property or proprietary right that would be ARCUS IP or Precision IP but for such assignment, transfer, license, conveyance, or encumbrance, except in each case where such assignment, transfer,
license, conveyance, or encumbrance is (a)&nbsp;terminated and no longer in force or effect or (b)&nbsp;not inconsistent with the rights and licenses granted to Gilead under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.5&nbsp;&nbsp;&nbsp;&nbsp;A true, complete and accurate copy of each of the Existing <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements has been provided or made available to Gilead in an electronic data room maintained by Precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.6&nbsp;&nbsp;&nbsp;&nbsp;To Precision&#146;s Knowledge, each of the Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements
is valid, enforceable and binding on the parties thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 54 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.7&nbsp;&nbsp;&nbsp;&nbsp;Precision (or its Affiliates) has in all material respects
performed its obligations under each of the Existing <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, including with respect to any obligations relating to funding received under any of the Existing
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, and neither Precision nor any other party thereto has given or received any notice to terminate, or asserted any breach of or default under, any Existing
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement nor, to Precision&#146;s Knowledge, are there any grounds for the termination, avoidance, rescission or repudiation of any Existing <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.8&nbsp;&nbsp;&nbsp;&nbsp;To Precision&#146;s Knowledge, no Person is infringing or threatening to infringe, or
misappropriating or threatening to misappropriate, the Precision IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.9&nbsp;&nbsp;&nbsp;&nbsp;All material adverse information with
respect to the safety of the ARCUS Technology within the Knowledge of Precision has been provided or made available to Gilead in an electronic data room maintained by Precision prior to the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.10&nbsp;&nbsp;&nbsp;&nbsp;All current and former officers, employees, agents and consultants of Precision or any of its Affiliates who are
inventors of, or have otherwise contributed in a material manner to the creation or development of, the ARCUS IP or any Precision IP have executed and delivered to Precision or such Affiliate, and to Precision&#146;s Knowledge are not in violation
of, an assignment or other agreement regarding the protection of proprietary information and the assignment to Precision or such Affiliate of the ARCUS IP or any Precision IP, the current form of which has been made available for review by Gilead.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.11&nbsp;&nbsp;&nbsp;&nbsp;Neither Precision nor any of its Affiliates has been debarred or is subject to debarment pursuant to
Section&nbsp;306 of the Act, or is the subject of a conviction described in such section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.12&nbsp;&nbsp;&nbsp;&nbsp;Except as set
forth on <U>Schedule 8.2.12</U>, the inventions claimed or covered by the Precision IP (a)&nbsp;were not conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal
government of the United States or any agency thereof, (b)&nbsp;are not a &#147;subject invention&#148; as that term is described in 35 U.S.C. Section&nbsp;201(f), and (c)&nbsp;are not otherwise subject to the provisions of the Bayh-Dole Act. With
regard to any inventions set forth on <U>Schedule 8.2.12</U> that are subject to the Bayh-Dole Act, Precision and its Affiliates have complied with the applicable provisions of the Bayh-Dole Act, in a manner that protects and preserves
Precision&#146;s right, title and interest in such inventions to the maximum extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2.13&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement satisfies the requirements to be a &#147;Commercial Product Sublicense&#148; under the Duke Agreement, as amended, as that term is used in such agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3&nbsp;&nbsp;&nbsp;&nbsp;Additional Covenants of Precision.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3.1&nbsp;&nbsp;&nbsp;&nbsp;Neither Precision nor any of its Affiliates shall enter into any agreement, whether written or oral, with respect
to, or otherwise assign, transfer, license, convey, or otherwise encumber its right, title, or interest in or to the ARCUS IP, the Precision IP, [***] or the Gilead ARC Nucleases (including by granting any covenant not to sue with respect thereto),
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 55 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any Patent or other intellectual property or proprietary right that would be ARCUS IP or Precision IP but for such assignment, transfer, license, conveyance, or encumbrance, in each case where
such assignment, transfer, license, conveyance, or encumbrance is inconsistent with the rights and licenses granted to Gilead under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3.2&nbsp;&nbsp;&nbsp;&nbsp;Neither Precision nor any of its Affiliates shall use in any capacity, in connection with the services to be
performed under this Agreement, any Person who has been debarred pursuant to Section&nbsp;306 of the Act, or who is the subject of a conviction described in such section. Precision agrees to inform Gilead in writing immediately if it or any Person
who is performing services hereunder is debarred or is the subject of a conviction described in Section&nbsp;306 of the Act, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Precision&#146;s
Knowledge, is threatened, relating to the debarment or conviction of Precision or any Person performing such services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3.3&nbsp;&nbsp;&nbsp;&nbsp;With regard to any inventions set forth on <U>Schedule 8.2.12</U> that are subject to the Bayh-Dole Act or other
inventions that are subject to the Bayh-Dole Act in the Precision IP, Precision shall, and shall cause its Affiliates to, to comply with the applicable provisions of the Bayh-Dole Act, in a manner that protects and preserves Precision&#146;s right,
title and interest in such inventions to the maximum extent permitted by law.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>DISCLAIMER OF WARRANTIES.</B> EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH HEREIN,
NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF ANY IP RIGHTS OF THIRD
PARTIES OR THE AVAILABILITY OF ANY LICENSES WITH RESPECT TO IP RIGHTS OF THIRD PARTIES. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification of Precision.</B><B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B>Gilead
shall indemnify Precision, its Affiliates, Duke, and its and their respective directors, officers, employees, and agents, and defend and save each of them harmless, from and against any and all losses, damages, liabilities, costs, and expenses
(including reasonable attorneys&#146; fees and expenses) (collectively, &#147;<B>Losses</B>&#148;) in connection with any and all suits, investigations, claims, or demands of Third Parties (collectively, &#147;<B>Third Part</B><B>y Claims</B>&#148;)
arising from or occurring as a result of: (a)&nbsp;the breach by Gilead of any representation, warranty or covenant in this Agreement, (b)&nbsp;the gross negligence or willful misconduct on the part of Gilead or its Affiliates or its or their
respective directors, officers, employees, and agents in performing its or their obligations under this Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 56 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(c)&nbsp;[***], or (d) [***], except, in each case of clause (a) - (d), for those Losses for which Precision has an obligation to indemnify Gilead pursuant to Section&nbsp;9.2 hereof, as to which
Losses each Party shall indemnify the other to the extent of their respective liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification of Gilead.</B> Precision shall indemnify Gilead, its Affiliates and its and their
respective directors, officers, employees, and agents, and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims arising from or occurring as a result of: (a)&nbsp;the breach by
Precision of any representation, warranty or covenant of this Agreement, (b)&nbsp;the gross negligence or willful misconduct on the part of Precision or its Affiliates or its or their respective directors, officers, employees, and agents in
performing its obligations under this Agreement, (c) [***], or (d) [***], except, in each case of clause (a) - (d), for those Losses for which Gilead has an obligation to indemnify Precision pursuant to Section&nbsp;9.1 hereof, as to which Losses
each Party shall indemnify the other to the extent of their respective liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice of
Claim.</B><B> </B>All indemnification claims in respect of a Party, its Affiliates, or their respective directors, officers, employees and agents shall be made solely by such Party to this Agreement (the &#147;<B>Inde</B><B>mnifie</B><B>d
Party</B>&#148;). The Indemnified Party shall give the indemnifying Party (the &#147;<B>Inde</B><B>mnifyi</B><B>ng Party</B>&#148;) written notice (an &#147;<B>Indemnific</B><B>ation Claim Notice</B>&#148;) of any Losses or discovery of fact upon
which such Indemnified Party intends to base a request for indemnification under this ARTICLE 9 within [***] after receipt by such Indemnified Party of actual notice of the Third Party Claim; <I>provided</I><I> t</I><I>hat</I>, failure to give such
notification shall not affect the indemnification provided under Section&nbsp;9.1 or Section&nbsp;9.2, as applicable, except to the extent the Indemnifying Party has been actually prejudiced as a result of such failure. Each Indemnification Claim
Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all
papers and official documents received in respect of any Losses and Third Party Claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4&nbsp;&nbsp;&nbsp;&nbsp;Control of
Defense.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.4.1&nbsp;&nbsp;&nbsp;&nbsp;<B>In General. </B>At its option, the Indemnifying Party may assume the defense of any Third
Party Claim by giving written notice to the Indemnified Party within [***] after the Indemnifying Party&#146;s receipt of an Indemnification Claim Notice only if the Indemnifying Party has acknowledged to the Indemnified Party in writing that the
Indemnifying Party is liable to indemnify the Indemnified Party in respect of such Third Party Claim. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any
legal counsel selected by the Indemnifying Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents (including
court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, except as provided in Section&nbsp;9.4.2, the Indemnifying Party shall not be liable
to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically requested in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 57 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
writing by the Indemnifying Party. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and
against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including attorneys&#146; fees and costs of suit) and any Losses incurred by the Indemnifying Party in its defense of the
Third Party Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.4.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Right to Participate in Defense.</B> Without limiting Section&nbsp;9.4.1, any
Indemnified Party shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; <I>provided,</I> <I>however</I>, that such employment shall be at the [***] cost and
expense unless (a)&nbsp;the employment thereof has been specifically authorized by the Indemnifying Party in writing, (b)&nbsp;the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section&nbsp;9.4.1 (in which
case the Indemnified Party shall control the defense), or (c)&nbsp;the interests of the indemnitee and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both
Parties under Applicable Law, ethical rules or equitable principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.4.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Settlement.</B> With respect to any
Losses relating to a Third Party Claim, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, at [***] cost and expense, on such terms as the
Indemnifying Party, in its sole discretion, shall deem appropriate; <I>provided that</I>, such settlement shall not result in the Indemnified Party&#146;s becoming subject to injunctive or other relief or otherwise adversely affecting the business
of the Indemnified Party in any manner. For any other settlement, the Indemnifying Party shall have the right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss only if it obtains the prior written
consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the Indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend
against such Third Party Claim and enter into any settlements of otherwise dispose of such Loss at the [***] cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.4.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation.</B> Regardless of whether the Indemnifying Party chooses to defend any Third Party Claim, the
Indemnified Party shall, and shall cause each indemnitee to, cooperate in the defense thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and
appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information
that are reasonably relevant to such Third Party Claim, and making the Indemnified Party and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder,
and the Indemnifying Party shall reimburse the Indemnified Party for all its reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.4.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Expenses.</B> Except as provided above, the costs and expenses, including fees and disbursements of counsel,
incurred by the Indemnified Party in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 58 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with any claim shall be reimbursed on a Calendar Quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party&#146;s right to contest the Indemnified Party&#146;s right to
indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Special,</B><B> Indirect, and Other Losses.</B> EXCEPT IN THE EVENT OF A PARTY&#146;S BREACH OF ITS
OBLIGATIONS UNDER ARTICLE 7, AND EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 9, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE
LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS,
DIMINUTION IN VALUE, OR OTHER ECONOMIC LOSSES) ARISING OUT OF ANY ACTIVITIES WITHIN THE SCOPE OF THIS AGREEMENT OR WITH RESPECT TO A PARTY&#146;S PERFORMANCE OR NON PERFORMANCE HEREUNDER. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6&nbsp;&nbsp;&nbsp;&nbsp;Insurance.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.6.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance Maintained by Precision. </B>During the Term, Precision shall have and maintain in full force and
effect, at its own expense, insurance coverage to include: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Commercial general liability insurance, including
personal and advertising injury, and Licensed Products and completed operations, with limits of liability not less than [***] per occurrence and [***] in the aggregate. General liability limit requirements may be satisfied by a combination of
primary and umbrella or excess liability insurance coverage; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Workers&#146; compensation insurance in
compliance with Applicable Law (including the local law requirements of the state or jurisdiction in which the work is to be performed). Employer&#146;s liability insurance in amounts not less than [***] for each of (i)&nbsp;bodily injury by
accident (each accident), (ii) bodily injury by disease (policy limit), and (iii)&nbsp;bodily injury by disease (each employee). Where permitted by Applicable Law, such policies shall contain a waiver of the insurer&#146;s subrogation rights against
Gilead; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Automobile liability insurance for bodily injury, property damage and automobile contractual
liability covering all owned, hired and <FONT STYLE="white-space:nowrap">non-owned</FONT> automobiles with a combined single limit of liability for each accident of not less than [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 59 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.6.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance Maintained by Gilead. </B>During the Term, Gilead
shall have and maintain in full force and effect, at its own expense, insurance coverage to include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Commercially purchased insurance in accordance with the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Commercial general liability insurance, including personal and advertising injury, and Licensed Products and
completed operations with limits of liability not less than [***] per occurrence and [***] in the aggregate. General liability limit requirements may be satisfied by a combination of primary and umbrella or excess liability insurance coverage; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Workers&#146; compensation insurance in compliance with Applicable Law (including the local law requirements of
the state or jurisdiction in which the work is to be performed). Employer&#146;s liability insurance in amounts not less than [***] for each of (A)&nbsp;bodily injury by accident (each accident), (B) bodily injury by disease (policy limit), and
(C)&nbsp;bodily injury by disease (each employee). Where permitted by Applicable Law, such policies shall contain a waiver of the insurer&#146;s subrogation rights against Precision; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp; Automobile Liability insurance for bodily injury, property damage and automobile contractual liability covering
all owned, hired and <FONT STYLE="white-space:nowrap">non-owned</FONT> automobiles with a combined single limit of liability for each accident of not less than [***]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp; Clinical trials liability insurance with limits not less than [***] per occurrence; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Self-insurance substantially equivalent to the coverage described in Section&nbsp;9.6.2(a) above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.6.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Requirements.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Insured.</B> Each Party shall name the other Party as an additional insured on the insurance policies
maintained pursuant to Section&nbsp;9.6.1(a), Section&nbsp;9.6.1(c), Section&nbsp;9.6.2(a)(i), Section&nbsp;9.6.2(a)(iii) and Section&nbsp;9.6.2(a)(iv), as applicable, either by endorsement or blanket additional insured endorsement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Evidence of Insurance.</B> Each Party will provide evidence of insurance maintained pursuant to this
Section&nbsp;9.6 on request of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice of Cancellation.</B> Each Party will provide the
other Party a notice of insurance policy cancellation in accordance with the provisions of the applicable insurance policy maintained pursuant to this Section&nbsp;9.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>Policy Type.</B> Insurance policies maintained pursuant to this Section&nbsp;9.6 should be occurrence type. If
policies maintained pursuant to this Section&nbsp;9.6 are claims made, then insurance shall be maintained for at least [***] following expiration or termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance Carrier Rating.</B> All insurance maintained pursuant to this Section&nbsp;9.6 will be underwritten
by companies with an AM best rating of at least <FONT STYLE="white-space:nowrap">A-VII.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 60 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term.</B> This Agreement shall commence on the Effective Date and, unless earlier terminated in
accordance herewith, shall continue in force and effect, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of the Royalty Term for such Licensed Product in such country (the &#147;<B>Term</B>&#148;). Upon expiration of the Royalty
Term (but not on early termination of this Agreement), on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis the license granted to Gilead pursuant to Section&nbsp;4.1.1 shall be a fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable,
perpetual license that will be exclusive unless and until such time as a Biosimilar Product launches or has launched with respect to the applicable Licensed Product in the applicable country (and from such time will be
<FONT STYLE="white-space:nowrap">non-exclusive),</FONT> and the non-exclusive license granted to Gilead pursuant to Section&nbsp;4.1.2 shall be fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable and perpetual. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2&nbsp;&nbsp;&nbsp;&nbsp;Termination by Either Party.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for Material Breach.</B> Without prejudice and in addition to any other contractual remedy the <FONT
STYLE="white-space:nowrap">non-breaching</FONT> Party may have with respect to this Agreement, either Party may, upon a material breach of this Agreement by the other Party, terminate this Agreement by providing [***] prior written notice (or
[***]&#146; prior written notice in the event such material breach is solely based on the breaching Party&#146;s failure to pay any amounts due hereunder) to the breaching Party, specifying in such notice the breaching Party&#146;s material breach
and demanding its cure, with such termination being effective upon the end of such [***] (or [***], as applicable) cure period or, if applicable, the end of the extended cure period set forth in the immediately following sentence, in each case if
the applicable material breach has not then been cured. Notwithstanding the foregoing, with respect to a material breach that is not solely based on the breaching Party&#146;s failure to pay any amounts due hereunder, if such material breach is not
reasonably curable within the [***] cure period, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party&#146;s right to terminate this Agreement pursuant to this Section&nbsp;10.2.1 shall be suspended only if, and only for so long as,
(x)&nbsp;the breaching Party has provided to the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party a written plan that is reasonably calculated to effect a cure and that includes a proposed extended cure period (not to exceed [***] after
the original [***] cure period), (y) the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party confirms in writing that such plan is reasonably acceptable to the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party and (z)&nbsp;the
breaching Party commits to and does carry out such plan no later than the end of the extended cure period set forth in the written plan described in clause (x)&nbsp;of this sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for Insolvency.</B> In the event that either Party (a)&nbsp;makes an assignment for the benefit
of creditors, (b)&nbsp;appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not discharged within [***] after such filing, (c)&nbsp;proposes a written agreement of composition with its creditors,
(d)&nbsp;proposes or is a party to any dissolution or liquidation, (e)&nbsp;files a petition under any bankruptcy or insolvency act or has any such petition filed against that is not discharged within [***] of the filing thereof (excluding a
reorganization proceeding under Chapter 11 of the U.S. Bankruptcy Code if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 61 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
debtor Party is continuing to perform all of its obligations under this Agreement), or (f)&nbsp;admits in writing its inability generally to meet its obligations as they fall due in the general
course, then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3&nbsp;&nbsp;&nbsp;&nbsp;Additional Termination Rights by Gilead.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.3.1&nbsp;&nbsp;&nbsp;&nbsp;<B>For Convenience.</B> Gilead may terminate this Agreement, for any reason or no reason, upon: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;[***] prior written notice to Precision, if such notice is provided during the Collaboration Term; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;[***] prior written notice to Precision, if such notice is provided on or after the expiry of the Collaboration
Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.3.2&nbsp;&nbsp;&nbsp;&nbsp;<B>For Certain Events of Change of Control of Precision or Assignment of Agreement during the
Collaboration Term.</B> Precision agrees to notify Gilead promptly in writing in the event Precision has entered into a transaction that effects a Change of Control of Precision or assignment or transfer of this Agreement by Precision, or would
effect a Change of Control of Precision or assignment or transfer of this Agreement by Precision upon the closing of the transaction, or an event occurs that triggers a Change of Control of Precision or assignment or transfer of this Agreement by
Precision. During the Collaboration Term, Gilead may terminate this Agreement in the event of a Change of Control that results in Precision being controlled by, or assignment or transfer of this Agreement by Precision to, a Third Party that is
clinically developing or commercializing products in the field of HBV, upon [***] prior written notice to Precision, so long as such notice is sent no later than [***] after Gilead becomes aware of such Change of Control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional</B><B> Termination Rights by Precision</B><B> </B>[***]. <B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Rights in Bankruptcy.</B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>All rights and licenses
granted under or pursuant to this Agreement by Gilead or Precision are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses
of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their
rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the
U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party that is not a party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual
property and all embodiments of such intellectual property to which such Party is entitled to have access under this Agreement, which, if not already in the <FONT STYLE="white-space:nowrap">non-debtor</FONT> Party&#146;s possession, shall be
promptly delivered to it (a)&nbsp;upon any such commencement of a bankruptcy proceeding upon the <FONT STYLE="white-space:nowrap">non-debtor</FONT> Party&#146;s written request therefor, unless the Party subject to such proceeding elects to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 62 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to perform all of its obligations under this Agreement, or (b)&nbsp;if not delivered under clause (a)&nbsp;above, following the rejection of this Agreement by or on behalf of the Party
subject to such proceeding upon written request therefor by the <FONT STYLE="white-space:nowrap">non-debtor</FONT> Party. The Parties acknowledge and agree that payments made under Section&nbsp;5.1 shall not (x)&nbsp;constitute royalties within the
meaning of Section&nbsp;365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction or (y)&nbsp;relate to licenses of intellectual property hereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6&nbsp;&nbsp;&nbsp;&nbsp;Effects of Termination.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.6.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination by Gilead for Convenience or by Precision for Material Breach or Insolvency. </B>In the event of a
termination of this Agreement by Gilead under Section&nbsp;10.3.1 or by Precision under Section&nbsp;10.2.1, Section&nbsp;10.2.2 or Section&nbsp;10.4: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The rights and licenses granted to Gilead under Section&nbsp;4.1, including any sublicenses, shall be terminated
and all such rights shall revert to Precision, except to the extent and for so long as necessary for Gilead to fulfil its responsibilities under the surviving terms of this Agreement as provided in Section&nbsp;10.8, it being agreed that all such
activities shall be discontinued and cease (unless otherwise agreed or required under Applicable Law, by transitioning such activities and responsibilities to Precision) as promptly as possible, subject to Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a payment pursuant to the Gilead Funding Commitment is due after notice of termination is given and before the
effective date of termination, the payment due by Gilead shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the portion of the applicable six (6)&nbsp;month period of the Collaboration Term to have elapsed upon the effective date of
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If at the effective date of termination, Gilead is Manufacturing Licensed Product(s), then, if
Precision requests in writing to Gilead within [***] of the effective date of termination, Gilead agrees to Manufacture and supply such Licensed Product(s) to Precision for a reasonable transitional period (not to exceed [***]) from the effective
date of termination pursuant to a reasonable and customary transitional supply and quality agreement to be agreed by the Parties in a form reasonably acceptable to Gilead and Precision. Such Licensed Products shall be supplied at [***] of COGS as
further defined in the Supply Agreement, plus any amounts due to a Third Party as a result of the sale of such Licensed Product by Gilead or Precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;[***].<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;At Precision&#146;s request, Gilead agrees to enter into an agreement with Precision, to be negotiated promptly
and in good faith, that includes all terms reasonably necessary to transition the Development, use, Manufacture, promotion, marketing and Exploitation of the Licensed Products to Precision, including the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;a worldwide, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as permitted by
such agreement), exclusive or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> (as requested by Precision), license (or sublicense, as the case may be), with the right to grant sublicenses in accordance with such agreement, to Precision under
the Reversion IP (to the extent not licensed pursuant to Section&nbsp;10.6.1(d)) to Exploit the Licensed Products in the Field in the Territory; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 63 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;transition to Precision of all reasonably necessary materials,
licenses, Third Party agreements, preclinical and clinical data, safety data, Clinical Studies, Regulatory Documentation, Regulatory Approvals and applications and product trademarks; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp; provision of technical assistance (including reasonable caps on hours of access) from Gilead relating to the
Manufacture, testing and supply of the Licensed Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall negotiate in good faith the
commercially reasonable compensation to Gilead for the obligations of Gilead under the agreement entered into Section&nbsp;10.6.1(e), based on Gilead&#146;s contributions to the Licensed Products up to the time of termination. In the event the
Parties cannot agree on such compensation terms, or any other terms of such agreement, then either Party may refer the disputed terms to one or more arbitrator(s) under the principles of baseball arbitration (i.e., each Party submits a proposed
resolution to the arbitrator, and the arbitrator is required to select one of the proposed resolutions), the procedures of which shall be reasonably acceptable to both Parties and shall include express consideration by the arbitrator of the fair
market value of the license provided by Gilead in Section&nbsp;10.6.1(e)(i), the materials transferred under Section&nbsp;10.6.1(e) and other Relevant Factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.6.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination by Gilead for Material Breach, Insolvency or Change of Control. </B>If Gilead is entitled to
terminate this Agreement pursuant to Section&nbsp;10.2.1, Section&nbsp;10.2.2 or 10.3.2, Gilead may elect to terminate this Agreement subject to the provisions set forth in Section&nbsp;10.6.1(a) and (b)&nbsp;and, in the case of termination pursuant
to Section&nbsp;10.3.2, Section&nbsp;10.6.1(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Remed</B><B>ies.</B> Except as otherwise expressly
provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Acc</B><B>rue</B><B>d Rights; Surviving Obligations.</B><B> </B>Expiration or termination of this
Agreement shall not affect the rights and obligations of each Party under this Agreement that have accrued prior to such date of expiration or termination, and the following provisions shall survive expiration or termination of this Agreement:
ARTICLE 1, Sections&nbsp;4.1.1 and 4.1.2 (solely to the extent provided in Section&nbsp;10.1 on expiration of this Agreement), Sections 4.2.2 (to the extent that the applicable Information constituted Gilead Dual
<FONT STYLE="white-space:nowrap">Know-How</FONT> or the applicable Patents constituted Gilead Dual Patents, in each case as of the date of termination of this Agreement, including, for clarity, Patents filed or issued at any later date covering or
claiming applicable inventions conceived on or prior to such date),&nbsp;4.3.2, and 4.3.3 (solely to the extent applicable to the license set forth in Section&nbsp;4.2.2), Sections 4.4, 5.8, 5.9 and 5.10,&nbsp;6.1 (excluding the proviso in
Section&nbsp;6.1.3(b)), 6.2.2, 6.2.3, 6.2.4, 6.3.2, 6.5.3, ARTICLE 7, ARTICLE 8, ARTICLE 9, Sections&nbsp;10.6, 10.7 and 10.8 and ARTICLE 11. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 64 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Force Majeure.</B><B> </B>Neither Party shall be held liable or responsible to the other Party or be
deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond
the reasonable control of the <FONT STYLE="white-space:nowrap">non-performing</FONT> Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist
acts, insurrections, riots, civil commotion, strikes, lockouts, or other labor disturbances (whether involving the workforce of the <FONT STYLE="white-space:nowrap">non-performing</FONT> Party or of any other Person), acts of God or acts, omissions
or delays in acting by any governmental authority or Regulatory Authority (except to the extent such delay results from the breach by the <FONT STYLE="white-space:nowrap">non-performing</FONT> Party or any of its Affiliates of any term or condition
of this Agreement). The <FONT STYLE="white-space:nowrap">non-performing</FONT> Party shall notify the other Party of such force majeure within [***] after such occurrence by giving written notice to the other Party stating the nature of the event,
its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the <FONT STYLE="white-space:nowrap">non-performing</FONT>
Party shall use Commercially Reasonable Efforts to remedy its inability to perform as promptly as possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Export Control.</B> This Agreement is made subject to any restrictions concerning the export of Licensed
Products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it shall not export, directly or indirectly, any technical information acquired from the other
Party under this Agreement or any Licensed Products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do
so from the appropriate agency or other governmental authority or Regulatory Authority in accordance with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment</B><B>. </B>This Agreement and the rights and obligations hereunder shall not be assignable,
transferable or delegable by either Party without the prior written consent of the other Party; <I>provided tha</I><I>t</I>, either Party may assign or transfer any or all of its rights and assign, transfer or delegate any or all of its obligations
under this Agreement to (a)&nbsp;any of its Affiliates or (b)&nbsp;a successor to all or substantially all of its business related to this Agreement (including in connection with a merger, consolidation, or sale of all or substantially all of its
assets related to this Agreement), in each case (a)&nbsp;and (b), without the prior written consent of the other Party. Notwithstanding the foregoing, Precision shall not be required to obtain Gilead&#146;s consent to sell, assign, pledge as
security, contribute, or otherwise transfer, in whole or in part, to any Third Party its rights to receive any payment under this Agreement, and, as it relates to any such transfer, Precision may provide to such Third Party (i)&nbsp;a copy of
reports received from Gilead pursuant to Section&nbsp;5.4.10 and (ii)&nbsp;the result of any audit conducted pursuant to Section&nbsp;5.9, in each case of (i)&nbsp;and (ii), so long as any such Third Party is bound by confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> obligations equivalent in scope to those set forth in ARTICLE 7 of this Agreement. Any attempted assignment, transfer or delegation in violation of this Section&nbsp;11.3 shall be null and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 65 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
void, except to the extent otherwise permitted under Section&nbsp;4.3. Notwithstanding anything to the contrary in this Agreement, the Patents and Information Controlled by an Acquirer (or any
Affiliate of any such Acquirer existing prior to the closing of the transaction) of a Party under this Agreement shall be automatically excluded from the rights licensed to the other Party under this Agreement to the extent (A)&nbsp;such Patents and
Information were filed or developed, respectively, prior to the transaction that was the basis for such assignment, transfer or succession or resulted in such Person becoming an Affiliate, or (B)&nbsp;such Patents and Information were developed
after such transaction under a separate and firewalled program not under this Agreement without use of any Patents, <FONT STYLE="white-space:nowrap">Know-How</FONT> or Confidential Information of the other Party that is licensed
hereunder.<I></I><I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Se</B><B>verabilit</B><B>y.</B> If any provision of this Agreement
is held to be illegal, invalid, or unenforceable under any present or future law, and if the rights or obligations of either Party under this Agreement shall not be materially and adversely affected thereby, (a)&nbsp;such provision shall be fully
severable, (b)&nbsp;this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a part hereof, (c)&nbsp;the remaining provisions of this Agreement shall remain in full force and effect
and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance herefrom, and (d)&nbsp;in lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as a part of this Agreement a
legal, valid, and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives
any provision of law that would render any provision hereof illegal, invalid, or unenforceable in any respect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;Governing Law.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law.</B> This Agreement shall be governed by, and construed in accordance with, the laws of the
state of New York, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Jurisdiction; Venue; Service of Process.</B> Each Party irrevocably submits to the exclusive jurisdiction of
the state or federal courts located in the State and County of New York for the purposes of any Action arising out of this Agreement. Each Party agrees to commence any such Action either in the state courts of New York or the United States District
Court for the Southern District of New York. Each Party further agrees that service of any process, summons, notice or document by the U.S. registered mail to such Party&#146;s respective address set forth in Section&nbsp;11.7 shall be effective
service of process for any Action in New York with respect to any matters to which it has submitted to jurisdiction in this Section&nbsp;11.5.2. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any Action
arising out of this Agreement in the state or federal courts of New York, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action brought in any such court has
been brought in an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Waiver of Right to Trial by Jury.</B><B> </B>EACH PARTY HERETO
WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY. Each Party hereto (a)&nbsp;certifies that no Representative or attorney of the other Party has represented, expressly or otherwise, that such Party would not, in the event of any Action, seek to
enforce the foregoing waiver and (b)&nbsp;acknowledges that it and the other Party have been induced to enter into this Agreement, by, among other things, the mutual waiver and certifications in this Section&nbsp;11.5.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 66 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Equitable Relief. </B>Each Party acknowledges and agrees
that the restrictions set forth in Section&nbsp;4.5 and ARTICLE 6 and ARTICLE 7 are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence
of such restrictions, and that any breach or threatened breach of any provision of such Section or Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach or
threatened breach of any provision of such Section or Articles, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall be authorized and entitled to seek injunctive relief, whether preliminary or permanent, specific performance, and
an equitable accounting of all earnings, profits, and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party
may be entitled in law or equity to prevent such breach or threatened breach of this Agreement and to enforce specifically the terms and provisions of such Section or Articles of this Agreement in the state and federal courts of New York. Both
Parties agree to waive any requirement that the other (a)&nbsp;post a bond or other security as a condition for obtaining any such relief, and (b)&nbsp;show irreparable harm, balancing of harms, consideration of the public interest, or inadequacy of
monetary damages as a remedy. Nothing in this Section&nbsp;11.5.4 is intended, or should be construed, to limit either Party&#146;s right to equitable relief or any other remedy for a breach of any other provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Dispu</B><B>te Resolu</B><B>ti</B><B>on.</B> The Parties recognize that disputes as to certain matters
may from time to time arise that relate to either Party&#146;s rights or obligations hereunder, including the interpretation, alleged breach, enforcement, termination or validity of this Agreement (a &#147;<B>Di</B><B>spute</B>&#148;). For clarity,
Dispute shall not include matters within the JSC&#146;s authority, which are resolved under Section&nbsp;2.3.3 including through the exercise by Gilead or Precision of its final decision making authority in accordance therewith. Any Dispute shall be
referred to the Senior Officers of the Parties, who shall confer in good faith on the resolution of the issue. Any final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are
not able to agree on the resolution of any such issue within [***] after such issue was first referred to them, then, either Party may initiate litigation in accordance with Section&nbsp;11.5 or with respect to Disputes that involve the infringement
or validity of any Precision Patents, Joint Collaboration Program Patents or Gilead Dual Patents outside the United States, such Dispute shall be resolved by a court of competent jurisdiction, notwithstanding Section&nbsp;11.5, in any country in
which such rights apply. Notwithstanding anything herein to the contrary, nothing in this Section&nbsp;11.6 shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction or
other interim equitable relief concerning a Dispute, if necessary to protect the interests of such Party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp;Notices.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.7.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice Requirements.</B> Any notice, request, demand, waiver, consent, approval, or other communication
permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 67 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section&nbsp;11.7.2 or to such other address as the
Party to whom notice is to be given may have provided to the other Party in accordance with this Section&nbsp;11.7.1. Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission
confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable
thereafter. This Section&nbsp;11.7.1 is not intended to govern the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business communications necessary between the Parties in performing their obligations under
the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.7.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Address for Notice</B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If to Gilead, to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Gilead
Sciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">333 Lakeside Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Foster City, CA 94404 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attn:
Alliance Management </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">333
Lakeside Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Foster City, CA 94404 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attn: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email:
[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If to Precision, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Precision BioSciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">302
East Pettigrew Street, Suite <FONT STYLE="white-space:nowrap">A-100</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Durham, NC 27701 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Michael Dombeck, Vice President, Business Development </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: (480) <FONT STYLE="white-space:nowrap">393-5553</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 68 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Smith, Anderson, Blount, Dorsett, Mitchell&nbsp;&amp; Jernigan, LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">150 Fayetteville Street, Suite 2300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Raleigh, NC 27601 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention:
John R. Therien, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: (919) <FONT STYLE="white-space:nowrap">821-6800</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement.</B> This Agreement, together with the Schedules expressly contemplated hereby and
attached hereto, and together with the Supply Agreement and the Quality Agreement (once executed), contains the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements or understandings between
the Parties with respect to the subject matter hereof, including the Confidentiality Agreement and the Material Transfer Agreement between the Parties dated as of February&nbsp;22, 2016 (as amended). Each Party confirms that it is not relying on any
representations or warranties of the other Party except as specifically set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Engli</B><B>sh Langua</B><B>ge.</B> This Agreement shall be written and executed in, and all other
communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English
version and such translation, the English version shall control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp;Amendments and Waivers.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.10.1&nbsp;&nbsp;&nbsp;&nbsp;No modification, amendment or waiver of any provision of, or consent or approval required by, this Agreement,
nor any consent to or approval of any departure herefrom, shall be effective unless it is in writing and signed by the Party against whom enforcement of any such modification, amendment, waiver, consent or approval is sought. Such modification,
amendment, waiver, consent or approval shall be effective only in the specific instance and for the purpose for which given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.10.2&nbsp;&nbsp;&nbsp;&nbsp;Neither the failure of either Party to enforce, nor the delay of either Party in enforcing, any condition or
part of this Agreement at any time shall be construed as a waiver of that condition or part or forfeit any rights to future enforcement thereof. No action taken pursuant to this Agreement, including any investigation by or on behalf of either Party,
shall be deemed to constitute a waiver by the Party taking action of compliance by the other Party with any representation, warranty, covenant, agreement or obligation contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Cumulative Rights.</B> Except as expressly provided herein, the various rights under this Agreement
shall be construed as cumulative, and no one of them is exclusive of any other or exclusive of any rights allowed by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Benefits of Agreement.</B> All of the terms and provisions of this Agreement shall be binding upon and
inure to the benefit of the Parties and their respective successors and permitted assigns. Except for the provisions of ARTICLE 9, this Agreement is for the sole benefit of the Parties and not for the benefit of any other Person other than Duke to
the extent required by the Duke Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 69 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Further Assura</B><B>nce.</B> Each Party shall duly
execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary
or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.14</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Relat</B><B>ionship o</B><B>f the Parties.</B> It is expressly agreed that Gilead, on the one
hand, and Precision, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture, or agency. Neither Gilead, on the one hand, nor Precision, on the other
hand, shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so. All persons employed by a
Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.15</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterpa</B><B>rts.</B> This Agreement may be executed in two counterparts, and each such counterpart
hereof shall be deemed to be an original instrument, but both such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or other electronic transmission
shall be effective as delivery of a manually executed original counterpart of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.16</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Sched</B><B>ules.</B> In the event of any inconsistencies between this Agreement and any Schedules or
other attachments hereto, the terms of this Agreement shall control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.17&nbsp;&nbsp;&nbsp;&nbsp;Descriptive Headings; Certain
Interpretations.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.17.1&nbsp;&nbsp;&nbsp;&nbsp;Descriptive headings are for convenience only and shall not control or affect the
meaning or construction of any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.17.2&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise expressly provided in this
Agreement or as the context otherwise requires, the following rules of interpretation apply to this Agreement: (a)&nbsp;the singular includes the plural and the plural includes the singular; (b) &#147;or&#148; and &#147;any&#148; are not exclusive
and the words &#147;include&#148; and &#147;including,&#148; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation;&#148; (c) a reference to any
contract includes permitted supplements and amendments; (d)&nbsp;a reference to Applicable Law includes any amendment or modification to such Applicable Law; (e)&nbsp;a reference to a Person includes its successors, heirs and permitted assigns;
(f)&nbsp;a reference to one gender shall include any other gender; (g)&nbsp;a reference in this Agreement to an Article, Section, Exhibit or Schedule is to the referenced Article, Section, Exhibit or Schedule of this Agreement, unless expressly
specified otherwise; (h) &#147;hereunder,&#148; &#147;hereof,&#148; and words of similar import shall be deemed references to this Agreement as a whole and not to any particular Article, Section&nbsp;or other provision; (i) &#147;extent&#148; in the
phrase &#147;to the extent&#148; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#147;if&#148; and (j)&nbsp;a reference to the right to &#147;approve&#148; includes the right to reject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.17.3&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree that they have been represented by counsel during the negotiation, drafting, preparation and
execution of this Agreement and, therefore, waive the application of any Applicable Law or rule of construction providing that ambiguities in an agreement or other document shall be construed against the Party drafting such agreement or document.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 70 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>SIGNATURE PAGE FOLLOWS.<B>]</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 71 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GILEAD SCIENCES, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PRECISION BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John F. Milligan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John F. Milligan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>OLLABORATION</SMALL> <SMALL>AND</SMALL> L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.45 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Duke IP </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Precision Docket No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Country</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.112 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Precision Existing Patents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Precision Docket No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Country</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="17"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Precision Docket No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Country</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="17"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="17"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="17"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.113 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Precision HBV Patents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Precision Docket No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Country</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="17"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="17"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 2.1.2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Initial JSC Members </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For Precision</U>:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For Gilead</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 2.2.1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Initial JRDC Members </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For
Precision</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>For Gilead</U>:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 3.8.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Template Report </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GILEAD SCIENCES -
PRECISION BIOSCIENCES COLLABORATION REPORT </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Preclinical R&amp;D</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> R&amp;D Progress: Months 1 &#150; 6</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Key strategic goals </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Milestones achieved </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GO/NO GO decisions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plan amendments (scope, timelines, resources, other) </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Details: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilead Funding: [***] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Activity Goal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Details</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Timeline</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Costs, FTEs (Budgeted/Actual)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> R&amp;D Progress: Months 7 &#150; 12</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Key strategic goals </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Milestones achieved </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GO/NO GO decisions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plan amendments (scope, timelines, resources, other) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Details: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilead Funding: [***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Activity Goal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Details</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Status</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Timeline</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Costs,&nbsp;FTEs&nbsp;(Budgeted/Actual)</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> R&amp;D Progress: Months 13 &#150; 18</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Key strategic goals </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Milestones achieved </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GO/NO GO decisions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plan amendments (scope, timelines, resources, other) </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Details: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilead Funding: [***] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Activity Goal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Details</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Timeline</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Costs,&nbsp;FTEs&nbsp;(Budgeted/Actual)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> R&amp;D Progress: Months 19 &#150; 24</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Key strategic goals </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Milestones achieved </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GO/NO GO decisions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plan amendments (scope, timelines, resources, other) </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Details: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilead Funding: [***] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Activity Goal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Details</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Activity&nbsp;Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Timeline</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Costs,&nbsp;FTEs&nbsp;(Budgeted/Actual)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Clinical Development</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Development and Regulatory Activities Progress</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Activity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Details</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase 1 Trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase 2 Trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase 3 Trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Development Milestones Progress (as described in Section</B><B></B><B>&nbsp;5.2.1 of the Agreement)</B>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Development Milestones</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Comments</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commercialization Milestones Progress (as described in Section</B><B></B><B>&nbsp;5.3.1 of the Agreement)</B>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Commercial Milestones</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Comments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***] and less [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***] and less [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***] and [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The first time aggregate global Net Sales of Licensed Products in a Calendar Year are equal to or
greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Functional Group Resource Allocation:</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representatives from the following functional groups worked on the program during this semiannual period: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.1.2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invoicing Template </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">[Company Name]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g367280g53v88.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[Street Address]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">[City, ST ZIP]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>INVOICE&nbsp;#</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DATE</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone: (000) 000-0000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[123456]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5/1/2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BILL TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts Payable
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gilead Sciences, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">333 Lakeside Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foster City, California 94404 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APInvoices@gilead.com </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Gilead Funding Commitment Pursuant to Section&nbsp;5.1.1 of the Collaboration and License Agreement between Gilead Sciences, Inc. and Precision Biosciences, Inc. dated September&nbsp;7, 2018, for the six (6)&nbsp;month period
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">XX</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>XX</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment Terms</B>: <I>Payment shall be due within [***]</I><I> of receipt by Gilead.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">If you have any questions about this invoice, please contact </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Name, Phone, email@address.com] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 6.2.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS Patents and Precision Patents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule to be provided upon the timing set forth in Section&nbsp;6.2.8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 7.4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Press Release(s) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gilead&nbsp;&amp;
Precision Biosciences logos </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>CONTACTS:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sung Lee, Gilead Investors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-524-7792</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amy Flood, Gilead Media</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-522-5643</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heather King, Precision Media</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">919-314-5512</FONT></FONT> x1332</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GILEAD SCIENCES AND PRECISION BIOSCIENCES ANNOUNCE COLLABORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO DEVELOP THERAPIES AGAINST HEPATITIS B VIRUS USING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS GENOME EDITING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOSTER CITY,
Calif. and DURHAM, NC, Sept XX, 2018 -</B> Gilead Sciences (Nasdaq: GILD) and Precision Biosciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the <I>in vivo</I> elimination of
hepatitis B virus (HBV) with Precision&#146;s proprietary genome editing platform, ARCUS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An estimated 257&nbsp;million people are living with HBV
infection around the world. Current HBV treatments suppress HBV viral replication but do not completely clear the virus. The presence of covalently closed circular DNA (cccDNA) enables HBV replication if treatment is stopped. Preliminary studies at
Gilead using ARCUS nucleases to target HBV cccDNA <I>in vitro</I> have demonstrated significant activity against cccDNA and integrated HBV DNA in human hepatocytes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Gilead is committed to developing innovative therapies to achieve functional cure for patients with chronic Hepatitis B virus infection,&#148; said John
McHutchison, MD, Chief Scientific Officer and Head of Research and Development at Gilead. &#147;We are excited about the potential of genome editing and Precision&#146;s ARCUS technology, which has demonstrated promising <I>in vitro</I> activity. We
look forward to exploring this technology as an important component of our HBV cure research efforts.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the collaboration
agreement, Precision will be primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential
therapies. Gilead will fully fund the research and development. Precision is eligible to receive milestone payments of up to an aggregate of $445&nbsp;million and tiered royalties that go up to the <FONT STYLE="white-space:nowrap">mid-teens</FONT>
for commercial products developed through the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision Chief Scientific Officer Derek Jantz commented, &#147;Gilead&#146;s cure-based
approach to Hepatitis B is comprehensive and exciting. Precision is pleased that initial studies with our ARCUS platform have established an important role for genome editing in their HBV program. This is an excellent application for our technology,
which has made notable progress toward therapeutic <I>in vivo</I> editing in relevant models over the last year.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- more - </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Precision BioSciences </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences is dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet. We are striving to achieve
this goal with ARCUS, our therapeutic-grade, naturally-derived genome editing system that combines both specificity and efficacy to help overcome life&#146;s greatest genetic challenges. For additional information, please visit
www.precisionbiosciences.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Gilead Sciences </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical
need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Gilead Forward-Looking Statement </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential
benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from
those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead
assumes no obligation to update any such forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>For more information on&nbsp;Gilead Sciences, please visit the company&#146;s website at&nbsp;www.gilead.com, follow </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-GILEAD-5</FONT></FONT></FONT> or </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-650-574-3000.</FONT></FONT></FONT> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 8.2.12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Precision IP Subject to U.S. Federal Government Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRECISION BIOSCIENCES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>2006 STOCK INCENTIVE PLAN </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
<U>Purpose</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this 2006 Stock Incentive Plan (the &#147;Plan&#148;) of Precision BioSciences, Inc., a Delaware corporation
(the &#147;Company&#148;), is to advance the interests of the Company&#146;s stockholders by enhancing the Company&#146;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by
providing such persons with equity ownership opportunities and performance-based incentives that are intended to align their interests with those of the Company&#146;s stockholders. Except where the context otherwise requires, the term
&#147;Company&#148; shall include any of the Company&#146;s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f)&nbsp;of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder
(the &#147;Code&#148;) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the
&#147;Board&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Eligibility</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s employees, officers, directors, consultants and advisors are eligible to receive options, restricted stock,
restricted stock units and other stock-based awards (each, an &#147;Award&#148;) under the Plan. Each person who receives an Award under the Plan is deemed a &#147;Participant&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Administration and Delegation</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Administration by Board of Directors</U>. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it
shall deem advisable. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and
final judge of such expediency. All decisions by the Board shall be made in the Board&#146;s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director or person acting
pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Appointment of Committees</U>. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan
to one or more committees or subcommittees of the Board (a &#147;Committee&#148;). All references in the Plan to the &#147;Board&#148; shall mean the Board or a Committee of the Board to the extent that the Board&#146;s powers or authority under the
Plan have been delegated to such Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Stock Available for Awards</U>. Subject to adjustment under Section&nbsp;8, Awards may be made under the
Plan for up to 200,000 shares of common stock, $0.0001 par value per share, of the Company (the &#147;Common Stock&#148;). If any Award expires or is terminated, surrendered or </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">canceled without having been fully exercised or is forfeited in whole or in part (including as the result of
shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered by such Award
shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the grant of Awards
under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but
unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total number of shares of
Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable percentage as calculated in accordance with the conditions and
exclusions of Section&nbsp;260.140.45. of the California Code of Regulations (the &#147;California Regulations&#148;), based on the shares of the Company which are outstanding at the time the calculation is made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Stock Options </U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The
Board may grant options to purchase Common Stock (each, an &#147;Option&#148;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the
exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An Option which is not intended to be an Incentive Stock Option (as hereinafter defined) shall be
designated a &#147;Nonstatutory Stock Option&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Stock Options</U>. An Option that the Board intends to be an
&#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code (an &#147;Incentive Stock Option&#148;) shall only be granted to employees of Precision BioSciences, any of Precision BioSciences&#146; present or future parent or
subsidiary corporations as defined in Sections 424(e) or (f)&nbsp;of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently
with the requirements of Section&nbsp;422 of the Code. The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or
for any action taken by the Board pursuant to Section&nbsp;9(f), including without limitation the conversion of an Incentive Stock Option to a Nonstatutory Stock Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise Price</U>. The Board shall establish the exercise price of each Option and specify such exercise price in the applicable option
agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Duration of Options</U>. Each Option shall be exercisable at such times and subject to such terms and conditions as the
Board may specify in the applicable option agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise of Option</U>. Options may be exercised by delivery to the Company
of a written notice of exercise signed by the proper person or by any other form of notice (including electronic notice) approved by the Board together with payment in full as specified in Section</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
5(f) for the number of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company following exercise either as soon as practicable or,
subject to such conditions as the Board shall specify, on a deferred basis (with the Company&#146;s obligation to be evidenced by an instrument providing for future delivery of the deferred shares at the time or times specified by the Board). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Payment Upon Exercise</U>. Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) in cash or by check, payable to the order of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) except as the Board may otherwise provide in an option agreement, by (i)&nbsp;delivery of an irrevocable and unconditional undertaking by a
creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a
creditworthy broker to delivery promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) when the Common Stock is registered under the Exchange Act, by delivery of shares of Common Stock owned by the Participant valued at their
fair market value as determined by (or in a manner approved by) the Board (&#147;Fair Market Value&#148;), provided (i)&nbsp;such method of payment is then permitted under applicable law, (ii)&nbsp;such Common Stock, if acquired directly from the
Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii)&nbsp;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar
requirements; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(4) to the extent permitted by applicable law and by the Board, by (i)&nbsp;delivery of a promissory note of the Participant
to the Company on terms determined by the Board, or (ii)&nbsp;payment of such other lawful consideration as the Board may determine; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(5) by any combination of the above permitted forms of payment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Substitute Options</U>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of
property or stock of an entity, the Board may grant Options in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute Options may be granted on such terms as the Board deems
appropriate in the circumstances, notwithstanding any limitations on Options contained in the other sections of this Section&nbsp;5 or in Section&nbsp;2. Substitute Options shall not count against the overall share limit set forth in
Section&nbsp;4(a), except as may be required by reason of Section&nbsp;422 and related provisions of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Restricted Stock; Restricted Stock
Units</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Board may grant Awards entitling recipients to acquire shares of Common Stock (&#147;Restricted
Stock&#148;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that
conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period or periods established by the Board for such Award. Instead of granting Awards for Restricted Stock, the Board may grant Awards entitling the recipient to receive shares of Common Stock to
be delivered at the time such shares of Common Stock vest (&#147;Restricted Stock Units&#148;) (Restricted Stock and Restricted Stock Units are each referred to herein as a &#147;Restricted Stock Award&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Terms and Conditions</U>. The Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for
repurchase (or forfeiture) and the issue price, if any. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Stock Certificates</U>. Any stock certificates issued in respect of a
Restricted Stock Award shall be registered in the name of the Participant and, unless otherwise determined by the Board, deposited by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the
expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to the beneficiary designated, in a manner
determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#146;s death (the &#147;Designated Beneficiary&#148;). In the absence of an effective designation by a
Participant, &#147;Designated Beneficiary&#148; shall mean the Participant&#146;s estate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Other Stock-Based Awards</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares
of Common Stock or other property, may be granted hereunder to Participants (&#147;Other Stock Unit Awards&#148;), including without limitation stock appreciation rights and Awards entitling recipients to receive shares of Common Stock to be
delivered in the future. Such Other Stock Unit Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other
Stock Unit Awards may be paid in shares of Common Stock or cash, as the Board shall determine. Subject to the provisions of the Plan, the Board shall determine the conditions of each Other Stock Unit Award, including any purchase price applicable
thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Adjustments for Changes in Common Stock and Certain Other Events</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Changes in Capitalization</U>. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event, or any distribution to holders of Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and
class of securities available under this Plan, (ii)&nbsp;the number and class of securities and exercise price per share of each outstanding Option, (iii)&nbsp;the repurchase price per share subject to each outstanding Restricted Stock Award, and
(iv)&nbsp;the terms of each other outstanding Award shall be appropriately adjusted by the Company (or substituted Awards may be made, if applicable) to the extent determined by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Reorganization Events</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Definition</U>. A &#147;Reorganization Event&#148; shall mean: (a)&nbsp;any merger or
consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b)&nbsp;any exchange of
all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange transaction or (c)&nbsp;any liquidation or dissolution of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Consequences of a Reorganization Event on Awards Other than Restricted Stock Awards</U>. In connection with a Reorganization Event, the
Board shall take any one or more of the following actions as to all or any outstanding Awards on such terms as the Board determines: (i)&nbsp;provide that Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the
acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that the Participant&#146;s unexercised Options or other unexercised Awards shall become exercisable in full and will terminate
immediately prior to the consummation of such Reorganization Event unless exercised by the Participant within a specified period following the date of such notice, (iii)&nbsp;provide that outstanding Awards shall become realizable or deliverable, or
restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv)&nbsp;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof
a cash payment for each share surrendered in the Reorganization Event (the &#147;Acquisition Price&#148;), make or provide for a cash payment to a Participant equal to (A)&nbsp;the Acquisition Price times the number of shares of Common Stock subject
to the Participant&#146;s Options or other Awards (to the extent the exercise price does not exceed the Acquisition Price) minus (B)&nbsp;the aggregate exercise price of all such outstanding Options or other Awards, in exchange for the termination
of such Options or other Awards, (v)&nbsp;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof) and
(vi)&nbsp;any combination of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of clause (i)&nbsp;above, an Option shall be considered assumed if, following
consummation of the Reorganization Event, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities
or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of
consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the
acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of common stock
of the acquiring or succeeding corporation (or an affiliate thereof) equivalent value (as determined by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent all or any portion of an Option becomes exercisable solely as a result of clause (ii)&nbsp;above, the Board may provide that
upon exercise of such Option the Participant shall receive shares subject to a right of repurchase by the Company or its successor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at the Option exercise price; such repurchase right (x)&nbsp;shall lapse at the same rate as the Option would have become exercisable under its terms and (y)&nbsp;shall not apply to any shares
subject to the Option that were exercisable under its terms without regard to clause (ii)&nbsp;above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) <U>Consequences of a
Reorganization Event on Restricted Stock Awards</U>. Upon the occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company under each outstanding Restricted Stock Award
shall inure to the benefit of the Company&#146;s successor and shall apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same
extent as they applied to the Common Stock subject to such Restricted Stock Award. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in
the instrument evidencing any Restricted Stock Award or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock Awards then outstanding shall automatically be deemed terminated or satisfied.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>General Provisions Applicable to Awards</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability of Awards</U>. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned,
transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant
to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documentation</U>. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each
Award may contain terms and conditions in addition to those set forth in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Board Discretion</U>. Except as otherwise
provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Status</U>. The Board shall determine the effect on an Award of the disability, death, retirement, authorized leave of
absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#146;s legal representative, conservator, guardian or Designated Beneficiary, may
exercise rights under the Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Withholding</U>. Each Participant shall pay to the Company, or make provision satisfactory to the
Company for payment of, any taxes required by law to be withheld in connection with an Award to such Participant. Except as the Board may otherwise provide in an Award, for so long as the Common Stock is registered under the Exchange Act,
Participants may satisfy such tax obligations in whole or in part by delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided, however, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#146;s minimum
statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares surrendered to satisfy tax withholding
requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. The Company may, to the extent permitted by law, deduct any such tax obligations from any payment of any kind otherwise due to a
Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendment of Award</U>. The Board may amend, modify or terminate any outstanding Award, including but not limited to,
substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option, provided that the Participant&#146;s consent to such action
shall be required unless the Board determines that the action, taking into account any related action, would not materially and adversely affect the Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Conditions on Delivery of Stock</U>. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to
remove restrictions from shares previously delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&nbsp;in the opinion of the Company&#146;s counsel, all other legal
matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed
and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Acceleration</U>. The Board may at any time provide that any Award shall become immediately exercisable in full or in part, free of some
or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Miscellaneous</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Right To Employment or Other Status</U>. No person shall have any claim or right to be granted an Award, and the grant of an Award
shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant
free from any liability or claim under the Plan, except as expressly provided in the applicable Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Rights As
Stockholder</U>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming
the record holder of such shares. Notwithstanding the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to such Option are adjusted as of
the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the
close of business on the record date for such stock dividend. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Effective Date and Term of Plan</U>. The Plan shall become effective
on the date on which it is adopted by the Board. No Awards shall be granted under the Plan after the completion of 10 years from the earlier of (i)&nbsp;the date on which the Plan was adopted by the Board or (ii)&nbsp;the date the Plan was approved
by the Company&#146;s stockholders, but Awards previously granted may extend beyond that date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment of Plan</U>. The Board may
amend, suspend or terminate the Plan or any portion thereof at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Authorization of
<FONT STYLE="white-space:nowrap">Sub-Plans</FONT></U>. The Board may from time to time establish one or more <FONT STYLE="white-space:nowrap">sub-plans</FONT> under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of
various jurisdictions. The Board shall establish such <FONT STYLE="white-space:nowrap">sub-plans</FONT> by adopting supplements to this Plan containing (i)&nbsp;such limitations on the Board&#146;s discretion under the Plan as the Board deems
necessary or desirable or (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each
supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. No Award shall provide for deferral of compensation that does not comply with
Section&nbsp;409A of the Code, unless the Board, at the time of grant, specifically provides that the Award is not intended to comply with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the
laws of the State of Delaware, excluding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of such state that would require the application of the laws of a jurisdiction other than
such state. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>2006 STOCK INCENTIVE PLAN </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALIFORNIA SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;10(e) of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of
Section&nbsp;25102(o) of the California Law: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Awards granted under the Plan to a Participant who is a resident of the State of
California on the date of grant (a &#147;California Participant&#148;) shall be subject to the following additional limitations, terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
<U>Additional Limitations on Options</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Minimum Vesting Rate</U>. Except in the case of Options granted to California
Participants who are officers, directors, managers, consultants or advisors of the Company or its affiliates (which Options may become exercisable at whatever rate is determined by the Board), Options granted to California Participants shall become
exercisable at a rate of no less than 20% per year over five years from the date of grant; <U>provided</U>, <U>that</U>, such Options may be subject to such reasonable forfeiture conditions as the Board may choose to impose and which are not
inconsistent with Section&nbsp;260.140.41 of the California Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Minimum Exercise Price</U>. The exercise price of Options
granted to California Participants may not be less than 85% of the Fair Market Value of the Common Stock on the date of grant in the case of a Nonstatutory Stock Option or less than 100% of the Fair Market Value of the Common Stock on the date of
grant in the case of an Incentive Stock Option; <U>provided</U>, <U>however</U>, that if the California Participant is a person who owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or its
parent or subsidiary corporations, the exercise price shall be not less than 110% of the Fair Market Value of the Common Stock on the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Maximum Duration of Options</U>. No Options granted to California Participants will be granted for a term in excess of 10 years. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Minimum Exercise Period Following Termination</U>. Unless a California Participant&#146;s employment is terminated for cause (as defined
in any contract of employment between the Company and such Participant, or if none, in the instrument evidencing the grant of such Participant&#146;s Option), in the event of termination of employment of such Participant, he or she shall have the
right to exercise an Option, to the extent that he or she was otherwise entitled to exercise such Option on the date employment terminated, as follows: (i)&nbsp;at least six months from the date of termination, if termination was caused by such
Participant&#146;s death or &#147;permanent and total disability&#148; (within the meaning of Section&nbsp;22(e)(3) of the Code) and (ii)&nbsp;at least 30 days from the date of termination, if termination was caused other than by such
Participant&#146;s death or &#147;permanent and total disability&#148; (within the meaning of Section&nbsp;22(e)(3) of the Code). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Limitation on Repurchase Rights</U>. If an Option granted to a California Participant
gives the Company the right to repurchase shares of Common Stock issued pursuant to the Plan upon termination of employment of such Participant, the terms of such repurchase right must comply with Section&nbsp;260.140.41(k) of the California
Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Additional Limitations for Restricted Stock Awards</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Minimum Purchase Price</U>. The purchase price for a Restricted Stock Award granted to a California Participant shall be not less than
85% of the Fair Market Value of the Common Stock at the time such Participant is granted the right to purchase shares under the Plan or at the time the purchase is consummated; <U>provided</U>, <U>however</U>, that if such Participant is a person
who owns stock possessing more than 10% of the total combined voting power or value of all classes of stock of the Company or its parent or subsidiary corporations, the purchase price shall be not less than 100% of the Fair Market Value of the
Common Stock at the time such Participant is granted the right to purchase shares under the Plan or at the time the purchase is consummated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Limitation of Repurchase Rights</U>. If a Restricted Stock Award granted to a California Participant gives the Company the right to
repurchase shares of Common Stock issued pursuant to the Plan upon termination of employment of such Participant, the terms of such repurchase right must comply with Section&nbsp;260.140.42(h) of the California Regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Additional Limitations for Other Stock-Based Awards</U>. The terms of all Awards granted to a California Participant under Section&nbsp;7 of the Plan
shall comply, to the extent applicable, with Section&nbsp;260.140.41 or Section&nbsp;260.140.42 of the California Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Additional
Requirement to Provide Information to California Participants</U>. The Company shall provide to each California Participant and to each California Participant who acquires Common Stock pursuant to the Plan, not less frequently than annually, copies
of annual financial statements (which need not be audited). The Company shall not be required to provide such statements to key employees whose duties in connection with the Company assure their access to equivalent information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Additional Limitations on Timing of Awards</U>. No Award granted to a California Participant shall become exercisable, vested or realizable, as
applicable to such Award, unless the Plan has been approved by a majority of the Company&#146;s stockholders within 12 months before or after the date the Plan was adopted by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Additional Limitations Relating to Definition of Fair Market Value</U>. For purposes of Section&nbsp;1(b) and 2(a) of this supplement, &#147;Fair Market
Value&#148; shall be determined in a manner not inconsistent with Section&nbsp;260.140.50 of the California Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Additional Restriction
Regarding Recapitalizations, Stock Splits, Etc.</U> For purposes of Section&nbsp;8 of the Plan, in the event of a stock split, reverse stock split, stock dividend, recapitalization, combination, reclassification or other distribution of the
Company&#146;s securities, the number of securities allocated to each California Participant must be adjusted proportionately and without the receipt by the Company of any consideration from any California Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT OF 2006 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FIRST AMENDMENT of Precision Biosciences, Inc. 2006 Stock Incentive Plan is dated as of December 8, 2010. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of Precision Biosciences, Inc. (the &#147;<B>Company</B>&#148;) has adopted and the stockholders of the
Company have approved the Precision Biosciences, Inc. 2006 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of
Directors determines that it is in the best interests of the Company to amend the Plan in order to increase the number of shares of common stock issuable pursuant to options granted under the Plan (the &#147;<B>Shares</B>&#148;) from Two Hundred
Thousand (200,000) shares to Four Hundred Fifty Thousand (450,000) shares and to make such other amendments as set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, the Plan shall be amended as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The first sentence of Section 4 of the Plan is hereby deleted in its entirety and the
following substituted in lieu thereof: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;Subject to adjustment
under Section 8, Awards may be made under the Plan for up to 450,000 shares of common stock, $0.0001 par value per share, of the Company (the &#147;Common Stock&#148;).&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section 4 of the Plan is hereby further amended to delete the fourth sentence of such section (beginning with the word &#147;However&#148;)
and the following is substituted in lieu thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding the above, if an Option (as defined below) should expire or become
unexerciseable or otherwise terminate for any reason without having been exercised in full, the unpurchased Shares which were subject thereto shall not return to this Plan and shall not become available for other Options under this Plan and shall
instead be immediately canceled.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Section 3(a) of the Plan is hereby amended to add the following immediately after the second
sentence of such section: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;In addition, the Board shall have the authority to: (a) interpret this Plan, the Awards and any agreement
entered into with respect to the grant or exercise of Awards (including Options); (b) to authorize any person to execute on behalf of the Company any instrument required to effectuate the grant of an Award or to take such action as may be necessary
or appropriate with respect to the Company&#146;s rights pursuant to Awards or agreements relating to the grant or exercise thereof; and (c) to make such other terminations and establish such other procedures as it deems necessary or advisable for
the administration of the Plan.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Section 8(b)(1) of the Plan is hereby deleted in its entirety and the following
substituted in lieu thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;(1) <U>Definition</U>. A &#147;Reorganization Event&#148; shall mean one of the following events: (a)
the merger, consolidation or other reorganization of the Company in which the outstanding Common Stock is converted into or exchanged for a different class of securities of the Company, a class of securities of any other issuer (except a parent or
subsidiary of the Company), cash or other property; (b) the sale, lease or exchange of all or substantially all of the assets of the Company to any other corporation or entity (except a parent or subsidiary of the Company); or (c) the adoption by
stockholders of the Company of a plan of liquidation or dissolution. Notwithstanding the above, a Reorganization Event shall not include a merger, consolidation or reorganization of the Company in which no person acquires more than fifty percent
(50%) of the combined voting power of the Company&#146;s then outstanding stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Section 8(b)(3) of the Plan is hereby deleted
in its entirety and the following substituted in lieu thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;Upon the occurrence of a Reorganization Event, except to the extent
specifically provided to the contrary in the instrument evidencing any Restricted Stock Award or any other agreement between a participant and the Company, all restrictions and conditions on all Restricted Stock Awards or Awards under any other such
agreements then outstanding shall automatically be deemed terminated or satisfied.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Except as herein amended, the terms and
provisions of the Plan shall remain in full force and effect as originally adopted and approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned
hereby certifies that this First Amendment was duly adopted by the Board of Directors of the Company as of December 8, 2010. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRECISION BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/Matt Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matt Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRECISION BIOSCIENCES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Incentive Stock Option Agreement </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Granted Under 2006 Stock Incentive Plan </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement
evidences the grant by Precision BioSciences, Inc., a Delaware corporation (the &#147;Company&#148;), on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200[&nbsp;&nbsp;&nbsp;&nbsp;] (the &#147;Grant Date&#148;) to
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] an employee of the Company (the &#147;Participant&#148;), of an option to purchase, in whole or in part, on the terms provided
herein and in the Company&#146;s 2006 Stock Incentive Plan (the &#147;Plan&#148;), a total of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares (the &#147;Shares&#148;)
of common stock, $0.0001 par value per share, of the Company (&#147;Common Stock&#148;) at $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Share.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Unless earlier
terminated, this option shall expire at 5:00 p.m., Eastern time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;Final Exercise Date&#148;).<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that the option evidenced by this agreement shall be an incentive stock option as defined in Section&nbsp;422 of the Internal
Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#147;Code&#148;). Except as otherwise indicated by the context, the term &#147;Participant&#148;, as used in this option, shall be deemed to include any person who
acquires the right to exercise this option validly under its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Vesting Schedule</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This option will become exercisable (&#147;vest&#148;) as to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
original number of Shares on the [first] anniversary of the Grant Date and as to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the original number of Shares at the end of each successive [three-month]
period following the first anniversary of the Grant Date until the [fourth] anniversary of the Grant Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of exercise shall be
cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final
Exercise Date or the termination of this option under Section&nbsp;3 hereof or the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of Option</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Form of Exercise</U>. Each election to exercise this option shall be in writing, signed by the Participant, and received by the Company
at its principal office, accompanied by this agreement, and payment in full in the manner provided in the Plan. The Participant may </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This must be at least 100% of the fair market value of the Common Stock on the date of grant (or 110% in the
case of a Participant that owns more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary (a &#147;10% Shareholder&#148;)) for the option to qualify as an incentive stock option (an
&#147;ISO&#148;) under Section&nbsp;422 of the Code. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Final Exercise Date must be no more than 10 years (5 years in the case of a 10% Shareholder) from the date
of grant for the option to qualify as an ISO. The correct approach to calculate the final exercise date is to use the day immediately prior to the date ten years out from the date of the stock option award grant (5 years in the case of a 10%
stockholder). For example, an award granted to someone on October&nbsp;1, 2001 would expire on September&nbsp;30, 2011 (not on October&nbsp;1, 2011). </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">purchase less than the number of shares covered hereby, provided that no partial exercise of this option may
be for any fractional share or for fewer than ten whole shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Continuous Relationship with the Company Required</U>. Except as
otherwise provided in this Section&nbsp;3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee or officer of, or consultant or advisor
to, the Company or any parent or subsidiary of the Company as defined in Section&nbsp;424(e) or (f)&nbsp;of the Code (an &#147;Eligible Participant&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination of Relationship with the Company</U>. If the Participant ceases to be an Eligible Participant for any reason, then, except
as provided in paragraphs (d)&nbsp;and (e) below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), <U>provided</U> <U>that</U> this option shall be exercisable only
to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the
<FONT STYLE="white-space:nowrap">non-competition</FONT> or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this
option shall terminate immediately upon written notice to the Participant from the Company describing such violation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise
Period Upon Death or Disability</U>. If the Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated
such relationship for &#147;cause&#148; as specified in paragraph (e)&nbsp;below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of
death by an authorized transferee), <U>provided</U> <U>that</U> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this
option shall not be exercisable after the Final Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination for Cause</U>. If, prior to the Final Exercise Date, the
Participant&#146;s employment is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment. If, prior to the Final Exercise Date,
the Participant is given notice by the Company of the termination of his or her employment by the Company for Cause, and the effective date of such employment termination is subsequent to the date of delivery of such notice, the right to exercise
this option shall be suspended from the time of the delivery of such notice until the earlier of (i)&nbsp;such time as it is determined or otherwise agreed that the Participant&#146;s employment shall not be terminated for Cause as provided in such
notice or (ii)&nbsp;the effective date of such termination of employment (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate upon the effective date of such termination of employment). If the
Participant is party to an employment or severance agreement with the Company that contains a definition of &#147;cause&#148; for termination of employment, &#147;Cause&#148; shall have the meaning ascribed to such term in such agreement. Otherwise,
&#147;Cause&#148; shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any
employment, consulting, advisory, nondisclosure, <FONT STYLE="white-space:nowrap">non-competition</FONT> or other similar agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">between the Participant and the Company), as determined by the Company, which determination shall be
conclusive. The Participant shall be considered to have been discharged for Cause if the Company determines, within 30 days after the Participant&#146;s resignation, that discharge for cause was warranted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Company Right of First Refusal</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Notice of Proposed Transfer</U>. If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively, &#147;transfer&#148;) any Shares acquired upon exercise of this
option, then the Participant shall first give written notice of the proposed transfer (the &#147;Transfer Notice&#148;) to the Company. The Transfer Notice shall name the proposed transferee and state the number of such Shares the Participant
proposes to transfer (the &#147;Offered Shares&#148;), the price per share and all other material terms and conditions of the transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Company Right to Purchase</U>. For 30 days following its receipt of such Transfer Notice, the Company shall have the option to purchase
all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to the Participant
within such <FONT STYLE="white-space:nowrap">30-day</FONT> period. Within 10 days after his or her receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate or certificates representing the Offered
Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. Promptly following receipt of such
certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for such Offered Shares; <U>provided</U> <U>that</U> if the terms of payment set forth in the Transfer Notice were other than
cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and <U>provided</U> <U>further</U> that any delay in making such payment shall not invalidate the
Company&#146;s exercise of its option to purchase the Offered Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Shares Not Purchased By Company</U>. If the Company does not
elect to acquire all of the Offered Shares, the Participant may, within the <FONT STYLE="white-space:nowrap">30-day</FONT> period following the expiration of the option granted to the Company under subsection (b)&nbsp;above, transfer the Offered
Shares which the Company has not elected to acquire to the proposed transferee, <U>provided</U> <U>that</U> such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice.
Notwithstanding any of the above, all Offered Shares transferred pursuant to this Section&nbsp;4 shall remain subject to the right of first refusal set forth in this Section&nbsp;4 and such transferee shall, as a condition to such transfer, deliver
to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section&nbsp;4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Consequences of <FONT STYLE="white-space:nowrap">Non-Delivery</FONT></U>. After the time at which the Offered Shares are required to be
delivered to the Company for transfer to the Company pursuant to subsection (b)&nbsp;above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the Participant to exercise any of the privileges or
rights of a stockholder with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to such Offered Shares, but shall, insofar as permitted by law, treat the Company as the owner of such Offered Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exempt Transactions</U>. The following transactions shall be exempt from the provisions of this Section&nbsp;4: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) any transfer of Shares to or for the benefit of any spouse, child, parent, uncle, aunt, sibling, mother or
<FONT STYLE="white-space:nowrap">father-in</FONT> law, sister or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law</FONT></FONT> or grandchild of the Participant, or any other relatives of the Participant approved by
the Board of Directors (collectively, &#147;Approved Relatives&#148;) or to a trust established solely for the benefit of the Participant and/or Approved Relatives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) any transfer pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) the sale of all or substantially all of the shares of capital stock of the Company (including
pursuant to a merger or consolidation); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that in the case of a transfer pursuant to clause (1)&nbsp;above, such Shares
shall remain subject to the right of first refusal set forth in this Section&nbsp;4 and such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the
terms and conditions of this Section&nbsp;4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Assignment of Company Right</U>. The Company may assign its rights to purchase Offered
Shares in any particular transaction under this Section&nbsp;4 to one or more persons or entities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Termination</U>. The provisions
of this Section&nbsp;4 shall terminate upon the earlier of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) the closing of the sale of shares of Common Stock in
an underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) the
sale of all or substantially all of the capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities
who were beneficial owners of the Common Stock immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities entitled to vote generally in the election of directors of the resulting,
surviving or acquiring corporation in such transaction). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>No Obligation to Recognize Invalid Transfer</U>. The Company shall not be
required (1)&nbsp;to transfer on its books any of the Shares which shall have been sold or transferred in violation of any of the provisions set forth in this Section&nbsp;4, or (2)&nbsp;to treat as owner of such Shares or to pay dividends to any
transferee to whom any such Shares shall have been so sold or transferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Legends</U>. The certificate representing Shares shall bear a legend substantially in
the following form (in addition to, or in combination with, any legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The shares represented by this certificate are subject to a right of first refusal in favor of the Company, as provided in a certain
stock option agreement with the Company.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Agreement in Connection with Public Offering</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant agrees, in connection with the initial underwritten public offering of the Company&#146;s securities pursuant to a registration
statement under the Securities Act, (i)&nbsp;not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common Stock held by the Participant (other than those shares included in the offering)
without the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the Company&#146;s securities for a period of 180 days from the effective date of such registration statement, and
(ii)&nbsp;to execute any agreement reflecting clause (i)&nbsp;above as may be requested by the Company or the managing underwriters at the time of such offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Tax Matters</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Withholding</U>.
No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be
withheld in respect of this option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Disqualifying Disposition</U>. If the Participant disposes of Shares acquired upon exercise of
this option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Nontransferability of Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT
STYLE="white-space:nowrap">option-may</FONT> not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the
lifetime of the Participant, this option shall be exercisable only by the Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Provisions of the Plan</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this option to be executed under its corporate seal by its duly authorized officer. This option
shall take effect as a sealed instrument. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">PRECISION BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF STOCK OPTION EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Date: <U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2225 Gentry Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27705 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Treasurer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sir or Madam: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am the holder of an
Incentive Stock Option granted to me under the Precision BioSciences, Inc. (the &#147;Company&#148;) 2006 Stock Incentive Plan on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the purchase of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock of the Company at a purchase price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby exercise my option to purchase
<U></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock (the &#147;Shares&#148;), for which I have enclosed
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the amount of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Please register my stock certificate as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Name(s):
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Address:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tax I.D. #:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I represent, warrant and covenant as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in
violation of the Securities Act of 1933 (the &#147;Securities Act&#148;), or any rule or regulation under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. I have had such
opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to
make an informed investment decision with respect to such purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding
such Shares for an indefinite period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. I understand that (i)&nbsp;the Shares have not been registered under the Securities Act and are &#147;restricted
securities&#148; within the meaning of Rule 144 under the Securities Act, (ii)&nbsp;the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is
then available; (iii)&nbsp;in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock, adequate information
concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock
of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Signature)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRECISION BIOSCIENCES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Nonstatutory Stock Option Agreement </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Granted Under 2006 Stock Incentive Plan </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
agreement evidences the grant by Precision BioSciences, Inc., a Delaware corporation (the &#147;Company&#148;), on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200[&nbsp;&nbsp;&nbsp;&nbsp;] (the &#147;Grant Date&#148;)
to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, an [employee], [consultant], [director] of the Company (the &#147;Participant&#148;), of an option to purchase, in whole or
in part, on the terms provided herein and in the Company&#146;s 2006 Stock Incentive Plan (the &#147;Plan&#148;), a total of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
shares (the &#147;Shares&#148;) of common stock, $0.0001 par value per share, of the Company (&#147;Common Stock&#148;) at $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per Share.<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] (the &#147;Final Exercise Date&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that the option evidenced by this agreement shall not be an incentive stock option as defined in Section&nbsp;422 of the
Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#147;Code&#148;). Except as otherwise indicated by the context, the term &#147;Participant&#148;, as used in this option, shall be deemed to include any
person who acquires the right to exercise this option validly under its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting Schedule</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This option will become exercisable (&#147;vest&#148;) as to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
original number of Shares on the [first] anniversary of the Grant Date and as to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the original number of Shares at the end of each successive [three-month]
period following the first anniversary of the Grant Date until the [fourth] anniversary of the Grant Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of exercise shall be
cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final
Exercise Date or the termination of this option under Section&nbsp;3 hereof or the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of Option</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Form of Exercise</U>. Each election to exercise this option shall be in writing, signed by the Participant, and received by the Company
at its principal office, accompanied by this agreement, and payment in full in the manner provided in the Plan. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for
any fractional share or for fewer than ten whole shares. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under the Plan, there are no restrictions on the exercise price; however, if the exercise price is less than
100% of fair market value of the Common Stock as of the date of grant, the Company will incur a charge to earnings as the result of the grant of the option. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Continuous Relationship with the Company Required</U>. Except as otherwise provided
in this Section&nbsp;3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer or director, or consultant or advisor to, the
Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#147;Eligible Participant&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination of Relationship with the Company</U>. If the Participant ceases to be an Eligible Participant for any reason, then, except
as provided in paragraphs (d)&nbsp;and (e) below, the right to exercise this option shall terminate [three] months after such cessation (but in no event after the Final Exercise Date), provided that this option shall be exercisable only to the
extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the <FONT STYLE="white-space:nowrap">non-competition</FONT>
or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon written notice to
the Participant from the Company describing such violation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Period Upon Death or Disability</U>. If the Participant dies
or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for &#147;cause&#148; as specified in
paragraph (e)&nbsp;below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), <U>provided</U>
<U>that</U> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final
Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination for Cause</U>. If, prior to the Final Exercise Date, the Participant&#146;s employment or other
relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship. If, prior to the
Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date
of the delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i)&nbsp;such time as it is determined or otherwise agreed that the Participant&#146;s employment
or other relationship shall not be terminated for Cause as provided in such notice or (ii)&nbsp;the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the
preceding sentence, terminate immediately upon the effective date of such termination of employment or other relationship). If the Participant is party to an employment, consulting or severance agreement with the Company that contains a definition
of &#147;cause&#148; for termination of employment or other relationship, &#147;Cause&#148; shall have the meaning ascribed to such term in such agreement. Otherwise, &#147;Cause&#148; shall mean willful misconduct by the Participant or willful
failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure,
<FONT STYLE="white-space:nowrap">non-competition</FONT> or other similar agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
between the Participant and the Company), as determined by the Company, which determination shall be conclusive. The Participant shall be considered to have been discharged for &#147;Cause&#148;
if the Company determines, within 30 days after the Participant&#146;s resignation, that discharge for cause was warranted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Company
Right of First Refusal</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice of Proposed Transfer</U>. If the Participant proposes to sell, assign, transfer, pledge,
hypothecate or otherwise dispose of, by operation of law or otherwise (collectively, &#147;transfer&#148;) any Shares acquired upon exercise of this option, then the Participant shall first give written notice of the proposed transfer (the
&#147;Transfer Notice&#148;) to the Company. The Transfer Notice shall name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the &#147;Offered Shares&#148;), the price per share and all other material
terms and conditions of the transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Company Right to Purchase</U>. For 30 days following its receipt of such Transfer Notice, the
Company shall have the option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice
of such election to the Participant within such <FONT STYLE="white-space:nowrap">30-day</FONT> period. Within 10 days after his or her receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate or
certificates representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company.
Promptly following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for such Offered Shares; <U>provided</U> <U>that</U> if the terms of payment set forth in
the Transfer Notice were other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and <U>provided</U> <U>further</U> that any delay in making such payment
shall not invalidate the Company&#146;s exercise of its option to purchase the Offered Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Shares Not Purchased By Company</U>.
If the Company does not elect to acquire all of the Offered Shares, the Participant may, within the <FONT STYLE="white-space:nowrap">30-day</FONT> period following the expiration of the option granted to the Company under subsection (b)&nbsp;above,
transfer the Offered Shares which the Company has not elected to acquire to the proposed transferee, <U>provided</U> <U>that</U> such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer
Notice. Notwithstanding any of the above, all Offered Shares transferred pursuant to this Section&nbsp;4 shall remain subject to the right of first refusal set forth in this Section&nbsp;4 and such transferee shall, as a condition to such transfer,
deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section&nbsp;4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Consequences of <FONT STYLE="white-space:nowrap">Non-Delivery</FONT></U>. After the time at which the Offered Shares are required to be
delivered to the Company for transfer to the Company pursuant to subsection (b)&nbsp;above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the Participant to exercise any of the privileges or
rights of a stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to such Offered Shares, but shall, insofar as permitted by law, treat the Company as the owner of such Offered Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Exempt Transactions</U>. The following transactions shall be exempt from the provisions of this Section&nbsp;4: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) any transfer of Shares to or for the benefit of any spouse, child, parent, uncle, aunt, sibling, mother or
<FONT STYLE="white-space:nowrap">father-in</FONT> law, sister or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law</FONT></FONT> or grandchild of the Participant, or any other relatives of the Participant approved by
the Board of Directors (collectively, &#147;Approved Relatives&#148;) or to a trust established solely for the benefit of the Participant and/or Approved Relatives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) any transfer pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) the sale of all or substantially all of the shares of capital stock of the Company (including
pursuant to a merger or consolidation); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that in the case of a transfer pursuant to clause (1)&nbsp;above, such Shares
shall remain subject to the right of first refusal set forth in this Section&nbsp;4 and such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the
terms and conditions of this Section&nbsp;4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Assignment of Company Right</U>. The Company may assign its rights to purchase Offered
Shares in any particular transaction under this Section&nbsp;4 to one or more persons or entities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Termination</U>. The provisions
of this Section&nbsp;4 shall terminate upon the earlier of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) the closing of the sale of shares of Common Stock in
an underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) the
sale of all or substantially all of the capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities
who were beneficial owners of the Common Stock immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities entitled to vote generally in the election of directors of the resulting,
surviving or acquiring corporation in such transaction). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>No Obligation to Recognize Invalid Transfer</U>. The Company shall not be
required (1)&nbsp;to transfer on its books any of the Shares which shall have been sold or transferred in violation of any of the provisions set forth in this Section&nbsp;4, or (2)&nbsp;to treat as owner of such Shares or to pay dividends to any
transferee to whom any such Shares shall have been so sold or transferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Legends</U>. The certificate representing Shares shall bear a legend substantially in
the following form (in addition to, or in combination with, any legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The shares represented by this certificate are subject to a right of first refusal in favor of the Company, as provided in a certain
stock option agreement with the Company.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Agreement in Connection with Public Offering</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Participant agrees, in connection with the initial underwritten public offering of the Company&#146;s securities pursuant to a registration
statement under the Securities Act, (i)&nbsp;not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common Stock held by the Participant (other than those shares included in the offering)
without the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the Company&#146;s securities for a period of 180 days from the effective date of such registration statement, and
(ii)&nbsp;to execute any agreement reflecting clause (i)&nbsp;above as may be requested by the Company or the managing underwriters at the time of such offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Withholding</U>.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision
satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Nontransferability of Option</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of
law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Provisions of the Plan</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this option to be executed under its corporate
seal by its duly authorized officer. This option shall take effect as a sealed instrument. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PRECISION BIOSCIENCES, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF STOCK OPTION EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Date: <U></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2225 Gentry Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27705 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Treasurer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sir or Madam: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am the holder of
Nonstatutory Stock Option granted to me under the Precision BioSciences, Inc. (the &#147;Company&#148;) 2006 Stock Incentive Plan on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the purchase of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock of the Company at a purchase price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby exercise my option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock (the &#147;Shares&#148;), for which I have enclosed
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the amount of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Please register my stock certificate as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Name(s):
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Address:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tax I.D. #:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I represent, warrant and covenant as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in
violation of the Securities Act of 1933 (the &#147;Securities Act&#148;), or any rule or regulation under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. I have had such
opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to
make an informed investment decision with respect to such purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. I can afford a complete loss of the value of the Shares and am able to bear the
economic risk of holding such Shares for an indefinite period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. I understand that (i)&nbsp;the Shares have not been registered under the Securities Act and are
&#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act, (ii)&nbsp;the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption
from registration is then available; (iii)&nbsp;in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock,
adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with
respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Signature)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>PRECISION BIOSCIENCES, INC. </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Restricted Stock Agreement </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Granted Under 2006 Stock Incentive Plan </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGREEMENT made this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200&nbsp;&nbsp;&nbsp;&nbsp;, between Precision BioSciences, Inc., a Delaware corporation (the &#147;Company&#148;), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;Participant&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Purchase of Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall issue and sell to the Participant, and the Participant shall purchase from the Company, subject to the terms and conditions
set forth in this Agreement, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (the &#147;Shares&#148;) of common stock, $0.001 par value, of the Company (&#147;Common Stock&#148;), at a purchase price of $[ ] per
share. The aggregate purchase price for the Shares shall be paid by the Participant by check payable to the order of the Company or such other method as may be acceptable to the Company. Upon receipt by the Company of payment for the Shares, the
Company shall issue to the Participant one or more certificates in the name of the Participant for that number of Shares purchased by the Participant. The Participant agrees that the Shares shall be subject to the purchase options set forth in
Sections 2 and 5 of this Agreement and the restrictions on transfer set forth in Section&nbsp;4 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase
Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) In the event that the Participant ceases to be employed by the Company for any reason or no reason, with or without cause,
prior to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, [&nbsp;&nbsp;&nbsp;&nbsp;] &nbsp;&nbsp;&nbsp;&nbsp;, the Company shall have the right and option (the &#147;Purchase Option&#148;) to purchase from the Participant,
for a sum of $[&nbsp;&nbsp;&nbsp;&nbsp;]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> per share (the &#147;Option Price&#148;), some or all of the Unvested Shares (as defined below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Unvested Shares&#148; means the total number of Shares multiplied by the Applicable Percentage at the time the Purchase Option becomes
exercisable by the Company. The &#147;Applicable Percentage&#148; shall be (i) 66% during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200_, (ii) [75%]
less [6.25%] for each one month of service completed by the Participant with the Company from and after &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200&nbsp;&nbsp;&nbsp;&nbsp;, and (iii)&nbsp;zero on or after
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In the event that the
Participant&#146;s employment with the Company is terminated by reason of death or disability, the number of the Shares for which the Purchase Option becomes exercisable shall be fifty percent (50%) of the number of Unvested Shares for which the
Purchase Option would otherwise become exercisable. For this purpose, &#147;disability&#148; shall mean the inability of the Participant, due to a medical reason, to carry out his duties as an employee of the Company for a period of six consecutive
months. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This is generally equal to the purchase price paid. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If the Participant is employed by a parent or subsidiary of the Company, any references
in this Agreement to employment with the Company or termination of employment by or with the Company shall instead be deemed to refer to such parent or subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of Purchase Option and Closing</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Company may exercise the Purchase Option by delivering or mailing to the Participant (or his estate), within 90 days after the
termination of the employment of the Participant with the Company, a written notice of exercise of the Purchase Option. Such notice shall specify the number of Shares to be purchased. If and to the extent the Purchase Option is not so exercised by
the giving of such a notice within such <FONT STYLE="white-space:nowrap">90-day</FONT> period, the Purchase Option shall automatically expire and terminate effective upon the expiration of such <FONT STYLE="white-space:nowrap">90-day</FONT> period.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Within 10 days after delivery to the Participant of the Company&#146;s notice of the exercise of the Purchase Option pursuant to
subsection (a)&nbsp;above, the Participant (or his estate) shall, pursuant to the provisions of the Joint Escrow Instructions referred to in Section&nbsp;7 below, tender to the Company at its principal offices the certificate or certificates
representing the Shares which the Company has elected to purchase in accordance with the terms of this Agreement, duly endorsed in blank or with duly endorsed stock powers attached thereto, all in form suitable for the transfer of such Shares to the
Company. Promptly following its receipt of such certificate or certificates, the Company shall pay to the Participant the aggregate Option Price for such Shares (provided that any delay in making such payment shall not invalidate the Company&#146;s
exercise of the Purchase Option with respect to such Shares). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) After the time at which any Shares are required to be delivered to the
Company for transfer to the Company pursuant to subsection (b)&nbsp;above, the Company shall not pay any dividend to the Participant on account of such Shares or permit the Participant to exercise any of the privileges or rights of a stockholder
with respect to such Shares, but shall, in so far as permitted by law, treat the Company as the owner of such Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The Option Price
may be payable, at the option of the Company, in cancellation of all or a portion of any outstanding indebtedness of the Participant to the Company or in cash (by check) or both. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Company shall not purchase any fraction of a Share upon exercise of the Purchase Option, and any fraction of a Share resulting from a
computation made pursuant to Section&nbsp;2 of this Agreement shall be rounded to the nearest whole Share (with any <FONT STYLE="white-space:nowrap">one-half</FONT> Share being rounded upward). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The Company may assign its Purchase Option to one or more persons or entities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise
(collectively &#147;transfer&#148;) any Shares, or any interest therein, that are subject to the Purchase Option, except that the Participant may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer such Shares (i)&nbsp;to or for the benefit of any spouse, child, parent, uncle, aunt, sibling, grandchild and any other relatives approved by the Board of Directors (collectively,
&#147;Approved Relatives&#148;) or to a trust established solely for the benefit of the Participant and/or Approved Relatives, <U>provided</U> that such Shares shall remain subject to this Agreement (including without limitation the restrictions on
transfer set forth in this Section&nbsp;4, the Purchase Option and the right of first refusal set forth in Section&nbsp;5) and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming
that such transferee shall be bound by all of the terms and conditions of this Agreement; or (ii)&nbsp;as part of the sale of all or substantially all of the shares of capital stock of the Company (including pursuant to a merger or consolidation),
<U>provided</U> that, in accordance with Section&nbsp;9(b) below, the securities or other property received by the Participant in connection with such transaction shall remain subject to this Agreement; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Participant shall not transfer any Shares, or any interest therein, that are no longer subject to the Purchase Option, except in
accordance with Section&nbsp;5 below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Right of First Refusal</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) If the Participant proposes to transfer any Shares that are no longer subject to the Purchase Option (either because they are no longer
Unvested Shares or because the Purchase Option expired unexercised), then the Participant shall first give written notice of the proposed transfer (the &#147;Transfer Notice&#148;) to the Company. The Transfer Notice shall name the proposed
transferee and state the number of such Shares the Participant proposes to transfer (the &#147;Offered Shares&#148;), the price per share and all other material terms and conditions of the transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) For 30 days following delivery to the Company of such Transfer Notice, the Company shall have the option to purchase all or part of the
Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to the Participant within such <FONT
STYLE="white-space:nowrap">30-day</FONT> period. Within 10 days after delivery to the Participant of such notice, the Participant shall tender to the Company at its principal offices the certificate or certificates representing the Offered Shares to
be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock powers attached thereto, all in form suitable for transfer of the Offered Shares to the Company<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>.
Promptly following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for the Offered Shares; <U>provided</U> <U>that</U> if the terms of payment set forth in
the Transfer Notice were other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and <U>provided</U> <U>further</U> that any delay in making such payment
shall not invalidate the Company&#146;s exercise of its option to purchase the Offered Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If the Company does not elect to
acquire any of the Offered Shares, the Participant may, within the <FONT STYLE="white-space:nowrap">30-day</FONT> period following the expiration of the option granted to the </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are California blue sky limitations on the repurchase of shares. This should be reviewed for any
Participants who are California residents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company under subsection (b)&nbsp;above, transfer the Offered Shares which the Company has not elected to acquire to the proposed transferee, <U>provided</U> <U>that</U> such transfer shall not
be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred pursuant to this Section&nbsp;5 shall remain subject to this Agreement
(including without limitation the restrictions on transfer set forth in Section&nbsp;4 and the right of first refusal set forth in this Section&nbsp;5) and such transferee shall, as a condition to such transfer, deliver to the Company a written
instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) After the time at
which the Offered Shares are required to be delivered to the Company for transfer to the Company pursuant to subsection (b)&nbsp;above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the
Participant to exercise any of the privileges or rights of a stockholder with respect to such Shares, but shall, in so far as permitted by law, treat the Company as the owner of such Offered Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The following transactions shall be exempt from the provisions of this Section&nbsp;5: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) a transfer of Shares to or for the benefit of any Approved Relatives, or to a trust established solely for the benefit of the Participant
and/or Approved Relatives; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) any transfer pursuant to an effective registration statement filed by the Company under the Securities Act
of 1933, as amended (the &#147;Securities Act&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) the sale of all or substantially all of the shares of capital stock of the
Company (including pursuant to a merger or consolidation); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that in the case of a transfer pursuant to clause
(1)&nbsp;above, such Shares shall remain subject to this Agreement (including without limitation the restrictions on transfer set forth in Section&nbsp;4 and the right of first refusal set forth in this Section&nbsp;5) and such transferee shall, as
a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section&nbsp;5 to one or more persons
or entities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) The provisions of this Section&nbsp;5 shall terminate upon the earlier of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) the closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration statement filed
by the Company under the Securities Act; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) the sale of all or substantially all of the capital stock, assets or business of the
Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beneficial owners of the Common Stock immediately prior to such transaction beneficially own, directly or indirectly, more than 75% of the outstanding securities entitled to vote generally in the
election of directors of the resulting, surviving or acquiring corporation in such transaction). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) The Company shall not be required
(1)&nbsp;to transfer on its books any of the Shares which shall have been sold or transferred in violation of any of the provisions set forth in this Agreement, or (2)&nbsp;to treat as owner of such Shares or to pay dividends to any transferee to
whom any such Shares shall have been so sold or transferred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Agreement in Connection with Public Offering</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant agrees, in connection with the initial underwritten public offering of the Company&#146;s securities pursuant to a registration
statement under the Securities Act, (i)&nbsp;not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common Stock held by the Participant (other than those shares included in the offering)
without the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the Company&#146;s securities for a period of 180 days from the effective date of such registration statement, and
(ii)&nbsp;to execute any agreement reflecting clause (i)&nbsp;above as may be requested by the Company or the managing underwriters at the time of such offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Escrow</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Participant shall, upon the execution of this Agreement, execute Joint Escrow Instructions in the form attached to this Agreement as <U>Exhibit A</U>. The Joint Escrow Instructions shall be delivered to the Secretary of the Company, as escrow agent
thereunder. The Participant shall deliver to such escrow agent a stock assignment duly endorsed in blank, in the form attached to this Agreement as <U>Exhibit B</U>, and hereby instructs the Company to deliver to such escrow agent, on behalf of the
Participant, the certificate(s) evidencing the Shares issued hereunder. Such materials shall be held by such escrow agent pursuant to the terms of such Joint Escrow Instructions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Restrictive Legends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All certificates representing Shares shall have affixed thereto legends in substantially the following form, in addition to any other legends
that may be required under federal or state securities laws: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate are subject to
restrictions on transfer and an option to purchase set forth in a certain Restricted Stock Agreement between the corporation and the registered owner of these shares (or his predecessor in interest), and such Agreement is available for inspection
without charge at the office of the Secretary of the corporation.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The shares represented by this certificate have not been
registered under the Securities Act of 1933, as amended, and may not be sold, transferred or otherwise disposed of in the absence of an effective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
registration statement under such Act or an opinion of counsel satisfactory to the corporation to the effect that such registration is not required.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Provisions of the Plan.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) As provided in the Plan, upon the occurrence of a Reorganization Event (as defined in the Plan), the repurchase and other rights of the
Company hereunder shall inure to the benefit of the Company&#146;s successor and shall apply to the cash, securities or other property which the Shares were converted into or exchanged for pursuant to such Reorganization Event in the same manner and
to the same extent as they applied to the Shares under this Agreement. If, in connection with a Reorganization Event, a portion of the cash, securities and/or other property received upon the conversion or exchange of the Shares is to be placed into
escrow to secure indemnification or similar obligations, the mix between the vested and unvested portion of such cash, securities and/or other property that is placed into escrow shall be the same as the mix between the vested and unvested portion
of such cash, securities and/or other property that is not subject to escrow. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Investment Representations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant represents, warrants and covenants as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Participant is purchasing the Shares for his own account for investment only, and not with a view to, or for sale in connection with,
any distribution of the Shares in violation of the Securities Act, or any rule or regulation under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Participant
has had such opportunity as he has deemed adequate to obtain from representatives of the Company such information as is necessary to permit him to evaluate the merits and risks of his investment in the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The Participant has sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the
purchase of the Shares and to make an informed investment decision with respect to such purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The Participant can afford a
complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The
Participant understands that (i)&nbsp;the Shares have not been registered under the Securities Act and are &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act; (ii)&nbsp;the Shares cannot be sold, transferred or
otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then available; (iii)&nbsp;in any event, the exemption from registration under Rule 144 will not be available for at least
one year and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and
(iv)&nbsp;there is now no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares
under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Withholding Taxes; Section</U><U></U><U>&nbsp;83(b) Election</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant
any federal, state or local taxes of any kind required by law to be withheld with respect to the purchase of the Shares by the Participant or the lapse of the Purchase Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Participant has reviewed with the Participant&#146;s own tax advisors the federal, state, local and foreign tax consequences of this
investment and the transactions contemplated by this Agreement. The Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant understands that the Participant
(and not the Company) shall be responsible for the Participant&#146;s own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. The Participant understands that it may be beneficial in many
circumstances to elect to be taxed at the time the Shares are purchased rather than when and as the Company&#146;s Purchase Option expires by filing an election under Section&nbsp;83(b) of the Internal Revenue Code of 1986 with the IRS within 30
days from the date of purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">THE PARTICIPANT ACKNOWLEDGES THAT IT IS SOLELY THE PARTICIPANT&#146;S RESPONSIBILITY AND NOT THE
COMPANY&#146;S TO FILE TIMELY THE ELECTION UNDER SECTION 83(B), EVEN IF THE PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON THE PARTICIPANT&#146;S BEHALF. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>No Rights To Employment</U>. Nothing contained in this Agreement shall be construed as giving the Participant any right to be retained, in any position, as an employee of the Company. The Participant acknowledges and agrees that the vesting of
the Shares pursuant to Section&nbsp;2 hereof is earned only by continuing service as an employee at the will of the Company (not through the act of being hired or purchasing shares hereunder). The Participant further acknowledges and agrees that the
transactions contemplated hereunder and the vesting schedule set forth herein do not constitute an express or implied promise of continued engagement as an employee for the vesting period, for any period, or at all. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Severability</U>. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Waiver</U>. Any provision for the benefit of the Company contained in this Agreement may be waived, either generally or in any
particular instance, by the Board of Directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Binding Effect</U>. This Agreement shall be binding upon and inure to the benefit of
the Company and the Participant and their respective heirs, executors, administrators, legal representatives, successors and assigns, subject to the restrictions on transfer set forth in Sections 4 and 5 of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Notice</U>. All notices required or permitted hereunder shall be in writing and deemed effectively given upon personal delivery or five
days after deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party hereto at the address shown beneath his or its respective signature to this Agreement, or at such other address or
addresses as either party shall designate to the other in accordance with this Section&nbsp;12(e). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Pronouns</U>. Whenever the
context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the parties, and supersedes all prior agreements and
understandings, relating to the subject matter of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Amendment</U>. This Agreement may be amended or modified only by
a written instrument executed by both the Company and the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Governing Law</U>. This Agreement shall be construed,
interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) <U>Participant&#146;s Acknowledgements</U>. The Participant acknowledges that he or she: (i)&nbsp;has read this Agreement; (ii)&nbsp;has
been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of the Participant&#146;s own choice or has voluntarily declined to seek such counsel; (iii)&nbsp;understands the terms and consequences of this
Agreement; (iv)&nbsp;is fully aware of the legal and binding effect of this Agreement; and (v)&nbsp;understands that the law firm of WilmerHale is acting as counsel to the Company in connection with the transactions contemplated by the Agreement,
and is not acting as counsel for the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">PRECISION BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">[Name of Participant]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Precision BioSciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Joint Escrow Instructions </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">________, [&nbsp;&nbsp;&nbsp;&nbsp;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Secretary
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision BioSciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2225 Gentry Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27705 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sir: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Escrow Agent for Precision BioSciences, Inc., a Delaware corporation, and its successors in interest under the Restricted Stock Agreement
(the &#147;Agreement&#148;) of even date herewith, to which a copy of these Joint Escrow Instructions is attached (the &#147;Company&#148;), and the undersigned person (&#147;Holder&#148;), you are hereby authorized and directed to hold the
documents delivered to you pursuant to the terms of the Agreement in accordance with the following instructions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Appointment</U>.
Holder irrevocably authorizes the Company to deposit with you any certificates evidencing Shares (as defined in the Agreement) to be held by you hereunder and any additions and substitutions to said Shares. For purposes of these Joint Escrow
Instructions, &#147;Shares&#148; shall be deemed to include any additional or substitute property. Holder does hereby irrevocably constitute and appoint you as his
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent for the term of this escrow to execute with respect to such Shares all documents necessary or appropriate to make such Shares negotiable and
to complete any transaction herein contemplated. Subject to the provisions of this Section&nbsp;1 and the terms of the Agreement, Holder shall exercise all rights and privileges of a stockholder of the Company while the Shares are held by you. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Closing of Purchase</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Upon any purchase by the Company of the Shares pursuant to the Agreement, the Company shall give to Holder and you a written notice
specifying the number of Shares to be purchased, the purchase price for the Shares, as determined pursuant to the Agreement, and the time for a closing hereunder (the &#147;Closing&#148;) at the principal office of the Company. Holder and the
Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At the Closing, you are directed (i)&nbsp;to date the stock assignment form or forms necessary for the transfer of the Shares, (ii)&nbsp;to
fill in on such form or forms the number of Shares being transferred, and (iii)&nbsp;to deliver same, together with the certificate or certificates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evidencing the Shares to be transferred, to the Company against the simultaneous delivery to you of the purchase price for the Shares being purchased pursuant to the Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Withdrawal</U>. The Holder shall have the right to withdraw from this escrow any Shares as to which the Purchase Option and Right of
First Refusal (each as defined in the Agreement) have terminated or expired. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Duties of Escrow Agent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in
relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as
Escrow Agent or as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> of Holder while acting in good faith and in the exercise of your own good judgment, and any act done or omitted by you pursuant to
the advice of your own attorneys shall be conclusive evidence of such good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) You are hereby expressly authorized to disregard any
and all warnings given by any of the parties hereto or by any other person or entity, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. If you
are uncertain of any actions to be taken or instructions to be followed, you may refuse to act in the absence of an order, judgment or decrees of a court. In case you obey or comply with any such order, judgment or decree of any court, you shall not
be liable to any of the parties hereto or to any other person or entity, by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been
entered without jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) You shall not be liable in any respect on account of the identity, authority or rights of the parties
executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) You shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with
your obligations hereunder and may rely upon the advice of such counsel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Your rights and responsibilities as Escrow Agent hereunder
shall terminate if (i)&nbsp;you cease to be Secretary of the Company or (ii)&nbsp;you resign by written notice to each party. In the event of a termination under clause (i), your successor as Secretary shall become Escrow Agent hereunder; in the
event of a termination under clause (ii), the Company shall appoint a successor Escrow Agent hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) If you reasonably require
other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) It is understood and agreed that if you believe a dispute has arisen with respect to the
delivery and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such dispute shall have been
settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty
whatsoever to institute or defend any such proceedings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) These Joint Escrow Instructions set forth your sole duties with respect to any
and all matters pertinent hereto and no implied duties or obligations shall be read into these Joint Escrow Instructions against you. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j)
The Company shall indemnify you and hold you harmless against any and all damages, losses, liabilities, costs, and expenses, including attorneys&#146; fees and disbursements, (including without limitation the fees of counsel retained pursuant to
Section&nbsp;4(e) above), for anything done or omitted to be done by you as Escrow Agent in connection with this Agreement or the performance of your duties hereunder, except such as shall result from your gross negligence or willful misconduct.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Notice</U>. Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal
delivery or upon deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties thereunto entitled at the following addresses, or at such other addresses as a party may
designate by ten days&#146; advance written notice to each of the other parties hereto. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">COMPANY:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices to the Company shall be sent to the address set forth in the salutation hereto, Attn: President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">HOLDER:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices to Holder shall be sent to the address set forth below Holder&#146;s signature below.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">ESCROW&nbsp;AGENT:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices to the Escrow Agent shall be sent to the address set forth in the salutation hereto.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) By signing these Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint Escrow Instructions, and you do
not become a party to the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) This instrument shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRECISION BIOSCIENCES, INC.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tide:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HOLDER:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">(Signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date&nbsp;Signed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ESCROW AGENT:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, I hereby sell, assign and transfer unto
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
shares of Common Stock, $[0.01] par value per share, of Precision BioSciences, Inc. (the &#147;Corporation&#148;) standing in my name on the books of the Corporation represented by Certificate(s) Number
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herewith, and do hereby irrevocably constitute and appoint
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; attorney to transfer the said stock on the books of the Corporation with full power of substitution in the premises. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IN PRESENCE OF</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTICE: The signature(s) to this assignment must correspond with the name as written upon the face of the
certificate, in every particular, without alteration, enlargement, or any change whatever and must be guaranteed by a commercial bank, trust company or member firm of the Boston, New York or Midwest Stock Exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 STOCK INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
<U>Purpose</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this 2015 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;) of Precision BioSciences, Inc., a Delaware
corporation (the &#147;<B>Company</B>&#148;), is to advance the interests of the Company&#146;s stockholders by enhancing the Company&#146;s ability to attract, retain and motivate persons who are expected to make important contributions to the
Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to align their interests with those of the Company&#146;s stockholders. Except where the context otherwise requires, the
term &#147;<B>Company</B>&#148; includes the Company&#146;s present or future parent or subsidiary corporations as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Internal Revenue Code of 1986, as amended, and any regulations promulgated
thereunder (the &#147;<B>Code</B>&#148;) and other business ventures (including, without limitation, any joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Company&#146;s Board of
Directors (the &#147;<B>Board</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Eligibility</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s employees, officers, directors, consultants, advisors, advisory board members, or other service providers (each a
&#147;<B>Service Provider</B>&#148;) are eligible to receive options, restricted stock, restricted stock units and other stock-based awards (each, an &#147;<B>Award</B>&#148;) under the Plan. Each person who receives an Award under the Plan is
deemed a &#147;<B>Participant</B>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Administration and Delegation</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration by Board of Directors</U>. The Plan shall be administered by the Board. The Board shall have authority to grant Awards
and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the
manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&#146;s sole discretion and shall be final and binding
on all persons having or claiming any interest in the Plan or in any Award. No director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good
faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Appointment of Committees</U>. To the extent permitted by applicable law, the Board may delegate any or all of its powers
under the Plan to one or more committees or subcommittees of the Board (a &#147;<B>Committee</B>&#148;). All references in the Plan to the &#147;<B>Board</B>&#148; shall mean the Board or a Committee of the Board to the extent that the Board&#146;s
powers or authority under the Plan have been delegated to such Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Stock Available for Awards</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to adjustment under Section&nbsp;8, Awards may be made under the Plan for up to Eleven Million Two Hundred Fifty Thousand
(11,250,000) shares of the Company&#146;s common stock, $0.000005 par value per share (the &#147;<B>Common Stock</B>&#148;). All shares reserved under the Plan may be granted as Incentive Stock Options or any other form of award permitted under the
Plan in the Board&#146;s </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discretion. If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common
Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered by such Award shall again be
available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan.
However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any applicable limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued
shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total number of shares of Common
Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan or agreement of the Company exceed the applicable percentage as calculated in accordance with the conditions
and exclusions of Section&nbsp;260.140.45 of the California Code of Regulations, as amended or any successor regulations (the &#147;<B>California Regulations</B>&#148;), based on the shares of the Company which are outstanding at the time the
calculation is made unless the Plan complies with all conditions of Rule 701 of the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Substitute
Awards</U>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based
awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not
count against the overall share limit set forth in Section&nbsp;4(a), except as may be required by reason of Section&nbsp;422 and related provisions of the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Stock Options</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The
Board may grant options to purchase Common Stock (each, an &#147;<B>Option</B>&#148;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to
the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An Option, or portion of an Option, which is not intended to be or fails to qualify as an Incentive
Stock Option (as hereinafter defined) for any reason whatsoever shall be designated a &#147;<B>Nonstatutory Stock Option.</B>&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Incentive Stock Options</U>. An Option that the Board intends to be an &#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code (an &#147;<B>Incentive Stock Option</B>&#148;) shall only be granted to employees of the Company
and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently with the requirements of Section&nbsp;422 of the Code. A Participant who owns
more than 10% of the total combined voting power of all classes of outstanding stock of the Company shall not be eligible for the grant of an Incentive Stock Option unless (i)&nbsp;the exercise price is at least 110% of the Fair Market Value (as
defined below) on the date the Option is granted and (ii)&nbsp;such Incentive Stock Option by its terms is not exercisable after the expiration of five years from the date the Option is granted. The Company shall have no liability to a Participant,
or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or for any action taken by the Board pursuant to Section&nbsp;9(f), including without limitation the conversion
of an Incentive Stock Option to a Nonstatutory Stock Option. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise Price</U>. The Board shall establish the exercise price of each Option and
specify such exercise price in the applicable option agreement. The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is granted; provided that if the Board approves the grant of an Option with an exercise
price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date. The term &#147;<B>Fair Market Value</B>&#148; shall mean, as of a given date: (i)&nbsp;if the Common Stock is
listed on a national securities exchange, the last sale price of the Common Stock in the principal trading market for the Common Stock on such date; (ii)&nbsp;if the Common Stock is not listed on a national securities exchange, but is traded in the <FONT
STYLE="white-space:nowrap">over-the</FONT> counter market, the closing bid price for the Common Stock on such date, as reported by the OTC Bulletin Board or the National Quotation Bureau, Incorporated or similar publisher of such quotations; or
(iii)&nbsp;if the Common Stock is not listed on a national securities exchange or traded in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, such price as shall be determined by (or in a
manner approved by) the Board in good faith and in compliance with applicable provisions of the Code and the regulations issued thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Duration of Options</U>. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may
specify in the applicable option agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise of Option</U>. Options may be exercised by delivery to the Company of a
written notice of exercise signed by the proper person or by any other form of notice (including electronic notice) approved by the Board together with payment in full as specified in Section&nbsp;5(f) for the number of shares of Common Stock for
which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company following exercise either as soon as practicable or, subject to such conditions as the Board shall specify, on a deferred basis (with the
Company&#146;s obligation to be evidenced by an instrument providing for future delivery of the deferred shares at the time or times specified by the Board). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Payment Upon Exercise.</U> Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) in cash or by check, payable to the order of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) when the Common Stock is registered under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;) and to the
extent expressly provided for in the applicable option agreement or approved by the Board, in its sole discretion, by (i)&nbsp;delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company
sufficient funds to pay the exercise price and any required tax withholding or (ii)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company
cash or a check sufficient to pay the exercise price and any required tax withholding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) when the Common Stock is registered under the
Exchange Act and to the extent expressly provided for in the applicable option agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant
valued at their Fair Market Value, provided (i)&nbsp;such method of payment is then permitted under applicable law, (ii)&nbsp;such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if
any, as may be established by the Board in its discretion and (iii)&nbsp;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(4) to the extent permitted by applicable law and provided for in the applicable option
agreement or approved by the Board, in its sole discretion, by (i)&nbsp;delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (ii)&nbsp;payment of such other lawful consideration as the Board may
determine; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(5) by any combination of the above permitted forms of payment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Restricted Stock; Restricted Stock Units</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Board may grant Awards entitling recipients to acquire shares of Common Stock (&#147;<B>Restricted Stock</B>&#148;),
subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions
specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. Instead of granting Awards for Restricted Stock, the Board may grant Awards
entitling the recipient to receive shares of Common Stock to be delivered at the time such shares of Common Stock vest (&#147;<B>Restricted Stock Units</B>&#148;)<B> </B>(Restricted Stock and Restricted Stock Units are each referred to herein as a
&#147;<B>Restricted Stock Award</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Terms and Conditions</U>. The Board shall determine the terms and conditions of a
Restricted Stock Award, including the conditions for repurchase (or forfeiture) and the issue price, if any. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Additional Provisions
Relating to Restricted Stock.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Dividends</U>. Participants holding shares of Restricted Stock will be entitled to all ordinary
cash dividends paid with respect to such shares, unless otherwise provided by the Board. If any such dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock other than an ordinary cash
dividend, the shares, cash or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each dividend payment will be made no later than the
end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the date the dividends are paid to stockholders of that class of stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Stock Certificates</U>. The Company may require that any stock certificates issued in respect of a Restricted Stock Award shall be
registered in the name of the Participant and be deposited by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). After the expiration of the applicable restriction periods, upon request of a
Participant or as otherwise determined by the Company, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to the beneficiary designated, in a manner
determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#146;s death (the &#147;<B>Designated Beneficiary</B>&#148;). In the absence of an effective designation by a
Participant, &#147;Designated Beneficiary&#148; shall mean the Participant&#146;s then living spouse, or, if none, the Participant&#146;s estate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.
<U>Other Stock-Based Awards</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference
to, or are otherwise based on, shares of Common Stock, may be granted hereunder to Participants (&#147;<B>Other Stock-Based Awards</B>&#148;), including without limitation stock appreciation rights and Awards entitling recipients to receive shares
of Common Stock to be delivered in the future. Such Other </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise
entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. Subject to the provisions of the Plan, the Board shall determine the conditions of each Other Stock-Based Award, including any purchase
price applicable thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Adjustments for Changes in Common Stock and Certain Other Events</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Changes in Capitalization</U>. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i)&nbsp;the
number and class of securities available under this Plan, (ii)&nbsp;the number and class of securities and exercise price per share of each outstanding Option, (iii)&nbsp;the number of shares subject to and the repurchase price per share subject to
each outstanding Restricted Stock Award, and (iv)&nbsp;the terms of each other outstanding Award shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting
the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the
distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution
date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1)
<U>Definition</U>. Unless otherwise specifically provided in an Award agreement, a &#147;<B>Change in Control</B>&#148; shall be deemed to have occurred upon the first to occur of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a transaction or series of related transactions in which a person, or a group of related persons, acquires from stockholders of the
Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the closing of the sale,
transfer, lease, exclusive license or other disposition, in one transaction or a series of related transactions, of all or substantially all of the Company&#146;s assets; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the consummation of the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which
the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold a majority of the voting power of the capital stock of the Company or the surviving or acquiring entity); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions in
which the Company is a constituent party, to a person or group of affiliated persons (other than an underwriter of the Company&#146;s securities), of the Company&#146;s securities if, after such closing, such person or group of affiliated persons
would hold a majority of the outstanding voting stock of the Company (or the surviving or acquiring entity). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Consequences of a Change in Control on Awards Other than Restricted Stock Awards</U>.
Unless otherwise specifically provided in an Award Agreement, the Board may take any one or more of the following actions as to all (or any portion of) outstanding Awards other than Restricted Stock Awards on such terms as the Board determines in
connection with a Change in Control: (i)&nbsp;provide that Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) in compliance with the applicable
provisions of the Code, including Code Sections 409A, 422 and 424; (ii)&nbsp;upon written notice to a Participant, provide that the Participant&#146;s unexercised Options or other unexercised Awards will terminate immediately prior to the
consummation of such Change in Control unless exercised by the Participant within a specified period following the date of such notice; (iii)&nbsp;provide that outstanding Awards shall become exercisable, realizable or deliverable, or restrictions
applicable to an Award shall lapse, in whole or in part prior to or upon such Change in Control; (iv)&nbsp;in the event of a Change in Control under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for
each share surrendered in the Change in Control (the &#147;<B>Acquisition Price</B>&#148;), make or provide for a cash payment to a Participant equal to the excess, if any, of (A)&nbsp;the Acquisition Price times the number of shares of Common Stock
subject to the Participant&#146;s Options or other Awards (to the extent the exercise price does not exceed the Acquisition Price) less (B)&nbsp;the aggregate exercise price of all such outstanding Options or other Awards and any applicable tax
withholdings, in exchange for the termination of such Options or other Awards; (v)&nbsp;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable,
net of the exercise price thereof); and (vi)&nbsp;any combination of the foregoing. In taking any of the actions permitted under this Section&nbsp;8(b), the Board shall not be obligated by the Plan to treat all Awards, or all Awards of the same
type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of clause (i)&nbsp;above, an Option shall be considered assumed if, following consummation of the Change
in Control, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the consummation of the Change in Control, the consideration (whether cash, securities or other property) received as a
result of the Change in Control by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Change in Control (and if holders were offered a choice of consideration, the type of consideration chosen by
the holders of a majority of the outstanding shares of Common Stock); <U>provided</U>, <U>however</U>, that if the consideration received as a result of the Change in Control is not solely common stock of the acquiring or succeeding corporation (or
an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of common stock of the acquiring or succeeding
corporation (or an affiliate thereof) equivalent in value (as determined by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) <U>Consequences of a Change in Control on Restricted Stock Awards</U>. Upon the occurrence of a Change in Control other than a liquidation
or dissolution of the Company, the repurchase and other rights of the Company under each outstanding Restricted Stock Award shall inure to the benefit of the Company&#146;s successor and shall, unless the Board determines otherwise, apply to the
cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Change in Control in the same manner and to the same extent as they applied to the Common Stock subject to such Restricted Stock Award.
Upon the occurrence of a Change in Control involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock Award or any other agreement between a
Participant and the Company, all restrictions and conditions on all Restricted Stock Awards then outstanding shall automatically be deemed terminated or satisfied. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>General Provisions Applicable to Awards</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability of Awards</U>. Except as the Board may otherwise expressly determine or provide in an Award, Awards shall not be sold,
assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option,
pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant. For the avoidance of doubt, the Board may not expressly provide for the transferability of an Incentive Stock
Option in an Incentive Stock Option Agreement or otherwise except as may be permitted under Section&nbsp;422 of the Code. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documentation</U>. Unless otherwise expressly determined by the Board, each Nonstatutory Stock Option shall be evidenced by a Notice of
Nonstatutory Stock Option and Nonstatutory Stock Option Agreement substantially in the form attached as <B><U>Exhibit A</U></B>, each Incentive Stock Option shall be evidenced by a Notice of Incentive Stock Option and Incentive Stock Option
Agreement substantially in the form attached as <B><U>Exhibit B</U></B>, and each Restricted Stock Award shall be evidenced by a Summary of Restricted Stock Purchase and Restricted Stock Purchase Agreement or similar agreement in substantially the
form approved by the Board for such purposes from time to time. Each Award may contain terms and conditions in addition to those set forth in the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Board Discretion</U>. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other
Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of
Status</U>. The Board shall determine the effect on an Award of the disability, death, termination of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period
during which, the Participant, or the Participant&#146;s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Withholding</U>. The Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding
obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may decide to satisfy the withholding obligations through additional withholding on salary or wages. If the
Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of
withholding obligations is due before the Company will issue any shares on exercise or release from forfeiture of an Award or, if the Company so requires, at the same time as is payment of the exercise price unless the Company determines otherwise.
If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery of shares of Common Stock, including shares retained from the Award creating the tax
obligation, valued at their Fair Market Value; <U>provided</U>, <U>however</U>, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#146;s
minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares surrendered to satisfy tax
withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendment of Award</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) The Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the
same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option, provided that the Participant&#146;s consent to such action shall be required unless the Board
determines that the action, taking into account any related action, would not materially and adversely affect the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) The
Board may, without stockholder approval, amend any outstanding Award granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Award provided that such amended
exercise price is at least equal to the then-current Fair Market Value. The Board may also, without stockholder approval, cancel any outstanding award (whether or not granted under the Plan) and grant in substitution new Awards under the Plan
covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Conditions on Delivery of Stock</U>. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to
remove restrictions from shares previously delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&nbsp;in the opinion of the Company&#146;s counsel, all other legal
matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed
and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules, regulations or contracts of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Acceleration</U>. The Board may at any time provide that any Award shall become immediately exercisable in full or in part, free of some
or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Miscellaneous</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Right To Employment or Other Status</U>. No person shall have any claim or right to be granted an Award, and the grant of an Award
shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant
free from any liability or claim under the Plan, except as expressly provided in the applicable Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Rights As
Stockholder</U>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming
the record holder of such shares. Notwithstanding the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend or otherwise and the exercise price of and the number of shares subject to such Option are
adjusted as of the effective date of the stock dividend or split (rather than as of the record date for such stock dividend or split), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend
or split shall be entitled to receive, on the distribution date, the stock dividend or split with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the
close of business on the record date for such stock dividend or split. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Effective Date and Term of Plan</U>. The Plan shall become effective on the date on
which it is adopted by the Board. No Awards shall be granted under the Plan after the expiration of ten (10)&nbsp;years from the earlier of (i)&nbsp;the date on which the Plan was adopted by the Board or (ii)&nbsp;the date the Plan was approved by
the Company&#146;s stockholders, but Awards previously granted may extend beyond that date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment of Plan</U>. The Board may
amend, suspend or terminate the Plan or any portion thereof at any time; <U>provided</U>, <U>however</U>, that if at any time the approval of the Company&#146;s stockholders is required as to any modification or amendment under Section&nbsp;422 of
the Code or any successor provision with respect to Incentive Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance
with this Section&nbsp;10(d) shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment does not materially and adversely affect the
rights of Participants under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Authorization of <FONT STYLE="white-space:nowrap">Sub-Plans</FONT></U>. The Board may from
time to time establish one or more <FONT STYLE="white-space:nowrap">sub-plans</FONT> under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board shall establish such <FONT
STYLE="white-space:nowrap">sub-plans</FONT> by adopting supplements to this Plan containing (i)&nbsp;such limitations on the Board&#146;s discretion under the Plan as the Board deems necessary or desirable or (ii)&nbsp;such additional terms and
conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected
jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. It is intended that all Awards granted hereunder be either exempt from, or
issued in compliance with, Code Section&nbsp;409A. The Company shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Code Section&nbsp;409A is not so exempt or compliant, or
for any action taken by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by
and construed in accordance with the laws of the State of North Carolina without reference to conflict of law provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * * *
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT OF 2015 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FIRST AMENDMENT of Precision BioSciences, Inc. 2015 Stock Incentive Plan is dated as of May 24, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of Precision BioSciences, Inc. (the &#147;<B>Company</B>&#148;) has adopted and the stockholders of the
Company have approved the Precision Biosciences, Inc. 2015 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of
Directors determines that it is in the best interests of the Company and the Company&#146;s stockholders to amend the Plan in order to increase the number of shares of common stock issuable pursuant to Awards (as defined in the Plan) made under the
Plan from eleven million two hundred fifty thousand (11,250,000) shares to Seventeen Million Five Hundred Thirty Thousand (17,530,000) shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the Plan shall be amended as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The first sentence of Section 4(a) of the Plan shall be deleted in its entirety and the following substituted in lieu thereof: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Subject to adjustment under Section 8, Awards may be made under the Plan for up to Seventeen Million Five Hundred Thirty Thousand
(17,530,000) shares of the Company&#146;s common stock, $0.000005 par value per share (the &#147;<B>Common Stock</B>&#148;).&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
Except as herein amended, the terms and provisions of the Plan shall remain in full force and effect as originally adopted and approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows.] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned hereby certifies that this First Amendment was duly
adopted by the Board of Directors of the Company as of May 24, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRECISION BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matt Kane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice of Nonstatutory Stock Option </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Nonstatutory Stock
Option Agreement </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF NONSTATUTORY STOCK OPTION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. 2015 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Precision BioSciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), grants to the undersigned (the
&#147;<B>Participant</B>&#148;) the following nonstatutory stock option to purchase shares (the &#147;<B>Shares</B>&#148;) of the common stock of the Company, $0.000005 par value per share (the &#147;<B>Common Stock</B>&#148;), pursuant to the
Precision BioSciences, Inc. 2015 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Participant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>*[</B>Participant Name<B>]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Total Number of Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>*[</B>Number of Shares<B>]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>*[</B>Grant Date<B>]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$*<B>[</B>Exercise Price (Must Be at Least FMV at Grant<B>]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vesting Commencement Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>*[</B>Vesting Commencement Date<B>]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vesting Schedule:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><I>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%]</I></B> of the Total Number of Shares shall vest and become exercisable on the <B><I>[first]</I></B> anniversary of the Vesting Commencement Date and an additional
<B><I>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</I></B>% of the Total Number of Shares shall vest and become exercisable at the end of each successive three-month period following the first anniversary of the Vesting Commencement Date until
the <B><I>[fourth]</I></B> anniversary of the Vesting Commencement Date, subject to the Participant remaining a Service Provider through each such vesting date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Final Exercise Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>*[</B>Expiration Date<B>]</B>. This option may expire earlier pursuant to Section&nbsp;3 of the Nonstatutory Stock Option Agreement if the Participant&#146;s relationship with the Company is terminated, or pursuant to
Section&nbsp;9 of the Plan.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This nonstatutory stock option is granted under and governed by the terms and conditions of the Plan and
accompanying Nonstatutory Stock Option Agreement, both of which are incorporated herein by reference. By signing below, the Participant accepts this nonstatutory stock option, acknowledges receipt of a copy of the Plan and the Nonstatutory Stock
Option Agreement, and agrees to the terms thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>*[PARTICIPANT NAME]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>PRECISION BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE OPTION GRANTED PURSUANT TO THIS AGREEMENT AND THE SHARES ISSUABLE UPON THE EXERCISE THEREOF HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR APPLICABLE LAWS OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NONSTATUTORY STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Granted Under the Precision BioSciences, Inc. 2015 Stock Incentive Plan </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Nonstatutory
Stock Option Agreement (the &#147;<B>Agreement</B>&#148;) evidences the grant by Precision BioSciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), on the Grant Date to<B> </B>the Participant, a<B>[</B>n<B>]</B>
*<B>[</B>employee/officer/director/consultant/advisor<B>]</B> of the Company, of an option (this &#147;<B>Option</B>&#148;) to purchase, in whole or in part, on the terms provided herein and in the Plan, the Total Number of Shares of Common Stock at
the Exercise Price per Share, all as defined and set forth in the accompanying Notice of Nonstatutory Stock Option (the &#147;<B>Notice</B>&#148;). Capitalized terms that are not otherwise defined herein or in the Notice shall have the meanings
given to such terms in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that this Option shall not be an incentive stock option as defined in Section&nbsp;422 of
the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#147;<B>Code</B>&#148;). Except as otherwise indicated by the context, the term &#147;Participant,&#148; as used in this Agreement, shall include any
person who acquires the right to exercise this Option validly under its terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Vesting Schedule</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Option shall vest and become exercisable at the time or times set forth in the accompanying Notice<B><I>. </I></B>[In addition, the Option
may vest and become exercisable on an accelerated basis as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective date of a Change in Control, one
hundred percent (100%) of the Total Number of Shares subject to this Option shall vest and become fully exercisable; provided, however, that in no event shall the Participant be entitled to exercise the Option to purchase greater than the Total
Number of Shares as a result of this provision. Such accelerated vesting shall be contingent upon consummation of the Change in Control.] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Exercise
of Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Form of Exercise</U>. Each election to exercise this Option shall be in writing in substantially the form of the
Notice of Stock Option Exercise attached to this Agreement as <B><U>Exhibit A</U></B>, signed by the Participant, and received by the Company at its principal office, accompanied by this Agreement, and payment in full in the manner provided in the
Plan. The Participant may purchase less than the number of Shares subject to this Option; <U>provided</U> <U>that,</U> no partial exercise of this Option may be for any fractional share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Continuous Relationship with the Company Required</U>. Except as otherwise provided in this Section&nbsp;3, this Option may not be
exercised unless the Participant, at the time of the exercise of this </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Option, is, and has been at all times since the Grant Date, a Service Provider to or of the Company or any subsidiary of the Company as defined in Section&nbsp;424 (f) of the Code (an
&#147;<B>Eligible Participant</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination of Relationship with the Company.</U> If the Participant ceases to be an
Eligible Participant for any reason, then, except as provided in paragraphs&nbsp;(d) and (e)&nbsp;below, the right to exercise this Option shall terminate three (3)&nbsp;months after such cessation (but in no event after the Final Exercise Date);
<U>provided</U> <U>that,</U> this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise
Date, violates the <FONT STYLE="white-space:nowrap">non-competition</FONT> or confidentiality provisions of any employment agreement, confidentiality and nondisclosure agreement, or other agreement between the Participant and the Company, the right
to exercise this Option shall terminate immediately upon such violation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Period Upon Death or Disability</U>. If the
Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of the Code) prior to the Final Exercise Date while the Participant is an Eligible Participant and the Company has not terminated such relationship for
&#147;Cause&#148; (as defined below), this Option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee);
<U>provided</U> <U>that,</U> this Option shall be exercisable only to the extent that this Option was exercisable by the Participant on the date of the Participant&#146;s death or disability, and further provided that this Option shall not be
exercisable after the Final Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination for Cause</U>. If, prior to the Final Exercise Date, the Participant&#146;s
status as a Service Provider is terminated by the Company for &#147;Cause&#148; (as such term is defined below), the right to exercise this Option shall terminate immediately upon the effective date of such termination. If the Participant is party
to an employment agreement or other agreement with the Company that contains an applicable definition of &#147;cause,&#148; then the term &#147;<B>Cause</B>&#148; for purposes of this Agreement shall have the meaning ascribed to such term in such
agreement. Otherwise, the term &#147;<B>Cause</B>&#148; for purposes of this Agreement shall mean the following: (i)&nbsp;Participant&#146;s willful failure to perform Participant&#146;s duties; (ii)&nbsp;Participant&#146;s gross negligence or
willful misconduct in the execution of Participant&#146;s duties; (iii)&nbsp;Participant&#146;s failure or refusal to comply with the Company&#146;s policies, procedures, practices, or directions; (iv)&nbsp;Participant&#146;s conviction of, or
guilty plea as to, a felony or any crime involving fraud, misappropriation, or misrepresentation; or (v)&nbsp;Participant&#146;s breach (and subsequent failure to cure upon applicable notice) of any employment, consulting, advisory, nondisclosure, <FONT
STYLE="white-space:nowrap">non-competition</FONT> or other similar agreement between the Participant and the Company, as determined by the Company, which determination shall be conclusive. The Participant shall be considered to have been discharged
for &#147;Cause&#148; if the Company determines, within 30 days after the Participant&#146;s resignation, that discharge for cause was warranted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.
<U>Bylaws; General Restrictions on Transfer.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant acknowledges and agrees that the Shares are subject to the provisions of
the Company&#146;s Bylaws, as amended from time to time (the &#147;<B>Bylaws</B>&#148;), including without limitation, any restrictions on transfer described in the Bylaws. The Participant may inspect the Bylaws at the Company&#146;s principal
office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Rights of First Refusal</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If Participant proposes to sell, pledge or otherwise transfer any Shares acquired upon exercise of this Option (the &#147;<B>Exercise
Shares</B>&#148;), the Company shall have the right to repurchase the Exercise Shares under the terms and subject to the conditions set forth in this Section&nbsp;5 (the &#147;<B>Right of First Refusal</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of Proposed Transfer</U>. Prior to any proposed transfer of the Exercise
Shares, the Participant shall give a written notice (the &#147;<B>Transfer Notice</B>&#148;) to the Company describing fully the proposed transfer, including the number of Exercise Shares, the name and address of the proposed transferee (the
&#147;<B>Proposed</B> <B>Transferee</B>&#148;), the proposed transfer price and all other material terms and conditions of the proposed transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)<U>Exercise of Right of First Refusal</U>. The Company shall have the right to purchase all, but not less than all, of the Exercise Shares
at the purchase price and on the terms set forth in the Transfer Notice by delivery to the Participant of a notice of exercise of the Right of First Refusal within thirty (30)&nbsp;days after the date the Transfer Notice is delivered to the Company.
The Company&#146;s exercise or failure to exercise the Right of First Refusal with respect to any proposed transfer described in a Transfer Notice shall not affect the Company&#146;s ability to exercise the Right of First Refusal with respect to any
proposed transfer described in any other Transfer Notice, whether or not such other Transfer Notice is issued by the Participant or issued by any other person with respect to a proposed transfer to the same Proposed Transferee. If the Company
exercises the Right of First Refusal, the Company and the Participant shall thereupon consummate the sale of the Exercise Shares to the Company on the terms set forth in the Transfer Notice; provided however, that if the Transfer Notice provides for
the payment for the Exercise Shares other than in cash, the Company shall have the option of paying for the Exercise Shares by the discounted cash equivalent of the consideration described in the Transfer Notice as reasonably determined by the
Board. For purposes of the foregoing, cancellation of any indebtedness of the Participant to the Company shall be treated as payment to the Participant in cash to the extent of the unpaid principal and any accrued interest cancelled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Failure to Exercise Right of First Refusal</U>. If the Company fails to exercise such Right of First Refusal, the Participant may
conclude a transfer to the Proposed Transferee of the Exercise Shares on the terms and conditions described in the Transfer Notice, provided such transfer occurs not later than three (3)&nbsp;months following expiration of the forty-five
(45)&nbsp;day Right of First Refusal period provided in Section&nbsp;5(c). Any proposed transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed transfer by the Participant, also
shall be subject to the Right of First Refusal and shall require compliance by the Participant with the procedure described in this Section&nbsp;5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Transferees of the Transfer Shares</U>. All transferees of the Exercise Shares or any interest therein, other than the Company acquiring
such Exercise Shares through its Right of First Refusal, shall be required as a condition of such transfer to agree in writing (in a form satisfactory to the Company) that such transferee shall receive and hold such Exercise Shares or interests
subject to (i)&nbsp;the provisions of this Section&nbsp;5 providing for the Right of First Refusal with respect to any subsequent transfer, (ii)&nbsp;the Right of Repurchase established under Section&nbsp;6, and (iii)&nbsp;all other applicable
restrictions set forth in the Plan and this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Transfers Not Subject to the Right of First Refusal</U>. The Right of First
Refusal shall not apply to any transfer or exchange of the Exercise Shares if: (i)&nbsp;such transfer is in connection with a Change in Control; (ii)&nbsp;such transfer is to one or more members of the Participant&#146;s immediate family (or a trust
for their benefit) provided all such transferees agree in writing to the restrictions of Section&nbsp;5(f); or (iii)&nbsp;such transfer has been expressly approved by the Board, which approval may be granted or withheld in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Assignment of the Right of First Refusal</U>. The Company shall have the right to assign the Right of First Refusal at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Stock Dividends Subject to First Refusal Right</U>. If, from time to time, there is
any stock dividend, stock split, recapitalization, reclassification or other change in the character or amount of any of the outstanding stock of the Company, the stock of which is subject to the provisions of an Option issued pursuant to the Plan,
then, in such event, any and all new substituted or additional securities to which the Participant is entitled by reason of the Participant&#146;s ownership of the Exercise Shares shall be immediately subject to the Right of First Refusal with the
same force and effect as the Shares subject to the Right of First Refusal immediately before such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Early Termination of the
Right of First Refusal</U>. The other provisions of this Section&nbsp;5 notwithstanding, the Right of First Refusal shall terminate, and be of no further force and effect, upon the earlier of (i)&nbsp;the occurrence of a Change in Control, unless
the surviving, continuing, successor, or purchasing corporation, as the case may be, assumes the Company&#146;s rights and obligations under the Plan, or (ii)&nbsp;the existence of a public market for the Shares. A &#147;public market&#148; shall be
deemed to exist if (i)&nbsp;Shares are listed on a national securities exchange (as that term is used in the Exchange Act) or (ii)&nbsp;Shares are traded on the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and prices therefor are published daily on business days in a recognized financial journal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Escrow</U>. To ensure the Shares subject to Right of First Refusal will be available for purchase, the Company may require a Participant
to deposit certificates evidencing the Exercise Shares in escrow with the Company or an agent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Right of Repurchase on Termination of
Employment With or Cessation of Service to the Company</U>. The Company shall have the right (but not the obligation) to repurchase any or all of the Exercise Shares upon the Participant&#146;s termination of employment or service as a Service
Provider of the Company for any reason. The price per Exercise Share to be paid by the Company should it choose to exercise its repurchase right under this Section&nbsp;6 shall equal the then Fair Market Value per Exercise Share. The Company&#146;s
right of repurchase pursuant to this Section&nbsp;6 shall commence on the date the Participant terminates service with the Company and continue until the first anniversary of such Participant&#146;s termination of service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Legend</U>. Any certificate representing Shares shall bear legends substantially in the following forms (in addition to, or in combination with, any
legend required by applicable federal and state securities laws and other agreements relating to the Company&#146;s securities): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;The securities represented by this certificate, and the transfer thereof, are subject to the restriction on transfer provisions of the
Bylaws of the Company and the Nonstatutory Stock Option Agreement, copies of which are on file in, and may be examined at, the principal office of the Company.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Agreement in Connection with Public Offering</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant agrees, in connection with the initial underwritten public offering of the Company&#146;s securities pursuant to a registration
statement under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;): (i) not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common Stock held by the
Participant (other than those shares included in the offering) without the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the Company&#146;s securities for a period of 180 days from the
effective date of such registration statement, which period may be extended upon the request of the underwriters for an additional period of up to fifteen (15)&nbsp;days if the Company issues or proposes to issue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an earnings or other public release within fifteen (15)&nbsp;days of the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> lockup period, and (ii)&nbsp;to execute any agreement
reflecting clause (i)&nbsp;above as may be requested by the Company or the managing underwriters at the time of such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Participant agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters of such offering which are consistent with the foregoing or which are necessary to give further effect thereto. In
addition, if requested, by the Company or the underwriters of such offering, the Participant shall provide, within 10 days of such request, such information as may be required by the Company or such underwriters in connection with the completion of
any public offering of the Company&#146;s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section&nbsp;8 shall not apply to a registration relating solely to employee benefits plans
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or Form <FONT STYLE="white-space:nowrap">S-8</FONT> or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction
until the end of the applicable period. Participant agrees that any transferee of this Option or Shares pursuant to this Agreement shall be bound by this Section&nbsp;8. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Tax Matters</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Withholding</U>.
No Shares shall be issued pursuant to the exercise of this Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding or other taxes required by
law to be withheld in respect of this Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Code Section</U><U></U><U>&nbsp;409A</U>. The Exercise Price is intended to be not
less than the Fair Market Value of the Common Stock on the Grant Date. The Company has determined the Fair Market Value of the Common Stock in good faith and using the reasonable application of a reasonable valuation method, for purposes of
determining the Exercise Price. Notwithstanding this, the Internal Revenue Service may assert that the Fair Market Value of the Common Stock on the Grant Date was greater than the Exercise Price. Under Code Section&nbsp;409A, if the Exercise Price
is less than the Fair Market Value of the Common Stock as of the Grant Date, this Option may be treated as a form of deferred compensation and the Participant may be subject to an additional twenty percent (20%) tax, plus interest and possible
penalties. The Participant acknowledges that the Company has advised the Participant to consult with a tax adviser regarding the potential impact of Code Section&nbsp;409A and that the Company, in the exercise of its sole discretion and without the
consent of the Participant, may amend or modify this Agreement in any manner and delay the payment of any amounts payable pursuant to this Agreement to the minimum extent necessary to meet the requirements of Code Section&nbsp;409A, as amplified by
any Internal Revenue Service or U.S. Treasury Department regulations or guidance as the Company deems appropriate or advisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Nontransferability
of Option</U>. This Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the
Participant, this Option shall be exercisable only by the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Provisions of the Plan</U>. This Option is subject to the provisions of the
Plan, a copy of which is furnished to the Participant with this Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>Entire Agreement; Governing Law</U>. The Plan and the Notice are
incorporated herein by reference. This Agreement, the Notice and the Plan constitute the entire agreement between the Company and the Participant with respect to the subject matter hereof and supersede in their entirety all prior undertakings and
agreements of the Company and the Participant with respect to the subject matter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hereof. This Agreement shall be governed by and construed in accordance with the laws of the State of North
Carolina without reference to conflict of law provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Amendment</U>. Except as set forth in Section&nbsp;9(b), this Agreement may not be
modified or amended in any manner adverse to the Participant&#146;s interest except by means of a writing signed by the Company and Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.
<U>No Guarantee of Continued Service</U>. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF OPTIONS PURSUANT TO THE VESTING SCHEDULE SET FORTH HEREIN AND IN THE NOTICE ARE EARNED ONLY BY CONTINUING SERVICE AT THE WILL OF THE COMPANY (NOT
THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). THE PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT
CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED SERVICE FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#146;S RIGHT OR THE COMPANY&#146;S RIGHT TO TERMINATE PARTICIPANT&#146;S SERVICE
WITH OR WITHOUT CAUSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * * * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF NONSTATUTORY STOCK OPTION EXERCISE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. 2015 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned (the &#147;<B>Participant</B>&#148;) has previously been awarded a nonstatutory stock option (the &#147;<B>Option</B>&#148;)
to purchase shares (the &#147;<B>Shares</B>&#148;) of the common stock of Precision BioSciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), pursuant to the Precision BioSciences, Inc. 2015 Stock Incentive Plan (the
&#147;<B>Plan</B>&#148;), and hereby notifies the Company of the Participant&#146;s desire to exercise the Option on the terms set forth herein: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PARTICIPANT INFORMATION:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>OPTION INFORMATION:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Grant&nbsp;Date:<U>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exercise Price Per Share: $<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxpayer ID #:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Total Shares Covered by
Option:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXERCISE INFORMATION:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares Being Purchased:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Exercise Price:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Form of Payment (check all that apply):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Check for $_________ made payable to the Company</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#9744; Cash in the amount of $_________</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Please register the Shares in my name as follows:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Print name as it is to appear on stock certificate)</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REPRESENTATIONS AND WARRANTIES OF THE PARTICIPANT: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant hereby represents and warrants to the Company that, as of the date hereof: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in
connection with, any distribution of the Shares in violation of the Securities Act of 1933 (the &#147;<B>Securities Act</B>&#148;), or any rule or regulation under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such
information as is necessary to permit me to evaluate the merits and risks of my investment in the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have sufficient experience in business, financial and investment matters to be able to evaluate the risks
involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such
Shares for an indefinite period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I acknowledge that I am acquiring the Shares subject to all other terms of the Plan, including the Notice of
Nonstatutory Stock Option and related Nonstatutory Stock Option Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I acknowledge that the Company has encouraged me to consult my own adviser to determine the tax consequences of
acquiring the Shares at this time. I acknowledge that the Company has encouraged me to consult my own adviser to determine the form of ownership that is appropriate for me. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I acknowledge that the Shares remain subject to the Company&#146;s right of first refusal, right of repurchase,
voting agreement and proxy, and the market <FONT STYLE="white-space:nowrap">stand-off</FONT> (sometimes referred to as the <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;),</FONT> all in accordance with the applicable Notice of Nonstatutory
Stock Option and related Nonstatutory Stock Option Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I understand that (i)&nbsp;the Shares have not been registered under the Securities Act and are
&#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act, (ii)&nbsp;the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption
from registration is then available; (iii)&nbsp;in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock,
adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with
respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Print Participant
Name)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice of Incentive Stock Option </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Incentive Stock
Option Agreement </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE OPTION GRANTED PURSUANT TO THIS AGREEMENT AND THE SHARES ISSUABLE UPON THE EXERCISE THEREOF HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR APPLICABLE LAWS OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCENTIVE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Granted Under the Precision BioSciences, Inc. 2015 Stock Incentive Plan </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Incentive Stock
Option Agreement (the &#147;<B>Agreement</B>&#148;) evidences the grant by Precision BioSciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), on the Grant Date to the Participant, an employee of the Company, of an option (this
&#147;<B>Option</B>&#148;) to purchase, in whole or in part, on the terms provided herein and in the Plan, the Total Number of Shares of Common Stock at the Exercise Price per Share, all as defined and set forth in the accompanying Notice of
Incentive Stock Option (the &#147;<B>Notice</B>&#148;). Capitalized terms that are not otherwise defined herein or in the Notice shall have the meanings given to such terms in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that this Option shall be an incentive stock option as defined in Section&nbsp;422 of the Internal Revenue Code of 1986, as
amended, and any regulations promulgated thereunder (the &#147;<B>Code</B>&#148;). If for any reason the Option, or any portion thereof, does not meet the requirements of Section&nbsp;422 of the Code, then the Option, or any portion thereof, as
necessary, shall be deemed a nonstatutory stock option granted under the Plan. Except as otherwise indicated by the context, the term &#147;Participant,&#148; as used in this Agreement, shall include any person who acquires the right to exercise
this Option validly under its terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Vesting Schedule</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Option shall vest and become exercisable at the time or times set forth in the accompanying Notice. [In addition, the Option may vest and
become exercisable on an accelerated basis as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective date of a Change in Control, one hundred
percent (100%) of the Total Number of Shares subject to this Option shall vest and become fully exercisable; provided, however, that in no event shall the Participant be entitled to exercise the Option to purchase greater than the Total Number of
Shares as a result of this provision. Such accelerated vesting shall be contingent upon consummation of the Change in Control.] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of
Option</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Form of Exercise</U>. Each election to exercise this Option shall be in writing in substantially the form of the Notice
of Stock Option Exercise attached to this Agreement as <B><U>Exhibit A</U></B>, signed by the Participant, and received by the Company at its principal office, accompanied by this Agreement, and payment in full in the manner provided in the Plan.
The Participant may purchase less than the number of Shares subject to this Option; <U>provided</U> <U>that</U>, no partial exercise of this Option may be for any fractional share. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Continuous Relationship with the Company Required</U>. Except as otherwise provided
in this Section&nbsp;3, this Option may not be exercised unless the Participant, at the time of the exercise of this Option, is, and has been at all times since the Grant Date, a Service Provider to or of the Company or any subsidiary of the Company
as defined in Section&nbsp;424 (f) of the Code (an &#147;<B>Eligible Participant</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination of Relationship with the
Company</U>. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs&nbsp;(d) and (e)&nbsp;below, the right to exercise this Option shall terminate<B> </B>three (3)&nbsp;months after such
cessation (but in no event after the Final Exercise Date); <U>provided</U> <U>that,</U> this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the date of such cessation. Notwithstanding the
foregoing, if the Participant, prior to the Final Exercise Date, violates the <FONT STYLE="white-space:nowrap">non-competition</FONT> or confidentiality provisions of any employment agreement, confidentiality and nondisclosure agreement, or other
agreement between the Participant and the Company, the right to exercise this Option shall terminate immediately upon such violation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Exercise Period Upon Death or Disability</U>. If the Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of the Code) prior to the Final Exercise Date while the Participant is an Eligible Participant and the Company
has not terminated such relationship for &#147;Cause&#148; (as defined below), this Option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death
by an authorized transferee); <U>provided</U> <U>that,</U> this Option shall be exercisable only to the extent that this Option was exercisable by the Participant on the date of the Participant&#146;s death or disability, and further provided that
this Option shall not be exercisable after the Final Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination for Cause</U>. If, prior to the Final Exercise
Date, the Participant&#146;s status as a Service Provider is terminated by the Company for &#147;Cause&#148; (as such term is defined below), the right to exercise this Option shall terminate immediately upon the effective date of such termination.
If the Participant is party to an employment agreement or other agreement with the Company that contains an applicable definition of &#147;cause,&#148; then the term &#147;<B>Cause</B>&#148; for purposes of this Agreement shall have the meaning
ascribed to such term in such agreement. Otherwise, the term &#147;<B>Cause</B>&#148; for purposes of this Agreement shall mean the following: (i)&nbsp;Participant&#146;s willful failure to perform Participant&#146;s duties;
(ii)&nbsp;Participant&#146;s gross negligence or willful misconduct in the execution of Participant&#146;s duties; (iii)&nbsp;Participant&#146;s failure or refusal to comply with the Company&#146;s policies, procedures, practices or directions;
(iv)&nbsp;Participant&#146;s conviction of, or guilty plea as to, a felony or any crime involving, fraud, misappropriation, or misrepresentation; or (v)&nbsp;Participant&#146;s breach (and subsequent failure to cure upon applicable notice) of any
employment, consulting, advisory, nondisclosure, <FONT STYLE="white-space:nowrap">non-competition</FONT> or other similar agreement between the Participant and the Company, as determined by the Company, which determination shall be conclusive. The
Participant shall be considered to have been discharged for &#147;Cause&#148; if the Company determines, within 30 days after the Participant&#146;s resignation, that discharge for cause was warranted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Bylaws; General Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant acknowledges and agrees that the Shares are subject to the provisions of the Company&#146;s Bylaws, as amended from time to
time (the &#147;<B>Bylaws</B>&#148;), including without limitation, any restrictions on transfer described in the Bylaws. The Participant may inspect the Bylaws at the Company&#146;s principal office. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Rights of First Refusal</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If Participant proposes to sell, pledge or otherwise transfer any Shares acquired upon exercise of this Option (the &#147;<B>Exercise
Shares</B>&#148;), the Company shall have the right to repurchase the Exercise Shares under the terms and subject to the conditions set forth in this Section&nbsp;5 (the &#147;<B>Right of First Refusal</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of Proposed Transfer</U>. Prior to any proposed transfer of the Exercise Shares, the Participant shall give a written notice (the
&#147;<B>Transfer Notice</B>&#148;) to the Company describing fully the proposed transfer, including the number of Exercise Shares, the name and address of the proposed transferee (the &#147;<B>Proposed</B> <B>Transferee</B>&#148;), the proposed
transfer price and all other material terms and conditions of the proposed transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)<U>Exercise of Right of First Refusal</U>. The
Company shall have the right to purchase all, but not less than all, of the Exercise Shares at the purchase price and on the terms set forth in the Transfer Notice by delivery to the Participant of a notice of exercise of the Right of First Refusal
within thirty (30)&nbsp;days after the date the Transfer Notice is delivered to the Company. The Company&#146;s exercise or failure to exercise the Right of First Refusal with respect to any proposed transfer described in a Transfer Notice shall not
affect the Company&#146;s ability to exercise the Right of First Refusal with respect to any proposed transfer described in any other Transfer Notice, whether or not such other Transfer Notice is issued by the Participant or issued by any other
person with respect to a proposed transfer to the same Proposed Transferee. If the Company exercises the Right of First Refusal, the Company and the Participant shall thereupon consummate the sale of the Exercise Shares to the Company on the terms
set forth in the Transfer Notice; provided however, that if the Transfer Notice provides for the payment for the Exercise Shares other than in cash, the Company shall have the option of paying for the Exercise Shares by the discounted cash
equivalent of the consideration described in the Transfer Notice as reasonably determined by the Board. For purposes of the foregoing, cancellation of any indebtedness of the Participant to the Company shall be treated as payment to the Participant
in cash to the extent of the unpaid principal and any accrued interest cancelled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Failure to Exercise Right of First Refusal</U>.
If the Company fails to exercise such Right of First Refusal, the Participant may conclude a transfer to the Proposed Transferee of the Exercise Shares on the terms and conditions described in the Transfer Notice, provided such transfer occurs not
later than three (3)&nbsp;months following expiration of the forty-five (45)&nbsp;day Right of First Refusal period provided in Section&nbsp;5(c). Any proposed transfer on terms and conditions different from those described in the Transfer Notice,
as well as any subsequent proposed transfer by the Participant, also shall be subject to the Right of First Refusal and shall require compliance by the Participant with the procedure described in this Section&nbsp;5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Transferees of the Transfer Shares</U>. All transferees of the Exercise Shares or any interest therein, other than the Company acquiring
such Exercise Shares through its Right of First Refusal, shall be required as a condition of such transfer to agree in writing (in a form satisfactory to the Company) that such transferee shall receive and hold such Exercise Shares or interests
subject to (i)&nbsp;the provisions of this Section&nbsp;5 providing for the Right of First Refusal with respect to any subsequent transfer, (ii)&nbsp;the Right of Repurchase established under Section&nbsp;6, and (iii)&nbsp;all other applicable
restrictions set forth in the Plan and this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Transfers Not Subject to the Right of First Refusal</U>. The Right of First
Refusal shall not apply to any transfer or exchange of the Exercise Shares if: (i)&nbsp;such transfer is in connection with a Change in Control; (ii)&nbsp;such transfer is to one or more members of the Participant&#146;s immediate family (or a trust
for their benefit) provided all such transferees agree in writing to the restrictions of Section&nbsp;5(e); or </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii) such transfer has been expressly approved by the Board, which approval may be granted or withheld in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Assignment of the Right of First Refusal</U>. The Company shall have the right to assign the Right of First Refusal at any time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Stock Dividends Subject to First Refusal Right</U>. If, from time to time, there is any stock dividend, stock split, recapitalization,
reclassification or other change in the character or amount of any of the outstanding stock of the Company, the stock of which is subject to the provisions of an Option issued pursuant to the Plan, then, in such event, any and all new substituted or
additional securities to which the Participant is entitled by reason of the Participant&#146;s ownership of the Exercise Shares shall be immediately subject to the Right of First Refusal with the same force and effect as the Shares subject to the
Right of First Refusal immediately before such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Early Termination of the Right of First Refusal</U>. The other provisions of
this Section&nbsp;5 notwithstanding, the Right of First Refusal shall terminate, and be of no further force and effect, upon the earlier of (i)&nbsp;the occurrence of a Change in Control, unless the surviving, continuing, successor, or purchasing
corporation, as the case may be, assumes the Company&#146;s rights and obligations under the Plan, or (ii)&nbsp;the existence of a public market for the Shares. A &#147;public market&#148; shall be deemed to exist if (i)&nbsp;Shares are listed on a
national securities exchange (as that term is used in the Exchange Act) or (ii)&nbsp;Shares are traded on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and prices therefor are published
daily on business days in a recognized financial journal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Escrow</U>. To ensure the Shares subject to Right of First Refusal will
be available for purchase, the Company may require a Participant to deposit certificates evidencing the Exercise Shares in escrow with the Company or an agent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Right of Repurchase on Termination of Employment With or Cessation of Service to Company</U>. The Company shall have the right (but not the obligation)
to repurchase any or all of the Exercise Shares upon the Participant&#146;s termination of employment or service as a Service Provider of the Company for any reason. The price per Exercise Share to be paid by the Company should it choose to exercise
its repurchase right under this Section&nbsp;6 shall equal the then Fair Market Value per Exercise Share. The Company&#146;s right of repurchase pursuant to this Section&nbsp;6 shall commence on the date the Participant terminates service with the
Company and continue until the first anniversary of such Participant&#146;s termination of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Legend</U>. Any certificate representing Shares
shall bear legends substantially in the following forms (in addition to, or in combination with, any legend required by applicable federal and state securities laws and other agreements relating to the Company&#146;s securities): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;The securities represented by this certificate, and the transfer thereof, are subject to the restriction on transfer provisions of the
Bylaws of the Company and the Incentive Stock Option Agreement, copies of which are on file in, and may be examined at, the principal office of the Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Agreement in Connection with Public Offering</U>. The Participant agrees, in connection with the initial underwritten public offering of the
Company&#146;s securities pursuant to a registration statement under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;): (i) not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise
dispose of any shares of Common Stock held by the </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant (other than those shares included in the offering) without the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the
Company&#146;s securities for a period of 180 days from the effective date of such registration statement, which period may be extended upon the request of the underwriters for an additional period of up to fifteen (15)&nbsp;days if the Company
issues or proposes to issue an earnings or other public release within fifteen (15)&nbsp;days of the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> lockup period, and (ii)&nbsp;to execute any agreement reflecting clause
(i)&nbsp;above as may be requested by the Company or the managing underwriters at the time of such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant agrees to
execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters of such offering which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested, by
the Company or the underwriters of such offering, the Participant shall provide, within 10 days of such request, such information as may be required by the Company or such underwriters in connection with the completion of any public offering of the
Company&#146;s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section&nbsp;8 shall not apply to a registration relating solely to employee benefits plans on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> or Form <FONT STYLE="white-space:nowrap">S-8</FONT> or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction
until the end of the applicable period. Participant agrees that any transferee of this Option or Shares pursuant to this Agreement shall be bound by this Section&nbsp;8. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Tax Matters</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Withholding</U>.
No Shares shall be issued pursuant to the exercise of this Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding or other taxes required by
law to be withheld in respect of this Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Disqualifying Disposition</U>. If the Participant disposes of Shares acquired upon
exercise of this Option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this Option, the Participant shall immediately notify the Company in writing of such disposition and shall timely
satisfy all resulting tax obligations and shall hold the Company harmless with respect to any such tax obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Code
Section</U><U></U><U>&nbsp;409A</U>. The Exercise Price is intended to be not less than the Fair Market Value of the Common Stock on the Grant Date. The Company has determined the Fair Market Value of the Common Stock in good faith and using the
reasonable application of a reasonable valuation method, for purposes of determining the Exercise Price. Notwithstanding this, the Internal Revenue Service may assert that the Fair Market Value of the Common Stock on the Grant Date was greater than
the Exercise Price. Under Code Section&nbsp;409A, if the Exercise Price is less than the Fair Market Value of the Common Stock as of the Grant Date, this Option may be treated as a form of deferred compensation and the Participant may be subject to
an additional twenty percent (20%) tax, plus interest and possible penalties. The Participant acknowledges that the Company has advised the Participant to consult with a tax adviser regarding the potential impact of Code Section&nbsp;409A and that
the Company, in the exercise of its sole discretion and without the consent of the Participant, may amend or modify this Agreement in any manner and delay the payment of any amounts payable pursuant to this Agreement to the minimum extent necessary
to meet the requirements of Code Section&nbsp;409A, as amplified by any Internal Revenue Service or U.S. Treasury Department regulations or guidance as the Company deems appropriate or advisable. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Nontransferability of Option</U>. This Option may not be sold, assigned, transferred, pledged or
otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable only by the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Provisions of the Plan</U>. This Option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Option.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>Entire Agreement; Governing Law</U>. The Plan and the Notice are incorporated herein by reference. This Agreement, the Notice and the Plan
constitute the entire agreement between the Company and the Participant with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject
matter hereof. This Agreement shall be governed by and construed in accordance with the laws of the State of North Carolina without reference to conflict of law provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Amendment</U>. Except as set forth in Section&nbsp;8(c), this Agreement may not be modified or amended in any manner adverse to the Participant&#146;s
interest except by means of a writing signed by the Company and Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>No Guarantee of Continued Service</U>. THE PARTICIPANT ACKNOWLEDGES
AND AGREES THAT THE VESTING OF OPTIONS PURSUANT TO THE VESTING SCHEDULE SET FORTH HEREIN AND IN THE NOTICE ARE EARNED ONLY BY CONTINUING SERVICE AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING
SHARES HEREUNDER). THE PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED SERVICE FOR THE
VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#146;S RIGHT OR THE COMPANY&#146;S RIGHT TO TERMINATE PARTICIPANT&#146;S SERVICE WITH OR WITHOUT CAUSE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp; *&nbsp;&nbsp; *&nbsp;&nbsp; *&nbsp;&nbsp; * </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF INCENTIVE STOCK OPTION EXERCISE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECISION BIOSCIENCES, INC. 2015 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned (the &#147;<B>Participant</B>&#148;) has previously been awarded an incentive stock option (the &#147;<B>Option</B>&#148;) to
purchase shares (the &#147;<B>Shares</B>&#148;) of the common stock of Precision BioSciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), pursuant to the Precision BioSciences, Inc. 2015 Stock Incentive Plan (the
&#147;<B>Plan</B>&#148;), and hereby notifies the Company of the Participant&#146;s desire to exercise the Option on the terms set forth herein: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PARTICIPANT INFORMATION:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>OPTION INFORMATION:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Grant&nbsp;Date:<U>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exercise Price Per Share: $<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxpayer ID #:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Total Shares Covered by
Option:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXERCISE INFORMATION:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares Being Purchased:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Exercise Price:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Form of Payment (check all that apply):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Check for $_________ made payable to the Company</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#9744; Cash in the amount of $_________</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Please register the Shares in my name as follows:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Print name as it is to appear on stock certificate)</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REPRESENTATIONS AND WARRANTIES OF THE PARTICIPANT: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant hereby represents and warrants to the Company that, as of the date hereof: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in
connection with, any distribution of the Shares in violation of the Securities Act of 1933 (the &#147;<B>Securities Act</B>&#148;), or any rule or regulation under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such
information as is necessary to permit me to evaluate the merits and risks of my investment in the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have sufficient experience in business, financial and investment matters to be able to evaluate the risks
involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such
Shares for an indefinite period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I acknowledge that I am acquiring the Shares subject to all other terms of the Plan, including the Notice of
Incentive Stock Option and related Incentive Stock Option Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I acknowledge that the Company has encouraged me to consult my own adviser to determine the tax consequences of
acquiring the Shares at this time. I acknowledge that the Company has encouraged me to consult my own adviser to determine the form of ownership that is appropriate for me. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I acknowledge that the Shares remain subject to the Company&#146;s right of first refusal, right of repurchase,
voting agreement and proxy, and the market <FONT STYLE="white-space:nowrap">stand-off</FONT> (sometimes referred to as the <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;),</FONT> all in accordance with the applicable Notice of Incentive Stock
Option and related Incentive Stock Option Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I understand that (i)&nbsp;the Shares have not been registered under the Securities Act and are
&#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act, (ii)&nbsp;the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption
from registration is then available; (iii)&nbsp;in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock,
adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with
respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Print Participant Name)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSIDIARIES OF PRECISION BIOSCIENCES, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company&nbsp;Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Jurisdiction</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ELO Life Systems, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ELO Life Systems Australia Pty. Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g367280g02p15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g02p15.jpg
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M"Y6J.B+(2S,1[2\%R<' U^9=AAV"46H^K.)0I<]VUX;7LQC_ )=S&0J[9V\
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MJK4C>S+$2.X$_EBOU#NOF\@@CG41WUG9-N;6RN3KGIMI"M>FW /1:MR)7BE
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M#.DFU1[,M&QP,RM-7D["V\T(-RTMO['\/Z^8K+;V_G*5_&YF!DZRL#LC16D
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M-/5C.6QU*USCK5Q JK+.8U$CLJJ RQ3A&'3%+)96/S)<:>\1WI6M?Q]J[>W
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M-U*X*  %N;O#K>U;9^%MXW(X7<-B>?+6+R/1Q\<D0BEJ4:ZJS3V:[^8'K.2
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M"@]G[V?);PT\#L&"FHP%^4@)H3#;$B=:JK$0D1 DY&U[%R5A-/O 1F$V)L_
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M=:7N0W/Q6Y!=LNL[7IE7OERH$Y#7+D$X*X[)4RP2U:^]B,-Z'?DJC9!G0WB
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MV+1U#@,:DL-/8"0AG5MBGYLF3 N?K'QG+T/L!>8RKR1A2&D1,O7:M&^^1^H
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M,RA*WGW'22'?602\\0ZXZORMV[-^U8NW)GL6K4TD]B:0\O++*Q=W8^G=B>P
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MX*^6S0=SZ\?;JI[#TY^S5!-X7NG\@QZ)':HUQLQOD3#WFCR-:L4UJBZ4>5U
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L1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g367280g03d00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g03d00.jpg
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M&?T;8F_I6/\ _.E*8DUH<_K\B]=^/JQW_7G]&/\ 7W?ZNAD.@'0#H!T Z =
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M@QRKV=N7E/:J[8I=^E;[QRU(GQ/Q)HV\"&V>T9"6!W[;O^VZ.W)7')K!2R1
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M,4?.@<69I%*^\>NXJ0H@HV;[(RM],*/1XO*HJA"TI@*O)\NI/>IN]W&?&O\
MGN@J\GRZCU-WNXSXU_SW05>3Y=1ZF[W<9\:_Y[H*O)\NH]3=[N,^-?\ /=!5
MY/EU'J;O=QGQK_GN@J\GRZCU-WNXSXU_SW05>3Y=1ZF[W<9\:_Y[H*O)\NH]
M3=[N,^-?\]T%7D^74^9*OQ_[M-S_ +L37_\ ,_&.@]&N'T9\]61[L.^\6_\
M4.A1ZLCW8=]XM_ZAT ]61[L.^\6_]0Z >K(]V'?>+?\ J'0'W!5^?_=IN/\
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M_4FWT=_#OT)/H4= .@'0#H"+<58N#KAD.9W<Q36^17;FB4<T. ;L%9GC$N^
M&:\'65=W=?6/*C.<8LSG!=?E]<"/ZKY_3$E.A1T Z = .@'0$6MJQ58US@.8
MGFM++<SG;FW!F<B!P]97C,<>3"?@\G%6/%C$J)3\7Y_=AEW2]_N,^ZW+]B4Z
M = .@'0#H"+858L+1S]',GR&EUN+H79KBOSE*XH]9;#$<^HA/%V0,4YS'$;#
MJ[_%WT8C)GW6]?N3+SX7/]B4Z%'0#H!T Z TYS)_FE/_ /4;?_QI]81X>OT8
M/!^S<!Z'MH@P#;VS, :MO7$.LZB5?B=-F#DV^FPD(DE>3,MH;79<IO F:',<
M-GD^@!?$7B!7VW9T0[,^:LMI<6M%$SVK'6$%*D&(^LE;&2]*V@C,W4]A$;D/
M)[&W\5URT7V=,^\A9 4D=1<J G-LX5%=Z^-KJ'8"M:$]H[I8>1Z&+(NY#R$>
M<RVS7@)0,6CA#FF&^8(26.UF%$4:OR;XPSX@."WL[\9*Z<##++\#0KH%KHA(
M(.,5@CO3GP*NZ:T &X^@,W1TD(&L[371(\CXL&IEI>;H 9D."=%JTF[0Z*BQ
ME%S6ES,@8=",=[0&6#)!B8QI205P+%4!B!C,XK,-J+Q1W53".PTUMX@1%O9L
MXOMDTGE<1&QF=4PS/-:B[-! VR9V\'S8DJ+ZWD0=DG<RIQM4'\K(WV+C)%*<
M5 5@9_[ 6D154H:"=@$1BTE5 IA& HRT'+/4BM)=W#"U+XPS<ZU\TD<F5_GQ
M7WWWE(()[B297 9P?!^DB'ULN]R22*D#U=;DEC'-:O5E>Q*-H3:Z'"D:C$EZ
MALFIL#O,R6ULI)+'.8F5R'P,!FLN)U3/87&S6;%M-#5K>M*&N'(29GKY"D7(
M <M?)(1$'A"P"(;T257F%ILV["_8871:L[3X@8S_ (1T#8TV=?.6V12Y#0K,
MKH2&)&]E:ZF;Z\ NA!D(?FB'L=VP#R:/FEL/.=)JYB"Q&'+K VYC'=]6/JQC
MZL8Q_HZ [8?H_P"/_+'0'M;N8_:"^[O_ !.OH [F/V@ON[_Q.@'<Q^T%]W?^
M)T [F/V@ON[_ ,3H!W,?M!?=W_B= .YC]H+[N_\ $Z =S'[07W=_XG0#N8_:
M"^[O_$Z =S'[07W=_P")T [F/V@ON[_Q.@'<Q^T%]W?^)T [F/V@ON[_ ,3H
M!W,?M!?=W_B= .YC]H+[N_\ $Z =S'[07W=_XG0#N8_:"^[O_$Z =S'[07W=
M_P")T [F/V@ON[_Q.@'<Q^T%]W?^)T [F/V@ON[_ ,3H!W,?M!?=W_B= .YC
M]H+[N_\ $Z =S'[07W=_XG0#N8_:"^[O_$Z =S'[07W=_P")T [F/V@ON[_Q
M.@'<Q^T%]W?^)T [F/V@ON[_ ,3H!W,?M!?=W_B= .YC]H+[N_\ $Z KVT8/
M]DX\4Q,8]KZY]<:KLY[_ *1*O#]6;.[N\7=XO_E[^[Z^JL?1_)D>'JOFBP]S
M'[07W=_XG4*.YC]H+[N_\3H!W,?M!?=W_B= .YC]H+[N_P#$Z =S'[07W=_X
MG0#N8_:"^[O_ !.@(RZIAEPOM\JJ4H+VL,%0Q?@6G%A"C.:+X>/\ZXGR\3&E
MXL>" Q./#+QYS&['YKZDVKR?T)/N8_:"^[O_ !.H4=S'[07W=_XG0#N8_:"^
M[O\ Q.@'<Q^T%]W?^)T [F/V@ON[_P 3H"+<5,+0ZXRIJ*QADFGY0N+X6XS4
MX!MQ?+.)R[Z!<PP45#N_/%INAWQ\7BQ5]'\B/#U7S1*=S'[07W=_XG4*.YC]
MH+[N_P#$Z =S'[07W=_XG0#N8_:"^[O_ !.@'<Q^T%]W?^)T [F/V@ON[_Q.
M@(M;4PKM:YQ351YC2RS,K\7RB3G(@<?4#8\>/ /+$<5QCCQ=UE5N?%]?=AD1
M;?/HN^A*=S'[07W=_P")T*.YC]H+[N_\3H!W,?M!?=W_ (G0#N8_:"^[O_$Z
M =S'[07W=_XG0$6PJ83+1RS35=FEI=9&RG%\:Q,Y2N*O4%X\6?&/*-N18Q[X
M]Q9(L_%^9X9,^]J)EY\+G^Q*=S'[07W=_P")T*.YC]H+[N_\3H!W,?M!?=W_
M (G0#N8_:"^[O_$Z =S'[07W=_XG0&H>8,%^RE/G2'[O:%GA\J%F,]_II_I\
M<\X[N[_5UA'AZ_1@T!W3^U'X<_K]<0'=/[4?AS^OT [I_:C\.?U^@'=/[4?A
MS^OT [I_:C\.?U^@'=/[4?AS^OT [I_:C\.?U^@'=/[4?AS^OT [I_:C\.?U
M^@'=/[4?AS^OT [I_:C\.?U^@.V&)]W^5']/V<_ZL?\ S] ;GY![1>E<;;!M
MNM/UFRW,M4TW4]WQ%<(MOAL"S:-I8ZI>,@Q<U'N(/U8D,1GL]9M((X25PO.#
M)8>6RJ YM9*JON!G$=HWB&BL64=E+(M852(6T4ZQM49'BRNUH8!E3?>EI#I0
MNS=QU<'7MG,)&UI\6\"I4MRY9M\IK+AN[QV;&#H:]HKCI7I>D<@XM<LM2WE@
M<&$Y4IC60:P51JVS;@\<L; Z[_.4*U&HNOWXFPUBS)JI@GPP'LD57:K'9TK7
MY R'':%XT4022]>W8VO-CU_5Z@0->=>UPV6R;D[T '!Z4X()L/@?:M;V%<S'
MP',]?[&.MN"\&*//:RNWW<Z>GZ W?U0.@'0#H!T Z \V\X\2[#R+M/';Q4!K
M3A9J:W=!62C8B-=JC>:_8:(6K+&JVKBSE95/ P^M-QB+QE:9V/@^F*YU2/>Q
M'OC5:;N\G\O7,4V_AGF^S< ]FQR/YL%FOM[5U=^TO?%7M[;D -K=38/%'D:6
MG6Z,D0)[4F?&#EF%=;E59:<Q:GS5=;WGQK\J+# $&GXI[664;B;3E9"MVN!
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MW.)8AX<EU^7TQ#Z?/ZX$IT Z = .@'0#H"+6VXLL:XP5:3Y32RK,;:\PP)G
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MUJ"(P4-6;3&ZNN[$<QSWPE^;959'/AN'MQ,>^.(QNJLQ&., 370#H!T Z =
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M;CJ5+4A907"BYJ*K8E+:RA@2K:E5Q[_;/8*+)<$1#;F+B-'-N(U=:X&X3T;
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M]V,8_P!'0462X(^^SE_\1#_HU/ZG0462X(>SE_\ $0_Z-3^IT%%DN"'LY?\
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M!HUA?6^Y)W+D1T%59FP-+JS?6-1DN:+]3JBP:MS5:U[P\P1K+LY;<7P[IW'
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M=<TZ4R]=E]X)1#P)MJ3A;9.-,;HKO;O=D3.:C_H^%["#6+R-0]KH:D%PI"&
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M@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T
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MY5:-[<M!1:;>;*NM<'ABJ;Z?-^M-@('GO3N373UPSU'52-TG=H:9;QW'VW4
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M9,X5XE>5?<1;F5MLYRD."\D"P=4#H!T Z = .@'0#H!T Z = .@'0#H!T Z
M= .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g367280g07t67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g07t67.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2KX4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(R.3,Y.3@< @4
M0$UI8W)O<V]F="!7;W)D("T@27-O;&%T960@5V]R:VEN9R!$<F%F=" M($)U
M<VEN97-S("T@9F]R(%)21"YD;V, .$))300E       0R:5:YYIOB"G (UK:
M<F34H3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              &P   #J          !
M                          $              Z@   &P
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   &P     %)G:'1L
M;VYG   #J     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !L     !29VAT;&]N9P   Z@    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
M    ($H    !    H    $H   '@  "*P   ("X &  !_]C_X@Q824-#7U!2
M3T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A
M8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4A0
M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
M,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"?
M *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!
M&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q
M ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$"
M>@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F
M W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$
MC 2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075
M!>4%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'
M80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0
M"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+
M"PLB"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF
M#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/
ME@^S#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F
M$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5
M$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;
M&$ 891B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;
MBANR&]H< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3
M'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC
M"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8
M)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDK
MG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U
M,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U
M336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT
M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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MO^D]%G6O)=;27L]2Z&$!S'$>G6W^2_Z35;Z*Y[Z+7/)<[U-2XDG1K?%<??\
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M"^VPAK6S5:T;GN_E.7I=G4>G_9KK7V-=357OMT)EA!_,C])O_-V_368?J/\
M5<@@X9@B#^FN_P#2RT[.FX]KAOW&H5&D520V""S=I^D]3TWOKW;_ ,]$5UM=
M")B*T?*F8]67=99C-^S8UE[:Z*B#9L%NYU3'N;]"NNMGT_\ K?\ +3LZ=G!H
ML: T.E@<''W!^VO:R&[K&W-O_,_,]1>A-^I/U::(;BN:"(,7WB1X&+D__,KZ
MMZ?JKM./T]^GP_3(+/;/@\"S$ZHPFIM@8]A:#67<#;8-V[::_2;3B>[W_P"B
M]F](5=5=MBXN+2T@;MT$^B^OW-:_]-^GJ?\ \5_UQ=]_S+^K@B,9XCC]/?IK
MN_TW[WN2'U+^K8XQGB>8OO'_ *.23[9_D7SQW2\MI(AI</I-!X/'IS'T]WM]
MOZ+_ (5$Z?191USI]=D;OM6.9:9$>LUG/]=CVKO_ /F5]6_^XK^"/Y^_@_2;
M_/?G*5/U.^KM%]>17BD6TO;96XVW&',/J,=#K7-^FDKVSX/_TO2O38.E&KT+
M&L%!;]F+@ZT#9'H^H'VM=;^9O]:S_C%S]6'20*7=.S/3 #!OLL]* &M;H&^K
MZ;]O^@_1_P"$JJ_P70UQ^S&[/6 ]'VBPGU_HZ;W7;G?:/^-_PBY_U\&IK*W9
M74P\-V-J$[B*@ ZIA8QOJ>FZYK77L_[>24S&/CN8]MN#U"0*6@M?876"YOK/
M:[<:JVLHL'HW_N)]F,9J&#U';N#@XR"T-%K-[==WN]:VO_B?^#3O.&VY[+,K
MJ9V$;I)+' !MGI^UFW:UOL_X7_A?T:=KL2ZTL.7U,>H]L;@]C6.>_P#1M!])
MOM:_]%_KZB2G5Z3AT45NOI%[#?\ 39D.<7 M+F[BUY=[OY7Y[-BOKEL?*Z>P
MU.Q\GJ;JZ]CF4@$LV>U[-WZ/^;]-O[_Z6K_2+H<+.JS&/=6VQGINV.%K',.Z
M&OX?]+Z?TDE-A :QOVY]GI/#C4QIO+AZ9 =8?2;7ZF[U&;M[W^A_A/YW_1G5
M=NW[>_2W=Z3))W>C&ZSZ'^#]?_2_G^GZ22G)ZGCXUG4G/MPLN^QHK].VJ7,E
MH<YOL>1C;:Y?]/\ TUOJU;/338M[,!WJ8G3LU[LFL;M[>/3<^NIEG.W]'_X#
M]G2ZNW#9F669-F92"T/W4'V$,8_>9K#GU-I9N>_U-B%9DXEU=F1]JZDRMUA+
M2P.'TP^S94QK'?H&?F.>W\S^<24ZE'5C=:RLX654'NV!]K UH.UULGWN=LVU
MN]W[_P"C6@N89E4,NJL9?U(&IXLMKL:Y[7-#?=6_Z/\ A'?ZXZU+/K!A5L8Y
M[+QZFX@>DX$!I8S<YI^BU[K6>FDITTEFU=>Q;;&L%.0W>]M;'.I> 2Z W=+?
MT?\ UQ:22D%&WU<F&V ^H-QL)+2?3JUQMSG-;3_Q>S]8]?\ /6#D5XHOO]1O
M4F"VYP(KU8X![G[JOSJZFV^I=_I/^MK?H+3;D0^QQ%@EKVD-:?3J]F.XL9ZE
M7^$W-=;^G?<SU/\ !5\_E95=>3?MZOD8[1>\65NJ]4-,/]E3FM?Z3/;^C99^
M97O_ ,)ZB2EOM6-HZNWJA])TP XAVP[WT$0UG_!_VT2W[)47L%W5"RJ:B*][
MF^TN]P]KM[7M]K7_ ,W_ &U YN,[>QW6<E@+@&[ZMOM EVUS:F.]SW;=_P!/
M_!_Z-6L/JF'CS?;U"[*J>' %]9#&^F6^H?;6WZ'J^])2L'"Q\ECZZ<CJ%'HP
M +'NKAKAMK;6UP]-S6L8KN-TEN-<VQN5DO#.*WV;F:C;[F1[_P![W?GH^%G8
MV=2;L9Q<P.+3(+2"->'?R7-<K"2G_]/U5))))2EG]6ZLWIKL)KJ_4.;D#'!+
MMH9[+<A]KM'_ $:\=ZT%3ZE_-T_T?^>9_2OH\_X'_NS_ *%)3E8WUVZ7E9>-
MC45W$Y$E^]NUS)#G4_HAOLL]?;N_1^RNO^>?7]!1;]>>D/P[LEC;=].*<P4E
MHD@5-RW4^I6ZVNM[:[*??9^A_2_H[+/3N]/6J_I=?]&_FW?0_G>1_-_\#^^A
M8_\ -Y']"_F&_P WQ_AOZ1_W5_T?_H0DIS<OZ\=.Q*GBVJPY3&L_1#Z#GN8W
M(L97D/V-_5Z[&>MN9_Q==EGL3N^NW3:7VMRZ[*0R^^FL@%VX8[W8SK>*_;;D
M5OJ9Z7K^G_VI]!7F?T.G^@\U?1_FOS?YG_W6_L(F3].O^A\9'\[S^=_-_P#N
M^DIS6_7GI+CD.#7^AB4>M=8XL!W;JZ?LS*W/]]F^YK=^_P!*S_M/ZZD?KMTE
MUM5&.VRVR^^JFK<WTVN9;:W$=DL>_P"E55:[9L_GGV?X/T_TJML_F+OZ!_,5
M?1^A]$?SW_=7_N-_(1W_ $Z?Z+_.M^ES_AOYG_NQ^Y_Z$)*<L_7GH[;<FIXL
MG&OLI'IC>7,J8^R_+]OT:*WX^57_ -8]13;]=>E-=:W)#\<T.+;=T>PQ<]E=
MFK?TSVXMWLK]2OU/T/J^M8@=>_I_1?\ DS^=_P"U/TOI5_T/_OG_ '<^R+5R
M?YX_T/@?SOT_Y]O_ $?_ '>24YE7U\Z0,9UV6RS&>S=-?M?NV,IO?Z'INW6>
MS*J^DRO_ #$6[ZX8FC<3%ORK1F?8;*6MAPL#+KKO3^E7:ZG[+=6_W_F?SGV?
M].KMG\Z/Z%W^E]+^;''^O]&1ZOZ3;_1_YX?0_G/YK_"_]V/_ '524X3OK]T]
MV,'8^._(R36UYJ8]FP/>RNYE1R"[_A75_HZ7V_H+?T".?KUT05OL:V^QE8!>
M65S <++J_P [_"8U%N5_P=5?Z;TLC] M!GTF_P!#_GF?1Y_FC]'_ +L?Z/\
M[K*57\R[^B?2L^A]'Z>1]+^7_IO^&^V)*3]/SZ.HXC,N@.#'ES2UXVN:YCG4
MVUO;^_7;6]BLH='\W^9R[Z'T?I'_ *7[_P#+1$E*22224__9.$))300A
M  !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M$P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X
M0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    D   "PAVD !     $   "\    Z  ;=T   "<0 !MW0
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C$P.C$W(#$V
M.C(S.C4R ')R,CDS.3DX       #H $  P    '__P  H ( !     $   .H
MH , !     $   &P          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M"0   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,3 Z,3<@,38Z,C,Z-3( <G(R
M.3,Y.3@       .@ 0 #     ?__  "@ @ $     0   ZB@ P $     0
M ;          !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              /
M     0   \     !_^% 'VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! ?_  !$( .8!\P,!$0 "$0$#$0'_Q  ?  $  @(" P$!
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M0-J:;RZXBN%X$T@$,OI;2I7N")S)5:&G7&AZV497C2=I>3G:/9>%U54Q15M
MP R5M$YTD<()P#/&]D<L0R0-\L,>2 7Y("PETV9N=KC,\C&ST[?MIH2XAGA>
MU[6O:/#C Z<+:%S0UKR<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB_*EX1CSS_-]_/\ )PBUW=B/%5Z1=93LZH[
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MES$%_1C*V1A!,Y6$Q1\E:.W\C6U-/;JNIV>KI1%%<I6ST$CR&L[-#0Q\!<=
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M(D;6/*!*YA@8:DR8PZ%%8DR2+ [!XRW3X!7A-D;B[LL$.7K&_P"VK%#K6H;
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MAIKC='0QT[KC6PW6J955IIX<10=DSB280Q@,B:\1M #54K0'_A;7O_G/8?\
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MVEI=Q4AR-<[F.VJRV(YI>PZ^L/PA^99Z+71)1L%5Z\^6<F!UOQ),J?-;A/\
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M[.;<.Y36WUEV=W)\T,4AJY3%S+:/FS1FVEVX][JL&<3[I&"UV_O#=6!=??\
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M0'3&.I228YM^C1AKB"&@$$ D$$#(P5_3>'I3F!#^7_P5C[__ )I/-?E<1(\
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M,GS\>DGRG)\G#J3SSG\N<^7Y//Y8QC[V/LQ][DN2>)\/K]7F3)/5KC@ T9P
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M,C8YS*4-;)#:;;N-,];54M,RFC>]QYR5T#7.DDD>YS]R)F99GN<7.:" 3(X
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MK?A/[-/J%^@_X#N/]*$O]4\=OF>X.SOQ<_TE.XZT>VK?A/[-/J%^@_X#N/\
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MT>VK?A/[-/J%^@_X#N/]*$O]4\=OF>X.SOQ<_P!)3N.M'MJWX3^S3ZA?H/\
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MQV8+5_8<[9UEVT6V5:^R768<4-U?>%JK8:3HBK:^ZW)W+/HXH+=!(ZG@SU_
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M,1=A/*:]^R16[X11_M>],:PUG?=C2!)8\U1JC8+5D$ @2RIPVL(+E3V0X<;
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M6&U(PO*<XSA.<9X183L[9;% U]=[F' E-B&JG3K1;!FO:>^/D7"ZN5@?)EN
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MO"\:R)N8AXF/@S0^NYS7U;W.]9^QB*&:VH*-FM?P"^*S4%..68777HQJ9#5
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@33&6T9RGA%FO")PB<(G")PB<(G")PB<(G")PB<(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g367280g10x21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g10x21.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1W>4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9F            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  (A   "?0         !                          $
M GT   (A                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (A     %)G:'1L;VYG   "?0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "(0    !29VAT
M;&]N9P   GT    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     $TT    !    H    (D   '@  $ X   $S$
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M?8WT3_/._F65.?\ H/6_POI57E_YQ9!;/V-U1^U_9VNMWM:ZDAUE&2W]%O\
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MA#A[_P IKP(>Q*1)]\'T0_R<H>G?_G_IM^KZS=-%;0UN0\  !Q823&DN4_\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(
M P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z  ;4#   "<0 !M0,   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$X.C$P.C$W(# X.C(T.C(S ')R,CDS.3DX       #H $
M P    '__P  H ( !     $   )]H , !     $   (A          8! P #
M     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   "
M 0 $     0   48" @ $     0              2     $   !(     3A"
M24T#_0      "           _^$!2$U- "H    (  @!$@ #     0     !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@
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M 0$! 0$! 0$!_\  $0@!) %6 P$1  (1 0,1 ?_$ !X  0 !! ,! 0
M       ' 04&" ($"0,*_\0 9Q    8" 0$$! 8*#@(. Q$  0(#! 4&  <(
M$1(3%"$)%18Q&4%15Y?5%Q@B4V&1D]'2UR,D,E155EAQ@9*6L=;PE:$E)B<S
M-D)#1U)VM<'3\6>%X0HT-3<X1F)C97)T=7>'ML74_\0 '0$!  (" P$!
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M0*<L!Z$8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# (:W;HBA[_K\!7;Z-I;(U2X0U^K$Q2KE9Z#9X"V0"3YO&3$39JC*
M1$RS61;2;]N<B3P$5T'*J:J9P$.@$?RG#K25AKMVK=I86ZVH;&UK4-37>7M>
MP+E8;-9*51K!9;/6V<I9929<33B09S%NG%E9DSSUH[1<)-73I5NU;)I 86MZ
M/?B\\O[S84E4+%+.7<SM"P)TV6V'?9+5D;+;MJ-EI.X'D-JUY8E:)$J;*A+;
M/C;? P2)9"2D74L4J,@Z=N' $ ;.H/H^N$\=#V?;]NLZ5@3LFNK;45[YL[:&
MW-JR!](*38ZV@:PWEYRS6Y:CTA>US?@X---*J(/9UT\GE#O7BCLWOZ#LOKVT
M]>5#1=-KWKI[O35DE2MJ&\\1=>YK.%&FWSC&4]^23<8O!Y>IZSIFCTE5U&[I
M6ZEGHZ;>]6JM<U2HQS4G]4<+K?,\K]L<S_1CWD30:O'_ )-OH=8^[F<W+U78
M+O6[JT5_D1;$KSMRJV U>VK&RMDI=LMS5A8C52;73C&+V/9E9-&J!5&R]GT/
M0/M9.FIUK_1;>H\?>77NJLHY7*4X6G1YSP>Y*:X93?'&'5/27HD98IVVH58Y
MQOJG2@L<]Y1E6WFL<>2[^PVTTUNGT6G(ZUW>OH3>T=32^[(I2M6_5-[V%L*A
M:UOLM-5&+UTM/*04%<W^I'FQ9&K0T+7"SBSI"TOO5\:NV*O)))NPQ;7_ $5[
M9;/4:EU<:=&^LZ47.I=:94];A3A%)RG4I;M.YA".>,Y4%%8?$]K3-M- U2I&
MA2N_5KB?"%&[BJ,I/CA1GO3I.7#*ATF^UAJ+3R>H+GAAHV1LFQ;"HVO:<1MQ
MI8D-C:Z9[1V"RU+;G=MJJ5,LDY)ZT:6)&HFG)JO(HH2$@C&)'<R!/7ZA36 Y
MY4U=&5F!I^CHX[)TJWT$'FZE(+8KN)5V.JMOW;RTOL"-AJ:77K2LW"85MQWT
MU4_8I-"O'KBZH1A6C=!=!%"03!X($N:JXIZITI<9RVZU5OU;93K^R3"FNT=F
M7MSJ2-G;E+'GK;/0>KWD\XIT/+6*=6=S4BX8Q21/6\C+2C9)N_EY1=V!LG@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M>L0DUU9BJ4DNUI-I<5QYFS>A?0/M8V7CIOD=MAE8H]HLFNZH6LF<BR82?=F
MP-G]VFBL)8&*O3L.4(RN1CTQ!,"$HW,('#%MH/3U=W%&K;[.Z5ZC*I%QC?W]
M2%:O3RDG*E:4LT(S7%QE.M52X-PSD]C2_1G0I5(5=5O/6%&6\[:W4HTYX>8J
M=::C-Q?#?BH)RXK?W'NK]!%1J5<HE9@J=4H:/K]9K4:UAX*$BVY&T?&1K%(J
M#5HU1(  5--,@=3#U.H<3**&,H8QAU^N+BXNZ]:ZNJU2XN;BI.M7KU9.52K5
MJ-RG.4GS<FV^Q<EA)(M&E2IT*<*-&$:=*E%0ITX+$81BL**2ZDOM,B$ 'W@
M_P X9TG8.@>_H'7W8!'5KUTRFGGM%7WAJ?>444TFENBFR1UG"2 F.C'62-$R
M+6T0?:.<IXR2/WB!555HA[$R'<R" 'TI=R<33B5KMB:(P]VK?A0FHENL9=D[
M9/>^"-LL NKV5G==FA;N2-%5R$=,7S1_#OR%?,%NV!(6 , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M(DVBU5AR0FQXT#D?49Z5::!,"B$A09%=LWNC1T0RJ/?)Q<87VK8IE.*WK2OM
M$D4UO$*MUP\]I+!#%, =D>H= Z?S>7]& <\ 8 P!@# & , 8 P!@# & , 8
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M/@#O$_OA/ZQ?SX [Q/[X3^L7\^ .]3^^$_K!^? .0" @ @(" ^X0'J _S"&
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MI*, Y61Z;&=>/I"<9H:IO+=M-O9-<[B1<S"*'(E-.44?JJ'%X+\K@')#&26
MZ(BG@G'GSY][,$L_HB;U9C,Q7Y+5)N+,JP$[G0<R<3]Z8AA[7;WP/3L]WT+T
M'SZ^8?&-?[;^C^QVWGITKR_N[)Z=&YC#U:%&:J*Y=%O?56+:W716-U\<O*ZS
M&]>V;M]?=M*M<5J#M544>C4&IJJX.2>\FTUN+#Y8RL-M-8M\#%<OY4%;^@"5
M_7QF"?,%HGY]U7_DVG\!C_S=V'Y==>ZE_"?!SZ&JV-$%G3CE+5T&S9%1=PLK
MH*4(FBBB05%53F'?'0I$TRF.<P^12@)A\@''S!Z&O^_=6?9BC:?R_ ?-W8?E
MUU[J7\!P8>APLTHQ9R4=RIJKV/D6K=\Q>-]!R:K=VS=HD<-G*"A=\B51%=%0
MBJ1RB)3D.4P#T''S!:'^?=5_Y-I_ /F[L/RZZ]U+^$[7P,5R_E05OZ )7]?&
M/F"T3\^ZK_R;3^ ?-W8?EUU[J7\)E%8]$5>JPH\.WY+5-R+TJ)3=_H*:+V 0
M%02B DWQT^Z[P>H#Y  !TS.MB/1_8[$5-1G9WUW>_*,;:$_6848*FK9UY1<5
M2A%O>==IY;Y+&.O(-!V;M]!=RZ-S6K^LJDI*K&,=SHNDQNN&,YZ26<I<EWMY
MA\%OL3^4;2_H&G/U\Y8)D>%W^]^(^"WV)_*-I?T#3GZ^<#"[_>_$?!;[$_E&
MTOZ!IS]?.!A=_O?B/@M]B?RC:7] TY^OG PN_P![\1\%OL3^4;2_H&G/U\X&
M%W^]^(^"WV)_*-I?T#3GZ^<#"[_>_$?!;[$]_P!L92Q__8:<_7R/_?\ S#@8
M]OO;_>>J&I*2^UQK.DT.2F&L^^J=?80CF:8Q2T&TDE&*?=>+0B'$K.+1Y%2@
M4?#J2[\Q!Z_M@P"  ))$P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M1[WM"J5BYZ=GIW0]>H >:/PG\]\QT/\ 2<^_5U@X[\>WX/P'PG\]\QT0(CY
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MO1><[Z2Q^S)BGPS$I_)S8?2TX_5IE??/_I_^'+S]>H_R#'?G&M?S9<?K%/\
M@-YN%W,MQRW^R #G72%$&C>S@E%&VJV@)/U_ZY]_>5JO>"%J,1_Q?%]_XC_D
M>Z_9+$V%V^M]N%J,K?3J]@M.=LI]-7IUND=PZ^-W<A!QW513><YWL<,<<DV?
MVCHZ^KKHK6I;.VZ%R52I&IO*LIXPXQBENRIR7U)KA@[_ #*Y>.N)<51Y5OKY
M"_>V<C,1XH+VH]8]7!%-FCD%2JIUNPB[[_Q(D[LQ&O= 0# 903=DO/;G;JAL
M10L*U?3ZU_Z]5KTHJC6A1Z-T84YMR<XSSO=(DDEPP^/;V;0;04M I6U2K;U+
MCUFI4A&-.<8;O1QC)MN2><[R22-"OAF)3^3FP^EIQ^K3*X^?_3_\.7GZ]1_D
M&+_.-:_FRX_6*?\  975O2VS-H4>%2T#&-/!%0,?O-JNU>WW_?  % NMR].S
MW?4?/H(&#XPZC8&PGI"MMN9ZE"AIM?3WIM.VG-UJ\*ZJ^LRK1BH;D(;FZJ,G
M)O.>"1D6S^TM+7W=*G:U+;U6-*3=2K&>^JKFN"C!8W=Q\WQ,R^$_GOF.A_I.
M??JZRQ#)-^/;\'X#X3^>^8Z'^DY]^KK WX]OP?@/A/Y[YCH?Z3GWZNL#?CV_
M!^ ^$_GOF.A_I.??JZP-^/;\'X#X3^>^8Z'^DY]^KK WX]OP?@/A/Y[YCH?Z
M3GWZNL#?CV_!^!0?2?SWS'PX#\7^Z<^^0?\ T=8&\GU\N/6>G&J[HML77-,O
M3B,2AE[7 ,)M2*1?'DTF!GJ?>^&(_49QYW8)@(!WQF343CU_82AY8.1G^ ,
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M4?\ K?\ E9^D[C+_ /)^U!Y@/^T2"]P@(?\ O4OQA@[B<\ 8 P!@# & , 8
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MPC(+H 8D8V]G*=.+I.W8D15<H)-""*JY.H$F /4 $?(>GG[_ /O\\ K@# &
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M98(96*L,79-V\PYG:/#MO8%7XQ+KU#I+:5!K42L+@M69W:I:\EHZ25C(LJF
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M4! 0Z@(#\8#[^OQX!RZ=??@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# . )IE$PE(0HF_="!0 3=?\ I" =1_IP#G@# & , 8 P!@# & ,
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M9T[0;N)-XDT<OU&D<BJH11ZZ38LW3U1!L554C1LX7,0$D%3E N'[HOG\?O\
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MQ.&+9>0+" V3$XZ]O7/2I\FUM4I[2=-;4J=S<05&-M.I<VEI7="M>45Z@H=
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M-QE8L,BBBG&DC8[UG)R<D^0DI!R=X<1\>?G]V<_9B%EXQ<\) :\ZC>/$<9S
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MEV@^YOVYU2[HU[>]V?C&G05+[Y>WBEO=).3X*QW7'=<>;SGCS3SN7]R_Z4-
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M*'$.T<PB!GV , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@%#>[^D/[PP"/:8(>T.S_/WW9IT_#_M#I6 2
M'@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8!Q,'4HATZ@/0!#\'4.ON\_=@$#ZJU%*Z_LUTF9:TJV&.D
M9 K:A18(.T!JM2]6038\;+++OW19V:,YAVK0)HR3<20<1#-BH@[];.7X$]8
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M3F3,!BA4VA!$!_XQ%G!3E'Y!*8! 0_!Y8/H7!)=AL!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8!01Z?F_S^(/P_@\\  /7S_P _Y_O\AP"N <#G
M GF/NZ"/41Z '3I[Q]WNZC_1_/T $.50.T40,40 0,'00,4P=0$!#R$!]X=/
MBZ#\> <\ X'.4@ )A .I@*7J(!U,;R  Z_&/N  ZB(^73 .8>8 /RX!\^\+V
MQ)]SV^G:[/7[L2AV0$W9Z=>@=H $?<'4 Z]1Z8!7M^?3\(![_E_H_P AT'KY
MX!SP!@# & <3& H=1P"I1[0 /RX!0YBD*8YA I2@(B(CT  #WB(^X #XQ'R
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<A0 I2% "E*4 Z !0#H       >0!@'+ & ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g367280g11s18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g11s18.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1P"4&AO=&]S:&]P(#,N,  X0DE-! 0
M     '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @ H' )0  AR<C(Y
M,SDY.!P"!0! 36EC<F]S;V9T(%=O<F0@+2!)<V]L871E9"!7;W)K:6YG($1R
M869T("T@0G5S:6YE<W,@+2!F;W(@4E)$+F1O8P$X0DE-!"4      !!)$G:7
M:M\43K,_PLHGKW!N.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&=0$&         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-! H       $
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              (&   $F          !
M                          $             !)@   (&
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   (&     %)G:'1L
M;VYG   $F     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "!@    !29VAT;&]N9P  !)@    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !    !$X0DE-! P
M    $50    !    H    $8   '@  "#0   $3@ &  !_]C_[0 ,061O8F5?
M0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/
M%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!
M#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_  !$( $8 H ,!(@ "$0$#$0'_W0 $  K_
MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MQ>A>:RJ.H7VMLR;JGO?6V'-PLHM@[BUL4]1<UENKOZB6.S.HM]2JZIC]6@G
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MGCYS<BS8VFY@ ES[&%C1_)]\;G?\6AMIZL-'9%1Y$^D9CL?YSZ2?9U4MCU:
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MF(_.V?R=J:_]@>J_UH]23N_G)G6?HKYK224_23/^;OIOV;=GM]2-_&[V;_\
M@_4_L*6/^P?M#?1CU=XV_P Y&_3;]+V;U\UI)*?_V3A"24T$(0      50
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[
M  (    )    L(=I  0    !    O    .@ ''4\   G$  <=3P  "<0061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HQ,#HQ-R Q-SHR-3HT
M- !R<C(Y,SDY.        Z !  ,    !__\  * "  0    !   $F* #  0
M   !   "!@         & 0,  P    $ !@   1H !0    $   $V 1L !0
M  $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M     $@    !    2     $X0DE- _T       @          /_A 4A-30 J
M    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@
M P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "P
MAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$X.C$P.C$W(#$W.C(U.C0T ')R,CDS.3DX
M       #H $  P    '__P  H ( !     $   28H , !     $   (&
M      8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M     0 "   " 0 $     0   48" @ $     0             #P     $
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!"P)= P$1  (1 0,1 ?_$ !\  0
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MLXZ \$W?2M.&J#/W<59.::8MXZWDW;GVQ0WHMX[U[#A6ZJW$?=15-B!IY W
M9'V-Z,Q.F1W'KM\-_M^SKU_(<NF^WKMZ]/MZ=/S^TS=ZWMZ=@:]H]Z1@$E-Q
MJ=?LZ4U>S1+I6TI."HI+& -O@1($*T!\8D^@X_$A1(Y:)\*<S&8;?2TGY/HG
M7@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%N=_ZG
M:%VMN>I;XV;01>P+U1-?V+6U1CW)";)4 (&V&Q1VPS1]+,(F5MFS$Y(09$?L
MV!^3.!45(MN6B&MUI8?'Y]/Y%LLWQ,]*)$J)+&T6XU)8_96U-G#$4+:FPZ$V
M*(;OCAXVV*D*Q4+"&6-UM>4@AKAN@0ELUMQYE;L>&PI][XF=U^?AY??\?,QL
MGYJOX^9.(3QK=3JW"Z\#050LPN#UDH-NU/KJ)#OML9BE-57MR/(MFM-BQDD\
M1]BT<S+APILNOVMHC"7+A1G?9_)^F2JJ^?K_  "(B>2$B0/$=TEA5"^T=ZE7
MPX ONO(6HLM6K;VRK9+H^J(%E$VZ-K;5LRQ60F_KBFI/ @TM86JJ'L/(&0HK
MN5QH[326Z_Q_O]_WC9/RV_N^?=[BK!WQ\=6K#V#1V7*4@X]L-5VK>T)HEB]7
M.-K,OM>G FJS5-K&]5QSC5#*[%KH*/%'B[9,!.DXZ8<21EU<R.U(PW7R,[?/
MS^I8%H+Q-'->=SJSO,Y!U'3=%ZJ5V5SKW4E$ON[M@Q3F.Q+$L(6B2Z5L_$?7
MNH*XV#)EB1NIZV9*CSEG(N.NRF1C$6(QE5Z;>_;?HGI\?7[?YF-NN_NW_/;^
MOZ^9=M5_$_TEJP6]UM.N[/9*[>=3V7138*\[/V+=A- T];I+$T_KO4L*RV0B
MSK"MS9D(9(Q%IZ1CC*PXA#+R&1\=I&-U_C_?[_O&R>[Y_AY': >+KJ[5:7M&
MDUR5O4,QN@I0R^S+1 [#[@9V#;96NJT4J%?;*7_%LS:GH#E<,3!1<9DI].*Q
M$Q&9493<&&EENO3X>7EZC9.OQ\RYECJ]H1GKI%ZEN:SKT[KS$U]%U<C6)-I\
MB"<I,.$W!CB7U2WW9SKC3;3<ALDJ7]3;((02:EHG(1(3CX^IG9-MO0MF@^+G
MJPQKLAJ0RK==YUD2N&K[B]1=D[^VUL6LM/:?,NGZ17(@JY6DS&B4N,36PZ6J
M;"$!S[0\7&,1YD<=$;:SNO\ <B)^@V^5ZDP;.\9_3?:I38I4QJB+67-LZ5SU
M_P!AP-<$9FN@MHUNFXPKW&B$0E16+&+.0+%!;?@65,5)N+$=DCVYGR;ZV<MU
M_!=_O,*B*7&:_P! :TU?L_=^W:6+("K=V',4VQ;03]9(O@2UAH]5CTL0='UY
MY]0D*7EUV&/A'IXR-'?/*&P)!-4A^*VYC'\#)^E+T)K:@;@W9O2LBYT38W8-
MG6<?9Q-\N0F0BS6HJ\3J](Q %2'EP ^8 <O.8E9',L9(N.(?F?%=;0K#?R3W
M>0V\U]_F8_=B^+'7F_\ N7V$["=@9$NTZRV=K_K+4JIKNK[$V+4V2KFFB&PR
M]Q#[CK &0%JUZI1XL:HL\,",2;#'R^ (*DQ!F'LI(9WZ;?%?X>7N,;=5]W3[
M]M_/\?GR+L3_ $=ZVVJL]D*=8Z,\8KG:VY![_N(;)/FVTD;?7:M2ZC73E<D1
M9L>73YP ;KZI2@SU<?'N#S(EHO&4B:MQU3=>GP\C/O\ C_<4L7XP.HZ]:M:X
MS6]@8DL[;QOA&UT[?V7C?>-P8 YJ>+]G=GWE_2(HU]T?2I^F3GR/W=2@9\G\
M%..-U^?+\/(;?/S_ 'DRC_'EUV#;,%;;!N[B W&*JB2K(L'OC;8D)LXWK8.*
M U&T[;KL&VL!=DVJ$*""HDX_:H1"><1!9R<=(J]^5-_G9!M\_/S[R24>+3JV
MW3]E5%,W??Q-Q'JV;VC=%=C]SKV5>H=0K-DIU<I]DV NX*LQ.@BJW;K&,8ID
MB>L"ILFZZ[$<D-L/--U_#RZ)^AC9.OQ\R^G7M I^J:'3-8Z^!Q*Q1=?5<'3*
M=78'Q/D@=9K8V,(""HN7G'7LL0!T2/&;4ZZXZI+>%.+6O.59P9)QX X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M.8]JM7S3=.BJA,X)HK,,5B![9(9XV2Q2-7=KXY&HYCFK[G-5%0F3G <HX X
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MSCF,3[43?FU\\6A64NI\L1KQ0(F;,FNL?-O 9O> . . . . . . . . . .
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M"12\8]H4?$Q\<3'*]S]F)./1./\ ;^/]O^?3GJ;[3Q*?7 ' ' ' ' ' ' '
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MKXY&M>Q[5Y->QR(YKFN3HK7-5%14Z=2*<XS[' ' ' ' ' ' ' ' ' ' ' '
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M?^_YFQKSO&]R'"6T-)]2:/;-6ZFNM:D 95S@Z]+;CJVSY)8&606@0B$M\C8
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M,P,D#$ ;06,^N,9_?C&?[> <\ < < < < < < < < < < < < < < < < <
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MK0RN0=:KI9OSUYVM='&U62Q^#>U'-<Q4W;(YKMT5%\T2Y?\ TWG2K_V-M_\
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M1)%5:V='LL%90:MR*;;JA?:=!TP1*-O2Q92PUY;X:;."+$SY 'I\8_+']6.
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M?'1V=8"0W9KV:@"=)LQVENO8KD6[UB7:)"6FL96MN-7V"4F1C&,XQ&:>4O\
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MM7J774O.MK99V926)ZNRO60=]+>KA]^0J1DQL'3^ LK!#*I%@U^13\S.; V
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MJ\!)7;3:&Q=7;/T)9*F:GM4FL"-N; W#48K;;K-NUU5E:V$6*0IOX#TE9"C
M[@9OH=B'E,DA-K^ Z<+^I)] +9F>WFUJJQN>U&K0-AF-A7"E&-&4^U 8A('5
MJ*6UA:;R("O-E+]J@0-+'*)3X=NLC]GV %2.LALW"'M&'AX\-+ G9'='=!0
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M0$X4*P$/LP#).OCOF8ZB"V9!1X#J$^YN^&JE*ML #07(A39VM-1@F8P>*IP
M3MO6JB[]+W*RDKWNG55/E#E$[#/H8&JOVRIO2I,T'/3:IY3+=:+@9&=2V>P7
M76=%MUK"PZY9;'5PY@X#'&A-C&C24Z$T_*CCCH$D8#%8'Q%*7$FC2Q*&\PI"
MF9TE/\LL"HGIP#CTQ^[' .> 6N=K.U=$ZJ4*!9[+ -VVWVX[%I>J=5U)C$R[
M;3OY7U;$U:MQ,84EO#B\I>*&)6,#@T#"Y<E:W<Q8DJ1Z9TS>U1>?5K/BJ5*D
M*W,KE+:\*6,H1KO-:L/]=D14BA;O+,_9C$_><W4YC,5L/6;-*U\\T\K:].G
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M**$K#L<58Q@G58P2')3YK1HX)+QWYC"/1B0U'>AN@72>N?AX_'/K^&/7_?\
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MK,"(H$PO2 XVN6BRQ=^23'Q[ I'S#C8R5I<Y L$U4\Q%>BQQ$VJBWGY$R)-
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MTH5[=[H+L ^H/5L:[8,.I0F?U^ZW-W.VBI/^NB9#V&<"WZY4R5'5GW-%A5I
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ML60 08PTG%D0H[;20(M2=8:-'HA5^DTT?$'U9G65H"O08AGZ A%?K#U7UQ/
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MV"U*M^Q++#,!Y$^P%I&(,V+L69!G0IJ'I2Y@M@DW,;;G/#XX%<^ . . . .
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M\. <\ < < < < < < < < XSC&?SX!C8W)T9O,7;=F[(]--SKZZ;JN^(:MG
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M*?=CU],^GXX]?3U]/Z_3'K^_TQZ_EP#Z]N/W?Y_S_P"'X?EP#CVX_=_G^O\
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M7VR%>1,1'A1IH\\6'3&O:!MJ\ < < < < < < < < < < < < < < < < <
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MSG\_3'KZ<H)/)"SRGVVZZ1N&J]E5$/AC)>U4&X5L5B2[\"-DD;KI$;!Q(?\
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M9.!HMT#?-QGUQC/_ %]?_'@'/ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M:N7@),6V/P!&=5^1@U7._G7+MIW",]M&=M]>-@5@@33:+J?W.MFD#2\EVQ4
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M])E=)'V)INY=(Z.3BW=KGHU7<53J9F\?EC^K'*D)P<\ < < < < < < < <
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M4",$V;)8R]9.S:E*&KU#;[W&M@<B/H4@.W'$6L4#J4V<6VD)]A%9,2Y1"&9
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MXRAX</YTY/\ N,WW_AKP!_&4/#A_.G)_W&;[_P -> /XRAX</YTY/^XS??\
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MO_#7@#^,H^''^=.3_N,WW_AKP!_&4?#C_.G)_P!QF^_\-> /XRCX<?YTY/\
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M!:0YISL?,KY:(^UN\!8<4PM VC8!>SQ5HC[>V%C8E),5TWKNNSMLUUBNTUP
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M9H]U:].+HY(GIT='-"]&R0O1=_8>U%]4W3J52M4X6'"$#A4/.-QQ,9R5F (
M2K*9D?BE/P!8>!%ESYLIY64(2S%94K/^LO*6T*6G3&P)8U]9=?[.J\.WU,>P
M\)F3#0Q39.M/@RH\O6S1"N6$.5#F!\(D-)ACHHB*G19<9M:)4-W+>7&,M/.
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M/$-$/D@D**&CJ5@#I=(+=Y9/$7Y)M']<-OWBWG0VR-HZ1H5YT7*V 3V7KJZ
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M=:[!K%C7!F<)*:XA:Q)HUS4*HJLD<$6D@XPFF0W)[\TBF IR8\^\!:^7TO\
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MVCK_ %-TFJ5EICFRFNQW8=6N]@;8VZ4T7LJ8]9MC[BN5>4>,3;P<U[)H<@8
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MM4]Q6KRMENX:+>:VZJJS28]J1L9M5L\U>O3JK-NJ-W540PM^2O5F\>O(J3Y
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M'*=D1!LU9(=%?<?9<6]'@$7')\)ES*FXLU:Y3"6WU*<R!!R.O:"8DQII>CU
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MI5[\--X7[LK]V$)PKWJPG"E>OIZ^Y6$IQG/YYPG&,_AC&. ?K^7 ' ' ' '
8' ' ' ' ' ' ' ' ' ' ' ' ' ' /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g367280g12p10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g12p10.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1A$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R,CDS.3DX' (% $!-:6-R;W-O
M9G0@5V]R9" M($ES;VQA=&5D(%=O<FMI;F<@1')A9G0@+2!"=7-I;F5S<R M
M(&9O<B!24D0N9&]C SA"24T$)0      $%U@25_+#(S.9SG[AEY><A\X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9F            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  %>   $0P         !                          $
M!$,   %>                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   %>     %)G:'1L;VYG   $0P    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !7@    !29VAT
M;&]N9P  !$,    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #;0    !    H    #,   '@  !?H   #9@
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MSL?[-_TE2=A_6P_1S<4:Z?H7<?RAZKO<H_8+&6U.-_4II@N:;F%K]7;/6_\
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M>YK6Q;M^AZGT4JQ<ZK-NMJ?3ZKVEC;-NXAK*J]WZ-]K?IM=^<C=0;+2_T!8
MQP>\D"&<FMO/NW!K_H[%!PQ[-CW9_O%!AL=D88R76%F\/!!=8]H$OKU:^W_J
MEC/^MF,,K97B@XH!:VP@27-^F[:![6*\S,;1T:S&L9>R]C;0?U>XM^D\_3;2
MZMS?[2XFR^M^+4&[Y@D?HWS_ %OH*;#"/%$$7QRX#_5]$Y\7_,8.8S3'#UU[
M/9XO4:^K='Z@XXXH?758((!]KF.=6[</Y*VF_P!-=_Q3?^J>N3Z-E-'3NIUL
M;<YUS RMM=%SO<:BUOT*=C>6+K&_TUW_ !3?^J>H[$@) </%&,J[<4>)="^$
M<6_5_]'T3*=C-S,:MC8MMO?):.'C'M.YSO\ BU@]=Z/:>H-NQ[/3-XV/F70!
MKZAC>[VKI\S"HS*O3N;,26.#G,<TD%DMLI=7:WVOV^QZKNZ1C^BS:QIOKC:]
M[K'"9W/_ ,)ZCF?R'/3H3X;T!!W!V1*(D*(L.'TGZN&K,J==8^QK7"RQ@T:7
M-]]+G?R=VQ_TEUBS?V+0'$-TKVB!+@XV1MWN<Q[=G'^ ]%2/3"=KM_N+3ZNK
MX+OI,:QN_:RIKG?\=L_PJ4Y\1M481B*B !X-JEH=78UPEI>\$>1<5FBK$R_M
ME&.#L:*6RWZ)!JW5[?W_ -&^M:>+3Z%#*IDM&IU.O?5VY_\ GNWH&3TVB^]M
MT.:XD>KLMMK#F@. W5T65UVO]W^%;]! &C:7A!A9PO?T]C]M=0<YKXU<#HWV
MG\[][]Q=-]5^F78SKK\AQ<\?HJ01$,TL<?ZSW;?\Q7W="P?7]2NIK&O!%S@Y
M^YVFUK1[O\]*OI3JV#TWEC]T$BRR!7]'N\^K=^?ZE^_WI\YP(TA&)),K$8\7
M'+YYW^]-CAAA$V!K_+TMW*_HUO\ 4=^0JIU>\-JKJKN-=YR,5VUC@'FLY-%=
MGM^EZ+]_I6IW=.L)(WGT]X+6FRT^S5S]VY[M[G.=_-6?J_I_F('7:::VU]0M
M>&"FS'8XN@-##E8UCWO?^:UOIJ-D=.T,=6X/,,(.XR6P/Z[=NU5NGNQS9F-H
MB*[PUP$0'>E0?S?Y)4#U[H1!!ZABD'0CUF?^20Z+NC9N197A9K7WNVW6UX]X
M)@12+',K<=K/T;:TE.;USH[LKJ;;6O=6VQFVPQNF/FUS%;Z5]7\7 S!D-W.=
ML( <1 /T=^GY^S]&K=72PUSB^_(=^D<]LWO.CA]"!LVLKG]'6E7TYXN)==<*
MFF6#UK'%TZN]3<=K6M^BUG_@B?[AX:\-=/FK:UO!&S*A9ZMG,_HUGP5?JK*1
MB6W7/+!76Z#) !.GJ>W\_P#-2;T]QM/J6VFEIEK?5<XNGD6S'Z/_ (-6,K$H
MRZ7TW-EKVEA/<!T3M=_9:F+F5[!92^LF ]I:8\PN;POJGB $W.>\F6L<3JT&
M)]/;[=W]E;>1B99K/I9EX=+3#11J 1O;^DQW?3;]/_P-)^)E,K>69=]C^6M_
M0@G^1N-&U/CDE$$ U:#$$@D76S+IF!1T_$;CT@P"7.<=7.<?I/>[\YR(/Z:[
M_BF_]4]!.-FBDN.5:ZWZ6UHI D?X-I?1]!W\M%Q<>RLFVZUUMKP =VT!L?F5
M^FROV[O])O>FDV;*0 !0T?_2]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDD
MI^JDE\JI)*?IG(_I[?Z9])G\W_,<M^E_(_TJT5\JI)*?JI)?*J22GZJ27RJD
MDI^JDE\JI)*?JI)?*J22G__9.$))300A      !5     0$    / $$ 9 !O
M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z  ;4#   "<0 !M0,   )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C$P.C$W(# X.C(V.C(Y ')R,CDS.3DX
M   #H $  P    '__P  H ( !     $   1#H , !     $   %>
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,3 Z,3<@,#@Z,C8Z,CD <G(R.3,Y.3@       .@ 0 #
M ?__  "@ @ $     0  !$.@ P $     0   5X         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M1XNE)?7NM[AKZXVVT:MB=>\PEMF-NS-.V721KK?2QY*7=J,%!HB6:[J13MT
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MB42I"TQH"5MO.DMJ2D1*D$/X4E\A&<=,I>?2M27G4]''4J4E:E8SG'#U)?\
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M[72&7X[7DWK:I..6M#]X@RQ)XDD,8Y4+%!2\DPQFNTWRMOE%8VL5T6SZJIU
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M6;8A61#&,U:W'FD\I588GG2.C:!S54V&WY5HZX<H!9]4AH1FAD:YYE8#5LK
MT>1J@=YN=)%VCH>QTO8\B[M.D1TZ!8V]CR5>KTM$1J,K8QII<WG/LODB-AV"
M;V1S*4_F[U'=]U"QWHAEK.U5.4O=ENJ-0I,K,CZZBV=SP E!>AW@MA0U'KC6
MS A(FZX  =**%2QC#<UUPYN.76]\FE7T1>+A=:"_1^8J&V+B\:EF=U6'96PZ
MOK$2PZ7C+Y?*H[7WZ<?:K(-)184ZH2%AWCT/(DW#,K&!0QB76#RG'E#K  ]9
MM/Z!$)K<7A<T\F]\L?,!%2=A IG*9I_;UWJL5''V&J2T;+V#=LULS5=7LC\;
M)1@N8\)H*+MA<2Z_+,??[_?]&7^8\HUY1IJ\<R$(7H*LT>G43=$?KZ#L!N@.
M82^S^IM<.\P[.LO=@GH"K&#QW,! RFH\JVPT'K>?K!P#I0R$BR%>9D)$)]]L
M9@0%JY_F^67R:%[BW]OVZZUN6YQ]J;BUI+U3<</9-KVC5>N-][#TM1]@&XN,
M!;JS6;C98*MU&N5&[,S@9$E-U8>1C[,S&HK<PQC,<M/.5S];IW9I_7LG6*4W
MJ:>M=W+N&^3N5??&K@K14Z=K[4=UD:C7:'L78H\OK^Q"6ZUW350EYM$E/P5B
M>AEV&"K)Q$(?%EL9#=CYO^?/1^U-PTZGZZM%MA);FAWO-:^7?=*[OVMG:0K&
MUM5T^K:'HEJJ,O$P6E*_BASMLV!"[&MS$U2V6(9U L<H$*:7PQDB:OY]?*)6
MCF@IG+U;.6H.(K<]MV9U)+[B1JW8H-0BGM&6NQ6W=ER)*.G%1@=-V;I.1UO$
M:,G%RI 1&R2+8EUZ?;C6X7#&>#:GE /*(UW>W.#2:9R^UA^KZ8"D<:1K$EJ7
M<\A:MJRD=<M2Q-%R!?(Q_&OYJ(W:Q;;;!9-&7"YU6ZW%VR338HFK6\1;&1+&
M>5'Y\I:ZPE2@]:U6PV@;6&M[A=-7C<L._![)#R.P='[VOMJ)E;GFXKK=''U#
ML+6]-IC=7M$4N?VDS9'G:Z0 X9&.I8R0F.?+RFT+MG3FOK#I_5I,5:>6^G[<
MM5H.T/S%P->E;;>]?[#N\W PTE5)+:#U7>TG,1%(I=BJLT)(V:WY-F9,=,!)
MRU;@6F,B^U>4'Y\[MK&M09>IK&^3L;E<YAY*?32^5SF(H]Q3M>FL[F'K\T%.
MC[2"]R_5<FW3:B-K^R1EAM&U[M+SC*SZ'K5FQUPX1C)!M'E ?*(P,GM.NTC1
MD?(G4]JVP\34)[EVWZ87K@.J[6U+0]77:S;1?N ]:WH)OVD6NX[ 9@:&F$FJ
M(#!(3-RA[L5.$/,9M^Y0-@;HV)J:5-W]&0H.RJIMS=VMCY&N4ZP4"OVZ"UOM
M>W4VGWJ&J-FG[7*PP%RJ</#3[;6;// D.&N&1<F]'$C(:8QI.&,.&,XY3A7M
M][AC./91Z\=KY/;CWO;C\>,_U8Z,98IBRU>OK81/V."@UDI6H9$O+QT8HA#6
M4I=4PDU]G+J496A+F6\*PC*TXSV>UCJQEG]TC6_ZH%*_=7 _#C/_ &]\GYYX
M8P]T?6^/9L"E?NJ@?GZ9.Z?P<,8>Z/K?]4"E?NK@?^7?G[_KX8P]T?6_ZH%*
M_=7 _P#+N&,I[H^M^O7W0*5^ZN!^?_7WM][[W#&5]T?6W3IZ?TG'M_[*H'U=
M?_/N&,C.\5_E9V;,5:P[&C]%WR>HYJI&FS-O;H=BDZJ<MUA]9< =+8*)BGU/
MBBOJ<"<95E\49[/Z*PTM+&29[I&N/7_I@4OU]/\ LL@OG_U_[<^_G/7AC*>Z
M/K?]4"E9]73UVN!S_P#]WX_9[W#&6"KSFD*1!1]7IL_K&JUN*2\B,@:_,U:(
MB(]!)+QA" XX$E@49+YA)!3N&6D=X0^ZZOM+6K.6,R#W1];]>ON@4K]U<#][
MWCOS^_G/5C*8V-K;'J]T"E9QCWO2N"_XCL9^7V^W];HQE]B)^N6%#ZX">AYM
M JFT$KAI0&22.IS"E-I?4$\_AE3B4+RA*\IRM*%93C/9SGAC+YC&,?-C'S<,
M89QA6.F>&,X=VGW^OO\ MZ>SYOQ\,99IV?KE6C\RMFGH>NQ:76V,R4[* Q "
M7W\YPRUDR0>''PZ]G"L-MY<[3F<9PE.>G#&85[M6E_U7=8_N^JG\Z\,93W:=
M+?JO:QQZNGJOU3]7WO[J^KAC*^[5I;]5W6/ZU_JGK_\ W;AC#W:M+>O_ $W=
M8^O_ /']4_G;AC*>[3I;WMO:Q]?O^G]4SG^&5SPQE?=JTM[<;>UCC/PXO]4Z
M_P"=?A]?3/O^SITQT8RGNTZ6Z=/=>UET_P#+^J?-_?7V<,97W:M+>K_3=UCZ
MO9_H_JG\Z\,9B=IM_++=UUAVW7G35B<I=JC;S4URMSJ!:J]<(@8X.,L<5ER5
MSX66!%DY!@8MOHXTT80A.<8<SPQF6>[5I;]5W6/[OZI\O_?7Y?SZ<,93.Z=+
M?JNZQ_=_5,>WI_WU^]_T<,97W:M+=.GNNZQZ?)?ZICIZ^OO2W#&7*'VAJZP2
M(\1 ;'H<W+%J7X6+A[?79.0*4TVMYS X0<@^2_EMIM;J\-M*RAM"UJZ(2K.&
M,D#&.F,8^#U<,8<,8<,8<,8<,8<,9P["?E^_U_/\_;ZO5PQE.PGU>OY,>O'R
M^SWNOO>KAC#L)]?KSZ_EQZNGP>KKCV^OAC*]C'3IG.<_-\WL]GR?\7#&'=X^
M'/\ !^3K\W#&&48S\/O?![W3Y/DQ^><]6,,HQGVYSZ_S^#AC#N\?#G^#U_?]
M7#&=)(@QC#XI;#1(Q++@Y(Q#:'AR&'DY;>9>9<2IIUEUM2FW6EI4AQ"LI6E6
M,YQPQF!:VU!JK3<,37=2:XH^LH V0>EC8:A5:$JD67*/H;;=D"080((=\Q;3
M33.2'&U.]RTTSV^Z;0C#&2)V,?+_  ?DX8S'C:C5Y*PP=MD("'.M%9%F :Y8
M2XX-^:@0[ @1N=%B)-QE1D>/,-@ HDFAGFT&I#&P1ASN6^RQF0=C'3IUSZ_;
MU_Z/G^7AC*8;3CX?S]_[_P O#&5[&,>OKG]?I^3I^?KX8P[*>OM]OR^_ZO>_
MXO9\GKX8SGPQG#+:<_#_  ?\>/\ I]77KTQPQE.[3GX?G_/U_+[>&,.[QUZ]
M5?>Z^K\7Y_-T8RN6TY^'^#];WO>]GWO5PQE.[3\O\'Y/S^;AC*]C'R\,8=VG
MIT]?3];\G#&'=I^7\_UN&,.QCX<_GZO@^#AC#L8^7WO@][];W_S]_AC#N\?#
MGW_@]_\ 6_JX8RQ U2LQ<[/6>-@8@"R6EJ(8LL\)'"#R\^S ,DC0;4Q(M,H*
MD6X@<PMB-06ZZD)HE]L?#:75XRQE][&/AS_!^3AC#N\9Z=<YST^'IG_BZ?K<
M,8=WCKG/7/K^]ZOO>KAC*I3A/7IU_7_/\?#&5SGIZ_>]_AC#U_#CYL_EX8S$
M[Y=H#6],M%^M9+X=9IT%)V2?+&",D2!HF'$=./?:!CV"3"EM#,NN89'9<<5V
M>O3"<*5AC(,E;5[LEGCX/6-QME:*U=M..S?B0,-Q,?-5R$D9\.<C6V)2+.;L
M\-*62IR5"-<#<!7'E)F3AB<NQ@_?,8EFS;/<FN:7F2S=!M*[!QJCE*>MVIVB
M=:2SR*T_/7PYUN*O8\W<I\2R2(2(B)??-K1%)</$?6AZ+C4O!$Y8QG6^6[96
M4(SZ0<J^.J<9Z9Y/T]<=?7[V[<?K>K'JX9YY8^\1_?&<_L;=E?[(>5;]Y_C^
MF[ACEC[P/[L/L;=E?[(>5;]Y_C^F[ACEC[P/[L/L;=E?[(>5;]Y_C^F[ACEC
M[P/[L/L;=E?[(>5;]Y_C^F[ACEC[P/[LL=FT1LFMUV>GU2_*P;B$A968R(GE
M%2/XG$8"^;D?Q&=TOX9R]AGN\.Y:=[O*NWW:^G9S)L-Z"'.Y>?HJ8WEWY>;I
MA)\O-M/+S;;<VT\N^^TQOE?I6G^L]3T[38;")U"_3HPZ5"V%3;L+KPV5\R^>
M%]3GY.<.?EY>8=^:,)KFG.8JQ5Z!L#<)R2BM3L-%S#8[ND)A:V$28+!J&%K3
M(X2M327\-J7C"<*RG.<8QCU8IDV;CD)=%.N/66MD#-\YF(,(/:9C3]IF-_=\
M)R^ZIHG#6EZGJ.F'Q#K;CTZ];HFT>$=/$6%4L,KDP1GC*9$3(.:(F9F-XB9G
M+S[@G,;_ (KY(?@_^8Z:_G+B9U+O_%*W]O9_\!E!X/AC^O==_P"J6F_ZY8>X
M)S&X]L9R0X_]!TU_.7#J7O\ BE;^W,_^ QX/AC^O==_ZI:;_ *Y916A.8[.,
M](SDAZ^KIGW#9K/3KGIC/3SECKZ_9CKCKG'3&<9]?"&7=^]6MM[_ .?L[?\
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M.M/H/3/7U^Z5/>]_Z+/S]GO\.>__ ,5J_P!M;_\  Y&:W"?]=\1?GX8TV/\
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M2+OBF:70U&O9\=3AN=.6IQ4J79IJ$FE4BP%UR)M"M:D2I%P.K6IV8W-@1"0
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M.S4F0TR,!%0^S(N&"641E X$3$@"#(RIL8$1M&$MXQ/3M-IVM/IW+EC49=:
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M*=6I2K1>2T*M"I7HTTE8H5+#1KU*BTUJZI:TR%*%+2N"Y5K (@8DW[ /9/\
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MA]QK4E.5);3&:23E6<8SG",*7I_/3M9]756>F.O7.<)QGAZOM_UWJ?V6D?\
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MY2?=D)C(<F,Q/%$6461S#AOA>N_3 ,DC6;9 X\:Q/B8JUHN\D55MMUK"4/\
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M* 8!D L$2$I64E LB)WD"D)$H$H[3(S!?"<C]_\ '\V01R'XRGDHY2^N>O\
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M\KEBZN):EMD=ZO3:H>?FC$-2](%]EZJ)\0:DV_J4-NBM6HL$6J8MYK>0K/\
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M]$U4#0K+4Z!*]A5HR3!QD!'.U42,L,],RPU1BAY&*$2[7X:-DVH )HJ/%:6
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MSU5%2U5<K4]/NTT6$J9ICQKRFU=O+KMJO-J+EEM=[(<%<A$I+I&X[-INQPM
MH7HM7-@6!^L7%%[J\Z/*2,%YD38HN>KUI->N<'"$UPR=)DIR.)+<?B#4$1Y+
M@IF)PITJ&I7>'^(;\Z3%Y5O4ITMNIIT&\MU/QNA:C9@*O$-('TRMW8K#4\)9
M*J;;"W@J'E44ZNV>@/1[I&LHX.GTBWJ6N%Z.@U1?"U[BNAIZ9JJX]T="SU#A
M!8TV:G4T_5=7]8JM);TK&E2OUE:J-O.HOK@U=+V3-ZGN;ER5(RY3)3UEE9B2
M(>7!HL<8LY5R)E-AVB"+ME:NSE@;?E!@I"(@+;<KLB0=BXQBKEF@'-6H]"IW
M=,'3E"F6*Z:CWYK%A5R5^&**E:Q%5])@-6.ZS?6HT.F'.+EJA.9+9XMM:K?=
MJ(ARUW=$**ZD5"TZK12,IKT!*NRTTATVHRL#U60!\Q#63:;,6'&B%VL]PM\L
MN\V:Q$%A3S@5M&DE$$!>--->D1@W*PU*"X(@_%RDLRN)A.XC 8-N)$<DQQW@
MSWG:[4.)=#T5@<.D*:YS89IP+ ZS;-LZE/UIJ]>U2.-KM33-(K"6J. K$L7J
M L!H=1*LY-X]XJA/%MEFII;/"U2$2K4M/:-*Y4=1)-.U779>*FVDV[S*5JQ7
MJ\I6*^ET:YM&$/*UNG\E"L.0&(0S8+\'*U(R;AIF#FS2P*T.IU(:1ZLW&G0\
MC&2$W'I:0>\S$6H@F$'*R/@\E/B&$X7Z6R,?#G"-,8FZBK80ZI 6&D,B1%>5
M84\""I:G\B&U0AGLP2ED.^=)>B:RV[PW7LON6=2LG!>)U!U::4V"W$^1]5HC
M8AU<C8D;#  WBLV$ \\<^\]M>,X[/KZISC&>J<IQG.4]KKCKC&,XZ9QUSCKC
M&?5G/7&<8T9'E]Y\IV_N]^;2Q'F_^N6F_P"\9C/Y?);B.,>;AC%_CONH[;^
MFB?Q\OW#&,!PQE,YQCUYX8R%&=P-O[N-TZY7)$1L>JYL(=N,==:BYF194"[(
M0$0QB/6P23$1TK%G23SDFPXU@YAMD)]O#KZ&/O\ MQ.=EQ2X;D[\I"&X!#1N
M5!<TYV!8'Q'@,IE-/#R:"E>);:=Q('H+2=+]$=UF5),\.MP?#3BV,GOD"^X3
MY+O]ZAR\?R1U'AC&WX8R+ME2J*["S-EE9(^,K]?$C9@V11*XAP(@$0PA,_)/
MN".MEG( B'%R3X$BR;%D>#':;%?>6^RJOH!XAZ:J@6RQ9-J 62^JQQL7$UUC
M![@,L=$+$U$MHP9S)#'*6>2VB)(BY8'VIG>8@8CSF9CW1YSOVSY>_*,;M<G[
M-)/QI$9.$N J'JNW(66;$@8E,C'+B&8RT+P_;)^0D#(>W,+A(<G-066Q*$C/
MQ00;,B.KI3@O0HHZ#9NG#*I:7!:D^A;5(Q!TI9;ZL.%"*]:M#:1)N6%JO?B1
M/IF]QI@]4<=>D)?"4K4RG=U6MK]#5M++3-'7-G4M26RG#+%=%9/6;)II@Z_6
M;,UK-:VJH=;F?$0"'5/S=>Z_XR%+*D6P9.+CWQAHTM62<HE<D"+DFT1&7ITZ
M$R0 T])I!==[\KH5-CADR"C>:*OI^T]7&6FUDZS;B:2K^I:\YNKZ8.EAJ@NI
MUGW:,AJ?A%:?JLW;73H:9Q"XTF-F-*T35U,52I<X>ES\'7TQ^B36[E+TFZ';
MTG5]=&MQ%HJ'J]76;&A:F[6W5CU"AI]N=3TZS;MZ.XF4M2T_3[MD8TX630%D
M2W!82+'CRCZV_9)B9ADFF54WQ#<>",W'GY;+ML,ZJ6FH>?I<A.Q4*:H-@=A;
M:&8(W.6Y8)R04YVGH/$M?B72Z.NT7Z+=6ZG%H&:9-F\#&BBDW3K5)BDV_7E=
M,7D=74.:F/0NH9"5.CE&S\#ZWK-9GJYU1].DC6:RM7MZ6O4Z]N035H*>-P3T
MA]2Z^U6E2'5E6[+@LLJKN'2:H"R8K%,70;4@1$_<28V-()Q&$P L^;9==1%,
MEDIFAA)H=I!+95QF[0F1L\[%6OSS$I3YX\WPPQD;+@-3JX4E7WL73AY('Q4,
MA!5]0?9K+,717W"8E*:D*J(*MR63DDQ$L%JV9T!Q!J[ATRQ:JL69SHVI-K#'
M3O,F>HN-/82J#8U(*UQTL>#55_"K,)ZCUOE-1]MI=!@FZ7AU^$' >'9>Q)R@
MP\?'OX$%?#?.BUD L)DW8.05C$*4C'A'@HP-P3"EO$"/ \2\?^G364^FZMPP
M>NZ@M-GB;ANE5TJ=)U%R:9M'4:NFV]-TW5VTJ2=:2N_I^JU[*AZ6JWATF[7
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M*>I!35&X<K-@U&.ABT2:["XL#8A:QF&#B>M)BP-B %H/Y@$%UR@UVES! 2R
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MECCQ7)(E8^!19-FN6 UMGO15OQ KF7WF/A]_O^O^^/74X[?^OP1Z%%)T/)L
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M!U(0\ D26,MP,ELF#&$,HYD.8X[1ZXNC%23J'80*55E%;0;"V6LU@\=;-K,
MD$#V"Y4M+U6*"H 5%#$JIL<%@S&^#PB+UF)!0\KV(V\1M8KVK83!5%FKJ582
M,!+IWYN:)8<"0SLLHF82'O\ 9#;V?8.1DHF9WC,4LMJW)Z-2-[$J?+3=HKM1
MML9G&)6U.2PT%/TY-:;F2-=4V'$;LAE5'F643D[$AA.JJ\Z!, %GKB51LU6T
MZ[9>JBYEZF_\;5- N+PYV*]Z;!*'4[R#*LNX*I)"7R?+;0:& (NZ]?RTMU=0
M>G \L,CE$N>(((D2$4MF2D&;=20V@US,#S;<I\.7_F:N--(DX&E@:9.DJ]'
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M&P;\D-/RQ=H[)L&1:-<LZ]-AH9Z=@V&$XFJY.^G.9J<EO&G#LQ8&$-D(DXZ
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M4JQ8I<R<B2*]<VIMXS+LA'FUEF>GE-RD'%O "2SXT7%E!Q)R1]C34I#1*[F
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M5<VC+10U;F1 FP)*$R8B1B,,E7,004%&Y#!%.=!?I_NF?T^?GO\ J^9/8L/
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M*"AJ+#N:[2L7+5)^N37IVU5KJFLNN4*+BKQU6;1?(RF2:(+>%:%DY^*>CMD
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MO)"X&*DNK<RYW(7(KAR[XG5]&EMRFX)8M&NM]8JN4W>';>2BIX[3V6EU2J^
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M^5+EZ0XVY)A(<;6G4E1PI"T*?PI*DYQG"DJQC.,XZ9QUX8QKB+55V&'GW[)
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M[X+D/:7JU@034![3:(;PSD+TSIU)]FA:J/I0VFQ;J5?4'*%F]CH6-N=M,A9
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MNUL*JW=3A,W;:(5T@E"=+K-3UI7-DYK:GJ#WU[HE:)O4CIU],7AMS3%N'KC
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M9'>LDU+!F/TX+9'"VJZ:OPSV6(KL>R >^:%@$"]EJKT5):))J)JUTRQ?(31
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MG&/;PQB@X5A_G4+*BB*P:XKES0!()%;2U-B)$V@-XE,O(L$&J,4TA_K#1Q
M"0E^/PX2[@S/<1B!F"YN;\F=N6(G<MNT3O,;#,]IF.\1.\1.VV,FR5#7EAEN
M=S,+"S'! N&/Y"):CRL.E.YEB&0T+;)D%$"1^%E-Q8S4:R4X^.0PTHS#-6HX
MF9\/"H.&,; QU(E@[",)&3VD%0)-F ZI2WDB)$Y@-XQYQ\)G;;M\8]_GW\MM
M]O+Y\7/F)U'%V86I%)5+2[(Z9H@RN#SH]8K,BWYADGI65F)/$=*&1 Y3#C[3
M+JF)*(!F#!24@1T@838&,CX=U9M4K8STDD?1 +!(.Q95/B%0E*50Q0.()@9F
M(E3V)60RQJUC7*G>N#F)]J8@IGE@H@2V AB"G:9VGFVVV*/+>(G8H^?;F3Y9
M1'A9RT@A[ F8LHI5C$EYNS#2-5H<7:H82P090,<!FWQDLM<G7R*Y8I%HQ^,?
M>%#F)RPC2DL#@;H?A?B@URJN94DL6$)9"JQC:NMJV.@X2E@UC7[+@L5UD -Y
M38E*#4DN; N(-#7<Y!(R(G=4:Z2.%H6,U[!?T#@IY5<PE E*]_QDB)%)0L,S
MHR<+'A:];)N(2"%4UH&:HYK4J+##DS$]%-7@B.K4N7$V#$Y)0EO K=:6DLQJ
M" 6^;F/C0)QM&5^OJ\'8M5*QQ89:B+!6ES7998*:[1J2UR@-'ADLI&YP]-?5
M.%K%C>B68=HG"%/3K-CD!0C9$&H=TDV#$5H&N^=YF;5B'E#D\SF/:R1)TMA;
MC7,QQW*C8?'5"Q0D=:9&2KMPB;##19H_I%+&:_G)&C!1!^?.4.F(D'C(Z0FT
M2%?CB>YK,X4,/;A,8'7--6!O%2>G:39;7$74V56M&90$W:R[Q6 *5-ABQ%H+
M+Q!KWM*@SJ%L<*S+*?#ZJJ:B$=0Q40G#+#080&R52MH22X)KF1,RL!9"T["!
MA$+&,:2'Y<<0M=E)V8KEF8EH6-M=.I&#V@Y&K1TD<#:0)*;/#D/1'S*<](2U
M;$@RR*W*1\)$1]>>JK*QB8C$KC+^).O8!*+*"6]E:Y<Z1&NP:X;5-=<6+BS+
MP%:K)/"+"R>XWC9VD6]*\JTKD%/47,^' EC+#CF@E P2>M,[K63#D"B5@)"&
MQB?,,%DL5#E?UX9L>JR4BR5L&3A3SJ) 56<J4A"0; TPGTQ [,*ARF5&&<"
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MLC;.W//+UCB6$/($.5O$,:M:X.9GIEL(8TD'R[58%$A.UTR'K3]GG&";';X
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MTJ[V,;-^F-^M<6:22H3\+8L./H5"%-=2 '8%%[#0")GD2/14O*X86U:Y @:
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M8WSH:R.XL6/S($(6.#@M]*&,EOH4T/A?>N8RA&<98Q.>1G8^-KT?;EU531*
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MS';E[S$S&WEV+:9C;M/?XY?H0HKOV921,CY@8@"*C!)."C7"DNG/EF9.<:R
MR80%%KQYORZX66\ RME1#CXR4+4NG<*N4E@LTF)M:Q=AD!,*$0A7-U) 39_I
M8V$!,H+EY3\\]>[_ ![;]_=O/N]_N\OGR\MB*+!<9:-?#;P>9EK(T>.'CPR2
M7T>$4.<.0R2.KKE62L-8P>GNRF5X:=QE4F2@&#,@!3 1$Q+2*.:0'VA("$@+
M?^C,S %$@7>-L3\)WB>W?S_3VW[_ *OGF,OJ1W,/,+2^M S0[C/@TH8PPXI6
M6,LO95W7?MJ&0TXVTVTZAG*"'.]:6I#"FH;Q,3$C$S,P74F2DHVWWC\KEF#Y
MMRF8DO9B(*(DHF&<TC]"LD]X]_U'#&&<NJR/A*5Y7AQ+/7LX>SVNSEWIVLMX
MPC.>F,8XA$SMR[1MOOOM[7EMMOO/:.W:8COWWQ[MOU^_/5PQAPQAPQAPQB]Z
M4_3US1?AZ!_D&TAQ"/+\\_MG&,'GV9^]G\7$<97AC#AC#V\,9$^S=):NW&31
M2-GTJ%NZ-:VLJ[T\"P#XD8@"S&5&TT1V2)AB%*C)92:S<["$R/+"F"C/&MR
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M%I=4R,"QCSZ>TB+K)MB=E;+<+KL22IM7J]MM5LN=DM*3UP""RB%0XDZ>2/#
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M_-PQE,XQGV_G^?J^;AC#LX^#^'/R^K[WKSZO9PQB^[DW8YJFTZOK[5<;FD[
MG6HM\EV47'.!,N62G5GNX@=,>;B:F\OW%B83%+=CTJ@H*P'9,PH-+:V,8''K
MQC/XO?\ >^3[_3U9QG[W#&5PG&/9[_M^7AC*YQUX8Q/]K<S$AKZXV6F)IPSG
MF=ZD)'G#K.B.9D@;;5=JV4G$>RW"27=V%O.KRH&M0[V5>?[!,QK+K\>/TRZQ
MDEZ&TF)I""MD,):[#<<6^\2=\*E;./",RZ#YF'@(XY@IZ!C8H60=??A,R1,@
M^&@PHPXA1*W5XPXIC)TZ8Q[WY_G[_#&=)3CC0Q#K+'B7FV75M#X<0UE]Q*,J
M0QAUS.&V\NJQA&'%YPA&5=I7JQGAC->4AL%SFU9C]/&Q#VN5S59KVPPYD&Q'
M2DY"V"$&IUL;45$1[=9=-J>'+,Q$1TX/80/.-@@I<-X%# 64D,AO^G]GTX_T
M+'+BXF,C'RR)!R.CP@5GEX924>X(,V.LTE(R&ATODJ;R\ZEAIIG#BU=TVA&$
MXPR.7;AC*9]F?O9_%PQE>&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.
M&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.
M&,.&,.&,U4>6W@+!9/)@\T<;6*]/6F6:A]?RZ82L0\C/SA0$!MBB3LNZ!#Q(
MQ<B>H&)CC3W61!GGO#C.K2C/9SPQF'_V=#D+Q[5\T&<^_P!.2_FFZ?PZJX8P
M_LZ'(7_A<T/[R_FE_HJX8P_LZ'(7_A<T/[R_FE_HJX8P_LZ'(7_A<T/[R_FE
M_HJX8P_LZ'(7_A<T/[R_FE_HJX8S"-E^7^Y%*!KVZW@*(YG+$54:O-V-B =Y
M4.8:IHF7(>.(/1&9LUJUQ&5F!\:IC#'G:P20$,!V_$R)HHC;KZ&,??D:YY-*
M^4$T7"<P&B6+\)3Y9Y8#X.PZ'8*1,1TN.TTX='MJE1O,=C:#4[AER:ITS8X!
M;Z5L-RJB&GF6V,<?AC#AC#AC#AC#AC#AC#AC#AC#AC#AC#AC#AC#AC#AC#AC
M#AC#AC#AC/*0"&6L9TH08EP-[!(;C[#3RQ2,(6WA\93B%*8>PAQ:.]:RE?84
MI/7LJSC+&>G&.G#&5X8PX8RWDQ4:;G"C  BLX>'(QDD4=_/?AN*=$=ZNMKSW
M@CJUN"N8SVQUK4II2,JSGAC+AC'3'3AC#AC#..N,X^'U<,9X&HN.8(\6R"(R
M7X9 ?BFAF&R?!MK4ZV)WZ&TN>&0XI3B&.UW2%J4I*,94K.6,]_#&'#&&?7ZN
M&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.
M&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,.&,IG'7'3[W\&
M>N/X>&,,8Z8Z<,9@VQMBUC5=1EKO<"R!(.(\ RO ,>=+RDA)3$D)"P<)#1$8
MP5(RTW.S<A'PT/%@C/%2$D<,*RG+CN.C&+^?SBTZ/DDU][6&\W+8/&W6<FZ@
MWKSLV"!K] 337;%.N-$3#(%FC&V;]5UQ[E D+@_+O&D1\<.1*1DD",QF5:_Y
MI]4[.V !KJHDV N1G:&]LNIS9=<DX^L72EB)IZCIVL29;;;Q<<+F^59I$@8$
M!'RA$@2/!%2S\+/-QC&,APQEDLM:K]Q@)BJVN%B['6K#'%P\] 38(TG#S,2>
MPL8Z-DXXQMT0X T=QP<H0EIQA]AQ;3B%(5G'#&>R,BHV%!#BX@ .+C(\=H0&
M.CA6 0 Q64X0R.*&,VT..PTC&$-LLMH:0G&,(0G&,8X8SW\,8<,8<,8<,8<,
M8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,
M8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,
M8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,
M8<,8<,8<,9%>YM=PVT]?S50FS9B*9<?A;#&3=?)%$G:]9J;.1]OJEBAGCPI.
M.Q)05D@XN5%:DXR3C"'!,#R,<:$\0,ZQFJ>?!V$\YR\;77O+:>;]N)O8.O[+
M.K1K5Y$34[S,:YBI"*I\,1KEZ JZ8[W/8:3BGX^+21YY-FY.5=E2)'JRQC4Z
M<Y?:O1>8S#,98[>=!Z'U# TW5%=E7JRZ'5:M=0HB*DH#,V#5P+G/Q #6NXDJ
M$C;/:9H&.D9"8/2.X0Y'+C&,V!\,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<
M,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<,8<
(,8<,8<,9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g367280g15w60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g15w60.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[17R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %4< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q,#<P,C$< @4
M+$UI8W)O<V]F="!7;W)D("T@,2!2:61E<B!$;V-U;65N=" Q,"TQ-RYD;V-X
M,#A"24T$)0      $!JW[(6)+:; 6D12B?XOT=XX0DE-!#H      14    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ /      0 ! \     !  $X0DE-!"8       X             /X   #A"
M24T#\@      "@  ________   X0DE-! T       0   !X.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-! H       $  #A"
M24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              #_   #L@         !
M                      $              [(   #_
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   #_     %)G:'1L;VYG
M   #L@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    _P    !29VAT;&]N9P   [(    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     @X0DE-! P
M"QH    !    H    "L   '@  !0H   "OX &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( "L H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M@_<95A)%3__9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(  P
M  $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z  6XV   "<0 !;C8   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$X.C$P.C$W(#$V.C,V.C,R ')R,3 W,#(Q       #H $  P
M  '__P  H ( !     $   .RH , !     $   #_          8! P #
M 0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M     0   48" @ $     0              2     $   !(     3A"24T#
M_0      "           _^$!2$U- "H    (  @!$@ #     0     !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H   #P
M  $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z
M,3 Z,3<@,38Z,S8Z,S( <G(Q,#<P,C$       .@ 0 #     ?__  "@ @ $
M     0   [*@ P $     0   /\         !@$#  ,    !  8   $:  4
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( *,"70,!$0 "$0$#$0'_Q  >   ! P4! 0              !@<( 0(#
M!0D$"O_$ &L0   & 0("! 8*"@H-" @' 0$" P0%!@< $0@2$Q8A,0D4%4%1
MD2)4559A8I*6T=,7&3(V<7*!H=76(R92=92BL<'2X1@E,S0U0D9S=K*UMO D
M172&L[3$\3<X8V5F=X*F0U-DDZ.EPL/_Q  < 0$  @,! 0$
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MCJ@ZT3_MPWR4_HT[X5'C>H=4-9-WGZHZH]AIJT%+SBH[*3L'F,V]CL/=V]&
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M]1IP.G\3UGKAKYGC0=;+'[J'_@S3ZC3@=/XGK/7#7S/&@ZV6/W4/_!FGU&G
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MCE!85C<86NHJ5LWFZMCW&UGO%]9/#G56(8HWC9?9NS!S&4-Q$\$_#1&\+O\
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M8^M+RT6"C3E ;6U$UH9S$Q4JR1NZ<A9"-U(TK1^PDXXCUE(E!%8H:SZ;[O\
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M>V0=,2,$%=W+9/F!$F33VD:*=13*>EFH4%:3G3TIEIP(U*I,@)64D)=UI6D
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M!FW5AZ?.)2<S.UN AE&F0&XNJ6V3FIR8CXH\Q9&X"K&0)78S2I $3,"!JR=
MZ24SRI<L*5(2DS9\J7B54RUS9*4A:@5%:$*-@0"&)>)$J<<I*_!0JYEI&&9X
M!=4Q(=;62^-LTB-;]A7*)9& B%J?(-96SNK^RAH]XLQ9NW+S%PN OC55!R[2
M.R<5[Q5?ITGH-SN0*!F .RG()H.@](A4M!DI"IO"L#S9?^YE:9[\:V!4M8#Y
MD6V0$J<3A$E>(A9"24 G5@F8+K =#%P3G8/&Q;8&R@O(1L7Y$BV\E(5MW;SL
M'UPIL>\AJVRAVE@=2UI;OK W5J+=."?-98 LQ8E0[%4%R)F*13ELC0.DEKE2
MTRY97.D<(0G72P=3AQ8U<9DC#>YROE> E3B4IU*L2T&8D%4H$RPQ*B\P!(90
M+*PEKM#8RD>M$OGD<N:.=N6*JR)U8V482T:NJF0#$%I,1+I]%OFJHB'1O&#A
MT@H4>8BPEVUSA*$N<N7.( EDA120M+I)!8I=_8;<\8E.DE)#*&:7!N^04@J&
M>T$@[[O$DL+<(V5>("G#<L>W+"8E9N@B[%7)BVW)E:ZI, 4%086&-0HCU!('
M#<4G,;(,G+B-DVZIEF+QR0ASE]/IV@[EM"+H)IKM,3J#2,H3)-7P6AP%8''E
MOK^(H'),QED!\-B([%#W.5FE I6CJ^CJ$@D?-399M<LF9*0KBBQ)#$BUF,=#
MN$GAWXE>%Z5R#*NHC"%V"\Q,!&$;M\E7*%4CP@WD@[Z5<ZV*GI77C/E$"I=I
M#)>+B4Y-C$.-]$]T?<;HG6U")^GJE4VGGTJ:=--3RB$U"I>L6MZJ6BR98*.,
MHAU<4O'<H.XW3E)PN:5TLU<Y,H(E^"'E%3,HRU)#OQCDS$$EHW^2>#)UFJC6
MJ3N/56E9X=Y$R%>Z=9JY)25A@(N*MLN:3:T&SR2T+ 2,[779CG%^=.)2<PKT
MR<A#JJF15;.\>F>[W16DM.R9,^5I.L[FUZ*H*.:NK$I$^@G4<VJ5)FTTN34S
M%F2@5#5"4 +*$IU8FF7@/=7W+3ZW1Q%9)D(KT&89*)2DXEX@"IYA2D**2D,I
M69(< W'$NS5NRTRQSE)NL$ZK-TK+PK.>@7IA47:J'1!5L]:.")D;R4',H'![
M!337=M*,Q%1'E4(X11Y>F-%*T>9$P3)=52U2$SZ*MDJ49=13J2DILK"M*@E2
M<0F(2K$-QCY?@J**;44=7(5(FI5A(FL#98/%(<*V.4DY*!\$MZJ92K+D"Q,*
MI4X\LG.R:<BLS9G>,8Y,R$3'.I:275>R;EFP;(,XYDZ=K*N7*)"I(GV,)M@'
M0HJ*HKZA--3("YJPH@%02 $ J4238, <XR2I<R>LRI*#,F /@24@D9YK4E.5
M[J%H7## V3I-L6081$.YA3M+A(=9$[I2>JQ6%!5KZ%O?J6<UA"!390:]I@D'
M+L\@5!1=\"39191NZ*ANR]!:0FA)EHE+2M,]25"?+PE-.$JFJ=\DA:;FQ<;Q
M 2IRDE:9*E(&+CI7(*604A9Q:UF25)!+YFSQJV>',B2,W2Z_'023^1R*M-HT
MD64U NH^Q!77KZ/EW$?,(29XDS)LZC7I2OU'J;)RDB+AJNLW.FJ?$=$5V.E0
M):%&L)%.4S$*"V6I#V+A)4DLHAB 2#8M4)F*F2I0EJ,R<A2Y2<4OY1*"H*(.
M/"&*5>$H.SAP03K;%C*[560KD;+PP=+<6R3NHNHR2B9V(L[=9\:,Z2!G(-](
MPTIT$B0S)X1H_448N2BD\*@;LUBJ='U5*90FH2TY]4M"TKEK9>K++22FRP4E
MSX0(S! A0*$RE+& 3B1*=2#C((!; I0S+7(N^XQCN6-[M0+8ZHML@'4;;68,
M1<0:1V\H\+Y29(R#$J?DA9\DX.X:+I*)D;J*G$3<@E!0#%"*G1U725/ YTE0
MJ&21+3QR0I(4&*7!L;[HF8E4E9ES4*1, Q%%EJ8Y'Y,K%]SOO 8PF31,LD1Z
MLK%R::<6=4DD=2.>D)'*-CI$73D#G;@5D= ZZ!%R.>C,B*Z *E**R8'Q\#J@
M5 R)@*?"!27#9OS1C,Q(S"[!S\G,MS\5AYSNWB%+*4&TQ5*@;^_BE&57LM@E
M*S".W '0<OY6&BXR9=]&S7Y7!F2D;-1[EI)%3!F_!<"M5%!34 EYFCZR332Z
MR;(4BGFK,N6M13QE!*5*XH.( !2;E+<MC%PE6!$PI9$PE*5'BXB #D;@,H$$
MV+YQZ[EBV[T&/KLO9HILWB+862ZO2\;-P5@BY)6%5;H3+-*0K\E*-$Y"(6=M
M4I./762>L5%TRN$"";62LT964$NFG5,L)E5:,<A:5)6E:0 3=)(<!0<9A[QD
M7)G2DA<R64)4'22J6H*&\8%J\[LSAX0290%5HDHZ81R"SM!![*RAWQ6$2U6.
M"9Y-XG%L92179L>85WA&,>X<IMBG6(DMT8$UMZ!HJ"OK12Z0K)M$B8DZE<L(
M94TV0E2IA3+EA1_#6I*;9O8X"L I!,I*5J"=9-2O"E6P$I0I@V;L-NUXG<P\
M'-Q$RL=&3]=NG#Y.0\HW92L1*QEYN+F.E8Y<R:[=VP?-\=J(NFCA$04263.=
M,Y-O\<HE"\^?W+Z/J9LBO5W1IK*.<E,V4:6@(*<5E(Q5B2I"T JEK;"M(.$D
M/'J$]QNF:VGUTBKH%RUAD)EA2M_X9EX USF"<3B.BO$)1.)'-^%;%B-&HX9K
M2D[U33ZPGRM;),K5*O3T/*K*!%)XE8],99&+,5%N=^0@*J]&=8I1%4/HE;_2
M?W&*HP*9.GT3J&?0U%*E>CJ1")RJ9<I7&5+TC-5+"4I*242]8HI2$ ADGJJ[
MCM+S9$A$R93H*:FEFS,)QJ2B3.ES9F ZA+DA)">.X-\VB,O&[P6J^4K'G7!,
M(HN+U5W.9-QG$MSJJ*<P=(]N]$CR%4$[TNQWMLK*!!&13(>6A$BR7CK)]X'1
MVFI'==.J='Z653T&FIRZFLT3I NB3I"0EL-!,6D*,NJN^&HP AR%XB4"G=-W
M*+DR9-=22%34H9,V4A4L%*E7U[%21F+,2MR006$<DTSD=ID=-3D6:K@"B"Z8
M@**I#!S$Y% ]@;F+V@ #N(>8-A .#/IY]--7)GRU2ILM12N6IL22.3/#M"O!
M(8@W$>%"TW!*B4DI4Z5@XDD@N"D',%[17HS^CS;]X=W;W^CN_DUCP*)9K@@9
MC,NVWD,2%).W*)&<*UJK]%S&QLEKG3UJ':4W)C49=!RW:O$)%_0YYE$)QKER
MW=H(2Z\FJV2B556ZJ:;\Z)SD$H:[6@*FGI*Y4VJ7JI?!:E*5$*/'73S$RP,*
M5$8E$ %F&;B,DF8$SY:BID!,X*.XJE*$LBQ.+&0D,"Q5=LXE'C#,U%2H,?XS
MD91A=G6,>(UB@[MU_BZGD%K9+3DS%4A4DIS(8P;YA#V&1@(6;<,I4L0HFJS:
M/"IHI%$3F]105^CA34[5%.F>G1NEI94$+2$3YU1(7)<J2<.-"5$*Q!( *5*2
M%-&_23DJ%++6HIFKIJN6L+6-8)ZY\HRDJFX<.)<M*B%!P&+@$ '3T*XU%IDO
MAANLQDO'Z+>CT[*-<O3F1NC-[,1EMGW>6UH>6?"9DBO,,W3J6B'!;D0H,5%%
MB/"IMQ,01QRJND2O0:E54@FGHJV34K" $R9TR7.PH5=5U*6@ RA-0DG$9C$*
M."6F6E="5398PHFR5I*P5ZU15A<,'#GYPLESLO#)Y$M999[PWIKY&K<_EZI5
M\S')V6(F9!&&\H&MB\C4V3R^C!/TI>7K$ )F+RVF@I9%BH[;CO(BS.=+FZ0J
MY4Q>BDR:F0NIE2IB:A81@2DJGS%20M38"=690"@I024D%8 <JJ<9<RG2%)4I
M"):)JK$&8%)N%@<;"D*"E7:V<8^*RVUFXW*ARM>L;.QO6N&Z-"6]XPFT[:*5
MOB4Y-N_))7I&/BT+Y,*H&9.I"PI1K=%0YR,T^D*W]AH]T4Z7/J:92)J)JD:/
MHY<]22%!,]$L)F(Q"RRD@.I)4CC,"0D*52L6E=4%2U!29DB4-I9:2O$,>%(F
M$@@XV&P-9A%CD,._=W;]_P";M\^N#A5N]D:V-._\(IR.8SV>O+EC&MTZ2"RR
M" .%4TSF3;BL1OTQBEWZ,%C@8B1CAN!#F#E _+N)0$3!NZ,DTD^NIY-=43*6
MD6LIG5$I(4N4"A6$@'B\:9A222  HDD /%%K+-+;$6 *DJ4D7NZ4A2C9\DF)
MHX\X$\RY9ID-?\=7O T]69MN*J*P6RZI/6+Q(H>/P\NQ4QR*\;,QBHBA(QRY
MC+-U2B8!Z$Y##U=+R.Y[0=7P:NJM,S70)B)DJ13*DS9:@#BE5!GID3@G$D*5
M)F3$C\(V+>BH>YFNTG3(J*>JH0%-=&(MLPJ:7Q;V.(AGY8GMPFX&XE.&$+^"
MT)A.ZC=1K1TA1R?;X<L>>!\J&,!P5Q3("X(LI)!T9=P)RI[F3*8B9M=WN7[L
MNXWN>F52ESNZ">B<A(3J-'T*R6Q."5:0IR/" &%039VN2.O2=QNF*>75DHI%
MJGJ1A2%)00$D%P3*4V6TA0NQ+AD)D_@%D[)@['CBOGK[3B)QU1V$#8!BW2Y:
MKE!I%BY<=6G4B[:,5QF&17!V]2LSI@QYC?VMFB$C'("TX,SNRT7W0:5J]&Z4
MX1(T94SD#0ND:F4@5&B5*3\HBNE4BZA(DSIRBI-1)$V1*04B>N6I*L&]7]QL
MT:+IM64JTA2RRN:BG 3P@AR 3A0$I2&'&+@DE);%'(!RU?,W#N*D(Z2B9:&>
MN(R:AI9DK'RT-+M#=$^C)1FO^S-GK94O*JD;<@@)5T#G;+(G-S-)4$W1]2J1
M,4B8D'Y*HEJ"Y%1+_!F2IHXDQ)#%TDLX!8Y_.7F:R89\E5/,"C+5)5A*DE!+
MDX"H!][LJQ!-HQ$2,!BB(!MY_/V=P]GGVWUHL7R.W8<_-RQ"EI4%)N+&^$Q,
M[$>;ZWB7AYL[8Q1L=QD<K38MZ",HS91=@K<UB25K*;FZ-%HU\[E:@PFWJ+M*
M/9*L')K&UBUR.T@2/S^QT1I31]#H><B9+1-JEU! 0I.4M4HH4M:BG"4HQ%00
M"%$L1OC<I*Y%)1S$+O,5,XLO"HE25):^%*N+B+7/A,Q!M$DIC-V%)J8IR*MS
MKJ[:EV^JJL7=E5+.Q,/*..&@U;K%JHS!**.$/3ZEDX!')D0JC*G3GDXFQF7Z
M%NJDGVY>DM'*D4@%73IG)E(2GY,B7+FJT5J@5/*! X2E:#A*A:6<+$J&S4U,
MD3 ,:1JIH2O&"H)4JFF(EJ0TM0")<_!K@ H/@620D@MQ'Y1$*$_AWV=*0OQ#
M*X.M<0.7DK>1G'NY.7RO4YZHUD,CF8)(OYB)K;*?6</$TG!(^/DB0_3N.<Z
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M!G+0F24I\$!15,2I08!939"%*\)[CBEVA[2\#MEZ5LP'(,4XD$<JR] GF45
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M2E:5.&9E V8'"6L6<^EYQ7P<_+LK[9Z-/=?:K.9[E*6TAYN,)3G+?.$6:/\
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MNT&GI%/(D2IE(N;,,G2:535S 2.%)2 [I.)B@XMX(*"Z&-Y%<F738-6E) G
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MR:1]RA]T!D@-S"/(3<3=@B82]HCN ]VO-*!25!6>(AN46.1+-LON>.;++S%
M[!8,;7&T[LN6,6P^@?4.J1L0;#Z!]0Z0B5? ]_ZV.$_](IK_ ')M.O4=QW_\
M@H?SA_95$2O]H:._/K_<KCZ>Z']Q*?CLO^S6U^@])>%)_(5^U'JI7ASORQ]\
M-IQ'' F-\V&-W!AW(?F,;_(N;$-BD QA$?, %$1'S;:\)IY0":D%&L>AG, '
M+X%#( [O9"LQ%%1@LH4=0V=R9<S" VTG+8";Q\DK5=+Q= >;O12$1V,(<W(
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M7KJ"KJJ*:[XJ:>N0M\G>6M)RL[Y<EXP39M,HA1G3;#"Q2L[SXHWCFYH\!XJ
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MHNDJ*E.2;DY9#(:<JPN))9.&\L%B"3;B[R<K/D(RC1Y\.T:QCT _%0_575N
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M1Y4RE A #LT9)E@ X 3BU>%272"M@Q2H%+.;@#DC5(^1; D)*T)"2&2RE)2
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M'O=O]RCW>G[U.W\FG 9_T/1?HZ/<AP4^+(^S'NP=1Y[M_:QCSL[_ &*'9_\
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M.-SU'L':'5C'H;^;9'MV[?>KV[?EV[?/K9&CIH+BBT6^_4)?S\6_GC(*50#
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M"7[D:-:+>0,N>'?14#&K.(Y"1%6 .4I%DP=G:)D=%3C(CI1((>QW!4I .<0
M#;"/2T:NF6N;3RZ.5)*)>L.K0D)4"HH8@)#GSFULGB%*733%I2$!,\ S A"!
MK '\+BAKA[-?([#GA:=,3D6A+1==HJ4>_%<Z(.DT$G)B(.EVX*+@6LK<ISF1
M%02@J8I!-[$?/KF"=3J"PG0U$I!6M)49B9)F8%%''EIIREP4L"2HD7)B4TB2
M=9)13RPH @:E"N>ZDG,WY-C1M0QU:0[ @L?^;N%/\G^2FK:V06'>6B+6 X1D
M!:PX-S18TBS<FG/_ .O*_AQ8;'=G4 2#"8_'N'8#)[]@CZ*KYA ?P;::RG_X
M'1,;?/\ _C1*:68DNDTX-P_!Y6W/^[W6/(8L#&]EYM_(>/Q,&P=IR?DV#JKZ
M/R!Y]1CIVPC05"!FPJ"W1P=O5%M1.9B:=C_RTG?^;Y.QB\<=V;L$8+'O;W;]
M%^'WJ:!=/LT'1>:?_P"-%."3-\C["5[D5^QY9P_YBQ]MM_[/S?\ 53\W?J,5
M-_P.A^W'_;1' U?\OZ/*_AQ0<<V<W;Y"Q_W"'88@!MV>BJA^0?5IBIO^!T.;
MCY?;R?ZMGZXL*58RX-F#_9I)N,LY?LBW[&]FV#^T=!$ ^,4>_P#ZJ_G#4XZ:
M_P#^"H;M_?[O_P!:_G?DBW!YHVT]_P#EI'\* ,:6;?F"!H'8/F,3;L_ZJZ8Z
M8YZ"H3SSW_\ \[>J&HG,1BIV.8X-)_AQF^QW:_<*@>M/]5-1K)/_  .A])_\
M6,? U?\ +^CROX<'V.[7[A4#UI_JIIK)/_ Z'TG_ ,6' U?\OZ/*_AQI9NJ3
M%;:!/24'3TTF;R-;>,1FP/VXRTBUARK-C$K[+90IY H#NNF I=(41$#=ETU,
MB3JUHT332IB:B0E.K*)A GS9<B8M*C*0I"@A=VV)!C'-IDRT:THDZR4<2%H0
M):@S,P2 DWS<9&'*H6X%E0 QB['9AV;=OL' =NX#Z/-KI:3'&D@.&$P<X"@V
M;\V_?R;=.2M*EKNI1<OY^0-RL(3&61_8+%\$6F'K(7Z?S:\5IA3*7^1+/ZQZ
MO7&&H2%+4-Z5!_\ ID_RC89S?YVB\=N77#C7<;VG)X3%;2:1&59V<KE04KZL
MPQ):G+B3KT?)21))K!&>KPZ!6XHKOB)$6,)?8*>A&0YA[.W.8WT@!W)8DFPY
M+;=^?)#U' >C)SB':)>8 #F*&X#OL80 =@\QA !'LW !'L,.7I/L=H1PLQQQ
M&\5T7D_)[5PQRCE>,893F4D*IY)F4V\$K$YMS/#,:J244Q[ -81O8L=L,<!7
MH)K*6J%?1R#FQ25EBW"B(3QN4Y]O-ZHL2-R>?G86!S/.1[8=VM<7/$_<(=K8
M(G'<7,2#=Q*Q,++QE(RY 8ZG'DDCALB@357G6W7!56@35TMT+)/DGC-I(KU=
M\YCRDZ&619,]_3U&#@ V=VYPWFV[>;8(\,GQ"\5<79Y;)L] >3HNKXZKU$?P
MK>DY,=8TKUH?<1F0L?7C-[Z C9#K#9:XQI-+K]B8P#07\[#Q5@:/$I489R]D
M5G\^U_5E$/FP&?JW;_/8[(<FI\3/&#=:\E-H8AIE36>H\/M?8,K'3LI+++SV
M7<DNZQ9;PHD1Y'N&]'JM*9H7$L Y(C/Q83#-M<)6&!LX QNWMRY,O-"VT',^
MK(9<[FVQH;*S<<W%;1,13%KM>"&LE?C1]+GJO!4G'V1).'>>7ZW?9*1I<RI,
M3T.ZC)8LK0BLFTX15T85[9!PZ%8?2RK,[Z<NS_&%GRMR$;;/D-O,POL:+%.*
M_B:J#FT+ST4235AKADVN2-ADL7Y$2I&-JR3-M&AJ?.6JN5Y(\I;1A\:V89=.
M5K4J@$JQ4\;,4K2/EG24-S[=^1OTC(-_*7%AAW&SOM#/]W7#[GXMLEM:1Q&V
M!_2UWTCBN?I\?2']2QO<9JNS47;W[2/:.'?ENPUB1>S,2DL,E=XE?JNA1&[I
MHNYD9R,.C).Y[9]NULHAQN??]P?S9VSV0V43QG<6,A7*MD'^QQ;&@YC'=8D7
MF/"US(B.029"LF!,@Y:48IR9TEHAM#1=IID50'#%:.5>C(VMJB>1)(I-FKQV
MV^S+[XA^3?NR['/X0_\ P.9"R;D^K9@MN2Y-26\=S.Z"DNFM6N5/K9*=]CW'
MZS=.GPE_;M[&E )3:LV3IES.FZLL,F+5P) %)%$DOD&:W;X_&)%9%*(V&HB(
M[\K>>-ML';["/#;7G]+(Q5FCU!1&KEULQGLHI3)8*=RW-SQSJLM.I>77#]W%
M^.0V>778VVTO$]NW;][<7OV?A'L\_9Z=;&C/G:X;$398'G1B]L9Z5\*^58_=
MHZ_;'AQ3)YU>2>5D\RU[',%#LLC2+7#3B@S<W,/I[%98V./%3%Z1F63).(N"
MLD:21>QL4*T>FW2;G15,)A,;KM\+GU]C&SNYK\_)R0UV=,O2>*LR</I7TG,L
ML<VJ)S-'V=*-K$K86DI;&,72G&/8MVM#1DDZ8/G+A:Q>22'<,$) P.D5%SG2
M3*#MV;FYHD&Q#.[7W-NY\HYZ_P!FWQ1V%>K9%CL=2=;8P=ERS0F]4L.-,F)0
MF6SF@\(66A-T(FJ/+8O5[I)R-DM-*@Y:8GGM>C9*'GC22/C3=W'M9;LY;H@X
MW9\H<'S[-[7\T/>/%SQ13-MO=.K6):TF^872NU:+-,TC*QT,<C(9J2Q^*&0)
M!,S*-N#R;QR9?*D/(TI\U@XMBW%*6=K1KAE(N$+;CZNESY_B8U4OQA<04Y?)
M^#K="DJW3L?YWQ+ S=KF,669-2>HEDG\AU&VUD61[#)J,GA9ROU!XTN GBR,
M(JSL).1@F4*X3E0=NW;E@X R>Q&>1=WMR6W$[+7VV*>+'BLRO-U2N1V+Z;#C
M8[K&QD]:I:C9=CX+'J"^,LCWJSXYFV<TO$.)&^T>>J%9ILK;F[IG29!]<FR<
M>T!\W!BH[=O/S]0-M'F=GRY^4PC;+Q<\0-YP;2\S0-;98Q/7.):/H5B24K>0
MKM!.6%1QK>(K*76R*I;=W8I&B-\RM5:K7I&+,P;O5H>&DG#XR;U--Q'L'/L<
M>?[X"SN'<=#L7VW;L\;V1XY.(()R>A$L&&KSJ)P%"Y%EE+E4KA%0U1OZT=B.
M4?U0TRA)N75J1DTLA6./@ - 5%$]BISN#>S'*RGY.,GI]?J[?? 6N0_G'LN?
M5&>3XU>)!.2R4>-P<QBH"G4BN3T8:YUF_,+2HPL##&CD<D/ZG$&DWKVIP;FX
M6]*RT^/=)6&,+1G:#2:DWYG2#:&&?WEO:T1L\Y WGLUN?GB7W!U9KY<L&Q5G
MR0]?OK3,7O,[GQM]"3]=(O7B9BO:%.4BX.T((6"-@#U%&%-76TN!W9((8X3.
M'(&*NHMD_K+[?/\ RB27.0&5AS1*38W[K\P:-S])ZXB(DQ(<U5KWFYI&L[]W
MN_'?S:\A(DB8)7&*=95XK %@B8.+?-]K[XY +RTC<J5^VANW-#FY@D,XQ[:B
M&P;7\=V%VYR55V>2"9$FYJ$1B\5+G=];Y>JFA&+TTA<V216/D6-D?%XUP"BX
MN5@$I 'UXR!WWSW^W;\-G8#;?5OV>;F]<.ZL90K1V=$3](1%<R8E*!SF5!(1
M(8H;CS&YN4 +YS!MMHVV_3U6]L1'&SA[XD.)&&PMC>3=1,]FB_9-R2_QG92V
M8UWEG>-<B2[&#>U5>U-U,?X]+2Z W8-;8M;6S%C8HV ?C IM;H\!ZNF0W*?.
M3V;?F\6*@?P6 V!@3U\F1;IA4L^,7C#LD-(N(#!])AI4+/=F015AA<D2LI5F
MM(QOE6\O:Q;(J#41(6?E9*D5*L0D\A+%C9:1N:I640H#6'&<=>\[.W,<XAQN
MS#6W[<P>7)FV<KD1W$QFJ!H7%#;[3!NWTY4LH49GBRH-,6V5RZ@Z+D&E8V>Q
MJTSTLW6FMDC(^QSMH;2MC+*Q",(:)D%)OH$6I699^[S=NSP?(MLR</\ >QY#
M\8;^N<:?%E-,JY;5N&]JWKTMCIG(NJEU>R,E=6]\><-,UFQ0OE!PD$*G6V5Q
MAD\=G8%:+RR\C*(LR/1F4&C21-UYGMYO5 L+,2;.S-F0PV'G\[YQIL=Y\XGE
MZ6.1)"8\I1LUQTMJS*R!\6Y"3K;G!4IA>O%9-*/ 60C.W5ZLOLGF08)V%X:1
M9L9QW+B+T\:)S)QVV\O;=ZH%0VIV,&?/-]KVLVWGC8RW&?Q+QK;"%7G,+O7M
MRRSB"5O=V2IV/KS%1E%=V''V2K75V4)8IN8D)!>=J<K4("JVZ-7JK@[66LL6
M]77BS2L/'+&Y]V9[><PWVR;;UYNXV;[,\2FX/<DY6OK;,;++BQD9BJY4385:
M(7J$O67T509F@4RR0"3U])<K:TJF>2LJ"LRR2;K%>(NV4@W0=-#H)&Y^D]O/
M\7'F MOV[3R<WJRB:&QOW7Y@T8<O2>N(@V-^Z_,&C#EZ3UPAE[^ A<H(1'?]
MJTY^ =IB [P_+KSVD48M)20Y#4,SE_WB7O\ 5&G4%ILOE2L=)3V_G&RQ>(EC
M+*/?^W:<WW[]@;QW=W;CV=PB4.WOWV VQH8?)5H<_P"T)V7YJ0W1VY+4CF6L
MG;,5YK)$:S"4CG:1K4NKQ U['-8MQ+S<FU?8XRG9NPP;G'J$RX3H\G)O)UA'
MN4;-(094%YUD@CXD@[,((BGS"BEV6[.>G9=L_;9XVRVS*V8#['W[<N2(S<03
M[/P\3%50Q^^M2>,:GP[9$R!9XV)EUH&(E[G&SK1E762G04BR&MDPY;&61:54
M9ZL"F@<\HFX<F3%+1N4\S]B?.88L(/%"G;8Y'->(R)<4G%;>J\X@AQG*TQ6G
MV'AK4=HL&%L/E"51D,A8+<3BKM%1BJPD:OD" L5[;33M1*'4K$;%B,@:1.M.
M&@I[=MO:\39S_P#+F-BS; UFWG+*,U8XD>*>W8+XI<RL^>OVV"1P+)U&&/BS
M(YZS2FJR,(OEN CZG96Z5ALTY4VKF>CK8_@C.&;B4BQ<1S-!9,&X0SWN/NZ>
MC^9A:P86<.]CG=_9O#0L77&MQ$(?9/EG&*ZI'P-)R!#5AC%&A;W(Y%=PCB]6
MJNI.HBI(G18VB1O%1@H6]TY(T]5VJ;2P#&*+2SU!IX[+)LX=G+$]NK9 ,&]=
MRWGL]G(Y?/?QP/$-Q:+7"\PR-?;SLZSS#E>@5Q6;H%]AZ55JLXXA\;UC'CJT
M1D20CJ<>Q^(;<ZN#:?8331K(1Z)T70IBRFG3>N%-N*' WD^=CS^;+; FV6P-
MYL\]YY1?SPJ,/\:F5<A<16,<,6VITVCLY6GD7OR4I%V>+E7%Y<8^<7-O7Z8_
MG)1LD6<_Y,I*+49_"R,VWI**]D<RJ)2)MEC#<+<@Z,NW3%7(:^X._J[=$=2N
M0OH_./TZEAN'0(0<A?1^<?IT8;AT"$'(7T?G'Z=&&X= A&GL( 6!FQ#W)DO/
M_P#HE]8YH ES"  0A1%MP)BJ_ 5^2KV&(TP?8ZQX/G-,5DHCW; ,:N/9^#^3
M6W6!2M"Z.6I94H=[9SEKF9,D@I(V "98B_%Y8Y=+<21LUI/0E4.-DQ_G-C<\
M/M\55W'$S0I"UR*&<9&YS<]&66O4PD*Y4C)#'C&+8.V$S.JSH-FSII,+M6Z;
M,_.F(\RJS? PW#HCKC;<CFV\][6<[;VVPK<G.I>.QGD&1K@N@L3"C6M] &9-
MQ>/2S;2 ?N(HS-IT2WC3HKY- 6[?H5>G5 B0I*<W*)AXHZ!$91RTP_D_CLQA
MCFON;W6ELD+2V%;SG'R1<TI6TY-8&K%%Q(QAL=/)^F0]8@4K#:<A6*\VP896
M'E9Z,JC!"MQ+>4F$7)(^5,HOA2#R) %N3*^W+DO DN=WWDG8PLS#I>$U<N+_
M (G;C3(&#A:RW@%;#>F<3#Y2J6-<RI-\FPT1E#%3%XCCF*>,W4A1GAJQ/6]6
M;D+Z5Y$OHVMRKF),9AXT\8@R;A*2<N,D$7#9>>VXWV1-[[L]W3ZCM=]\.7/<
M=&8?&7S&-Q:VK#6"GJ15KW=+1CG+LO7,=S$U=,OPEC4DF,*T;/;-'L8RA4=J
MU<UQ=5HVD<EPLS(/_(IT$U(PIW#H^^%]_KV#JV1+CA/O62+W6,IGRI(,GUDJ
M^?LQ5*,(RI\Y3",Z-%7!\;'R0MIM59283=4QS"R32>:'%N_9O6Y51%ZBZT9)
M_! V9;N??$;NV?LY1F-L2HY"^C\X_3HPW#H$(.0OH_./TZ,-PZ!"#D+Z/SC]
M.C#<.@0@Y"^C\X_3HPW#H$(.0OH_..C#<.@0A@;\/[>VP>;JFB/_ />*?2.M
M[1!5PN<E_P#=D+=@3QIB@!R &.77OC0!9TY[6XUH4U//-I8B36K2$:[LJ4%8
M3UYM,N7#2(<SA'$J:);RKMHDX=-HU9^#=-\X;(+.$6IE5$4E%"E(/,E 85A@
M2F?5(<YG5U,U )Y2$N>>-VEM3RLSQ!N??R"/3AEUEB1QC3'N=H6E5W+[B$;*
M7^$QS*RTW2(VP"93QEM7)6;:LI5ZP(7H]E7:!3=**I"&53*14^0 ;AT!O-&?
M?F0]GS;82,@6S MRQS_SYG;-V(.(J_.:6RN.8XA'$97U=Q17X*=:U_'4BQZ%
M>2N]^,:H"QME:?IJ*.64S4[ZC9F,FS7J0U-X@[-+L+6;#A0V;X>,_/N['8TO
MNS&WD899<NUMVV-<CQC\49)^NQ(8,J,VDZQ1-9!*>&"Y ;(B[2*R7(LFU#67
M;BW:RC(:K2TIFKOA?JF<6E\@PG%4$()[+QA&P#H @20]SYGNYW>N&Y3SKQ*R
M6"+]E(EF74E6W&QB=O%6".QMEQ"B(864C,6];%F%'?QQ<DKXX:JN+,K.&(<4
MU'2,LL:4;-"K"A((\5/@E-TC(EWRSW*SW&#LUS?VWO;[VS\Q5MNXQL_SU#8T
MY/$]BJ>4+WBR2L?35REY',\KC!SPXY!OC>UP3YY$N&+)V?*U8AZE$PT\HC-L
MPFFL2_8&L H]+# 7"4EKL0&+;"]H7R>V[L?NY8=;ASS1Q"O9;,5-M>-[//.*
MUD>QJTZ1LJBT3(3U%DK):"(W%A(R:#&)=5>OKL&%884=GS7;E14GE"#"S4"H
MM)8W*4@V#)2 +<@ %]IS.V(?=;:VY[$<[=/2S&VCPB&9$*E69:#QU7H"4GW,
M#7^:YXXS8L56_ML$6K)MVHT37HJ.0GY)^PO==;XZ;OVI%V$4XD#JOCO7:"*+
MF&2[,.2PZON&< 2V9%KC9RC/MZXZ\5>0?3-;@)>6AUH"5E(6*D)."<JD6<0D
M@]8-W3V(762V266C7*JC)55/V"AT#'+L @&C#<.@0C>\A?1^<?IT8;AT"$'(
M7T?G'Z=&&X= A#:Y9)^TA_L.W]MZAMV;[?MQ@A\_IV#6&<HHU6&W^M40\RJN
M4D^J->J#R)F_"+__ "';?'AH([DE#?NCM.ST; YUW=(C&J7LPF:G?D4E_7&&
ME6<!RSA+99_N%C_>Q+_4)KPNF?#F?FY?M5$SO#5S']T8?Q  Y '8-PVV';M^
MX)Y]>C&0YA[(W8JMVE /.)@ -@W'?MV[Q ._SCV!WCZ=3".;MD\(6WKE*D,H
M&PQ8Y#&TQ$YG<8@G&5P@DI7),QA16:+(Q$A7W3% :&C;6M=FY&I2<G(R:*C%
MB!;$WKTBX;1ZSMVO#,MS0HG'']3%K!!Q%<H-FL3"2PW%92E)HDI%L$J]/2^1
MJ#CU'%TDS<"=P-NCSWDLS-*%,#**:1A6:J@NY-$$3<^_:S?S)W9#=#X=O9TQ
M=8.-J9AL6R6;6^%'Z^)G-R)5:=<WU_91[>0CT;5.561O=[9LZU,K8TI"#B%,
MZ;RS\9IQT$G%!/,:\4[]2/C<WJRR[=LF?/LSON%A$[X1^A*Q4?*MSH*H23-K
M((*MG+9ZW.B];).4S(/6AU&KQ$2*%Z-TW4.BX3Y54SG(8IAF$;7;;N_#I"#2
M$&D(-(138-]]@W[M_/Z](0T>1 WL%3 /:L__ *D?KAZ5+55)^CUYZ$R(Y]9\
M]2_];_ZXOQN8 >W0P]P3$2/Y.K<3K)HOY[2'YZ5^ZC/3>"ODF-T2Y8CSXMSU
MBK-$GE"(QM8U;!(X9R)(XIR,@>!L$-Y O<3'L)-_"IK3L5&(3!464FS5"3@U
M)*)4%44TGQSD4*7KV^[MT^:-G8#O#CE#D/ZH1V=LQ7C$4GB=A5L8L,@HY0R#
M'8Y.[=Y!1I9J]+2C&2DF#M5LI5;(>48"SAI$RQT#ME&ZI44Q3,5<5DIB'^_U
M>KI,>1UQ@8&CI=S77MFG"6-MDNOXE4@4*%?G\KUUM,':+-!M2LV5:77)!NX"
ME6V6&TN4VU<:,8!\L_DFF[<J[UQ,(XW'[PK#T)ELD.V*3B>+ M5WU,NS)%]T
ML94YA.<9J.8!+QFIGC;W37)+2B!X,Y;+%D!X*BIR)NVUNUNSPC>U3C#Q1/XZ
MI&1G[6^UYKD3(%HQM4JN\H-LEK?+6&HR]CBY=5I7JY%3$@I!-FU7E9IS800"
M%812('?/6ZX@B*$:UQQY\,*#:17Z[S[KQ.6C(=DVC<99.E'UF5FAMI(J1IK&
M.J#IU;J^^/0[@1"RP"3Z!-Y =G&1*FJR.Z0ALZ_QL83I[JYL&$9%4[!5#.Q5
MB;O%P]J!I9$IK#\WQ$V&?JM7KU$>(RS E835>'1CGBDS(2R\AS,PD%F#*0=N
MWPZH@<PW>;9L'5M>'#G>/KABJLJX@+!;;A&RT>V:N)1LMB'+BH1 N*U6;HX:
MRSMM25V4>_AJ=;X&SV)DZ<D<U^&=*.)@C-1H[21=NPB>W;M]T;F]\8V(:;:S
MT8JEKG[DQOV+:)+UN"J4ZYD8XF7+.\J%7MQ059HI2=0";8/FSN8B#ODRJ,CD
M3 W2(F41'*W7"88<?G#7Y+"5F[D^CA08'5<K1=,R19(%Q+)GABKU: L3"D)M
M;3;FB%B@G3BL0Z"L^BTD/&3QPHLWZC5V[>>\3\?5$H<;9'J.6J9$7VCOW,C7
M)H7Z395]%RD'(MWD3).X:6CI.&FV;"6BI*+EF#V.?L)!FW<MW394AD]@*8R$
M,%$?>K7/WQK/^\$=KRU'X--^DK_>1QQX _*D_MIB6H &P=@=WH](:].GP1VV
MQV(L661;)*++J$11124654.(%(FDD43J*'$>P"$* F,/F !'N =6A$&FW'UA
M5>_4F!(>U)T3(%1>SU<R*_HF2&,8Z?I7ZET.) [)Y3$3LJ?8'UXAEX?(<FNP
MJKXSI!%J]6(+A9M'0_;J]4(<G^S'X?\ K62BEM4TM=E<B-,6)51K0;Z\GS6U
M_7Y*V-$U(]G6UUFL(K5X66L V9X#>O(QD:Z6<221R%3/,.S[-WGO:V^,#?C%
MP/).B1T38+'*V +C,T-6L1F/[V^LK*?@8.$LDN:5@VU>._AX1E"V:MOW5DE$
MF<$W).QB*T@1RZ! (.[;VYVY_OA#>5'PA?#/8JW3)Z8MDS2I&WXV+E(*Q9:I
M9BSL!6E*Y:K>DE8$H^*>I,I)Y6:/;9V)8"J+J9C8<SF-2<^/1@/I[=LX?'ER
MS;?"VB>,'$$I,PD<H\L3<ENMU#I5/.%+ORL@YF\C5!O=*RA:HA6HMWE"*^AE
MC/2JV/H&K=DBHYEG$69-=NE&7.6=NW\MNV$)2P\>V$6,@TB:^K8K [4;YA"9
M<]7;##QM)D\.4^LW>9C[X9[#'EJZ6:K]N@GM??>17S5Z1ZD4 Z8P(A,/AZW-
MNB%"KQT<-;):;8.[I-C)0"[1FJS98ZR3)*3SUU<H['9V](,PJ*Y;X1C?I:-J
M$D[J02K6.F7C=-^JU14Z4$(D9CS(-2RI2JWD.B2H3=2ML6A,0<GXH]CSN63C
MF*'3Q\FV9R+!T@JFJV=L7[1L\9ND5FSE!)9(Y 0A9Z0AEL@??E!?Z+3O^V*]
MK@5_^U)/Z!-_Q$N-*I^<E<ROVDQM<6F L99@$.8PW6<Y2]G:/0Q_8 F$"[]W
MG^'N 1#/H;YNM_\ <)W[J1%Z3YM7YQ7W1XL*YYQ5Q"UJ7M^(K&K:*_ W2W8]
ME7RT!8ZZ=K;:-+K0=GB_$K/$0S]8C"2;J(IR#=JK&OR 1Q'O'3<Y5!['Q^/K
MC:R]7KN/5"#S%G&X8TRMAO'\7C&/M4%EQ]/1@W%Q?TZ\:K.JM7Y>VSBKRNFJ
M<RM)-&]=AU5VBS:5;J/'ZQ(XS=N4/'=(1HB<;7#](UJB6>+M$N$;E6'L4OB]
M[.TB_59C<RU^%GY_HF[B:J:+N-+*1-:F).*5D(]$\A',Q=L4'?C#%%W&?;MZ
MX<G8=N1XP4?C H5[J]GMK"+G(F-J.8J;AV0?V-I)Q\/+2UR84:08S=4E$8=T
MI.0IV]]C2,5U&,:HLLDH$@$.@H5R6?; V^%^W;>(2C3PAG#=..Z&%:G;3,PU
MWFIB-7LJE%N5?C*E&1>'Y/-S:X6=O:(2$DVU,EJ%&GDHZQ(,EHU4HK*'73*Q
M?BV0A40W'EPPV E=\B7N4E5;)8259HW84.^.'+"54=5ED@,ZW3KACP,>Z<7*
MK%;2<IXLP5+.,SE<"0'!D$(0[_B5X-6KBM<0C6"*ZN.0L<6RWX\MZ^(K+7[G
M?*[4:I89]2-A)*SUB%?EEYJIU.87KC&568/92":H@B)8YZQ(Y>?M;;YCV:'+
MOMS<[=L^6%(QX\,#M(=K-VV6FJFU?LX6638.:E=I::@*_)TNF71Y.7V.B:LX
M"D1=>:WJ#93DK)KJP;!1VU.O+E,LHBW0[=FAY<;\1^(LM7"U46B6&2E+%3_*
M8RR#ZIVVO,G*,):9BD3;N E+'"14=9V,/;X&5KLB^KSF3:-Y%KRF6%!=NNJA
M#YZ0C2V/_ $W^],E_P!R7UCG?-3?S:_V3%5^ K\E7L,1JA/[XQ[\$K5Q#^ +
MZVJK_85#^;T/_B*>.52Y2?SI]BHE>(;]@]H#V" ^?6&.O&CLT_"U2O35GL<D
MUAJ_7HM],S4L].*;2,BHULH[?/G!BE,()-6R2BQ]BF,)2"4I1,( *$0>K?A$
M< OWUN2M,E,4>+B\AL*-3UK#4[Q'S]L;.,=XSO$A9W=0DJNPL58A8ESE"$AG
M#N6CP9[N(V0!YT,D0J2W/T;6<??V:&6=L]NP$A_5"^LG';PLU6,BY:<RBBP9
M2K1@_;CU;M:[DK9ZWGG2WC3)O"*/&;B&:5J8=6-FX;D>5]!NB>5;M?'F .D(
M\-6XV\0/G36$ND@[IUI<6ZX5M2-3A[+9(:+)"9&O^/*DO8[;#P:U=K#W(;C'
MLRZJ\3.OF#V2=(J1K%-TN9H9V[=MO;GA'F?>$*X48RJ(W1]>[(T@7#@Y43JX
MFRX61/'$I[3( 60T)U&\L(5-2D/4+.A9W+%&$7C"N.A>G=-7+9)V[>V$*,W'
M#PSI/*K&NL@+QTM;[ _J\;#2M2N45-,9J/MD?15&MBAY&!;259*XMLO$P;!:
M<:L4G[F2;+-#*L^F<HH1HX'CGP7=9[%\10EKM;C93O+2B1;MKCVY0Y(DTGCR
MP9+A+1*M+-"PLEU-GX"MODXRR-&;F+6<D6*9<I&+XS=;+MVY1MAV^[MR7B9^
MD(-(0:0AA;T(!>FPCW!4T=^S?_GQ;^?6WHC^W3OT*3^^F=4<K2#XT 9X;=)?
MU"%+3IV*K&)DK--N19PE>A+!.2[L$'#D6D7$.)1_(.0;-$EW3@4&C=97H&J"
MSA7DZ-%)10Q2#SY7]]^EUO\ C)\;U-\Q*O\ @"_WW^^/5A[+N/L\XTIN7\5S
M:ECQ]?X1M8JI.*Q$S!'DXAV)RH.31-ACXJ98F$R9RBA(1[5<O+S"GR&(8V7E
MWQG(()!L02".4%C$9<N<:D%AG(N1J;:L>V<\7C['C'(*$FQ<E4L-_0?/FC1T
MWQI3E&!37!I757B25HD8V=\>@79DB/X(C!PVDSQVZ+[O;O,(54IQQ\-E?6MK
M28N<^U<4PQD91,,:Y,=#(R*%P@,>R<-4P9U-T-RF8&]6>!JMABJKY7>0$Q))
M(2Z34J3I9&8=NW1&XLO&/@"H2=RA+'9YJ,L-%:UE[-UU:CW12P+-K>X?LX)2
M$B4(%5[/^-/HJ58J%B$G9FSF.=E< F0A3G?#UVA&VQCQ8X%S#<.H6/[N6:M0
MUQ&TDBU(2?C14BSL8&1>$(YDHQJU"3AFUG@!G(8ZQ)2)5E$$'C1)8C@B*$2,
MV#T!I"-(\@(J2D8:7D8J.>RE>6=N8*0=M4'+R%<2#)6-?N(MRJD99DL\CG#A
M@Y5;'2,NS65;*B9)0Y#(1NB% A0*   !W 'F_P"/5Y@[ TA%VD(-(0V>7.RC
MOA]$Q3_]\X#Z=:U4'1)8L>&4/^,D=NS1AJ \F8!N'M!C7X_,!DI3;S*-?S@Y
M'7H*[PD_ES?:B-:0"D*!WOTO"9RQR]#8]]_\&)[[;?N"=WYOSZ\)IEL2\_ E
M]&)7W/ZHM/\ G#^27Y]6?4WGA^$E!* %Y=_8E'?M_<E] #Z-]O/W]P#KT8R'
M,/9&[&97[CM#?X-S!YA[-R]OX.[MV[M3"(;PW";PKW%O=9F&KY;3 753)-=D
MXUK>;/*TZ ?VNQN"9:8TZ#+-K0E(DYVU1SPMNZN-HUR:5;O&PBAS.D3H0KV_
M"#P\,G%A<L<;-&BEJGK;9IWQ63F4DGLW>;92KM9G@(DD.B0+(67'M2DP0:$1
M;-#114&:"*#ATDJA&N=<'>%5VMSC6S?(<'#7B:>SLK!5S+&2:] Q[^8D)*4L
M'5J'BK*TCJTRLS^:F'%ACX9NS92BDF]Z9#D.4"0^7+_/V0Y85B>;.'S&$C$8
M@Z[TVF/X.1KF.*[35W8QPDE'$%'/X"IP:"J0$?NV]?>0[I1FQ4<'CV3Z/5?B
MW*\0,I,(<J3R12(6F+9%E[)%1U%09MI!6U.')2PQ&;QRDS;N1=  AT*KI=!!
M,X ('.J3EW =](1L4KC7%K<\H9)=B>WQ\!&VI[7R*B:1;5V7D9*)C9=5'EV*
MS>241),T5.;<RS)P @ % 10Y(4^D(-(0:0AHLB" 3]3'MW\5G]N[;[B/UPM*
MAZJD_1Z\>8ID=4<^L^>I?^M_]<5QSR^.70OLAVF(@![NT>K408NW?Z0 =PV[
MQ[M9=%MKM(@;)TD7_,C;&>E+I6?_ %#^PA^SPZ"8(D QDTP**IA.8"@ =(<Q
M0W5.)0]D8>4"B;<3;% !'8 #78C9B/\ G2_\.M5D<7M\[W.HU233NS2S8O;V
MB>&%6D+I$,WT>V4ATP52\JO4&DR]2+'B5?I"KF5\7-T/.FB/Y]NF$Y2N#3A\
MQ\X>OZ52%X"1?VM*[I22,Y,O5F-E:U_(%7CY-DF_?.VP)1L/E"Z(,V3A%9E_
M;D55D%E&K44$3#7X(\']CK"L=!-'-HM5J=T^6)(4MY'O)*EDKZ*\77F%C;"G
M$3+ES)%OK^L0UGO39W(C!25C9(/(: @6Z";$J$.PVX9<"6"JP$3"L)4]?K>2
M[+E"G2-7R#:VCBL6Z>>3#>W-ZQ/PDXF]C*_*+RMAC9JILG@5]5.1D6:L<!Q$
MJ+L/A"-?'<)G#3CA9>VEJJ$,E&2C68;2D]<+ :-J[9JE;649!0IIB749URJ,
M5L@6I1A66'BD(V?3[A5%J"Q6O1(BVWML@C>%7ADL%54JD73FDE6(=\Z@%6K6
MR6!4C)_"8]<85>1JKDLIXR#AA1E'-;7145-RJ&4=J@9^/C(.WQ\[Y[1"U^>_
M.(W\OP^\/EZF\@-I"KLYB;EW4D:^-4YJ8(N5U=,?5NEO/'6Z#\A6)Y>B5NNL
MTRI$2+T#4CQ$I72BJYT3"&D^%'A4ITS=;A)P:=8L-\D65UFIP;Q88B6%WCNW
M/,K-Y:#42F&[F/"OVB3E+,Y5B4P,@20<-G1@C!2:)(>?M;JCWQ7!#PQLG#>4
MBZ X\3$6$I'1I;=;G%>92S=Q NPM$5"*S2L4PLLHA6X%A+6!FV2E)B(8%8/G
M"[5R](Y0B25&H]8QY ]6ZA&!$0PS%AG19E<.7(>5+1/2-DG'/2NU5EMWLS*/
MG8I\_1I"L*21$TB$3*^Z$1YA^7JM7>_;RC6=N[?[X([OUY:C\&F_25_O(XX\
M!/Y4E^;&G+SOG$KNF$-B@4!'8?..VX#MV[ (AV (B/< ;?@UZ=/@B.Q%JQ&[
ME!PDY(FHV.BHDN13E.DHW52$%2*;^Q%,R9C <![!*(@/9OO:$<^<68ZX"[*U
MC:CC*UUR^H/32%(KT0SRO9+D,>TJ,W5\H*TN#(XL$@:&A*L]JM=FXZ%:&091
M\8SZ!@B+%RZ25=ONAVZ(>''_  7\.6+[&-LI6.1BYT)]U9"/CS]@>&3DW58M
M%+$4DGDFLEXJA5[E88AJT,0R*+=]S@3QE!!9-#.QA.5?@BX6\11D6^JM4D**
MQIEF<7XDTRO]PA3M5$ZW 5V2:S<MY>0.YJ#FMT^M,9F DECP4@VK\<XDVZZZ
M!W!WW=K0\^7J[9QO*]P:\.\,S5;UZJRK>'E:+(4&18M[Q;EHR?H\LE9$H^'E
M$QFU22C&O1MOG8FH+.#J+5Z$<H1L2JDQCXTC9#MR9-VZ<X]S_AOP%9,EM[,6
M.D$+]3'4?,OT(2ZVB.$4I"FMJ%'DL,.RE$F4C'R=.@RP@MGK=1)=HF]#<3NW
M9UG;K[<W/"$K < O"U5X1*O0>.WD;&)R4_(J$1MEJ(N_"T8_C\83D=(.0E^G
M>1#ZEPT'$K1;E0S0582)D@(,FT3>"A"QA.#CA\@K.[N+*E.AG'$S'SC,[RTV
MF095]Y'7)GD(4JM&O)=6/K4=*7E@SM<[&0K9FPFII!-S(H. 33(5#EA\:%0J
MMC*IQ%'I48$/68(CM.+C0<NG8-2/9!W)N"@X>++N5.=Z^<J[JJG,'2<H#RE*
M (0L-(0RU_VZY07?]ZT[YO\ WQ7OA#\G9ZM<&N;OG)S?@,WHX1+^_L8TJGYR
M4^Y3=*?AUQL\7\H1EE[!,'76;[1#;;]AC1'TAMV;=O:/8'G'6;0_S=;_ .X3
MOW4B+TC:M6[6*SYA#EI$13,'(F5,3F4.($+R@)SFYC'$  H"8YA,8QC!S"8P
MF$1W$0[$;4,/E:<X?DLA8QB<HV6KL,C,26J<QE!RL^,?,N4I2">5&SR,?%I.
M$U'S0(B7<1SAPNBJV;J.D^C$KOHATA#,V3A8X-&*&*\E66MQ;2,I4#0,;8TG
M75KLA(DL?,I2M QS&MP\J= _=OD\FRD#!NW!57+E6S@*RJJZ;)9JA#@5;!/#
MDT<WO'5:BTE5FMKQA?+I3$;/.O$8.U5F$@4J!.'C'$DHC%N7<138-57Q4I"3
M98A%>23<J<YC(&^?\^N$PWX7>$U]8AQZSJ[$;-1X6@S;RMM;'/%?L*HC0K/A
M>K)2S<)'9W6)^B-[53)",>BX96!BW>%DFRZJ*:Y8Y?NOU]LH<D(RV< 5(G;Q
MB6VU^[W*L-L2PZM>AH]T[?VN4;PCJQ1,Y)M8.QS\HLYBC3<=$A3)=*69V6/&
MJ.W9(QA%SJH3>GF]C<T(<">X/>%EO8J+>K#1HYK)T6LUO&E1=R=FF&\>G$LX
M*R8_JT$LV>RQ&<F_\AWNQUI@#LJ[E\%B62-XR[*R50F$7+\#7#8^BH6&>TJ:
M>,H=JQC%3.+O<Q=6&!9P%9K1JO;WI9PCJV5=]$4RJ-Y>OSJKV+DE()BL];*J
MD6.H[=C>#^U]U]\.MCW&>)8"==V^@Q30)>/3N=,>2+.5?O?%@F<@R]_MT,LD
MY=*H%<!?)B5D%R"7G9G7.T;F3:)IMRH0\XG[=N[M  $W8 [CZ_P;AVZ0C4V/
M_ $U^],E_P!R7UCF_-3?S:_V3%5^ K\E7L,1KA.7QG'8>R[9BLE\W:'DY<0W
M[>SX=M;=4/\ \%0<LK1!Z)U,>3?V:_+I,I/YP^Q1B51SB3;LW#8=Q[>S;;;?
M8![._P#+L'GU@CK0G[=&UJ;JEBB+FUC7M1E8.386=I,F3+$+P#QDLA+)29U3
M$2(P.Q46*Z4.<A$T!.<3D O,"'/$/</<-/"1.P=;R#AU9S:6+.SO9Z)R-"96
MNEGEI61;157ILK&/K<XL3^2DX92,Q[3XE_ .WIX[EJ\286Q%FJ:AH:_3YLAS
M;\[[,GAGR[(4UNX;^%V@0]DR)88)O0H^.R5:L]62[-;18J^XB[C<6;.,NDTK
M+L9%-RRAK"R:M6LM!-S$A5 _9R,47(=. ]MOFS$(\2W##PO6N[3[>*B2%O=.
MZ*4LT5&6FQF;,IFVS5WO51L=NJGE/R#/RL18+?=;)1W4Y'OAA74BZ&-Z!-HQ
M(TE\K=N7M]T1O /P)]60'J>&_C^&'@]P;2:=BZ^2!7D@O4EJZC-WNZV=2PVU
ME(5ZC8*DU!=N9=<[1BNVF*E5XJ&8K)1==7GFK.!;LSNU#G=NW;;$Q(17ABPP
MI= R"A5G<;;S35FG9"6B;%/QJTRYMSR-D)QE.$8R"2<M$.)2*82"42](JP:.
MD#G:(I)NGB3A"/)&\*6"H9>F/(FGNH=_C]:@K5*1C[%8FC^(#&L!+U2K-TW:
M4F55=HWK5@G(229N#+(34?*/$91-WTHF!")*:0@TA!I"&&O10->6Q1W#>IH]
MH &W9.+?#O\ F_E[-O1']NF[^!ROWLSK/;/EZ0LM!VA/J<CVG?"YQB4O4&"*
M/:7H7^X#YP\J/MP[-<^5E._2ZW_&3_OC=IOF)7Y A<-RID+T:2?1$3 I"D H
M$*4H;\I"D  *4I0[  H;%[2^;8,L9XA]DS%G"KD6_P"1SY*F6$I;:OC1W*7F
MN2F3YQLUQY2+7"S,"KD,E5+8$HRBNY*OQ4['I7J/8QCT&C%^*;\#$=*F/V[?
M?]T&VWOT6^^X]4>FI<*?#)-IHY#K< I:XZ]HP5VAYU2\VFQ03L)"R5G**=IJ
MI7,XZC&!KO:J[6KK8Y.'1;$MTBV1?RAG@.%2JNW;S0[=NW/#+7W@.X8LW+9*
M>X]7:U^Y/<J1[W*$LU<3-G8NK15GTS;5J;/0JM@B%&+8D]>5;>HW@Y2)73EU
M&'2.5XD%H=Q'7V]<2YVG8!Y@S#U1(?$.)\381FPCX6V24SD&P-HZO69U,VLZ
M[VXV^*J["3EK+*59DLC!,[I8H2(:6"P/&,0S6>(IE?&3 BYUEW8<]WB(DV"I
MA#?HS;^</W/GV'LVW .T=MP[@#M'4PC, [@ ^D-](172$&D(-(0VF6]AH[X!
MW[9>H=W^F5?V_D[?@[=:]261*/\ SE#_ (R1VV1AGG#)F'D]I ^^-?0"D*G*
M<O-L*C3O$/,#D/AUWJX'$G+PINSE3RVZ3UZ\E6(*+-=NAX2^6?[A8_WL2_U"
M:\+IGPYGYN7[51,[PU<Q_=&-GG7!]6XAL=.L:7*7O<' O9FL3JLACB[3N/[.
M1Y5IEA/L$DK'77+6238+NV224BR!047K4RB)RD/T:R7HQ=(YAV[9Y&-T$BX]
M8!SL;'DZ,X>DX 4J9>T0)MVB(F,($+OWFYC&$=O9".XCVB8>_4PCE3(<%&<;
M$RK%2F+_  ,71*3F/,]XBF=)M]MJLO.Q.6,A2UZA[++/D*^Y<15ZQT#PT9$$
MC'1V4@$O-N4)>%<>+'%NSY>SWA>_3VM_/GB--3X..,')-:RU$R;]3#MQMF4&
M%SD,AVY^G)R#DT1*9 &K(TT(B;N"S>4JZ4G 2;^])+Q[RS,7S2 A#U!W4O*#
M^/4X]?-M;;YH>L;CE?MY]L/]=N#_ (@DY!<*]9&;B2R%Q#39KYD*KVFYQUFF
M^'_)"UG>71O=VLK8&L;%3U)KI*E4,<N*0511@Z@XQRS;QD4Y>1R$[.W;JAM)
M;D%^WMN,[LSMT7A'MDC8L,Y:O<^ZJMXA[3F+*63HBM3CYHZDK?DEQ6TZS6EI
M>'>G8RU7I%7J\%5)*+.JK%S#:';J-DDD>1,D6^ SZ/,W)R0%NW+Z^QSAGV?@
M]\NKMK$A:\S$M#J5QA3J=%2DG-69>,B#P;&D,YJOO*LLT5"?K4C)5F6M\;(2
M$^$C&V.R/G L%G8#)'GM?MVSO <N7(=O0>G:V4/YPI<*-_P?E+)61+S::M9W
M%PJT+5 EXA:XN[-;G4->;U:CWF[K6B3?L&,]*,;6PC',364D(=J>*,9J)&@M
M&;2/-T>;>>G?R6$!EY_-T-]YB?VIA!I"#2$-#D7[X*G_ -%GO]6/UP]*?VJD
M_1Z[]F3'/K/GJ7_K?_7%<=?W]=NS?^W41V; ._[5H?LV'L'X-_/Z-7T7\_I+
M\_)_<IC-2> O\X?V$1X<582K.(93*LQ6Y>^2KK+V1I#)UE0N=VG;>SB;!)QL
M;%N&%-:33IPG5:RFVBVZC:OQ8IL&ZYU#)D*F)2)]@=KO&T_-:P8 =+9GE-]F
MR,.8\7/<ER&''4=*1T6&-LP5W),FF_:+.!EHJ'@[+%KQ+7HC$Z%TX6G&S@BJ
MQA0 K50JI#"(;3#=V[7:(053@FS(6P6&>R5DZ!L\6[S] 9L0IU8/8JK /%*M
M0\Q5Y%J$>R<QB*;B<L5RQU8'S&POK0V.\HR3F4EI11O#A'HCS<G*WGY>7EB.
M& N"CB/LL+ R&4'MLH,G$Y!+9KJTD;VK +W.>D:MC)LXOD&%8<75ZPL5+>TV
M=KXRKJ9*.0W-RL]N:O:QX]XDZAL]QB7-N39;)]MNQME$AYG@5R(VX>JQA.GS
MF-VC2J9ERK>%84760*[4KW 7U:[.JW*V@]4E(Z>9W&AS5LCK*P8-7CVM/IBK
M,E!%F\-'R41/;MV;([H=NW+RYPU;[@ SEDK^R#@K_<(5S$V.!D:-6[!<Y>X6
M*6RX@SJ&$^KTO?*^C8WM6@ZA'WFB66QL6L(P9V%O-V&8=@T;$</U[ Y?CZKP
MYK<W3\.:'ED. FTW*\/+7D/(19B'6M3"9C*FPM&2F<97J\^RW9[I<:HS)'V"
M*;.F,U09Y#'1U56*17,2U.Q<-TXI46HH@;.3[LCOY?B(\41P69KC93"R\YD6
MJ9"88]L6/I^;5L,UD-E+,Y''^)6./XQ[7WJ#MVL_:O)Q)2T6"'D'+-&SE91L
M?*OC I++O43V]KV;H,-G#^#JSMY+92-GRQ0)>]1UTS9,5V5:Q]DCV..X?,F!
MH;&;]S0"1Q&*\/(Q]^AEKJWCS%.46D\_(\G7M@(O./XV]N3J]L/-N=B=AZK/
MR#.XAR_[!'+$M/9&"R90C%*U=YN"5G5XV?R:A8,F0;3.-0R<+>^)A8$H^'7J
M-#KLEB"JMZF=!G*5FP2*<Z!(Q0(<LQ'W,S]L^SYQ/+A^QW8,2X;H>-[18S6R
M8IT4O#*3QEY-T9XQ1DGQX9(SF9<O)1<8^&4CXT5GKI==06?,)Q 0TB8:N(^]
M6N?OC6?]X([7EJ/P:;])7^\CCCP!^5)_;3#G9@PI5<TM**TM<O=XA+'V2JOE
M*$-1KM/4I=[8:BHX7C&%@5@G;4\_6'!G2@2M;?BHPD.1(5B 8A3!Z=.0Y&R)
M%QY_AYH['1M!< V(;;[<QLAVSI'<,W2'L2F6261 3=I2F42$FX@&WL0$=]@V
M[-P#S"-H1R'<>#!=%Q?0*ZSR6Z?9*K%,M;&3O4U*65(S2X$QW)5/$SFG)UEQ
M7CPM6QC.R3F<C(MP1R\5,X,Y=O'TFBV=((=LV[;K[.2T+4W ?D";L637=URJ
M^LD=D')E9LLHY4MUT8]9Z%&7AS;5:1,U^$"$19*P<09K1(>03L$NA(U5LI'O
M6;%G(R+1U#V?S[CO^&P1+MVV]%NG/D80D'G@]\QV5O$U^Y9CAIR)^Q OC:>M
M+M[?Y*TNHE7$%JQ@YQOY)?S0U^6QW*3T[&Y.DI*:%S:'5DB 3<&=*E82C*8C
MD:UB;[>UP>6$7:.$#B;1B[I5J\@T6J\-'<-"6/Z;$WNU0M!6M4Y><4AQ/E:K
MH6J,LZ6,V%(Q/$*Q46\22D$W%ZR2PAXV00DG+.4=FMV^Z&[SW?HW<O+D;PO7
M?@\\KS5(JU-LF;$WC. JK)D5FC-Y+;,&%CBZ1F>&KYX]9.S)R+R'IEBR%3'-
M>-,.W;]=A08UZ_WE4(T6*'F]?/VVF%EPJ8ES?5.+3/\ ?\JU&P#%V&+EH*MW
MR0L,:,6ZB&5U\9KK1K%HS<X^M#F:@P0DFDLJ6N)4*+:(TM:*=.')WA$.QY^?
MV[XZ@%4*!0YA$![>_<1  W[1'8?,'>/H'M$=(1454P[1$=O2!3"'?MW@ _E]
M ;B/8 CI"+@.41  'O[NP?.&_H] Z0AF,@??E!?Z+3O^V*]K@5_^U)/Z!-_Q
M$N-*I^<E<ROVDQM,6AO&V40 PB%TG>P!#;^X1XAN ]@]H!^7;6?0WS=;_P"X
M3OW4B+TGS:OSBONC580PA6,"UN6J-0F+U-1DS=[I?7;C(-VGKY+H2UZFW=AE
M6+"5L+IV[90+5\Z63AX=!0K5BVW#95<ZJZG8C:^&0 %@!D !D/.;PUF6N&V4
MR+F]IEUG>I:LC#8$N^+8:+AY.7BTW%GM$TWDH^<L*<<X20FH2)215%*,7**J
M,@=-XW4(<F^D+]M\1$K_ (/?+3<M@&TYJ5L,X[DL+R$;;'D[9GY/$\=VW$-K
M<1#ZH.6Y&JSNL+XUE$*#87DY)KMNLSE0\=&.'MB4EHW#S=MFSJS@Y<G?][WR
MV.[;6:,$+P7YXQEPWY^J4;+56UY.RB^P4C']4[)?XHLP>@R=2C+I:;99K#9$
M+ A(WI@SG;':F<%*MR F^D(]H:3>.%%'T]NW;VPC:T_P?&0J_.U&Z'RI&0UU
MJT;3(N'DZZ^OJJ=3@H[*&=KA-4^"\ISBWEJNQE0RU"8_JAK*B[4"*J2 N6[%
MHH@Q;QVW[>CDOZX;+\N1YN1[??L,:J'\'/DQ'&=<J\AEMT:V5QK?)$LXI=\A
MO&$ADN3J^,X2G912:1JU6\F2:,U3)^WS,2NE,B6<LJ[TLM)2:SV05GMV[<L+
M[?:YZ6%M@&YA>/7:O!\90MTMD61G;O2)Y*6R%2+[$LYIQ?'Z&19.G<04)F*&
MELF-G\B^CZ_-T^F1KG$%05I;,[9*!>'=NDB,F\="LG;M_*')LOMS<<V66^&P
MM7!GQ27!M'54LJ\5BD\KYGJM<D[E?K<@QI.":[4IB$P'8GY*9<FLW.W".LDN
M]LT$<QQ,=9M .; W@I..;KLX]AR[=LH<SN6?(<_0&%KG:8D;/<%.4GEM=Y##
M+CZ7LM=L25EQ\H>;N<>[C 4R[*7:RL1;MY]I7BO+=0'QZ"NLLQ,Q:E<J$(FE
M$)HH)S$<W1VV]$;3P:V)\N8IQ5=H_-%5L,%=;%;H.PS$O8YIF]=6:9-C^IQ=
MA>-XII,V0T>FTG8MZF\FG$Z\6NTXK*VOH&*,@FV*^^)/JV=K=KQT(L?WOS7[
MTR/_ ')?6.=\U-_-K_9,57X"OR5>PQ&F$_OG'7[]5C_9B^MRK_V'H_\ ,Z)_
M>TD<NDRD_G%?LKAR<F82J^3[EA^]3LQ>XZ5PG:Y.XU=A5+K.UJ!F)23@W, L
MUNL'%N46%OB4VCM11K&RY%$4'.YR?L:SE%?7/LOV^//LCK=OOA=W>$"S4NS5
MP6,'*%GX"4AC1MH:JO:[($DF*S,S.=9MCI+N8ER584I!!!5)51J=4J2A#B40
M0YNG=RQRZJ/ ?GAA+XSD;+G1TE#4="PLZO4ZU<K>#;$#=>:\HUXM5M$['2-L
MR4FA&[0<F2ZR$0^=PR#.">2LI I+,5W;L>LP['X=NAKH6?\ !N9HFL/0F-%,
MH5Z8?F/926E2Z6W)\U!.+)+PM$CF^88)E GJRK>YK.JG//'E;E?*<4=>\SLB
MZG)&47>N'SM\>WLAZN;<-EQ:UMK0_P#EC@PR)?N)6UYCKM_@J?"VVLQ4.M,1
M[R]-;[$$AL9Y'HAZZDPCYIG4)*N6"6O,/9I!PY00E&CBG1P(=.["/>12%]]M
MVS(;/-ZS"&LW SGO)U-EV=\S77:M=YJ7EW3:S4!*RR"M*CWC[A==,!J3BW*/
M@3DF"^!K)+)&=,?$"R]K8J@@=1K(N7KMVSB XY<L_7>Q/J\T.U>^&C/DGC6D
M1M(RO#Q=[A8IY!2\/+O[<3&$<VEL06G%K]Y3!C%T[V0[>6GV%^;HVV;L[MQ+
M1HMS3;1P*<H#FAYWRW#[MWP:$GPW\,>;Z9Q"VS*%[GVK2MPDA/UN#<$LENF+
M+E&LNZ#BV$AS3,6^L<E582G0%CKMHL5<9IM"6%*8EI%59NQ!^_=3#MVW]LKQ
M+G=[.7MRVW6Z; 8#!N [_P#&W\O9^'LTA%=(0:0AA[Q]_;7_ $31_P!N+:V]
M$?VZ=^A2?WTR.5I#PD_D#]HPHJC"MK)B4E=>K/VS.?@[#"NW$6^<Q<F@VE5Y
M1BX6CI-DHD\CGZ22YSLW[15-RS<%3<('(JF4P<^5_??I=;_C)\;U-\Q*_($9
M<+XI@,'XOI6)ZM(6R6KM#@6==AY*\6F5N=K>,67."2LW99I=Q)2KO8_+T[A0
M (B5)%%-%!)-(F6,YO??N#>H6',(A=FS@BM^4\ZW'*D3?:] 0.1HJC8\R%7G
M,$]=O+=AF$AI]Q:Z*^>HO$2$-.W1O2739R4IDFU:"ZQ2B1E+"51-#MV[>>&?
M>^#\X@Y%U%1@YSK<-3([AVIV#'L35&5EJRLVWKL'BJ+55?+PSEO-_P#(W5,N
MBD-(%LNS2-N35FPA(EZREY&;&_9C 6+M?V?RSY6C;W/P?>5W4[F1>FY=9,:5
MDF]UJW15!4=3T0R@ZY6'E92>XS;OVZ,LU;UO(45%"ZN#YQ"2\@$]6ZP13RK6
M7#V 9NWL[<^VS0[>J^^_W6.^,T]X/K(YC7=K2<E1]23ND5 *2-L\OW]S?I>:
MCN&US@M=.T6)D_C'LYXE,HQUTCK&=RVF%G;A\HHW:2"#5T+MVZX=LNS<PA V
M'A2SI2^)G!J$'7IV_P"!*5DQW>*VWCK<K'Q&/8V:RC*S)8EP]L5D>RD<VH56
M>)2+J,:5V1:Y!;%:4EA(PJ2!ET4#EDYVN7?I]>TQVC#_ (WTA!I"#2$&D(;3
M+?WDOOWWJ'^^4#K5J_FY7Z90_P",D1@J?F)G,/VA'@H/]SE/\XU_\3KT-=FG
M\N;[41K4_@J_*/M,);+/]PL?[V)?ZA->$TSX<S\W+]JHO.\-7,?W1A_4/N/D
M_P"H77HQD.8>R-V+E! H (]NP[]G?ML/-MVAYM]_S]FIA'&VHY-X]ZU4+/4X
M;'[]A,Q.6,[25<E[MCZT7_R_B]I&9ION/WX3"5HKJ"$S<[A#5R@HU]0J0U*"
M6A09H2PV:%DR.P[?= L,MOFNXY#O)>S[K&''3XCN,_KU>UE<+O7=3J,;-6EW
M46V*+>D^3J59EJ!(1C.FWYW/(0V1K[E6FR&0&\758>,!>I6:+BFLH4WB;]M)
M(';?S[/NA&W#*G'4^90%X;XG<JV_%4ED&)3J\#7K=&U:ZV!+&DZX<6&59>47
MLC+THBL]6@J#)(BCJ6LM=FF+5<TD[8M6B'.1T=.W:W7E'AR%F3C =2.(D;#%
MNVE<A)J@Y*G)ZC8FR>RKUPK<%>[N\M#N[7"<5JPXMBJW4(&G*6BKV6K@>R*6
M&06B2KQ2S%9FAVOL+%VMORY(T^#N,#C(S(;'CF%A\>N8V<M:*EN<R6.\@(&J
MK201QC)HXWLJ%)"\DKDVO4;+;KI6;@^DD*[*12=31EI&.D$['').W;MN@=MW
M.S=]_1GT7[2)_<@'X?PB&X]OY>_?S]^D(OTA!OI"#2$-#D7[X*G_ -%GO]6/
MUP]*?VJD_1Z[]F3'/K/GJ7_K?_7%<=#L_NP_^^H??\'5>'W_ #:OHOY_27Y^
M3^Y3&:D\!?YP_L(CR8J3SPA)Y4-F>1Q8_AG&0Y%?"R6-F%H9R+#%9H]@6*99
M&4L2JC9W>DY0LD=^O7MH4[,S7H !3I")]GMV]<;=K,^5^=SER,WG>(P\7ZV2
M2Y:X4"U@U]^Q\M:[V&21IPY4(P*N#:FEJ 6$<31\@_.'3'GABT;5XM2E3>/>
M6'22Q66[MV\\5.7+;VWROVS$-;8<\\>P-VS**Q-6*^\C,E2N,9>R6"@Y#E(*
M6?5>&F'Z%VC8JGDM=C'&N391[6H>"L36,51A%(N?1?.4G$A&KMD-N=O6_P -
MV<:O(>4N.U5"RBG#/H"#;WZ G(J4H.'9Z6L$%1*IQ:HX]G:XLT=3$R>Z==,*
MIH7UVYC(V+DVT+Y2?QC$6*Q#LW;U=L^J)C7Y0XR>(-OQ$9GQ7B^*K$A&X^3:
MP%?B7%*FY>2F7XIX:F;1:8Q]!R$K*3S['-2NMWG;+3$*PU<.$HZJI0GEQXO,
M,TD/;?MT[;\V];)YIX\H^2C7GV-J?<8].G@V6A83'M\A6UCMKG"&0L@1L^VL
MUDDHB4@8H]_KU+H[Z%F*:R7:O;4_8*+I/?)9B.W9H1?6<T\: PYI^RU5E,04
M1BC*-Z5)0<*WKK;;+#'R]2AZ#3F\-D)_0?(]D;#+6B:DHI./?)6&,@&1H:0.
M89 HNP@_JS)RVY>J[[[9&&V@LL<<-C<5VRVFAW1BO8*16V[?&S#'EEBH)6T5
M#BQ?5J<M4M.,G3.3JSZ>PH:M6=6'F'A821B'SR0:L'L5%OFIE^N%LN:XR^[L
M+YQ[6'$#X0.?IZSB#QRW:SI99TZ=R5CX?[O!^3W<;AJZ7.?QZWJTA=VKR29Q
MF28BI42%R2B]6C;4G8GK:):N7\>5Z*#QUBJTA(RU9KLK,1QHB7DX*(D)2).5
M0AXR1>Q[=R^CCD6 JI3,G*BK8Q52E4**0@< , AI"-[I"(D1'WJUS]\:S_O!
M':\M1^#3?I*_WD<<> /RI/[:8=#+J6=EV]&#!3_%[!VEDBKJY)-D]C9GK=UB
M<AW'7!E3@K*R!T+VNF+3R O,"I"IF!P+T@[I[>G&0ON_EU1V.=_,V>S/9OVM
MD7AUG9W8,77B IF>^*N19=/S=#XUT)@:@J8!#9(5Q(!]NWDWV].K0CC9AFV\
M8K"9-&,ZOE8;G88G"$7E*]9C@\D6&M5*_P ]D].#R\VJM/<R%?QU(5R!JR[Z
M?J-AQN_)!LZ\WC.LAGQU$NF1'(-G5:VSS/[87<QGWCZ;L[LY1QE3XLJ.4DZ@
MV*?'>6II[CZN(R^36K*TO$8JKND,B0-GC:_C18TC11LJE>/=9-]*HQ[%!DDU
M1/G;[\K/LSZKFWBR?>./"W163JMU9;0S)\7R;39&C8_N35U7YRH3W#Q)(6+R
M\\LC:0LE?M2UMR>W\C*Q%;<*UVH=$HY:R",PW.AGR=MOWB^Z\*9//O'*UMU*
MK;[%23Q8L\[@EQ;8EMJ,)DN-99QR10++;7]M"S.83#+>M8EK5(RO L9U:6+?
M'-Q")ACJHF;)MXVY;K^OGZ^:\+;]_;V@[F@JG$YQ<V1O1I61PW.U]F>XX;K5
MW@7.&[W'VN57G*2NKE4M/4F7A8!*'JM]$J:MHGI&-@!K$?*!"3LS,),D)*>W
M;H[7AZ^;S]&49H3.G&VO@7*%_LU*J4/D&%L=,+6Z1%XRS!)S\:U7DED\@T].
M.<UYBRMDJW:)-&5%N$4ZD*@Z?O1=VB4BXH"/DD.W;MY[0CY?/_&?C9/-2B6.
M,C9$>RF0<QFQ=&OL*V&3-7 7QUCBR81K!5ZE)^*251<RCR\,;#80>N&,?-QK
MJ'?3L<Y3;D<H6W@9<SN,]UK]FA-6?)O&X_R9D&VQ6-;I-O*G%N*Y6\<)T2]T
MNCE>QO$.@E7Q3NA;.$9?W-GQ=%Q5ID+!'-D8R(CI^1B)1!RU(=DW0MMY&NVW
M++H^_*'SP7F_BYG,CXNA<LU9@]I5SBK&J_?4O$N2JU(5IVRCG#MF]R1(Y'85
M:'@(]&18.J\BPK 3LNYDWD&MXD^AY1:9BT0]VY_N[9_"8%\$1N$$(AM^U>?
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MI3B*:-:6)87J)=W8M]\:<\A4Z6"6&!9?F*3Y]W.\;C%?L8VS=@C^W2:[@_\
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M<WXOROZM,7XJNB#C>.D0<WXOROZM,7XJNB#C>.D0VN6A_:0^_?BGAW[AVW*
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MAPN;Y!'I _AQY'^0;&[8O68UB-(#MHY:\_6%4>3QA!1$#@4(4 -R\_,)3&*
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M7]9?K-.]\S<KH^$.#KW'H^,5ZN2I?NV#@WHV AMOR=*'KTX!,'C#S-#4S$Y
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M\G2>N#JI8O<ISZT_K].'4WC?JCW(<#/)TGK@ZJ6+W*<^M/Z_3AU-XWZH]R'
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MWT[=4(O]EMW%W_".W?V_XOH^#O\ 7I" >;S 7?S;B/Y?-I"*CS>8 _*(A_\
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M;W9PU@YS.;6V$^J\*JC\0_%W$9#=X/P38X+%/7_.N8H>4OEFQO8<KF816)^
MC#&8X1VSAK/<6L4Q>3-G1DJX)8Y6-KI"O=T8%:2;J"X+SWVZ,]WWQ"0,((/X
M()OF79N<"_FW0KL0^$HXU\JY>X4X>3;XQQU%Y!P9P89$L5.MQ:S4F>6W.<8,
M[[-$I4%[0^Z\J/ZI('7AZE6:0F^-#3,*<EO!^PF&QVT,.3IY,FSL<\SNO$E@
MXN2"H=&3VL]G.3&V1;Z2M5A!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"
M#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0
M:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(H8I3%$I@ Q3 )3%, "4Q1#80$![!
M0[! >P0[!TA&(&[<$/%001!J"70^+ D0$.AY>3HNAY>CZ+D]CT?+R<OL=MNS
M2$9"E*0I2$*4I"E I2E "E*4H;%*4H; !0     -@#L#2$6&01.JFN=%(RR(
M'!)8R9#*I H&R@)J" G(!P  .!1 #!V#OI" J"!%%E2(I%5<<G3J%3(51?HR
M\A.F.  93D('(3G$W*7V(;!V:0BY---(A$DB$223*!$TTRE(0A"AL4I"% "E
M*4   *4   [ #2$7Z0C$"*)53KE22!=0A4SK F0%3ID$1(0Z@!SF(03&$I1$
M2E$PB !N.D(M%JV%'Q86Z MQ[VXHIBCVGYQ_8N7D[3^S^Y^[]EW]ND(O.BBH
M9(ZB2:AT#BHB<Y"G,BH)#)B=(Q@$4SB0YB"8@@(D,8N^PB H0$222Y^B333Z
M10RJG(0I.D5-L!E#\H!SJ&   QS;F'8-Q[ TA%A6K4I>0K9 I>F%SRE13 OC
M GYQ7V NW3"?V8J_=\_LN;?MTA&?2$8R)))<XIIIIBJH*JG(0I.D5,  90_*
M <ZA@*4!.;<P@4 $=@#2$ ))%,H<J:93K<O3' A0,KR%Y"=(8 W/RE]B7F$>
M4O8&P=FD(L\6;"DFW%NAT"71]$CT2?1)]"("CT:?+R$Z(2E%/E*'()0$NVP:
M0BXB"":JRR:*1%G'1BX5(F0JJXI%Y$A64* '5Z,GL$^<3<A?8EV#LTA&72$8
MDT$$3*F2122,NITJQDTR$,LKR@7I%1* "HIRE*7G/N;E  WV -(0'0144254
M12.J@)Q04.F0RB(G+RG%(Y@$R8G+[$XD$.8O8.X:0@4115,D=5))0Z!Q41.H
MF0YD3B42B=(Q@$4SB41*)B" \HB&^PZ0AJ<48LQ_C(<B*42LLJ\I?<IW?)-N
M5;*O7"LU=KB\:NK+.KJ/W3LZ"LJX:MUEFC,S>.2.D46S-'<VZ(&WG^X0[>D3
M&(B"":BJJ:*1%5Q**RI$R%46$@<I!5.4 ,H)2]A><1Y0[ V#2$54225Y.E23
M4Z-0JJ?2$*?HU2[@50G, \JA0$>4Y=C!N.P]HZ0C)I"&B4Q/CQ;.?V:5:NQ5
MR>7%C;&Q;:HJ].\+2&UN=VI"!*S,Z&+*BE8'3B2([*Q"1!544_'.@ J0(C:!
MSGSV'LAV.@0!<7((I X%($1<=&3IQ1*83@D*NW2"D!Q$X)B;D PB8 W'?2)C
M+I",1T$%%4ECHI'60Y^A5.F0RJ/2!RGZ)00$Z?.'8?D$.8.P=PTA&72$&D(-
M(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA'_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g367280g20j13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g20j13.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[18^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(R.3,Y.3@< @4
M0$UI8W)O<V]F="!7;W)D("T@27-O;&%T960@5V]R:VEN9R!$<F%F=" M($)U
M<VEN97-S("T@9F]R(%)21"YD;V, .$))300E       0R:5:YYIOB"G (UK:
M<F34H3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              $.   $BP         !
M                          $             !(L   $.
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   $.     %)G:'1L
M;VYG   $BP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !#@    !29VAT;&]N9P  !(L    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@
M  $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    )    L(=I  0    !    O    .@ '"2Z   G$  <
M)+H  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HQ,#HQ
M-R P.#HS-3HQ. !R<C(Y,SDY.        Z !  ,    !__\  * "  0    !
M   $BZ #  0    !   !#@         & 0,  P    $ !@   1H !0    $
M  $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !
M  $              $@    !    2     $X0DE- _T       @
M /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    D   "PAVD !     $   "\    Z    \     !   #P     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C$P.C$W(# X.C,U.C$X
M ')R,CDS.3DX       #H $  P    '__P  H ( !     $   2+H , !
M  $   $.          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M 0$! 0$! 0$! 0'_P  1" "- ET# 1$  A$! Q$!_\0 'P !  $#!0$!
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MC05O#".EO)(IAP#MS>(Z<[ K[DGDISU?=G$<Y".*]G'MNJJVYXS.^)D21NQ
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MIBE,4IBE,4IBE,4JEL&*ORM7D#**"D%/HXIIBNX,B0XR-O\ $,FV/+KM4CG
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M1(PKHP&:I@D984@$X$[YL,UGIM&DM13;$W+5-1%3%6)"V@RM?68K,DA386X
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M[2*>X37ZATV(U5#W]*X5!Q9U7\E:7L"HQ41FGL6#--!K#215R'*T!853*IF
MQQ)X?0.\.V^COHSCZXM\Z<]=G[>8<T1$MM1&Y 6"PV\7"I;S12?MFW:!C SG
M)P,&U5J]W3DJ-&;@MR@_'+Y6M]36TAU3>P)2VO/(;LY\XQY:M^?/\73V:JM]
MY$O_ $4S8?L?8'I-,^:VO6ZQ7PGR?<ACY<Y]53Y_BZ>S55OO(E_Z*8]C[ ])
MIGS6UZW3PGR?<ACY<Y]55\/AER#?\I./%)W=)5EK3WEN<6=!2OLI-:8;,0KU
MIF:Z04Y!=FP57\I3BRNC 9JGX1UC) )RD YM%:STVWI/4<^Q-2E3$1$Q%"0M
MH,J<ZQ$9DG+:5N!.TO%(PHY R>9K9.GKLN]VJ-<ELICJ?4^"TE9<">$^XR,+
M*49SLS[4=M1LYUR4 PM%"+-3$#&J*04L9 DM:*- **$+(( 8R25MW1JUPX*4
MP@!U&C*51*;]:HY;'$$CY/T>(DKB7$LL2'1UAD*+,.=) /"5C*H=ANZ4DCL"
MW&20,A*QXU635:FDO0][S;1X;V N0RP2-Z>>';I;RH? ET#.-R>PW-\U?6:U
M#&/Y0\:M*O;'KS8V[=54JWQ5NMDA*UI]::^U?1X6.PR%C8"^;L82LI(.GD;+
M-'RR2T<L]*=R;RZ6FW?C2SS,UZ6U1?!'N5ML5VFPGH4-MF4B+(4TX8T9J,X$
M*=DRU%*'&5H24NAHA.6V8Z"EE&/)O5EMI<B2[E!CR&WWRXRI]H+0775/#>EM
MID)4I+@604%7C94MQ1*U6QNU[Y0<>-Q<68FJ:NW'0;W9$=K5:65A*U8&4G(D
MC&L+:4'+X6R"AC@W06=MDU5!Z%(99,!']<&;3Z'=+:BLNJWI=VLMP@156B6R
M'Y,=3;?%6_$4A&Y7+<0VHC_=-87KV]6FXV1#$&X193R9S+A::=2I>Q+3X)P.
M?:H#EY2!4$.Q%_#3>?W%;[_GVEYGG3I_(<?\<M__ ---K&.CG^4@_P"'R_[;
M%9>H>H/V@_BSCVM^5U-@_P!X9O\ Z(DO_4UL]H_\(8_KFO[::\WOWIW^K7_9
M-?G0F_W0?_QC_P#RSZ0).$@_MVX%<F'M^\/)[PR>7QGXZSGJKSOX;M*Q76KG
MDGJ-%PV@XINNBI<(PITED6*":J9RBKU Q#E,4P#ZA <X0DZ!UHN3)6G3-W4E
M4A]25"(Y@I4ZLI(Y=A!!'O5TJUJC3P;;!O$$$(2""\ 00D @@\P0:[[S]^&/
MM+Z@^V,7^ESP\'^MO1B\?(W/HJ?OIT[[LP/QZ:>?OPQ]I?4'VQB_TN/!_K;T
M8O'R-SZ*=].G?=F!^/37BMD\Z>'DGKJ_1K#D?J5V_D*5:6+)HA;HU1=T[=P;
MY!LW13*J)CJK+*$33( =3', !Z\K[7H/6;-SMSKFFKNAMJ?#<6I4182E")#:
ME*)/( )!))[ *IINIM/N0I;:+O!4MR+(0A(?3E2E-+"0/?)( ]^L'DXAXAA#
MU"<1 ?Q=.\/IZ_1^7.YQR3V=@_0/@^][W97.':>1R/(?/GR@>_VCS@@^6LY*
MC\[>'+&EU%B\Y(ZC;NV57K[1T@K<(PJJ#AO$M$5D5"BH E.DJ0Y#E'TE,40'
M.$IN@=9KFS5HTU=U(7*D*0H1'"E25O+6E0/E!2H8/EKI./J?3Z(["5W>"E09
M;!!?3D$(2"/A!!!\Q&*]3Y^_#'VE]0?;&+_2Y3>#_6WHQ>/D;GT5Z]].G?=F
M!^/33S]^&/M+Z@^V,7^EQX/];>C%X^1N?13OIT[[LP/QZ:>?OPQ]I?4'VQB_
MTN/!_K;T8O'R-SZ*=].G?=F!^/33S]^&/M+Z@^V,7^EQX/\ 6WHQ>/D;GT4[
MZ=.^[,#\>FGG[\,?:7U!]L8O]+CP?ZV]&+Q\C<^BG?3IWW9@?CTU\K[GKPS,
MS=%)R5U"<QFZQ2E"XQ?4QA3,  '[+Z1$>@ 'TCDR= :U"D'O8O'):#_ W/(H
M']505JG3I21W9@9(('V]))Y'L'E^ 5@I/#%.[='*(&*=PL8I@'J!BF4,)1 ?
MH$! 0SO1'M$YY':G(^\*YI4<J41V;E><>4^?!K@#UA^3T_F].1/8??Y?'4M9
M2O91<J^.&I>(D!3ME[HU[2+2A=KN_6@;'8F,;)ILWSY!1FY.U74*H5%P0ICH
MG$.AP 1#U#G*G2WI34MXUB],M=DN,Z(8$)L2(T=;C16VE86C<!C<DD9%;IT-
M>[1;[ B/-N,6.\)4E9;=="5!*U)*21Y,CLSCX,8JY3Y^_#'VE]0?;&+_ $N:
MS\'^MO1B\?(W/HK,.^G3ONS _'IIY^_#'VE]0?;&+_2X\'^MO1B\?(W/HIWT
MZ=]V8'X]-:#SWX8@ CYR^H/1_P#;&+_2X\'^MO1B\?(W/HIWTZ=]V('WGTUA
MY\ZK=6;YRYWS<*;.1MEJ\_?'[^%G8AR1Y&R;)1!L";IFY2$4UD3"4P <HB B
M4>@YV5H*)*@:/L$.:PY%E1[>TT_'>24.M.)*LH6D\TJ'+D?/6@M2OLR;]=)$
M=Q#S+LMQ;;K9W(6DX 4E0Y$<NT5$W,NJQURHB +)"(@  H01$?4  8!].2J]
MJ>6>78.VG[<ZSGJSSPX;MX"!:K\D]1).$8>);*HGN$84Y%TF**:B1BBKU*<I
MRF*8H]! 0$,X-D:"UHJ0^I.F+P4J>=4E0AN8*=ZB#G'E\GO5TLSJ?3Z6FTF\
M00I+;84..G(\4>3MJ1-!%\O-[%DE?+3Q$O9(61K3M=2048/X=6B5,HNX8SNS
MSK08\[\CTIABHFH,S/2.CJPCQZ9U89G'9W#2Q;6@$!]F*\U*0E+:7$/)N$W"
M)&R)&7Q@WPS]N>FN!!0!(0WPXS%WC;BY+42HMK>;4RHJ6I"VS&8\9HJ>=3L*
MMW[TAA!5N/#4LJ=<J9EMJKIBE<*ZZ+5%5PX4(B@BF=5994Y4TD4DRB=1550X
ME(FFF0HF.<P@4I0$1'%*H#YV_%/VF^/8?D'<^N.H?D'_ &28I3SM^*?M-\>_
MOHUQ_23%*>=OQ3]IOCW]]&N/Z28I3SMN*7M-\>_OGUO_ $DQ2MIN7'%$H"8W
M)SCR4I?2(FW1K<  /I$1LO0,4K8ER\XFKE[Z/)_CNJ3O&#OI[JUL<O>*(=X.
M\6RB'> ?6'K 0]/JQ2N7SM^*?M-\>_OHUQ_23%*>=OQ3]IOCW]]&N/Z28I45
M.9G:,TO0NC9O:7'=YHOE7>:U*0SB0T]!\F-74VS2]-,Z'XTR53<.WTRG.V:*
M8%!:*JZ38CJ95.*390ZZ:;5PI7S]GWVMO##M'*\*NCMB)0VSHU YKAH;8)V-
M;V[4G38YD7Y5ZXH\73GXQJY(=(9ZL.I>+Z 0'2[1R8S8BE7-\4IBE,4IBE1/
MN^\M&Z,V[/K[:V?KO7;^V4FH#$(V6>KT5,RC*'EK>DLN+<T"RG#QZ#AV=-JJ
M_LLQ'F7%X2-BX94C]:4RRWV*_7^S1T6BUW*Y-0Y\WC*BQY#L=IQ]F"H *ZRM
MCB+2@%26HK+@2$%UYX%M+5BE7.V6RX/&?.AQ%R(T;AAYUI#JT-N2024AE+NQ
M)40DK?<025;$((<*XT\O>:?$^X\7=^56K<@=73UCL.J[E$0D-&6J.=2$G)/8
M9TBT9,VR:HG7<.%C%322( F.<P &91H[1.KH6JM/RY6GKK'C1[M#=??<BK2V
MTVAU*E.+4>24I R35GOVH[#(LMT99NT%QUR$^AMM+R2I:U((2E(':I1( 'E-
M8+O)GT<=]W_W+;K_ )@>YU5KC^1NJ?\ E^\?W?(K2NG?X_LO_%H ^*4V*V]A
M_P#@O7_^[9.?R-I&? O[*?\ EU9?^5XW]YW2OM9]B1_(&^?\VRO[HM57FP]8
M?MA_'G,A[#\!_1751[#\!_14#-B^B]V@?HF'/\89^C_[%W_\//1!_P CV?\
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MWD3+V;<C;7%YX_.;7L"D2L+.&1LFKY2\N()ZHWF18F$[JD<E]%LW"J;EF\;
M9W&SZI#MUB)/VA"F;J8SIEJ)8UW2WZB1"M\]E^.#&NS,#CH"HX< ")NEK^M
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MWY#%^JK"TY[P4+6^8_(2#KD/%P$%%[$DVL=#0D>TBHJ.;$2;"#9C',44&;5
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M&Y14HY)).^M$VRW2--0'9%OA/NJ5+W./16'7#B6\D!2UH4H[4A*0">02 ,
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MN-7P!M-\7]<T2JWAC$WQQ$1!9HR"LE/P488[M074NY/Y0+1%HW.)#@F)6Y
MH" B.GM0='^C=53&Y^HM/P;M,98$9I^4ETK1'2M;B6D[74@)"W'%<@#E:L]M
M;2TYTB:VTC#=M^FM1W"SPGY"I;T>(II*')*FT-%Y0<:6K>6VVT$Y'BH2,<JK
MX;A?Q=$! -*TX!^GPY'T?_OLL7@8Z+O)HNSY\GB/_7FL@\-_2QZ<WK\./^IB
MJ VGLM^*<U*R<]"46*@)25>&?NFS^,:6N!5<G /$ZL)D#2S5N<2EZM8>Q1*!
M0 P(D1$_>+N^P:LU%I>S6S3NG[I)M=EL\1J#;+?&X8CPXC.0U':#B%KV-CQ4
M[E*..6<=FF[W:[?J2\7"_P!]BMW*\764Y,N,^1DORY3N.*\Z4[4[W,95M2D9
M)P!4@-:ZWO.@Z;&T#7-*U+(TB#4?.&$177UFULL@:2=K2<AY)$2:6Q6"[IW)
M.G;I05[+&MS'6$ \ .@9;;G=+A>9CEPNDMV;->#8=D/;=ZPTVEIL'8E"0$MH
M2E( Y =IKVAPXL!A,6&PB/';*BVTWG:G>HK5C)/:I2E'X>0KW"6X#QQE$KIK
M/:=/,01\)T6JC?HQR0!$#+%?:J>7H8] I2BH=6?0A133_7J%)Z0"@JJKU-9V
MEKBY.E(^K7FJSLF@F"CF'CIR.7FV91 1$'\*#@)5@H0 -XB+UF@JD)3%4(4Q
M1 %*]T)@$! .O40Z?G]'K]7^7K^;%*B9<N"O$O8=IG;M=M%4FQVJR/U9.;G)
M!.4%[)/U@ %73@49%)+Q#]TO42)D#T?V(9ET'7NL+9$CP(-^FQXD9L-,,M\#
M8TVGVJ4[VE*P!YR:L4G3-AF/NR95KC//O**W'5A>Y2CVJ)"Q@_!BI Z]UY3=
M55**HFOZ^PJU0@DUDH:!C 5!DP2<.5GBY$07464 %'+A98W>4-U.H8?0'0,Q
MZXW&==ICUPN4ER7,D;2](=QO<*$A"2=H Y(2E(P!@) JZQ(D:#';BQ&DL1V@
M0VTC.U()*CC))YJ))R3S->URBJHIBE,4IBE,4K:8.H"'T_3ZL4J)MUX+<2]C
M6N;O%XT72K+;+(]/(SDY(IR8O)-ZH4I#N7(HR"20J"4A"]2)D#H4/1^,<M@Z
M\UA;(C$&#?9T>)%0&V&&RSPVT DA*=[:E8!)P"3CL'("K')TU89CSDB5:XSS
M[RM[CBPHJ6K&-RL* SCM..?,GF37F/FXN$'LW:\_Q4Q[URK\)>N_2.X?%&^J
MJG[T-,^XT/\ !7_CJL^GN-FD./ZU@5TWK:O:^&U%BR6$8$KPGPH2%%^:,!R#
MMTYZ^1FE) 4>YW/^^U>\(]0Z6.\ZFOVHNK=VKG)N B<4QP_P\-%[AAW;PT)]
MOPV\YS[0=E7*WV>V6KB]SH;,3C[.+PMPW\/=LR"HCQ=ZL8'E-5TRQU<J8I3%
M*C_M_BSQ^WW+Q4]N#5E9OTO"1QHB*?SA7QEV,:=TL\.T1%J\;$!(7*ZRP]XI
MC=\YOUW3H&9#9]5ZBT^R['LUUDV]EYWC.ML</"W=B4;SO0HYV(2GM P!5KGV
M2U71Q#MPA,RG&T<-"G=Q*4;BK:,* QN)/9VFJ2?-Q<(/9NUY_BICWKEW\)>N
M_2.X?%&^JJW]Z&F?<:'^"O\ QT^;BX0>S=KS_%3'O7'A+UWZ1W#XHWU5.]#3
M/N-#_!7_ (ZD[K/65&T_3XV@:WK,;4*=#G?*Q=?B06!BR4DW[F3D#(@X575#
MRI^[<.E.\J;]D6.(= Z%#%;E<[A>)KUQN<IR9-?X8=D.[=ZPTVEIL':E*?%;
M0E(P!@) Y]M7N)#BP&$18;*6([>XH:1G:DK45JQDD\U$DY/::]]E#533%*8I
M3%*VFZB'H]?^O^#\^*5@O]KYV8MYW#SWX[[6YJ7R/MJ7,_M#*-Q1T[7-?RTV
ME'ZEXAM*5:30[(A'R+!-"^3ECF!M$Z1-)ZR:3<6JX;/7#:<=M$U*RO>SDU!R
M9X_<0]4:/Y7WFJ;,VEJ=G*4%G?:FXEG*-GUU69-S%ZRD9]::;-7JMK&EMXA"
M?4,5?O/$3'5>OG1W#M92IRXI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I41^=O+BC\%^)N[.4E^,@O%ZKISZ3AH)
M5P9LK<+L_$D31*2S4(114KNVVU]$09%4TE1:I/%GYR"@U5,"E0?[&[A?=='Z
M>L_*GDZF,_SJYN22>Y^15LE41&8K#&< ']%TO%>*=0T-6M>0"S-HI!LQ2:MY
MDSIJ4%&49%$;*5>8Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5M-ZOS?QAB
ME4@T>?R:D*5L3!UH]LO-(11_6@=O$UNVS#&LIJD*!02%2J%@G29!#O> X1.
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M%\S6*(=!*JV<D514*("("!R"'01^G%*I>MHK6R0'-78=_0U3")P/K>PS^OD
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M_O%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*MK1*"3_M7;:9X4'(P?#:(5B?%
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M5F^H[B@J7J!NZHE2Y),Y>H"(#T,40Z@(@/K >F*@/;#X1^FJ'=G?^!1QT_M
M1_SK)XJ*_;'[WZ!4S\5+3%*BA:OPW='_ +F3DM_I,XNY#RGX!^DTJ5_7IZ_1
MD:4Z]?5BE>3OTV\K-%NEDCRH&D*_4['-L2NB&4;&>14.\?MBN$R'2.= 5FY
M5(11,QD^\4IR"(&!2K3_ &/G;":6[5?2WPO"FCZ-R)H$;')[NTNLZ-Y5#.W
MBV3N-.,Y.+B=U]..DS"R?E%5U!/%BP<[X;OR%U)J5<XW1M6+TKKBR;,FXV0E
MHFL(-%WC"*\G\O<%>2+2.(5N+M9!L!BJ.R'-XJQ \,I^G4W= <7UEJF)HO3E
MRU+-C29<:V(86['B</CN"1)9BIX?%6VWE*WDJ5N6GQ0<'-95HG2<S7&IK7I>
M!)C0Y=T6^AF1+XICMEB*]*5Q. VX[XR&%)3M0KQB,\LFK>_SM6G?JUV1^_K7
MOC- ^RMTCZ-ZD_-OKE=$^Q$UGZ3::_!NOJ-/G:M._5KLC]_6O?&/96Z1]&]2
M?FWURGL1-9^DVFOP;KZC3YVK3OU:[(_?UKWQCV5ND?1O4GYM]<I[$36?I-IK
M\&Z^HT^=JT[]6NR/W]:]\8]E;I'T;U)^;?7*>Q$UGZ3::_!NOJ-/G:M._5KL
MC]_6O?&/96Z1]&]2?FWURGL1-9^DVFOP;KZC3YVK3OU:[(_?UKWQCV5ND?1O
M4GYM]<I[$36?I-IK\&Z^HT^=JT[]6NR/W]:]\8]E;I'T;U)^;?7*>Q$UGZ3:
M:_!NOJ-/G:M._5KLC]_6O?&/96Z1]&]2?FWURGL1-9^DVFOP;KZC3YVK3OU:
M[(_?UGWQCV5ND?1O4GYM]<I[$36?I-IK\&Z^HU<(TKM:)W=K6M;.@HZ1B(JS
M)R*C6.EO)AD&X1LL_AU0<"T67;_LBS!15/PE3AX1R=_NGZE#?VC=4Q-:Z;MN
MIH,>1$BW-,A34>7P^L-]7EOQ%!SA*6WXRV%*&U:O%4GRY YVUOI.9H;5%TTM
M/DQIDNU*C)>DQ.+U=PR8<>8GA<9#;OBHD(0K>A/C)5C(P32#C[_QX\[/W1.N
M_P#J><8LRBL5J6>*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*58$[:;\)3L/O[Z
M7K/^3,OBE7^\4JWCL[@P:_[@W[LEO8M5,6G(35,MJ^PR4WHPEEW-3F<EJ66U
M:4=>;@+L"(^ *^H+]M/2M8=TR52E%D9%G\(-0DTW3%2J63W9:U28MVT;$&QI
M$J5[DI*ZUE238W.?EJ%LF34I+QY(,X^1V@;54C1GTA1(L96IEU-&V*8AW;VN
MOKZI%^3)ME*JG.\()VXV&V62Y;6A91QLVDZ+K^S8V-U0QA8:3GM#<@K)OBN2
MU5CRVMZ2OPLPI=;34Y^!L!KI*R+7X"G7%K5EFDV:R*51_DQV<=@VA6M_DJFQ
M$'J-R+R*VCK.@OJG!Q,FUWYO+C5=..CPMIVBHN\&8U>C7[A(/8BK.ZBE)Q<R
MM'J2=KFZS7H6LLU*V..R\4DH2[-GVZSI2N]ZOL&B\AW*&L*\5E-TO9#NNKRK
M+3T<A,-V^H;3&Q]7C(QI9U#7EC(.3.;%,5M_.HQ#V*4KT6Y>S5-M2@Q&N8K>
M5EI=8^4#D;?+7&QL3.-V5H?;]WPXWJFZ>LZM?*8G)SM'?JC48QS>!O-8E:\\
ME'3RG(SJL;)1*E<6R>S0:;"1>-UMK+ R;;AY ;(KD1(PE\9Q(5OD\[7EMMT:
MZ!K7<&L)FX)C-O'AZC)(S5>CXZ".G7[77+FW5D'3Y2KGD!#M*_"1$$P2(@PA
M8N/B&**93%32:1K1)FV33*=14X)D11(4@'54.!0 #',8!,*E=QBE,4IBE,4J
MVW7?^5<V'^XSK?\ I-9Y#RGX!^DU/_DQ_OG^R*E5O'DYH[C<UKSW==]949M:
MW,DTKHN8N?EEI1:(2:+20(MJ_%2S@A&9'[,5UET4D2BY1)X@G.4!C4H!/8,X
M[:AGN'M+^$5CU)M&O0N\F#V8GM=W6&B61:;L9$SN2E*W),6+8%7%0202%=TN
MDD"BZJ2)!-WE5"$ Q@N^G_X_L7_&;5^6?'%45T0KN9<O)^Y\PYR/)&=-89QO
M7^;^(,^B [/OG])KE.M,C2F*5J'K#IZ^N0/8<]F*5:O[6JX@E6.,%=AYUZUE
MHE;=\E,,62[YH*+6:=:R3B7"BJ?A-U_*C0\F1,B2JJJ(-S^,5,%4!5Y!Z=\]
M^<0D=NGX1_\ /7,=GWJWMT:#&GWQVXN;_P#]+"_7]'DJRU\9[+_](9S_ -+/
M_P#M&:6K85=:[>O'ZXN7SIP\<&*4IEW2RCA8Q2!W2 954QCB!2@!2@)O0
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M)]LM2H;P2E/^THX ^&KM85H;OEF<<6EMMNZVY:W%D!*$)F,E2U$\@E(!43Y
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M%Z9+_&C,,HCMLNK>=N%O1%4B0EU3 9E&3U>2XX&']K<=QU>67$[<H4!4(O\
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,F*4Q2F*4Q2F*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g367280g24b05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g24b05.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2<F4&AO=&]S:&]P(#,N,  X0DE-! 0
M     'D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "   <
M E  "')R,CDS.3DX' (% $!-:6-R;W-O9G0@5V]R9" M($ES;VQA=&5D(%=O
M<FMI;F<@1')A9G0@+2!"=7-I;F5S<R M(&9O<B!24D0N9&]C #A"24T$)0
M    $-&J"0">F';^9%DRC[7=;D$X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9F
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \
M   !  $X0DE-!"8       X             /X   #A"24T#\@      "@
M________   X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-! H       $  #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              &E   ";          !
M      $              FP   &E                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     XX0DE-! P     '%D    !    H
M &T   '@  #,8   '#T &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@               0  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( &T H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MU]^_Z%;/I(*=9)9[<CK+O1<[$95O)%K-X>6PYP:38"SVV5;7_HZ[OTGL]/\
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M73[ZZV_2_3_3]3_!_I?S[$%F)17EY'I-VORK:Z[()V^G36Q^UM?T6-VGTO\
MKB7NG]VB--1\V3]'_ 7#'$];!]6A^7'^EQ?UV19U-C:+</(;E4#W6,O %CV;
M?9Z5U0K8UV[W_I*DS^M5/-E&.V,JN ]MWL967"?T[Y_Z%6_UO\%^B_3(UE65
M4]M6,)HN)WND33W<ZMKOI[_S&?X&S_@OT2LUTU5L]-C0&Q!',_UI^DEQR-:
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0
M 1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X
M  !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\    Z  ;
M4#   "<0 !M0,   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$X.C$P.C$X(#$S.C,V.C R ')R,CDS.3DX       #H $  P    '__P
MH ( !     $   )LH , !     $   &E          8! P #     0 &   !
M&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $     0
M 48" @ $     0              2     $   !(     3A"24T#_0
M"      !    _^$!2$U- "H    (  @!$@ #     0     !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M%    )P!.P "    "0   +"':0 $     0   +P   #H   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,3 Z,3@@
M,3,Z,S8Z,#( <G(R.3,Y.3@       .@ 0 #     ?__  "@ @ $     0
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M 0$! 0$! 0'_P  1" #B 4T# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MCS!#[R4Q>:S)CWFV'<ME+3NPA1$-$QE"J0=#JD#22CDVJQAG"0KI\/;UZ?\
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MT02^A#B4K<5\1SU]=YTC#U)*^%H".2Q>KU:52 Y%['N$Y; P,FEE(+0^P )
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M")A$PB814R\SK?(4JM<\DZA?>J5'JQ=U* Y9 \RH,GUH?H,^S5IV<EZS?^7
MNA-VJBLU>%F9B8(W/5.6@=1Z)&M6F+GODFRZ'[Z;^_OJJC\-_/J!TV.Q/G]?
MPTM<GAXQJ^^5=8[5T*VQW-KM?9[H71:C&R%.N;%@[Y%6"J6F!/YC6NVV*U1$
M7;><<G?).L#7C_.\EJ?7>22%,@&+/$:8K1-JFJ#K\OIWUOSV?EOYC77YJX]
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M2-!CE'38EB)CD!U_N:3K0(!Z@'8$P9IUE)A$PBKGY+R1QE+B.701*Q['V^R
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MU"Q,5*1\Y&1TS$E-'1<L ')QIK"O>P8 >.V4&4RO7V+9('=;=;5K[%(5K?\
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M>,BWI>ZD 25>E^P,'.1G-N5R#C?P2=.VT<.2<G[J(E?M'K52!E2XTAQ#TX;
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M695*I->N5:==O-/9L10PCR\21X8TG_:W?,XGH&@DKRFD9#%)*_\ H8QSG>H
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MJ221OA>^M/+ ]\4@T^-[HG-+HWCHYCMM<.A!"]'6O3[-?9K7V:UK^&>XZ?\
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M;;;2E#:$)TE#:$ZTE*$)3K24I2G6DI2G6M:UK6M:]-9+&M#6AK0&M: UH
M &@ !H  =    .@&E W.+B7.)<YQ+G.<22XD[))/4DGJ2>I*YTE.M[WI*=;W
M]N]ZUK6][]/3UW_C]FO3[?X?9E51?K")A$PB8UONBA7KW.#;%$2%HH+GU?Z_
M$1):*=: 2&X\AY_2-N-04ZIQE\&:@#'$[;5&SH9X C[B3QFQ366RVXMQ)A9[
MM6>]AW>Z<1UZ\@QUV)XA<]^G:JVR0Z*U4DWTKVV2PLEY)&B-[>837@_B2#&W
M*V*XA9_$>#KER!V9Q,\;K$;&<P:^_C^5S+%#(PL.Q;H2P3RQ!U><S0/="[\<
M!%ZN'S*'8[,4Z7>]&2ZCG7GHQ\C0*I$C<6V0]#)3'N.H"^%K:F?<KV>S3JU.
MZ7O*\'Q<00X&I'Q-*9,NU\_CN+H7N\,S/,#7OA'AN<(N79'4 @.V1LU]H4W"
M4_%%V3@F(0X PTQ QC+<<9G%:,6G1QW2;+&.G#]!^AOF+ &%H&6]8Y^'UGEG
M2N5R,K*P4?TOG]RY^?-P1'RDY#!W.NR-<*E88K_Y:5CF))PN/(]/5DMEES7^
M[]LH^_7\E"1T(/?7D>WYJB7+OV?IE/['S+R*NO0:S<.[5B[3,I=>A07.6:2]
M+\J:XG8>.T;@%*C1I^6^IO)J^1*Q/1I>MO'38<]T"$:L.F C]AO1]NM]3LG9
M^74:(U_8]^_?NKN;X>76FZZ#?GL?%^.OA[=CH'7?9;ERM41]7B+=-(IHE2%D
M]+;N4+(3,W%V1R%>@X6**9DRE*C=2T4/8T3"Q&X(J.-V8*S%R,B7L$QUML,I
M]C[^_P!J'[ZZ^_P7ZXU!72OU5\.]$ED3#DB.YKYV9<GGD_!KT#'RQ3<DZ02Z
ML2;LX4_8P!'-L*C09D>.T($D1(C(^6OOO_C7RZHW>NO]]_?7:RZC_NQ'?S)+
M^JFX55EF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(G
MIK?^O]?X8UM%QZ:_P_U_K[?\_M^_"+PHRJUB%D9:7AZY!14M/NH?G9.-B0 9
M"9?:VO;;TJ:,PT3(.M[=<VAPMQY:=N+WK>MK5ZX<&.H59[%FK2J5K-QP?;G@
MKQ0S6GMV0ZQ+&QKYG#9T9'.(V==RMA:RV4O5J=.[DK]RGCV.CH5;5RQ8K4F/
MY0YE2"61\=9C@Q@<V%K 0UH(Z#7O9F+7IA$PB81,(F$3")A%QO6M_?K[LH !
MV^^_[HN<JB81,(F$3"+$Z/\ NQ'?S)+^JFX199A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$6)T?\ =B._F27]5-PBRS")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBXWO6M;WO>M
M:UK>][W]VM:^_>__ "U_'"+S8F;AI\3Z0@I:,F@/C/#_ #T2>+)"?,#KVT0Q
M\R&Z\S\9AS6VWFO?[VEZVA:4JUZ81>-1_P!V([^9)?U4W"++,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3"+SY>.:F(F3B'W7F692/-CGGAE_#(::.&=&<=8<]-_#>;0[M;
M2_3?M7I*O3[,(L9Y_5"Z96@H V5$F'PFQ1]'!P^X1ET<".!BQ-* W(RGM(^4
MCV5%/Z*]A!*G76V!FU(8;'K]_O\ ?S0=OL+Z:HL$C:],OV,5"W7GOEP[?:@Q
MFUONK>=^ *-,-#CM[=<6K33+3;:/=Z(2G7IK"IK\?J?W7Z^I$1^/MGYXN/ZY
MA-#U^I_=/J1$?C[9^>+C^N830]?J?W3ZD1'X^V?GBX_KF$T/7ZG]T^I$/^/M
MGYXN'ZYA-#U^I_=/J1$?C[9^>+C^N830]?J?W3ZD0_X^V?X?OQ</US":'K]3
M^Z?4B(_'VS\\7']<PFAZ_4_NGU(A_P ?;/SQ</US":'K]3^Z?4B(_'VS\\7'
M]<PFAZ_4_NGU(A_Q]L_/%P_7,)H>OU/[I]2(C\?;/SQ<?US":'K]3^Z?4B(_
M'VS\\7']<PFAZ_4_NGU(B/Q]L_/%Q_7,)H>OU/[I]2(C\?;/SQ</US":'K]3
M^Z?4B'_'VS\\7#]<PFAZ_4_NGU(A_P ?;/SQ</US":'K]3^Z?4B(_'VS\\7#
M]<PFAZ_4_NGU(B/Q]L_/%P_7,)H>OU/[I]2(C\?;/SQ</US":'K]3^Z?4B(_
M'VS\\7#]<PFAZ_4_NGU(B/Q]L_/%Q_7,)H>OU/[I]2(C\?;/SQ</US":'K]3
M^Z?4B'_'VS\\7#]<PFAZ_4_NGU(A_P ?;/SQ</US":'K]3^Z?4B(_'VS\\7#
M]<PFAZ_4_NGU(B/Q]L_/%Q_7,)H>OU/[I]2(?\?;/SQ</US":'K]3^Z?4B(_
M'VS\\7']<PFAZ_4_NGU(B/Q]L_/%P_7,)H>OU/[I]2(C\?;/SQ</US":'K]3
M^Z?4B(_'VS\\7']<PFAZ_4_NGU(B/Q]L_/%P_7,)H>OU/[I]2(C\?;/SQ<?U
MS":'K]3^Z?4B(_'VS\\7']<PFAZ_4_NGU(A_Q]L_Q_?BX?=_C_[\PFAZ_4_N
MO:BH86';>;%?E'TO+2XK<G,RTPM.TI]NM-.2QICC*-Z^W;;*FT*W_>4G:M>N
M%7[[[_NO6PB81,(F$7DRP9IC*&Q"&&V_5[1HI#2]HDA7!7VM@_-M+T[&_$>6
MTM9S+!;K2$*T@=:E:VDBJYR7A-UI,O1#9LBJM,U(% JR8:8FI611$L5(JK#4
M,-4A7H9+M4T>L:[*,(>9>1.Z6&F%5IIN86[G?7O]?7H>GW^=H';L-?+[[>?X
MZ5E[;$[GJQ8(308<C]+PTC': /,)CP2_G!7A]CF'!BG%"C._$TAY]@,IUMO:
ME('=5K3:GX]/7I]]E<?O:@#F''+I5+5 V"Q2%?<U%5R-C"2(R2E3Y!U(G/:1
M3'JLC9T/&-N5AF<JLC=A3''6R%RTVZSN##<25(G5.O+?T_7O]_/R5H!'?7;]
MAK\//\3Z;5E)%IQ\ UAEADEUX0AIL8EY0XSZW&5H0R0^D8Q3++BMZ0ZZD0K;
M:%*7H9_:=-JHKBJETCQ_N-:LM4E"9&NMQ\)8"YU*A)(\F5KXK\UTF4-K,+\*
MM0$7(1MFU>(YN9(0%6! VX-@8>!/2P"2./\ ?Z#S_3\1^*M#=:UY?VZ]/+Y_
M\JX'W:^S_P O3_6_3_\ G"N5. ?'V\"GP#;9U5%K\%/A&1 >I PR7K88=JYU
M9294>6%J,"BRV"99J$Y"/NR84::'&6#8Y5@GQM&"EM_7_'8_?R\E: ?36]_/
M7YZ'X=M^>U<C7^O\_P"/_P!\*Y4_MOCQ89N:GYR)(J<659YJPJ=98V> /7!G
M?JL-3KI#I!BU(.O-6;@YZ42T0U':(E;U--)LK0X3*C7WZ??WZBT@D>7?[_/7
M_*N!A7*GMP\>+/,V^T6*)/AW8R;.-*?KUBF27A+$N7C)813\R2#3VS045&1,
M"E*A'$$6Y+"QW!1)* 8T)H5O6OO[^_-6D=^@_,GS&O+Y?GWZ$=E:> C"8>N0
MD,:>[,&1<+&QA<F1[FWY0H(%D5\][U6\M#IKK2R'=;6ZI*W5>JU[UM6W;[^:
MN51S?'^^$052C(\>EPQ%=.[8G;C%OM!C+%<Z-/3DU!UH7XU.868(EB0 B)T@
MG0CHHHSCP&Y-26F%-[Z_/[_'K]Z5NNW0>?Y;\@=?\!63YG53Z;4FH23>#V_N
M:M,LV'&N/.Q<&#8;/+ST;6(EY\8)QZ*K $D/ 1KNX^-0X''LJ9C(UG: 6'W^
M?_E5"KW/<%O$O$VJ(C7JM6G9?LAG1Z[80[#*RIU=$(=K)*BM &TX9]Z6,.B)
M \B,C+'""H?+::<G30E&!ONGTZ=O/?SWU_'\E3E__L3WU]_I\NVU-?(*-*T.
M!EP95N%!5*6!<P)!5LHTZ"@!MP<)%.!1Q9X$40_H\Z*,L!>]QHB4R$R6CVOK
M2LTD>O?Y=2?/OW_)5 U]]O113;^(VN:LG0)N*&JH[D[:*G:ZF898CR-"3\%3
M)VI/S-DKLC19N*D&6T2K"V:^P5MHYH5IY,S!FBC/:)H]=:W_ .-#RZ_@=_BL
M\XMS2Q<\;F]V ^))=D@Z\"I,,\<\U+2$(F7U)7>5^=$"4/8[;])")E@F]2*1
M40P2?IR4]VMCCY>GI^']NNOQV@&OOOKS_$_GY+P+AQZ<LUE[ 4T-5&8?IM.Y
MM5VCCCCI"5"(K$G;FYZ:W$%5]V,"D&:];7$5E\63)]LQ%"/FM#-D./-/E\_O
M\/KZIH]>VOL'R^71>KR#D\WSJ=M!QYT6Y&R,>)$QH\8^>^]((!MMYGQIV;28
M*,@:6;AK1$5C3##TI_U&N"JW)[&^2CHY]_?3\4UU_P ?F?WZ_-=?IW)Y>[7)
M,V&/%HC'.=RM5/(W:9"'F#I!5MJUJ@PW E5"RPRH%AVO&C2JRTF[D!)LN/)A
MBP?>AUO1'7Z=^_W\NOFA'X=M>O\ ;M]?P6.\7X=;N<6464G)Z*E!@H.Q1SD@
M&\8J7G_K$]3"XJ(E!51<;'APO-6ZY)P%.V.Z6HF&E$N_(5Y[9PAK?Z_?V/S\
MDUUW]G\>GEY=SZK/[M0IJS]!J]@1%UA^ KU>LH[K[\Q(Q=DDY:<B):$9B"EB
MUR11JI,A21+[[;4JR2[+%BR7RFUU\9F3)Y[Z??Y=OORZQKQWA]VHTQ2Y"PE5
M5":O48:O/D04M-29Y;$7SVITG593N1@8="JRF5KA%T8)<<2^F5D-#?1+:T$2
M90]^F]?9'V/P*H!K]/[:U^'G_A29T"BSUINM)FPHNJD1%6$LQ11)\J9&V0R5
MDX&4@8Z%:6U5YP9-5>9F#2II&RFGR36XQS8A0P#P9Y5Z_P!_OL?S47\QX3<J
M=:X69E#JS\C%V*>GVR8TX\B:'A9B*ML>WSC2-5V#CB:ZU+6(2YNR0K<(%N:B
MV AJ8,VT-(LOOZ'_ )"H!K7[_H.W3S_'R[:E?IE'F+G-4%P(&O.1-=F2)J8D
M#),R,L[.V6F41\=72!J_+H8#D'UK?L+OSL:^4%'L0NOC!RY[PA5(^_/U_#[[
M=U#5 X!=JM:ZK)'2%6;@*N5#?0S()9)$Y7X&#A;S%.UUHP:J5J.L6[03; I"
M?G20($E:(<,8V.G30PYEJOZ_OT^OV50 ]/+7RWVZ_P#CZ?2;NMT^9O$)"0T.
M%724-VJ%DY8J</-CC8V(C77#'RJL6%"3FQK(\^R, ,6ZR+H( R1*8*08T,E=
M/[??<JI_S]_?]NZAX[Q^L+MN(LX!=6C]S%T782DA()CU506-LM$*B"ZRR+$>
MV1FY:L4PR,L?SC\2A,A:YMQ@X^.<>#/??W^GWT5-'T[_ (>8].I([_BIKZY5
MYBZT&=JT$%7#CYMEJ/W]:7GF8T(0E]MJ0DF/@PM@]\O'A+?*@T$1KPFI5 ;A
M.]#H<UL/S'^?U\_KZ*IWY:_-5DL_B[<9*>FY&#G8QB-E(.9AFH^?L,C*DLRT
MZ-)+&O;LL-48^2+GJ&<>IJFQTD5).-Q[S[(UFKS0\>(*W]^GY_X5.7[)V!Z^
MNO7R5N;O"E6"J2T(**!($'CMCH8E#&8\-S?QVE*==)?KMK&;<80G9#"7Z])L
M.OMMM.CI;7MUMY^GWZ_7MWZ=1UN543/'.]N)C&&MTB0%$YYSNJ33$C/V9L:W
M2U/I?0ZFLR3$77)/Y(.+,NL39(1Y)$D47(U$3YAF*,-;E(QOO]_3Y=OPTK='
MIT'EY]]?EOZD]@K:+AC6Z;N 6ZU.R#=;^B''Y-WY1J8+1&?)+>D'_D9CY9![
MNMN$N[C9336G5;V$;I/P7"NUTU^2J0[XX7KY.D#,/4W2ZD<62<@F7.<&L5=*
MZ"[<%T&02+1PGVP7P6P(<N=2\NN."HDQ1N4AL& NQ#?F//Y>ORWZ*W7H.GKZ
M[^7;S^6_)6IYO69"FT2K5>5D$2DA"1(X)1C>WE,K6W[MZ9&63_UA8H:%)#%<
M?TAUP9AI;C;:E;;2\_O[_%7#I]_?Y+-L(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F-(F$3")A$PB81,(F$3")A$PB81,(GIA$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBU[>?7G=3/$7E/6=P\DW(=
MWKG#[9U6E5=^CWBYUL'829&*J$GT@RGB)%J=6LMP!=KT:;/V"MLRYP<@(%(M
MJ#*>8M<= _, D?\ GY#Z*]C>9S=_TEP:3L#N?+?<CT!4O6'S%XW2KU!<WN;U
MZAI^:EZE4FK"KE/2=\T7?KO# S-6HX_2M5I=*>LEC:D018:/8G2-$RYPE?40
MF>=U'978[?O_ '[*W1UO\^XW]._EUZ=.ZZ$EYU>+T10>==-DNDH%IG5.56SM
M5/D]UZS/O$<ZH\9"25HF9*+&B'Y6%*BUV.#A50<J$).$V:2'K(<<1.;4"EL=
M/7LG*>HUV/*>W?9&OD>Q[;'GV4N5OMU+LG,9[K:P[K5JI5P;'(V$>^T"X46S
MQ(=4$>/F7R:I9X:,GUM-@L**$>&!(8D&E)^1=?7[D);'^?RZ_LJ>>AH^70@C
M?X@Z_507SW]H-XI=+$GY.#Z)(1$) <H.[INPWFBWSGL!/<>B$,;G>C5"7NE;
M@P[?5H%PH1B8D:\Y((#<,!7M*QY %\EL?IOMKZ;T/OJKBUP[CSY=;!._EH$D
M'IV/5<Q7[0#QBD:_>K 9:[95D\]KU6MTU W?EO3*7<)"K7NP#U.BV"J4^R52
M.L=QC;C:C *U .5J-DW2IZ1CXEYH<XT9AQL???Z=U0M(\OIH]NNM]@?Q(_0K
M'+1Y^4*N]3\;>:M\Q[@7_P!(M'0/D9,KD'3X>2IA-$4*,X)8:L=2OI32B3GW
M?I-YUP!BN0K8]F/<=A#QBE-]N_7T_#O\O^=IKN>G0Z[CKZCKU'J%)7EEY50'
MB=5>?VNP4F[7AB^];H/*F :17K#/FQKMWG!HE<R0S7X*>><5'-/+?CX;;#!E
ME/2S"13WSY3>L$_C^0W]Z\^WH@&_U/7T^_L+SU^<GCFST>P\I*L]D!N-*JH-
MWZ(P?SV]A0_,:I*4-/1XV;Z78R*\W 444^M_,:$;LDC'DOS $E!H8W*1Y8K5
M=C[\OQ3E.MZ[G0[=?+H-[/7IT_9?"!\Y^ 6.&MDK%D=/4=3XFF6$NG%</[ #
MT*9K/1I,^%H5IJE"+I3-JM%:M4K%R80$W#19<>(\ 7N9>BVV'%ZIL>OT/[)R
MGTZ[\QY=QWZ'T/7M\U%]T_:2\<KBN$$5RH=;O,=V?K]VXU*-P_*^FMVCFEIH
M%:LDW8XRU4G=**L35D$-@6 D50@2.D3(@XFVQ[ID!$DON-^O?IV_/KOT[?71
M"<IZ]N@WW&CUUT/8_70['KT603G[2CQ%KMGE*C)WBVZE(?H=SX^40%R/K$G"
MO]@HTA)QTMR:+G8VF%1$ST<YV)*=KM3B"S92QL+"<B&2E2 +;[8^_G\OQ].Z
M<KOEY;ZZ'3Y]3O1^?;\UEN_/#QN7SZJ=%"LMLE@[G9;Q3H.H0G,NBS'4=VGE
MY$B+TV#DN7QU9)O,,9SM^).;N*I6#$&A%(&221[Y&,28V/L'^W=5Y3]-'>QK
M3M$==ZZ@['7MU7CWS]HEXF<\6'],=#EI<0OE=9[HJ5I//N@WV&C^+VM4O]'=
M4F):G5F: AJ.,U"'D2T[)OBCQ0Z6G3/AZ>1ZN8#O^/Y?/IY?90,<?+SY>I ^
M+Y=2.OIW7L43S(J-]\JNG^+4=2K^U(\[IO-[@/T+ZI6UZC6!CH 5XD=(U/?5
MIFOQ$<*)34:@YTNPOQUT.D"XR VX; R;6@^6SY'R^_S\_(]"J<IT#Y'?F/+T
M^]>>MC=Q,JJ)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PBU?>8?A)V;N5@\A"^0=-YO383RH\8H+QPZHST*IV6QR=?'I,QTR4K
MEEHCL#8(<7XTU']6LM>G 9EI;$4MB)LH.I5\<N#/M<W>]'7,-'IOIU[?7]M>
M?HQX;R[!/*_G&CKOR@CZ-&M>N][6(]9\!NZ].[Y%WZ0[!5Y>A0'D=XR]SJC-
MFD^NO3E'J/"3N92$SQJG\_BKD%QX :S3])G[E_:2;73[&8=;7H*7B'5QL;:@
MQ!)[^8^@(.M;UUZ]>_8>2H'  C7=KVG6NO,".;9!/0$#E'3;>;8V0L%\?O#B
MR/7SSZ/(@JW9*([9^@<#\9Z%WBB3S//6>8= MKW=^]Q+\6T:V=+<]M_7+]*T
M.NST0Q\HS5^9U=Z.CI.+C!8Y]KJ01TZ]_7J?KO7RZ>O07=&_,:.QW!:.5OY@
M#??_ %'LK-4+Q\Z=QCPN\@^8VVUE7V7GZUVZ3HE1A9:]WD'F]9L=+*#K''J7
M8[_)3/0[C$0)+#^X4F=?:*0Y+_0D/%QL-'Q8#+6@=^>__ WUWWZ'OU[>2H2"
MX'MVV>@WKS([#?G_ ')ZJJ'._ WNGD)P#ET=Y#WZD4U-=\"R?'CEH-%HEJC;
M3 SG4*YS Z2N?5H:X6!YK<G3U\ZK,&1SN*>:#E2$60HZ?CM2 ,5$-=/_ (Z^
MH52X!Q(&_CYCUZ'J>@Z>>^I/T4^37B#WKI\W?.E=S>\9+_<Y#@4?XZ57EWU6
MO^^-S-/(Z)7N@7J<O<B?*O6MF?LYE9B$4]N$!('YB6"S)((N13CBDM'ST>^N
MG3\^_P @J<P&M;'4'>P3T^70=MG\>BZ]'\+_ "$H._$^TL]>JETN?C]T#MQ,
MC$7TWH]GA ^1=R:;C_J#4[U8)B=Z)/G\GAPHL"I35\*.*L[([C,P1#,)%;8:
M/SWW[_(GMOOT'SWL]==M5YA\736P.WS'IT&B>^M:\@I.['X.58KG4C&^.0%9
MYMT%7;>/][^;M)=PGZO:K9R&^C78.*L:7)B1DHF/G4_2<:\? L_%CUGMF?1I
MZ1&Q-U(Z=/QZ_CM6@C?7MVZ:WU&OS_S\UU9SPKE^AQGG5&="M\2$UYJTFB5D
MQ=1#D%.4@ZN\9%YQ,%,+DG1W)4%4\A^7BQE.B/.Q>D"ED#E/..M4Y?ZO7]M?
M?Y*O-_1T_I_7XMJ 1/ 'LPE!M@E=+X;RGJ!W]DD.Y=N76CR(!E>H4*@W9JV7
M3GEJN<E<7+ORFG](98V"N.YK(2,G773CWUST\TYH?8CZ]/S&]D>GGV/3IW[*
MH<-]>HZ]-#H2-;UK3B/4#?HNQ3/V?O:^;U.F253O?)'>F4?S2M?E;%Q!\?TI
MSG1$->^82_,ICGQ4Q-V6U= <.@@+&<>!;3#I%4\9%CN$P\"Q+K!A&CU^?-L;
M['IK\?OIT5-@]]_T@'MW#@[IZ=!TZ?GH%3+$>$]KCV:6AZ^0*UU;]H5U;S/?
M^#$R*4EUCH<_U.7#H[6U$>Y$X U?PV2Y-?K'N+"+VTRI"FOB5UV]"3]=_P"#
MY[_MH':YM_ZFAH_(-'_^5"M]_9L6N7LH?1XFP\[MMJA>^^5G3 Z9=W>BUFFS
M-'\FYRO3CD(79.>S,?:H&XT\VIPCX\R*)-0LLPN6C"X=&S Y6,:_S^OW_?\
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=$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g367280g25i86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g25i86.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1XR4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R,CDS.3DX' (% $!-:6-R;W-O
M9G0@5V]R9" M($ES;VQA=&5D(%=O<FMI;F<@1')A9G0@+2!"=7-I;F5S<R M
M(&9O<B!24D0N9&]C SA"24T$)0      $%U@25_+#(S.9SG[AEY><A\X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9F            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  (5   ##          !                          $
M PP   (5                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (5     %)G:'1L;VYG   ##     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "%0    !29VAT
M;&]N9P   PP    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     $Z$    !    H    &T   '@  #,8   $X4
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M=^PNL?M<Z=,ZCLIZD9,57#]'B9[OS6U6-_4\KZ'_ &FM_?70*-C2ZMS0))!
M!1$N&S5BM1W55H;067>K3#K(BRH$2YH[C_A&?F?]M_\ %R(IRJVN:XZ&6/;H
MYKAI^=]%_P":^M__ !=BQ++7] <,G+W#"):V^ZMAL:T$._2WAOZ2JJMP]]WY
MBV6MIR&MR\2UOZ4!S;JR',>V/87;3LM9M_/_ /!%#RV7)EQ\>7%+#+B,>&6O
MR]I?I+\L(QE49"8J["UF1;BUE^3M=4P2;FD-@?\ ",L(_P"@]ZY[.RNAY/4&
MY1R\G0M+A6T[/;]#;+-RK]?S[<K-..YP]'&=L#1HTV#^<MVG]WZ#/W%0=4T
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M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(  P    $
M 0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ  ;4#   "<0 !M0,   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$X.C$P.C$W(# X.C(X.C4T ')R,CDS.3DX       #H $  P    '_
M_P  H ( !     $   ,,H , !     $   (5          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M 0   48" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$!2$U- "H    (  @!$@ #     0     !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M    %    )P!.P "    "0   +"':0 $     0   +P   #H   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,3 Z
M,3<@,#@Z,C@Z-30 <G(R.3,Y.3@       .@ 0 #     ?__  "@ @ $
M 0   PR@ P $     0   A4         !@$#  ,    !  8   $:  4    !
M   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 1X!H@,!$0 "$0$#$0'_Q  >  $
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MY#+ZFDBEGCM:U\(XOUQ,K3Q'1#AHZ5JESR-E5L0R.'G;\^16Q>Z&5/=_9O\
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M@@B3RW>24J@W/906W9ME4$D#*[3M-U#6+M?3M*I6M1OVI!'7ITX)+%F9SO\
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MD=[7+$2C5==EC46+3D!GKUAL35T^-]_!A1@TNRS6&ED(*VN<UGMFV-A\OO\
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MI964>IO:/HD"5V:KK)>Z*LM" 5J0FU&E>2R]34*8DO*C5[ JSK%7DDAU)G0
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M!13U!K5^,,L[*>QDLD1-L1[L5V=I'"S9[R.U6%@=HH]A9._;ZR7=UC!'<+$
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M5BB4[(O(*T\SD%(:T6^\T\K)'&/,DD V#J3J31>E=+LZSU!J$&FZ=54L\\[
M-(X4LL%>,,9+%F4=H:\*M+*?)0NYSTM^D+THY_TT8QS)9AKSL31QPS;#31Q>
M(E^6JN@HJ;YK?G#TM>Y?/ERMFL2T>>2V/R,,)]'O9-[+*'LVT=E9XKO4.HJC
MZOJ:J=NWQ)1IE@&2E">_<!K$V\\@&T<<?S']L/M:U'VGZTKHLM#IO36==&TI
MGW;XAQDOW>&R27;'_P!2UH=J\9;ZV26\#FV\T]E-ZK(YS:TY%#J:@*[J2/8]
MX9L*2-C(@=\P4P65/;.%8!3HP@"Q"E@. *CC*#(@(CCE9-@GGJRK/7E>&5>P
M9#Y@@AE8$$.C D,CAD8=F4@D&7+%',A25%=#YANX&W<$?X6![AALP]",AB*W
MU/2A$ VKM2==U)--$(/M[HN+^*.N/F>V$0?<G3+$W3Y629\8D.R<C+ZG<X==
M8MT/*7I@[CP@U,.U=(ZVHA>358PY@O$=V:H@Y&&QMN[5=Q%)LWNW A8&I0TE
M,@2LTM7L%F?^\@W[#QF["2+?91*!SCVWF+ EUN'BD;*U)&.:^-[6OC>Q4<U[
M'IY:YKD54<US?"HJ+X5%\I]N6G*[(([LZVUW;-''CJC2UN6SA<C)[XB:KFM;
M.Q2&5LHP0\:$!PBBLE8TB69)UGFE9'$WY<#96D<Z_2$]E'6WMIZ<@Z%T/JS2
M.C^E+DT=CJ:U/I4^K:OJON\RRU-/J0B:G6J4HI8X[,\ILFQ:D$,0:&".9;.>
M=!]4:1T?J3:W<TFSK&I0*4TV)+B5*E5I%*2SRMX4SS2&-FCC3AX:!F<AGX\;
M<4]"&<#J+*5VNN[R]8 8ZJ&>T*AIB+-HTJ@Q6,S ;P^$&4I(F%2B^XB,=7NB
MCD>C6NYGZ;_\-CV<5I:[=6=?]8:M&LB^.FAU-(T(&/<<POOD.NL=OB8;.AWV
M^L4;G-C:C](?J.5&&EZ%HM1@C<&MO<NGGL>._A2TX^Q['E$_J=M_ARS+X?\
M\2+5:+U%=B^AKU0]>572/:F,L$K.IJ44XPL"VJJ.G&B,S4MK91P2W%F9 -)L
M<_=,BA'OZJT)A&''8  PKZGP>Q;0/9M[-.CZG0%R]JO2N@:-4TH2ZA)'-?6O
M"2E:Y9:&.*/<EO=K2I&JPSQ;_P [!.68NN-0ZBZGUE.HH:]/5[UV:VL==62%
MG<[O$BMR8!NTT+,3S60J#\(&9U&K[FHO[^?_ #_7F)9DF?7&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8POV15_;C&>=SU:^L[MOU!?$0ZG]"WI:"R^DS6&NI'>H@_24\5I03L2-DN
ML'DMA_D7-%%@:-7K#99VSJ;(K:$1TLDI8\+P3,HZG]A'LU]H?LDUP>U_0(]9
MTW58 ^APEGKZCI]D,8Z5_2;<3QST]0L3'=94)VHI(75HY&1L;H]?=3:'UII\
M?1M\T[-&3;490HEKSI\+V*]J-MHY:T,8^)2&YV&0*.2 YDMZ\]&P60[0727%
MG!H,?3?+L<R 3$K;"2V9+[ADN8T8@TD%6C&SQK$[V'3M'64>%D<L4GRW]EWT
M"-+Z&]L#=5ZUK%;J;H;09$U;I/2[*.-1FU=9S)2BUZ$0K4EAT?B+(>%O#U&T
M(/&K1U_'K-U+U+[<K>M])#2J=233=:O!ZNK6HF4UO<FCX2FBW(RH]SDR.''*
MO&9.$IYJR7Y21-D]OE&K[%5S/*>?:[PK?*?LOA53RGW\*J<^CS(K<=U5N#<E
MY*#Q.Q')=Q\+ $@$>A(]<Y^W_KVR$NP-K>V5U'U5UI-''MRPQ['1Z=\$)M;U
MAEBI)1FWYL$S9!3=1;?)+'Q&=)9)$<8,3<6D+Z*G.A*N=2M$D)O7E/NB.8X(
M Q5[\Z@'P4;L5@C!5K<P.Z(RQIO-(H%'/,[2>ZP':9EY22[;K6C)V#G?L97.
M_@H?,JSL.*[-7^&PU#U_1Q4E!#,V)\T]A9GFD2G7%]<FN26RO;VT(<\JTN+*
M?S*680]RN_)#"V$:&""*ELVIKDQGF(WV"1HJ\(X8D'%(8HP (XD4#BJCSW9B
MS,S&HBB2% B#[V8G=G<_:=R>[,Q[L3YY67)&3,T<OM15_;Q_W7QQC(3N>YA"
M+,W,=;YZP[-T]>4H%LVE('"R68+1J*Z+6;0QJU%>1#Y:L]-5MO-/&U[)$H71
M.^:ERCTTK&L]^9-/KR('B,JL]FPI.P-:JGUKJ=CM+)X,'8_7;C;*-[8+F*LA
MLRJ=F"D+%&?E+,WPJ=N_%>;_ /*,Z:?JS;]BPK#W)K*4O.$2,^OZPR&=K'XZ
MQ@C>DL8NAO-6!;:6_5CO;[YJM<<+-[&^ZL3QY6BU6KT_J>G6=)L:+!J=.Y&8
MK!UG^UB1"/\ =U$*U(>^S*T@LS1N T<R'OE?I5[6M)O5M4HZK8TR_4E$U:72
MY&KRPN/_ .3MX[;C<.JF.-U8HZ,I(RQ7N;X5>)O22;?IG73X2>95D3+Z%I=[
MG&/55=[ K#YS[X")SU\^TF2X9']V0QQQ^(^<E=8?1<T:^\UKH_59-$D<\UTN
M_P"-<TU6)W98; <VX4.YV68VPO8 !0 .N>C/I8:YI\<5/K72(]?1 %_BNG&*
MAJ9V "M-6X#3YW  !:)*;-]IF+DL;$]-\-OU441,D5=E\[K!VO<UAF>UE0QD
MC$\*U_TU[)2%L\IY_*L+O"I]UYI#4?H[>U&@[+#I5#5(P3QFT_5:@5Q\PEUJ
M<R[G?8-&/+L3F^]+^DQ[)[Z*UG5]0TF0J.4.HZ3=)C;U7G12]"?3N)-SOOMZ
M9T59\/+U:64[(7]:053'+^8FVUF4@'C3^;G_ $UP9.K?'_\ ;@>J_P D7[^*
M*K[ O:K9D5&Z:%4,=O$M:II2(O?;=N%R1_\ [48_+?+A;^D;[(:L9=>IWMD
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M8XQCC&.,8XQEA?Q(?5T'Z+O2MV!VP/,,NW-&3']8 $>V1#M[H("8JJ=P[O\
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M:-CBA@B8V**-C4:QC6M:B-1$YH1F9V9W8L[L69B22S-W9B3OW)W)^?GYYLP
M* J@!5   &P  V  ] !V SDN>C$\K^GW_P"WW7_MSR3M^_P'^N1RW_J^%.P]
M-<=UF*DU85";D^J(G.D6(;"C'1NM-1%&Y$8A78-W7LLH"F1_VF3J\K[',?,8
MQ]UO;4X8]+  E4K8U [#<VF0<*YVW^&I&W J2?[0\Y&X"G**OO/(]MNZL/#K
M#T$ />0#T,[ '?UC2+R[[W I^B?X<M>5N?,DC(F.DD<C6-15<Y51$:B(JJJJ
MJHB(B(JJJKX1/NOVXQELU9 OJ$O8-)9,<[I#/V#)\=1SL5!NU;ZOF9)#N[N!
MWY2\-2EQ?_T/4SM<)?V<3]F9#.*+D)FWF7;2(_ 0D:M*#[U("-]/B=2/=(B!
MNMN1=Q;D1MXHR*P.[V0;>H]^<2-L:2[^$GF+,B,I$[^ABC(!@7N'8^+_ "QG
M+FFM1J(GA$\?;[(GZ?R\?].6;8?]_7]<N&?7&,^5>C5\+^OA%_S7PG^:IR!.
MW_H<9:5W9ZZ/2CZ?22*WL_N/+UVA%:Y9<G3.)UFLB>UON;&3G\R/:V->Z3_T
MWV<(4#O/GYJ-17)F&A=!]6]1HLVEZ+:DK-MM<L!*=0@G8E;%IHDE ]?!,A^[
M+#J74^AZ2Q2YJ$2S#_X>$-8GW] 8H%=D)]/$X#8$[]LQ<=C_ !E/178VDQPO
MIRU?9]A[4&_'=)D.O:YQ$,'N:.UA-S86END'C_A1S!Q.B:Y/[%J^6IE;?1>;
M69C;U^OT;):9$1I[6F)JUKB@[(\TM$$J@V"CQBH!/$C?+?![=;^C0K3T/4^J
MZM16:05Z6K6--K!W^TXA@M\.3;?$0@8D#EOMVH>@^,7Z.TL!I+3T<6%&V&:*
M2.PIZ+JZS,&DC5'-GCBD92N;)$]K7M=&2CT5/<WVN^W#_1,TN#C-2J=#O/&P
MDC+=.P5F612&1HY4J2LC*1NKJ 5(!!&V^3O_ ,0W4,Z/%9UKK,PRJT<B'J&[
M,CQNI5T=&N*KJZDJRM\+ D$$9D/ZD^+#Z)NUIA %[.DZYNRI$A95=H5!F3B^
M8]?;&UVB>A>1;[U5&L]^@C<YRHWV^?LM!J_LCZXT@/(-*74X$!9IM)F2VP W
M)_LWP7#L!WXUV^9VRGH===.72%-WW.1CQ"74: $^7:0EH>__ ,P;_?F1>LMJ
MRZ!$LZ<\.UK#X&$@V-<3":"8-(U'QD"EC/D@G@D:J.CEB>YCT5%:Y>:WECDA
MD>&:-XI8V*R12(T<D;#L5=' 96!&Q! (/F,RY'25%DC=9$8 JZ,'1@?(JRD@
M@^A!VSL.>,]8XQD,]D]?6QQXW8G7,@53VAGPOIAWE.4:FW5#'*XJ?![)T4<K
MW51LBR/I;ML!%CC[B5MM7,(#FNJ>YN%.W&BM3N*9-/F;=PH!FJRG8>]U2>PD
M4 "6,D)9BWC<JPBECI9X6)$\!XV(UV7<GA,GF890-_A8_9< M$WQ+N.2/5O7
MNZJNP\Y%?UD98<K""*N[I+.-(+G,Z*MD4>YSEV*CWH-:5135AG:QSX)XUA-#
MF("*&(EI[562G,89"KCBLD,R$F*Q"^YBGB8]VCD39@3W'=2 RL!,@F6>,.!Q
M.Y5T/VXY%[/&X]&5MQ\B-F4E2":YY3Y.R->T\3/M<RD-01#6:Z@/@T^&O7QH
MYU+K*J.?\/(>J)\S\/L1YS*&^@C5%.SEO;USE]A;N5=&TM6<-(OB5Y5:&U$/
M][7D($@^7-#QEB8_8FCC?^7)%B+QH]E(62-A+"_^"5-^/?S 8%HWVVWC=UWV
M8YSNM=N-V'CJ?3PB35A1+"@;NE*<CC,_I*8V>HTN>-5OY7&4=X$?6S2,_LIE
M'0B!7CS1/=YN5FJ69("P=5XO%*.RS0RJ)()E_P"66)DD'R#;>8.1@F$\2R;<
M2=U=-]S'(A*R1D^I1P5W\CMN.Q&5YRFR=F)7XSGI43U+^C+9VM& TCL;H]L_
M:^((AC5Q[QJ,99-A3"O8BR?_ +KG(2"(H6)YFLJNL3RBM14V)[+^H#H75-5)
M7VHZMQTZVI(X\I6'NLC!OA^KL<06/DCOL.YWQ7K#3/XCHTS(A:Q2WLPD#=BB
MCZ^-?4<XQ^J#\<K/X1OJF?ZJ?11UII+RQ;8=@=?LFZK["<K_ 'D/N\C'!!56
M12KX>^>[RLU#;$SN14E.*,3W.<QWBE]HV@#I_JF]#$G"G>(U&GL-D$5K=Y8U
M] (; FB &P"JH  V&3>D]3.J:-7DD?G8K[U;!WW)>+LCL3WWDBX.2>Y)).9-
M^8+F2XXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCSX^Z_9.,91/8.VI\'D[O16ME3@J!5GDU\-U=5E"/96(XLLH
M=9'86Y(H44QI#8AHW2RM8QTJ.>J,15Y[C5'DC61_#C:1 \FQ;PT+ ,_%02W!
M=VX@$G;8 [YY8D*Q5>;!253< L0.PW/8;G8;GL-\\Y'PS0<IZ6NSO4EZB?4_
MN<[H.\>^-!(6R#K\72;%E#56UU8ZG3CDWZT0%,\BSO2:]/ETY]B&L%5"L9DD
M;F,;LWV@]8:7K=+0]"T$6?X3HT03G/$(?'>&):U9@A;GM' ')+JI+R$[$]\P
M_I?0;NGV-2U/5##[]J#@\8W\3PT9FED5F"!=VE(VXDCBJC?MF:&H]>_IIM)F
M03;&TJ'/<C4?;9/1Q0^7+X173BUQ<,34_P"9\SF,1/NKD1%YJ_,RRN]_NZ+M
M7#AYCJO3UVH;V/<AXBTNLI8QGKE\O9CEF;2X-* >]]"=!D*^[%HYCU$>FF,I
M1V>9YXHW7#33%'.UN8IQHQ/;2-]CXUB,J*L7 ]W4V7B:90#]0LIV[92VP[QB
M! =[#B!F&_P1."9FW'V6$2N(V/E(5^>7!UM<!4@AUE8+"$!7"# A"#QI% *&
M)$P<8>&-J(QD4,,;(HVM1$:QB-3[)R@9VD9I'8L\C%W8^;,W<L=_4GOE2JA5
M"J-E4!5 \@ -@!^ [9SN0R.6]]I2E=B:6NZ.J2)HJZQ 32]N'#/DC<)UW]3(
M$)D6$PO8\2S[*L8B:I%^STR%1M)H91S_ ,,F==:(%.&34Y /$1O!TU6 (:Z.
M#-9*D$,E*(\__P"Q+6!W7F!0V=[#K34D*P$EHC?M!N0(N7;9IW'$^9\)9#MW
M4Y/008P(HP@H\0HPL$0XXT#&Q0#P0L2*&&&*-$CCBBC:V.-C$1C&-1K41$1.
M6HDL2S$LS$LS,=R68[DGYD^I]3N?4Y6@!0%  "@  =@ !L !Z #L!\LY7&1R
M+NXNY>N>AL!>]E]I:8++9.@@:\DXOWR3EE2^6AU=2#"V0NUM["5/E UH44Q1
M#_<YL:1QRR,NFC:+J74&H0:7I-5[5RPQ"HO944;<Y9I#\,,,8.[RN0J^6Y8@
M&AU#4:>EU);MZ98:\(W9CW9F/V8XU'Q22.>RHH+'Y;=\\HGK+^+/W7ZA3K/)
M]4GV_3?4*NF%C#IS/I=UK!%58_J--H07I+6CD-17?@%"1",R.1T%C87"HUT?
M6G17LAT/IU(KNK)%K6L?"YDG0/0J/YE:E9]UD93V]XL*SDCE&D(W3-']1=<Z
MEJS25Z1?3Z&[*%C8BS87?LT\J\>"L._A1@[ \69S\68E7/>]SWO<Y[Y'.?(]
MRJY[WO<KGO>]?+G.>Y5<YSE57.55557FWPH&VPVV&PV[; #8 ?( #8 >7IF"
M[DDD]RW=M^_([[_%OY]^_??/GSY_U_[\CC'_ +\AL//;OC?-555_7_7^O_MQ
ML/E^Q^_]?/([D>1(_#]]LNK]-'K0[_\ 2C>#V'5FT+;GU*2>XZ^OGSVN%O6.
M<GSVE4DDS&@%RL\M2VIIJVUC7]"U8CHY,2ZGZ)Z?ZM@>/5J*&P%*P:A7"PWX
M#L>/"< \U!V)BF62$[=T/8B]Z-U#J>ARAZ5A_"+ RU9B7KOW&_U>_;<;[,C1
MR ^3#U]:7HE^(!U3ZS,])%4*F/[2HPXR-9UK9F1S'#Q(K(I+K.E_+@;?YU\[
MF,4R&&,NN?+%#:B"22CN(Y#ZY]GNL=$V5:?>[I-A^-/4XDXQLW<B"T@+&O:X
M@D*6,<H4F)VV8+O7ISJFCU#$1'M7NQ#>>F[@L%[#Q(6V7Q8MSL2%#)N.:KN-
M[^45%_3F YD^:KQC(#TM4=@.R*GL2BA:W.;HRKR/:E>V:.&&(R3Q78;?P1/<
MV)UE7V4PF/O_ )7LFL<_;UIA4LD>.!A==('%NE)2DW,]4/9T]_/ZM07MTB "
M>+QAK4)[".2)T WL.11RJ8)UL(!X<Q2*RN^VQ)X0S >18.5BD]3&RMY1 &>T
M5%_3EKRLPJ(OZ\8R (2A.L.U]5/9$1UF#[(I'[.>U*\"4.:VV3;64>BDMK:;
MV!5R:_.E9DJNB(F'B>9D]$3YD(.?RNLV:[:3'/8FBKOIC^[R//*D8>I.7E@V
M+L%VK2K85SN=DGA7L% R35JV9=1]WJ5Y[+WASBAKQ/,YL(52152-68M,AC(4
M#=C$[ '<G(OV/Q O2=CBI@2>U@KPN!5:^/(U%[J!W.1?'M9:4]:33O=Y^WAM
MBY$_5?'V\Z_M]?\ 2E1BAU19V WVJ06+2^>WVXHC$?+_ (GEY>>;3T[V.^T/
M4HUE30)*D;#DIU*W3H2$'N#[O9G2R!\]X0!Y'(_;\2OTBWD155:Z72" G0SA
M%?BF$T<H9 Q+'0S13-!!/E6&:*1S'M=#]VJY%1/MRCA]IO2W-3[U;@96#+(U
M*SL&7X@P,:NPV([';SVRYV/85[04C.U#3K *_$D6K402"-BGU\D*DG<C[6Q]
M#WS&'\([$:/T[^L#U/8#('9W5^E[N,JPU_6.DH-30ESU!V>N"2L_6W>-EL(=
MKF"Y\Q?GU1$EOGA0RBJ0..$N97#^_H+J;VB=$^T/IG0;FDZ]3L=1Z:(X;^G-
MXL%MH[4*^/(D=A(S*B681(OA<N(L-N 0^VB:_LYZXZ U?4Z^N]-ZE1T>V[O4
MU$QK-1YQR,8XVLUS) DCPR<5#,-Q"H!;MOZ2T5'?=%\\UWEVS7C&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCSX_7C&
M8_\ U5>M6LZCF.P77C [_L2.-([,Z;Q-2Y!TK&R1L+8U?%G<K&]KTK&/9 (U
MR26$R/\  4K&87-GN]CV'=3Z';:2TTMO,YZ_5V9+YFP,>[WK "-^46O%:[_A
MB P#C1)X2.)J<9#T[_IE)^5_Z>?/^O/&1QY7^G^2?_3C&=WG-/HL?;BW^6N[
M//W0;FO'LJ@R<$MGM<CO8LL#V++"_P!J)+!+[X9F)[)8WL\MXV'F0#MY;CR_
M#Y>7IC]_Z9EZ]+/KJCV)E?U[W%*'7:8Q\8=#LV,B"J[TN1[8QZ^YA:U@]7:D
MJK8Q2HO97'SJT=6"%201DL9DGM;8&EJC[FS*B$KJD$NRL2Y7>(1@0!92RR9'
M>%\1000R3/=^B,8J_HBISTB-(Z1H"SR.J(H[EF8\54#U))&P&>6945G8[*BE
MF/R51N3^0&1'T54V,F;.["T(ZPZGMBR=N+2.6/Y9-93FP108K-2HOYF_PWD(
M:D$J+_A_C+K<QK$>;*YUPU21?>%J1'^SZ='[I&0=Q)*K$VIQYC:>P9) 0?[O
MPE\DVRFIJWAM/(/K;+&9O^5" (8_3^[B"KY \N1.Y)R;^6W*O*?U.GHL9F[[
M6::T$I<]F:D^]O+8Z1L(E=558SS3S")'?9L4 L4DCOU<OA&M17*U%GU:T]VS
M!3JQ-/:M31P5X4&[RRRL$C11\V8[?(=R>P.2IIHJ\,L\SB.*)&DDD;R1$!+,
M?GL!Y>9\AWSQ+^O;UM:[UD=JDV:D'574V2+,"ZRQTCOE1C!+_83:>WAC7V3:
M6_:Q)B'O]_X:"Z"H'?[(")R^XO9_T/3Z+TE8>,<VKVU1]4O ;EY/M>ZPD_9J
MU]RB@;>(_*5AR8*O./4_4=CJ"\TG)TH1$K2K$[!8P=O&D [&:4?&=]^"L(U.
MPW-AZKYYG_EF-8XQCC&.,8XQCC&5KUUV)L^I]OF^Q.OKXS,[')V45I1W +O$
MHY$?ELD,T2_V18)L#I0[&O(;(+8 SSADQ203/8M!J>FTM6H6M.U&O':IW(C%
M8@D&ZNI\B#YHZ$!XY%V:-U5U*L-\J:EJQ2M06ZLSP3P.&CE3[2=_B&WD58$A
ME.ZL"00<]NGH:]76;]8/2E7O06C56SII8<_V3EHI/=^!:J(6&664)KWOG?0W
M43_Q&B(E_,X=\H<CE, +:SAKKOH^ST9KDNGN6EHS\K&F6V'_ +Q5+D<7( 7W
MB!OJYU7L&XN $D3.C^FM>BZ@TU+:@1V(R(KD(_W<X4$E023X4F_*,DG<;C<E
M3EY_,+S(,IC9Y2KW&6OLE=,>ZLT-4;5%NB=["!V%PK&PP27PKH#@I?EF E1^
MV44R" B)S9(VN2=7G>M8ALQ_WD$B2+OY$J0>+#U5ANK ]BI(/8G)<L:S1O$_
MV9%*G;L1N/,'T8>8/H0#E'=,:>STN)@AT3E=K\G8V6'V:JU&+-I<J2ZL,LV1
MI_PQ=$-&'IZUJ_F6KN@7JB>[PE1J-=(+3-$-J]E([=8?*O8!=$/_ #0L7@;_
M )XF'IDFI(TD(\3^]B9H)=_,R0L4+?A(H65?N<>O?(+]67K'Q?IBHHA9(H]/
MV1=C/FS>,@(;#[!_<Z)+S0DL;(^LI62M?'#XC<79D12# QJV(TH' >JNKZ?3
M4"KQ]ZU&==Z]-&4<5.X\>P1N8X 1VV!>4@K&#L[+M3V=^S;5.N[;.&:CHE60
M+>U-HRQ+;<S5IQL56:R5VY;N$A5@TAY-'')YS>Y_4+VSW[=26_9&K.M(&SNE
MKLZ,]X.7IFN5?:RKHH7_ $D3V,5&.-G0BQF3PI!<SO*ISWJ^N:KKTYEU2T\Z
M;[QP &.M%L?A\*N/A4@;CDP,A'VV.^=I]+]&=/\ 2%?W?1=/AKN4"SW642WK
M1V()FM.#(RD[GPT*0@[%8P NT*^?]?K^B>$_[<M/$>>YW^?;?]=MQ^ [9E0
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MN^RBNB%TD;TY+8\%8S\Y&[;;YU-[=ZVF2]"3V+S 6ZUZF=)?L7-R67A-&O\
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MBA\#G)4DAN-*UGLBK$!N6;CD8]#G=;*^)6%B"6I"(39KE"]EK2/&\G+@DRM
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M%PWDV)/8B=CR&Q#KLIV[[\\;U-]AU,M6F3 Q^*KJ&:E*H*3-TA2U-*;2;?\
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MX!QH(FHR*""")K8X88V(C8XHVM8QJ(C6HB)RD5%151%5$0!550%50!L J@
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MQCC&.,8XQF//XG7H_B]:/I0W/6U8)#+V'G8_X[ZJ*D1C'MVU *4X6J^H>B)
M/I IS:"=ZO2.-3XBGHJBL5,QZ#ZD/2_4=2\[NE*<BGJ(3<[5)F4/+QW^)H&5
M)E'KX9 VY$Y8.I=(_C.E3UD"FQ']?5)_XT8.R;^8$JEHF(]&RU;X(WK*G[\]
M.'^P[?E3#]U>FOZ?$7U?:ND9<VN,$D<#F+F<<CP5]15LA=E;CYGODA,K!YR7
M,DL(VKD'M5Z9_@VN_P 5J(O\+UQGLQM$%,45P@-8A5E[%9=Q:A(V#1R$C=5[
M6OHK6#J&F"G.2+FG 0N)#]8\"_!$[*>X>,@PRK_*4'SS-KS5V9GD4=I8FST(
M-3H<A-"%V'B#9KS'&$.<P(Z609XEME+Q\:*YV<UM8^6JL/<V9*XQ:S1BP/M*
M*N?'6T;$4,CPV59Z5M1%:5=BRKR!CL1 D#QJS?6)Y<U$D#'A,X:FLQ/(JO$0
MMB$EX6/D?+G$Q_X<H^%MNX.T@^)!E08#<5N_SH][7Q$@S,G)K+JDL6LBN,UH
MJR7Z6YSEU!&][(;.J,:^"=&/?!/'\DT.4@$H8F65:K25)VAD*L  \<R=XIX7
M&\<T1.Q,<@[@_P I#(VSJP'N"99T#KV[E74_:CD7L\;CT93^H(8=B":WY3Y.
MRGM1EJ#8T5IF]+5"75)<#?2V-:;&DD!$7O9(Q4_1\,\$T<1 I4+XR1"H8"AI
M8IX(I&38)YJLT=B"1HIHFYI(OVE/<;>6S*02K*P(925(()&2Y8XYHVCD0.CC
M9E/D1_H1Y@CN"-QWR$A-A<=)K#G.RB+*RZX@<P;-=P'D.LGU(SU58*7M@E((
MI:=]>WR(#V 8DM):!1"IJ;.OT4BDW=R:O'J8,])8X[K;M/IJ#PQ(WFTNG+]E
MU;[3TP1+&Q;W=&@7:.E65ZFT=CDT V$=ICOQ!\DLG^4CLHG^P^PY\7(YW#CD
M0DPQ3PS0SPS1LEAEAD9+%-#(U'QRQR,<YCV2,<CF/8JM<U45JJBHO+0002&!
M4@D%6!# @[$$'N"#V(.5P((!!W![@CN"#Y$'-_C&<*P)E##(*A#)/D@B=(P,
M-(7%$N:GGY4"$3#P+(Y//L22>)JN\(KD\^%@3L"=B=O0>9_#/2*&8*65 2!R
M;?BOWG8$_P!#F!;UM>H+N:F[F*_@[0]K]<YI::K@BJSF7&6@EL!XGM/G%@^<
MHI4;WJQ5,%DDAF=Y5KW>%7F%:O=MBUO$]JNG%5X-RC^(;[E2#Q9?+X@=M_4^
M>;IZ2T32VTB/WF#2M0G\:5FFC$%I@CD&-78J70A1L$<*1W[>>UN'7?J0]0]I
MN,J*_LWM+0"K?5CCJFMMKNV*,"87"I4,8 TDDI+GP^]ORFL7W^?;X^Z<H:]V
M\TT8-BRX#H60.[DKYD<1OOOV\AO_ %R_6]%T5*L[#3]-A^JD42O!7B1':-U1
MFE9.*!7(;D=Q\/EGI=RFBETU9'9NH=!GXI/"0C:0!E98RQ^QKDF<#]3.0,BJ
MJM^68P>;RU?[)$\*[8$4GBKR\-XP>X$B\6[]]]MR0/N8*P]1OY<_6:_NTAB\
M>O.5[%ZTGBQ@CS ?BJM^*<E/HQ&51R9E/FBN1/U5$_Q5.,9"FM[6(==EX'K"
ML'V^_@2**U3YLK,C@6$M166&\O1D?&(0R-["A,> Z767<7L>*$)6N)N0KE7H
M#PA;O2&K2VY1G;>S=(.Q2E"1\8]'LOM6B_F9Y.,3TDMD\S!77QK VYCN(H =
MMFGDVV7MW6->4K^BA?B'=]=];#8];6\MK$C4;[3N'EUNTL((AR[114D^BJJP
M*-9(J+*4ZSSQT.=$D? $R:<LJ8^X-L[0Z3;N&UPCCC]WJ0<EK54)XH#]J1V\
MY9Y0 99F 9B H"(B1I[@KB'D[,99Y-C+,P 9RN_%0!V2-.3"-!]D$DEF9F:4
M>4>5&;4\\ T,I!,T0X\$;YIYYI&10PPQ-5\DLLCU:R..-B*][W*C6-17.5$1
M5Y$ D@ $DD  =R2?( #N2?0#($@ DD  ;DGL !YDGT RWS"PR=LZ^#MRR9(F
M*H(C0>F:R>)\:FLL8'!7?:A4$[&/85?A.EH\5[HFR@X^:ULHYWQ[><42ZVMJ
M%8Z<A_M4W!]3D5OLE"'BH @[,L# 36/1K/%"N]8,U%"/>9A:9=HH^2U%8;$A
MNSV2#W!D^)(CY^#NV_UFRW$(GA$3]OMRTY79MRR-BC=(]S6-8BN<]ZHC6M:G
MESG.541K6M155RJB-1/*_9.0._IY_KO\A\^YV\N_RQGE-U!Q/Q>_BOTF9K%G
MMO25Z.97S6I<"K/1:,NGMUGL2O?_ ,"1_8NJK0Z,+V?,4G'9V0^'_P!96]"0
M*/9O[.Y;#_5]1]3 A%VXS0\XPL2$^@H5Y)9G[@I:G"D'D -6RD]6]61QJ2VD
MZ-W)'Q1RE9/C8'NA-B>,1CU,,/)>S;YZL88VQ1LB8QL;(VHQD;$1K&,:B(UC
M&HB-:UJ(B-:U$:U$1$1/'CG/8[]^YW.^YWW._J=^_P"O?-I?OY9N\CC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'
M&,<8QQC/EW^Z[_\ Y7_QQC/+/\1+K/=_#2];.(^))T/2ES]3]B:".K[\R58B
MPU?XI=/2+2@G1L_NXH6]"8ZWJ3B8U'KMP&I2HCY H)-_=%7ZO772MKH;5YE7
M4*4//2;,GVA##L:TJD F22DW**5>S25)"I/P@C6'4-6;IO68>HZ*GW6S*%O1
M)]CD0!*KC;BB6$7=7/V9PNVWKZ4.H.VL-WGUKCNV>M[H>_Q.ZHPKZALH%1'/
M&+C]SQBXO<YPE@#,D@5B#+XG".'(&F:DD3DYH[4M.MZ3?MZ;?B,-JG,T,J'O
MW4]F4_S1R#:2)Q\+QLK#L<V/4MP7JT-NLXD@G0/&XW[@^8(/<,I!5@?)@1DE
M<HLJ,@7<9:_R&BG[8ZX!EM3YX1X.Q\"*YD2=@4P3$B@MZ5)%:.-V+G _<VF(
M>Z"#55D:9.Z(C^7G;;/72K/%9A73KD@C168TK; M[G+)W,<FWQ>YSMWEV#&"
M0^\(I!F26CFC>&1K4"<V( L0KV,Z*-@Z#L#8C'V"?[Q!X1(^!DE+(Z[/[>AK
M])F;*&TI[".3Y)#&RQ2Q3C2O&- .$(;$77V=<9%.#9UAT YU:>.0$;! 5!)$
MV@G@FK2O#.ACD3;<;@@@C=61@2KHRD,CJ2KJ0RD@@Y41RI,@DC8,C;[$?,'9
M@0>X92"K*=BK J0"",JCDK)F;,X\),4L!$;)H9F.BEBE8R2.2)[5:^)['M<Q
M\;VJJ/:Y%1R*J+Y3[<;D$$'8@@@C<$$'?L1MD"-P0=B"-B"-P=_F/4?=D#2]
M1W&(F4WI+1Q8\19WDD]=7@D]QUD=)(GE[*JNAF@LL"Z21%D<N1*@I$F?,87F
M+$R>662Z_P 1CL]M5@:TVP478B(]04#R\20J4N >7]I!D  19T4 "C-5HN].
M00@'<UW7G6;Y\5!#0,3ZQ'AYDQLQ).]'W/9YMJP]L]=Z?#OA1/FZ2A$.[$Z_
M(1/^(3%HLQ72W%(%']OF$;C,9*)BK[8Y)V(DKH'34F(_AUR"YOY0RD4K@/HG
M@V'$4K^@%6Q8W\^Q^'("X8^UN"2#;_>H#8K$=OB\6->4:]^YGCBVV/F/B,DY
M'L'#;T)]CBMCE]8#'_Q"LY>UEQ%"OW16D.KRB$@D:OY7QS>Q['(K7(BHJ<H[
M%2U4;C:K35SZ":)X]^V_;FH![=^Q/;OY94Q3PSC>&6.7R'U;J_<^0(4D@_<=
MC]V1/V=VEZ9D$*R_;.YZE('<US#*#47>;/G8YWEOYJR>><J*5/"^V1D#)8U;
MY8YCFM5+38L:>5*69:Q4]BKLC;_EW/[_ "S(-.T[J$,MC3:FIH^VZRP13)N/
M^KBJLOH0=P1YCSR.>K.QO1!AV.K>KMMTIG)B)')(X:]IJ^S+=)(JHR6QMB([
M IB/7Q%$XF2.)OM;$UK?"<D5IM'A/&M)4C)\N)52=_\ F;8[?=OM^F5^IT>L
M+A$FI5=7G5!L \<SQ1@=MECC!C3\%4=]R>^78S:;."4JZ$F_I1Z%D"3ONY[4
M&*I;![?/SGV4D[0FQ_\ ^Q9D9^R_RY=XE>P56NC3N_V%A!D9_P#I";EOR!S%
M90:_(3CP"F_,2CP^&W8AN?'CL00=]MMLB5?4%C;=)8>MPM!W >QZPL9UO6+:
MY]9D=['1D]@6$]7UT ^-?O+";K(2T:UZQ"S/8YG+B-)M)L;K0::GFQO2&.;;
MUX4XUDNO\MQ6X[]BP&Y%$;T+;BN'MM__ !U+Q@_)ISM74_-3+R'F5VSB.RG;
M'8KE_C[0P]<Y<A%;-B>M+4V;2&CN3Q\F][->/6'5Z2-\).+B:RF+@?Y9!JBH
M_P S_0LZ;3/]CA:].-MK5Z-5@C8;[^%0Y2+)M_*UIY%)!)KKW @8K-@$3R"O
M&?\ <UW/BL/D]D!2N_?D(E7;?82$C<R_F,CG,94BT.5IZ^AI@_<H]=6#1BCI
M)(Y7S3R)&B.G*)E5TQ9<[I"BYWOF(EDED>]UOGGGLRM/8E>:9MN4DC%F('8*
M-_LJ/Y4795'90!VRJBBCA18XD6-%\E4;#OYD_-B>Y8[L222223E1\E9,S1SD
M:BN<J(B(JJJJB(B(GE?*K]D3]U7]./P\_3&6S'$S>H4^:G!21G1-26Z+06\:
MJUO<5B),Z.?,4\GE'2];UY47LT]M'_=MJ3&N< F)SC;Y;.\@?P=%D;_\W==X
M8O/^&HP^&>7;RN.NY@C)Y5@1,X$WA*MO.]YB@.U)3\;#<&TRG^[0C_X<$;2-
MOM,=XQ]7SY7*001#QQQ0L;%%%&V*.)C6LCCC8B-8QC&HC6-8U$:UK?#6HB(B
M>$3EFW))).Y)))\R2>Y)/J2=R3ZY7@   =@.P [ #T  ]!Y#-WRG[I_GQD<P
M>_&>]=MCT1UC7>F+I@HRQ]2/J)@905 6>=)->Y/%VYBTQ5M%$-[IX[K5E+/F
M\Q'&C)U<EO8Q.CDKQOG[5]E_2:ZM??7]45$T/1'\=VG[06K42^*(BS KX59
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MQKG.5&M:BN<YRHB-:B>5557PB(B)Y555$1/NO&,C7J3N/J[OC$A=D=.[C/\
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0QCC&.,8XQCC&.,8XQG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g367280g28u01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g28u01.jpg
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M%2$*%B(7,3AX(R0E,CEA>;<:L;8V6'1WE[2UN-?_Q  < 0 !! ,!
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M_*L&6)EL>;7/6_3&LD?EGW3YG5ZJ-,USZ[D5ZTUMRC<*N&.K >0G./:D;B9
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M(DA*GQ<M%E+'8>;%()?)8>=7664@HULC<@QEQLACXK$B4[K0O UB 'ZN1HI
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MCBC5G8^@X!(V<5B<CF[T..Q=62W;G/"1QCLJCCJEE<\)#"G(+RR,L:\CEN2
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M*Q6E>&9#Z'AT*MPP[,O/2RDJP*DC6]<I4\C6DIWZL%RK,.)*]F))HG [CE)
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M/E.""F(6.(/R&-E6,IP29EC H_K_ $^\ZCU?I\](.Y ^>@G@$ZC[5]3[<O\
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M+1_YIL>VAX>EURMU]!+2YE8B 9R;F+/8'0TO"PP4( _$_.=9+D9E@%AQ+Z\
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;'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g367280g36a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g36a15.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Q44&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9R)F8         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  (0   $CP         !                          $
M!(\   (0                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (0     %)G:'1L;VYG   $CP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "$     !29VAT
M;&]N9P  !(\    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     $<0    !    H    $@   '@  "'    $:@
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M =<T;W;?3V>[\YVYRJYN1FX]U5&'8;K\BPRZW45["?T=?YCK;6;O2IML_?\
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M*/M_YK]3>BWQ/C\_%3*^5DDU<*Z/_]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H !P]?@  )Q  '#U^   G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,3 Z,3<@,#@Z,S Z,#( <G(R.3,Y
M.3@       .@ 0 #     ?__  "@ @ $     0  !(^@ P $     0   A
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.#HQ,#HQ-R P.#HS,#HP,@!R<C(Y,SDY.        Z !
M  ,    !__\  * "  0    !   $CZ #  0    !   "$          & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M P$1  (1 0,1 ?_$ !X   $$ P$! 0             &!P@) @0% 0,*_\0
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MDG)%JR;6M@(]EKY$E-'CCCD?(UO2E*:JM*Z[K:^XJ31;*KM0AK&ML IF$!G
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MF#MY.0-AR]4Y4*R /R7&F@IL3F:&&J:0;&G(U99V[[EM,D$L%"0*Y3(U*?\
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M!;Z2BW7'&XREC65(-]F8SR,:2-MZBPW=5QS :#8UNJ, S,4>DOZ%QDFU)H(
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MY?+KY^7QJ5?!7%P?#.+GS#;T:V=9Z:_U!$H=:)G,^&;ICW%OJ<EFA)YP,YG
MU],=52A3S11HLI#Y9229Y7J4\[2!GO?&PB%\D?I]R-LC'/C1R*YGN,1RNC];
M45S4<B>6IY3I2HW=UX4QO%L*0<EY_C- ]CE+.<O5Z,_(9?7BUEA\:5Q[?Z>I
M,!N*2KUL$,@)!]7,\J/TL1X=@*XD E2HS5,F:YV__"X-GZ'9X2YO:P+D?4#M
MWFUD/SG&'&5LZ$2MD-;<CQW(.]U\M/75ES9A_&:;(/MBB$\*L$:HZ^O7KD>=
M*K/Y>HL+/NNY&R\UV-B:3C_9\2YH*?3:>WIK[05%/8W7).NB"N+@\!5AT,@.
M+JR!H&?!/RVAB&=&/8RQR*GS_P Y]?[^4Y<FOC)YA7+X3\W:3ZKY\>?E@OG_
M )^O2E=]7-_>;_[R?J\>?U_J\I_#_#I2CU-^WJ;Y_9Y3S^OZ_P OHO2E>*]B
M?=[?V?54^_[/OTI0CV*OCUM_]Y/O^SI2M*RL&5U>;8)"2=\$(06@=='\2<5[
M$3Y4'#'1S5F(F]'HAC14]3W(GE/KX4J!W(HU94\T<=;'DC(;+?Y*YXIY55[H
M>*+75$55O;ZGC*RR^<M:W+U%J@ML#3#7XE879>W.V-IT$93(W2,Z4I@LSB>[
MZH;VSGW>(L=#68N]!?0TAO(18%E5MNPM\9*[E$1M-;S3D4-(7F<Q 8;9GAUK
MJ\GTNDLKM)H%1Z_V/M_K-26[3\]SAGN0.:G\QYHL*PT4V'ORM-^=TVDI;2_E
MK+)EB!EH7U%8/6T-4)\%7B !>IE>. )"=[]@44=.H/7K\_#KYYIX>3^:=%G-
MVWCK#9G*VMS7XE_(VKT&^V$N)QN9R\MO/15K2;06CT!9%I;609_L0J$.",&
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MS7E/<P<KBQ6E/9CZ.;-U!4*4=0'K3-&,^A<@R9&PE"F-$*%)?)& #YY_(XJ
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M%%\_X>?YIY3[*O2E;?"Q15CQ^*6>3.62_1[^!9R97SS+$)O].(+&LDKG.5D
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M\,4TCVKZ_P"ZDB>Q'HY5:YB+]E*;.E[=^W>I)M1JG.5[)-!G]+DUJIM/=%!
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MPI36N'30Y[CLBLAJ"82T9FR)'$Q.);$BE,7HNTG9:2YN;BVYPK5UVAPVJ(Y
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MQ@=-BZI>(MI>1W(6BMZX+1&S939 5-_>APVYE8!J/E1EHZ=7 %5AAU:4_/\
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M:=[,G>XR=_0\X^7GU'&CNNRW9?M5IC06]V&OI9FG++B3NBV5[KW1PHDQ\NN
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M:21B#R':A0F2/?"Y)'NBA)?/$C4DD<Z)5:URM7KL.RDMC:W$ES=-M:(+[AP
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M^:1G-]+EEX[LD157RYAF8(!:]/X*^I>Q/"^/+'?;I2L.;?\ P;S'_K2XK_\
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MC@_W?+X\C'3YHLKV?LUK8O[*;OGTR\200LR=U(TEV5V2APRD(&YX(XS\ZG>
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M,^).!QFO(]5T+4]%"F]@7N3@>TPOWUN<G&$G4"*0C_L$+8\2,$#[<*<@]O\
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M2CCR.B]:L^JE0=T/!L>IX@ W_(FRM]!N+2EL-+&0(<<,\4*OJI3XH T@G:L
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M_"36_P!KV_\ <_VY8371@%MJM;5@\A90?/&Q ZN@>6]7SS%_*%68%TSFSP7
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M#V8UR7&/ O\ =D-RX:3 O(8_W%,N9A&,E^'F6)4#UQCZ_P 59Q\[JOB8A%L
M?BIYYAX1OCQ/B99QT\DPQP^ZLLDHZ+YGB8Q9(_\ MM;TJ:^HEI7G3$0AF"&2
M!R^R6P8J"=XLOCRD1+87O=!*J?B2.5&/5$7PGT7I2M_I2CI2CI2N9<U%=?5-
MG2W L)]5;5YE79 D)ZH2P#AY1RAY$^B^W-#*]C_2K7>%14<BHG2E1WHN1&\-
M0+@^7#YQ:ZN:P/"\EV\_JJ-I3M18ZRGNK)S&05V_KXO:K2PC58FK]F.YJ)R"
M"3Z^NKC1I9%C0$LQ4?#DXY/A_'/@:Q[BXCMH9)93MC2-GW$\':I)&?,XP///
M7KBI;\X49=[&]-M9I^5N03K;55-=7)#!>$?'O(@KS&UTSOBVU-33##5XZ0Q(
M]S17O1WJ25>O;[2>VCMM-TP7-O#;VB?^P&!(E;:,[2I VELD%L<]>,5\336M
M\;CM-VE]FO[K6M4N;JXM)HD.89G<PV6\L"3;VMJJQ".,9R1C(SN9<KCQ^BT
M W)!%;M1[JLN\TV ZG0.*IT%:95Z,86$AYDY3C(@(;SX3U_#G0HLI"RI_=M3
M(EO+8W4!@FB*)@3C&3(N", 8Q@<'H?KXZVQT'4;G0M2CU^674KPW5K<VUQ)
MT4EH4D9I5M)2>\W'?M#;U? P3BOIS6./J,SE.-I-%S-6MXVTF:T&<BS-AJ)[
M$2CSQXBZ6PKPQ&7M:7GZJL_%-8:"NL:NF>VOL%;#/%'"_2Z]8::+=)6%K;-<
ML<2-&"V[)QG^W''@?U-=GV.U7M'WT]AIT>O:G;:,@+6\TA<RH#C_ -<O)A4R
M"%9B5]WH!D5;5Q/W5TNUX]U!NCK)<'D\A@3Y#-#KKR0QA$$4 U>!9E7MBP>2
M8<Z$AOJ..3WSS'RD)+-&ONR<#K>A'20C^U17(D"$"%6XW@MGWCR,<\=!7N?8
M/M^_;&6]MCH]UI<M@LFY;IUD:4QN%RI0#CGJ>ISC@&H":#E/,:G(<3YW!Z8K
M(<@AX2IO9[\5 S;+2L>)7EZ$"KKG&N1*J*.,6(TZ6'^[1\40D2)&V9]>A:&-
M60RR&2)1D8.,C@GPQ]\X/@.M8O;+\3$[.:LNGV3B[OHXA-<6LN 8E)&=P8$$
M*I.#CGG/3-1W3OI=Q1J=_3;V*RUY)7(I9Y(5=B+:*6U!8$-5G0OC<*4VQ'G8
MT<NK>,]6Q/B21$1I*HRH=GG]GND"!GAR=V#R,L,#Q\!T\ZQKG\6+5=7MK);9
M4L)[+VMI#+'MW;0S1KCCC./+KUQFFZ[%^X/.\4KR]-K[S=UG%M_R?8;'BJ0"
MFL!S,!5'V5F/:9>VH7H.6[/N,F&* N01K$8";XX&QD@CA80VQ'V;U&3&U4'D
M"2!\NG'7Q^F323\8NS>FW%]#K$S6L5EW1[]2LR2B90RF/81G"D9YQG@=#5H_
M+?.N>O\ Y9)Q_/:+4OJAX[XZS'9*!:S3HQ4E]<WKED<CW^&K'Z6>7HL?7<=G
M>SSVJ3W%[L[R%=Z%<\#:2,<#D\Y\>,8KS?M_^(NFZP>\T&:3_C1'%WLTL8$=
MRURXPD:Y;)'_ &XRH&[YQ/S%3B>1P-'4W0='<Q%;;4Q3C>X)9P-22YE;,XB%
MSIY16_C:CXG>%5KW.:G]XB=;&$&=9W&)??8A5V>;>?!..O&?I7'ZC!#+/:17
M$<EI-+;0JJA61F# 9<D%9 IRO/+<@8SBD_P#F<S@>X7?G:/(5]WB.WWAZQY-
MX^I3+ -'W.Q,T 8%/5,BM50&!N9(%FDS$KY7SLMKF%(/90(>-=/VKN+FVM["
MSMW,$%YL2= V6!; 8G _M(Y/.2 .OCD?ACH^GZ3KG:SM+JL*77_B]NTFGM=3
M1JC7<VT)"TDS!5>-O<C=A[Y<E,@ "2'$GY4_B?:Y.YY8U_'FT#S]18-S]PDE
M2TT'-^[:RU;)"2WNGB@CM)/#VA%SH^!$8CYXQIV+'R=YV=>TO39I>0NQ@[^%
MU5E#C&[:N?\ MP1X<GPY ]:T+\<;/5-*$]YV9U'OK?4S#JLMDJWUK LI'<33
M7" PI$ 2=A.4.2<#WJ?'NSL. ;FTR>^--.,N<4(3\4)B"ACFV%+.#,T8&P'
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MMW$=<'([*<.X#&8*_P#67:4 &<J606_O1M_VBQ%6%[9 FM8GH#\_#QK))+'
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M<IRM@,AE@(!8MT:1EKBGK7K&RMJ1)0K8PIM= J0L1U/765-(@PT*&,M86O\
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MUJ@OM02-9%:U$4!A>.?< RR,Y&!L92,\CK3D]TEIF,[HMURR-R")4@5E3D\
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MQX\^N/MG]*8GO-'Y+<1Q/MN-['+@[J3</&Q6,NCV5#^19M %\J.RM';3-;5
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MMS@V0)##)$BH\6:21/2YSY/$<K$\HU&_5?*ITI3TY_M]X+XYKR:?\S(JRO\
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MAPV20.!N!X)ZTA^ZCM]J;=^)I(L9B+W(G8&3@[".T=P?00<(7$@I]M%R%2?
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M;?0YN"Z&N,^$.R[B,@#@K)U*"G)@:JQU-9.2LD;HP6/<]K%3QCZ=?'^>?O\
M6DMV@4?/0U-?\A8H02XQN@L]._*&WTU@VP,R,6IOYL\9*A+&S?[77DQDPN(:
MR1P$@R2,8[U]*<^&/KY<^7Y4J,7LA@>1MUON>:.A6/0Y\ #'7[X8S*=*ECK#
MU,FDE9*@R+9$1S31R>TZ>+TP.D1'*C9(5MBM_:#[V.N,^'Q_+Z]*'C>:&Y56
M7O-A-L#GB3!VDD>&[ . ,CSJ ''7(BW?-'*--G^4BI^0<IQYJM'@,UQ1DS]M
M"W>2?" @9Z.22LD_-_#Z0<JO,6)753ZZW:;)#95[HF2G;&6*UW6<\+!8ED42
M1$CO&/"L< <H6&%Z?7@UP&D7'::>S[1:%J\;&_BM99;;4K0DP&&96>VBC,BJ
MW>PH51_=P'4E>,5)CMZ[G]9P=6WF;Y7RFKH^<=ZTS3F%'9V$^MET0M-7L%PY
M^KM9 REK7*.A]2V:SL9XV%6#")8"(G1R=1J.A+J<EE?VDPALV55]G _J(X 6
M1L#@@L"<@=#\./$.R7XBKV(M^T&A]H+6_E[0&\N;JVO'@1WGC]YK>TN;MSN,
M)+H3AFVH,@@J:5G"W/H_=/R579[D;)7,2.CO8!AA0T*SY-EG)727#CU:9,X:
M0*!XK4]Q7PS$O5XTDC%:C=)K?9FYT4*96CGMGVRAER6S(N[!)(QSQPO'CR37
M>?A7^-=A^(-QIVERZ-<6VL?^_'/(-D=@392-'M1>^,N[806)B );*L1R71[F
M%PV(GN[GC5M>?SF-BUS.</LHK,8S-YR0V-76%[**[U6&>KI5D+@K6#R%G2"M
M!0N,-)TBO=G](FU2ZMU%Z\5K9DSM$S-W4F0,A0/^QXR2<=.G6MA^*>OZ/V2'
M_)6=@@[77EC=P6CQ];>P;W)I[QP!_1B\%&7)VY& 2(2UHM1@N+::CTMG765?
M835H5Q9#SL?$46__ &BPB@A5_O*+Z1YIF0>ARB -<C_$$#WM]2F%G%&'N2ML
MN"B!CM#'_J1P?[NI'@?GS\GZ197AT](K3=J[7,[7%X]H1*T/>2AI7?.,1;L8
M.,J/<P>#3VT6$X%BD,UNJ&IJV"CS:VE(<V$;TR0CM<8DP$L#',F=,KH?:EC<
MY7L<GMH]LB>>6[1VK#3_ &FT=65O>!7@YR/'./OX\=*]M_#$:;8=I&M[Z&..
M>: PHEPO]Y5G1Q@[O[7)#9P<CG--+LN?".:9..:C*<7F%D8K; GUUH: \2$%
MAD$]*?9#1K.-(2XVCL38T:]$\>XU8F.F1C5X/3]6O=/NH[N)PTJIL99.8V!Z
MDC!.?#C&<#->]:YV)[/]H+:*SN8.X2*Y>X+VZH"'>, ,@]W@87C(ZGQQ6[@N
M->?>2.6^10<#58^AWX'';U!?4:!:A8<OHM!$$*=?VQ()AM+M++-L*KI"*R)Y
MP(HS1VDPCN']%S5-4_Y25+AK>*WF"X<PJ%#MDG<< =,^?TJ_V5[,1=E]/%A#
M>7%TJW#R)WS>XD1_M15YP><L <9 P<#!M [9.Q6FX^"M=CS,#D=MRII*!,M*
MHH3CZ#(9-LDD\=#1&6@T1QIQ)$CI[:^GA@((G1L0L4,+))"<&.[N8"IAN)H\
M$$@.<,P.<D9P?+PX)K.U#L]HFJ33S7VFVMT\\,D#//"DI6.12&5-RMLW9/OC
MWAX$&MKC'M!PEAI2]$79VY-#@^9]7<4V++DA*JIKW/V\J4YUB21$\PN,&5T)
M<0[G_B+&'DEE='$D76XN>TE_=6/L4B1(K*5DD10&D7PR?/G]<^%<Q!^&^@6N
MJV.HPB8QZ:EN;*SD<O$ES"I!N)&;<TK<D)N/ "^1IJ.X+M]H-!RSI&[?-8M&
M:BXDY6'Y7)M;E^L?E<[19W#P\11YT2N<IC"]385),+(;":OF +D/=6OT$4#E
ML:/J=Y9WEMW4SB)" R!MJE=VYBV2!Q\<?.LCMKV9[.:SI&I1:M86LOM,)Q/,
MH:X>X*X"1LJ=[RVU45"3@]:JCY&J>0;;E/)=M-[B[7B'*\F6]B/6\N\TULE1
MQ[5!A %2PBUR_$AGK):+ HE6(9,&IA$S87F0QN8B]YJG:**:-Y(X(Y1&N)6A
M4&1AD?W9S[Q(ZY'&3C-?,_93\.]0CU:+1]5D_P""LV:>33VOH^]>3*XA2U8,
MI0%6X5FX VCG.(+W_9IQN;HUTFJT. .H<C>:8>TM\2E?34NA(RUM:T(CHIJA
MH!QP-I(*EB YS9V?+2('.,>_U1NF&+1[S2C/%%[/<N4*[SSGW200,#^T$ $\
MGPKFM2N^WW93M6^A1ZM::MIUD\[PF"UV3RM,O=QPS%F<M)!M$BD,%7>/>(&!
M^E_\EOV\6O%G$]KR1JZ,7+:+E%:Y,_E@HGB"9OC*A0G\SA)@?HD-E;O/L-"?
MZD^(:RP!A(<V>&5G7":Y=QSW"P0@]U;@J#_]G/\ <?R\?/RP!]2?A7V8GT31
MI=2U*6XGU?6W6XNGN23*D:DF*+ECA5W-CJ/EX6E>%^WCZ_LZTE>I4=*4=*4=
M*5G(J(]ZJOA$7_G^GU\_JZ4I*6MW&.Z42K%4ZQ9.)#*B+[00DQTB,B4\U$\0
MJC'^])%$R8I8E:C8T]UCNE*@ES_P3C.'^).2>0N/<V+FMV3B-%4W/(-! 3+H
M8Z:TE,LS@R(2IR?C**,XT@CX))QY18F^ IAWQL5%/7C]?''Y<5Q>R_B$JI[>
M0(M715NY(N@YI\_=5]T)9U]WGS*2NGKWENN"(9:R1QSS188(X)6#APQ/E\OG
MF?*H.E/+F.!:NP@&K[3/YZFN<E4TE1%;2CC:!ZJ%6.C@8R)7BM= "I1'H4J7
MP]'1QN@=Z$=TI3#[3D&]S'*/'G:U>UX:X[5%V98VXRX#QW3M#]N>:JNJ@=9$
MIYB)#'*PT/W@IH4]"M&D8GJ4J4=?A:3A:^H",."T6IT1[*G2,5CFU\;)VJ\2
MQ]*._P"_OB6,9ZHVH^1'+[Z*GCI2G9T?Q$9-;!=0P6&6DD3X@U__ 'W"9.[T
MB,)'C9Z'AJK_ $J^-&JBM:V3RGE>E*B5W9=H&(YLKA+P^UT>3,R8IKJW3XF^
M=0Z:F'*8Q#*^,A\!8=K1D/9$7/2W AH\<[7& -&,]4LBGZ509SSVO]TW9?2)
MS+Q9SKF>0J))9B;>OY B1YT8!3IGP3 Z>F <3"^ =(VDPD4[V?A>^.1B>/4J
M.GK//K.3GY_"(G;7NA^;^XW$\D=P_*_'45'3Z*/3T./=96H8$MW+!&*_3,.O
MZD!FB<@\(PU8V!!81T;+(Q)'K&CE//U\?WJS_P#*)_E3Q<R 5QOPS&[2C 4D
M<MO>U=I65L5/7QQ?"O#$LBW$O^86$<7F".K /M&CQR/8P=CV$HJ:CQ^2UYXU
M_%\.HYXM:2NN> +H@@[5EUVQ76Z/CVW>9,\BS, +$#FEI9H"!ULW5\AT@DD/
MS2>*-A!20*CS^G/KP'Q\SX5)CO4_* \6\FZG'U?"G(Q%L?9NSP][G@$'N\T/
M05^JI;5UW;50LXZ$O83[,4(UB2E828X92&S.@8QBAQZY\/#SSY4U_"/?EVV=
MKN@M<O9<C \C_/@)V55#94^?JRJ[>330OEMM">#/&5)6L5"$.'BB4H@B1Q">
MJ5R2-?KZS3\_I_K'7[=*67-7Y1NLV' &MS^>$S5U>45SGK0_D+-9<RCR0PL>
MB'N1@IE*.+B',KW5[(G0CEV$APT+YYQ@'Q^Y*IZS\_KZ\*CA^2@[):KO/Y.Y
M-[I^9I09\M'HHZ2PS<PL0FSWA=>,.4+7W,PR(_,<?@C$00D@#2?/-99H>PLZ
MOKX%'+5(^X\_GZ_3Z?I6E)XD[?B)DQ@V;IQ#*?X>DX\S@(=6*1%0^&E)GXZ^
M.  5!/B(G'*L:CQND1T\K9Y$=*I45;&X-&N*HBZJ5FAY-Y"AO#S1&#L)J)]#
M<,'@KG^Y.D<K:\*:.-Y;U]*P02._"BMC;'!)^WA]O/Q_*G'.?R\_7UID.1>W
M[@"@[BAN:+2JHH=#QC@[.5UA7&"I5E2\AV!U70!W 3H7 SV%)7YZ\-&*$= 3
M\1;!R$S3QQ1L<&-RG_N#E/@1CD>'3\ZH)9<@#^[ 49VK]>/'/ECGX8K*LS5G
MW,\:%9>\,L:O"U@!]'5TU:TEA-E2BOF]H@JP5CC&#21(UT(S9D8R%B>KUM5$
M36ZO$TJAF5>\3<3(P  4J1D>.1UQ@#SKL^QFK0Z?J40N\QV\Q1)ECRV\\@#"
MX!\,<8\>O-5D<G\<#<!<>0-QNMMZW6UE;J*2DOK\.TMQ9(FV_LU(I<_M63%:
M-/"UXC2 )4@/A'.$D:_W43R#4I[A[V!88I'99>9HU/=*N<8+D]?/ \.,$8K[
M-[*Z?:6G9S6)YF@FMWLVNHB[$-!#M#/OA/O;N[94]T\LQXJUW8\:[;DCM#S:
M[R\HR>9Z2DH+FK)HK@3/P![*J)BD"N?SFTM? (Y6!)YM!K 2N"M_4;"C*YL[
M"&>I3QRQ:$L4O<2RS0J09FPB CQ\=WECR/2OD+2-2T__ ,_BOK:"Z6QFU.62
MVMK*$2WDT2)*LD2PAD :1]CH6(& "QQFJ9JFPWVFVK=WGP;VKYFRG+U(#+GI
M+6EN<^^PD)ALL_KIB_:%@NJV(VE*,E G#CK% ]D*%KCHGR.\\L([BUNHKJVN
MH[AD 66$G=&NTX)48 '.1D>'TS]0]HKO1;_2[GLO=VW<I';[2X,(N(;B=.\
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MC?'J1K_:1DJ)ZXE>QR/<J:15._\ [O.]3Q]5XMXP\I]/_P#)^4D7Z*J+_O\
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ML5*)]4SE00/OZ(^H'[U1KW)#]W'8I86G'3^6L!J..-*%..+=:M#LW>CQ$Q2
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MG=M9B N< ,HY(J5&+[8*;C[D_C2]P;8RZ"UNE$LI+TZ[+E&5**[E>=80)9Q
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M5:6"KRV=Y"O9!MY=3XMD%9#!F5XTQ@X4,Y8"N>B[PP(F1Q%;*UE54UJD\/\
M)O.79R9F3+S9VUSRER#C=[3B;G630ZG*\80\H9715M1^<:0#FB78N#I5N?4J
M,,'O["44>6-\4'MJ@C(^?KZ_IX5]M#Q9W&YKAJL[=<UBQ-?A!+NXQ5MLZ/7Y
M;*:NYX&40,RLJH:^X^'!#V=S$<9@-3=R2/=*#4V6N&BDM] +&"I^G[>NOZ<U
MYQ[VU\FY[N0"Y)ESE=1YV#::363DP;"$W-1X^[XQ$QU-B*KC5D+@*?D:DLQ
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MTI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI7OE?'CS]/^?\
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M^)/NG2IVG&<<>O6.M9=*IHZ4HZ4H\_J_Y_7_ *K_ )KTI0KO'W7Q^S_#RO\
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M5C\'#X\>'?Y_7Z?7[^//]>@  QU'_P"XEO\ _K-1M'D*^B0,3]Y?YK_].FT
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MG)GG<]@\0D+&02N*60?*EFF:Z%K"4C"VXGFE=2Q4/(T<2HI*KDF.1G+9VA0
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M%RUU;))*H2=&D@N$'1+B!VBE"YYVED+QYSF-E;)!S7?ZLUFT=*5KS_\ 8_\
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MR.]!K7%V1\S841WIDK73N^>\FO;6&225OZ06YE8-&D>R.)_<C"JO))P_O.S
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M-"&MJN*O)?8.JX5C&CF!,'6Q@@B=/\'.^5Z6XTO[5!:P16\L2*4@GDE:,QQ
M8B66(1N96B7"9#IW@4,Q#%C61<7&@:K.VJ7]SJ%I=SMWVHV-O9Q3)=71YFEM
M+QKA!;K=ONE=9[>3V:21@G?H%%<#59+D&HU ?(6(&SVLN2\J)CMQE[\^?,":
M6OKC#+*HM::X@ O8JFRJ3;6[9\N-KC +(&XEAE,#G"'FEV:A@JASN<#WFP "
M?' \!G]JYF5HFEE:%&BB:1C#$S]XT<98E4:3:A=E4JN[:N2I.T9X37"G$)V(
MUW(F[EP>'X\_/"FR%-48G(',-&KFYE^C(-L+"T%HJ0-I=^1=BM(@ K9V0Q5
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MZ/;VT9#W,A9YHK?46G"P6LLN2C/:236\;[ D[('.Q;T.EK[NPOJ(*MT$-_6
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M=H@UK+=M+H5RUTD$,$R6\QNDGBM;BV$<SJI>>".*16$D,DL>7'W/YAP8OQ3
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MS)WMM72HBQ,!=\,0Q)WN:WWHE@_Z[PQT_P#+Z;Q_[MOS"+CB1?\ X#NQ*3G
M3W&P20"5('-!V0[3D,?^#U$;+_\ XM@;=U8:CF,&S"'#&X'?1L8P"0CAS[GO
M5\O[8>,?A1CEW.<:&982U(T[K&%K);&"$2<@5%<YOI<+&<'\8YZ-C$<5!&1)
M#+*UG4?\OI>Q9/;K;8TAA#&0 =XH1F0YZ%1)&7S@+O4,02*G_P .[4F:6V&@
MZH9X;=+N6,6KEUMY'GCBEP 05F>VG$(7+3"&1H@RJ36W0\F8_1"ZD\"XA97X
MVULZ?0G'-4$4 FI;ZC)7S$I&Q1(T]2H1ZTC<D;W(OH]+G5P:E:7*W4D<P$=G
M++%<.X,:1M#PY9GP-O4AAQA2<XQFS?\ 9G6M-FTFVN;-S<:W96M]IL$!%Q+<
M0WA*P*$BRPF8@9BQN!8#&>G#O>:\'0US;@BW^(K/:OYIB!$A=*.N< @L+ :6
MO(E&M'%^P2.Z.$<*=R)/#)/[$$C)GV)]9L+>/OGE+1;+AV9!DJ;6-995*,RR
M%MC*0%1A[RDL 0:SK#L3VAU"Z-E#9&.ZWZ>B13;@DHU.:6"VD6YC22U2,R0R
M@O-/$#W;K'WDB%!WZ;DO#Z"P&IZC3U)=P7706L54PJ)+!0YQHC&N<,Y4>V5@
MDT1,T'A9X89&2OB2-S7+DPZE8W$B0Q743S/&)5A##O=C*'!V?W#"L&(QD Y(
M YK7WW9K7M-MY;R]TJ[ALX;F2T>[:)C;":.5X& E VE3,CQ))_\ &[J55BX*
MCFV'+V#I2;$;0:*MH'5UP72.=:&A1M)+!KZRS,^':.01(QHPEN%).PU@A$3'
MNF? @WIG=:DU;3X9)(Y[F*%HY9(2)'4$O%'%*^ I8^ZDJ%MP0@'(!7#')M>R
M':*_CMI=.TN[U!;FSBOE%I;S.8X)[FZM(3)OC0$RS6DRQ&%I4<KLWB0-&.KJ
MM]3Y0.I)E8=<DZ R,#.5% -$?:7YDHLIR15L;R!Q?;8"/.9,668(".-&Z8@N
M)GI5;EW?PVB0LPEE>YD6*VAMT#RSR,AD"QAF1  BL[.[JBJ"68=:Q-)T&^U:
M>\B1K>RBTZ%[C4KS4)'M[33X4D6$M<NL<LH=IW2&."**6XEE8)%$[<4EX.;L
M2ZWHJ*Q+,S]IH*L>R"$T8;:8ADI5M)205)(QDS"HK6:P@GCAC9#*),QC9(C9
M&SC+/C)K5D9H()'>WEGA654N4[AU+R]RL+(WOK*7!VJ058#*R$8SM9.P^OBR
MO[^VAAU*UTZ\EM9Y]+F%]$4ALQ?R7D<L*&)[1+9XW9RZ2J6P\"E9-F_2<QX&
MZ2-K;T>N)F)NAX [.2 <@AE&9;BSEQI'++$T<N.BM+"N;++$276A3E-'1L4J
M1W(=8L)@#WZ1%GF55E(0L(7G4N"3MVNMM-)'D@O'&[*"%)%B^['=H;'<S:?+
M<1)%8R23VJ221QMJ$%C-%"VZ-',D3:E9V]R41HH;J>. R%I$W9"<T\5'O9&%
MOLT5)(V=[(H;&*29S!ZYUM*]L355ZM;7,>4B^/[QD<J1^M\<C&$UG2I" E_:
ML2"0!*N3B/O3@9R?Z8+C'502,@&HE[%=K;=2TW9[58T4H"[VD@0&2Y%DHWXV
M9]J98",^[(Z!MN]<[MIROQW31/FM-A1A,8\2'U$F1Q(LQ];'<"1HKE1JNEJY
MQ[!WU\0B$03D+#'-&YUR75-/A4O+>0( 5'O.!DO$)U SU)A99/@C*3@,,V;3
MLGVDOW$=IH]_.Y65\1P%L)!=/92L0 3A;N.2WZ9>6-TC#,C <_-\R<?Z2.N;
M!H@0+.RI67T='9D"CVXU=(#\T:\P:*>>.&9*Q6V+QDF?,P)R$NC2+\26K?6-
M/N1&$N8TED@%P(9&595C,8E]]=QVD1D2%<YV$-TYJ_J/8SM'IC732Z;<3VMK
M?/I[7]K%++927"7'LF(93&A=#=?^LLFP(TX[H,7XK[5G,O%UN0,'7;W,F%&.
M<P6**R@]<CF@?-'?1SF^AOR_R4Q[_2V2)DKF*Y8I6LJCUC2Y65([^U=G.%43
M)DGN^]&.>AB]\'H5!(Z'%-UV,[5V44T]UV?U6&&  S2/:2[4#7'LHR0#R+C$
M+*,E9&56 +KG-G,/&,M9)<1;G//K(;&*HD-;80K EB1!(4*+Y^KO<+&BDG$\
M-5A43%= Z1/KU(U?2VB,RW]JT0D$)=95([UAN5, DEF4%@ .0"1P#4-V-[5)
M=)9/H&J+=/:O>K UK()#:Q2+#+-@CA8976.8$AHG8+(%-=*/DK!RR4L;-92O
M70B#G4SF&1NB/%,9/()-'.GF%C2F"%?#-EDC>0X8EL37N'E1MP:E8$P@7<!]
MH57A(D!617#LK!A[N&$;[<D;MC 9(-8K=F]>1;UFTF^4:=-+;WH:!U>WFA,:
MS1O&0'+0F6+O@JMW0DC+[0ZD]#,;7*;)ALN6OZR]CKI60&OKB&3I!),U9(%=
MZ?K[4\:.>/,WU0SL17PR2-152Y;7EK>!S:W$<X0@/W;!MNX$J3XX8<J?[6 R
MI.#5C4]$U?17A35M.NM/:Y1I(!<PM'WBHVR3:3QNC?W9$.'C8A752>53UDUJ
MZ.E*.E*.E*T%^Z_S7_?TI7G2E'2E'2E?6']/_!>E*V^E*.E*.E*.E*.E*.E*
M9F_YGI,Z=MJ\RLM7D8L.N+>D2!K\[=8?!^1ZM'$-7WA?F('Q/Q/P[6,(;(US
MV([QMX-&N;A+&1)(@M\\B MN_H]V7&Z7 Y#=V^W;GE3GJ,\G?=KK&PGUJWFM
M[HOHT-O,P3N3[;[0(?Z=KF9</$;BW$O?=VH6564L-VW:DY=IFN+CCK[:60'#
M%[HE/AF0QH&,*&6M;"1/)' 4>L1L2O<,^46%51DT['N1B4+I,[",F2$"2^2P
M7WB3O8LO>,H!*1@H1AL,? <5=;M39*TJ+;W3-!HDNN28C55[F..*7V=)'98Y
M9RLRY,3/$C>Z[@D5S >;*XMA$$N>NH+ELM'!7TL4])8$VTVCC+EJV#% 6LU<
M.]S 2Y"FGEBN$AA6:1JM5/-R319E92+B!H@L[RS8FC6);9D25GCDB$I7<ZA#
M&K;R>,#D8T/;"WE$B/IU['>![%(+)7L;B2Z;44F>V$4T%V]M&0MO*TPGEC,*
MKN88(SNW/+<5"-3+99>_$M+@JR$CIS9J&NEB?5>RA'H//MAJHYY'O1NK(0#2
M);%JO]AG]VY$H@TIIVG[NZ@>*%8B9T6>13WQ(3,:1&9 I4]Z6C'=#!;!.*O7
MG:F.QBLC<:9?0W-[)<1K9S/86[HUKM,@$\][':3-)O7V5(+B1[C/]-3M;&R1
MRO717<F:'JK0W0N(IX0ZEB!PEE16M=':D&/9.3'\&'3"2(MG,2K/1+Z886SR
MO8UU*:5,T'M331);!9B\Q#LB&*01!<@?U'F;_P")4Z@Y.*N2]I[5+YM,CMKF
M;4#):)%:J85EE6ZMUNGG*O(IB@LX6S<O(!AAMC[QF K[Y;E2FU5W9T@@IXTP
M$-@6/,3\$YM@'5V;J:PFB'$*(,%4>P:D;8#QA9YX9(R(6/C<J,B[TR>TABG=
MXV65HT95W@QO+$)HU+.B(P:,AMZ,Z@Y7=D57I?::RU6]N;&**>*2!)Y4>0P,
M+B&UNC9W$B)%-)-%W5P-NRXCAD="LB*5/&S3<J9*Z"JCHC"@V7$R#AQGUIXZ
M^Z\R0 =I$WL.$&^+)C6,1TI#(R'K[<+GO:Y&TS:7>0/*C(K& ;I"DL9P @D;
M"EP[;$8%\+E>I %7;+M)I5[!:7"321)>-W<(GM[B,[S,T$8=NZ,2"61"L)9P
M)3PA8\5X[EK!1C(;)H8T$60YC9UK[1(W_+6(ZPEC5 5]8H"N9&66U5&@G<T>
M6=L[DC<&E:@S]V+9B^$.-\61WI(C4_U.'?:2J'WV4;@-O-0W:?0UB[YK]!$6
MG4/W%UM/LRJUPP(@(:*'<%EF']*-R(V82';6-KRSBJH>VE?;_%S4X$UB2($(
M3*1+####/+"(KHF#SE0QD#N(';/[H;)6R&I!'Y>B+2KZ5HE$.T32+&K,Z  N
MYC4N,[E1G5E5R-K,N%)/%1==I]&M8[MFNN\>SMWN)8H8Y'D98T221(CL$<DJ
M+)&98U?="KJTHC7D=TO;4 (U208;,.MV,IM=!\O/F+E#9&/+,1,% )*4-",T
MH="I2(88QW2,;,L;E]/5A;.XD:98UW=P_=R-OC5 V64*'<A3N*-@ DG'EBLZ
M75K&!+5YI63VR/OH$[BX:9H@L;/(84B:5%B$L?>M(B+&6 <J3BDU-RWEP[N2
MD/E(%EC)O()#5A?)7#19\ *Q/(.*C8K1&M@.B]+7HJ-5%]US$='[F0NEW;P=
M^H4@K P3(60^TR/'$(U)_J99>HXZ^1%:]^T^EQ7ALII&BD$EZC2E&:WC6PMX
M+F>2>4#;"JQSI_>1@\,067/=7>T,V>-TE>8PVO GB&)563"30$2SC0) 0.9%
M"0+(GQ4,B1D0,>^*2.1B*R1CEL&RN4G6WDC*2.I9<X92H5F+*R$JP]T@[6.&
M!4X(.,P:U826$VH03++! XCDR'B:.0O&@21)D26)CWB,!)&I*,K*"K*3]JG<
MYN[M3*.MM8R;0'XSX@5HY43FK7%M L/;D('B@(<&6]D)#1Y95A=)$LGALL:O
MB:RNH(DGEA98I.[VOE",2H9(\@,2-Z L,@$C..:JM=8TZ\NI;*VNEEN81-WD
M6R5#FWF]GG"L\:HYAFPDG=LVTLI(PRFN %RSDB'W,)9[JPBB,MAC8"QYU>L-
M1;)3S&0O@BF@GB>3(,[VH99"((RH%)BC]:+UD2:5>H(2L?>+<)"T;(R\F:'O
ME0AB"K; Q&0 =O!SQ6%!VGTF5KQ))S;26,UW'/'*CD[+2Z%H\R,BLDD;2-&<
M(S.BRQ]XJ;A6_9\G8JGED@LK\862(HP.5'C'JD)%>X!IK9GL%='%$-\S 66>
M1R0,^(:JS*ULBMHATV^G :*W=PRHXYC&5DW[,9<$ENZDP,9]TXJ]<]HM&LG,
M=U?1Q,DDL+[HYR%D@]G$P9DB*JL9NK??(2(P) 2P .,V\EXUXL!K;N-12")A
M4F^#L$8/,.5$%,ARJ(BUT<9<\$"RGH/&LDL:(]4>WS2=/O0Y0P-O""0+NCRR
MLC2*4]_^IE$9@$+' /''%0[0:08DG%XO<O(\7>=S<;8Y(Y4@=9SW6+<++)&A
M:?NURZ^]R,[M5N\Q=7!5!76T15N(XYDXB0%Q*Q]87\%8L9+,/'!.\(ES(B&0
M22.C62)[D2.6-ZQ+8W<$"7$L+)$_=E7+(>)5+1Y"L67>%)7<!NP<=#5VVUG3
M;R[EL;:[26ZA,X>(1RH0;:7N+@*[HJ2&&4A)!&S;"R[L!U)2>SY9"QML15ST
MMC9MKZ<>\M2@BZ8=H(1)1 L+6CV5@&2>7*X:5T08$<\\B(UK&K(]C79-GI<E
MW"LHFCB[R5X8E=)6[QHT#DYCC947D LQ"J3SP#6KUCM1!I%U);-9W%U[/:17
MMW+#-9QBWAFD>.->[N+F*6>5C&^R*!)'<@!1E@#T0>1V6=@D5?G-&71H>75O
MT\(@CZMEB#[S2XE&:6ZU<+ 0/,&ZQ0! T+8Z/W59Z9%HDTYH8P9;FV2<QI*+
M4LW>=W( 5._9W6XJ0RH)"Q4Y(%9,&O+<W!2WT_4)K(3S6IU-(XC;"XMRZS 1
M][[5W*21O"]SW!B$PV;@ 6*?'YKJ)Z.UT<U-;A5-=\"Z$LB2H>*<P^TAJ(V/
M*%L28:PZ B>.4NLM'!'CC>97P*C7HV^VC3B>*W6>%YG[S?$!('C[J$S$@-&O
M>QLJL$EB+(SX7/(SKXNV-G)8W.HM9W<5I 8.[F=[1HIQ<726J@R17,B6TT;R
M*\]M=F">*/+-'P:S.YGK!*X:W2CNIZT]+$ZM(C6LA4[.U+('6&D9&6= Y@"?
M$0_!C/\ %F;[D;H@O2]OE'HT\DC0^T0)*ABCD4B4]W<SY$5J2D;[I#@EF ")
MC#D<U5/VNM(;:.\%E>2V\XN9[>13;)WVG6BH;C4U$MQ&5MQWB=S&^VYGW*4A
MVL#3RPR-FBCF:OELK&R-7PJ>6O1'-7POA4_"J?=//[>M.002#U!(/P(.,?3I
M76*P958'(8!@?,$9!KZ=*FCI2CI2CI2CI2M>?_L?^U_PZ4K7Z4K:="CE5?*_
M7^'2E>>PG[R_Y)TI7V:GI1$_9TI7O2E'2E'2E)C99D;89:_S)4T@\5Y5EUR%
MQ-1\H4I$+F#G0-56HLP4_ME0IZF_WL3?Q)]TQKRV6\M;BU8[1/"\8<#)C9E.
MR0#(RT;[77D>\HYK9:-J<NC:MIVJPHLDFGW<%T(7.$F6)PTD$AP?Z<T>Z)^#
M[CMP:CW1]L=;1/5\&GL"'K:<?6C%( :](I\<3'9V[F?[4OB377+9+2RE5?5
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MQ9)&>_+"ILHZ11QY-GH?LMZ+Q[GOF]Z0H80N+F2$02RQL'.Q70?V8)&2-V,
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MWK-IK&L=Y<R1!W&IM96]H4 18;9,$3.S,W-3MO<TK+>UN+-E;E:JH# KY:>
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M9Y7>*369-C*NTG6;R*\E&1R!"\02/J64G<<UOPX&B?I[;5608MK9GNK%#E/
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+.E*.E*.E*.E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g367280g36u48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g36u48.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2/44&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #U    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    ) %@ 10!2 $\ 6  M #( ,P      #W!R:6YT4')O
M;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R
M;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP
M<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U
M=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S
M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  $#P     $  3A"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8             !(<
M  ,@          $                          0             #(
M!(<                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!(<     4F=H=&QO;F<   ,@    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MS*[6&YU=;OLVYO\ H]C%39F.=TC(N&!<,$7M%]?VL[/4<UXWV,^S?2_-]_\
MA5&I[\X%[?KQ9E M=33TD;&@@@>X-8TS^8]U=FS^HJO^+*MU?3>KM>(>,IP<
M#I!%;>RY?$RNH8G5*<;%Q;J,G-QZRUWVKZ5;JQZ+';L5V[T?3].K_1VKK?\
M%O8VWIO5'^A9C6'))NKML-CMYJK<_<75TN;RD@[.]]501T:J3(WV0(X][EKK
M)^K#=O26<ZOL.I_E.'M_=6LF<'H]O^KP?APL-_T>_P#5_P#</__5]522224T
M<X=9%S7X!H-0;#Z[MP)=)]S?3;_W]0>WJ(Q<_P"V.K<PML-'IR"&19M:_</I
M>GZ7_7/46BH75-NI?2XD-L:6$CF'#;HDI\%H'LH/D/\ J47M=',?]]7HS/\
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M]1&'=4\1:6L%;PYX).\O<?5^U.R7/_E?::O]&HDO_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$
M(@     !+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"'
M:0 $     0   *0   #0 "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3@Z,3 Z,3@@,#4Z,S0Z,C4   .@ 0 #
M ?__  "@ @ $     0   R"@ P $     0  !(<         !@$#  ,    !
M  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0
M   !   !+@("  0    !              !(     0   $@    !.$))30/]
M       (          #_X0$P34T *@    @ !P$2  ,    !      $:  4
M   !    8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R
M  (    4    D(=I  0    !    I    -    /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HQ,#HQ." P-3HS-#HR
M-0   Z !  ,    !__\  * "  0    !   #(* #  0    !   $AP
M   & 0,  P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P
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M 0$! 0$! ?_  !$( 7,!  ,!$0 "$0$#$0'_Q  ?   !! (# 0$
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MV-CEESU'=$!(-<['UXW[.Z_:<=/5UYA<ALASS#\2T5Q@@BAZS7&+FGK*W?\
M38^36^HV6#\0PU:.MW^"F!3@%(L@RJV) BQKD-KD([4,\-W:AFJ\.?Y?.H^$
M"D)N:YTM^GK+G&@XU]I1YQ8/G.<6^,ZNXOUMIG%S0)E)38IN>P!*D4S#8_7M
MBU-GO2934*0*F(* "/05M7']@$<18Y1QHS!14]NEN(N>=\A2O&)ZL<?6GKX0
MYG/OM(OJ887KS"-B&UMQ=92YF6?&BRCZ[V&\220$BDBA[-VV/Q(:!(^)<Q7/
M5K7"<[P1R(X21GY>M?*PYP"4DD5-NSU;6T+3IC[1!SBV'C/(RYN<-XZADZHX
M[6VUL997X/G 0R,D@[$UCBHH]NAMF272JE:S,;5[XT9\*4Z6.$9LMH@E!(;V
M?"WYUS^6M;7@I(%,\Z>K0B.(_:3?4GSK9N':ZQW7?&*1*RN56Q6.9K+9$LH?
MB+%(THW8&VD3VPQE4B]T7VG?K".]OOV5)I3(U[KVU[,CQST%*0-?7='')[[2
M)ZFO'O;&6:Q-KSBZ:1B\ZS 21,U?LIZGC#IAV=9(8X>W8[7C.0XPN*QOMR/
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MQ"R;#3XQUWKNX_CM=M_&<UH:P];*R9DNC><<-\-;2MHAUYAS+6$9_N$F>=N
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M]ZO$5RY4IG>M8<G]E?<KN0/+;NO=?Y(-?=U_?_MSM5[_ .?]_P#T2@?NG/\
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M#++DPYN;ZD)4H,M.*"">L<*0V@+<4A"FXIQ:6T"JB%$"H%: J.=!]U).=Z
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M^)J)F6?=.;A^'8TGG\!90ZTDQ!^4@(I#'E:CGO\ #BB4DC=3N42@$!15502
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MV)=QZ7L(=5 &6L$Z;;%JZV=,^#CC4[X\"7(0+!A)X0 :FQ_FIG8 7YTH*V%
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ME23%]U00E9% YO\ 5D7KNFBLJFRLZ@:6N([OA/QHS?>T7/J^*>9$G4F'%LZ
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M*YB$;8BHY$<U4<UR(K7(J*BHJ=T5%3Y*BI\T5/DJ=(0GV4[<U5@T6UG9ILO
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MQ%5Z<K;^GY#[%BU6.QK*JLM7X8R_M"W0JXM%&!E.8/BR8]<Z#*?=/E2%6.\
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M<J^$AK57R7LDG3U;/Y"_UB0?</K,4B<'U7((*WAQG.*QY!U67AEZJ1I+W/\
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MUCC;+./8VS+I2W+LXMB3;#:4A"4,(G7DLH0D4"4I;2E( L!0   1[\<J*@I
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M1UH(W4KW/\6]N[] .%!F2!D!6AHT7T%8V68[QGV*:''ELKLQVIE9:XS!M='
M&HCPZ8@S/1KT\#SPSCD*-&N>D=(Z.^2=_@%ASYT%<A\:<=.R(7GZ]?G$5'*&
MTR+)_62U.!U>KONO/=:0Z(00*0DBN+9E6TLA(Y?)QVCCV!2*KO-AH9%[HJJB
M3:OD+>K9=G?$C[ASOY99_E7RBQYSKV70:6XFY-+RJYIR6^:XUE59A$,CF,NY
M8*RCG6%B2&5@W$]R3&/'%*]P3 PO?BC>]9!PC-]LMA\].2\_-RLJZ_+88TV_
M/O(2-R59=<#+:W22+*<-!N@G="ED=6VXM,);6H*4!4(IO&H%*UTK4V!)"02$
MI4H^Z"13KXCL5E#R^3LGDO"7:CG?/NJO=FFK'+W5>_=5[_-5^:_G\U7KCTG.
MN=*^=3QU-^ZU:@9%9 ?XAS_6)"_0MJK%W*O(<GBA:<-/A"4@(I$8@Y-S?V 7
M1'.<Y/)WPD>&>0T;?D\BB4J^VUR+*3W 4SH*?6O'P BKFG?#DOM)NPY!<9TE
MJDE6*,%+?+\^MI7ZM%6SJ\:=0)$]L;&M5SDR$AR%\E<Y0IY*O?J:9#G2AU%*
M#EST\8A&=>[Q([].[6)?>,V>6X^#FN#?<0(89>L,9GV8UBME0G(RACI&I[#W
MFD]DY83!=C=W/\AE8T:HY4;.M="/T/A\HI%:#@5"G;2]4BX+ K!UL&QS';-[
M;5LP#3.K*Q^<D=(CH%49XD98-C]FJG8(T>WLB(J]!F?A]>TY>69BZJ;@K?PI
MW]GRB73[1UDEC7ZRU'CDBNC(;*]@8I\7(4+/=#58O'E6-4T0T[- IIJ*C6H@
MV=G'&GDB)V*R/YBU*^M*1#=*\?/,T^<.H]#77^2S/36+;29\:FBY#E^96L1I
M*V,XCL.@7-]4_%^4E[$\3*L^2Z0SQ*5I@(B^#/QAD..OJIB%'WC^N45>9F?W
M&0^JV//0UP;&Y=R3Q^EC1XPA]I0XT.TQ#[R:,B*)SAP'FNRH5BL1!&1R.<J]
M1_,*'/,7OG?RTBX^Y?Q[;C4YU\XLB^J1;L-Q.M;TU<DRUJ,6;<!9(]KVYC$B
MD]_]6T?M#.($D_F43/+P:URHJ-7M/&_Y>O0XT&8[1\>4-3^RJM\-^<L6I]$T
MWKM._P"_MF5JBKW_ .O;JS?\%=J4<:K_ -E[SXQ+GWT'_"OXH]#OXQ<(Y"$]
MK2.SR?X&(6KOZA=:=^T"WUO0KTEMFX7LIB*:<:H3;OB6G"TX'!_("H=H"HCK
M]/Z5\5O/:;NZKXZGPY/G\_KF&3?^C_KWZ\M_8#E!*;/=) H!OXU@![:2.(<<
M\_RXWF9KVI^M_<9;%^:WKVXT\HEWZ_06,,'2$8N_9_I)_;TA^4?,T<$A&-D!
M"=HR,,-IAL*C##7N,K$>UR-(Q?FQ[>SFK\VJG2$=':XEC5Y/Q^TMJ2NGV&*W
MSLHQZ7(CL<:JR)U%<XPMS%<G9$GI09!=53)#T>]D2QD,9XJYKFH1W+84-A#E
M;$C-+*1$DD: 2$D(WOXH=Z,1QD3NO;W%=V[KV^O2$:[GG]X^9_\ )3(OI_\
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M.ZBV=--,^ROA\JZ9*G=\ <Z6KD/C?,1,_P"I5I#([?1V0QRM0M;$U]EE?4U
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MG;B1\XH$GA8&A SMI\OA'=_9<@K'Y"<M(ZM4;H^H\$CN$[^<QX<UM!O:[O\
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MU<]\O),SCO'?U5?,CU^01A,1"18UQ'F!B'[GCL&55>NJ/LZ&N%[3G_K##_\
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M[G!M3CFK6?''%[2N5V&HYK1=WJ=$:OX1N:U556]  ;BOQK:E;\C\B*VBWO\
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M5)*30W!(-B8D$@@@D$5H18BHH:$7N+'E&/\ (GIK_BDUC\E[I_M"Q7Y+^_\
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MQL5M1\32AMQI3MMIJ<S&19K3LKW6S\^[.-S^T?W60+L/4F&.B0TQ!)OZ2EM
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M &V^*(GBSOXM[?DG;LB(G7Y^3DXYB,SB6(.I0AV?Q%Z>=0W3<0Y./34PM"
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g367280g40d80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g40d80.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4: :'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B"B @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N
M861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B"B @("!X;6QN<SIX;7!44&<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(@H@(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @>&UL;G,Z17AT96YS:7-&
M;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E
M;G-E+R(*(" @9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@
M("!X;7 Z365T861A=&%$871E/2(R,#$X+3$P+3$X5#$S.C4V.C4U+3 W.C P
M(@H@("!X;7 Z36]D:69Y1&%T93TB,C Q."TQ,"TQ.%0Q,SHU-CHU-2TP-SHP
M,"(*(" @>&UP.D-R96%T941A=&4](C(P,3@M,3 M,3A4,3,Z-38Z-34M,#<Z
M,# B"B @('AM<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*2(*(" @>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HR1C4Y
M1#(S1C Y1#-%.#$Q04,V,$,U,31%0T-$0T-$-B(*(" @>&UP34TZ1&]C=6UE
M;G1)1#TB>&UP+F1I9#HR1C4Y1#(S1C Y1#-%.#$Q04,V,$,U,31%0T-$0T-$
M-B(*(" @>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED.C5$,C X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X(@H@("!X;7!-33I296YD:71I;VY#
M;&%S<STB9&5F875L="(*(" @:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4]
M(E!R:6YT(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#TB1F%L<V4B
M"B @('AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/2)4<G5E(@H@("!X
M;7!44&<Z3E!A9V5S/2(Q(@H@("!P9&8Z4')O9'5C97(](D%D;V)E(%!$1B!L
M:6)R87)Y(#$P+C Q(CX*(" @/&1C.G1I=&QE/@H@(" @/')D9CI!;'0^"B @
M(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY0<FEN=#PO<F1F.FQI
M/@H@(" @/"]R9&8Z06QT/@H@(" \+V1C.G1I=&QE/@H@(" \9&,Z9&5S8W)I
M<'1I;VX^"B @(" \<F1F.D%L=#X*(" @(" \<F1F.FQI('AM;#IL86YG/2)X
M+7)E<&%I<B(^5&AU($]C=" Q." R,#$X(# V.C,X.C0Q($=-5"TP-S P)B-X
M03M'<F%P:&EC('1Y<&4Z($%R='=O<FLF(WA!.R8C>$$[-"!H86ER;&EN92!R
M=6QE<R!W97)E(&-H86YG960@=&\@,"XR-2XF(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z(%M497AT
M1F]N="!!<FEA;$U472PL6U1E>'1&;VYT($%R:6%L+4)O;&1-5%TL+%M497AT
M1F]N="!!<FEA;$U472PL6U1E>'1&;VYT($%R:6%L+4)O;&1-5%TL+%M497AT
M1F]N="!!<FEA;"U";VQD271A;&EC351=+"Q;5&5X=$9O;G0@07)I86Q-5%TL
M+%M497AT1F]N="!!<FEA;"U";VQD351=+"Q;5&5X=$9O;G0@07)I86Q-5%TL
M+%M497AT1F]N="!!<FEA;"U";VQD351=+"Q;5&5X=$9O;G0@07)I86PM0F]L
M9$ET86QI8TU472PL6U1E>'1&;VYT($%R:6%L351=)B-X03LF(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M/"]R9&8Z;&D^"B @(" \+W)D9CI!;'0^"B @(#PO9&,Z9&5S8W)I<'1I;VX^
M"B @(#QX;7 Z5&AU;6)N86EL<SX*(" @(#QR9&8Z06QT/@H@(" @(#QR9&8Z
M;&D*(" @(" @>&UP1TEM9SIW:61T:#TB,C4V(@H@(" @("!X;7!'26UG.FAE
M:6=H=#TB,S8B"B @(" @('AM<$=);6<Z9F]R;6%T/2)*4$5'(@H@(" @("!X
M;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%0DQ!17-!040O-U%!
M<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!0DQ!04%!045!
M)B-X03M!445S04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!
M0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-
M1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(
M=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&8O.$%!15%G04I!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%1
M14)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%
M04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C
M1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!"
M)B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&15
M6DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P
M6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/
M16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7
M;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#
M15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$
M4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95
M,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:
M;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO
M)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A
M04%W1$%104-%44U2040X03=T2' S;'%"3'4Q+WA(3$9*-C9M)B-X03M93F1*
M1S!C<UI936]5.%%!-U-F1TMB;DUG-FUZ>41J:E0K6E99+TM-3GIP=#!D23$K
M-D56-$%K539Z971(1TDU4U-)=41)0E%,=T9$)B-X03MT:VAQ9'=414=M2C R
M>$%K4F%+="]*9F\S26XO045Z<4QK5&EC;S Y5DE$1G5"1E!S+T91-$1Q3$9C
M36588VMA96IF1DQN,W12*U-%)B-X03M74EAF5TY3:T-H2TLQ=V%646<Y9T]T
M3CA4<68V369K;S S.4M8>E-N569,1V<R56M1,4AZ5&0R.#ES:&Q1>EAA22]"
M:T5826-H5VYW)B-X03M(<&MV>F8X05)I>"]+8W963&)Z5$136E!,96PV:$Y-
M9DUV,6AP639',W5B=4XP5#0K4EE!:U5.5&Q75$YX0W%!8G-E2&A*3FMS<5(P
M)B-X03MD1F1'1$EW1$MY;6])3S1)27EL=&)X5F)*2DA(1S!K:D)),$):,DIO
M04%+:VLT<6QY*UHO3&),1W<Q5S!P2V]E3W,X64I6=6AO5W)V)B-X03MI<31E
M6F9,<%E+3E5T0U<U57!02"MZ5&PK,3)R:7)H-6PX=6Q1,S95=$]*<5%X;FI!
M24(T;6@U94]+<6QP<FUI,VMI>%=M;U<Q>$LT)B-X03M*4T]+6DA99V1A0E-4
M=&EQ>5AZ1&]-5C=*67DV:&)X6&M10FMT,VQ26%5&47=Q0U(K>7=/2W1F-&HX
M=F-L6#E+5VY*:5969EAI<5-")B-X03M59V9&,D=+;RM34T]/3G!*1T-2;T-Z
M<U1104%62DIX5DQJ-6XX=4,Q*W1(53=55S166$UN<DI12S1*56YF=4%C5EAX
M95ET06QD56DQ)B-X03M+,6MD;E=.1E-A3FE896Y&44%D>6$T<7)A;'$R;6%:
M0W,K;S-55G!#-VE.6DIM0TM824Q"86YV4E1I<6EF369L.%8O,THR=3-H4$=E
M)B-X03MP-#EM.%141E5W>%9,-VIZ0F]6=&5M>'5.470T3'A61&U#4U9%9FEE
M:&]X1TMQ;'1R3VM857EW,C$W0E!+-G,V2D9):FMQ=DAK9FA*)B-X03LV8S$K
M+T956FEQ5E%E82],13AF<5$V=%IS;E1L-CA9-E508RLK2V\K,'9R3SA2<$Q3
M9$HP4GI'-U)S1T%D97%K:G5-5E=8,G!A9G X)B-X03MC8VPY8WA7<V-R:4M.
M-6Y#0G!'0DE51FE.>E$T<6AV.%1E5R]233,V5G,O4D)).50Q-'5.5D%9:79+
M;7=C9F9I<E5F;69Y-4EV2DY5)B-X03MT1T9+,44P9E-G4&HT2$97;C@Q*U=%
M474R<E=944AI5#8X9C)Q03!'*RMZ1$96>2M:=DQB16AD5G-Y44MM;'A&,$IP
M+TXT-'%M16-K)B-X03MC:V%Y4G-(:F-":V130T-#2V=G:G%$:7)!.5-8>7IF
M-C%.0F4K5F)U95=+4W(S=C%:0W)L6E=8;%94>6178F8S0C-W2VER6'IJ65=.
M)B-X03MV1&$V9F]/<4IB2VAD25ER4E9#9WE5,E5(=5=,63)R2CE,=F8P:%I*
M9$ML>&)H>7=%3GA'235">%ER57%2=%=L4FA61CA'+VYB+VAF)B-X03LV67%X
M3'IG+VQY3SA6=%DP2S0Q47!!1T8S2&%P3W%,>6(T3U)O4E-H631&4U0V>#5+
M6G!1=FLV-V]Q4$EV3%1K54U54FTT.%-0:$I%)B-X03MD0E59<7HO5$%J-F1A
M=$5J,C!447AM3S):5E5X<59&14MG8D92=%1#<4HT3B]/,R]!078Y3597>5%,
M2D<P8VI&-#-"5C%)56=G:6A")B-X03M&35999&9A3C513W4O5D8P2DQY5WAT
M5VUM:W0P9UE28S5&06EE2E-$>5I*5VM!6F9I54AH>4Y123-V5&0T2CA0:G9R
M5F1F9C=V9'DV)B-X03LX>%EI-3AT*U5)<$IR9'9,;G%2,C0Y6#%)-U-.,&9L
M>%=1<%%66FM6=U-+8VI1.$%X1DUK,'!G+VMF>6\V4F\K;5<W4GA!<D=H:51I
M)B-X03M!4W!0=S!P*W=-5E)&:#58,$A4-W!R=7AS66)A-5E&5VUI:FI6:4=.
M5'5&-S1Q.$8X=V9N=#5D:C$K*U,W.&Q16'0S8GIY45-8:VQZ)B-X03M(>FLY
M3#EY1TYB5G8R5C96>EI2-T]S03A8,F9T9&106#A*231E6&XK>$QH*V4S;$E0
M1S8K47)D1VEC4V]5=6M7:DM1469H=%)89%)S)B-X03MD<VPO2FXY3#=0,G-F
M-5(O;R]B*WA/6F8K8W%23$<P8VYL9W1'-#1U<'9L24MN66=J-G(S1U X04IV
M.$%3*WHY<2]Y:B]2*S,Y:58O)B-X03LX<C<X<7I/<5-E47)C<3%%3DQI2FU#
M,6):4CE62#@U,G)I97I0-E@R9G133S!F-E R=F5T23AR*U9N=#=456)84TDW
M3U(Q:759:V4S)B-X03MJ:6UI86Y*95,X9FAD95)R-S5R0TM.3WE"5%<Y,'EY
M=C$Y1SEI4S5I6#1L:FQ22%5&;%I#849E-G-2.4]"54)"-4LX<E<X;G%1-EIB
M)B-X03M2>6)J:TE9-C=M<"]:.&-65&YG,S@W9CA,+U1&57-V4$Q/:&%J2V)I
M*W-O3&UE=3AS<U5B=#A/=S-+.6AI<3=4=DQ/:#9:24I.4',T)B-X03MR5U%+
M5C524F]H;S-(;#!(9C Q*S=&565Y<T(O94XQ2#AV:CAS5E-A6'E.-5-L24UM
M;%=R14M%1EE9=G-Q06](,F5W541&57IS=$US)B-X03LW1TIO<D].8F5*;4QS
M:U-O;TQ'9TIO0C$R>%9*=D]Z5U5E;5).9E=$-G)#2E%287)#:S="-D5"=VI$
M<T-D+V9!5EEA,3,U8E<P<S%0)B-X03ML850P6E$P<7=M>FDO9',U-&YM<$@R
M;3E)9FA7;4M5-3!Z>3DU6G9,4T,Y1VEW,C5L44515%<X87-M.60P<%%'=F9&
M55502VYL;U)R)B-X03M(*VDW5&=H-4M046E.0U%!5#EN+T%#4FEQ,&559DLT
M-"]W0S1M,"M%54@W:4DO.$%'=4MS;C!K0DQ946]!<U5)5T]+3E%&5E5554-G
M)B-X03M!1%E$0VA)=%(X.'@R5C-,8F9O;E9:,FED;R]6:71A>&YH*S!R;6Q6
M3D11+U1G5F\K9DE+5B]23W(W04U18E-N=VMG8F(W+V$V97AX)B-X03MT6%<S
M;BMY=4QK45(V9G%L9E5J:6MC,G9W;S!L2V-Q16M5-4-U3G%N,FPV:$9Q5FUT
M,T(V>5)U5T%76E!48C135D]X2'1H5DDO3G9M)B-X03LK-C!+-&IG9W15=7DP
M9G%-6DQU,W1I=DHK2R]$2CA20F]D=T]T0F=62U4O36I5:7!",'5(,4)11VUP
M5V1+<V9H*VEN9D<P,'(R9FXO)B-X03M!1F4K85),3%%:<FU73FM$2DAC=W1X
M1$)Z5GE&;VTX9%!I-FY',7!K*VDS97 S=&U:=%%S<$Y.;D1L4F)V2D9+4V]!
M;R]*0E1E=E1#)B-X03MH2#A'+VY0-&8P>%9I:BMF65DO>D18>59,<#DV3&EA
M,E<V=#E15EEM9UI/36I/>C!02D5":D-+>$<W,49!04,Q+V=F=2M/=S K3C8K
M)B-X03M#;58X1R]N4#1F,'EH=61W8BMC+V@O5$988T<O;E T9C!X5C@X-G8K
M9E8Y6F%T93)9.&\R.'=T<#594DTS5B]48W)Y4#=O.6%6>F%1)B-X03LP44E"
M-&Y!;G$U06MC4#0K5#!,.'%F3FMF;F)4<GDV=E!,<3998E=54G)*-F-B47DX
M:%=I37E+,TIF,FA4=4XX>&14:3A-9T-6=5)G)B-X03MY;5ES:6UC4&\R;# O
M=T(U665O+S-62#0O=T-R;5!X2'9B<5A,<$=M<7=:8F%*5U4Q5FA&1T-#4#EJ
M9S1J,W)32S1.+T]F=R]P9U-T)B-X03M#3GI0>'0P2&@W*S)+<G5$9GIN.% V
M67$W9S,X-2]$*VU+<E52<69B8G%F1'@K5TMR=41F>FXX4#99<71D1W Y='5O
M.%!(-5EQ=31.)B-X03LO3V9W+W!I<G5$9GIN.% V67%K+VUB544P-C!J=4I%
M;6U4:U9+=W V:CE+:C112SEQ64-R1U X04=L=C944VI49%0T:'A'06)59VQI
M)B-X03M'4%$W,$A$=C0T<%=R-3)G37%P*VDY54%903AV<75W2D9A1V@W1$96
M5S0X,FU'0G!4<&5O='AD27A'25)Y8FU(4$I26&]05#,Y:4U6)B-X03M42%-D
M56)556U9,C%X84=&=VY'-%%)5W%I=E9A5G%0:7!I<DE.3$)%8C<Q,T=&0U$S
M=FY/.7-F5RMS-DAQ5&-(;5-)=U)R2TA736=+)B-X03MX24$T:#8Y<6=E*T)6
M:W9N-'AY<6XV13%D>%AJ27E7=TE"<%@T9C5H6&%U,DYQ=FLX*U%P17-N-DDQ
M:'519'5)=$)50TYI<')5-V)R)B-X03LK3TYQ=F)Z<VDR4G5M,&Y6:GAE4TUX
M2F)+>FMX3D=P2VEO<7)'6#14,V]F1$95;W9F34]G-FQF26(O>7)Q3C%+5C1,
M3DY927I!26%H)B-X03M35S)P5FU05V<K;D953EHS6&Q3-&0P2&MY.&IB:$DV
M3DI92GA)5U!K07I52D1..6Y92&9&57I(;FDQ<S1M1G8U93%:07%Q<V-A5V%Q
M)B-X03M7239,44AT6&(U-'%J2B]/<G=/3V5J86\X56EO.$1244LW2&Q&2$MW
M9%1X-$9F5S0Y5'5R94=+<59T-3AL;4AX84IQ<V)!<7)G,BMW)B-X03LU2'-3
M0E=G1E0T9$UB5E1K+TU-2W)L3D4Q9'94<4="=&Q"1$M!>$153%4K1F=2:F%Q
M='@U-FQT6D-L>&]M<4%'5FMJ94]&6$1)0U56)B-X03MV,F%&;C)#;C4T,G)P
M4'I"=&\T:DLR:S9W1E979#8R:6II<7-Y5E!X54<V2$<Q8C O=T$K=S-D-4AB
M>398<61N2$Y)26]P-VU"63 U)B-X03M53F5D5#A05#-X=%9V*T]:-$E6830P
M2%9L2E1N=VAG5U=G,TDV1F8R84=N6'0R>'164V9Z,49&87A89C9-,4EW3SAK
M8W8W;$$X6FHT)B-X03M53$-T4&HY4V<S-TA',54P."]W4VQ13D<Q;6IC4W)'
M,%=M.4186G9F1S%B=%!0.$%$4$Y%:VUL87)B4GE0=V5A83(T<$A5:FE84%EC
M)B-X03MF:5!H-S0R<F-N;F]X5'I1>39*<35-3&QE8V1S<G%Y-R]'1%9F1$<Q
M430O351N25=I,%!6,FA535AL3G5!9C-D95%50W14554V.6-B)B-X03M61S-F
M;DHT25=K:C!V54HR:6Y-53A#43!L5TE6<$]&22M*5S1N:FEQ1U1Z+T%#17-4
M;V5R0D4U96]F<3%444U!3T\Q1T\K*S1P-S<T)B-X03LR<G8X96U'-BMQ6$=I
M-F]S-TE:;%=+1DIA>&U2:S5D5DDV5C9D.&)685!Z1VDT96]D1#%S4FM+5B]W
M0D1(3&1Q9EIR,#99,G%+;3@U)B-X03MF=EEL:# V.6YG2T-A85E2:&93:F]P
M<7=+-W-(2E5Q3CEJ:F$P<'DK95I)-W!R9CE$-FQ)1FUL:CEA3T=S9G!X1F@V
M;DEH9G1C9&@W)B-X03LY8V)69EEE94DW=31T-V0Y2S%7,F5D>$@V:S%U<7AQ
M>&)G87-4,$(S-F1-5E5V.$%&+S$S,#%H,%15,FM9,%)B:4511"LX:6I,12]&
M)B-X03LX4#<R=&9"5&EQ1FLX-E=I=DAX,$175$5W2F1Z8D5%04Q58U9"874K
M,CE-571Y96,W2T)K4S4P5%95:VQ14$5I43AY,UAK;T)+-W)I)B-X03MQ-EAZ
M:&%O4E113EE934%6+W="2#,S0EEG9TUF,E)T:7$Q4$]L:7A)+U%/<S O6B\P
M8C5D9FDR,T]+;W5Y.#910U995C!45E5$4T-/)B-X03M34C=F-$%X:T5646$W
M:FMA.5!S-RLR2T=7659D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S)B-X03M69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<B\O6B(O/@H@(" @/"]R9&8Z06QT/@H@(" \+WAM<#I4:'5M8FYA
M:6QS/@H@(" \>&UP34TZ1&5R:79E9$9R;VT*(" @('-T4F5F.FEN<W1A;F-E
M240](GAM<"YI:60Z,D4U.40R,T8P.40S13@Q,4%#-C!#-3$T14-#1$-#1#8B
M"B @("!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.C)%-3E$,C-&,#E$,T4X
M,3%!0S8P0S4Q-$5#0T1#0T0V(@H@(" @<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/2)U=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X(@H@
M(" @<W12968Z<F5N9&ET:6]N0VQA<W,](F1E9F%U;'0B+SX*(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" \<F1F.E-E<3X*(" @(" \<F1F.FQI"B @(" @('-T
M179T.F%C=&EO;CTB<V%V960B"B @(" @('-T179T.FEN<W1A;F-E240](GAM
M<"YI:60Z,40V0SE$,4%$0D0R13@Q,4%#-C!#-3$T14-#1$-#1#8B"B @(" @
M('-T179T.G=H96X](C(P,3@M,3 M,3A4,#8Z,S@Z,S(M,#<Z,# B"B @(" @
M('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R($-3-B H
M5VEN9&]W<RDB"B @(" @('-T179T.F-H86YG960](B\B+SX*(" @(" \<F1F
M.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @('-T179T.FEN
M<W1A;F-E240](GAM<"YI:60Z,D8U.40R,T8P.40S13@Q,4%#-C!#-3$T14-#
M1$-#1#8B"B @(" @('-T179T.G=H96X](C(P,3@M,3 M,3A4,3,Z-38Z-34M
M,#<Z,# B"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RDB"B @(" @('-T179T.F-H86YG960](B\B
M+SX*(" @(#PO<F1F.E-E<3X*(" @/"]X;7!-33I(:7-T;W)Y/@H@(" \>&UP
M5%!G.DUA>%!A9V53:7IE"B @("!S=$1I;3IW/2(V,S N,# P,# P(@H@(" @
M<W1$:6TZ:#TB.#$P+C P,# P,"(*(" @('-T1&EM.G5N:70](E!O:6YT<R(O
M/@H@(" \>&UP5%!G.D9O;G1S/@H@(" @/')D9CI"86<^"B @(" @/')D9CIL
M:0H@(" @("!S=$9N=#IF;VYT3F%M93TB07)I86Q-5"(*(" @(" @<W1&;G0Z
M9F]N=$9A;6EL>3TB07)I86PB"B @(" @('-T1FYT.F9O;G1&86-E/2)296=U
M;&%R(@H@(" @("!S=$9N=#IF;VYT5'EP93TB3W!E;B!4>7!E(@H@(" @("!S
M=$9N=#IV97)S:6]N4W1R:6YG/2)697)S:6]N(#4N,C B"B @(" @('-T1FYT
M.F-O;7!O<VET93TB1F%L<V4B"B @(" @('-T1FYT.F9O;G1&:6QE3F%M93TB
M87)I86PN='1F(B\^"B @(" @/')D9CIL:0H@(" @("!S=$9N=#IF;VYT3F%M
M93TB07)I86PM0F]L9$U4(@H@(" @("!S=$9N=#IF;VYT1F%M:6QY/2)!<FEA
M;"(*(" @(" @<W1&;G0Z9F]N=$9A8V4](D)O;&0B"B @(" @('-T1FYT.F9O
M;G14>7!E/2)/<&5N(%1Y<&4B"B @(" @('-T1FYT.G9E<G-I;VY3=')I;F<]
M(E9E<G-I;VX@-2XR,"(*(" @(" @<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*
M(" @(" @<W1&;G0Z9F]N=$9I;&5.86UE/2)A<FEA;&)D+G1T9B(O/@H@(" @
M(#QR9&8Z;&D*(" @(" @<W1&;G0Z9F]N=$YA;64](D%R:6%L+4)O;&1)=&%L
M:6--5"(*(" @(" @<W1&;G0Z9F]N=$9A;6EL>3TB07)I86PB"B @(" @('-T
M1FYT.F9O;G1&86-E/2)";VQD($ET86QI8R(*(" @(" @<W1&;G0Z9F]N=%1Y
M<&4](D]P96X@5'EP92(*(" @(" @<W1&;G0Z=F5R<VEO;E-T<FEN9STB5F5R
M<VEO;B U+C(P(@H@(" @("!S=$9N=#IC;VUP;W-I=&4](D9A;'-E(@H@(" @
M("!S=$9N=#IF;VYT1FEL94YA;64](F%R:6%L8FDN='1F(B\^"B @(" \+W)D
M9CI"86<^"B @(#PO>&UP5%!G.D9O;G1S/@H@(" \>&UP5%!G.E!L871E3F%M
M97,^"B @(" \<F1F.E-E<3X*(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*
M(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" \<F1F.FQI/EEE
M;&QO=SPO<F1F.FQI/@H@(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @
M(#PO<F1F.E-E<3X*(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @/'AM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" \<F1F.E-E<3X*(" @(" \<F1F.FQI"B @
M(" @('AM<$<Z9W)O=7!.86UE/2)$969A=6QT(%-W871C:"!'<F]U<"(*(" @
M(" @>&UP1SIG<F]U<%1Y<&4](C B+SX*(" @(#PO<F1F.E-E<3X*(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" \17AT96YS:7-&;VYT4V5N<V4Z<VQU
M9SX*(" @(#QR9&8Z0F%G/@H@(" @(#QR9&8Z;&D*(" @(" @17AT96YS:7-&
M;VYT4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E("T@5%0B"B @(" @($5X=&5N
M<VES1F]N=%-E;G-E.D9A;6EL>3TB07)I86PB"B @(" @($5X=&5N<VES1F]N
M=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93TB,"(*(" @(" @17AT96YS:7-&;VYT
M4V5N<V4Z1F]U;F1R>3TB36]N;W1Y<&4@5'EP;V=R87!H>2(*(" @(" @17AT
M96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CTB-2XR,"(*(" @(" @17AT96YS:7-&
M;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/2(P(@H@(" @("!%>'1E;G-I<T9O
M;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/2(R,S4V,S0S-#DV(@H@
M(" @("!%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3TB,C,U-C,T,S0Y-B(*
M(" @(" @17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64](D%R:6%L
M350B+SX*(" @(" \<F1F.FQI"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9O
M;G1+:6YD/2)/<&5N5'EP92 M(%14(@H@(" @("!%>'1E;G-I<T9O;G1396YS
M93I&86UI;'D](D%R:6%L(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I/=71L
M:6YE1FEL95-I>F4](C B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9O=6YD
M<GD](DUO;F]T>7!E(%1Y<&]G<F%P:'DB"B @(" @($5X=&5N<VES1F]N=%-E
M;G-E.E9E<G-I;VX](C4N,C B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.DME
M<FYI;F=#:&5C:W-U;3TB,"(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z1F]N
M=%-E;G-E7S$N,E]#:&5C:W-U;3TB,S8S-C$W.3<W-"(*(" @(" @17AT96YS
M:7-&;VYT4V5N<V4Z0VAE8VMS=6T](C,V,S8Q-SDW-S0B"B @(" @($5X=&5N
M<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)!<FEA;"U";VQD350B+SX*
M(" @(" \<F1F.FQI"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD
M/2)/<&5N5'EP92 M(%14(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I&86UI
M;'D](D%R:6%L(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL
M95-I>F4](C B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD](DUO
M;F]T>7!E(%1Y<&]G<F%P:'DB"B @(" @($5X=&5N<VES1F]N=%-E;G-E.E9E
M<G-I;VX](C4N,C B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#
M:&5C:W-U;3TB,"(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E
M7S$N,E]#:&5C:W-U;3TB-# W,S,X,C4P-R(*(" @(" @17AT96YS:7-&;VYT
M4V5N<V4Z0VAE8VMS=6T](C0P-S,S.#(U,#<B"B @(" @($5X=&5N<VES1F]N
M=%-E;G-E.E!O<W138W)I<'1.86UE/2)!<FEA;"U";VQD271A;&EC350B+SX*
M(" @(#PO<F1F.D)A9SX*(" @/"]%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( %$"7P,!$0 "$0$#
M$0'_Q  ?  $  @(# 0$! 0          !08$!P(#" D!"@O_Q !3$  " @(!
M 04%! ,+!@D-   $!0,& 0('  @1$A05$Q95E=16DI32"2'3%QDB(S$R5%=8
ME]<8&B0S-4$*)T)B<W21LK,E)C0X45)A<8&6H;'6_\0 ' $! 0 #  ,!
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MK</]JKD'DGM!-.,F-.KJ>M#QOO\ 0/.K8KLD 4UZJN$]R81RW@AXUK=O*>D
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MT-9RN0UZ"W%T[DZN\*:\7S+7'&PP]VWRO"L4]\;5P@DFPVX"%Q6C35Q[ ./
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M@A4V0@J660A?G MJ2<N-P]_.]*C$9A8#ZJ=N3+.<:O\ ,U6B2"*[LI"/,:5
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MMV_NX"INZS"5&(S"I\''';^\)3HCG"OZV*5+JF%TULU9( !7;/*:[/Q"HVK
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MY"#.'EOJ[^:8HZ+E+9849HRX\+9FV2>T-^,[ J=$ML)U%41-ZRQKQ)VTLKT
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MG_=CIK'$YI08#(+E[MU7Q>'T"O\ B\?L_#Z6N\7M/9^U]GW>P[_'[+^-\/\
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MEI3[Q"L^6+.Q^*?,EL!V^6EHX21N&-><.>-5CU.H)?MDYI%='9+$H@^#"6C
M.3.LX8<(FV"]YB-(]<"Y\QW^Q_A]=*KMM33Q7HFJ,!DN#6V<'HQE9KASQNM$
M=V!C5$Y!DJ""%G9E!QBQJB!WWQC4EJM8+S@C@HL[3BDB$0S::;Q;XPJ[$X[T
MU1_]1DN+NW\&UL5H<_=\;* T=@BJCHH^:OC#J++.N@<1(F<LF,: M-U1(['
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M^;HB>Q+_ *9C\/I^;HBW7Q)I+K \]K-[7OE [OXO6/P_P"^_^3.>_O\ U?\
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MBNL$20<20 VJ:N^HPA>]+%IA?.[X^KEOK)@0!E,K<]QA$8V@1);5:F<,]"2
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M%.H7,ANBAP#NU="#'1-8:VL3K$FI/MKKUQ=Q.B)T1.B)T1.B)T1?Y-?:@_\
M67[1'ZM\?\>G+?ZI?]9C_P _[!^J3_GX_P"7_P [OZ_<MB_\&LG_ )9(?]K"
M7XXMC_BUJ?\ ,9W_ +F*M%]=-<Y9:\,]@>$ J%+.9G%C!K@E\$Q)YAY,VD(8
MH0PVNY!!9!&\<0T$&F\TLV^D<6NV^VN,XO<UC7.>YK6-:7/<\@-:T ESG$T
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M''OW;O2MZ*!$[7?'$0+MO8LR)TR4"IL,L!-'+70P:V4"K\@"FQZ[U];J$NT
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MVPA>B;>,W$\O$W(HJS47VLC0BKSZ@Z3QLT4K6U'KNPK7T18ZKM3\,N-(21;
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M.7CF5756[.0?+)9C8#*_*C9V:?$#JUA7AO.?#AC[HK0V[47%-:<0)+<S.J;
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M!AQ]>:**UX#XFUCSI[J[22R;[[%'S6"SSMV6LYUI9'#N'4[J1NZ";&76U2O
M&QI@3[1T7 Y'.']E%&U1AYGCS*+K"[/O$"_=;(+3H]<J)5&ZW$KJQE1APU_7
MPH5L413B:+T-+C6#TJO[:;(U^05>PB^+94MR*U1AT.MFQ%GJN$.*TNL>J^H!
MZ>QAT%@W(-;'S#@0&5,X-6-.P8%3#)UI%%J.%">"2-8G'1!!*Q! \2P2*#KP
MY#TV(LX+B/CY?7&]4$12Q)7K5<\9:9=V"5E(X2QHX43,=],UD?+S:]%6:[%7
M"%S(62O1HU.B78'5>+B)0;$4?#P;Q2.JU2CT\. #1EHZAQ":WB,&=1+DBL=V
M(TT8:LPW08E;0Y ;BF1,0#%(+((F!C!J5TH.J^O5UVQ%Q7<%\5*9AI@*II#Y
M4Y8VC'V<6 @'=XF8K6BVR%+B6TR\VTC%)U>GO08-/89@ 1E1#*57'@/I0=>O
M?QVHIBT\5T&ZLO5[/7HVA^RV-3++L>U$B(#&PW].\V("<*(86DD?NR:XR*@F
M8UHULQ.0%K3"YY]Q .U%'1\*<81B>4TJT.,>VG+V+RR=;MI&)0]P&*<2N]V6
MSB9Z3B_W(@A[*=NXF86 ]I(=LRVB+C4'7CS-Z*/BX XAAU&Q#3H8MQV\[[<B
M-Q8=#&+8PQ$R/+>FZML%V++1M6*\Z;POIV([=XF7.V41346(S5JC#S*+(@X+
MXJ& ]-AJNNHN@<BT/&SFPR$*%V3*JP&7(#9&VYM=7J3J14BJ\$B(7"UJ9"!O
M7XEF8]O$U12E.KN018^O '$6F=]]:AIK-MKIG!.'=C\Y"9%86%LB<"F^L>;$
ML<5F9E/(K,+-#88V6H96C/61:NR*U1AE<BL]<XPH52D'FKM:"63BG$M(YXI"
MY2-VAJ-76SF9,Y)$TQC$],E6BL#B]YRCI!\FERS'3DDS6G7/'Q114O"W%\H&
MZW-0!C%V=:633RQ+(0D:PPK%B<5Z <*;"<N< @I5&JUD 0,8L)6A'KYACQXR
M=90=>O?QVHHR;L_</$212$4D,CPD EE13L7<PSHE;%78P)K,)(SV%M<@NU30
M$P[66%KG5@!EE_M LXHE08=<<?%%F*.$.,D; 9JLKY4+,=@.SE/FLMK-+:&
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#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g367280g53v88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g53v88.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%R=FEN9"!*
M86QA;     60 P "    %   $*:0!  "    %   $+J2D0 "     S,P  "2
MD@ "     S,P  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MS-:X5@3AV_\ B:[>N%_X3;4O^>%K_P!\-_\ %5V=C.USI]M/( &EB5V"] 2
M:RK*IHYFE)PU42>BBBN8W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g367280g59c35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g59c35.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0
MT - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T -
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M[4R&XM)&9)<7%D,J<21FE*S41&9$1GM76X&J#0 T - #0 T - #0 T - #0
MT - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T -
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M,_,3?-+9.MH-:&@!H : &@!H : &@!H : &@!H : &@!H : &@!H : &@!H
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MG?8C#!8Z^,P,>F6&WQY*H4UVS;=CZPVR<B$\SDG=+J.V%M7;>_GV;P'IMKF
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MP =&\-QK=^QTTP=WJ"2:S:2YX23BUUYA,>,!@D=NJ%.)A1B,NR).1HJY2+7
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ML4.ZB95A=(U7Q+"WG^@&\]G&-R8K>Y,;<HK/-R&MU+'[424T:.$M/4AT77Y
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M35@['%Q4LE%5_P!L6;'+L<H83R>FF1 T,%J(R)!&2I]T)(;MSN6OMPN7=]?
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M;G)DU_<^ /@#1-.> P&)XTYS$GF(18I&K=; [;KX=OAL 887OO'60%R8$RC
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MI63)NO,9\N8[=/K<DD:1MHR_\3)(226DJ/%Q2;K<P)2LU*4EZUZZ..XAH :
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MPQ2T8DU#7+C-/(9+&D$@6_KSY\0E[-5J>,0.GD3TUSNEOC2",AT.J5/>NUN
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MC8UV<,7K980[-;G/5FR5-]A]BTT&S"GX;XBTE$+0H;A]$CNS[,AK+.4N0RN
MU;7^'8>-FR3)1$><:DW>P73M8)B3"'L.%MQ]O=QAXQB),!%'VH0R=M;48W8L
M3&8J^N??A1!V"<1D9"3[[^)'\/> @JYPK" SPU1 D2,QJS[8(=+@.&A\.-7@
MUEI$"B&(CCD6DIF&)Q$:-@39) G+?2P2@Q%B(@J&J?"G+:K[,"[K6W%K 2L7
MA@J\:1(><R7FH<@EA<.-+L\'+ H<<+6@Z2B0LQZ''??2^7N!V=A\J^2EM*D-
MQFI"(328VF:7;W;-NSV[;@,AJ^Q ^I7U>X(^6:DD<O65^.()6MF6 @.VQR*\
M9Y?&Q26B$-IYZ(R\F*R33$[?#DEUAV0ZXZJVQO\ T7< WCVQOP\5YS+]"U0#
MMC?AXKSF7Z%H =L;\/%><R_0M #MC?AXKSF7Z%H =L;\/%><R_0M #MC?AXK
MSF7Z%H =L;\/%><R_0M3'<7$^0!VQOP\5YS+]"TQW%Q/D =L;\/%><R_0M,=
MQ<3Y ';&_#Q7G,OT+3'<7$^0!VQOP\5YS+]"TQW%Q/D =L;\/%><R_0M,=Q<
M3Y ';&_#Q7G,OT+3'<7$^0!VQOP\5YS+]"TQW%Q/D =L;\/%><R_0M,=Q<3Y
M ';&_#Q7G,OT+3'<7$^0".%Y--1G4I#AXV,D2[G9MG93J5*>+37E2,J2'>QA
M<M2\RG&^OC+3CRFE-,*1EAN_3W"%\3]XD>V-^'BO.9?H6@H=L;\/%><R_0M
M#MC?AXKSF7Z%H =L;\/%><R_0M #MC?AXKSF7Z%H CG<FLEH3W)PZE('%&\2
MLG96'&4NR1"E1TM<GPI:).64N..88<PTJ(VE3K.74H?>?>)M]A_ 2/;&_#Q7
MG,OT+04.V-^'BO.9?H6@!VQOP\5YS+]"T .V-^'BO.9?H6@!VQOP\5YS+]"T
M 1Q?)IX60:4'#RTN1'T9C.'93+;^%-YQEI;J@\?#:5_O<KR^UA.,].7$X]_
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M2$=Q[?,;O?6;5CL.\)4G+/:_O>TPK&4=/3TXZ-"UEL[0/4>WL$GH : &@!H
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M$5^F">LZ ',)?@17Z8)ZSH HR"$OL'_]Q%<?N+GOY>">]^0KW_>,9S_[8SH
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M7^ZDN#O\W_B6^I[7?K%UG="M?ZUH_P":;\H,/I<HG5M5_+$^:#W4EP=_F_\
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M0?<6,<M-;=G8+35VNLIHL<'50S*XH$+,13XCA&JLR2\J8W2(]^TCY^&!?#6
MZ#VY@F!X<RT7;D1TOWF_3A$26K*Y,8%.N!F4,ZZLYSG$>6TZHD-CYZN8(F;
M'Y;9S$RRBE?&^\[=WG5V ,*WUI%[N,';V?MU.&0K+M_N+'W CM&"9$4,+X$T
MN["F*Z0DC(DZ1@;821R &+KS%D=S#S9Y-B/*F08L5\97M;8=P&AAFR/$$)K;
M&W3=Q@SJQ$W+Q;&;)(L\]DZ[6D;ECK.R*?0T 7-P45"A$#<J0@MEA) HT'96
M_#;<=C\2(R*VX\#]I;/9?7ML BPVUG$MAMNERSB(P:+0:VV0FNV1+X<@3F1-
MU8)T<IYNKMES-F433M>5FV23-:>;A"WU)6VZ4)1#ZQVS;86^)\=AG[<,0&<2
M-I^(&U[,6:EW>]B'K]-NNW!ZOV<;(FQ(HK-0L]'LI<M'Q'CHDLM/F !8J*!Y
MSF&MMY@:Y'#C)2@XVV.QE?'"Q\#]]_H0#%8^W7$Z(+6@=7+C!%3+VLYN4;D/
MK(&*U7;&]5ZT,9IU>+S0L9Y$4U;C=N?CN-J<D!Z[MS4)CXZ*NPS(TF&2MAZ\
M=>KL+QX$> "2&;9\5 ]!F0B]"<$SE@9+QI39O+<<8PR,V]$.-&H,JLE%&5O5
MBNV"OP6&IR^5')C%CF$#Y"8HZ*I$HCUX';X? K:S^("YM.VW%9' SH=)W/8F
M%Y_,4-3+081E(UQ PLJO28^1M9A.Y;9L4R%)+MX=RAP='2AZ$?'CVJJ365;7
MB=MO9LU6Q\"VZ@':C7:=DWVO1VO9H[3J^_CM.KCK]&>C'3CK=/1[V/>_BUR
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M;]/T .<Q/B2OD1OT_0 YS$^)*^1&_3] #G,3XDKY$;]/T .<Q/B2OD1OT_0
MYS$^)*^1&_3] #G,3XDKY$;]/T .<Q/B2OD1OT_0 YS$^)*^1&_3] #G,3XD
MKY$;]/T .<Q/B2OD1OT_0 YS$^)*^1&_3] #G,3XDKY$;]/T .<Q/B2OD1OT
M_0 YS$^)*^1&_3] '\R9AXQG/8EO>_X 3F<_U8P.SG/_ *8QH _'/8/Q!G[.
M6'TO4N7;P/D _>#4-6.G#);^L =3G_V4.QG_ /FKYU6]X#^\YB?$E?(C?I^@
M!SF)\25\B-^GZ '.8GQ)7R(WZ?H <YB?$E?(C?I^@!SF)\25\B-^GZ '.8GQ
M)7R(WZ?H <YB?$E?(C?I^@"-%&8>8KO_ '\__O(QCKR@9G+J>@O.QV*<IA.8
M[M&Z.[P\95A28;3"5H;7A3:7T\\Q"^)^\Q)<YB?$E?(C?I^@H<YB?$E?(C?I
M^@!SF)\25\B-^GZ '.8GQ)7R(WZ?H <YB?$E?(C?I^@"-=,P^;P<?[^3TC2N
M>[I!F>YN]$H/^[/IS"PO,ECIZD7*6U)PU)F84MO*D)<>??YX";2[C^ DN<Q/
MB2OD1OT_04.<Q/B2OD1OT_0 YS$^)*^1&_3] #G,3XDKY$;]/T .<Q/B2OD1
MOT_0!&&34/ DCGI/1NB&_P#N\,&93+9_<U?ND=2X32,/(^%O*G$8PK&,Y5CX
M=!#U'Y]PD^<Q/B2OD1OT_04.<Q/B2OD1OT_0 YS$^)*^1&_3] #G,3XDKY$;
M]/T .<Q/B2OD1OT_0 YS$^)*^1&_3] $8.,P\J)>^>>Z"3^.B2#-9PS^XQ_W
M&-U82^B,G]\C"NHKKK<Z48QG&5!"V]XD^<Q/B2OD1OT_04.<Q/B2OD1OT_0
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MPU+")S*==Z>A#T3+R6F&^KGM$39"L93V6<*;.&/'S[!-I=Q_ 2F@H: &@!H
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M#.5(D]C*"H[XJ1T]#2H/;]BEG..E_!!:\9QW?/2V<,>/GV!MXX<//M$GH :
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MLM'0P;.2.T:B. SE5:W!ERZX+955 K2AD05"Q:71;FKY\ZO./8+CY]GOQ_O
M7%01N\\2#3)#.X42#).!7Q0JR3&)"P U),*S>XM[FY?;:-R2E58GF :HD=\(
M#MQ<L JV>6!@LZ0\^??O#'SLW\^_#M'7.@H: &@!H : &@!H JH^#^O_  QH
M ZFYZ$\9%>81/OM9 QPYZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F$3[[0
MYZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F$3[[0 YZ$\9%>81/OM #GH3QD
M5YA$^^T .>A/&17F$3[[0 YZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F$3[
M[0 YZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F$3[[0 YZ$\9%>81/OM #GH
M3QD5YA$^^T .>A/&17F$3[[0 YZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F
M$3[[0 YZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F$3[[0 YZ$\9%>81/OM
M#GH3QD5YA$^^T .>A/&17F$3[[0 YZ$\9%>81/OM #GH3QD5YA$^^T .>A/&
M17F$3[[0!'"SX=49W+EA$RE8(ETX=Q)BQNJA!::AN-V>5-Y5F&VE$3,CJYQ+
MRQF5A;N'L.K?0"Y^_P"&H2//0GC(KS")]]H <]">,BO,(GWV@!ST)XR*\PB?
M?: '/0GC(KS")]]H <]">,BO,(GWV@".=/A\%H2,6$2EM0XHI<3O,567UIDB
M,-R<2NMG#.(J5N-9CY=1F3WS#F$.8B94T\^\-O'#AY]HD>>A/&17F$3[[0 Y
MZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F$3[[0 YZ$\9%>81/OM $<7/AT"
MR"V[$)AN)B/Y1*S)BR\1U8;5T/9C84[E_J9_*[+#:\KZ.KA.>GHT(0]1_P!B
M1YZ$\9%>81/OM!0YZ$\9%>81/OM #GH3QD5YA$^^T .>A/&17F$3[[0 YZ$\
M9%>81/OM #GH3QD5YA$^^T 1P^P!U*(]>Q"9'5)/I1C$B+'[LC#3&<1LYRI'
M>,HSG*^\8Z^%]IU.TSV?1AN$*^-]^'<)'GH3QD5YA$^^T%#GH3QD5YA$^^T
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CS_KT ._P?EL3ZRS_ *] %5$^#T?PV)\/REG_ (8__/0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g367280g60a59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g60a59.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1+^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     'D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   " "@<
M E  "')R,CDS.3DX' (% $!-:6-R;W-O9G0@5V]R9" M($ES;VQA=&5D(%=O
M<FMI;F<@1')A9G0@+2!"=7-I;F5S<R M(&9O<B!24D0N9&]C #A"24T$)0
M    $'DI741NY]1$_';L9<];1ILX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9F
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \
M   !  $X0DE-!"8       X             /X   #A"24T#\@      "@
M________   X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-! H       $  #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              "M   $9P         !
M      $             !&<   "M                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   "M     %)G:'1L;VYG   $9P    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    K0    !29VAT;&]N9P  !&<    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     TX0DE-! P     "#$    !    H
M !D   '@   NX   "!4 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( !D H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M![WQN:_W/3<G& .$:D]4$GHV<7J&#TN<?)SWY3["'A[Y=M!:UH:#+W>[;O\
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M_:!54W*OQ[ 2_9C3O</H^_9_@VS_ %$+K/UCQ.EN%&EN4X2*RX- _P",>?\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z  ;4#   "<0 !M0,   )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C$P.C$X(# Y.C(T.C4Q ')R,CDS.3DX
M   #H $  P    '__P  H ( !     $   1GH , !     $   "M
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0              2     $   !(
M     3A"24T#_0      "      !    _^$!2$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,3 Z,3@@,#DZ,C0Z-3$ <G(R.3,Y.3@       .@ 0 #
M ?__  "@ @ $     0  !&>@ P $     0   *T         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M$Q9YB,K#& 7/&06)(5 ?(DY/<*16"LM[2*V^<.:+QM -F15#="3^9D7CLR(
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M"?+$<!BC 'HJ@5E(^E>G8OH:/8?6T,4AP!QDR!V/UYS^&.-^6EK_ /:>>_\
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MV:BLNF(F'I$#)AP8>_'(:K)H^J7[$6.GW=R=Q'[&%F )^([FP$4J""=SCCU
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M7W3UQ8V;W<MQ'(8RBF*-7X5WV$[V?''&?V8!## SFK+N$B 8W!"E$P%*80*
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MD@C&YS&KNJ+S\3D<(O'<\5\,VPJ'94+$*H9F!8GL!D\DX/:N4*Q $ ]SDW/
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M/IGJCV>76E)+?:49+RR3+20,-UU;IW+?"%\>-?,JHD4$$JP#,,EDE2+$ Y!
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M []M4KKI;J2R0O<Z)J42*I9G-I,RJHX)9HU<#!QG.,=Z^HM7TN9@L=_:LS8
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M>S,_@;E^BRP")I2K J7V;AC(.!UZ[>&"."([6N2^]A](0HH#@'RWEU4GN5W
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MOA&]X@ ;G7,4]_>R-IUXUS-)<6,,%O:2N[,UO'8.9+5(G)RBVY(\( @(  F
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M[QQ*9))=B*,L[L%11ZLS84?/)X[FOB'<RUI=%CZ7!R5J>'-T%79(J(PR1C<
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M'I,,\DAATF80W#*(ECLX9FU2/Q+54NB\,"F61"WBT;=]$BF$RB"-QNPA:\=
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M53OP.?+[?G^<UXO\J6>,N^6LMW2#.56#MN4LA66%4* %(I$S=MEI".43 #&
M$U&CA$Y *80 I@X$=1DG+.1C&]\$8P?B(R/NSD]ZDL2E(HE/<1H#]>P54F *
MS*W'.6(*U#)*JR$MDFF-T11*<QD$R6!@N[>#X8"8J;%HDN\5.''0D@<PB !S
MJC<N([>9FX'AN/M92H'SY(JH!EE [[E_F/S]AK]$^MD43@XLBO(JE9H <1]1
M-X9>1'^?^FH:./S^<5D*[O2E-*4TI7G0]N"@N,_@MUP86R:.0$ '@>D%ERTY
M0 Y'L ]""@]/KVUN'V1LOC=0I\.YHM,89[E8FU!21]32@'[/E48ZD! L6'\5
MR#W\UM\<CM^]Y\\YK!?!CT@[?*@8HE_N,Y+(N^!]#)WJ4<G >_P073$1$0[&
M 1[:_/+](J"2+VY=;[^3</I4\?S1^F=+B7Z_\G''?Z^_??L1F1O9#TGM Q;O
MJ4;X.?B7J/4I6SC)'PRKG/(!'V7+RIR"L)^J95V7MW 3^ 8_S^ %-]_U!K%>
MPUT'614G#/IM^J!L9.%64@>I*QL?DJG!\J^?;VCMT4I X34[)GQV RT8.?0,
MZK@=]P)JC,<K *-[;<_G"235< ].$W$2DFF(!\NMLKQVX$0-]>LQ[>8V'4V@
M3$?LY-%$:G'[T6HW;. <=P)HR>?WAFM&>SQ@=-U!!C*7BL><';);1*._EE&Y
M//W5V,RJ!J!"K /NIEBB*"'ZS=P@DJ _(2G(8#<^@E$#!SSK7_1;"'KW1WDQ
MM76[-_B[8:[B(S]A&.WEBI)K8,G3]Z!G)L9 ./2-L\#OSFJSV])K*9MQB5$A
MCG+;X900* \E(FZ(JH;MSV*4HB(^@ '(]@UW3\CY8!\NP'//J.?M\C7/S')^
M6!Y?(?GC_6O5@Q 0:-P'U\)/^! #_4-*^:Y>E*:4II2FE*BX]J(BNIBJLG(4
MPI(VYHJJ(<B!"BQD4BF'CD  3JE+R/'(FX^/92H,H@X?3\&GSP8SQ13U .2)
MMEBF]?ARJ01UIKVX2(O25M$3\<NK1.G/E#:78? ^N= ?K'RJ=>S]6_7,K@<+
M9R \>;2P%<_])(^HYXJ]\&?Q++-@7T181:)N/_6#YA<0'X ($63'OWZ>!]!U
MR-(-MI Q[%IFX\@-JY\_,<\_>>W8WL]4BPG/.&NCM[X.%C'PY[Y(-8Z1ZY7$
MO+N$3=1'-ZESH&+\2*69?H$ [AP(#R \CV[@&NP]:3W7V-1Q3#XDZ1T6$JQP
M0[)IP&<\@JS!<#)SVS@FN8M$/O7MJ>2'XD/6&NS@@YS$LNHY_P#ZLN6R#C'.
M1Q605A5_\XJF@7],L=.JF#MR)!-#$+U>G83%-Q]@\?/7(, _P=Z<'!DM0/M]
MX/VG%=$>TEQXO3Z9P0FINW'.T_JY5^[;D?7YU'E>A&2W#6M)H/4HO<ZDP1Z>
M_+E*$K$>< Z>1ZA=IJ%$H<B!PXXZM?K%^C>IMO83TH9?A_P/4%Q\7?P7U[79
M<\^1CRPP,%<$=P3P'[23XG6VLE1G=+91CYLMA8QD?]:E?(9!\P:]R5+Z_P F
M(45 'Q/H]OU<_K= =7\=:T7Z*X[;1_*LD1@D>A(_&JIU]5Y32E-*4TI32E?)
MB$.'28H&#Y&#GG[>?72E6SN.(,?WINJWL5;BWY52B!S+,T#F'J]1ZA+Z^O?_
M '[Z=NV1G@@$X(YX8=F')X.1R>*?V^S';'ICOQY\]ZQ>L.R6!$QEJ9:)ZM=(
MF%)BD\.[C"<AV L:\%PR*!>_'2@7N/(\CJ :[[+?9]U&7?5>E-)>>3)>ZM(#
MIMXY./B>[TUK6XD;@8,COQQC!Q6<L>I==T["VFJ7:(,;8I)/>(1C' AN?%C
MQQP%^NK02^U3-<28QXN:K5B1*(B4KU@O'N#@ ]@%1@N1 IA+[O5Y,1$1YX#G
M@-4:I^B_T5<EVTO5=<TIFY1'DM]2@0G.1MG@BN&Y[9NOA!&=V"3*;7VEZU$
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M<@1H"D0.X@XR[#L3CMCR_'M7W'&4R2P8Y_=[#C'GS_>O0:F0$R%(4."E "@
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MFL,4K;9(C-V[FD<^-I%FD9$$GC6.7:[DLG-RHMW::Z)7,(=!TFM#(J**5?O
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&I32E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g367280g62i20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g62i20.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[34.4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #U    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  $#P     $  3A"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8             !%(
M  0?          $                          0             $'P
M!%(                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!%(     4F=H=&QO;F<   0?    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MXU4MOK]!@N<R_)?;5O\ =<VVG]'=_H[O\&ALZL*,OIN36??A/+K7ORFV&PW
M?:O3L<\>@WWV>G4W^;_TF]6.G=+Z5;1]9,:QM;<W?D5XE#BW[0YM!^TVU@Q]
M%SF>_8Q5.K]-Z8W"^K[,7T+67FMF6ZMS=OVBPX[\EEI'NK?Z>0W^=?\ 00N5
M=:4ZWU6MHR/KGCWTN>6FFQA-]K+;7%M>SU++*W?I'V,;^XNT=39^WGVU-:7F
MAP:7S /Z.':!<AT_"Q,3_&/A?8B+,>_&=8RUI:YKXI?0\UNJ]FQKJMO]==L8
M=UE@V@EE;S)Y$BL;FZ?V56YHGCP?[;7_ ,*RKH2H3\8U_P Z+=J];TQZVWU-
M9V3MY]OTOY*FDDK"Q__2]4+08D P9$]BJG6,.S.Z1G8-1:+,K'MI87DANZQC
MJV[RT.=LW._=5Q))3YQE?XOOK#E5TBS]GBZIM0=<VRX.L-3?2#K@ZAS';V_S
MGI^EO_KH@^H/7?M8R'-P'5MK-+:/5R&M+?<6>J^NIE[W>H[]/^F_3+N\VW*J
MI#\6GU[-S1LF/:3[CK"I_M'JKF-<.G/8=Q;8QSVDAH%;VO8YIVOW>HZO^PG<
M<_WCIX]E4.SYK]8NF9'0+\5N4ZBFZV[(R65TA]M0%GV>KTMKZ:_T7L?7Z+VO
M_1*C5UME>1FWL?6ZR^OTG.?03Z;9V;J6LK;739]G_5MU/^#72?XTO^5>G?\
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M=_2KHEGNZ'@NL]5P)LU]\,W:SN]P9N;]-RT$E/\ _]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$
M(@     !+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"'
M:0 $     0   *0   #0 "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3@Z,3 Z,3@@,#4Z,S<Z,C$   .@ 0 #
M ?__  "@ @ $     0  !!^@ P $     0  !%(         !@$#  ,    !
M  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0
M   !   !+@("  0    !              !(     0   $@    !.$))30/]
M       (          #_X0$P34T *@    @ !P$2  ,    !      $:  4
M   !    8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R
M  (    4    D(=I  0    !    I    -    /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HQ,#HQ." P-3HS-SHR
M,0   Z !  ,    !__\  * "  0    !   $'Z #  0    !   $4@
M   & 0,  P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P
M  $  @   @$ !     $   $N @( !     $              \     !   #
MP     '_X4(R:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K
M970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_
M/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P
M-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*
M(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C Q."TQ,"TQ.%0P-3HP.#HR.2TP-SHP,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$X+3$P+3$X5# U
M.C,W.C(Q+3 W.C P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-
M971A9&%T841A=&4^,C Q."TQ,"TQ.%0P-3HS-SHR,2TP-SHP,#PO>&UP.DUE
M=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @
M(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O
M<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V
M=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z0S,X.$(V-4)$,D0R13@Q,3@W
M1D,X-D$S,S-",4(R04(\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-3$T140Y134Y0T0R13@Q,3@W1D,X
M-D$S,S-",4(R04(\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HU,31%1#E%-3E#1#)%.#$Q
M.#=&0S@V03,S,T(Q0C)!0CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-R96%T960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HU,31%1#E%-3E#1#)%.#$Q.#=&0S@V03,S,T(Q0C)!
M0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C Q."TQ,"TQ.%0P-3HP.#HR.2TP-SHP,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!I;6%G92]P
M;F<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-3(T140Y134Y0T0R13@Q,3@W1D,X-D$S,S-",4(R04(\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3@M
M,3 M,3A4,#4Z,S Z,3<M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HX1$,P,D)!,$0Q1#)%
M.#$Q.#=&0S@V03,S,T(Q0C)!0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q."TQ,"TQ.%0P-3HS,#HT,2TP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z.$5#,#)"03!$,40R13@Q,3@W1D,X-D$S,S-",4(R04(\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3@M
M,3 M,3A4,#4Z,S Z-#$M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I#,S@X0C8U0D0R1#)%
M.#$Q.#=&0S@V03,S,T(Q0C)!0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q."TQ,"TQ.%0P-3HS-SHR,2TP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HX1$,P,D)!,$0Q1#)%.#$Q.#=&0S@V03,S,T(Q0C)!0CPO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#HU,31%1#E%-3E#1#)%.#$Q.#=&0S@V03,S,T(Q0C)!0CPO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.C4Q-$5$.44U.4-$,D4X,3$X-T9#.#9!,S,S
M0C%",D%"/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!8@%2
M P$1  (1 0,1 ?_$ !\   $$ P$! 0$            &!P@)!0H+! ,! O_$
M %X0  $$ @$# P($ @4&!P</#00! @,%!@<( !$2"1,4(3$5%B)!(U$*%Q@D
M83)4<8&3TB4S.4)RL;09*#4X=WBV)B<T0U)E='61H;*SP='P-C=&6&)C=H2&
MEJ*WPO_$ !T! 0 " @,! 0             ! @,&! 4'" G_Q !1$0 ! @0#
M!08% P($ P0( PD! @, !!$A!1(Q!D%187$'$X&1H? 4(K'!T3+A\15""!8C
M<C-28A<D)X())28V0U.2LC1&9:(U1%56<X.3TO_:  P# 0 "$0,1 #\ W])9
M8H(I9YI&10PQOEFED<C(XHHVJ^21[W*C6L8Q%<YRJB-:BJJ]DZ0AJ]3[WTSO
M>K/NM-;/PG9M75.K&V1F&9#77L8"75=%;TLIC0II)!Q[JIGBLZ<F5C1[0![3
M )2!_P")TA#L=(0=(0W=#M[4V4Y9<8#C&T-=Y'G6/*<E_A=#FN-6^64:U9<8
M%FEQCE?9D7%8M<=+$$=\T.#XA<D8Y'MS/:Q4(<3I"#I"$K89WA%3E%+A%KF6
M*UF:9*,4;CF(6&0U 647X8*/<:72T!)D=M:C!MCD4J<$2>(=&/65[$:[LA&5
M.O:2K.I:NRN*NOL\E-)KL=KSCQ1#KZP"JSKLP&F$GECGLS!*:LLK8D8*.>:"
MLKS3Y6-%%GEC0C*](0=(0=(0VNY,G,PK5&Q,MK\FQ;##\<Q"]N LIS8="\4H
MRP0)IQ["]%=>8TTD&*5K/,=U]5-F>K(W&1HY>Z$1E3EW-6XKP[L8J&MV#_:8
MK,.@M\JQ>Z9'086;<LP>"QRVX:"#<C#X2ZWR0C$A3X[!TC-EWFN,)DA8)EEG
MDF+H0VFY^5V3X;M;;VLP=Q:@QRNH++CF/-E$]57GF:$QG91VRZ_-<DV,$;FC
MA3YXC\;P2OK[:\AQ7'<>GV-B[[6JL8Y87WR'O]OS#[<0,PY$;$P.+8._*VFI
M'9QB^NLIQ6BJ*Y:5E(MOBL161URTYKBLC!B^:\(UT>56$UP-:FW%1$-'4U-;
M8VZ$2YZ0@Z0@Z0@Z0@Z0C\<JHBJGU5$5415[?5$_G^W^GI"($8KS6CQK2NY-
MH\BL2,P&^T#?XV'N'",9 ?=V&!4N6U.(7E7:J4MN4!FPHU)E<5_.1A1UE8V5
M8/(#48X1E+68[,A[X?7]H<#;O)B[U968?FTNND.UY=:BVALV]]W(X4V!66&
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MUTA!TA!TA!TA%9J^JEQZ958_9'XIM&O3),GK<:$KRVZGD/\ ;NZK#;FGLQX
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M17.5KWNE>UN&8EWY28=EIIAR7F6'5M/L/-J:=9=02E2'&U)"D+30@I4D?2L
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M%^BIVQ:K3L[Z_1?\%[*GU3Z=EZP#?QW\=-Y%^8,77NZ[]/&)@>D?_4I@N);
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MBQ0_$83Y.\6P2.<]6M7RZLD$F@!))L "22=P&^IT ^\0H$Y4I^:M@ *DFU*
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MNM(7:EI[ &W=%$LT!A5*LTLD<CU1JRK(5,U[D]UO:(=JQO2-J,@$5R@@D4J
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M J*2V' L'O RV*II6.-/2$CB+2&)^63,M-N]^A.9392[E"5?,FBLJP$YQ8J
M%%#6$MZG]MI_-0];4O'UMB_7>O:#-L2QXMD]G=CQ5#G2NK1Y+IL98\1P;0D=
M+#9V++ F:>65D+1_A^6H8EB$WBT_-XE/N]].3S[DQ,NA"4!;KA^:B&PE"0+!
M*0+ ;S4QRT4%$@!*0E"$)%@E"$A*$@$UH$@)%R: 5))K%B'%C*.#&MM3"<Q]
M@WF3)R&S&MS?!:O#S;[&7XJ#L>PQ:TQK*+L>G=2QVP?RH+=+AT]E:S!5\=JI
M0;6PS0"1[=/=H6T&([+RVR<R94X=+LL,*>2V[\8^S*NH=EVWG5/*;4&RVVE1
M2RDN!"2LE0S13*A+KKR64?$/)2AU_P"93A2A*$B@S4!4E 2L_,3H *F(Y^G!
ML# [GFOLO7N3W.8@8KRGUSFF+6]OC-_-1Y0-;V%I#F!+:>TJTF=7$  #%SC)
M#9WT9"!D0FS&AD%@=:AAT\[AD_*X@PAAQZ4>0^VB991,,*4BV5UASY7&R":B
MH()S)4E82H7"E(RK !*2H4-0"""G4$*2:Z*!"@:$$&\3']<.QTTNH-%Z>U'G
M(+PM6 )C9#LBR6K&@DCQC&U!JHK(RPD#4[*"0RCY290@_<.+)?*0R)CGRQUG
MIQW$)R:GIC)W\Y,.S+V09&PMY:G%)0FIRMIS$(14A*0$BPK#O%..*<5JHW J
M:"U *E1  M<DTWZ1&KT]-F\5N0&C\,XQ<R1<GBK./-CL#8VMK^KRY^+5/Y$M
MB@;+):?)B?;<^6N#DCB:0E9()>#@B0DU9T+)3_#O]F=L,;V25/+P9QAI<^RA
MEXO2Z'RD-%9;<:"S1*T=XH_,%MJK\[:J  NF4H6VVZVI:7,JPJSB K*?E6DV
MJ3\U4UI8$"(J>J+O/0NTN1&![>XREV%>E0'B^/T156.RJ&I[+7$>0QUEV4R9
MDQ9RO@#QIF,I#*(R.J E:;[J1C0)K#KCCSBWG%%;KKCCKBU$$N..*4M:E&WS
M*4HJ5SKRB1F45E9NHE1M0DJ_41U-2>%1%I>V]D<?^>.I^-7*C9)V3TF1ZCQZ
M'%]M4U/(,E1<2 &AF$T$Y#S84Q\]N3V$Y+;5!F%WU-<0"^X-,RI,#WC9C;W$
MMEL'QO")*6E'V\90,KSZ052CQ;^'<>R=VH307+T2EEU:6T.(2X0M*G&UX\J
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M#Y[8G#MEW,"93B.&/(,MC*7&RKN>\4XZ2GNDNAQY"^Y4WWBVBD!W/F"$)A1
M4X2MXA;;:$LJ4%,H4@C_ %FZD*;44@I6@ A52K-_;$"^0053DG.>#/\  'NN
M=>WNW=6VE7?#E,,KWPF7U"UD<!<I"R$Q0I$V-BP,?%!$D4$JLE;V=H536UQX
M<AQK;I$ _*1OH:"XW5OPCHOUO_@X#_X$+_\ 41]6C'&EGZE];/+ZF&V"!710
MD+L#3BCD$#O*'A(3!]:I#+,-'.*\B%DG@Z6!A8CYFHZ-I,#G)*WY/VFF:=M,
MNSFI_P"OMG4TOO;PXU\CNZ\H_:_LBFLO^ F:9S 5[*^UI(37<J;VU!^IZZ[X
MW1:6&Y'JPX<AL*ZUN8XW(?85%211UQ4ON/5KQ:DNXOR F)$L;'1RW!SG2-?(
MDK6O2*/ZPC\4(RG2$'2$'2$'2$'2$'2$'2$<WG=+N$DN[=FPVW(G?%?:R[4V
M-">-!Q9QNP"#L&9B7\Z.(_\ M("3%ABD$^(YC@!I"H(T(4(=SDA2*[J^GORU
MC("N@HD$6I\VZ/7FM7P>P^CQS$9^3VZ;YQEH_+0;2DXM5I $(^1@TM1&"@]G
MR&K/:)C("64X@>.>-[U2'W/*!R/F*_/4D)%=#>EQIQT\O6/IJ>EX17!%SD@G
M)W=,#*'%,E.?5V'%2M@L+F*TI'TJB5*5O(&WCEL&)D#;!(C'!#2#5QJ2&0.2
M)SUC^XI]8E172A2+FQ!\J\/,]-\-7 3P8291V<D.0:/(F05_CQ0QEK'HX:"9
MZ/5G)I/**2$AJ.1S7=^[FJU4^KHJ.>E=_P#'OA ]X?[4VWUT/+W^(=-][PPU
M=5WD$W)'D-)5;+PDRB,'J^+5*/#-"1;1$ULIK9N2 \)JUEI40&I!'[\7A+X-
MGBDDF:Q86\J_3GY^E(?.?[197'6WC3<#^UY;</H.,.0:-]0JLPW?.TCZF;B]
M6C9A>9IH03&V8G51;>P-H9]54TNY,U,R6>8QC I &1T:"CO0EMA(C5#D5%[Z
M:]*\CR_;=$'-F22D"^XZVZ6O3W4F&>K\"X?39;8XZ_F497R6V.7^-OFO..F7
M 5GR,BI2Q*YSBX\T+_\ 8EDX(Y6/A3S^+X,>V1T:K%./2_/=J=_&NM!%E%>N
M2P-?U</#^-=!"5LL>X=U%E(#_; R=Q=7-,DA07&O+O8G8TU:1RCR/SH>5T3R
M2&+X2Q1N6#LY[&_5O2HO6PYU&[K^/O"JB*Y*UI8J%-*\#O-.GE#C2X'Q$73M
M?E;>8-DM?6YO<13!IQWRQ;UTF1XYC\@TWX7^<T9&%#%B)#)"U,_5,2..V)7)
M(Y)J->/7A^WLPJJOZ;TTS4M??3B> ,8;6%CPYQC9F&7\'+O-1BL?N [R.8+C
MGEE:4K1_G-=#'819[)(.I<8984JHQ4<-,Z)Z>,SNT5&[TK3CTKZ[H'.013_]
MJI%S?]O6U\QEU3QOUG='8"5SHS&PA;;S%S24>@<[.QZWM'CN%=>#RGYN(\MY
M0HW@RR>(QY0J1M\G1^/:3;W[TBHJJ^0<OFI;AH/I7CI'DU]B/$$Y^1Y-%R[N
MOC5.(Y6I 1'&_*Q#;)<MIR\)2.LACS2:$@H.?+&WA LCAH_PRKLGQR>]#%#,
M!!O73V:TM[J(L2JP*1NI>NF[3PU%H:.:@X:F&@CNY<92KXRT<UJ\9<I5KE=7
M%*B(OY^\4_A3^2.5%[+^G]_I%KWY"UQ;=ZGZ1-5_\N[_ )O?G2OE0NW+C_%+
M$\3/H;7EMG246QJNJ-IX!>.V5NIWV]?=!G#GFPNSSX[RQP*ZP E8Q6SL88*Z
M57,9%X23NK<Z>?/WRW1%5$U"15-12O["P_,26X@4/&#"*WF)E0O);)LG %X3
M[BQ?((V:"R.N,HZ;8-GA6N!+T.$C,R77/X3>933*^B&44@D*6=\!,2CJQZUZ
M6I8[M+>GITUA150?(!>UZU/.V^_TWQ!S$*;A=7Y-C9<',2^/( OZ<R&O&XV9
M2\TZ8&Q&*:&+&W.WOD)G>QL4+&,<YTDC$\5543I;3TIPIQUIQ^IB25$?I U!
M^8'=T$>FYH^%C"K$,OF+=UY8UQ,XD0SCAD\!-?*'8*00&9#+GC)AR1O9E@GB
MD9&^)[)$D:G@Y$6._AN/$:\*T/7= %5J)!I;]0',Z \/S"SPJNX9UR7%U+RR
MR.WQ6*F.HLKG%XVY/\8$"^C_  T*68]<YD% *&N5KC*QY+FMDLPAHD1[E5%?
MO^>F_P ?.!S&@H-13Y@=!?76_/KS1JUO"B7Z?VS[#R_2GDO'7).[E1S4[-[Y
M\[[2.:BHGV>]K>ZJJ=UOQ;WNKIN\XG,K<D?_ %#\>_"ZTSS&^' EA1+<\KLJ
MQJT,PW"S"A[?C9DH;K0)U!7C8]D $,F;PRK4WV-QT%@$2]KV$N)<4-/(,0,J
MK>@\K^GI$ JTR@BI_NYW&EZ'?QC(ZM3BB)L.DR7&^8.:WMKC;+/(#X\?XYYA
M);OQ['Z&R-R@AY N=NE8&%B@5O/9E3*Z.&J%+D)?\>%_B'TM?WX^,0<U",J0
M/]V\FUMU3:G'RAL_'B'! @8G.;+Q60R13K#!Q]SF.-S$.CE+1X\.P6LE82\>
M9I*.8]CWH]9T>C7]/V'KY^NG'?/S?_+3S^8?C='N&JN(-#'292#R\S6O1+.?
M\!O!^,.<1Q/LZ9P,A3 28LU3SE#4\'Y$<:^/B9'&_P FSJU5=/N#^U.L#4DC
M("+U&;CRI3=]]8EIP:HN(I'-C3N8:^Y*95<MQK-;7/@,;LN/648^AM?BV.7^
M4V=7%=EY@0/#*RMKS&A3*',R5S1XGHU\RN;,0HJRFJ;4%3FO]OKSMI$(H\<X
M6-7M+S*NQGR?J4<KC9E,$S%E[*C9(Y,]\V._4B*UR?=6_P TZJ+:;S6E#O\
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MG:#MFE,0V);V?PW#7I7$)R13(X@76VS*2S?=I;F/AE9UEX.C,B7S-H+:*+<
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MTRFJ5.@J=*^Z*B5#(ATMMG-8I&51 2LV><>>"=IP[TCOWD5LW=N%EV.7\?\
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M]SWN$>I76;-UIDT6.7&_<#M=0C;!*JS9,;Q/8MG7STU+<>\@R1.E@/QRAN7
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M_!_CQXP2:UJ;G3=X<MWE:D*_TO\ TXL9WM?5FQ-D6]A^2$%M[SSH6PV-!6C
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M)=LJ[MAE%20A.=2BI2E+6M2EK4:QCJ211(2VA)2A(*B$BJE:JK<J4HDFU30
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M3/LY79+?%6-< 8%C@1Y45W9589?N3&DPQOEC \QU@G-C]KS>G?JPK2_&MJZ
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M4;FP)H*BI-*T%QK;G&JUQ_U[DG(;U5Z D,6I"8)LS*-B9%4@SDAUCL2QJVR
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M>%2=?Y].D2H_,?+RBC?U-<=S;>'/N'2&'#U=!<Y=D%+K_%D"B?0!EY%G5+8
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MQW:&:*-JRT"/_P!Y8,FG^XR'YC9' L +4."PJS@[( EJO&. )A,#(8USF.=
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MV:Q Q*\:(, 48(2!JM@%$@B&&A:KE<K8H(6LBC:KG.<J,:B*YRK]U7K[ICZ
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MEJR\(R_X"UK(K,R-H95Z(EI7_C-4!*8M2\J. N=A*/A:A#%^I[_R=W-+]_\
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MNL!@FS;77>/VBB=: \CQBCOAUY+J_P!0;R[N<O",]7?3M]5Y)<<E5/I]/O\
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MK94A99[L@*(3DJ*<"4P[#)!QUZ1PV0DWG22XZRV0XLJ2$DE2EJ_M^5)IF -
M00"&DQ(R/"]0Y"/08E>W!M7L+'6"V64PV0[4K<DBR:\-8N+U-A-5O?!8T<PL
M$Q9EC' -9JC4>[VD&ZO">TC:[!,(3@N'3[;<HT'D2RW95EZ:DVGP>\:E9AP$
MMM]X2ZE)#F59L0C*A)S#,*>GF<2?PW#W\18;4VQB#LNVN;9;(("$.G5(S&@6
ME5OE-4@)#9; R>[RW8.*Y]6Z[KL?N:7+HLIC2MI271V)HCFVK0;+R%C;+3I!
M4#U8]1 P:K KII00Q8X7^*::J;FU3?QZGWESGQ'Q9FE.*5,&:#G?A\N&JB[W
MH#F>M<YJ#41SPLYLY75=<V:HJ% U!' UH>HB=._MK:4J\SR2JU%QYN:.K=5V
M52;;7=K=71K,@MAO8L2\=K%-?25(=%(22+4R$LN'ND'1[88F+$^+=\2[3ML\
M5PQS")O%?^YO,_#S :EF&WIEC)W:VWG@A2BEU))=+?=K7IH5!7'2Q*AXS2)6
M3:FE)4@S"&4A[(NN= 6K,4)6=0V$ #]--(;CC75QQZX]0)E)CU\  O"0N$5E
MHR4@PR9O(WCJY[^T84$;9%1C_P"!![S4;&KT<U.[(] &^FEJ>.\5\=].(C*K
M^VM/U7.E.7NEJ5AC.*F<YAJS8SIZS7V/YC'E]09C$U)GN&.RBCB,F8AE/;C5
MQ<?LI:5]F- D<JM>V06<L:6-[)4[<J1GY_#7E/8?/3LB\I)0IV3F7Y9Q3:J_
M*I;"T*4DF^4G+6^M(N5$ Y5$5X&@53<>-->H$8C;^:9#NVAQP#*\1?1+23V#
MJ]N'8]%4U0Y5^0,;<EQ4B@Q.CGL$#!A);';Q@/@K@(V QM%']F9W$<0Q)X/X
MC.SD\^&PTE^<F79IP-IS%*$NON*6$)4I2DH"J#,HT!43$5O4KS4%!F5I>M!>
MPKN B;'&#FUM/C3H7+L<P?!* S,*_-,43&\MR'%:FQNJ>DLWY+;LBKYS:(JZ
M]N@MPBG0-%LX11UOX7,C@F17S$3\\W+"41.SB96KBC*HFGD,5> 2ZHL!P-5=
M"$ASY?G"0%5I2)SKT2ZM*-<H60FN^P(%ZW_>(J7.S\]M-X6_)*$;)@=KWQT]
MA;QSTT%EC!Q)PH@EXPN,B&,H^JR."!PYM87"YPH\CXV$F>(T@G&0XMI:76E.
M-.-J"D+;*D.(4DU0M"D%*DK20"E22"DZ&U15/RTHH"EPH*HH'<1>U.1^\2IY
M,\XMQ[OPL?1MGK^AQKCY^#XI;5^L\)QE^,5$EN3CE>8;;DE4U?5S$VHMD2=5
M_(A^$Y8@(XEG\6IUGFIR;G753$Y,S,X\H7>FGW9AY6IH7'5+72IT) J3O-X/
MS$%2U%0^7YE5H*Z"O'RY16S18>=6C.%AK[TZ'W)Y&D$4;@7K]%<[N,,I [&L
MD:YK?:>UKD5J-B8W]'7%N;:>?/>?J-VXBPN".(\QI_$>$[$IKIA8-E0W3H)A
MY8XI1@S&2#RN5(T?[?M-C);*.Z<9X\RM;[<ZSL5)XHUZ=!T\2+$&E+BQMYPJ
M.//T_%_*+.,9Y(ZDFT=4'Y?Q<_/')?!Y:(.WRVP*RFKQ;+,2!G;6Q95;T-99
M!5-SD,4$U</?035C'613?Q:R>?'*>KMWP[M%VSPS"A@TEC<PS(H;[ME!:EW7
MI=LT/=R\R\TMYM*0"AL9SW*24L]V$MY,*FF5/(?4S+K?;%&IA;3:WFP-$A:@
M:@:)*PK**!) 2D)1G# LS/O4ST!LIU$;2R9%NZ*Q6E!Q:"II:QEC)>V9"-+9
M.7:'F%'6)199MP8<1)-*K!GA@1"A1:3F*E5.:I))KOKO.^YJ;ZGPBRK(5<$T
MU)K4[_#EXZF*[*46]J;@&VCH;&=]5:C6*"O!.2,SXA#9I!971QMD;$7$R0>1
M8WMD:R571N1Z(J9I2:FL/FY:>E'5R\S*/M3$N\BZFWFEA;;@!"DJHM()0L*2
ML?*I*DD@Y0JA!!%1<5RJ'BE0*2.(4"DBH((K$CMMV,MT5G6%?D>^AQ">*""A
M&;:V\IE,%/-57TD@,Y%836RLLDB^&0.57D0%51<[)W./=!8C>DX[VM;78_A"
M\%F5R+,O,,I8GG9:5*)F=0$95!UQ;CB&D.#_ (B6&V]Z4*0@EL]9*83@\E-/
MXA)8;)2D_-I"9J:904O.I RT)*B*%-1<%0"B H))!>'@CR-W3PZRC+3-.,MT
M&M-<Y^WVK3&GOFCL ,>LKVMMNX;E(!<TL&."RA"LF#$B^$D_NR!#NB\S#KB4
M*:#C@94H.*:2M8:4M((2M38.12TI)"5*%0%$)(O7L%'Y<N<@5NG,:&XU%;D;
MB;CE#.[XVIN#D-E5/F>?-L[*_IK>LOX3R K@HDJY"*!++(+G)DD=(RU+#6<]
MJL]WPG>,R9(8XD;DEIJ9DYB7G)1UR7FI9U#S#S2LKC;J"%(6E5"/E.H4"E5T
MJ"DU!E%&R"E0!%*&QI32QJ".(-0="*6B:N7;]TEA&-P4FM.,IM-F^;ZJIY<G
MS"X)R?*%Q>PRRMKKAU?B->?E,+:KY O@PZW&(%R""LO"X:JPKF3/'ZW#'.T;
M;#:*03AF*8JMZ3^4NMLL,2OQ-*A(FE2Z$%U M5H4944I6MM2@%1QI>6E)4NF
M5E9644\I1?6PV&UO%1^;,;V.E$A((L01$&]5#TF.[UP[()]<V>4X99WS:?(L
M$<!?8Z,;0Y-9P0V%=5&PY+?W%?*.5-!:5ILM]))":%$V1'B22B)KV#8WBNSV
M(-XG@TVY)SK25(#J4MN)4VYESM+;=0MMQM02"I*DD9@E22%I24YU!*VUMN!M
MQ"TE*T+"5H<34$I4@BFH!!U20"DA0!A\>07*[8FQ==Y+QZPW6^/ZNTZ-DV2,
MJL;Q3'COE/'(:?0+;6^1E1R9==9"?5%FP6%G:9.?%+73Q488@M.-&*M,8QO%
ML>G%S^+SS\_-KHCO7B,K:!0);::0E#+#>_(TVA*E%3BLSBU+42D!*0D)2A ^
M1MM*4-H'!*$T2D6O8$D542:F/%QNRK6>+:B+,V9JW),PS+75?CC,/JH'6M;B
M^6@622BU<>9Q"?%-1V.RQH^9U98!26\$0C2V33R6,LVXX3VH[8X-@9P&1GVT
M2J6RS*S#K =G9)DG_AR[JU%O(@50R'V'2RW1MNB$-I1@?E9*8?8F7Y.4?FI8
M 2\TZ@K=9RZ4JKNU!(ID"T*I0 U 2 DKG,';6Y!46>D8M;"7>2;,U\;-,F-D
M@C@"UMA15L%<#"+D,E17U4$8_M1PLIIIHH4A:A:1QQP1^>K6IQ:EN%;CBUE2
MW%DK6I:E9E+6M1*E*425*6222:J))OR+T)*JUK<JJ234U)(J23J:WZQU">D8
MHU<_4 5!^6FX#'MF?&/;XB0]@X\Y9#V08?BDCFCBC1RDDS.1BI$./%+/,]6Q
MQ1OD<UJ_&NUC*SV^2Z@E13_F/9114!4#_NN$$U.[\4M'S)M=0[?NBM_Z_@&I
M'_S<+H/?VC9XI;<:^JP[<."T&&.C=+#!<T]KC]G&ULCXE0NGO Z^U!D5S%<V
M(T."1T:LE:Q8Y&.=]E1]-QE.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(@
MSZFLLL'IZ\S9H)9(9HN.>TWQRQ/=')&YN*V"H]DC51S')]T<B]TZ@Z'I$C4=
M1',8PHW*JC8,=Y-:6T=0.:,\=TMB82.L+JXN(A4$CEF7Z$/B1>\3/U/21J.[
M>25"M 3NWT\+[S]CJ2+Y2D</*&KO \_9;/#BL<B2,LGW*^..[/CAFDEM*=\3
M(44N/PD9 "0KF2M8B)]416RL<Z?'K6W'<;"M*](4X@>7,Z^%/&%^^JR9F"C@
MI-D4F21*Y7Q_B]W\A[I:>M?(YQ7RT$5K2630Q(DRN4AL_P"EL:^Y(KOKIKKO
M(IO&HWG\Q-!73QC^=(ZGW3N#.:K#L.K\SR.PF$JB+-![6Y>%313/NYY9[@R$
MQ[ (HXR!%=%W6254C9%!+(UK.FZ@-^-_KOX\XA674CCPO_.O+>1"\Y.ZNS[1
M>V7X/+89:V:E'QRPL)&6MX(D$UY5FVD(<\*V<CX'/5P;XHI'),]I$7FU'*J)
M-:;]+^'EN_F(%"#0#A[/2GC4B\-KAP.5IB-DEI;9;#:D @?$:1D&6,+F>\N-
MC/8?":L<79DC9B%F="UH[)'N<B^*+4DU(L#NUY:VIRKQM%J#@.M!"-QNJVO=
M745-72[4N+(DL:"&EJKG-#;!ZOKHU5WQ@399XXUD8][IGHV-7,=WD[R]WVKN
M_FO3Q!TIX:UZ@4YT%*FQ\M?#G$H.2G'39N@Z_5\]]E.:+9YF&?":)6Y;E!H(
MY88585)*.8ELZ:=T'XN.(=//! V*PCF9$SVH6SDM/?.WIYFG&(3>M !2E+#C
MK[/K$WN$%E:@\5/5.9!=WRQB\9M;3CN*O;<R<>>7>6-1RRQ%%F3$1O=%VB1Z
M2H](T1GEX)V2!OO6P'/2^N^_AO@H"J;#7AS$5_:KT]O#<^V*43!(\E*KDKH+
M*RMI;,H>I%4"TC+GEDD*,%'++*'9) &/[C?F$+\=\T;$D>P*_7?H#U]+#AQB
M54&ZAY6Z^_$7$>3DYJC96";OR?6M#;91D]B(22QS,>LCCBBK*TQ&<B$!H-62
MZ=LWF?"5"*D".BBD]QWN0L83*O4C70[K5.GERORM 4H"137I[(\]#PAV<1X=
M<E$T;F&X\NQW,,8QG&03C'$W]K;!61,P+K4IH[J\BT%]B2: )'JQ\BGP".AG
M6O5LC'.GQ/2WE_,1F38 :TZ#3]K:&(;8MBVV,RRBEQS'0\XM[2>4A2ZP*RN7
MJ(R8K%@XI3YFF(. .W\/L'/,(F@B]MDTCYO!SU<OX6^_3EK%K#6E?H+T^E(D
M7RUX^[1X_C:[$MC\F@N\NQUV3%0@W-ZV"NKAK."I22.;YJ>\'),A;6%IXM?\
M=96L1LS6M&U+WOPIX[Z=/&(!!K8  U_GW](93%8,G)=9G6UQET,<DF1SB2S7
MV5K[[T+DG%C&8(:YSI)&ND@&7P2)R^*/<D:>25K< 'QM0_2]:6!N-T6IXC<.
M%J>,-I;S;!K[>O@??Y[ R20*-8FY1E"(2YUO[<RPJEDJS-=!/%'YL\D:US41
M6^'Z+5J+<*Z<MWOZ@Q  '"O0#PT]>O2)3[(T+N' M%XOM7(#,^HTNKV,$4$G
M)<Q_$31#88"8IGLFLD5SH8B!)TA@;.SXL\C2)8BHW"HZGCY7Y?7?$ I)I06%
MS0:VMI3?X[K1*KTS#+FOY*!P+?9)(LG'[E+.4A^07)[G%C\6-MR-D7YID[F.
MB(8A$:,[)$0B21HUZ=^H!))].?/Z1"Q0"PK7=T,0WQ[6&[]U9%BU/KL;*[B6
MR88$?:NM3Q*@-9&@M'-M+2<F,=L0KV(UR,<00USHXX8'R2M18%;@UW<]]^0M
M2V[7C$JR@;ARTKP]D4K#@\O=+;+T'F5-B5S=W_X]-BV(WEM$/:3#RT_OFQ$M
M'(''LYWBQN"@5S?<=(U[8$6&21CE9%;QX^?GN_/A H1^G2M.%;4KI6OIOM>/
MWB?QAWCNBAR"_#&R],>H:R_L#<DEMK24-PHV/"V+(X9/Q2 :6-!FG/+D?/'"
M-Y-BF=[LL,+FNFGB#[KRX](E12-PKPI[]TM$42!\W6PA!8;E"J6:$L(\%S:S
MJ3"M=F#G/&2(Y[B&JI]8ON,\W,5T2L5/:3PBN^O+KISI7\UMI$D"]!>VX<O2
MUQ^T2?VSH';FL-6XKGF0U^:5+LG+,"!!D.R*,F-XP85PV17N.]LB1U<ON$0B
MLFC';-''+,AD9@PC2E2::;N=ZV.E[7ZF(&4D@ ;C7=K>D)[CMHS>.[LX6EQ4
M#8%J+[-(0ZX+MLQ@QX2!F/TC2YI#QR? AR6328V0 H45(3[L<$2N\_&37=^W
M0^!K Y1J+6H-^IK[\H9_=U+LG66P<VQN;(\W@7';2\K928,ER>$221*I9)H8
MT_%INT@KW$1.@;+(Z.6!ZIW_ $N5I;6GL5O_ #Z1(H14"E:;N'O[V,2@JN-6
MU2N,.;[_ +2WSJFH 9AR,:E*R?,X3;>.(J2N>V",@Q&1B%%),@GMOC<0D;"4
M>H\<+9%Z;OKJ1R\K<*Q6J2H "O&VEM+CE?ANW4RW 4^^@Y7<49I[S*E*.Y Z
MLC*98Y!?D>X,[9-4D<;Q3CY8XHY1O:16-A8U\/@CVN155:YKZVW:$;M=_$ZQ
M*@,IL*TO:_/0:](ZK3/\AO\ T6_]2=7C%&LESZ^.+R?W)8ESPBB"66,%%$D2
M,@'&'&Q'%Y)IYYY%;'#!#&QTDLLCFLCC:Y[U1K55/G''\*+O:RU.4J/ZQ@#A
ML#_PY;#AZ9(^6=L7/_$9UO>=H-GAOWN85H!;SOS%HV6:*_H\HJ0K_&KFKR"C
MLHW35US2'BVE6?"R5\+Y0SPI9Q28VS121.?#*]J21O8JHYKD3Z.CZFC+=(0=
M(0=(0=(0=(0=(0=(0=(1X;.R!IJVPM[0J(*LJ@2[*Q-G56PB @P2%%E3.1%5
M(AQXI)9%1%5&,541>D(;_7.YM8;:K#K; ,OK[T>KLX*:U&DA/I;BHM2ZD'(
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MHXK"R^%5R/$4F:%5L[$^9CV^S%JZ7Y=1>M-Q]WC(DG*23TY 6\23^(VKMO\
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MN K*S\')[JQ5HL$WLFP>$;-R.R6.;=XS@.*[:+P:;EY=.SF!2/\ 4L28;#S
M>FF\-<>:1B.5N91-.)RO!$K+NI90X]WJ!H/:+M?-;%8-+XG)R+<XY,S2I=QZ
M8469220EHKSS#_=/I90M02@O*:4E*W&DYD N*$4>?<F=5&<Z\I,[V9<;1LJ*
M:UQ,.[N[9UT6'4BTL!U<%[DY-@?7AL;)/&#5&'R.$E&LE8U?<>J;%VS8#L\Q
M@.SVTF#80G"G<5F4A\)E3).+9G))R=0)R5RMA$TVXW106E*T9W$$*%D]#V3]
MH&*;>R$]-XE(IENX4V6G4-G(3W\Y+NLB:#;2)Y),LE]J90@!33HIJ:,2,O\
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MMA>"S^R&QO:+LLSBLGLYMO(IGI7#,<#:,4PMQT..-2S@1F*V7&F'E(4XXXZ
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M$CR.%?#:2%T3B#FO<YB:%]Q9&QP1-8C)&-5>ZN[]^R 2=*&]^E?#=OO]:7*
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MNB/8Y$<B]E^Z=^_?KSE.M?&AX4 %0;VWUW^9V-S_ (:O#ZCW]85_IQ\C<7T
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M#4P]9C[:7 :^FQS( [<R6MF!&DLVG2V8)L$4$^/""2?)^0^T@%9$-%V4U-;
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M?:$XQ<8_D,0$Y(<+2G4]W5'K#Y-'-@>J/1$C4=1]8YL]QRT"HR1((^(7%V>
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M06/%>3[3?9A?[<3Y_*2*WTMQW>/#AK7C2(R?]2B2.1U.H%-+FM^M81F'>H'
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MLK\9Q^YR:K!M(37#7^0X[77!0+2C#%$-RJL)FDB'A<LCI4(\98_CQ^ZUZM9
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MG[&XH@T)J2:^77RW]>D/OZ3'#G&\PQ[']XRZUHS3,@I+^,R9[S@[,LL#(#V
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MJWSFA65\L/N-CG2.;W(XZBQI6M>6GEQKOZ7K6,JC5"B/^4_0QU5NK1AC1O\
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M$$8=-&D$))$/G>'X;B&*O*E\,DIO$'T-+?4S*,.33B6FR"MQ2&DK4$(JD9E
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MII:_@>>^ITWW.L5507X?D'[185R/X.S:?T!19!#39=;DY ]UG:Y*770PBXN
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M'8_+3V'_ .2%[?EY6T24_P!/DT8P%.SO_K%>%O8D9EW#%8FMS$3*MM"962D
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M$- R15?(GDY%5N!^^E/WH3OA4#EI%C'/+T_K+BYJ?CA'9D@&;&RFG2SO08I
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M> 8PX6<@Z$MHCH4Y"I:92R)A<L^F7*LJ7U,N!A2P$DH2Z4ALJ 6BH"J_,FH
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M \+4/J+VY$8K.Q? :K547P=<4S$7[_Y=N$J]^W=%\FI_J^R?94ZDTI3=36W
MW 'CPTX1!^Z?J-^A\(>9'?OW3M]6]U7Z]VJU._V3M]?IV7Z]_LO9?I:(IITM
M;0C??TK4\Z0WN&N_X>R)S53NV 2)>WT7N\PR3O\ 9/NC4_T(O=.JCA8_Q3IX
M<^%*R?=.HC+9X_SHV0_7O-9 ,:G=/'_C5D5%_=/HQ5^G=4_G]T0:T]VO]AJ?
M+D!O3W]*6K&2IWHVHKFJCD10H%7NG9.[F(OU1/HO^4G=/NJK^W4C0>S3G]^<
M+_SRX:V//J.>8TSN'86K=M[4%P/);'$X\^U1+A.3V5.Y(+2?&'VN(F752$6J
MLG%98PDLBL'B2#S%5_R*V6=*X\^"?V'L3P;"L8VN<.)LHF?Z?(*G9-ATCNC,
MB88;2\IL_P#%+(4>[!JA"UA925AM2.HQ^:G)'!I^;D$@S;3)[E1%0TI1H7+)
M60I.@4 K)7,E.<)*9*<CL3Q?7@60A8,/D!U2RH KC\FL(SXJVY(O06#E5PJR
MEG V3&2E"'16(CZ^/Y ULZ,!U>VM0#QW87MW[1^TG'NV?8[M(P[!V<*P96TZ
M]GI#"I"DYLZO9_:65PS 3B$XAJ7=0UB9#CBAB+<U,.+5)*:?ETKFV#[%.=DN
MR&S?^'KL([8I+M#;Q#;KM14_*;3[!_YCP3'P[*.[/XOCW^9)>0E)3#<6V9.
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MR$5QJERCE"UDT;949![Z*UD8?WE@<SA^/[#H9V8QEK9]3^#-RLK,X:S)S*L
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:14;W14_94Z0C[=(0=(0=(0=(0=(0=(1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g367280g72b13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g72b13.jpg
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M 0$! 0'_P  1" &) E\# 1$  A$! Q$!_\0 'P !  (" @,! 0
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MWCRH2TYM$*K6Z;Y>L2%ON]EA63EIKV>)]H:F&EP3]'4#AB':"O;04=/C#)Z
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MOXB^IHYHA_>UFD**/G7+@Q^L^SBC7,XL5DG,GKX0U.E*L*T*&I6"4URCA8*
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MY).<E@&C.^\C/>.>K>BT^?JOIURKIJ9CW5':Z+0Z-<:.-.4YI<Y2U)9:4K0
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MXR\$L9[?L;\HDN+5;<*QID;:NI?:BJH(BV*1UK_-YXVEV@[(F.9OT#_PR!A
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M"<^#,@7O.X]=P^\*=%85UWQ6H"&U=W-,J\#9(*PU/C*D?1#Z&>BQ8C-/W(Q
M:#D;>T:M?GQ1::5T!X6:NL K!/;!RY%E'CKO"B>YT\U? *WK-];@^]2BT!LB
M8HG=YV#<U;9@:OA+>-R%T,Q*71%6!EF[\M6L6V_F1Q1619^I^BB3FA)/:Y%3
M:Z677!A2F^5%*>KL1E_O?9?NSUR ))!#3'?8U@'V (QDLE/[&/G7<C4HTRV&
M>=M^K??:./)%85/IO5T"--0D-WCL> ^GQJ:CAQ9*ZR=:4$N.,4BRA1*Q8<29
M?X]RZ&NHPMDY,B=+@0:#.LV"PMJ!V<-7FW@BU[3PI]<C/CWZQI<%,C8:)>T6
M!,4VZ@I3(:B;.U< AZ V1/#9WU>$L;TQ!.J;[ORW#5:R6%-S]YVB./'4/AMV
MHI03PQ]7CUO2J$P.FR;4WKHR0)LRB+7F:=9+^LUJ,%BB]CCK;(,X;JBM8<9.
M2D%R>TN-%I:R$L>(-HCW>%NB*$U\)G6XNT$:=G:*^N!N\_9*A*ES4Q5*6\^_
M[,_6/5@TE2GDBA0R6H]<JKD\Q%2V70!^\T#)A[8P,:(^/MV'V7]7!%I$G@PK
MK-TR#L-L=-^NRE!,$=?QHI7NR'AT_4!!3LQXJ3K]Q9O,Z>58D'4:!+)H#XHP
M%:0E1(<Y:(]F>7+IYSN5WUGHNJ5AT)8AVEC8N1K4SN4IK,A/G<YRW@['A-R7
M&N2+H?9-]NT;(1H*)&+I%/&LS'G6(<B(RAH!OQO[^J*Z.5%PDCQECD"S8VS"
M3#*/+C3?>+?,<T>T<F-)(]M9(]O5VSZN^FVN^F?1MKMC;&,\K26D.&MI!%Q?
M,&XR.1]14(N"#J(MS7Q[]K_@K_%+U?XCZMX>.M/#=+WGX"2JQUXGA? M^D$K
M!=>BY:V?VKW_ &$7LD.R R]Q"F:7-(L/L-<8QS==,U=(0':+@ PQ/O=#VVP2
MMPB?%JW%_P!&]J&S5<AC+,3D8^F:)FT.%Q.HWPN&'N;\WD>V*9A%6R2IE:7O
M<YWQRJ[)XM28K#AM+A3:_LTZ&F87B3#&/BJ2Z)U9B<C*R.8/KF_W\;"^!P=3
M2-@B<T- ;]+'A*\. _@H\*--Z$IY!G8N>KU-W,4ZQZ#(2+(RL%JL]YT3 Z-&
M90BJ+)[[W(OD8--X(((H"#"<?X;;'QWM#C,F/XO68M)$(7U?<WC#@ZW<4T5.
M"7:+07/$0>XZ(&DXV %@OJ&"X7'@N&4V&Q/,D=-WNB\MT;][/+.0&W=HM:9"
MUHTC]%HN2<U?O7M2(J5>P.U+A:6EV:59+JZ@TWTB<6MMB/=G.-B;.Q,:A?'$
M*AK(94L\ZJJJ$:?,\NB_3?/26RXG7Y]R[1:YV3TK1NT%I(#]=Y,I$.\6&*_>
M00Z';?\ BETWBWUBWVU_+Z,3Q2X_BSCT9UQGG94&*UN&RLDIY0YK7-<Z*4%\
M;]'_ (=( M.5S;QRO?J\1PBCQ.-S)VN:YS7-$T1#96:0 .@2" 38$D@G+VCH
M=7/ %V1U*(^>]&=S*:UVI8+&7I+=K36<VD57UU[ UP-5%21QEL)"P.=[HF[I
MSC6.>395$(-G4"*4)A[JL[>4F,NIZ?',*GFPNEI!H4E'6BF=/B1<T.JIWQP1
MN$$<(='!2L>6!Q[UY=(7./AZ/L'6X,RHGP7%H(L3J:K.KJZ-U0(,.:UQ;2PM
MDFE:9Y)2U\U4Y@>6_P!TP-C:T"Q/W"?'9I-/+KXP*S+#(^5FPA[=0U2#>%#H
M:;,T2^\-%$N=R/8MUX@+/*_$F\L)A4\,6"8H!NM.,=AW.:3V0J+,AE:/_MBK
MN9G0B.)Y^GDT/N][ 3>[6BX:0[L&X+VW#3?M;3:;I(7$C"*8!L;9M.5C?H7)
M,?T&%PUW<;7R[?\ 45>[#JO7U?1=JWL?LJ^ ZL,/;J(A"K([K:9J<2!M$C7:
M:!@8#5S!+]M(L;9EW$VGDDDDEWWV\KBDU!45U1-AE&[#Z!Y9\WI'S.G?"!&P
M/#IGDNDTI ]P)_Y2!P'K,+@KZ>A@AQ.L;7US _YQ5LB$+)B9'ECFQ-L&6C+6
MD#:#F=:LKG 78)PB^:KN_P#X-]TUX@^[.Y>]'_B1[-KCCN#MKLGLA@A3U>HL
M%B<BY71V^V7!F$3^T31":G:P^DC&)]=M=HYM=9=-]<?7L,^5[$L+PW#\-CPB
MAECP^BI:)DKYYP^1M-"R$/<&_1#G!FD0,@3DOEN(_)=A^)8A78A)BE9&^NJZ
MFK?&R* M8ZHF?*6-)S(:76!.>6>:J_\ >KW0?]*OM_\ 4NF?M^<[TV8K]B8?
M]XJ5P_1#AOVO7?L:=/WJ]T'_ $J^W_U+IG[?CTV8K]B8?]XJ4]$.&_:]=^QI
MT_>KW0?]*OM_]2Z9^WX]-F*_8F'_ 'BI3T0X;]KUW[&G3]ZO=!_TJ^W_ -2Z
M9^WX]-F*_8F'_>*E/1#AOVO7?L:=/WJ]T'_2K[?_ %+IG[?CTV8K]B8?]XJ4
M]$.&_:]=^QIUB;_\%DZ)P? /CQ4=LY&D#+FDDS4*5@C6>&8+2'2.#VGUMX=X
MYY\RRXUSK%OI#IMG&9M<9>FS%?L3#_O%2GHAPW[7KK?_ ."!9?[U>Z#_ *5?
M;_ZETS]OQZ;,5^Q,/^\5*>B'#?M>N_8TZ?O5[H/^E7V_^I=,_;\>FS%?L3#_
M +Q4IZ(<-^UZ[]C3I^]7N@_Z5?;_ .I=,_;\>FS%?L3#_O%2GHAPW[7KOV-.
MG[U>Z#_I5]O_ *ETS]OQZ;,5^Q,/^\5*>B'#?M>N_8TZ?O5[H/\ I5]O_J73
M/V_'ILQ7[$P_[Q4IZ(<-^UZ[]C3KV=> 7\$-X;OP> %MLU+R=VQV]989P)>T
M>QA50S1/6I<PXS5:N(OUB!K2PO:/)#HT:;=L]FS' >?LM% 7"^*[6=O,8[6"
M&&H$=%00V>*&E<_NY)A?^_G<\Z4KV@VC:;1QC-K=-SGGUO9KL7A79GO9H-.L
MK9?HFLJ6L[R.++^ZA:T:,33_ ,4CA=\AL'.+6M:WVU\\0O8IPB<(G")PB<(H
MQ9IG34[TP#0>LS-WQ@:3$F)<;2>G$\WHWW]0F7_*FCSZN=-OR>IK_%PH/B?/
M7C=2?"J<(G")PB<(HR?3.6Z[?R!ML:A--<D;R8P5#G>1;Z(QXO7QG>&?U<Y)
MWQ'OY>T(^,[:>9C&Y-O/X*3X1.$3A$X1.$6*=_F1G_92/_*WX1>ORU]2U*Z/
M/?K_ %8DR9#7@2@QE1P RP+4_8J4;;TQ#X80$:C=FOB-2PSQB1SPTI8<HT@4
MWM?'6^P\^WJ5!TGI!%1ID&0[-<'(%9W7%IE+TBNRAC.EM #ZTT?R$JZTJ<%L
MB:N,3"5"8TG49,:GF0*QY-5^ 'P0"WLU:NBUYGX:*<]&RJ>V6^-:\'4F5+K-
M?V>AJ@Z8E8;+,8BKQM>4IG).PD"5.-!K:F=FADU4KYR8IS-"B#'P2W$Y @>?
M/-;E;>HE5R.")9V6W1 +ZR?61$412,Q7#ED$<N*L>DSQ W=ZVS8(W471]JXU
M)T&&R+KK[*UL,+DEN/NYZO/-8[#I6LM% RD]F^)Q!!;(YC9MD4LS">Z7M!V*
M^*9!2H=T9F"K%7A<;K)%'N"=46Q4FJ"PB=8HI;S[0?@EAY]8/O"L&JUP&H5Q
M-6%DA,J]&O'7![EY'\_, ^GJ1XVT$'#"'TUQ_!A$7AA+@H<1B+PA H8!HJJI
M_A$X1.$3A$X17-U5_F[K_;!?^ GFR/;[/BM<FSV_!6US8M:BO.=_1ZK[9+^!
M<(GG._H]5]LE_ N$3SG?T>J^V2_@7")YSOZ/5?;)?P+A$\YW]'JOMDOX%PB>
M<[^CU7VR7\"X1/.=_1ZK[9+^!<(GG._H]5]LE_ N$3SG?T>J^V2_@7")YSOZ
M/5?;)?P+A%HUXICFZ_BM-&U.J;*GV22T)VU9;)I3,'35>S5&<8J"U=?VA7.#
M,IM;/U]/=VA.A6@DT)46L4D<T(NBJBO^'(  V=TWU@+=379[<8]@74D"X74_
MLKKSL90G&'.K+ B!>G*ZKJ ,8XQ(PN(Y'\@0P&YX.5<#;<[Y>L$#P]Z+7J[X
M3E*G99JS:LW E8ULH%.!V<* QTB6T4B"AM8"=QJ#H8X9&+!0SYCV14\8S4 3
M90(K7;G+36COV9#U6MNVHI@;PMUB LDN:9T?B4%DL$%-L:G8=8N;/K/931!<
MC]>#D$XW<7!Z3J2V(9FZZE8@P3Y&-H]VCQ/DW]NLZ[ZT6R5/H4*G7[?L!<SL
M)9N?QCR.A9VX<FL@;6G99NVW7KXJ..6)F3=2)OKB)AC7;?&^Q&",^7Y;1%[Y
M^J^6>M%>OG._H]5]LE_ N9(GG._H]5]LE_ N$3SG?T>J^V2_@7")YSOZ/5?;
M)?P+A$\YW]'JOMDOX%PB><[^CU7VR7\"X1/.=_1ZK[9+^!<(GG._H]5]LE_
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MOW6T4F6"Y-JR &VNG7K6726"L/CS*X:G,PK&<E&)%EOKX7WG;;=P-\MR*_\
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M)AC>(XMB=?#6X4R*MQ"LJHF22U8D;'45$DK&O#*-[0\-< X-<X WLXC-4/\
MO7/QP_Z[_"G^LW;O]SG.T]-/9K[.QS]A0?S!=;Z),?\ M#!_VM;^!3]ZY^.'
M_7?X4_UF[=_N<X]-/9K[.QS]A0?S!/1)C_VA@_[6M_ I^]<_'#_KO\*?ZS=N
M_P!SG'II[-?9V.?L*#^8)Z),?^T,'_:UOX%/WKGXX?\ 7?X4_P!9NW?[G./3
M3V:^SL<_84'\P3T28_\ :&#_ +6M_ I^]<_'#_KO\*?ZS=N_W.<>FGLU]G8Y
M^PH/Y@GHDQ_[0P?]K6_@5P;?\%Y\<>"8Q_W:/"SMK)!/-DG%E[;\B/:&0?36
M"3/[CV-\338GVDAQC3;7.@\^=MM<ZZXW>FGLW]G8Y^QH/YA\4]$F/ZOG^#_M
M:W\"N?\ >N?CA_UW^%/]9NW?[G./33V:^SL<_84'\P3T28_]H8/^UK?P*?O7
M/QP_Z[_"G^LW;O\ <YQZ:>S7V=CG["@_F">B3'_M#!_VM;^!7TL?@L_P6G6?
MX.+K$C'M"Z]>(2]KQ8^UNU8AI=!]H(Y8S(J+18S(HC%E%5&1QS[R3PCM;8T'
MB>O(1M!T:.O?'^VW;6L[75C?HOI<*I7N-#1$@NN06FIJ2TEKZE[20 "60,)C
MC+B9)9?JG9'LA2=EZ0YMJ,3J&M^>5@!M8'2%/3AP#F4['9W(#YG@22  1QQ>
MUCGAU[!.$46[BQ.J-BV$E.QO#Z,B02>5+/\ PM<^II)C7;U-OR>GT^KG\F.
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MU(6T:5Q?5[\O7OV>&6191E^[Y"$6JZO3)FC0?L3L(.RL;HALL(FZ"6^N\]?
MU\I0+J-.$SJ>8<[VB3:9)71P5^CV: AI!G82X:AM.9W$Y:O(Y(M:G[%\5A1B
M!NKZO'VB#JUI L:8X0E4,5=-:+UF>EC"%+<XFF6S=JD7*I:6/5GD!?48#WL
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M%T"O]H17?%S.(JBSLRV]Q5ZA1H58.%_85RILM%8FL++!)DUNB55\UF-6D6
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MY^'<")A*4\?1;!,$($ <E>)A;MM+#6++<@V*Q$1+"\W6_BW3[$R&G+7!ROL
M1"U2"P&M$XS"Z0]WCZ[=$5Q,NVC@>ZZIU,/5(V2^SU4ZS[V8&Q#SLDHP,;#;
M9BWJ<*V65?5)2Q5Z$:QLG0!#*S.PUB5&U% ?LT]OG:WGSEG9%=/*B<(G"+UT
MT[\(($V1([;<^G;=5*>[!V>:VA7(_L"H:O049]?'!VDCBCTN5P54E*+,EOTK
ML;A&% R6[H+'9C9\K=,-/@;:_.7MUVMM17%MXUNBX[)O5Y6KF$V+L ;KF<Z5
M;!H@'=&F[+0)R'^3_=, Y[&.<();(7K:"9Q#<QU[,01<D-TQQUV12J[Q15:\
M]+VCN/IY.=V )79(M1TQGO&NSNHY5*:RQSK=PTMG:,,EU=V&S7KDB%T](9;Y
MJQ"@*R#-%JU?*XS^/G=KX(K]J-D#N-3K%N78UU7VJNI;(#KJ4&;KJ&\6C,QL
M:FKYR0"]<0%:8P4"20&1C_"C3RP[Z2;9#/-%L7")PBZ-W3QV=>]==KW/J^[U
M]LA_$^V[(OQDE)TG!L*:#HX;N!F\KXL8?F&&(V+%#1WB+>>'983:ZH])9:A.
MXQ(<2X V/G*_Y>U%.LO&[U3#L"$C37NR/3E_7SR-(%7<ARZ5SL/M"O=0JW>6
M+ F!3+#!=GA2CV84T@H^9 W(6QE*,!M2FD..H'5O-O-D6[WGQ4]4]?WP[K9U
M,_+MX<%;VT5I%.C:4TVUV[KVE)5 T8YGM$+ EWVE2-=<LH  )1&LQ(QQ&JIM
MJ$+@,O.SJBK)1XZ^LW3;$ E>MNB0DE$N1L2%TVC6U.;<CZ29U1/7D,<$OI.9
M,>]*I7SM'S-!HI/VU)DW(62%F+6D.G'5[-N_CJ1;1!XR.KXWQ"%T)95,FEA1
MI=2?<+F:)4-9->K 4YMPC)6KY:T21:>W:E6)EL>KC(9)NAI1<0@[G*9I"]O.
M[/V_G9%I>GX0?HR0G?;0>W92QJLDY>86KMPY7DE@6)0:N)M"VE&*9'!M(;%$
M7H9A5HHQZDAV&>)E\$TQN*+?5'B\ZY?.;9HJ7V.:FTSK.^=EM;P0J- #-!ZY
M;+U-F7HE!HL#-B0N*(8"E[3:@S0L54P>H<T1(QFUT@3PM>_Y(M(M?COZV2H[
M"R3UZT'-:X/;2"D5D7GU*8[\4*YV>Y8C*S?=CP:<G1AUB>IG]JP$)!JQ@,U+
M(F'W72M+AO\ 5J.KDBV7/C@Z'T(,'W:/-<+KT)UXR893;Q(@'Q#6TH)9"WYD
MXBH4,5]2K*IS"82,[.E"#+5)CUKVOFM!<![O/Y^Q%%K?'7T[+7XG[];>JQ'D
M-X26.96"&&5YBA??;$-7R25,A@^]C=4WK:TVY:N%V(BRL#A'G,B9GK CFD-N
M65_R]9&816!1_%;U)?[VOZU1E/XKD;^,@Y*=DB($E3-ZD_O%:>HG.VLD^HIX
M;3KBXQY*BR0CVPL&UPW\]Y7X&EN+@;[^&M%V2Y43A%6SFJ-K%N+N_5]</-@-
M&40.SBLELM@XG*TE,WC&R8=-Y&C5086K8Z1>KJ:N*(")Q(--)'M?H[CS'13/
M>.1ZJIWOAFICJG.J,-1.I:RB?^X?><=3I(Z.4K\6;!K:4FI6L'KB,8 7WG,M
M0VHAX,I)9LLXTFY9&TDLVQ%CGN('_P#%,]XY'JLNM>&^CU-4F4J.M^FO+1)*
M77PV#"E;M'DR_KN!!!3,L7K LALS,08JM;E!8'ESFQDHE)'G>:O$VA6;]7Q'
M1,]XY'JKI\N]_/*E]FN/BO+EN/,=$SWCD>J>7>_GE2^S7'Q7C+<>8Z)GO'(]
M4\N]_/*E]FN/BO&6X\QT3/>.1ZIY=[^>5+[-<?%>,MQYCHF>\<CU3R[W\\J7
MV:X^*\9;CS'1,]XY'JGEWOYY4OLUQ\5XRW'F.B9[QR/5/+O?SRI?9KCXKQEN
M/,=$SWCD>JUNP4DVV;@26A%UC9)%4DDRO=[5)VVRZ67<:664'8\R?(DDD@8D
MF^\&8]M]Q1]]LYVACSJ^CN/,=$SWCD>JTZ?H:G%,M'!/5O0I#:.$H;1G/UF#
M*?H.;,T(-AT+WVVGUC,G=N)BM,;XP1(T8;S8WV+GSO+-^KXC^%,]XY'JN&/P
M_4>$L9A%U1T#$<&_GM0AD?6(&A0MF)-4,B+ //KG$L+B5C7T+#9C'MJ7[<D4
M%^;@A:')"LW=QUC7R3/>.1ZKS!Z"I:OW'E;U7T(!FLM('==R'UF"/E$X&!KR
MP9HIS%MIE>>,NJ-3"'+%\J> 6KUR&+?71&KP*LWZOB/X4SWCD>JW6MTLZG"Y
M!J*3K*KA;#J1-A*]52$PV14"8"NHQLP+C1XLP)J^J6(U<.=?+ 4+@5PNL08L
M$.E^CN/,=$SWCD>JV/R[W\\J7V:X^*\9;CS'1,]XY'JGEWOYY4OLUQ\5XRW'
MF.B9[QR/5/+O?SRI?9KCXKQEN/,=$SWCD>J>7>_GE2^S7'Q7C+<>8Z)GO'(]
M4\N]_/*E]FN/BO&6X\QT3/>.1ZIY=[^>5+[-<?%>,MQYCHF>\<CU6MFTDUE%
M9H&*/K$Z"Z#QAW"$RJ$$Q6H2(#"J(:QQS&[ZNAXUF,+M(66"8] <8%UUQ!_
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MXQ@/!0 1&(<3"P;QSZ.[Q'\*9[QR/58)O4RQD!4%;"C]-G+>OYP2:*O+HFA
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MC)!JM$N0.!-B,>>JO<UM@%@VCFE+UGT!DJ<^L;74H:1EL1+B1&IU$BD/H-_
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MENZ^0N4#8"LQA[!2L(HH3Y!-AU\>1I#8888B]X<Z;$Q111S9WTCUQ@EQN/\
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M[%-I]0^*E.15.$3A$X1.$44YCQ*''KD8@O&&:23RAM_+DUS$Y EU(SMC7;_
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M4?YBGI>/ZOC]ZG^7)^^TH_Z!&_\ WH-?_E[X]$)_6 ?NH_S%/2\?U?'[U/\
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M3$&L0)DF9,:"SYC(N&6\4N 30^:W5F$*1:,XC+D>J]!I%)IL2P-GI-L5B/<
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MZQOMOA+J4B%45#,?O,+#5](N95_Q?:[Y0GXU3G#L)CGHZ"5EJR2<1MJ:D'7
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M:J)@=B-8<[QXEVAQ/F3$>9-,;YU]7.^N,^MC!^KV_ HNAEQ\/(=G& #$MSP
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M6EDSZ^V?X>W\>2+8^$3A$X17WTQ_FS__ &Z__P LOFR/;[/BBNWFQ%A^N?\
M-@_KTWP_A3/<.?Y)Z[#YL']>F^'<)GN',]$]=A\V#^O3?#N$SW#F>B>NP^;!
M_7IOAW"9[AS/1/78?-@_KTWP[A,]PYGHGKL/FP?UZ;X=PF>X<ST3UV'S8/Z]
M-\.X3/<.9Z)Z[#YL']>F^'<)GN',]$]=A\V#^O3?#N$SW#F>B>NP^;!_7IOA
MW"9[AS/1<$T$Q.8MB%JPC:#?,D&TQ&\N89-H]XMI(L[K-LQ[[12;QYVT]&V8
M]]],Y]7;.,DSW#F>BX<@:YCVBRF39BVE\_:/,F,Q[3YGW)S-MIE7ZN9<DRR$
M>9G'K^?)O+Z?,WVVR3/<.9Z+GAB('\WV=>M@\Z:0B;R2=XO-(ESC,L\OJ+=?
M,FDSC&9)=O3OOG&,[;9X3/<.9Z+F]=A\V#^O3?#N$SW#F>B>NP^;!_7IOAW"
M9[AS/1/78?-@_KTWP[A,]PYGHGKL/FP?UZ;X=PF>X<ST3UV'S8/Z]-\.X3/<
M.9Z)Z[#YL']>F^'<)GN',]$]=A\V#^O3?#N$SW#F>B>NP^;!_7IOAW"9[AS/
M1?F=V'^@4+.?^L^?'_\ +<__  X3/;;G^07YYC+YH#]H$?#.%4\QE\T!^T"/
MAG")YC+YH#]H$?#.$3S&7S0'[0(^&<(OW&[#_2*%C/\ U'SY_P#Y;C_X<*9[
MAS_)?OKL/FP?UZ;X=PF>X<ST3UV'S8/Z]-\.X3/<.9Z)Z[#YL']>F^'<)GN'
M,]%"ORV JW,V ETN<'*(_4F(DGT_P[<&#UO+W7XU]?3S/7BW_CBEUTEUQG;3
M&,T? ^ NH21L&S4;[?4%->NP^;!_7IOAW(KGN',]$]=A\V#^O3?#N$SW#F>B
M>NP^;!_7IOAW"9[AS/1/78?-@_KTWP[A,]PYGHGKL/FP?UZ;X=PF>X<ST3UV
M'S8/Z]-\.X3/<.9Z*-FD8>]E^/)38_Q%GGRY#)<L-_1,L_A";^[<YU%T]/H.
MUQG&-Y-P<Y]/J8]#9R]6WR/:F=]FH[?5P4EZ[#YL']>F^'<)GN',]$]=A\V#
M^O3?#N$SW#F>B>NP^;!_7IOAW"9[AS/1/78?-@_KTWP[A,]PYGHGKL/FP?UZ
M;X=PF>X<ST4:VD88$C_P*:/_ )P4?PCS)=Q_RM@L>IIC9=G&#)/_ *M=M_'H
MPV%WUSC.N,X#KJ]7F_!0WW#6-O'U*2]=A\V#^O3?#N%<]PYGHGKL/FP?UZ;X
M=PF>X<ST3UV'S8/Z]-\.X3/<.9Z)Z[#YL']>F^'<)GN',]$]=A\V#^O3?#N$
MSW#F>B>NP^;!_7IOAW"9[AS/11JZ1AG9C_@$V_\ SE/C_$S)=<Z?X*#^ 9Z%
MN/6-Q_'+MGTYSIF+&<_D]&"9[AS/127KL/FP?UZ;X=PF>X<ST3UV'S8/Z]-\
M.X3/<.9Z)Z[#YL']>F^'<)GN',]$]=A\V#^O3?#N$SW#F>B>NP^;!_7IOAW"
M9[AS/11QTC#VE/\ X%/IZ6,N/5*,EVGD_P":&F?479RNSG0S'H\S?;7T9ROC
M/T]/J[YQEO\ .T:_.NRF>60U[^!X*1]=A\V#^O3?#N%<]PYGHGKL/FP?UZ;X
M=PF>X<ST3UV'S8/Z]-\.X3/<.9Z)Z[#YL']>F^'<)GN',]$]=A\V#^O3?#N$
MSW#F>BISN+8S*U-YD VN/;B/1G0N63.<^1K_ !XV#C]'_M].?_9S!^K/?UXA
M7/;[[_ *@?3/\G%^FW_8<UY;SR'5$],_R<7Z;?\ 8<9;SR'5$],_R<7Z;?\
M8<9;SR'5$],_R<7Z;?\ 8<9;SR'5$],_R<7Z;?\ 8<9;SR'5$],_R<7Z;?\
M8<9;SR'5$],_R<7Z;?\ 8<9;SR'5$],_R<7Z;?\ 8<9;SR'5$],_R<7Z;?\
M8<9;SR'5$],_R<7Z;?\ 8<9;SR'5$],_R<7Z;?\ 8<9;SR'5%?O2V=\C6#U]
M==?\.N]'J[YW]/\ @S/3Z?3IIZ/]'H_C]/\ U>C\N;+9VX;+;^)17AS8BIF^
M=Y5'KNU!U-^$[V*+0263!H>$6T&P$6'>TT2Q68]"M%J8":HB96@%+KUD(1BE
MJCWNBP!D,5O";;#_ %\=FP(N<'OGJ8^':;6X!B>H"0?)$R$9+I=8@4S=\VBC
MP6'%H64B 0/-7X@6Y,Z-@G8J&F@K024/5<><O-MN[:BV"K=G4VX&!*TS/;=L
M?6P[6.NG&(CVE2F"I3-B!&.FDJ5KD"*Q(M6N$K1EJMD;K-2]X\'A[3@;^]%O
M_*B<(G")PB<(G")PBJCM7MI5U,"I8N$S5B$S(,AE/&)0J5"O4(;!6<-7UG<(
MD2\IAC/LR04UD-[T-QN/I-%B.236$V\]46@O?%;U.N8SID1S*YMPW@5<8 5M
M87-NN:L;JJH .2=S(A<3*R+$Q)AU=+<,%FT21SF$F:<:(>>:0\^S?;>BWP[O
M#K$$P@'\8"V4X\^H?IKM8MEI&+/RH%L.ZM4=6D38)RV'KQD%@-4J2#60"'SG
M)HL"P4HJ&W&KX%% Z>)?I:38OR;:83 &.V*W8"T^\%*"!TL-PG.F6N1ZU*I;
M:9TZ_NNH&51IGO>:L-QE/MQ F\7)I#R#QX<"B_&GB4ZD5DJU^[ER6U<LEJI>
MH%I]MU8S&'WD'KPD?,!B4/6,Y%9#<PV!/O)J]5C!,")%>_LV8]FD-_G5Y&O@
MBUT/Q9]23AJ3SC'"41K.WS&6V3'B@^Z4=*87EF_!/W@]C?K0UP0H!<-;F;M@
MF[M& >M%F908RTAKU7W^>'NWHME:>(SJ]6NKE@RYD*JMC27-_#9H!"<+P J%
M8*]6[+$P#FBC=0G@L[!Y,@&JO<J.14T'FCB*B@@GND->SH0/BBX#?$_T6L(P
M$SO<:L_ 38^1<SKUL7,QHD95E$9P&+344!P3*"6G6;?106/ V*%3E'"!3A>4
M1)-(;_ HKJ3M@7RE8\5R2S+7  C-?+.(8!-*&=!&2-)*"P@%.#DWADTVW&,&
M'*@VSF.>&.77;3&6M%)<(G"+5[Q:PJ)2K?>&4!)*ZFU>P6M@,%'F8P@*O*2V
MY4 D6N,[2DRP!R1P1ZXSG>7;37&,YSZ.;J:!U3404S"T/J)HH&%QLT.E>V-I
M<=C07 D[EJGE;!#-.X$MABDE<&ZRV-A>0.) RXKXP;O^%/\ PH%D9)?$G5WR
M>H[:4!>:O\*">"MGK%ZGL*RV#]SGL_L9 ZWCL&E:M-6<5L&A9E=16RZVF% 2
M&B65JQUXRT?H6F[%=BX628/-')/>J>U^.R&9KW24D,/SRBI)8P8>^AGCF?5?
MW9IZ: RATKYHI6P?%)^U?:N8LQ6!T<1^:L<S V]P=%M5-+\UK*MDCA-W4T#H
MFTX#Q///W=HV121NF^MWPD=[8\3OAEZ-\0&R3\6R.V>MZS<F"#622:%.V9 1
M^^%PD\V-9B5XK6,R)<5+KK(4#J.1OKC:3.,?"L=PS]#8SB6%=YWPH:R:G;+:
MQD8QQ[M[@,@YS"TO R#K@9!?7L'Q 8KA>'XCW?=&MI89W1WOW;WL!>P$YEK7
MZ0:XV): 2!>R[$\ZE=DG")PB<(G")PBZG^.GN9[X=O"%X@>]JPJ4O+%U)UVU
MOR5.^P9E*R95J49D(&TPO*".R#/+!KH1@0L8CR\[>5-IOZ-L=K@=#'B>+X=A
M\SWQQ5E5'3O?'H]XULAT26:0<W2%\K@C>%U6.5TF&81B.(0L8^6CI9:B-DFE
MW;G1-T@'Z):[1)&=B#Q7Q\_OJSQB?T=O#3^A[1_O Y]F]$V#?:6)_P#TOX=?
M&/2SC7V=A?*K_$I^^K/&)_1V\-/Z'M'^\#CT38-]I8G_ /2_AT]+.-?9V%\J
MO\2NU'@Y_P"%!M[QW=7J5XQ.J>M>L^I[3G5/^Z7UI^.&TM&>E3PZ+G-L66![
M8<GT_.<[CN2%6H[%-I+HVUB8#"D![=3C7R5M@H9)\&JZFJJXOI_-:KN0)XP#
MI,A?&R/1FVL#[M>1H7:2'+ML%^51\]='!C5)2TM'+]#YU2]]>GD)&B^9LDDN
ME#L>66<P'3^D&EI^P%:R7.5P#A.>$U4M0A62MHM*@.7,EQT$901X!HN\HQ@1
M@TL1 I0\LD!$$D<L6^\>^NV?CCFN8YS'M<Q['%KFN!:YKFFSFN:;%KFD$$$
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M=@2RPRFB;#/5;?LW9CSJSS)<^OA<O$\%=@;=L>^(%&%^L@!RAAH"/*O[)Q?
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M?V^"?*1CU-7Q'%9W8G12$1S0"GIHYFAQ $M.Z"&(NE8=4;R62 EGT'%LC/Z
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M[:+B6%S3VN#_ "?X!@M:ROA%753Q"\/SZ6&6.&39-&R*GA'>M_Y'/+PPG28
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M$"P3"X#^GO\ ?ZD7,%XI.LG^%FE.E;6LHRT4VLM(5ZEEJ-6)+K:@ZNJ,L;3
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M6'(R>UN'3L$2Q0'"U=V>::HA5ER2;\N1SRV_G?\ -%K^>O/#++F3<DBHLLP
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MJW5+$X!=O[)B!J/$NL2Q0+>;8T0U(M/%HY3=<U:D10[CL@Y 15G9YZ]7#?\
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MQ](L%<F2;=@]@UV-L4VH'8J6 =Y74RUD@F'CN+^FN,/@=Q'$"U.;"2(X]F7
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M>"KINWTRP]FNG%[<'U@A79=.SK%M/#LITK7O\L.TD47WY4QK+.L:[D5I<K>
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@.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g367280g97t94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g97t94.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5V\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B"B @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B"B @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @('AM
M;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M1F]N=",B"B @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O9R\B"B @("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!D8SIF;W)M
M870](F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0B"B @('AM<#I#<F5A=&5$871E
M/2(R,#$X+3$P+3$X5# Y.C0S.C$P+3 W.C P(@H@("!X;7 Z0W)E871O<E1O
M;VP](D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RDB"B @('AM<#I-
M;V1I9GE$871E/2(R,#$X+3$P+3$X5# Y.C0S.C$Q+3 W.C P(@H@("!X;7 Z
M365T861A=&%$871E/2(R,#$X+3$P+3$X5# Y.C0S.C$Q+3 W.C P(@H@("!P
M9&8Z4')O9'5C97(](D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O
M=W,I(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C4S1D9#-C<R141$
M,D4X,3%!0S8P0S4Q-$5#0T1#0T0V(@H@("!X;7!-33I);G-T86YC94E$/2)X
M;7 N:6ED.C4S1D9#-C<R141$,D4X,3%!0S8P0S4Q-$5#0T1#0T0V(@H@("!X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240](G5U:60Z8F1D93<U93DM,S!E-"TT
M,68Q+3@S,C0M,# V8C8X-F0S-#!C(@H@("!X;7!-33I296YD:71I;VY#;&%S
M<STB9&5F875L="(*(" @>&UP5%!G.DY086=E<STB,2(*(" @>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD](D9A;'-E(@H@("!X;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#TB5')U92(^"B @(#QD8SIC<F5A=&]R/@H@(" @/')D
M9CI397$^"B @(" @/')D9CIL:3YR<C$P-S R,3PO<F1F.FQI/@H@(" @/"]R
M9&8Z4V5Q/@H@(" \+V1C.F-R96%T;W(^"B @(#QD8SIT:71L93X*(" @(#QR
M9&8Z06QT/@H@(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC
M<F]S;V9T(%!O=V5R4&]I;G0@+2!'=DA$(&9I9W5R92!C;VQO<BYP<'1X/"]R
M9&8Z;&D^"B @(" \+W)D9CI!;'0^"B @(#PO9&,Z=&ET;&4^"B @(#QD8SID
M97-C<FEP=&EO;CX*(" @(#QR9&8Z06QT/@H@(" @(#QR9&8Z;&D@>&UL.FQA
M;F<](G@M<F5P86ER(CY4:'4@3V-T(#$X(#(P,3@@,#DZ-#(Z-3,@1TU4+3 W
M,# F(WA!.T=R87!H:6,@='EP93H@3&EN92!#:&%R="8C>$$[)B-X03LR,R!H
M86ER;&EN92!R=6QE<R!W97)E(&-H86YG960@=&\@,"XR-2XF(WA!.R8C>$$[
M,3$@8FQA8VL@<G5L97,@=V5R92!C:&%N9V5D('1O(&]V97)P<FEN="XF(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z(%M497AT1F]N="!#86QI8G)I72PL6U1E>'1&;VYT($%R:6%L
M351=+"Q;5&5X=$9O;G0@07)I86PM0F]L9$U4728C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+3PO
M<F1F.FQI/@H@(" @/"]R9&8Z06QT/@H@(" \+V1C.F1E<V-R:7!T:6]N/@H@
M(" \>&UP.E1H=6UB;F%I;',^"B @(" \<F1F.D%L=#X*(" @(" \<F1F.FQI
M"B @(" @('AM<$=);6<Z=VED=&@](C(U-B(*(" @(" @>&UP1TEM9SIH96EG
M:'0](C$U,B(*(" @(" @>&UP1TEM9SIF;W)M870](DI014<B"B @(" @('AM
M<$=);6<Z:6UA9V4](B\Y:B\T04%14VM:2E)G04)!9T5"3$%%<T%!1"\W44%S
M54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"3$%!04%!14$F
M(WA!.T%117-!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"
M9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$
M07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW
M14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9B\X04%%46=!;4%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%
M0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!
M04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$
M0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F
M(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:
M2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:
M6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M
M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%
M4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D12
M1&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S
M.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM
M9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F
M(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!
M07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T970V9M0G$O;38F(WA!.W@Q5WE8
M4VMV:EI-:45*<#A):TTP>&U#>4I.2S%N<4EI5EDV3716:D1B,6M7;4MP8D@U
M=2].965(54%U;#)C1GI$9GE2,G-B5U=P4'@F(WA!.W1)-V$V;2]E1GAB>'E0
M2DIB>$ES:T5J2E8Y>%AI0W%J9$XX,&9M0F5R-713-S V3WDK;W=43F]#43(Q
M-SE96C%6+U1,=E!&.59N3# F(WA!.U9L5T9I4CEL;')I<5572&UB.'=P24Y)
M=%A3.&Q&=V]E+VQM,#8V37)S,&MY>5)F5T9T9$Q3,E=.16I.5W1W>F,O9V,X
M95)+=70O3E F(WA!.S5O,E5T:F%#>FIN9VMV.$$P<FU3-C O5D-93%!H0S!5
M4WEW:39A5U)H22\W*U0T5DMN;6%N1E4W.'8V<#4Q,74S,3EB*U,T,'572TLF
M(WA!.TPV9S!&9S%S,$UO85EY4GAM.5,T4S5.15)7:U93:D$O0T9W2VE$<5AM
M=E1.13AU<DI04&0S5CAY9G!7+W5D4&MU-5EI-D(O5&$R,#DF(WA!.V)8,"]I
M4$%3371%<#AD8U931%(O3FXU<&%G26XQ0W=&;$HY64MY45=L;F5+16I.,5IQ
M16QA.&A53S9X4U16:VA9>&M625!W,7=Q:C4F(WA!.W9.+VYH+TI+86I(6G1&
M<3!L,TQB>7-U;%@W0T]&635':FMJ<VY:8G!W>G%K660Q569&>4MC4E1!<4LX
M<BM:=D\Y,W%6,V$V;G U4T,F(WA!.S-S,VM2,G,W:4)L;FHY35)+6C-B,&)G
M,T%:,S1W<79P.&5,8FY&575F>F@K6CA&<&%#9E-O;G9*2F=*5V@P*SEA3U%.
M0F%42D%&17(F(WA!.T=!.')M84TS16I'3E1%86=%.%%Q<39J-6PO365W.&Y.
M8S)T=D9F-C9U<E0R:W)81VY8-E)25VEY4SA*4'$Y<4HW:5I3<6]&:VE"6#0F
M(WA!.VA7=D9J:7%Y9GI&-3-T<FTY=51A>E)Q,#A%2UAB5TXO9E)1,C=F5VY:
M:W-B9&](;6\P8U-C;%5/3UE,:W%!0592;6YA:C4U:6LQ>4LF(WA!.T]*;3E,
M5$AU3D1S<#=E-6\Q-$IB9T)8=EIP2D$S27)(*S=9,31S3TY&1S9Q03!(>DHU
M+TAW:3%V9%%G;G9L<S0W<E5R5F]:15=14G,F(WA!.TIZ0VQR<'AJ:&I54V@V
M*V]/6$5,2S-D5D)J6"]!33!$6C(U,59,>E1R9&]B17I896U7<'9B<6MK,'=N
M9&]'<U@Y3UAG<6-O,5-12TXF(WA!.RLK2W91+TMS*W%Z*UAR1V)69W<Q0C0V
M>D=335%Y2&,X1VMJ2#)(6DM&;#=(8D%Q831Q-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3<F(WA!.T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8F
M(WA!.UA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@F(WA!.UEQ-T98
M67$W1E=.86XK62]K>E1.4G9.3G9.4318,6=I4UA-0U%Z>7-"23!32W$K;D<T
M9'EB:4PT17$S>')T=FER26)7-&IU8F%+-6HF(WA!.T1R2$UI>4ES<V)X4T)8
M1E%(:FM#3VIB-W%Y9VIO4FEQ<&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G,F(WA!.U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U994C5M+TM0>3DU:C%3-C%(57)Y*V0W;$528F9N1DI"1C9C:U5O
M-%)Z4E-H:TPF(WA!.W=+5$9*>6EQ5U!#<D5L5DI,+WE:;TAL,SAW4'DX9E1O
M0TQV;&1713$Y27AE96%#,C!Q6EDQ;&8Y<6Y!9'-697!9<3=&6%EQ-T9867$F
M(WA!.S=&6%EQ-T9867$W1EA9<3=&5D,O=30W3WAU3'529W-D=D4X<G,Q84%)
M<%DQ;T-E,UE9<UI3;T5V3F15+T]/>F9Y3RMR,F-Y4F%O,'8F(WA!.W!X,C!)
M.59L5E<S6C%M5U T860V6DAW<W!K35(T65I4-3,Y,75U;G)3655#235$,#5S
M<3 W>C=O1&56;TY9=7)W8U5I:2MU06AF5U,F(WA!.U)Q2V95:6I,8V9I4&)B
M27AY0W1J>$5D,B]W05A):')-9F@X5C-84"MX3C<S6'1.<SE(1W)Z3S,Q1FM3
M45-+:DUE16Q/2C1G13DX33@F(WA!.V=I3$QD:WI2:$1J4$I'=WER3D1(2V])
M5U)1-FAG5F%J0W4T3S1/4T)S5S)!,DQ15VPV-W K<'DS8U9O>G,Y:DHV3G=(
M4FMO-')S3U$F(WA!.T9E;F))47EI5C$P83AE84UY45 T5%)41$Q',3)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5FA0;E O>5E0-69F.'AU;R]W1&0F
M(WA!.TUN>%9M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2V]+,#%R4S=U.'5,2S)U
M56QU<E4P=4E6<GE19S S*VY)4GE22DE",T182$Q'4DU19'@F(WA!.WI2=51B
M14)R=7(R*VMA5&1A:$UY9U%2<S!A=7=8;DE&2E)"-W-D<W)Y>D5):W179DM-
M8T1).4='-DYQ1W8K93E,;6$T-%=';$E7:6TF(WA!.VAG3$-3-65G4$%Y341W
M:C-&86)N35-%<#5O-S=2*SDQ=41*4%9W3BMM2&PQ+U5'2U=E:U<X4#A!>FHY
M9GEM25)Z5$Q*3$I+:'%Z.$PF(WA!.VYI=DEK8D%C2V-F<#<U=C0T=TY8.%(O
M=5$U1U!!231J,S@R4V9N1#57,'AV248Q8W!!<C-M;GAX1F)T=4EL6D5)42MO
M.4MV='8X.'@F(WA!.TY$:4%Z44DU9R]O5'%.3D5X0D$Y565V5DQF>D4X=&$W
M<$@U8512,C)Q>D=Y=%EO4')&:DIW<6="031X>DEQ3GA6:4)X3S%-<C!/3UDF
M(WA!.WEX<SA12C-",V%:-F9*1$=!2EA(87=A*SEM1VUE5V9-># R,70Y4CAW
M5'@K;D9':E)7<5))=TMQ0E%Z<TI(8S=B=#-Z1SA02DQE574F(WA!.V9D46(T
M64UP:4]/6G9Y02]A:T@U4C9*9#)/<"MA6DHU;FQ72%5'<UEE5$MA:4EE<%9U
M2497<$MU*UI5.5!$2'<X365'-&=N8VTK9C0F(WA!.RM,2%(V65EZ26HW,W!/
M4F,Y,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6:%!N4"]!36U$*U@S
M+T%$1S9J+S-42CA66G1I<G,F(WA!.U9D:7)S5F1I<G-64V95=DYU9V%B<6M7
M;5@Q,$E,;5I05E5U0TEW=GAB=$EF:%@W0C9N2W U-'AL4DQJ-4Y8:FA-46MA
M2EE*<2]W0UHF(WA!.T=P4"M9,FPR3VI8170Q;U5K2DYX83(X16-J>GE+5S5'
M3C5/3%4S545H<41I8W1J;&=C57!!16M303(X+S=(1&YR<GE$9W559DMT*V8F
M(WA!.S0U<6YL>GI8-7(Q6'I8<DYJ63A694US4D)F>6-K=%96*TI"4TIA;&E4
M<TLO4V5U64U02#1I84E"-6-82G%W6C@X.'-G0E$O<&10;'HF(WA!.RMA0CAM
M84XU<V<X*V5A-4QA+S58545K87IF5S0S3G9-6FQ76#=+>45P+VM%5BM(=S9:
M<TUW>65&:G%R;S-T>F\P4'-B8U=,34IK9VDF(WA!.RMT:EDO8C-C=DI%850U
M<2]-8E=T5CAZ84EB4T98<S%E14]836%X37=)6# R5D]437EM<3%0=EA+6G=Y
M4FI'45!%6EAT5E92<C0W;VHF(WA!.VPQ16I)0W(S.'$O5S,K55AL-CEU+TQR
M879Q<GE8;#AS,7=M;&DY:V5E2TYO,DU:9F=39"MA54IR6&)B36I6-"M,3U1)
M8D1H<C5!;C<F(WA!.U=Z5%E*4U!(:S-)-657,B\R,GEJ>68U;G9,;GE+9DUE
M<U)W4CA%=4QI4T]Y4FM54E<U64=I>4\S>&9U>BLQ5$QC,D--8VY"1'DK,7HF
M(WA!.UE(,#)8;$HX,&%X9F9K>DYP,FLV5$LQ:F%I4DY4,5-:;VMI5E=N379#
M2D]29'I2,7%A8EIT9D)J2%5823=N:U!G,$=:34YG>7)Z8C4F(WA!.S)I=G9Y
M-C%F4G1B5G1..#!W,F%,9#).=T)'6EA$3'EL='E#56M2:4-2>$\R675$5#A/
M84UO-W=V;BMT<VQ/-&M(;E1*+W=!,E9G=5 F(WA!.WDS,6PY<$4Y0EI),D)Q
M1#AA;%="2%A-6%)J.3E'*SEL;4%-0WDV1T=/1T=/1TEC631L0TEU-6]Q:6=&
M5&U)0E%P<T%O57A8>4(O=E0F(WA!.S5S+S=B,7@O>5ET.'DY5GEH+U5(,VQH
M1&UF96Y7=F8T;"MR>"]O1#9L.5DU+W9V<B]Q.$]&4#)F4S-R6'AY;DAW6#8W
M*T1-,S!9<#4F(WA!.U0O-5A..5I0-F4O4G8Q6#%O+U4U+W="-S9.9C-N<&96
M+V@U8V5N4'9M5FXO04,Y96II=CAD-UA$:C8P;V9M0F]M<GEA>3A/;#(X,&PF
M(WA!.W0U='19.4DQ5V5&6$MW0TMC17IY1D%E24YP4&-,>4I(>$)&-S=93&%X
M=7DO-5=6<3DQ83)';RMV65)7,F\R-TPV3G)*>7-W:E-P>70F(WA!.S)K,"M'
M,$U1:7 Q;75+1VA*<'1H5D92-G0K655C4WDS63%#>F%73E)D86A:851(8UA5
M;'A&0U)#<VM0;W1Y4U(O=&UG0S=$;$=$6$8F(WA!.U9$4C<O=T1-*WDQ,GIS
M;V)A5WDP<6)58C)D;&QT<'I(2TQJ5W)T-7A-66)/*TUF-VAK84IJ8U%R.%%B
M;$EU0EAS,DMU>%8R2W5X5C(F(WA!.TMS16@O3F-34E%43C55,7E+2S0Y2VAD
M3$AM;VU+:%,X2S-B5$-N3#1H=W%/-'A63F16+TUR>59P5W!85VU8,G!E;F8R
M4V\P.75K33@F(WA!.W)6;&%*55)05&IF,4I#8FE0.3)L5RM)8F(T<6MN;4Q6
M3D\Q3'IT*U<Y,UDS0UA&=F,S1CEC475H<GEI;#!Q6FME;E=J2V$T<3E">%8F
M(WA!.S)+=7A62W(O04TQ849983%:-DQD6$12-FQF:FQA44-+5F<T<58K,G%-
M:3=J=7=Y,D]'56]M435":5I!1VYN4#4T95EH.59S-TA48G4F(WA!.U),:3-U
M5BMU4U<X:GAH0R]W<D<W259&5TA),%!3;5(P=6]R2UEI:C9:9EE,1')D9'%Q
M4$1!-S<S.'1K5')N;G9Z3D8U,#!B4V\Y3G4F(WA!.TQ3.'59>7)7:VMY1S)K
M:UEK2S5-66-L17)6<4@W<6(T;VA/551/*T5X;V-09F9,.&542$IQ379I0VAW
M;G5*,DXX=58W3$Y3.')A;78F(WA!.S5L*UAN,4LW:#%!86A(4$YD0U--9T(W
M34%L155(:G=P26Y'=&5H2C8U8FHP14I1;&MM4UIX23=Q6F9K06-O;DTX579S
M5'97271.2#4F(WA!.W1E6'I)>7!-=6TS26E4,4-M-&M54F=)0T)V5C9B8B]2
M;5I$2&5#4G(K269P8S)522M)1#5F:C<Q6'EP65=52#5I96-P65E%:FM*<U0F
M(WA!.WI64417849P2DYX+T\O>$AX3TA-9C-54#@W-S)526=32T8X;65:3D1U
M=GI$.#17;'9D;SEX3E!B1T9+34]9='):24IE2DE!4$=24TXF(WA!.W5V56)B
M-5IQ355H:6=33R\W5&%W:T])<&PU6"]!3U4T.#8O.'A&:"\Q07@U5FTO=6]E
M-"]E;4A-+VIO="]+-E))+TEL<DI)=U-.2G(F(WA!.SEN9&I104,Y;DI*2G<V
M=V9V5#A0=4,T+W K9C-S23AJ+U=03C-L+U102SA(2DY!,#1V3C5H=5%3=G)S
M,#=Y4E=58D1S=TEE46IT='0F(WA!.S-Z3E)72UIM9G%0,"],;BMP<F@V:%A4
M<6DV068X-#E804=W1G90468Y2&I:2"]K5U!F.$%O4V8W=&M(-3%A3%EA:#5#
M=C=I-%-S*VXF(WA!.V=81G1+079*5T1"4T]20E!&9S(T1U5D;C5$2$M!3W),
M3D5'2EDO.$%M2BM8=C9*.&<S>C)/=C9S8F5Y:%%'>'5,;C%O2&I1<6]J-%4F
M(WA!.UAI3VQ+1V<X378P=7$T<V]U360K=$U-;4]O-T5S;W1V25=V<F)X45A(
M;DQ66D921E=2;R]14FU+:G%(84]2>%4K2DHX4V-X:G%96%DF(WA!.VA(-U=W
M45!E574O2TQ16G1+=69.9G%8,'0V4G%R5S-+8C=234UA=5I73E0X5"MU061V
M,F9U<S$R6&E%3G$Y4#0K-6II:E8K.6UU<V$F(WA!.SEP3VI12E!Q52]O4E-.
M=U)U1'96<59P4D%X-D1.5FQZ4GAI-4=N3S R:WE:>5)J1FME-SE+4C9.*UHO
M;$Q6<F=7.$4P<U4W5$,S:FHF(WA!.VUH8T8U1U!%0491=S9N=E1+365U>'E.
M8VDW1%4Y:#9N1$AI24)&6'-2>59D8CAZ,S%J938O0D5K5$QP96EP<61V>D1%
M=$UZ6%%+=E(F(WA!.VA64#E(6'!1.60X>DA4<&9P;C5Q84I,26ME<'A3-EA!
M1FM75%8W<S(X3F=:;T)'6FM6>DTP:3=Z3'A,;T%E;&$W67%O=BMD6&MN.4HF
M(WA!.S-7;G=3=F13=T%I1G):-V%8-GA)0V\Y3T=.6G97*TPQ0GAD,%=.=7I(
M1E5*2"MA1W)'+VIT;3!M6#%P9%)7>6%X2U%R3$1%6B]336LF(WA!.W-P=51'
M>D1P4T]O3E%14TU.2W)A6"MD,VQ05FU%5VMW6%=O,VLP<5)79&QB1S!K;6Y%
M:7EY0C%!=4]-44-7-W-Y>G1'-$$K>G5-0W$F(WA!.SDQ-7 X,3-(:TQ39DUM
M;E,R3G!C,U,R>'4T3'$P;6Y5;39M:FA(04IC,C=2.%!52DE9=%AP=&EQ839Z
M<69M83%F4G1)=$IR2G19,44F(WA!.WDK=G%%<T5V,5I&=#0K8VI*87)0-FI&
M:5%&57HW8FUU,DMP5$HK83)K851Q,6@U93AW4U%J6&)H:VEU6',U669Q-E!.
M8TYB=VM*3DLF(WA!.VQW,TYK*TI9,&LY4#ES9V9&:7%5*U=V>F]393-S1C$R
M,59,=E4S<S!T;G0R:'0W9%1C85A96&MN3U,Y=4EG>F5R9G-%4TUS-55F6DHF
M(WA!.T)*5EEB<69K>696+TU0.$%I1U1Y-W%K3CEC,U9V96TR3VXR<7E1>FU7
M1G!1,F]#574P84Q'46A%44DV-%9E;C8O=T1L5F]U=#8S3G(F(WA!.TYZ<4]O
M>%AJ:5 V=C95,&9',V5+4TM65V@Y4T]19V,T1E!P<U=J<5=00W)%-$99>C5N
M,$1Y:#5,.#%E4614:G1K=%ED3TTY;F,V:'<F(WA!.TUL=S%V1G!R,C!#=555
M>5-F139$664O5$E:36M90S5C;DDP=6QY6C4X1TU83#-G8W9F5#%'.3%#0WHP
M-F$O:U8S9V=J37I,1VA:>7$F(WA!.VIK94M$8VUN8D=5=TDX5$1&:$TU:4%Q
M>6$S-69.5#!N5C=453E+=#E59S5X,G0P9VQI37EM3G5$9EI9:'5Z1&-E,DU-
M9VQ(:51Q8T4F(WA!.W-/47=L5G@R3DES4U)L4%5$07!3=D]O<%%E*U-T;W0T
M-35T,49V35 U;BM8671/;#E+,#1Z5SA6.&Y'3C)(265U,%1T56UG<4591#<F
M(WA!.U9A6D=%+T5X6DLU6$1F-'ED4&UY2$YK06=D<D%V-3-8-D=49FU*839,
M;V9L2WAS-%1&85$O<$MX6E$W0E=F:&-),&IS>D=R14%666XF(WA!.TTS<S=&
M56E):BM%+V,W2'<T-#1!1%E7:E!-9'%R+VU:-5)M3'5#3&95<4M'255C16DO
M6C9B.#DO2&)W=UDT+W5P;GIJ*VQL2TYZ0E$F(WA!.UAN-WI$<'5H*V103$XY
M9753='9B86MF46I(3U8R;%="26M20G57:V-C5B]S3UAA6$9+94]92&9(.4M:
M>4%K4&EX<69Y='%V;5 X>$XF(WA!.TIV=DTX:W5N,VPS6E1Z,F1R6E-E;DQ:
M>%<W<#9+1U5!:WE6;5IN4&EA6FM$3DA(:$EH=4%E=E<R=F=U44I895=V>3EU
M-WIZ>C5N<V0F(WA!.V(Q:3AV.4]T:F(K<D8Y6FM2<FM3<5=G1G=5-&-W:U%+
M:T-M+U1B2$YQ9TU51$=)0DXY3UAF4UDT>GA'>6UM9V9L,S5+=79.6&UY=VTF
M(WA!.S!M13)T<$Y:3&%O=DI$14AT16MB9S9K3W183F1J;%=85EI"0T)",TXO
M96U/3TYN6DQ03&8U65=K=FUZ>F19='$K;W<R54UK34EJ=' F(WA!.S-I6C!U
M64)-1FQC;'I)158K2'AD97 X37-Y-G=J2$$X36(O5552>&)N8W$O-6(O;&(U
M5'9V2G%Z,VE833 Q,4YD;WIF5UIO=V]J;FLF(WA!.V=8:6M44F]F:&I"4$I4
M=C=B64Y8<DUK8VQ#='$V959R:GA$:%0O.$%*-GAT9$PO3'$S;6=34GI-.7AC
M>6]V>$]Z<DDP9$5',C5724$F(WA!.T1+3F9)>7I%2'E:-&A554XU83AS6&UT
M+VQ42#5D=E)C-E!+-6QJ=5!7:$%K-&TT85A:2#=-1T<K4WI::$10>&EP9C)+
M23-'=5-:+VTF(WA!.V)&4$0K5BMR4EA%-75:-#=216QU4W%O6DA6:T1/5E=I
M<GE/.4)T;&5J24]C5G1U;DHY0E9F>EHO.&PQ<G8O34]0*TIR:V1&+V92.38F
M(WA!.S5F<$Q,8WA7>&E8:T0O96YZ6B\R,W)J+T%*35<K6E=Q-5$O<40W>3%W
M-6XS<W1Z1F)&1S%U3$M94#E6:VIK0W522C942S%(-SAU4&8F(WA!.TEX25!*
M06YX9&)92BM95GHU52]352\V6#!056121VXV971Z<60S63-#=U%P67E34V9"
M8W Y8G18=4DV=T]X:CE/464R.4UK;%0P-WHF(WA!.U@U2V@Q0C<Q=$AV9$]S
M-U,T,5HT=%IM35IT5VQT0WE8-TQ(2&-3>DM#3&1I=G%1<4YT<45G1E8P:VYL
M2V$Q,3-5.54P3%=.3FE.=#DF(WA!.V-U-TLT;&U71S538F1:26)E,W5:3%IB
M:#-J1DMH2F<Q1'-D.%919B]!1&\P9')94S96-64Q6%90<FQQ3F%%<T8S>'5)
M;%-:6E,X.'0F(WA!.S5E=U,K<4IV=&=->')53C-W<7-S-W(X=#=O,G5M5S)M
M-G K:#=Q4S)L=$PY8G4T4S!T8FEA>DXW0D9!;W5H4&%S8F%4<$1'<55B9U0F
M(WA!.W9407%9>&5A+TI!.'(R5VTR3VQ8='AP35180W=72T0P-5EO3D=M5#%B
M:&A03D9*-F-5;D$P<5AA;TA!.4U65&DU=E!+6&TW5EID0VLF(WA!.VIU2G Y
M3&IG,4-/.&EA93 T1V9M:4YB,U5447DX=4MS1TM';$11;G%-5E)D<#5#.'(R
M5GAA,T9J8E,R8W1M;U)$8EA6,4-*1D5J4S F(WA!.W5&:FQ56$@W>5(R+V9"
M=#)0:6-654(K5VYK-%=+5T-7:SAD9W!I3%=K9#5E2D9*.5AG:'19:$Y'<W=7
M5E9H=%EL-'E!:F%P,TI*5EDF(WA!.T8U1#@P,W5P+VU*3%EX*V%P3F$P>3-U
M8FMW<6(W4W%3+W5447)B5SA9=4I),35F1'AB:4-+,$9$:%8W2F=6-4@K9C1J
M5B]+=# U248F(WA!.VYF4$]01%I653AU.4M-96U9,G-"3TUG0WDW6'-7+WI)
M-6944&UA+V=K0CET36PX,69M0C578GEX<6-D;')T;"MK2'1*4%)62E5L2F0F
M(WA!.VLR5E9&86LY36U-*TUM:6)V;W=H,E9R23%)635#=#=R=5,K,G55+S55
M6$1*<49Y=T@V3%95;&I4:7=)2$="07)R=E0T54IP=C%R,WHF(WA!.TMK36-:
M.$YE9U,T84\O23A,<61B;4UO>6YM<34K;R\U,B\V95A24SAG5U8W-6DX;S94
M87E34U$K6&])149W0W=%.35/44AL5FEG2$<F(WA!.T)867%0,FU(6$UB55$T
M.&MO9V-/3TUI2TA7;D%W=T]74$0Y3TM/,SEA=C!F96\K9"].96IA2BM92&QQ
M,71,4G)Y-G-,839I4W=S,5$F(WA!.VYN9$-.3&5)8FIJ=D5A*T%.8S(R;#!X
M;&AL>6E.=G-C=5)J1U%!0U@O;48U5SAW87IP1G1Q,VUU-45,;3ET64Q44G)-
M9W<R.&1Z36LF(WA!.V-H:VQ)2FQL2VYQ3F@R,GDW4S5O46M9-'@P3S4V,2MH
M8VM#4EI883<U2CAX5VXU9V57-U14=DUD-DQ384<V3G1.8WEE=E!!<U%1,T,F
M(WA!.V]75&E1-G-G6&Q8<'8P1T1&<4E(1DEM279B-#EY>6=E25558F4K47)#
M>B]->GER8U0V:&8V;&-Y4C-C<E18,'EY:TY::$AI0R]!=D8F(WA!.V55>DAI
M3G9#;2M1:G%38TUW04%.=5AM:S1X>&=P-W)&-T)&*V$R:%)0>C5.<#$P;DE2
M>4UG85=24V=,:%-O<C9,9%0R.7AL3T]*3T,F(WA!.U@Y64UY9E=08W$K5T1E
M2'HU-7)M;'-,<3-T<FLR9W1R;6%)<$9*.5=J350X1S9.56UQ*S)2>E8T54YX
M678W57@K;W)V2WDS-BMD9DXF(WA!.VMS*VXS3G9B6&LQ=3ER9%-O;VEK1G9!
M<T1C4T=*3E=8:W4S,F9U>'I6-&-+27-8.7!T16)S<5AL0RMS-2]09FYA3T=:
M2DA7-',V<7 F(WA!.W%2-F1O<V(O05!!=7!5*RM(4$5J1FIV=5 S<D$K;W%N
M-5EY:4AY1&)Y;%=C4GDV9S5205=C.&(R8S!64G5397=W87=8;%!W*S1,:BLF
M(WA!.VXU+V5V+TMQ3S9H.&HR3G1D5W,Y;F-13DUK:TYZ13A,+T9--V<X6$%.
M0TA'*T17:TA+4T-#;D@Y3$QC>%=A5"MB=DQX.'AA0F1A3V(F(WA!.W!R3DQS
M2W-K>4MR;FE'1$9A3C0P>3=";#A/66Q6,'AN1WA31S@R*U<Y43%Z>6A0;U-8
M<7!C,TUC8U4Q-TQ(6&QX24QT=U%O05<T.70F(WA!.VAK<T=547EC5F));D=X
M4V4R<3-#,C!+,TQR2F-"1D4P:41I<D]".%)64U1113EQ-5)+<C):<%IO4&QI
M=S!39E5*<E-7-&MB535Z9%@F(WA!.TMZ>6U24DMD:7E!+UIQ2T$K=TAH;&U8
M35IG6%=Z1TU1159Q,FM7=7%13$1C4$UI23-)1T-6-%17;$YY:%=O,S9::GIX
M:5$S635C46TF(WA!.TM.+T$Q.7I(=DQV-6)A4F]S>&UJ=7)Q5U0Q56M4.38P
M82]U>E91>7AL42]V>7EJ1G!)=TXR6$0P+UIS35)S1UAZ+U5J8C=Y4&]/<&4F
M(WA!.UIZ<G5Q5V1R<45I5W-&=&%2,U9T2$TP1'=3>7EM5TXU3UA%=#9W-D%F
M6C8K1U4W0FEQ+VMR85-A<&983C5C,FXQ93EN,5-E4U<P<V8F(WA!.W$R;W5U
M<6EC3D909F5V2C9Q46DU4$%E:U!I5D0R>%9.8GIY1G(K<WA25S-M4'I#8C)X
M4U-!>3)T;F)Y5T%L4S-B,5%794\T9'A-,'DF(WA!.WAV-FE-;TA':7%+,4-Q
M0V(X;&9,;'=K,7)Q4E153DY%5C%$<&M.>D5:-3=16%5W;DQP8WIV33=/<VY)
M.&HQ0F]E;39Q3W-024=Q438F(WA!.WI$93-/<E%3,FXQ:3)V-WDQ:'-J03!T
M-6$R47-L9$A%-W)(15925SE09V1X<S%-5E%U=2]L52MP,EET:S%9=T)R,U5B
M<6-I2U5C-&0F(WA!.U1K36MK3EE:-$@K1V\K,'I2=%0T-#(R059:4%DK6$ER
M4%AN,5-'5VM2,"LR,#)/,30O6E<R:VQC4'IR=E5457!4=#%X5D]-5F1I<G<F
M(WA!.U95.'EA<BM9<DAY-7$X:T5,,U,S3G%42F-X=T<R2FI:;W9Q<VQO<4E5
M:45H3EI31W)1061I:#<Q9U,X9B]W0V-I-%DU3$A15V1Y<&DF(WA!.W5:1U9+
M9T-1:TEH5F=F=$-J13 Y<W4P.#52>4-U-E@K-4IA8W!.>$%&9WE&+VHW17@X
M-V%N<3%H-4MV2G)N5'1,,&$S;71Z1W-2:T0F(WA!.U1T-F=#<VM+0TY6-550
M4W4S,%II869";'EY06I'22](=5DO;3E4<UIE:V)8-FE4.7I".40Q5V4Y+TQP
M>BMH.5,Q=3AT3&53,F=K9$LF(WA!.S9D86]Q.%-Y+T5P85)58FQ8:6%F4FUW
M2%HX9GI%<%I*:C9Y44PU5V)',V9U>#%71T4V;%5P1&=J5FI95D522D$V*V](
M9&UN:U!Y.34F(WA!.W(Q,WEB<$-A:'%*,%A1>&))<T=N-EEH9W5*-'A64DQ0
M3SE76#%2.&8W<U593EA,<RM42&IY4S19,TMZ>C58-VU72T)-4C!#4&XX;RLF
M(WA!.U=T1S@K*U5R9E1D3VAG47AA;$DW8V5C:GE2<D-59#5(-4]Z2U=016LW
M9'-!>GIN:6U39C5V-E=804))5C5P;"MA<SA-6&PR,#E74EDF(WA!.S8V;%E%
M8VE".6TU46YR-$%6>7920S5N*W%F=5I:95AX0W(U9R]W1$II*U5F*UEF5F8K
M25%:2$8O8WHY.&8P<69Q2'A54$U..6)R*UHF(WA!.W9L4S-037E2,CDK6D-)
M-4-I+U=&:E=+<FAE2'A'1BLK,4XK;WE72THX1UHX>#EI>5!Q1$Y-=S)X,DMU
M>%91:W-R6C!M44E)>F-+5FPF(WA!.V50-$A0245%.&QO83<Y8VM*1E5&-6,X
M=#9:-64P-SE(-F%*1G1F56%53$Q),'!$4'4Q0S5*;U1V.#AN;'EY>4=Z>EEX
M:4%+0V%:57DF(WA!.V1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9E1V513F)T.5HO3TLY=3(Q3SAJ=35&9#,P8W%L>D5N1TIL.4HF
M(WA!.W)Y,75B;3(Y3F582E8T25-1=F=E4E8V8G%V-6LK4SE+,4LV,'DK,4%X
M,S%M<7900VM&>$M16$U15D9-8V)Q.&XK:U(O=3!*9C1G86(F(WA!.S1&961F
M.#5!-FIA6#%H-61J=$IG3'%A5FYJ=%I167 O,W%)>4Q*0DE&:U$P,TMU;TDW
M:F)->E%I2GEE;UAS9G50-DQA<W5355DK;2\F(WA!.W=B*RMM53-0-6,V6$(U
M6#%#*S%)=G%7=G9P.&YQ6#DX9E=-5&5K4U9H:BM&23%5+UHT9T@S=TA51U)%
M62MM1CAG;6HY5BMR=E-,>44F(WA!.SA/:BM4=&,P*S5N4TM#6%-,5%9);65K
M83!V3$E2=G54,3E32VYU5&U*:D(O3U1J+T%%-RLQ,C)Q.65J=UI$,&I+0B]Z
M5%DK>50P1#@F(WA!.W8U;UIV279L.31N5U)2<#%Q:%I#1T%:2592,7%/-G-P
M0CA$;"MQ1EI:9C%I-G)(.4DY>54K6F12<UEF>DTX;W=3>F]K,V]A9U!463 F
M(WA!.TY:;&E74&(O04,R4F=0;&QU1T)/1UHO<2]P4DDK;V9&;%=P84YP1W%2
M2D9Q9&IB,S!58F-K:G59:VU65W!3;T1H9T1436%'4U5F<$HF(WA!.T1->$(U
M;V4W.'0V2F0V>F$V,6-7=VLQ3WE5<&$S2$IW554Q<4])64MF=$AQ34UC,&A%
M>$(R2VU)=3!Z>71,<U9D:7)S5F1I<G-69&DF(WA!.W)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER>GIY2"M5:F569%<O4UDQ=319
M37)".4AS:T9N<%):=U%8*W$F(WA!.V-P=FE&9&IY>%9(95IV>7(P;GI*<4XU
M939N<58Y26PR:TUA,EI&;3EV0TE*16Q4,&QL='!$47E2:&Y2,EI(+V%59TQ2
M5C4S*V,S:S<F(WA!.U(Y151Y4BMJ8DE04%I806=N=GEI>5AK;'9B44)&.5=6
M5CE35&E!3G9U1UIE:$8U0CAF=4Q8;#508F12<V]T5C!M97I-<VM-3C=#,%HF
M(WA!.VUI;W-I<DET2W)Z5G%':#=J365%=4=6.7I-:7<X*S%T3DXX:39P;T-Z
M43-/<F%B8U=%;6EM3FQI;6UC<$UK;'-R0G924G%C;55E,EDF(WA!.V5R,4A$
M;D=1+W=!4390461L-DTV;E-4=V=G2$A)5#E82W%);'E"-V@P96M7<TU%3G9(
M2$)#='9%0CA-2W%%0S$S<'A865IK.%)/-60F(WA!.T-25WIB,CEU.'%Y=D5J
M4W Y:5%Q0W<K4C8T8DM&5$%R<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&DF(WA!.W)S5F1I<G-69&ER<U9D:7)S5F1I<D-F
M3V8O:W=F>2LO-6ID4B]W0S9:4&ER3G-664HK8CEV8TYO;6Q89'9B:31N<V17
M<S5L:C5H0V$F(WA!.W-50S%O9G1/>6HX93)95W5(<$(X,V]06GE91U=C6D=H
M3$9-9G K-C)D<GDT:FM!1W!U06%I=GHR>DYE9DQS5F1I<G-69&ER<U9D:7(F
M(WA!.W-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)#9D]F+T%*34@X=G8K63-59BLV6E F(WA!.VER3G-6
M678K67-6.4QO9'5L;%I4,S!O=C=35F]R8TMZ0DE*:$TW2&MY9&\V9DUJ35A6
M9VU/=W9D,C-9,&]$351/46=/0U%S*UER.5 F(WA!.WE:3VIC:U9Q1F%G2&EE
M;W(R3UI)9%524F)W;V1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G,F(WA!.U9D:7)S5F1I<G-69&ER<U996C5H+TY,
M4TY#,7544C=R5$Y3;'5G<V8Q6C1962]4=5I*2DE9>$A#,&MK9&9I=59Q-T%2
M+V%(2W%K67$F(WA!.VM(;4QZ<#58=B].;C5B-FY(<59V1&)Z4UA6-%)03$A%
M.&-.>G!5<&EA5E=B-$]83E)V,WA6;D@K3G9*;B]6+S W+W!,9R\U<GA6,RLF
M(WA!.TYV2FXO5B\P-R]P3&<O-7)X5C,K3G9*;B]6+S W+W!,9R\U<GA6,RM.
M+TID869P+U1A;F]0<F-(+TYE2W4O>'0U32\V=BMN9CE*8T@F(WA!.R].94MU
M+WAT-4TO-G8K;F8Y2F-(+TYE2W4O>'0U32\V=BMN9CE*8T@O3F5+=2]X=C5,
M<E0Y4#9B6'<K='=F.$%.94MU+W=!8F544"LF(WA!.W(O<#,O4UA"+W=!,31Q
M-R]!0G0U32\V=BMN9CE*8T@O0418:7)V.$%',VMZ+W$O-F0O,&QW9CA!3F5+
M=2]W06(K4S8P+U0K;3$X4'(F(WA!.V-(+TYE2W4O>'0U32]W0W(O<#,O045L
M=V8X,31Q-R]',VMZ+T%+=BMN9CA!4UA"+WI8:7)V.&)E5% X07$O-F0O=T)*
M8T@O3F5+=2\F(WA!.WAV-4QR5#E0-F)8=RMT=V8X,31Q-R]',VMZ+W$O=T-N
M9CE*8T@O3F5+;WI4=&8P3%4S95!49%)T8C$T>'EK4S-M:FQ+9S=625)M<&DF
M(WA!.W%/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS83%4.'502T]Q
M86AE86AF5S X=#%F:4583$,Y=DDQ4#%:9S!,2D=K>7!',&(F(WA!.TQ65U)1
M46%K9%165DID93AU+VQ482M99DQ.;'%6<&)W-FAB9W<V4F%I,CE33U-0,&AA
M2DAC4#9C9S1+2%99+U599D93;%1I<DIF.$$F(WA!.T)0:WHO<7=A9"\P:5%F
M.$%.1TMU+W=!12M44"MR0G S+U-*0B]W03!9<3<O04%4-4TO-G-';F8Y26M(
M+T%$4FER0F1A=69Y2W1V34,F(WA!.S-..49A=UAM:&UE,FQT;S=">D$W5&='
M5&MQ5S=,3UE28G-3>44K;E)U5DXX5EIX2#5..&MY4G)*2&]7;7-J9TUJ0S!G
M24E/-$DK1$8F(WA!.U8S*T-F2FXO04993D\O-E))4#A!;6I&6&8T2CAM9CA!
M5F<P-R]P16<O=T-A35995G)N+TMJ9$\X>790<4-734]O84Y'3%,V<V\W45,F
M(WA!.U%R.612<FA7;&IJ:&-&;&IT2&-T6#DR=%,Q06-66G%02EAK<VEO,$A4
M4T0O04UU:T@O3D=+=2]W5#5-+S9S1VYF.4EK2"].1TMU+W<F(WA!.U0U32\V
M<T=N9CE):T@O3D=+<T9N=69Y2FHQ,#9R2DAA0V4Q1#95,7-T:7AT*U5J*V]:
M9E1706AG<'0R2')G.$9!66-S2W,V+W=4-4TF(WA!.R]W0W)"<#,O045I468X
M,%E&9"]G;GE:+S%93D\O=T-K4T0O;6I&6&8T2CAM9CE71%1V.$%P16<O-6]X
M5F=K9#4K4DUM=')Q>5)7<&TF(WA!.V(O8U-,9CA!4C=I,S5C>$HV=G!M,S9F
M14(V+S)+8F-S2W,W+T%-12M44#A!<7=A9"]W0DEK2"].1T)56G R9V%&<&IV
M2G!U;E=T:S@F(WA!.V<T>5!B=WAX1F=.-D5O<3%X5DA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<7@W6%!*1VQA>G(R;38Q8WI8161X<'!5<D0F
M(WA!.T5Y0TMB,#56;6E%=UI'8CDS279*941,-S%',DMS:'A6,DMU>%9G=70O
M;$9P1W18="]E6"MR86LX="],-G5Z5V]-2RMJ3&)M1T8O<2\F(WA!.W%#3#!B
M:5)/1$U2.%)99D@X5TMS,W0T23=E0T]#26-9;VQ623$X1E5502LW1E8K2W5X
M5C4U<5@U1BM3<C(O=C<Q6F(K,6TQ2FDQ,DDF(WA!.V)P;E9H271W:S9G5&EA
M:7IR95-"+T1Q;D$Q2E9E:$MQ<6]64E)61D%065EQ,VER<U9E9$XK4EAK-S%,
M<#1R:3EG1C5C1S1M4THT1E4F(WA!.W$O<65P1%0P9FE35#%4>5IQ>6)+3V1&
M1D<Q96DT<3=&6%EQ.#9T9GE,.' R,SDS95@T<F-T8WEF2&)J;7(X0SA,,&=(
M2EA-4VQN4#<F(WA!.S%Q0W(T,G(P6$9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E9/-70T3&TS;'1R:4Y:64HF
M(WA!.S!A3V%*:%974GAX6E-006<T<3A-9R]+<GI8;W1N87HK5SE):C W5C%U
M.5IA839T;71%;%=#85)H655D;4DR:6-H4BMY3FU!=W%M1V\F(WA!.S9$*V5L
M=6PR;6UA;&5816)Z6$%";FQS5VQ.=D9E=4QB,%-F4T-Y4S(S0FTU161W94HR
M>%9.4$XY:BM916\X<V5I-&98-#E)=EDO5VHF(WA!.S1)=C9684\S-4U#87A)
M-U%,8VE-+UI5:S<P>%9J9&HU9B]/4WAU;T%0<C)N85),9EA.,7%D>#E9<TI:
M5G0W:31F;$I-<V)Q5$MK0E(F(WA!.S9X.#9K1VEQ,S)L5F92=BM6-&%R<'5H
M83%$8WI..5EU:CEE=$%9645&=F(K:D%K:D-F:DEO;3E'85A:2'(V;$]),EE+
M=E)V>79T-VTF(WA!.S,X:S)557ES:4Q,9"]5-#)"57):;3=L3F]T1#)&=G=P
M-UE&6E9I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U8F
M(WA!.V1I<B]!4"]:(B\^"B @(" \+W)D9CI!;'0^"B @(#PO>&UP.E1H=6UB
M;F%I;',^"B @(#QX;7!-33I$97)I=F5D1G)O;0H@(" @<W12968Z:6YS=&%N
M8V5)1#TB>&UP+FEI9#HU,D9&0S8W,D5$1#)%.#$Q04,V,$,U,31%0T-$0T-$
M-B(*(" @('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z-3)&1D,V-S)%1$0R
M13@Q,4%#-C!#-3$T14-#1$-#1#8B"B @("!S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240](G5U:60Z8F1D93<U93DM,S!E-"TT,68Q+3@S,C0M,# V8C8X-F0S
M-#!C(@H@(" @<W12968Z<F5N9&ET:6]N0VQA<W,](F1E9F%U;'0B+SX*(" @
M/'AM<$U-.DAI<W1O<GD^"B @(" \<F1F.E-E<3X*(" @(" \<F1F.FQI"B @
M(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @('-T179T.FEN<W1A;F-E
M240](GAM<"YI:60Z-3)&1D,V-S)%1$0R13@Q,4%#-C!#-3$T14-#1$-#1#8B
M"B @(" @('-T179T.G=H96X](C(P,3@M,3 M,3A4,#DZ-#(Z-#<M,#<Z,# B
M"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RDB"B @(" @('-T179T.F-H86YG960](B\B+SX*(" @
M(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @('-T
M179T.FEN<W1A;F-E240](GAM<"YI:60Z-3-&1D,V-S)%1$0R13@Q,4%#-C!#
M-3$T14-#1$-#1#8B"B @(" @('-T179T.G=H96X](C(P,3@M,3 M,3A4,#DZ
M-#,Z,3$M,#<Z,# B"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E
M($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RDB"B @(" @('-T179T.F-H86YG
M960](B\B+SX*(" @(#PO<F1F.E-E<3X*(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" \>&UP5%!G.DUA>%!A9V53:7IE"B @("!S=$1I;3IW/2(V,3(N,# P,# P
M(@H@(" @<W1$:6TZ:#TB-SDR+C P,# P,"(*(" @('-T1&EM.G5N:70](E!O
M:6YT<R(O/@H@(" \>&UP5%!G.D9O;G1S/@H@(" @/')D9CI"86<^"B @(" @
M/')D9CIL:0H@(" @("!S=$9N=#IF;VYT3F%M93TB07)I86Q-5"(*(" @(" @
M<W1&;G0Z9F]N=$9A;6EL>3TB07)I86PB"B @(" @('-T1FYT.F9O;G1&86-E
M/2)296=U;&%R(@H@(" @("!S=$9N=#IF;VYT5'EP93TB3W!E;B!4>7!E(@H@
M(" @("!S=$9N=#IV97)S:6]N4W1R:6YG/2)697)S:6]N(#4N,C B"B @(" @
M('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B @(" @('-T1FYT.F9O;G1&:6QE
M3F%M93TB87)I86PN='1F(B\^"B @(" @/')D9CIL:0H@(" @("!S=$9N=#IF
M;VYT3F%M93TB07)I86PM0F]L9$U4(@H@(" @("!S=$9N=#IF;VYT1F%M:6QY
M/2)!<FEA;"(*(" @(" @<W1&;G0Z9F]N=$9A8V4](D)O;&0B"B @(" @('-T
M1FYT.F9O;G14>7!E/2)/<&5N(%1Y<&4B"B @(" @('-T1FYT.G9E<G-I;VY3
M=')I;F<](E9E<G-I;VX@-2XR,"(*(" @(" @<W1&;G0Z8V]M<&]S:71E/2)&
M86QS92(*(" @(" @<W1&;G0Z9F]N=$9I;&5.86UE/2)A<FEA;&)D+G1T9B(O
M/@H@(" @(#QR9&8Z;&D*(" @(" @<W1&;G0Z9F]N=$YA;64](D-A;&EB<FDB
M"B @(" @('-T1FYT.F9O;G1&86UI;'D](D-A;&EB<FDB"B @(" @('-T1FYT
M.F9O;G1&86-E/2)296=U;&%R(@H@(" @("!S=$9N=#IF;VYT5'EP93TB3W!E
M;B!4>7!E(@H@(" @("!S=$9N=#IV97)S:6]N4W1R:6YG/2)697)S:6]N(#4N
M-S4B"B @(" @('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B @(" @('-T1FYT
M.F9O;G1&:6QE3F%M93TB8V%L:6)R:2YT=&8B+SX*(" @(#PO<F1F.D)A9SX*
M(" @/"]X;7!44&<Z1F]N=',^"B @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @
M(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(#QR
M9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(#QR9&8Z;&D^665L;&]W/"]R
M9&8Z;&D^"B @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @/"]R9&8Z
M4V5Q/@H@(" \+WAM<%109SI0;&%T94YA;65S/@H@(" \>&UP5%!G.E-W871C
M:$=R;W5P<SX*(" @(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D*(" @(" @>&UP
M1SIG<F]U<$YA;64](D1E9F%U;'0@4W=A=&-H($=R;W5P(@H@(" @("!X;7!'
M.F=R;W5P5'EP93TB,"(O/@H@(" @/"]R9&8Z4V5Q/@H@(" \+WAM<%109SI3
M=V%T8VA'<F]U<',^"B @(#Q%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(" @
M/')D9CI"86<^"B @(" @/')D9CIL:0H@(" @("!%>'1E;G-I<T9O;G1396YS
M93I&;VYT2VEN9#TB3W!E;E1Y<&4@+2!45"(*(" @(" @17AT96YS:7-&;VYT
M4V5N<V4Z1F%M:6QY/2)#86QI8G)I(@H@(" @("!%>'1E;G-I<T9O;G1396YS
M93I/=71L:6YE1FEL95-I>F4](C B"B @(" @($5X=&5N<VES1F]N=%-E;G-E
M.D9O=6YD<GD](DUI8W)O<V]F="(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z
M5F5R<VEO;CTB-2XW,R(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN
M9T-H96-K<W5M/2(P(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N
M<V5?,2XR7T-H96-K<W5M/2(S-S@P,30S,"(*(" @(" @17AT96YS:7-&;VYT
M4V5N<V4Z0VAE8VMS=6T](C,W.# Q-#,P(@H@(" @("!%>'1E;G-I<T9O;G13
M96YS93I0;W-T4V-R:7!T3F%M93TB0V%L:6)R:2(O/@H@(" @(#QR9&8Z;&D*
M(" @(" @17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E("T@
M5%0B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3TB07)I86PB"B @
M(" @($5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93TB,"(*(" @
M(" @17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3TB36]N;W1Y<&4@5'EP;V=R
M87!H>2(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CTB-2XR,"(*
M(" @(" @17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/2(P(@H@
M(" @("!%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M
M/2(R,S4V,S0S-#DV(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U
M;3TB,C,U-C,T,S0Y-B(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C
M<FEP=$YA;64](D%R:6%L350B+SX*(" @(" \<F1F.FQI"B @(" @($5X=&5N
M<VES1F]N=%-E;G-E.D9O;G1+:6YD/2)/<&5N5'EP92 M(%14(@H@(" @("!%
M>'1E;G-I<T9O;G1396YS93I&86UI;'D](D%R:6%L(@H@(" @("!%>'1E;G-I
M<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4](C B"B @(" @($5X=&5N<VES
M1F]N=%-E;G-E.D9O=6YD<GD](DUO;F]T>7!E(%1Y<&]G<F%P:'DB"B @(" @
M($5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX](C4N,C B"B @(" @($5X=&5N
M<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3TB,"(*(" @(" @17AT96YS
M:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3TB,S8S-C$W.3<W
M-"(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T](C,V,S8Q-SDW
M-S0B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)!
M<FEA;"U";VQD350B+SX*(" @(#PO<F1F.D)A9SX*(" @/"]%>'1E;G-I<T9O
M;G1396YS93IS;'5G/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ T0%A
M P$1  (1 0,1 ?_$ !X  0 " @,! 0$            ("08'! 4* @,!_\0
M3A   00" @$!! (.!P0(!@, !0,$!@<! @ ("1,1$A05%A@7&2$B.#E76'=X
ME)?5U@HD)3&VM[@C,S1Y)C8W071UM+4U451QD9.6LK/_Q  = 0$  04! 0$
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MCMM[CY=R?6</?[@/MN5N/R!=I+8J&!W5!Z'A@DO8<=Z;]@>PY2<G;!Q!?L<
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M)ZH&6=1!I)UCPMRP+,F+YN51YCMO\WG^A>97'<WL7BL^M\_EG;$I(@E(-K8
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M8^2.S>EFMOAO/I.R$0FFD<QML-#RT-72O##3V/TWI6*IC*E['UK5Z_>]"O\
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MYS8*M:-TT\KFL=(X1QL!<XAC'.( .S6D^065--%7C?-/(R**,;ODD<&L:"0
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M.&&1M@ADACW#7!0<[$4I=4C\L/7J.V_><. 6_98T>?6D%9Z6"V:5QHWQNR"
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M(Y1N^2-SNW<,5SEJ]X>G,IH2X2$<[044;3S6,T;_  @VSHDZ,87)1Y^/8H[
M$BFQS59T\=-VZ2>P[&^=U,>W7&,;9QQS%Z*U?5SN(CLZ9SD!^$Z3N<F,MMAX
MQV(WO(G,70(:QKG$B3;8?.%*;&7Q<E.TZ/(4WCT>4;-L1%V[F.:!P#N>Y)
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MXL+Z*2!XG[L@#M17T 9$-L9T'^NBF[23<#WS)^\C_AWJ5^4RWBR<59LG%TO
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MQ[*TEIKFX7)Y!U?ILMP$.L")LG(B,N+'AN'T#94XE/9SR"PN2R-V2BE36A2
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M8E6]E YOTCDPZ44U:CJ\(<M K6[ITI4-C0.2R<]4E7IQRQ68"3N@LACS$))
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MM\8EVH-4Z$/ASI6_9T93NQ7;%D4L-!)+B:M*]7+&YAT-RLU]AD)LN&S-OY<
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M &)W%^BRP?\ "1?D#P?W:P_]J8_]KA6YM_T6S^+S?Y;E%7Q9?B]NJ7Z+F?\
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M$_MG#+W/B?E7]H^E\)_MN6MBE_\ DM(_I2<#XD,EY<'<>E_%SH=7EMMT^O\
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M[FB:2>FV^^V?N:ZZYSG[F.<R:USW-8P%SGN#6M'<N<X[  >TDD *0$@ DG8
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M=<?<T4:NG2S95/[F4E4MT]L8SKG'-=X+W1D=6Z%OC;^6R5K1V\@9Z$DCF_\
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>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g367280g98e59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367280g98e59.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1M$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $T< 5H  QLE1QP"   "   < E  "')R,3 W,#(Q' (% "Q-:6-R;W-O
M9G0@5V]R9" M(#$@4FED97(@1&]C=6UE;G0@,3 M,3<N9&]C>  X0DE-!"4
M     !"T\]^MO6PZ")TQC1!@;CZ3.$))300Z      $5    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    9 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,0 S
M "  3@!E '< ( !' &\ ;P!D       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0&+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $
M 0/      0 !.$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             !$0   T8          0
M                       !              -&   !$0
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   !$0    !29VAT;&]N
M9P   T8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   1$     4F=H=&QO;F<   -&     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    &.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MO#WM=Z>W;[=W[Z.&1E1L^,3ZM>\IJ!L/.Y/6>L!S7CJ.6&V5L>(R+8G;L?\
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MWV_0VV5H-E9=?F.#18&YMS'DDM#9L=Z?JV>RMN_^4Y1JKK#K!=L+:P?T;WN
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M79Z?J"/3W_R/H;O?Z:'_ )9C3]K]O2W?98GMOV^_Z7^E_P"N?H5X"DDE]_\
M\I[Z?2_:^_T&^IN]+;NC7U/5_1^O^]Z7Z/\ ZVAG]N;+/1_:\[7;9^RSOAT_
MSW\G^:_P"\$224_522^54DD/_]D .$))300A      !5     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@
M P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "P
MAVD !     $   "\    Z  6XV   "<0 !;C8   )Q!!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$X.C$P.C$W(#$Q.C,P.C(W ')R,3 W,#(Q
M       #H $  P    '__P  H ( !     $   -&H , !     $   $1
M      8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M     0 "   " 0 $     0   48" @ $     0              2     $
M  !(     3A"24T#_0      "      !    _^$!2$U- "H    (  @!$@ #
M     0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !
M,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0
M +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3@Z,3 Z,3<@,3$Z,S Z,C< <G(Q,#<P,C$       .@ 0 #
M     ?__  "@ @ $     0   T:@ P $     0   1$         !@$#  ,
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M 0$! 0'_P  1" "O A@# 1$  A$! Q$!_\0 'P   00" P$!
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M= (GW]#M;K$;CZVZ=V@FP\MR!,\?4?&0[8/Q9/7%8.L2+J-A<(T:')]G3R<
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M^X^,_ITZ7FUL9[I'2_-S_F-XM)XM?$RZ*>N;XE^O.4OQ3%LJQ"&/N/6PS%V
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MO^G6!3U$?]Z;/_\ K7?X&!^OZ8QK1U/U[O7U\M\=)?TC/U6%,QT;1G1  6O
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MBYVO/RQ%-[KP2HP(6<QX=4<)AJ):PDP[)\::-5:04@:(J,9R3Y?NYNR^/IU
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M0-U>:&GI'E)7K9;<UA"DJ6  K8A:4A4G:8'3$RJNS#F6%H9J^AIQP Z&^-E
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MIV/ FHJ5.LI5[+04GP)3OWH3X=:B"2 2 D1J,3@;).EFH<PD&3)P7,L@FR+
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MOLY6XZNII5!"' 0$ 0$ZB%3L;#3 VC:_'NUE^+'J=KAJSC%SB@[S22HPYK6
MQSO".:T(5[VH:Q2.WVAX;VN=V'L1XR<'$"JIY2<Y>BF* %MMODV*7!(43:3>
M01,@QN/6>N4]B<O92IO,Y==42 '4R >(FYO)&YD<[8OQ]*7KVQ_5?%J?';]&
M"SP<$#)+7E8-D][4>Y\@(U\N5=FJK&N\;_1$3PTYXS49<4N-LI6VZH63/@!(
M!(W! WN3M><0WM1V/7DI75,N)73'4I*#^4 $D"#P!82?<3<K=3L[#'TTFRW&
M:LV?);":QCN"C5'L*]4V7QQ8B-1RJG+FOE=EVJ_[1,X8H.RKLE(?KU):;$PK
M652H^4  _..E?5+VEDK' $P8MOQ83 '3W8"/*Z(V59_08+13R-KLMFPA.<-%
M>(#7 ;*GG[6[&<AL0J*[;=51JINFR+YY'9^ESGM?1Y#0U3K^5URT/.+5.@@)
M2M:M-DA0.Q 'NWPS5BG7'VF&R!WJDB$V &D$GF+@;"3'O(N?%.^&[E>I>E.'
MDT*L9!;3&)2,M<8FRS1H>4]Y"(4TOVRHCI4=7#+%[["C8YBHYKE1-_6N1=FN
MSN092Y1T5(TS4 H_ZI#:0^\4Z4J+BM]:HE1Y)G%C]C<YI.SM6'7Z=M:"V HE
M(.IP) *__4HW.U[^L]?"G]!U]Z6M(; &H!HILLS0P++(8T1JN %[!]J/"9W&
M\GM %>#G.7B]RO<C&H[;IS+"]84E]P,*2C2U) $-H"C&PU+"E'S)QS[3]H?^
MT-4EX2A*50V1([L :83>TZ;#H3BV.4.'7@%15S!1E(Q1\&<!L&%G[RNXHC4\
M>%V3;;?K;3!TM3KWU#VAXMYVF>/EB+K5I 1&I2[DG<R2)48\O3KTPRWZP:6X
MYF53IF3)ZAF5VD9\B'3LF1WS"C!MW2/"URD5&*Y%<]S41&JWSMMTI#+A2"H$
M$";F"K:2!>=A/K&YC"K[JZAH.H9(;OJ(2;=)]?%;R,";8ER2")*"HCC:8)6J
MU45.3',<GTW_ "7PNZ(OYIUH>0>D$'H>#\-L<" H0H2.0;W&(,S+2''U@2[*
ML[L64-R'0:*BC5.:*K6ILCF^/**[SXZB=1V/R9^I-4W3-)JE*U@A* %'\Q($
M ^&9]TVWXOLMEI0" /9/OU)O[_[;8E:@KHT>BK8[HXG[0@<T<)B^5&W?EX_Y
M\[>//4D;:;:;;9"$_A@) *1 @\?L?0SC9EL)0!:"F"+7D?H1,C]3C#970T!J
MQZGK(G<.]D<3VA8QZ$,O%-^#-U;M]5^FR>5VZ3U>29?FP4W44M.M12?&II!(
M WD@?K^T'5Q"$IA*8*H@BUY^&W7R\L1MDOIXPG)*$D)P'P+= =R#=1T:V9"E
ML3D PRL;W%0;]N7S;JWQMU%W.P79]VE<H_NQ00DBG?\ STYX4T=]^I/K:_"H
MRYIYN0$IJ/RO)'C"HMP#&XD7C:]C"."XC;9B_(L.R:]-79?ADAL"?%[KG1[>
M*YJN@V@FN<O,<H",[CF[\2M>U$\+U6[781W,*VLRJMSFJI*VB)^[M]ZK16TR
MB>Y=4#NHMA,E,[DQN,:TH=?:4TZ?Q6CW:R2#J*?#JV_-%SL;08F/<NC-MBIY
M,\4L*M:)SC&:1C7.'OSW=R<U5VWX)NG\$1=O+-4=@LXR5UU#BQ64ZQ+=RMQ<
MF3R9A4I3Y)'4C"JGRMS67*8$/ $+T)OR18;R.(ML3:RP'7/'<'B65/>VXWU@
MI9B)8^X&5D VR.44ES5<@POX*JN<K48Y=^2.5$61?9WVL1EM4YV9S%+[1<J5
MN4ZWI'=]X$I#8U1"-2"I($B2K'1MFI9>2RXVM95,(4-)!)WCF3TV(Z8BK6OX
MG'I@P?&;N*#+&9/<NARZ_P##J91R6.D%&\3V$+W."*-R(B_,KFKMX1>O0[-$
M4.-...MI39:5ZKJ3(, CW'ZC%A9-]GV>9F45!;%,P=*D*,R2;@C>-)'F3?>;
M:R<JHS[4^+=YQBV*Y*_!I]O8LC38]=-DQ7O/,(1 L.%CF*02O79-N*(YWY+L
MMJ7FT._>:JJ8:ID KJ7ZE0\+"4DZD$Q"PJ(\BK%UJSBBRZC&75&8%5924H:=
M<6L!: DH&L*M!L$B;WYMBS#T(Z&!T,R'&=7]9:1]M?L)(#B&/%8V2['HD\8V
M-NK 1&D$RV>PCVB;Q[L0:N1BH1$<VELS^U.DJL]-#0.MKR&E<4A]]N0JHT$A
MLS,%)<"+#C<X\_\ ;?MZJHJ&\OHENJI"EQ%2Z=JE0VU3^34$E)W48BUS:!=Z
M3X%JI<S+G('D$.V,\,>$!58WL%3M*UK6(URF>,BHUSW._?5=DV79AJ6,B[2Y
M^AY3J62BH9>I=)@I[M:"(,\F.=[WQ5;-,$/M5R89+54V^R$#V7FUA:%@[A0(
M'/\ &**- _3_ )OI/\;?3K$GU%O/JL%R/))Z6P89R0X^&6F"9<M'8SY36*$
M3/F#C,<0J]V1NUG]U+RS"B6U_I#Z%ZJ9-%H#@,G4$%.E9L 2H$'^(GT949ZS
MG'86N6X_-<VFG:<2HCO%I"FQ>P)_JVD;]8Z?BT-61Z]M2D+8FD!C4.G6P@)L
M^O5N(P)20U:P03$-%>-,@K'"/(<66Y\7B-'>$JOT_0_H1P9GC%5,(26]KJ)Y
M^O*=YM[@>B&]I8M>\L6++D#>1TX(6.K#1W>Q;Q.@AB5LR:0R/G)(D&4<&60B
MMY(K>L$P)'3?YC]>@%_08Z]V)YF>IV\B;Q>.03A\PC*D"V?*_K#%"])=FUZ\
MQ#19(DKJQS111D1[NQ">T,:,%E>PAW)QXD=SU*Y-]_E'UMOUQT CB-]HOM;;
M;R-^AC'CKE#+@R56?-.@8[!]][",8L($F/VCR"]PO;N +VA/;W@A;"<4A&(W
MDU^^A,<[=>E_\_ XQ/&XXV( /&X%CM<FT=#AJVP'&=&B [EH*OR*$.)#LY(V
M.HDEQY##)N?\/22$Y',%">P+6#BIX$BL0S>)!!ZQ,>7Z2/G^N-@!'J)^HM)^
MK#',DA16K8106YXH%C\X<%TY!4KVEBA"0,CL3&2!;)%>8IWRA*2--"]SU0KN
MNR=AO:9^-C8=>=K'&I '47.VY)G;I^]KS;'M57#[+62K".V6<Y)L@CY$A9HB
MPBLDK$&9#R(X)KXPB0RQ@U3'A9)*)!C<QSN3J@DMA8<'>*"-;:"N]X!3!@;7
ML+\'&I6H6#94D"=4$0?,V$B_-^3>^,CB0T"-O2+$&K(38\J;,E/MU*Z9.C.2
MQ!8E]PX/OP]MJF"=HJ<2-X/<YS4W*%ZEM)85X-'XLSKU7)*)A, 1;?B(P!6H
M:M:4Z/:08)5O=)'D"(WFQ/)?N(8%E&HV<46!8.VRN,NRJ6$$;'(81RQR36$:
M*,^21CLD("'4]P';]U-8V#%AQ'F, 2;-=LX@H4%^%MA*27%*5)4;2D ^R9\0
M(M8@;V-6M*EI4$)0-1!B=P(N)!\0$1?TG%G*?"]GCJ*FO'ZB\.34(83?C^-V
M]9)3$X]HYSSPXT/+X<8DTB0W)&0XVQQPAR(BN@(C7\NF =I,J56&B55MI67
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M0NQ[C24E ,P"N8DP5#FT[C$49]ZA]2,Q#)K[*SFX?COLY))1,59-A3YQ@R+
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M5S$D1!L9X%A%L/S3:FBY'AMO812K7RL1C1+:QH(#N,^>V%8HLJSK$=R>4L.
M]72 F11@:-3-57N\.M"XEW2!X%3I.H0 ;D$[\B!P3ZXS5,*;&@ %(M(OSR +
M6/Z2<.C6V1#%7Y% J"37,RI"F#*LP,.KL?+)C6<0E;+(9Y OD2?>M89A/<\4
M<$R(WBG3L\"6PHC9(U1Q O %A:(V\H PT.D?=E*WT*[M43,[6XC:2?/@#&0T
MJQY(-7!AV4,;($:.?)K)DAZQAJ&3VF *<C%<XG9 X*1D(Y6%=->BHU7.3I,V
MA0()B%>(7ZW%N3$&Q]!CLR W2)=X/@FVK5,& .D?ON,.[*<P+CHP(VCEW.09
M"=JXS7QW+[HPPO4 K1D-B*2,)Y&H*&Y4[,:.SNHHQKR44^$K6E4JOX$IN=A8
MC@3T\AZ.-+3KIM#SXU*6-0"3J FZ9 VL!(_L,,,>=:IUC>8:4;9 I<8R6\23
M-/#KY3'#/"B5A'?L(X@$:,]F8;5GS)355'"$OE.JI=[BJ;4V%)[I1"AP5B+@
M05!(38FP*E$"<+JAAVM9)<#:DC7K00 E2$^+VKWX"2#!DS<8ONT,FZAY_C-W
M99U+OL2O*^&(T6%+ADC)-:L(!TEA[N[B,.Y[E'Q5RJB(GCRG52.Y92U]1W+J
MU-@O$P#$B2#/O@ >ML>8^U&<98O-%4F4TBZ<MK=14+4V4I44+"20K40--]-@
M52=L-2HSJ7K3I%J+C,9\@&38Q)EP"K+:4;C%"QT@4GBYB.5CN.[7#V5SOKXW
M1:DJN\[+=MD4S:M-+5U/@<F0$K0I4G:(,7_B<.^2U".S>=Y=F+106*QD-.#4
M/S.-K4%"T62#.^ HTXUH]1F%UUE4W&9R;FB1YA0J>T"LIL%&[B<"(<B,>T;6
M)P8->;6)^ZOE56W6LPIF&'%5^8,++:]:4%0*%MK@6/*@"2D'GGDV+VEINP]8
M',VKJFC8?4T%J:94A:UJ.\ID$DD[3U,G@M<;IZ(^DBW]B<,S.;I)<R<4?R-8
MLH;GQXKA(G-.RG%KOF7?94V^;S"<_?R.HR]RNIW$*=+AT: -6@3(X/G$];X\
MQ9PO*<VJS]Q90Q2A[NM24A+BTS!*D@D7Y,FQL-QC(?#_ *.U)J6VRN:!KK"#
MD%BD*>@7)[&F9"F!:]J/151912N1'M5%<SZJO'IN[-/H%?1L,,N+6G4MY0;\
M*$+2J"I<VW&XWMR<:KRVEHZJG4R0HE(O%Q'7;CY7XO4=\6&KR+(_B%:Q5N-U
M:R+,==IQ'C/CPB6!"(33S'"A,H_;%43FG(4$XP$?VJY@C&<-!\F637+IFV5K
MK'FD-)9<\!CO#W@4VB+'=Q0!/2=K##VE*4T_>/5++;-Y:7,J,D)]D'\^DCTW
MXP.9L-B-H8DJ\DY]0WV.S2WER7%V&?(1LJ*(5Y6@&2>SD\DE2%C2!,Y [KE8
M,8V^*L;SZI_U9%'2LY7]W*%,IJ*IN2VM=DG5I/B2=.D^<G# UFI34E@K;T.+
M#:!I]L*,  @6)FTVXMMB3='_ %-ZB^E^';Q-&[:4"PR^?&NLJDYK21+*TKJ]
ML*"*JI@O-.(BR##EQ9QU/.D,;.F2WJQ"1D:V5-L5V=/LU-;4*8#/X38H2E*'
MHCV9(2=MS VB",.Z*)RI)4^L,-1 7:#N-DZCP#M-A'7&7U7];WJ-U7J&Q<FS
MZTK U,28M@'&1Q<7AS8LIIR#=(2 _NSI1P"&R"6.23'C\!1W@*4I>GVGRJC9
M,R:HBX[Y0]9*;^ZWK<3C=O+:)!)?U+VB23'2P$ S$D1L(,8%/\>D%61#;:WI
M 2I#))X&0EER*Z=.*%O&6UTXBF:0K5:=7D1RI$$=4#P>J=*W:5I9;4@)IDIB
M4CPILD;;=(%K3A<T\RVA;:6TMI *4*'](L-AR/YP])<9QR5<E:2QMI,4K $]
MFV8*#&&$L@<8P' (]C21AMB1I2S8;45P9C4&HU&]^JGF$/I =;E,(2-0V(OY
M[D^72]\:(#;K0"5H*C,R0#[2HWO<<;X,C227AMOIJ)<UFW5'.ILBEQL*R"I5
MT>:6_F@@V=?[A8_;[M):HZ4(U816)^P<\8FF'NM;=LW,WRW,%MT33#]!4Y6Z
M]5(TI6ZVIU3J5NE?B(0I+:82%!5B8 PTYA35@@H:UM:=1 4@^*3R%<@"(&YG
MU]&HF/BEW\[)6YR[.8,"WD'3"8DF;1UPO:,-&JZ@]@4@6#8"8(US>R&E_9T<
M$8V-1)*H]N[/)RMO):&F7E:-=2X5I27$ZJI0*H[I(<)&C5!U &XC:W*C4@)*
M#2I"Q$I<()F\Z=)(W^9$8EW,<,N-3=#<((*[=D<V>*,@<C;! &38O&:P**T6
M$K1 _#Y$\RMC12L:Y\2)&>IW(JM=%:(/]G^T=?G;+*&!WBZ0L+2TM0DAQ(<;
M=2X /PX"HF39=U2PNU:*3,5J%.WJTZ5!$3IU3*AM$CJ3<$"-O'HAZ2<0DQH]
MGK5F#35H[V>W'].V64:"K[<CY'OK2VN>X.P[MRU RHU;7R +'"(8N\1JN:YI
M[>_:SG=,MZF[+92<MK7:%M%;FK(9<<6=04Z"%-A"&UH&DP"0%1,A.)-1YE0N
ME#A=987= 1;O#*/%,@I2F"8ZW%H!P8>GGIST6TYRK(\AQ_"X<,]T):J!#GR7
M7511TYGPY4J+5UTMTE@TEV,-D^7(EI)EH5C A(P*=OJELT^USMUG35)E=;G-
M51/,L*IF7:=I+*?$0 75(0C5! *E&50-IF5*5(+CCS@[QM+@[LEP* 1P81?4
M+S.PB$SXL"MZLO2;7BAQ-2=%Z:KA<K0WZWXPD\@L3.ZS:9GZPTU>O<;76:2Y
MO;NJ^O?%CR8:N,L?OA8J7)]E'VJ9L':C*.UKR,Q9J&BS09K3W92]W9+*'5:=
M16JPAP'QB9@X[+KD,I"F@I:%A2%)44J*3 V(W DR+J28FQL!E[J]<BL[2CK+
M8V+XFL^71MJL"'!@V&<3J&(V*R=8VX6K:3 5)XP9(E6>9A2PY+6Q&D<JMNGL
MOV5I&\NI\RKEU5;FBV%UR/O*BHTM14U)<26J5!+2E$>(:I3U'&.5!2([@ PY
MMO;I>\6B/E-\%AZ(M LUSG4"GR'52E$["0MN\R_#9N47,R/:36/C,I8SJMDD
MSFTY)'.=(:^9O+E1FM+&0)2#2$]O.UV0!S,\HR)JC_UMH-IKGUTJ U(TBH ;
M6CPU!<*@XI(C6508@X;0JB>J2SW%,K2I?> -G5X-0\4)N=0"2!,>*#88O)DX
M?56("/F1*RG&]K!UY(<2$.0 >XGJ".8(6%A1R.&)5BB>C7-8G<1RIMU6K-&X
M_1.);JG5K=<0]W: G3WH0FP2D>"]DI$6F;DC&KU,RLE+K3-(TH!*>["08!F9
M &GBT[S8&<-"764,Z0VHO[)4G$:;\/:\KAI)AB5J&=&5$[;CBWV^9%>B;JSR
MFZJNRRD*JJI&8$LU(6XA"W 1J T@H3 @K29!DWX-L,^:,4Q[AM;^I42T-4)4
MW-U)_*51UDF#8WQC)$2DHJBTIX53&C,/"DPPV,QRS9RL,)X1/!*.CGQR,(3N
M(P;D5',:[DBHBI+S098C6%T33BWFE%7WHE7>'O$ %!FUC,"\P>F&H52:9*D!
M"4MET)"[*44E)&YG2;V @C?>3C50R)ZP<HO:*Z>HP+G5W&LHHGD/;NFUQ(XH
M]\RQ<T=HVJ)(9*K)SFME1TCRRF*KWL81GH.D[K[I0)IPVW3?<J<MLL?[25!M
M(44R HG<*G^^+%IE)53M_P!1928,V!OS;FUA[\;-_P $*3-E>FS4HDVS'=%;
MK9>A_%$.<Y938^-XV#B[W(AR&1XKA^U@][ESAB&1CU:Y$Z5"XG"9SVU3Y<SP
M/K88I[_28/'J)]-R[[;:/93_ .UX_P#G_G=%5. 9!,#4)/3ZX\\:@ D V!W]
M 9_;&N_IIE1L,U#P?+1270G8_E5+:/FL V2^* $\'N3I&>K6&XQ5D,42O^?G
MX5JL1>FS/Z$9KD>9T*AK54,NE">2M+:BWY!6N(\\+*=U+5:RL*'=@I!5>!)$
MS-[ &+?+%T_K,QV%8>GK,YE=55[ITN#$S$(*N2:+$D4LK,85R+(Q584>*1:Q
M8A#ID->031Q12F2@F_8JO7GS[/:@ISS+BMW0M2G*"JL06G&DD(;6"/:D@")W
MZ6Q.LWIBYV;-0E.K_J-8((]C4+[V@"P$'B.,5Q^BV-C(=8RZB9KVRXGI#B=W
MJ';!>I$*63#:&LJ$"=BJV(8=G8A(V89KP1B#:7@]S41+<[>U50UEM)2,)47\
M]S5BB2VF-190"I1$D>%93$S-XXQ#LJ;+SS;J@.[I4K4XOALE,IU#>_$ \=1(
MWY=D9LLS#+,G,221<DR*XNU?-**1,>EA82)(_=21C$V0=HB,:4S6,:5[5)Q\
M]2V@IQ2T5+3(2=+##;8B#[*0#S&XOYG"&K<[VI?<F0MQ1!ZCB/*(CRPWT7[H
MO2OR(CJ#O?"?'-'/5=D7S_AUL@I1(F 2(WWQD$C8XFGTWWJ8YKIIC9D,@(ZY
M/%@2R*HVHD:T86 15>5KAMV60Q5Y-5%3=OT546.]KV14]GLQ &KNFA41'#*@
MLG;8 $GR!QWIU +\1XM]7PVM7Z),7U6U)QUH^#:G-+^.)$7<?MW6,@X""<B(
MUS'@.'BJ(UJM1',:C5Z6=GJM-9DF4/MK2M#U"TK4.5 Z5CRTQZ= >.:@4ET*
M$:U!2?,7/[R/TQ'K53BGE/\ E>GS&4J  !/U)QP>J;_7[=&-%$$VZ8Z^35^_
M_#_?T>Z/KRQK$?Y!_3'9R%LF[MO'V15_^[H^MI_3'$H,F!;BX_G"5X=EV0BJ
MB;[HB;;)]5VW_P"'1^^#0K^WU;YX.[T,U<=6>HK.&RJZNM<2T0R.NQ2PMIYJ
MV,VYRN+,ARP=YO&.I)-/#F1PMDO:]3&:.*CBD<BUMV_>6^O(<C0J/]3SBF<<
MBQ#-.4]Y/.G22;=#S&)#D+*8KJA5ONS!U'^@N).@'KJ($1/G W =KE:QB>&H
MK&/V14\*YC5<FVZ[;+X3\TV7SU933W>:U1I;2KNFC'M-L@-!0C@Z3O'IB/@J
MT@[*)43)']:B()M<&>N/O<7^\G^SKKK3U^1_C!*NH^*<=1G[B>BN1?E7\O\
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M#A9YIV8UA>P(:'6FS>LB\$L+-%1SF"R.M(X7/M,:RTK99B;,='1JX<<6XE0
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M5:3W,7,<BKH$>,"I-4.2J:=2.;VRJ:BAO:[O-!3!5Z29Q7-_KA^W%W1K4VY
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M&E"C<P#XDIVBY%\=*'+G%'OZEP)9[M93!\1)2H JN- !OI(N;'G$0ZM^IQN
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M*K&G[ZHK $5J%&U6[[.7I3E&;Y?24Z7GFFV>^="DZUI"X3#>H)5!,+0L@"T
M2>K)GKZJJH3EU*YK6B[W=>(H,B K0)UC59,BW-YQ 6IKK-XJ\+)<5D['IY21
MIL!_(KVG:K>$AV^\=ZM=N5J?(CN355WCKG5NME:JUHI*34.:5IA.Y"I,1'J#
MN-Y&(GF;KZ$MTR]*W*:VMKQ*A9)\<$E*AIN+1^OK_6*XL1T3I4BK% [+9$F=
M-*X"J5$4?E"(H'JKT;NBM39=U7Z>7ZFKP^:;O/NNHZ6PNH?;:C61X9<4 =1
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M2IF@9<S!:TI*FF7D.+"0XL#0VI0"=.L@D$$3:8+3%#&5Y@XDI+CI" A)&I0
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MX?46DY*PE[;Y%E%'"\CE1 Q#UU'9SE39Z18EJ1\='C3=II ^>[5VZCU34?\
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MQP&?=G,LR>JI11BM6$H4RM2K^,CP$_\ '3)F]]N,=<NIFTT[KCE+-2X5P%
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M18 >^NW:0B#B5$LSR..62B*4I'(82N,Q!B3VZ%ZVA*1(2I;L?A@20I?]*O\
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M]W'OZXW><3DK-Q#&9B\E67CM'*7??DJGK(A?*_7?=_E>KJIY[EC_ /QVM_\
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M'O\ 3U.I#C1U$.0!XKV!DC>)D QN,;4:$.-COW"EA"274S=4IE.F9W,S'[@
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M3\40*NDV01@5J6KF1F(YK4VV%@E(LE,!,; :=@/B)%YVC&2-1U*,JN!-S?\
M0<?+KB4M,K0'X1J 5LTS@NP6+&_$>+&F]V/+L0<.%:HD0+PPV$D%D2G-8CU[
M^_(_;[;=7 5-N)2;EM20KD&-NG/GUDXRDZ5H5N4J"HZ[D<W-N8V/F,3%J":I
M2VO(^35YXKTR[(LB@XC7QB3Y8X5C$=7$R))K3QH@8MLZ-+K@]XQ$#),#F!S>
M*,@F2A\55;W"U+#R,OIT."Y90EHPT#PF?([3L,:5U0K_ %2I5W<%=.V'%;:@
M(LJ!$"/@,.+TYZN9-IODMP+13$6Y5EN42XONUODBV%;/QR%:*^7.Y1^S!HO;
MD$:(*<9Q=FM:?8JL:-<=IJ-D+1F':+.FLNH6*(@LM.&:Q\202@%)4H\7.PL!
M?#95)I%%PUKY82H_AQ^3?:3$ G]M\2OZEK )[2OE1V1:O(IUT_+LCQ<$P=9B
M4^XLZQ(Q2]R&M6"_L*X,9(,.XD-'$FQ0&<X;GM[C85V7JF>TU0ZS3Y>\_2,I
M>83F;A*WV6$.$#2J26PL"0DJ2N#<=6IAM]]!8*>]I&U*[JI7!4A!42%-F)3*
M8-CR/4"_,OLL=;0Z_(;&RI\%O+,U2@Z:LA5< E6Z$8<&\AV-6^;$ 2IL&1K
MO=LV)(C*YL@0Q[KU8669#V=R= JJ)U+N94S3FM^L2HK:<A9*@5J6) ($@1!V
MPOI<IRVA0NK0KO7D))2^02X3?<DSU$1%@=C@N=-\2OHGJ$THR;(H\[MCJ<6J
M)EL[VSTO,LGTT* <S6NW0,7\. V=8."24%)(PB_8O<[JOG\VIZK(*C+6:EE;
M[N<UU4Z&" 4I9=;41_[U%6KJ1.Q$;9#4(K:ZG;:E6FO7WH)@K3N01TGFWQP,
M680<7JLHS&982Y^I-S&N+FTA8T.?+J\)P^7)EOCR27E]&6,>_,YX#P#4U2S\
M/%".$Y3/*Y&K:.7KS6OI*%+"#0I52LC6KPKTZ?"MLD$E) FQWYB,/%8E8J7R
MCP@O.)M/Y3"0-P !83OMA@%SK,)L-E777M7AM'7DL9?X&:%$H:6N KY/MH_8
M5!FN76;NPTCIYY4ODL3^LN:1S$>FLHHV%A;X54UEBMZH&H7OX9.F9MML0=AC
M@D*(4%RJ4['@[\#ISU, QC99^" N_IXU+Y3K&>9NK9&'++%VH[53#L=<-(3>
M;_V:A<-TI=]DFN*Q%<C=^G.+ 0($ 6'[#ZXPC< "B  !?81R?C\\4V?I-O\
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MY#N:1.')=U\M7[5;]I;56K[JMO66 E*5:9TI45+&HP#>#\L,&?H=<:1H2I2
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M,-#;DA$1=MVJBR(QK2M4$-)*PE0*D$IE7B3$*$C8V,\[8BC+84T38&% E2B
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M7U!IWPM/C<4I*2W;4$A.YN1-A,VPVU[3]0DH8J TJ -)U? $3O;@QY8)+/\
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MU3A[PA12I*4D%4;KB4J\DCG8DQ[\=Z?,C2IRVRBR%E'@9!BV;P9HV(1A1.?
MD(+AVT<HB"D\41S_ -FUJJCD;NG2+NRJHIU3^&HPA,>(1>YYXW].F$^4KU33
M@D:KD[1>#>%$;?I!Q*U97Y-3I5W>, D//!D!KHY"((Y06$54.WPQ5<R.YFRJ
M9J,W1.0]G-X].KH<:'X4>T;J$@GTO ^KX?TLN,/(J&TRXE*47\0,6]DVU'?4
M=S?G$X'U(H=5YX[%*HU)D(J%1ZBT79[-":TK^;/UWBI'5]A'G&[S32RPD)L,
M W/&,1'/7E35*'E*94LE] (<24Z4D1*=,024B #[L/F7YPTR.XK'-"'5EI!6
M$)"%JE02HV*B=4B)(1 V&)<C0)UY36 ;]DG*:>'40HRW4*8YM]B,6M8R=57,
M6LY%8R++AM;7S@#<2&H^+;%L,ZND=.*=7X=RE*ED'PP%$B+F+DV@BYZ$3AVJ
M&6F04 Z%*E8"R"72=BDG;5:!N"F^.JO%8PJJM?:B+>X>27[J"T;@P)7LW*D:
M)&DV$?DZM.-XQ2 PFD>)IU&YTMZ.<WIR;0%%:$DA0"8.JRMS82DD=2?7C"!U
MMMQLA3;K3T6*DI"8)D$@F#Q,"T7,8Q5E4'O+.;-<$Z/8=9CE.UHIKI!_G?/-
M($IJ]WMB\7$E17 DD17-8U$<1>E!;"2@!)&HZ1<D P2.9C8"/%QMNTN48*3W
MBR%I,I-TBT[P;G^,,6[HI="R/=$D@G1K/ORPR(I%/[+D1\8T6QA.$!Z6+&B=
M(]LU6C6O-&EL<Y7O:FS;24*<<7X0U90)U*6%@ *2D6*!/B.H00;6PA#SC:5,
MN D$C\2 $Q(( $223:W)F;3CPXCI#D>J5@RLQ?$F2(9W*(646S2LQBN$KF-+
M(9.,-QSD=NO]6!&<5R.:T:*]$58MGO;3LMV=4$YC6-J?)_!IV%)<4MS=*"2I
M(;*_9U'PB9(Q',][59/D;9-6I7?I05)IB4A3I"?9&I0!U&!!MUO;%T?P]_37
MB'IYU-Q=M<5MMEF1R)#<@R%1J)I$!56!V5U5'(G=!5!)R>/N*XQ7JTI51S>#
M::=[4-9]G=,L$4[:E.?=*5*P2H0HZG"%&21<1(!%IOCS?GG;>N[5YY2M% 8R
MU@N&FITJG20%>-RY&J!'@D#8QBHCXUL@/_X0_.40=>!6:?8> DT+>S/%)'CM
M5);*L5( +9, ,8W;:5)S!">]K>[W!*%)"Y%P02"D@P.L@'XGW#;>,.M.HH:"
MA%B?RA=M5_"2 9$\C$?:7II7D/IXU"QG US&1J9,QC'W9X II2!]S&OB)71,
M=DL4,;\-,\K8X5]RK'-(W@1Z<F=5CVK3F2^T62UM:XRG)J*O+Z05J4H!Q)1X
MD!F"02"H!PD1*-7LF+K':5S.&CWM*<M55(3W"D *33E9E:2&BI+ND[=X4@SX
MB#B'@Z:Y8,U7&D)%HB'18OXOD%_CU:S'FQ ":P.1!?).PPX8SDBR3.>PIRR6
MD43B-5>IK7YG0T; >4MWNFV@XID,.2X(F61I@QSJ*>GK-&$J*RC2K5S'BX,P
M1>^^W78$'$[W_I<ULP(4Z^N\)CX_35%7(N5L W=+=PF5C$!)=-0;VH688T0X
MIM?$BL.0Q!!:-RO,]&1'(_M"[+=H*A-+05JB^IXLI;>:+1*P 9W5"52"#OL(
MC MY*%]V=148V%KR1N0>9VYD]<"U3"5X*J0Z%-E#5Z&#.1DF/(?["8I$21#(
MU6@#7-"I2.:-&E$CA(I'J0?4WN#%SI)$@\SZ$QM;TY..OGM:8/%O/Y<_"]FW
MI;TY]-(\(O-6]>[?&-1ZJIK@C;BENTD0F+M+'&(<8=?'EPYMS<V?!8="$,1H
MMYQE<17HJK6G:K.,[J<ZI,ER^EK4,M%*15)0$TKG>)2Z27$**S!<4FZ/:3'
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MY>Y4-_>G@T\HK2/%(G221,R   =KG&E%V<RUW-:)EUE2&7^_1K2"H$I3(!"
MKV3S'Z21&UWUSS/6#.&BS++ZN37U-Q:BIL=QM'PJ*&R ^[A?BLSNF,\4H@0A
M9.&K"O> 9'L1&*B=3W(<IR_*D,,LTZTD,S4ON.-J+CJQ*2E*%J5[((F#'ONY
M4&4LY34O]R1W3KCOC6L"Z"$H3"@"%$7C3-CN0<0_'!6EKJZV6*6SDQVJ1MQ
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MW$D55/D1V.C0PU00/>]^[>H=E-=3TB\US9Q874YB]*$E*M2*-NR5:H( 4=D
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MGBJ9#><YI6J)>?K'B\HQI-DJ6H*F-(G>=,<\">9JONJ:E844A"F$*"B?"H1
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MQ&+X5$3GX\HFR;)U'LT^S-I3(<I'$LI)\+;:@4#3*3I('*A)G91(VPT/9&%
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MK^U71H-JT0VM56*B*Y$5&MZN;+TU=+DF4T542JI0RAA1,D^"UC_\>+P3B_\
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M+'ES.\P3FC3C=0KO*FI>4\HF?#WD!*8(X*23$0#(MAE2ZD6*4P'SD:4ZMY!
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MN-IPR.)TN*;CG?UB^_7X^^X$^IGTYNCNF:@X-#5Q%;[F_K(K$$"<YSG.+:Q
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MF)\QM OTQ8M-VJR?[N?QVP-Q=)/6WD1;SOUQ8%HUZ?J3$H+\LS&':YIDS*]
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MF"0(]<-%P]QB-5R"S)Z+LOA'([&?HB*J)X\?[TQ!5N?U_<G^?/&.]/51]_\
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MIJZU* 3G(]P@OG1CN$)ST1ZC&K6*_P"94Y>>LX,8=-+-,4^FG.!I_+$,?_\
ML_H@=,9D]3\<??Z+=,O_ )NL$_\ HCC_ /\ 9_1C&.P.F6G$8HSQ\ PJ.<+T
M((P,6HQ%&]-]G#(R"U[')OX5KD7^/6JDI6"E:4J2H:5!0!!3T(.X\L&$;3/3
M>04AY&G^$R#&<KS&/BM$8I7K]7$(2 Y[W+]U<JKUE*4H2$H 0E(A*4@)"0.
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MHT[08?IOE:,208EDFF%*%TK+,ITGR+/&TM]KA25<=6Q[N%-A75(:OA$--/\
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M+HP871@PNC!A=&#"Z,&%T8,+HP871@Q\7PB_R^W1@Q4)A'IY]7VCF=^K[37
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M8,.FD'13!BH<QTK-^ 6DR576=3'FV9Z>UJIU8LT1SRMS\_KSGY8S:9ON#'H
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B^S@0(<40HPS&O)\S;%@71@PNC!A=&#"Z,&%T8,+HP8__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
